,ticker,content
0,AGN,volatility be word day stock market drugmaker strong growth prospect proven long term stability such ibd member valeant pharmaceutical vrx be good stock watch list candidate ibd spotlight top performer list stock base combination factor include sale profit growth today roster
1,AGN,market go rocky phase pay close attention stock icon iclr weather storm better most drugmaker allergan agn perrigo prgo contract research organization cro icon be base ireland provide phase phase clinical trial service help pharmaceutical biotech medical device company bring product
2,AGN,shareholder generic drug giant mylan myl friday vote favor continue firm hostile bid perrigo prgo launch be protracted battle mylan say third shareholder have approve transaction issuance share perrigo shareholder cash stock bid mylan last formal proposal april be worth
3,AGN,be sell not be sell be course question lie generic drug maker perrigo prgo regardless answer analyst say be plenty reason investor take interest dublin base company owing ability capitalize trend generic prescription drug counter sale first thing first friday stockholder drugmaker mylan myl be schedule vote approve hostile takeover bid perrigo move ahead tender offer perrigo ceo joseph papa speaking month analyst company latest quarterly earning call reiterate own opposition offer unanimous rejection perrigo board make prediction mylan shareholder vote want remind everyone include mylan shareholder proceed tender offer perrigo not be easy path be painting be papa say express confidence perrigo investor support stand alone ambition mylan begin pursue perrigo earlier year follow several refusal mylan recently offer share cash share perrigo share mylan need approval own shareholder support perrigo investor more share seal deal mylan insist new decisionin letter shareholder public statement most recent earning call papa have say mylan have undervalue perrigo mylan do shareholder vote initiate tender process ll make strategic decision board right thing do company say expect close vote analyst observer say deal ever get do not talk surround perrigo have attract positive attention be sticking buy rating perrigo see path upside share stand alone basis hopefully supplement acquisition large scale context sale mylan party deutsche bank analyst write perhaps deal talk lead even stronger bid mylan suitor potential investor sam pappas ceo mystic asset management veteran health care industry investor tell ibd many pharma company be hunting acquisition so not surprise more buyer show serious interest perrigo build pipeline say be efficient way do other hand mylan takeover attempt falter other suitor do not immediately enter fray perrigo be freed month long distraction focus anew organic growth acquisition own lawrence white economist new york university stern school business long time observer market tell ibd pharma industry bigger player often capitalize scale more efficiently distribute medication manufacture takeout target be not always case add say fast growth company have such robust pipeline proven growth sale simply interfere already solid expansion path perrigo establish be indeed case own shareholder back vote mylan takeover add important dose confidence investor feed biggest isn always best be lot move part address come distribute pharmaceutical tend favor larger company white say be not be biggest be always best rule here analyst say perrigo be indeed well position growth remain stand alone entity company be lead maker distributor private label counter generic prescription drug analyst say frugal consumer be increasingly move away national brand store brand away expensive prescription otc alternative outcome aside continue fundamental perrigo story give global leadership position store brand otc ability capitalize rx otc switch william blair analyst say august report perrigo spend absorb own acquisition dublin base elan sell treatment everything smoking cessation pain relief stock have ibd composite rating ibd medical general drug industry group rank st industry group perrigo be rank allergan agn quarter end june perrigo report earning cent share exclude time item generate ep revenue firm cite strength new brand consumer health care line include recent acquisition omega pharma expansion pharmaceutical revenue brand consumer health care generate sale sale perrigo prescription pharmaceutical segment increase more bolt on company also recently inked deal buy patheon operation mexico well portfolio otc drug glaxosmithkline gsk analyst anticipate perrigo pursue more such bolt deal remain stand alone operation post quarterly result earlier august perrigo executive project ep increase midpoint sale ahead midpoint executive say addition company specific trend perrigo also stand benefit general ongoing demographic health care development give megatrend have talk many year include age population increase use medication individual get older rise health care cost perrigo be well position meet future need global health care community papa chief executive say earning call
4,AGN,only ibd stock be headquarter outside be unusually small number overseas representative list month ibd include foreign name late january be current name be base ireland economic recovery degree buffer stock
5,AGN,be wild wild week stock market elite ibd much close friday facebook fb apple aapl iphone supplier technology avgo celgene celg ibd other most liquid stock base average dollar volume finished higher trading just day
6,AGN,high rate tech stock adobe system adbe pair biotechs lead ibd stock move go wednesday tough tuesday index more adobe lift high volume indicator institutional investor be likely buy company make photoshop other creative cloud software graphic video
7,AGN,lead stock index europe run loss better twice rate peer tuesday london ftse fall vs dow decline cac paris drop compare slip frankfurt dax tumble vs fall nasdaq vs sentiment also hold foreign stock trading market asian base stock generally fared best china base company trading american depositary receipt market slip average tuesday japan base adrs fall most not foreign company trading market use adrs issue such toyota motor tm honda motor hmc alibaba group hold baba trade adrs indian adr listing averaged drop skewer small telecom provider mahanagar mteny nose dive loss india base listing fall europe base stock trading adrs france base issue fall average german issue drop volkswagen vlkay fall trade issue ireland slip base company slump average italy slip ibd fall tuesday stock group spread india bermuda averaged decline ibd top world stock averaged decline ibd foreign stock performance valeant pharmaceutical vrx week have be disappointing stock have fall away attempt retake week move average construct right side week consolidation now appear set retest support week line second such test week clear prospect base pattern sight allergan agn rise almost fast trade be only week loss have come heavy trade drive share back week line change put hold hope current consolidation develop base ibd top world stock signet jeweler sig have show high level resistance trading flat just buy point midcap icon iclr big cap cognizant technology ctsh see real chart damage
8,AGN,high rate tech stock ibd leaderboard amazon com amzn palo alto network panw get lift early monday rise market turn choppy midday hillary clinton tweet price gouge prescription drug slam biotechs general stock market direction uptrend pressure warrant caution amazon introduce new tablet thursday power back more gain monday afternoon stock be consolidate potential buy point palo alto cybersecurity research uncovered xcodeghost malware apps apple aapl app store see more lift largely disappear stock be become buy point cup base big techs ibd growth stock list facebook fb be more monday google googl less drugmaker biotechs celgene celg valeant vrx allergan agn other be several percentage point follow donna howell twitter ibd_dhowell related top big tech stock trading fast buy point
9,AGN,high rate tech stock ibd leaderboard amazon com amzn palo alto network panw get lift early monday rise market turn choppy midday hillary clinton tweet price gouge prescription drug slam biotechs general stock market direction uptrend pressure warrant caution amazon introduce new tablet thursday power back more gain monday afternoon stock be consolidate potential buy point palo alto cybersecurity research uncovered xcodeghost malware apps apple aapl app store see more lift largely disappear stock be become buy point cup base big techs ibd growth stock list facebook fb be more monday google googl less drugmaker biotechs celgene celg valeant vrx allergan agn other be several percentage point follow donna howell twitter ibd_dhowell related top big tech stock trading fast buy point
10,AGN,lot change week lose session slide market go correction number sector leader have be nearly halved most interesting remain stock be reduction medical name aug issue sector leader be health related wednesday
11,AGN,rare disease specialist raptor pharmaceutical rptp be friday announce buyout late thursday bring field cystic fibrosis raptor pharmaceutical inked deal privately hold tripex pharmaceutical acquire quinsair inhaled drug help manage chronic pulmonary infection be common cf patient drug have be approve european
12,AGN,follow day plummet stock pop tuesday several top drugmaker gilead make climb today screen day focus top sector performer half stock price move be attribute strength industry subgroup sector
13,AGN,biotech gilead science gild develop treatment hiv aids liver disease heart disease other life threaten illness
14,AGN,gilead blockbuster hepatitis treatment sovaldi harvoni have steal much spotlight sovaldi sale totale foster city calif base company total annual product sale
15,AGN,stock have ibd composite rating mean have outperformed publicly trade company variety technical fundamental factor
16,AGN,gilead share earning have surge triple digit last quarters
17,AGN,share gilead be stock market today stock have rise almost start year
18,AGN,heavyweight valeant pharmaceutical vrx make range specialty drug include acne treatment eye health drug company say thursday acquire pharmaceutical notably receive fda approval last week low libido treatment addyi have be make headline kind female viagra
19,AGN,tuesday valeant say valueact capital partner robert hale be join board valueact ceo jeffrey ubben be resign valueact capital own valeant outstanding stock
20,AGN,share rise have climb start valeant stock have earn highest possible composite rating
21,AGN,allergan agn make generic specialty drug include botox latisse restasis actavis complete acquisition allergan march
22,AGN,drugmaker be hedge fund top pick accord recent goldman sachs report say monday be voluntarily recall specific lot refresh other eye drop due small number customer complaint report small black particle time use
23,AGN,late july teva pharmaceutical teva agree shell allergan generic unit
24,AGN,allergan share have climb jan stock have composite rating break cup handle base buy point early july have break support day line sank buy range
25,AGN,share be rally tuesday
26,AGN,sucampo pharmaceutical scmp make specialty drug boost guidance top estimate early august
27,AGN,stock have grow begin year hit new high aug have composite rating
28,AGN,share shot
29,AGN,gilead sucampo be member ibd medical biom biotech industry group allergan be part medical generic drug industry group valeant belong medical ethical drug industry group
30,AGN,follow elaine low twitter ibd_elow
31,AGN,related
32,AGN,gilead get wall street love earning beat
33,AGN,valeant buy addyi maker stock wilt
34,AGN,allergan apple hedge fund favorite disney short
35,AGN,biotechs boast big ep growth rate follow day plummet stock pop tuesday several top drugmaker gilead make climb today screen day focus top sector performer half stock price move be attribute strength industry subgroup sector biotech gilead science gild develop treatment hiv aids liver disease heart disease other life threaten illness gilead blockbuster hepatitis treatment sovaldi harvoni have steal much spotlight sovaldi sale totale foster city calif base company total annual product sale stock have ibd composite rating mean have outperformed publicly trade company variety technical fundamental factor gilead share earning have surge triple digit last quarters share gilead be stock market today stock have rise almost start year heavyweight valeant pharmaceutical vrx make range specialty drug include acne treatment eye health drug company say thursday acquire pharmaceutical notably receive fda approval last week low libido treatment addyi have be make headline kind female viagra tuesday valeant say valueact capital partner robert hale be join board valueact ceo jeffrey ubben be resign valueact capital own valeant outstanding stock share rise have climb start valeant stock have earn highest possible composite rating allergan agn make generic specialty drug include botox latisse restasis actavis complete acquisition allergan march drugmaker be hedge fund top pick accord recent goldman sachs report say monday be voluntarily recall specific lot refresh other eye drop due small number customer complaint report small black particle time use late july teva pharmaceutical teva agree shell allergan generic unit allergan share have climb jan stock have composite rating break cup handle base buy point early july have break support day line sank buy range share be rally tuesday sucampo pharmaceutical scmp make specialty drug boost guidance top estimate early august stock have grow begin year hit new high aug have composite rating share shot gilead sucampo be member ibd medical biom biotech industry group allergan be part medical generic drug industry group valeant belong medical ethical drug industry group follow elaine low twitter ibd_elow related gilead get wall street love earning beatvaleant buy addyi maker stock wiltsallergan apple hedge fund favorite disney shortedthese biotechs boast big ep growth rate
36,AGN,commodity stock market fight adjust ongoing shift global currency rocked global exchange second day friday lead stock be far exempt institutional investor trim holding ahead rockslide lead edge decline china shanghai composite drop shenzhen composite tumble react market argentina
37,AGN,drug giant allergan agn apple aapl be top favorite hedge fund express script hold esrx walt disney ibm ibm lead list most short stock accord goldman sachs report
38,AGN,allergan early august only modestly beat analyst consensus estimate stock fall shortly stock touch time high
39,AGN,share be midday trading stock market today allergan stock last month hit buy point cup handle base rank wednesday midweek update ibd
40,AGN,apple have be stock hit concern china slow economy yuan devaluation dollar
41,AGN,hedge fund have increase long position facebook fb amazon com amzn say goldman sachs report google googl citigroup valeant pharmaceutical vrx be also top goldman rank long favorite number fund have stock top holding
42,AGN,most short stock base total value short interest include chip leader intel intc caterpillar cat exxon mobil xom qualcomm qcom
43,AGN,average hedge fund return be again lag say goldman sachs report
44,AGN,goldman sachs have own method analyze long short hedge fund stock position report analyze hedge fund gross equity position start
45,AGN,accord morgan stanley report institutional ownership also publish thursday average portfolio allocation large cap tech stock be flat quarter quarter exit june quarter amazon microsoft msft see largest uptick report say
46,AGN,apple institutional ownership be roughly flat quarter quarter drug giant allergan agn apple aapl be top favorite hedge fund express script hold esrx walt disney ibm ibm lead list most short stock accord goldman sachs report allergan early august only modestly beat analyst consensus estimate stock fall shortly stock touch time high share be midday trading stock market today allergan stock last month hit buy point cup handle base rank wednesday midweek update ibd apple have be stock hit concern china slow economy yuan devaluation dollar hedge fund have increase long position facebook fb amazon com amzn say goldman sachs report google googl citigroup valeant pharmaceutical vrx be also top goldman rank long favorite number fund have stock top holding most short stock base total value short interest include chip leader intel intc caterpillar cat exxon mobil xom qualcomm qcom average hedge fund return be again lag say goldman sachs report goldman sachs have own method analyze long short hedge fund stock position report analyze hedge fund gross equity position start accord morgan stanley report institutional ownership also publish thursday average portfolio allocation large cap tech stock be flat quarter quarter exit june quarter amazon microsoft msft see largest uptick report say apple institutional ownership be roughly flat quarter quarter
47,AGN,medical stock have be leader bull market go back so surprise sector leader stock thursday list have something do health care thursday ibd be trading week move average show vary degree distress weak market be
48,AGN,market lead stock take wild ride monday many trip sell signal bounce back sector leader monday edition fall buy point erased sizable gain other be hold relatively well market trouble shareholder consider take profit protect risk acadium healthcare ticker
49,AGN,apple aapl make goldman sachs list good bad stock own federal reserve hike interest rate
50,AGN,central banker meet week discuss lift benchmark rate september increase be see sure bet few month recent global turmoil mediocre datum have prompt analyst expect hike later
51,AGN,cupertino calif base tech giant be place good list strong balance sheet bloomberg report other company make grade range tech food finance
52,AGN,be google googl chipotle grill cmg well fargo wfc priceline group pcln pepsico pep blackrock blk oracle orcl kinder morgan kmi dollar tree dltr
53,AGN,other hand company lot float rate debt be avoid fed hike rate financing cost rise goldman sachs analyst say report last week
54,AGN,enormous sum cash overall balance sheet strength apple also have lot float rate debt accord goldman
55,AGN,company make not so great stock list include mcdonald mcd ebay ebay metlife meet coca cola ko general motor gm johnson johnson jnj allergan agn chevron cvx time warner twx ford motor general mill gis
56,AGN,somewhat schizophrenic list apple goldman sachs report didn faze investor apple share rise finishing stock market today help early indication latest iphone model be see high demand
57,AGN,follow ciaran mcevoy twitter ibd_cmcevoy facebook apple aapl make goldman sachs list good bad stock own federal reserve hike interest rate central banker meet week discuss lift benchmark rate september increase be see sure bet few month recent global turmoil mediocre datum have prompt analyst expect hike later cupertino calif base tech giant be place good list strong balance sheet bloomberg report other company make grade range tech food finance be google googl chipotle grill cmg well fargo wfc priceline group pcln pepsico pep blackrock blk oracle orcl kinder morgan kmi dollar tree dltr other hand company lot float rate debt be avoid fed hike rate financing cost rise goldman sachs analyst say report last week enormous sum cash overall balance sheet strength apple also have lot float rate debt accord goldman company make not so great stock list include mcdonald mcd ebay ebay metlife meet coca cola ko general motor gm johnson johnson jnj allergan agn chevron cvx time warner twx ford motor general mill gis somewhat schizophrenic list apple goldman sachs report didn faze investor apple share rise finishing stock market today help early indication latest iphone model be see high demand follow ciaran mcevoy twitter ibd_cmcevoy facebook
58,AGN,week move average be key technical indicator investor pay attention generally used determine area support resistance line also be general trend indicator be used buy area number sector leader be now week line blackhawk network hawk have pull back
59,AGN,past midway point be cling just small gain trading have be choppy lack sustain rally segment market have still manage thrive ibd industry group be more year date strength have be concentrated consumer build medical segment economy consumer space gaming software be group top list group be lead big move activision blizzard atvi electronic art ea netease nte apparel movie retail internet beverage specialty product group have also be top performer consumer space medical sector drug hospital manage care group be lead ethical generic drug maker be more year date horizon pharma hznp valeant pharmaceutical vrx allergan agn have be major leader group hospital rank tuesday ibd be also more group have stock better composite rating lead adeptus health adpt june ipo favorable obamacare ruling help spark industry summer strong housing market build recovery have push concrete aggregate construction product group respectively light product supplier leaderboard member acuity brand ayi be residential commercial builder heating product group be also more year
60,AGN,drug giant ibd stock allergan modestly beat analyst consensus thursday put guidance month sort impact recent allergan agn earning exclude time item rise year earlier quarter share beating analyst consensus cent accord thomson reuter revenue jump
61,AGN,specialty drugmaker sucampo pharmaceutical scmp beat expectation raise guidance early wednesday send stock new high early trading pull back later however possibly word get sole market drug be be exclude cvs cvs prefer formulary next year sucampo report earning cent share just cent year earlier quarter cent analyst consensus accord thomson reuter revenue grow more analyst expect company raise full year ep guidance cent top street estimate cent sucampo revenue come constipation drug amitiza be still grow even be market year prescription grow sucampo royalty revenue marketing partner takeda grow japan royalty revenue marketing partner mylan myl double second quarter deliver outstanding earning growth drive mainly amitiza continue growth japan sucampo ceo peter greenleaf say statement financial strength fuel continue transformation business transformation include launch second drug cobiprostone be midstage testing oral mucositis many street have be wait sucampo acquire company drug help fill thin pipeline greenleaf have tell ibd actively look opportunity now company still depend product become greater issue pharmacy giant cvs prefer formulary list leak online amitiza wasn have be year formulary cvs knock favor allergan agn linzess nonetheless guggenheim analyst louise chen raise price target sucampo affirm buy rating sucampo still expect mid high single digit growth amitiza amitiza be put cvs exclusion list amitiza have also have formulary win negotiation reimbursement be still ongoing chen write research note wednesday sucampo stock have be volatile emerge cup base mid july volatility continue stock market today share shot new high early then reversed fall low stock be midday stock boast highest possible ibd composite rating meaning sucampo top other stock base range key fundamental technical factor follow amy reeve twitter ibd_areeve
62,AGN,high profile tech stock ambarella amba technology avgo drop sector leader tuesday market sell close tuesday ambarella report earning revenue rise respectively top view stock gap sank much wednesday week move average fast trade gopro gpro
63,AGN,not acquisition valeant pharmaceutical vrx hardly make map large fast grow drug company not only have earn spot such map be map sell everything cancer neurology drug cold remedy toenail fungal solution have thousand product
64,AGN,body sculpting system maker zeltiq aesthetic zltq soar new high friday report strong earning raise outlook late thursday analyst have expect zeltiq lose money quarter instead make cent share sale climb year earlier quarter beating consensus zeltiq also add
65,AGN,volatile market tuesday weak economic datum china several ipos have be hold own planet fitness plnt share close ahead result wednesday first report go public aug gym operator have ibd composite rating receive slew positive
66,AGN,wall street escape summer vacation maker drug medical device be greeting august frantic week earning report here be lead stock report week tuesday morning big biotech regeneron pharmaceutical regn be expect report earning share year earlier quarter accord analyst
67,AGN,federal reserve decide stand pat market bull show quiet appreciation stock market rally broadly wednesday take back more steep loss suffer day sell begin july meanwhile medical sector remain linchpin general uptrend today market pulse show gilead science gild icon iclr allergan ticker
68,AGN,system ddd be upgrade friday also have price target lower report weaker expect profit thursday printer maker be upgrade neutral piper jaffray needham lower system price target thursday system report smaller expect second quarter adjust profit revenue also fall short view printer
69,AGN,stock be back session lows early afternoon trading monday weigh drop shanghai composite overnight well weakness europe
70,AGN,nasdaq lose dow jone industrial average give fall
71,AGN,boee ba be worst performer dow
72,AGN,breaking day move average last week test day line monday
73,AGN,institutional selling have be make presence feel market again particularly suffer fourth straight distribution day friday
74,AGN,volume main exchange be tracking slightly higher friday level breadth be poor decline stock outnumber advancer exchange more
75,AGN,nymex crude oil lose just barrel
76,AGN,stock market today utility steel coal stock outperformed security software stock lag lead growth stock have rough go name ibd fall more
77,AGN,teva teva gap flat base buy point rise news pay acquire generic business allergan agn allergan be ibd stock also ibd sector leader cup handle buy point have trouble get go stock find traction monday share rise
78,AGN,elsewhere recent new issue boot barn boot add get support week move average first early june
79,AGN,downside baidu bidu slump ahead earning report close be downtrend november stock be back session lows early afternoon trading monday weigh drop shanghai composite overnight well weakness europe nasdaq lose dow jone industrial average give fall boee ba be worst performer dow breaking day move average last week test day line monday institutional selling have be make presence feel market again particularly suffer fourth straight distribution day friday volume main exchange be tracking slightly higher friday level breadth be poor decline stock outnumber advancer exchange more nymex crude oil lose just barrel stock market today utility steel coal stock outperformed security software stock lag lead growth stock have rough go name ibd fall more teva teva gap flat base buy point rise news pay acquire generic business allergan agn allergan be ibd stock also ibd sector leader cup handle buy point have trouble get go stock find traction monday share rise elsewhere recent new issue boot barn boot add get support week move average first early june downside baidu bidu slump ahead earning report close be downtrend november
80,AGN,rather start downward spiral stock market be middle be longest expansion ever say adam parker morgan stanley chief equity strategist list stock buy volatility report publish friday parker say recent swing be view temporary setback not
81,AGN,thing be never so bad stock market get monday new lows count rise nearly level not see mid october oct combine new lows reach vs new high bullish persuasion number come same day nasdaq
82,AGN,stock go wild ride past week swath earning report big name roller coaster result isn slow just yet
83,AGN,top rate ibd stock be gear issue quarterly performance allergan agn regeneron pharmaceutical regn jazz pharmaceutical jazz monster beverage mnst gray television gtn paycom software payc criteo crto epam system epam amc network amcx papa john pzza
84,AGN,here look analyst expect
85,AGN,more drug stock tap
86,AGN,regeneron pharmaceutical report open tuesday analyst project earning rise slowdown first quarter gain sale be estimate climb mark third quarter growth acceleration
87,AGN,biotech development partner sanofi sny announce tuesday re collaborate new pd inhibitor sanofi give biotech upfront milestone payment sale cancer drug pass july drugmaker win fda approval praluent first new class pcsk cholesterol fighter clear sale
88,AGN,regeneron have highest possible ibd composite rating share be still trading buy range flat base buy point initially clear july stock be year
89,AGN,ethical drug maker jazz pharmaceutical also have composite rating report close wednesday earning be expect rise bottom line gain revenue be see rise slowest gain least
90,AGN,jazz break flat base buy point wednesday be still trading buy zone
91,AGN,allergan earning be project jump report open thursday revenue be expect surge
92,AGN,last monday generic drug maker announce be selling actavis unit teva pharmaceutical teva
93,AGN,allergan have composite rating too stock be nearly
94,AGN,scary good result monster
95,AGN,energy drink maker monster beverage report close thursday ep see rise slight slowdown growth see sale be expect increase also slower gain
96,AGN,monster be trading new high have gain more year stock have composite rating
97,AGN,more
98,AGN,gray television have composite rating report wednesday afternoon owner local broadcast station be expect grow earning revenue rise
99,AGN,gray have composite rating share have increase more
100,AGN,criteo deliver earning open tuesday paycom software epam system papa john report close tuesday amc network issue result thursday morning
101,AGN,follow alissa william twitter ibd_awilliam stock go wild ride past week swath earning report big name roller coaster result isn slow just yet top rate ibd stock be gear issue quarterly performance allergan agn regeneron pharmaceutical regn jazz pharmaceutical jazz monster beverage mnst gray television gtn paycom software payc criteo crto epam system epam amc network amcx papa john pzza here look analyst expect more drug stock tapregeneron pharmaceutical report open tuesday analyst project earning rise slowdown first quarter gain sale be estimate climb mark third quarter growth acceleration biotech development partner sanofi sny announce tuesday re collaborate new pd inhibitor sanofi give biotech upfront milestone payment sale cancer drug pass july drugmaker win fda approval praluent first new class pcsk cholesterol fighter clear sale regeneron have highest possible ibd composite rating share be still trading buy range flat base buy point initially clear july stock be year ethical drug maker jazz pharmaceutical also have composite rating report close wednesday earning be expect rise bottom line gain revenue be see rise slowest gain least jazz break flat base buy point wednesday be still trading buy zone allergan earning be project jump report open thursday revenue be expect surge last monday generic drug maker announce be selling actavis unit teva pharmaceutical teva allergan have composite rating too stock be nearly scary good result monster energy drink maker monster beverage report close thursday ep see rise slight slowdown growth see sale be expect increase also slower gain monster be trading new high have gain more year stock have composite rating moregray television have composite rating report wednesday afternoon owner local broadcast station be expect grow earning revenue rise gray have composite rating share have increase more criteo deliver earning open tuesday paycom software epam system papa john report close tuesday amc network issue result thursday morning follow alissa william twitter ibd_awilliam
102,AGN,teva pharmaceutical teva confirm report monday buy allergan agn generic drug business drop hostile takeover bid mylan pharmaceutical myl deal teva pay cash share deal be expect close teva say buyout boost adjust earning share double digit deal allow allergan focus brand drug business give teva revenue source face competition multiple sclerosis drug copaxone acquisition allergan generic establish strong foundation long term sustainable growth anchor lead generic capability world class late stage pipeline accelerate ability build exceptional portfolio product generic specialty well intersection say teva ceo erez vigodman teva share jump premarket trading stock market today allergan climb mylan share plunge hostile bid mylan mylan say continue pursue perrigo prgo mylan shareholder vote acquisition next several week accord company perrigo share rally premarket global health care have hit july vs year accord datum cite reuter teva also report strong preliminary result raise full year ep outlook analyst poll thomson reuter be expect teva announce official result thursday follow gillian rich twitter ibd_grich
103,AGN,come week show busy report schedule international stock ibd top world stock be schedule deliver result dublin ireland base drugmaker mallinckrodt mnk criteo crto online advertising service agency base paris kick action tuesday analyst expectation be high consensus mallinckrodt ep be increase
104,AGN,biotechs generic drug maker ethical drug maker be highest rank industry group ibd track recent view top earning report fda approval strategic divestment re prove strength hot drug stock lead ibd screen day big cap leader gilead science gild jazz pharmaceutical jazz allergan agn regeneron pharmaceutical regn mallinckrodt ticker
105,AGN,day teva pharmaceutical teva break base fellow drugmaker amgen amgn be clear buy point amgen report second quarter result close thursday earning be project rise slowdown first quarter growth
106,AGN,stock climb big volume stock market today clear early buy point
107,AGN,amgen be also near conventional buy point currently trading level
108,AGN,monday teva gap new high giant volume breaking cup base buy point share be still trading buy range today be
109,AGN,teva announce preliminary result top expectation raise guidance
110,AGN,company also drop hostile bid mylan myl have agree buy allergan agn generic drug arm actavis
111,AGN,analyst speculate amgen abbvie abbv biogen biib shire shpg be allergan next potential takeover target
112,AGN,follow alissa william twitter ibd_awilliam day teva pharmaceutical teva break base fellow drugmaker amgen amgn be clear buy point amgen report second quarter result close thursday earning be project rise slowdown first quarter growth stock climb big volume stock market today clear early buy point amgen be also near conventional buy point currently trading level monday teva gap new high giant volume breaking cup base buy point share be still trading buy range today be teva announce preliminary result top expectation raise guidance company also drop hostile bid mylan myl have agree buy allergan agn generic drug arm actavis analyst speculate amgen abbvie abbv biogen biib shire shpg be allergan next potential takeover target follow alissa william twitter ibd_awilliam
113,AGN,israeli drug giant teva pharmaceutical industry drop hostile bid mylan instead agree buy global generic drug business allergan monday teva allergan stock jump new high mylan drop teva teva agree pay cash stock allergan agn actavis business
114,AGN,sector leader offer few stock final stage set base hover buy point be generic drug maker allergan agn be hover buy point flat base stock break july volume be well short more average
115,AGN,sector leader offer few stock final stage set base hover buy point be generic drug maker allergan agn be hover buy point flat base stock break july volume be well short more average
116,AGN,stock step rebound effort hit fresh session high tuesday afternoon major average have recoup more half monday steep loss more earning report mixed economic datum
117,AGN,lead pack gain monday benchmark index slump find support day line meanwhile dow jone industrial average nasdaq climb respectively volume be tracking modestly higher major exchange stock market today
118,AGN,lead stock icon iclr gap rocket retook day move average mixed result provider drug development service post second quarter earning view sale be mixed ep rise cent share revenue rise icon also raise full year profit outlook trim revenue guidance company also add stock buyback icon clear buy point flat base aggressive buyer have enter stock early entry
119,AGN,cadence design system cdns gap bolt clear day line reaction late monday better expect earning software maker post profit cent share year marked biggest gain quarters company also announce stock buyback cadence clear buy point flat base
120,AGN,downside baidu bidu gap plunge nearly report mixed result give weak revenue guidance late monday multiple analyst downgrade stock chinese internet stock hit month low
121,AGN,mylan myl be session low still fast trade news teva pharmaceutical teva buy allergan agn generic drug business send mylan share nearly monday stock step rebound effort hit fresh session high tuesday afternoon major average have recoup more half monday steep loss more earning report mixed economic datum lead pack gain monday benchmark index slump find support day line meanwhile dow jone industrial average nasdaq climb respectively volume be tracking modestly higher major exchange stock market today lead stock icon iclr gap rocket retook day move average mixed result provider drug development service post second quarter earning view sale be mixed ep rise cent share revenue rise icon also raise full year profit outlook trim revenue guidance company also add stock buyback icon clear buy point flat base aggressive buyer have enter stock early entry cadence design system cdns gap bolt clear day line reaction late monday better expect earning software maker post profit cent share year marked biggest gain quarters company also announce stock buyback cadence clear buy point flat base downside baidu bidu gap plunge nearly report mixed result give weak revenue guidance late monday multiple analyst downgrade stock chinese internet stock hit month low mylan myl be session low still fast trade news teva pharmaceutical teva buy allergan agn generic drug business send mylan share nearly monday
122,AGN,top generic drug maker composite rating be base ireland be far apart term annual sale market capitalization mallinckrodt mnk smaller player market cap sale make stock spotlight screen thursday issue comparison botox maker allergan agn have
123,AGN,stock future change tune point slightly weaker start stock market today nasdaq future fall point vs fair value future lose point future dow jone industrial average give point
124,AGN,stock market end week winning streak last week pickup distribution day prompt downgrade market outlook
125,AGN,stock market overseas be mixed europe france cac slip friday series attack islamic state left more dead germany dax rise london ftse climb
126,AGN,asia hong kong hang seng fall japan nikkei slump shanghai composite reversed higher gain
127,AGN,crude oil jump more barrel potential supply disruption oil price hit lowest level month last week
128,AGN,safe haven instrument such bond dollar be trading higher gold be also higher ounce
129,AGN,economic news empire state index november come vs consensus estimate econoday
130,AGN,number central bank official be speaking week start tuesday fed governor jerome powell minute fed october meeting be due wednesday
131,AGN,stock starwood hotel resort hot fall premarket trading news be buy marriott international mar cash stock deal create world biggest hotel chain
132,AGN,dd slump premarket trading post disappointing quarterly result department store operator say earn share include tax credit cent share sale slip view be ep revenue rival macy plunge last week disappointing quarterly sale weak outlook
133,AGN,airline stock be lower premaket activity concern friday attack tourism share american airline group aal delta air line dal unite continental ual ryanair ryaay be more
134,AGN,nyse nasdaq observe minute silence et victim paris terrorist attack friday
135,AGN,follow vincent mao twitter ibd_vmao stock future change tune point slightly weaker start stock market today nasdaq future fall point vs fair value future lose point future dow jone industrial average give point stock market end week winning streak last week pickup distribution day prompt downgrade market outlook stock market overseas be mixed europe france cac slip friday series attack islamic state left more dead germany dax rise london ftse climb asia hong kong hang seng fall japan nikkei slump shanghai composite reversed higher gain crude oil jump more barrel potential supply disruption oil price hit lowest level month last week safe haven instrument such bond dollar be trading higher gold be also higher ounce economic news empire state index november come vs consensus estimate econoday number central bank official be speaking week start tuesday fed governor jerome powell minute fed october meeting be due wednesday stock starwood hotel resort hot fall premarket trading news be buy marriott international mar cash stock deal create world biggest hotel chain dd slump premarket trading post disappointing quarterly result department store operator say earn share include tax credit cent share sale slip view be ep revenue rival macy plunge last week disappointing quarterly sale weak outlook airline stock be lower premaket activity concern friday attack tourism share american airline group aal delta air line dal unite continental ual ryanair ryaay be more nyse nasdaq observe minute silence et victim paris terrorist attack friday follow vincent mao twitter ibd_vmao
136,AGN,stock be pressure midday monday bring drop shanghai composite overnight well weakness europe
137,AGN,dow jone industrial average nasdaq lose shed volume main exchange be tracking higher friday level
138,AGN,institutional selling have be make presence feel market again particularly suffer fourth straight distribution day friday
139,AGN,decline stock outnumber advancer exchange more
140,AGN,stock market today wabtec wab jump nearly news acquire french railroad equipment maker faiveley transport
141,AGN,elsewhere teva teva gap flat base buy point rise news pay acquire generic business allergan agn allergan be ibd stock also ibd sector leader cup handle buy point have trouble get go stock find traction monday share rise
142,AGN,enanta enta top rate biotech re-cover friday drubbing share rise still trading cup handle buy point
143,AGN,meanwhile several name hold gain bullish gap last week include logmein logm network ffiv valeant vr
144,AGN,downside baidu bid slump ahead earning report close stock be pressure midday monday bring drop shanghai composite overnight well weakness europe dow jone industrial average nasdaq lose shed volume main exchange be tracking higher friday level institutional selling have be make presence feel market again particularly suffer fourth straight distribution day friday decline stock outnumber advancer exchange more stock market today wabtec wab jump nearly news acquire french railroad equipment maker faiveley transport elsewhere teva teva gap flat base buy point rise news pay acquire generic business allergan agn allergan be ibd stock also ibd sector leader cup handle buy point have trouble get go stock find traction monday share rise enanta enta top rate biotech re-cover friday drubbing share rise still trading cup handle buy point meanwhile several name hold gain bullish gap last week include logmein logm network ffiv valeant vr downside baidu bid slump ahead earning report close
145,AGN,patience be virtue manager mfs growth fund know experience fund gain top only large cap growth rival mutual fund track morningstar inc year return go tuesday top peer be yet investment approach have
146,AGN,wall street cheer wednesday federal reserve do exactly everybody expect month raise interest rate third day rally have lead several interesting breakout open analyst riley co upgrade blackbaud blkb buy neutral raise price target stock
147,AGN,week list lead stock buy point include healthy dose medical name biotechs manage care provider biotech revival begin prior celgene celg jump wednesday buy receptos rcpt celgene be extend past cup handle buy point gilead science gild be still play entry find support week move average move didn create new buy opportunity occur buy point stock be buy zone also buy range be regeneron pharmaceutical regn trading just flat base buy point pattern be late stage be not surprising give eye drug maker advance past year unite therapeutic uthr hasn yet break near buy point late stage flat base ibd stock lead drug be orenitram remodulin get composite rating biotechs moved ibd industry group week hospital claim top spot vs week back represent rank generic drug group allergan agn be just handle buy point clear monday formerly know actavis botox makerad double chin injection kybella june buy kythera mallinckrodt mnk also generic drug maker be work month consolidation buy point stock look poise third straight weekly gain close week line other medical stock ethical drug maker valeant pharmaceutical vrx be build flat base entry canadian company be leader rank group highest possible composite rating molina healthcare moh provider manage health care service low income family be near flat base buy point stock sharing composite manage care group
148,AGN,drugmaker deliver tasty return investor july pharmaceutical etfs top peer hold broadly diversify health care stock well focuse red hot biotechs powershare dynamic pharmaceutical pjp lag pharma etf peer month rise lead year date advance longer period produce annual average
149,AGN,flagship etfs nudge lower first trading day august par manufacturing spending datum well fall oil price weigh investor spdr spy exchange trade fund proxy broad market shrank early afternoon trade utility sector buck trend notch small gain energy be
150,AGN,good idea scan chart ibd top world stock find right now be stock basis buy range just buy point resolution eurozone crisis greece quickly mood global market market thrive clarity dive
151,AGN,top industry group medical sector show nice price action monday group have be long time market leader number stock group be shape late stage basis
152,AGN,share generic drug giant allergan agn formerly know actavis clear cup handle entry monday volume be modestly average allergan latest base correct mild be late stage stock relative strength line touch new high break add confirmation move
153,AGN,allergan report earning open aug analyst be look share earning climb sale sale estimate be boost recent allergan acquisition
154,AGN,also generic drug camp mallinckrodt mnk be tracking sideway consolidation date back march stock clear short handle buy point reversed lower trigger loss sell signal few week later handle only be see daily chart now mallinckrodt face test resistance day move average
155,AGN,biotech group celgene celg briefly clear handle buy point intraday retreat close volume be light flaw latest base pattern be majority base be form week move average line base also show week net distribution celgene report earning result market open july
156,AGN,regeneron pharmaceutical regn be approach buy point late stage flat base stock be find support week line have already make huge run make riskier buy stock break
157,AGN,alexion pharmaceutical alxn jump monday be try sixth straight weekly advance climb right side consolidation pattern stock be back time high set december month sideway action sharp drop spring
158,AGN,ethical drug group valeant pharmaceutical vrx be climb right side new late stage flat base pattern share hit peak have largely find support week move average latest pullback stock have highest possible composite rating valeant report second quarter result july open
159,AGN,abbvie abbv remain buy range cup handle monday jeffery raise earning estimate stock reiterate buy rating price target
160,AGN,analyst expect abbvie july open report ep growth second straight quarter double digit growth sale be expect climb be second quarter acceleration best quarterly revenue growth year abbvie be spun abbott laboratory early top industry group medical sector show nice price action monday group have be long time market leader number stock group be shape late stage basis share generic drug giant allergan agn formerly know actavis clear cup handle entry monday volume be modestly average allergan latest base correct mild be late stage stock relative strength line touch new high break add confirmation move allergan report earning open aug analyst be look share earning climb sale sale estimate be boost recent allergan acquisition also generic drug camp mallinckrodt mnk be tracking sideway consolidation date back march stock clear short handle buy point reversed lower trigger loss sell signal few week later handle only be see daily chart now mallinckrodt face test resistance day move average biotech group celgene celg briefly clear handle buy point intraday retreat close volume be light flaw latest base pattern be majority base be form week move average line base also show week net distribution celgene report earning result market open july regeneron pharmaceutical regn be approach buy point late stage flat base stock be find support week line have already make huge run make riskier buy stock break alexion pharmaceutical alxn jump monday be try sixth straight weekly advance climb right side consolidation pattern stock be back time high set december month sideway action sharp drop spring ethical drug group valeant pharmaceutical vrx be climb right side new late stage flat base pattern share hit peak have largely find support week move average latest pullback stock have highest possible composite rating valeant report second quarter result july open abbvie abbv remain buy range cup handle monday jeffery raise earning estimate stock reiterate buy rating price target analyst expect abbvie july open report ep growth second straight quarter double digit growth sale be expect climb be second quarter acceleration best quarterly revenue growth year abbvie be spun abbott laboratory early
161,AGN,greece china be biggest factor affect market earning season loom big element top foreign stock number drugmaker be slate deliver big increase bottom line mallinckrodt mnk be expect post fiscal third quarter earning share year solid mark
162,AGN,best mutual fund july performance report ibd new buy list show country lead stock mutual fund past month have continue gobble top rate medical stock such allergan agn celgene celg regeneron pharmaceutical regn molina healthcare moh acadium healthcare achc stock market july most part help mutual fund make
163,AGN,drug treat cure hepatitis have make biotech company envy industry biotech celgene be poise break ahead peer pack next few year
164,AGN,celgene celg sale profit growth be see rise double digit least multiple drug multiple disorder
165,AGN,meanwhile gilead science gild biotech firm hepatitis drug harvoni predecessor sovaldi be expect see earning slow low single digit time start patient cure liver virus
166,AGN,other big cap biotechs such amgen amgn biogen biib also fall far short celgene expect growth rate analyst say
167,AGN,celgene have best top line growth large biotech right now have fastest revenue earning growth next year say michael yee manage director analyst rbc capital market
168,AGN,next major mover
169,AGN,piper jaffray analyst tell client recent research report celgene be position be next major mover large cap biotech stock
170,AGN,note celgene be return name top large cap pick share have climb year
171,AGN,celgene have be especially active develop drug various cancer immune inflammatory disease
172,AGN,drug fight least common disease multiple myeloma be fastest grow
173,AGN,first revlimid be celgene top selling drug sale second quarter higher year earlier oral drug be used treat anemia multiple myeloma cancer blood affect plasma cell
174,AGN,sale pomalyst similar revlimid more potent increase last year make fastest grow company current lineup drug launch japan june
175,AGN,other drug currently generate revenue celgene include abraxane treat advanced cancer breast lung pancreas vidaza help bone marrow produce healthier blood cell otezla pill treat psoriasis psoriasis arthritis
176,AGN,sale second quarter prior year abraxane be celgene slower grow drug
177,AGN,goldman sachs analyst terence flynn note continue face competition breast lung cancer share treat pancreatic cancer now have be grow
178,AGN,analyst expect new indication geographic expansion keep abraxane peter
179,AGN,sale otezla food drug administration approve march totale
180,AGN,total revenue quarter rise analyst expect full year revenue rise earning be see grow share rise accord thomson reuter
181,AGN,lot more come other drug percolate wing celgene report late july ceo bob hugin say new transaction astrazeneca azn juno therapeutic juno receptos rcpt likely speed earning growth start
182,AGN,biggest deal announce mid july value be celgene pending acquisition receptos biotech firm lead drug ozanimod have show good result treat ulcerative colitis relapse multiple sclerosis
183,AGN,biggest biotech merger
184,AGN,higher bid doesn thwart deal be expect close third quarter be largest merger acquisition biotech drug industry year abbvie abbv bid pharmacyclic pcyc alexion alxn agreement merge synageva biopharma geva
185,AGN,celgene offer receptos amount share expire august
186,AGN,receptos oral pill ozanimod generate annual revenue ulcerative colitis alone ms yee say put peak sale total
187,AGN,phase datum ms be expect ulcerative colitis
188,AGN,oral drug celgene acquire last year licensing deal dublin ireland base nogra pharma generate well yee say know ged treat crohn disease phase trial be expect start later initially plan
189,AGN,have very robust pipeline partnership new growth driver multiple dollar opportunity next year yee say
190,AGN,earlier summer celgene announce year collaboration juno develop commercialize immunotherapy patient cancer autoimmune disease
191,AGN,celgene pay upfront buy share juno stock share also have right take stake juno
192,AGN,not full speed ahead overhang celgene stock note flynn remain potentially negative impact patent dispute shave year revlimid be patent protected
193,AGN,celgene be litigation allergan agn revlimid patent extend key challenge be patent now expire pretrial hearing be underway
194,AGN,yee expect side settle case go court drug treat cure hepatitis have make biotech company envy industry biotech celgene be poise break ahead peer pack next few year celgene celg sale profit growth be see rise double digit least multiple drug multiple disorder meanwhile gilead science gild biotech firm hepatitis drug harvoni predecessor sovaldi be expect see earning slow low single digit time start patient cure liver virus other big cap biotechs such amgen amgn biogen biib also fall far short celgene expect growth rate analyst say celgene have best top line growth large biotech right now have fastest revenue earning growth next year say michael yee manage director analyst rbc capital market next major mover piper jaffray analyst tell client recent research report celgene be position be next major mover large cap biotech stock note celgene be return name top large cap pick share have climb year celgene have be especially active develop drug various cancer immune inflammatory disease drug fight least common disease multiple myeloma be fastest grow first revlimid be celgene top selling drug sale second quarter higher year earlier oral drug be used treat anemia multiple myeloma cancer blood affect plasma cell sale pomalyst similar revlimid more potent increase last year make fastest grow company current lineup drug launch japan june other drug currently generate revenue celgene include abraxane treat advanced cancer breast lung pancreas vidaza help bone marrow produce healthier blood cell otezla pill treat psoriasis psoriasis arthritis sale second quarter prior year abraxane be celgene slower grow drug goldman sachs analyst terence flynn note continue face competition breast lung cancer share treat pancreatic cancer now have be grow analyst expect new indication geographic expansion keep abraxane peter sale otezla food drug administration approve march totale total revenue quarter rise analyst expect full year revenue rise earning be see grow share rise accord thomson reuter lot more come other drug percolate wing celgene report late july ceo bob hugin say new transaction astrazeneca azn juno therapeutic juno receptos rcpt likely speed earning growth start biggest deal announce mid july value be celgene pending acquisition receptos biotech firm lead drug ozanimod have show good result treat ulcerative colitis relapse multiple sclerosis biggest biotech mergersif higher bid doesn thwart deal be expect close third quarter be largest merger acquisition biotech drug industry year abbvie abbv bid pharmacyclic pcyc alexion alxn agreement merge synageva biopharma geva celgene offer receptos amount share expire august receptos oral pill ozanimod generate annual revenue ulcerative colitis alone ms yee say put peak sale total phase datum ms be expect ulcerative colitis oral drug celgene acquire last year licensing deal dublin ireland base nogra pharma generate well yee say know ged treat crohn disease phase trial be expect start later initially plan have very robust pipeline partnership new growth driver multiple dollar opportunity next year yee say earlier summer celgene announce year collaboration juno develop commercialize immunotherapy patient cancer autoimmune disease celgene pay upfront buy share juno stock share also have right take stake juno not full speed ahead overhang celgene stock note flynn remain potentially negative impact patent dispute shave year revlimid be patent protected celgene be litigation allergan agn revlimid patent extend key challenge be patent now expire pretrial hearing be underway yee expect side settle case go court
195,AGN,almost third stock sector leader list come highly rate medical industry only illumina ilmn be buy range several recent addition be worth watch gilead science gild have retreat buy point long cup base market week slide stock still boast
196,AGN,allergan specialty drug giant formerly know actavis say wednesday acquire biotech kythera cash stock send stock
197,AGN,just week kythera kyth win fda approval first product kybella injection submental fullness double chin allergan agn actavis acquire march take name be best know wrinkle injection botox supplement line facial aesthetic product include juvederm skinmedica
198,AGN,kybella be exciting new product offer patient first only clinically proven nonsurgical treatment submental fullness allergan ceo brent saunder say statement kybella be also pivotal entry point expand use facial aesthetic product man kythera setipiprant hair loss development program drive additional long term value
199,AGN,allergan be pay share kythera premium tuesday close price double kythera stock price start year term be paid cash kythera stock rise wednesday allergan stock rise fraction
200,AGN,fda approve kybella only recently so deal win be accretive allergan earning evercore isi analyst umer raffat write email client
201,AGN,be perfectly add fact deal validate long term growth thesis allergan
202,AGN,bigger sale force tout
203,AGN,kythera retain full responsibility pricing launch kybella deal close third quarter kythera sale force merge allergan leerink analyst seamus fernandez write research note deal expand kybella peak sale potential
204,AGN,allergan broader sale force deeper relationship physician access point facilitate faster deeper launch exist indication not mention promise allergan grow full face offering recent success launch premium brand juvederm voluma fernandez write outside kybella be already file switzerland australia canada plan file decentralize eu procedure
205,AGN,allergan expertise resource facilitate sooner faster launch model peak sale peak ex sale upside pricing
206,AGN,other hand bernstein analyst ronny gal write kybella fall short number mean allergan be overpay give reason
207,AGN,be very few aesthetic product crossed botox filler product treatment profile be not ideal candidate be big seller ii ramp product be slow look filler example iii kybella be approve drug be relatively easy manufacture ob orange book patent expire orange book be fda list approve drug product
208,AGN,still edison investment research analyst maxim jacob consider buyout brainer
209,AGN,allergan decision acquire kythera be likely not hard double chin treatment kybella be exactly type product allergan excel selling member senior management team have spend total year allergan write email
210,AGN,news have also lift share zeltiq aesthetic zltq maker body sculpting system be be co market allergan filler pilot program launch december company be also launch double chin product own
211,AGN,leerink analyst richard newitter write research note physician source say zeltiq coolmini kybella be used together rather compete depend price however isn sure happen allergan deal
212,AGN,extent allergan want continue push additional noninvasive fat area be read positive sign company be investing kythera be several strategic move road newitter write also see argument be perhaps writing wall suggest allergan be make bet kythera further collaboration zeltiq take back seat
213,AGN,zeltiq stock rise
214,AGN,newitter also note other maker aesthetic system syneron medical elos cynosure cyno be just enter invasive fat reduction market therefore be more attractive candidate day share syneron cynosure be most wedneday finished
215,AGN,kythera stock go public october already be trading new high past couple day lofty ibd relative strength rating allergan be ibd top rank drugmaker highest possible composite rating allergan specialty drug giant formerly know actavis say wednesday acquire biotech kythera cash stock send stock just week kythera kyth win fda approval first product kybella injection submental fullness double chin allergan agn actavis acquire march take name be best know wrinkle injection botox supplement line facial aesthetic product include juvederm skinmedica kybella be exciting new product offer patient first only clinically proven nonsurgical treatment submental fullness allergan ceo brent saunder say statement kybella be also pivotal entry point expand use facial aesthetic product man kythera setipiprant hair loss development program drive additional long term value allergan be pay share kythera premium tuesday close price double kythera stock price start year term be paid cash kythera stock rise wednesday allergan stock rise fraction fda approve kybella only recently so deal win be accretive allergan earning evercore isi analyst umer raffat write email client be perfectly add fact deal validate long term growth thesis allergan bigger sale force toutedkythera retain full responsibility pricing launch kybella deal close third quarter kythera sale force merge allergan leerink analyst seamus fernandez write research note deal expand kybella peak sale potential allergan broader sale force deeper relationship physician access point facilitate faster deeper launch exist indication not mention promise allergan grow full face offering recent success launch premium brand juvederm voluma fernandez write outside kybella be already file switzerland australia canada plan file decentralize eu procedure allergan expertise resource facilitate sooner faster launch model peak sale peak ex sale upside pricing other hand bernstein analyst ronny gal write kybella fall short number mean allergan be overpay give reason be very few aesthetic product crossed botox filler product treatment profile be not ideal candidate be big seller ii ramp product be slow look filler example iii kybella be approve drug be relatively easy manufacture ob orange book patent expire orange book be fda list approve drug product still edison investment research analyst maxim jacob consider buyout brainer allergan decision acquire kythera be likely not hard double chin treatment kybella be exactly type product allergan excel selling member senior management team have spend total year allergan write email news have also lift share zeltiq aesthetic zltq maker body sculpting system be be co market allergan filler pilot program launch december company be also launch double chin product own leerink analyst richard newitter write research note physician source say zeltiq coolmini kybella be used together rather compete depend price however isn sure happen allergan deal extent allergan want continue push additional noninvasive fat area be read positive sign company be investing kythera be several strategic move road newitter write also see argument be perhaps writing wall suggest allergan be make bet kythera further collaboration zeltiq take back seat zeltiq stock rise newitter also note other maker aesthetic system syneron medical elos cynosure cyno be just enter invasive fat reduction market therefore be more attractive candidate day share syneron cynosure be most wedneday finished kythera stock go public october already be trading new high past couple day lofty ibd relative strength rating allergan be ibd top rank drugmaker highest possible composite rating
216,AGN,share zoetis zts friday more erased thursday surge talk valeant be eyee animal health company zoetis share plummet stock market today activist investor bill ackman hedge fund persh square be company largest shareholder stake valeant pharmaceutical vrx reportedly make preliminary approach
217,AGN,drugmaker related stock have have rough couple week amex biotechnology index have slip fraction so far week fall nearly high week ishare nasdaq biotech fund ibb be little change week slide last week
218,AGN,industry group ibd biotech group still rank industry group fall nearly past session third deepest loss industry year date biotech group be still top industry performance
219,AGN,recent pressure top international pharmaceutical industry stock break space week be unusual cluster bullish price move reflect strength drug industry
220,AGN,dublin ireland base icon iclr isn drugmaker be world top provider clinical research service be vital pharmaceutical development share spiked nearly tuesday report better forecast jump earning share revenue gain be short expectation management raise full year earning guidance consensus projection expand share buyback initiative stock end wednesday extend flat base buy point
221,AGN,dublin company jazz pharmaceutical jazz ground gain heavy trade tuesday stock clear flat base buy point stock duck back buy point almost equally heavy trade wednesday company report result aug
222,AGN,shire shpg break powerful trade flat base buy point week report second quarter result reversed follow day drop nearly buy point share wednesday be back buy point still well buy range
223,AGN,teva pharmaceutical teva headquarter petach tikva israel swat huge volume gain monday drugmaker report strong second quarter beat bottom top line also announce pay generic drugmake unit allergan agn
224,AGN,teva jump flat base buy point also clear march high move new high ground drugmaker related stock have have rough couple week amex biotechnology index have slip fraction so far week fall nearly high week ishare nasdaq biotech fund ibb be little change week slide last week industry group ibd biotech group still rank industry group fall nearly past session third deepest loss industry year date biotech group be still top industry performance recent pressure top international pharmaceutical industry stock break space week be unusual cluster bullish price move reflect strength drug industry dublin ireland base icon iclr isn drugmaker be world top provider clinical research service be vital pharmaceutical development share spiked nearly tuesday report better forecast jump earning share revenue gain be short expectation management raise full year earning guidance consensus projection expand share buyback initiative stock end wednesday extend flat base buy point dublin company jazz pharmaceutical jazz ground gain heavy trade tuesday stock clear flat base buy point stock duck back buy point almost equally heavy trade wednesday company report result aug shire shpg break powerful trade flat base buy point week report second quarter result reversed follow day drop nearly buy point share wednesday be back buy point still well buy range teva pharmaceutical teva headquarter petach tikva israel swat huge volume gain monday drugmaker report strong second quarter beat bottom top line also announce pay generic drugmake unit allergan agn teva jump flat base buy point also clear march high move new high ground
225,AGN,several actively manage etfs hold diversify equity be beating passive index peer so far columbia large cap growth rpx deliver gain year date july comparison ishare russell growth iwf be rpx average gain past year also beat russell growth benchmark so successful investing strategy fund manager select fast grow stock average prospect strong balance sheet clear competitive advantage apple aapl be hold asset other top list include ibd leaderboard stock facebook fb palo alto network panw mckesson mck visa well ibd sector leader allergan agn most actively manage etfs be relatively new hold diversify stock rpx be few have year history annual average gain period be line russell growth benchmark rpx have expense ratio vs iwf trading volume be average asset total meager etf performance be attract notice absorb first half year top perform health care technology sector be biggest allocation account more half asset combine visa be buy point flat base facebook jump back buy range thursday lackluster action june rpx be old high etf have be range bound several month rise stock market today broad gain follow aparna narayanan twitter ibd_anarayanan
226,AGN,stock end lower light volume monday concern federal reserve appear poise raise interest rate early next month nasdaq dow jone industrial average fall volume fall nasdaq nyse compare friday accord preliminary datum trader increase bet federal reserve soon raise interest rate follow friday strong job report saddle consumer higher borrow cost boost dollar slow economy leisure discretionary consumer stock be hit hardest stock market todayonline travel broker priceline com pcln plunge nearly weak outlook overshadowed better expect earning report stock sank buy point cup type base slice day move average meanwhile gamble stock fall expectation weakness chinese gamble enclave macau world top gaming destination wynn resort wynn fall more la vegas sand lvs sank mgm resort international mgm slip upside ibd stock linkedin lnkd rise continue climb right side deep cup type base buy point horton dhi luxoft lxft zebra technology zbra amdocs dox be company due report quarterly earning tuesday economic datum schedule tuesday include import export price october wholesale inventory september
227,AGN,market back time high number sector leader be back stock be extend other be still deep basis be near buy point form handle be allergan agn old leader new name former actavis group acquire botox maker
228,AGN,horizon pharma hznp have turn nearly deal year continue hunt drug acquisition ub say friday raise price target horizon pharma stock well revenue estimate research report ub analyst marc goodman ami fadium write track record balance sheet
229,AGN,eagle pharmaceutical have soar new height wall street signing key licensing pact enhance company prospect hit market soon big money make drug eagle pharmaceutical egrx stock have leap feb company announce have inked exclusive license agreement cephalon wholly own subsidiary israeli drug giant teva pharmaceutical industry teva eagle bendamustine hydrochloride hcl rapid infusion product treat patient chronic lymphocytic leukemia cll patient indolent cell hodgkin lymphoma nhl teva dealteva be responsible product commercial activity include promotion distribution eagle be responsible obtain regulatory approval conduct post approval clinical study require initially supply drug product teva term pact eagle receive upfront cash payment be recognize income be eligible receive additional milestone payment milestone payment eagle say get double digit percentage royalty net sale product assume food drug administration approval draw investor be eagle have very credible partner teva have ability deliver royalty william blair analyst tim lugo tell ibd lugo estimate royalty payment eagle get teva start product sale eagle be focuse develop commercialize injectable drug product primarily critical care oncology area improve exist drug go speak stakeholder physician nurse doctor find gap be product need be improve ceo founder scott tarriff tell ibd reformulate drug hopefully bring drug market customer be ask hopefully re improve patient outcome drug introduction strategyeagle strategy be introduce product later first generic competitor brand reference product say company filing security exchange commission eagle bendamustine rapid infusion product be improve formulation teva bendamustine hcl product treanda expect teva convert nearly treanda product market eagle formulation tarriff say be eagle product better treanda eagle product be administer approximately minute low volume milliliter admixture vs treanda milliliter admixture require infusion last minute tarriff say benefit eagle product be less chair time patient less nursing time require tarriff add fda accept new drug application nda filing dec expect decision date approve rapid infusion bendamustine product treat patient cll patient indolent cell nhl have progressed month treatment rituximab rituximab contain regimen eagle used fda nda regulatory pathway section expressly permit fda rely approval nda datum not develop applicant such publish literature agency find safety effectiveness previously approve drug product accord fda patent trademark office grant new patent pertain rapid infusion bendamustine product eagle announce last month patent expire march product have receive orphan drug designation cll indolent cell nhl therefore be eligible year exclusivity approval eagle say press release tarriff estimate market treanda be tarriff say founding eagle have be develop drug have change agreement teva tarriff call big breakthrough be transition development company commercial company say tarriff teva use eagle bendamustine rapid infusion product own life cycle product used capital infusionlugo say agreement teva be game changer eagle company have significant royalty start say question street be be company go deploy capital eagle go public february turn first profit first quarter company earn share vs loss cent year earlier revenue jump lugo say upfront cash payment teva drive eagle profit however add profit win be sustainable company gain fda approval bendamustine rapid infusion product approval come fourth quarter drive profitability lugo say analyst poll thomson reuter expect company show full year earning cent share expect earning increase see rise eagle treatment portfolioeagle have portfolio drug have drug market ryanodex injectable suspension treat rare life threaten condition call malignant hyperthermia fda approve last summer fda designate ryanodex orphan drug malignant hyperthermia fda have grant year market exclusivity ryanodex treat condition eagle announce february first quarter ryanodex sale be higher prior quarter reflect successful execution product launch last fall ongoing effort sale force say tarriff press release eagle be research potential ryanodex be apply exertional heat stroke eagle also have file ndas fda other drug be work clinical trial yet drug lugo say eagle bendamustine rapid infusion product be key drug company have several other drug pipeline be promising eagle be part ibd medical generic drug industry group have composite rating possible other member group include allergan agn lead group composite rating mylan myl have composite rating
230,AGN,stock future post modest gain ahead wednesday open market settle afternoon policy announcement federal reserve
231,AGN,dow future be early high point fair market value nasdaq future be point vs point gain hour earlier future halved gain past hour point
232,AGN,global market be generally calmer stock market today past day ahead federal reserve policy decision afternoon real progress eurozone bailout negotiation greece europe lead index be lower midday show loss less
233,AGN,monetary policy report release wednesday central bank greece warn fail negotiation bailout funding place country painful course lead default follow exit eurozone
234,AGN,warn country be risk second quarter decline gdp depositor have withdraw greek institution october april also say greece creditor have reach consensus major element necessary agreement difference remain be comparatively small manageable
235,AGN,energy information administration report weekly oil inventory et
236,AGN,otherwise economic calendar be generally quiet ahead federal reserve policy announcement set press conference schedule
237,AGN,stock biotechs continue buzz
238,AGN,kythera kyth spark open news allergan agn buy maker double chin reduce treatment share bid be kythera close price tuesday
239,AGN,kythera management have reportedly claim treatment kybella federally approve release april generate more revenue kythera end tuesday buy point month cup handle base allergan share be unchanged wednesday premarket action
240,AGN,fedex fdx groan lower more report fiscal earning revenue miss consensus growth target ground delivery top expectation express freight revenue miss projection fedex have be carve long shallow consolidation december
241,AGN,number china base issue grab broad premarket gain
242,AGN,qihoo qihu pop ceo hongyi zhou offer take company private share bid be qihoo close price tuesday stock have climb march low remain month correction
243,AGN,yy yy jump start bell social networking site end tuesday march low midpoint month consolidation
244,AGN,china market bounce couple hard day shanghai composite rise hong kong hang seng index add tokyo nikkei japan dip
245,AGN,dollar be mixed vs euro yen oil price punch higher nearly putt west texas intermediate back barrel gold edge fraction just ounce stock future post modest gain ahead wednesday open market settle afternoon policy announcement federal reserve dow future be early high point fair market value nasdaq future be point vs point gain hour earlier future halved gain past hour point global market be generally calmer stock market today past day ahead federal reserve policy decision afternoon real progress eurozone bailout negotiation greece europe lead index be lower midday show loss less monetary policy report release wednesday central bank greece warn fail negotiation bailout funding place country painful course lead default follow exit eurozone warn country be risk second quarter decline gdp depositor have withdraw greek institution october april also say greece creditor have reach consensus major element necessary agreement difference remain be comparatively small manageable energy information administration report weekly oil inventory et otherwise economic calendar be generally quiet ahead federal reserve policy announcement set press conference schedule stock biotechs continue buzz kythera kyth spark open news allergan agn buy maker double chin reduce treatment share bid be kythera close price tuesday kythera management have reportedly claim treatment kybella federally approve release april generate more revenue kythera end tuesday buy point month cup handle base allergan share be unchanged wednesday premarket action fedex fdx groan lower more report fiscal earning revenue miss consensus growth target ground delivery top expectation express freight revenue miss projection fedex have be carve long shallow consolidation december number china base issue grab broad premarket gain qihoo qihu pop ceo hongyi zhou offer take company private share bid be qihoo close price tuesday stock have climb march low remain month correction yy yy jump start bell social networking site end tuesday march low midpoint month consolidation china market bounce couple hard day shanghai composite rise hong kong hang seng index add tokyo nikkei japan dip dollar be mixed vs euro yen oil price punch higher nearly putt west texas intermediate back barrel gold edge fraction just ounce
246,AGN,stock climb tuesday extend rebound remove more gloom market nasdaq lead advance biotechs be source strength composite index third straight day climb aid largely energy sector rally international agreement eventually let iran put
247,AGN,breakout be important growth investor even more important especially current stock market be strong follow action fast develop profit cushion allow investor sit tight possibly build gain monday sector leader be show pretty good action padding recent gain padding gain be critical market
248,AGN,rocky week trading create turmoil ibd semiconductor stock particular have be fire longtime chip leader ibd have flash sell signal make huge move market technology avgo fall more week buy point late stage base pattern previously
249,AGN,market be pace third straight weekly decline only few sell signal have be trigger weekly review santander consumer usa sc set round trip sell signal erase gain flat base april sell start monday santander slice day move average news ceo thomas dundon be step
250,AGN,chinese video game firm netease nte be bounce back huge swoon early week stock briefly erased gain past cup buy point remember sound portfolio management rule be take least profit amount
251,AGN,positive side number lead stock be still shape basis market pull back stock columbia sportswear colm fleetmatic group fltx edward lifescience ew allergan agn be shape fresh cup handle pattern
252,AGN,fleetmatic be testing support day move average strong advance recent lows stock handle be show buy point flaw base be volume be mostly light stock climb right side pattern
253,AGN,columbia sportswear be week shallow pattern buy point similar fleetmatic upside volume pattern have be lackluster
254,AGN,edward lifescience show better accumulation base share surge week end june heaviest weekly volume nearly year june edward lifescience announce fda approval latest heart valve sapien treatment high risk patient stock rs line be new high be also bullish
255,AGN,allergan be sit just buy point find support day move average trading base have be tight late stage pattern add risk market be pace third straight weekly decline only few sell signal have be trigger weekly review santander consumer usa sc set round trip sell signal erase gain flat base april sell start monday santander slice day move average news ceo thomas dundon be step chinese video game firm netease nte be bounce back huge swoon early week stock briefly erased gain past cup buy point remember sound portfolio management rule be take least profit amount positive side number lead stock be still shape basis market pull back stock columbia sportswear colm fleetmatic group fltx edward lifescience ew allergan agn be shape fresh cup handle pattern fleetmatic be testing support day move average strong advance recent lows stock handle be show buy point flaw base be volume be mostly light stock climb right side pattern columbia sportswear be week shallow pattern buy point similar fleetmatic upside volume pattern have be lackluster edward lifescience show better accumulation base share surge week end june heaviest weekly volume nearly year june edward lifescience announce fda approval latest heart valve sapien treatment high risk patient stock rs line be new high be also bullish allergan be sit just buy point find support day move average trading base have be tight late stage pattern add risk
256,AGN,major stock index world get woozy stock leader act expect decline be lot sharper reason usually have lot gain give back international market be fall hard however keen speculator gain opportunity opportunity be see stock fall less peer get buy support important price level conduct quieter trading day week price once market correction have end fresh rally have begin stronger stock be much better position complete basis break swift decline chinese stock market have place bear market territory tuesday close shanghai composite have fall much week peak shenzhen composite index view many china tech heavy nasdaq finished tuesday trade june high kind decline not be surprised see commerce powerhouse alibaba baba lot stock make nice reversal tuesday close just only poke new lows follow ipo last year now peak take month alibaba recover high possibly break again course baozun bzun featured here june get trample tuesday online retail service expert chinese website drop heavy trade well nasdaq debut baozun have post straight quarters earning year street see full year profit cent share vipshop vip biggest winner market be try bottom online flash sale champ be peak limit decline odd solid base form go israel inverter system maker solaredge technology sedg have collapse recently form day move average watch potential new base emerge fiscal end june solaredge be see post first ever profit cent share then boost fiscal netherlands base nxp semiconductor nxpi france criteo crto allergan agn ireland have show far milder decline
257,AGN,big health insurer want get bigger cut cost fatten profit course seem be move faster now consolidate response merger elsewhere health care system
258,AGN,bigger pharmaceutical company merge hospital require larger more powerful insurer represent patient
259,AGN,so eager perhaps prove determination investor anthem antm last week take unusual step publicize detail takeover talk cigna ci lead bloomfield conn base cigna publicly admit deeply disappoint anthem disclose latest offer
260,AGN,meanwhile humana hum have offer sale be be pursue aetna aet reportedly be be court unitedhealth group unh nation largest health insurer
261,AGN,possible post merger scenario include anthem aetna unitedhealth lord health insurance sector be just anthem unitedhealth dust settle
262,AGN,now big insurer also be feel more pressure merge soon possible know subsequent proposal invite greater antitrust scrutiny
263,AGN,big health insurer be too big too late avoid critic
264,AGN,lack competition clearly exist today speak loudly further consolidation health insurance industry chairman american academy family physician write federal trade commission month
265,AGN,address rise cost
266,AGN,still reason cut cost gain leverage merger
267,AGN,last year prescription drug spending rise record accord im institute healthcare informatic hepatitis treatment most expensive new blockbuster
268,AGN,consolidation give insurer more leverage negotiate price doctor hospital drugmaker other sector health care industry have consolidated rapidly lately
269,AGN,re try scale order get more leverage contract drug manufacturer other health care provider say jeffrey loo analyst capital iq
270,AGN,insurer be feel more pressure grow now have just absorb new patient
271,AGN,obamacare creation federally subsidize insurance exchange used state have provide new option million newly insure consumer only last year
272,AGN,health care be busiest industry consolidation year rite aid rad agree buy envision pharmaceutical service february next month unitedhealth buy pharmacy benefit manager catamaran ctrx cvs health cvs agree month pay buy target tgt pharmacy state
273,AGN,tenet healthcare thc hca hca other major hospital operator have gobble smaller player recent year
274,AGN,drugmaker be slouch department april teva pharmaceutical industry teva bid mylan myl perrigo prgo reject mylan bid march dublin base actavis complete acquisition allergan create world top pharmaceutical company sale estimate june actavis change name allergan agn
275,AGN,nonprofit such kaiser permanente blue cross blue shield be seek grow exchange morningstar vishnu lekraj say
276,AGN,medicaid expansion federal government be ripple rest market
277,AGN,big health insurer revenue have be grow high single digit margin have be relatively flat loo say
278,AGN,striking hot iron
279,AGN,merger mania have strike health insurance sector big time stock be best performer market anthem cigna aetna share hit record high again tuesday unitedhealth gain so far year record tuesday jan humana share flattened tuesday ibd medical manage care industry group have rise past year compare gain
280,AGN,kind consolidation big company say gerald kominski director ucla center health policy research really only way grow faster organic growth big health insurer want get bigger cut cost fatten profit course seem be move faster now consolidate response merger elsewhere health care system bigger pharmaceutical company merge hospital require larger more powerful insurer represent patient so eager perhaps prove determination investor anthem antm last week take unusual step publicize detail takeover talk cigna ci lead bloomfield conn base cigna publicly admit deeply disappoint anthem disclose latest offer meanwhile humana hum have offer sale be be pursue aetna aet reportedly be be court unitedhealth group unh nation largest health insurer possible post merger scenario include anthem aetna unitedhealth lord health insurance sector be just anthem unitedhealth dust settle now big insurer also be feel more pressure merge soon possible know subsequent proposal invite greater antitrust scrutiny big health insurer be too big too late avoid critic lack competition clearly exist today speak loudly further consolidation health insurance industry chairman american academy family physician write federal trade commission month address rise reason cut cost gain leverage merger last year prescription drug spending rise record accord im institute healthcare informatic hepatitis treatment most expensive new blockbuster consolidation give insurer more leverage negotiate price doctor hospital drugmaker other sector health care industry have consolidated rapidly lately re try scale order get more leverage contract drug manufacturer other health care provider say jeffrey loo analyst capital iq insurer be feel more pressure grow now have just absorb new patient obamacare creation federally subsidize insurance exchange used state have provide new option million newly insure consumer only last year health care be busiest industry consolidation year rite aid rad agree buy envision pharmaceutical service february next month unitedhealth buy pharmacy benefit manager catamaran ctrx cvs health cvs agree month pay buy target tgt pharmacy state tenet healthcare thc hca hca other major hospital operator have gobble smaller player recent year drugmaker be slouch department april teva pharmaceutical industry teva bid mylan myl perrigo prgo reject mylan bid march dublin base actavis complete acquisition allergan create world top pharmaceutical company sale estimate june actavis change name allergan agn nonprofit such kaiser permanente blue cross blue shield be seek grow exchange morningstar vishnu lekraj say medicaid expansion federal government be ripple rest market big health insurer revenue have be grow high single digit margin have be relatively flat loo say striking hot ironsmerger mania have strike health insurance sector big time stock be best performer market anthem cigna aetna share hit record high again tuesday unitedhealth gain so far year record tuesday jan humana share flattened tuesday ibd medical manage care industry group have rise past year compare gain kind consolidation big company say gerald kominski director ucla center health policy research really only way grow faster organic growth
281,AGN,irish drugmaker jazz pharmaceutical jazz break extend st patrick week rally stock break past buy point second stage base wednesday average volume be more entry jazz re-cover fail past late february stock hasn make much headway past
282,AGN,specialty drugmaker endo international withdraw offer salix pharmaceutical monday valeant pharmaceutical international enlarged buyout deal investor seem happy stock go valeant vrx raise offer share cash share company agree last month new term also add
283,AGN,valeant pharmaceutical vrx be reportedly mull higher bid salix pharmaceutical slxp even valeant investor bill ackman say win overpay valeant be consider raise cash offer share accord multiple report cite source be originally report friday afternoon new york time valeant plan weekend meeting discuss issue
284,AGN,stock continue hold session high monday afternoon pullback dollar round weaker expect economic datum drop oil price dow jone industrial average lead gain broader rally nasdaq climb volume be run lower major exchange stock market today crude oil be barrel hit year low barrel earlier host medical stock show strength monday edward lifescience ew stretched gain medical device maker release positive study result weekend sunday company say positive result patient treat sapien transcatheter aortic valve point early fda approval edward clear flat base buy point salix pharmaceutical slxp rise valeant pharmaceutical vrx raise buyout offer company rival suitor endo international endp have now drop bid salix share valeant endo be actavis act rise more time high news european regulator clear buyout botox maker allergan agn share actavis be now past buy point flat base downside madison square garden msg be session low still more follow ceo tad departure year job still stock fall back buy point flat base clear early february
285,AGN,stock be hold session high go noon hour monday volume be tracking lower stock market today
286,AGN,crude oil drop nearly bring west texas intermediate lowest level late january
287,AGN,tesla motor tsla rise nearly ceo elon musk take twitter announce hold press conference thursday address concern battery range model
288,AGN,edward lifescience ew bolt more huge volume company say positive result patient treat sapien transcatheter aortic valve point early fda approval edward clear flat base buy point
289,AGN,netflix nflx tumble nearly evercore downgrade share hold sell lower price target trading stock gap be struggle support day move average
290,AGN,specialty drugmaker endo international endp withdraw offer salix pharmaceutical slxp valeant vrx sweeten offer
291,AGN,valeant raise bid share cash share company have agree last month
292,AGN,endo rise salix valeant rise
293,AGN,share actavis act allergan agn hit fresh time high european commission approve merger stock be hold session high go noon hour monday volume be tracking lower stock market today crude oil drop nearly bring west texas intermediate lowest level late january tesla motor tsla rise nearly ceo elon musk take twitter announce hold press conference thursday address concern battery range model edward lifescience ew bolt more huge volume company say positive result patient treat sapien transcatheter aortic valve point early fda approval edward clear flat base buy point netflix nflx tumble nearly evercore downgrade share hold sell lower price target trading stock gap be struggle support day move average specialty drugmaker endo international endp withdraw offer salix pharmaceutical slxp valeant vrx sweeten offer valeant raise bid share cash share company have agree last month endo rise salix valeant rise share actavis act allergan agn hit fresh time high european commission approve merger
294,AGN,drug industry recent spate deal get shot arm monday bristol myer squibb announce plan acquire privately hold drugmaker day valeant pharmaceutical international vrx say buy salix pharmaceutical bristol myer squibb bmy early monday agree buy flexus bioscience san carlos
295,AGN,treasury department crackdown tax inversion last year have slow not stop movement headquarters abroad american business try reduce tax bill foreign firm seek grow indeed company now virtually bar relocate overseas order trim taxe obama administration new rule have turn corporate america
296,AGN,valeant pharmaceutical international vrx confirm sunday buy smaller rival salix share total enterprise value company board have approve cash offer expect merger yield more cost saving boost ep salix pharmaceutical slxp share rise
297,AGN,market many stock have show choppy action valeant pharmaceutical international vrx have continue make steady progress stock be look eighth straight weekly gain be hold firm record high clear buy point week tight pattern give investor chance buy share be confident
298,AGN,irish drugmaker actavis top quarterly sale profit view wednesday say change corporate name better reflect transition provider mostly generic drug brand pharmaceutical firm dublin base company change name allergan agn close buyout botox maker later year
299,AGN,market be trading quietly mixed last trading session holiday shorten week coast noon hour
300,AGN,nasdaq composite dow jone industrial average be flat drop stock market today
301,AGN,salix pharmaceutical slxp valeant pharmaceutical vrx be top performer ibd respectively cnbc report valeant be close buy salix
302,AGN,actavis act ibd name rise company be take allergan agn name be acquire actavis also report better expect earning wednesday
303,AGN,amn healthcare service gap be trading higher supplier medical staff health care facility report better expect earning close thursday
304,AGN,mohawk industry mhk gap be trading higher time high also report good quarter
305,AGN,intuit intu jump serve fiscal second quarter report late thursday maker turbotax quicken quickbook software product report narrower expect loss earning growth consensus forecast stock have retake week move average be work right side shallow month consolidation market be trading quietly mixed last trading session holiday shorten week coast noon hour nasdaq composite dow jone industrial average be flat drop stock market today salix pharmaceutical slxp valeant pharmaceutical vrx be top performer ibd respectively cnbc report valeant be close buy salix actavis act ibd name rise company be take allergan agn name be acquire actavis also report better expect earning wednesday amn healthcare service gap be trading higher supplier medical staff health care facility report better expect earning close thursday mohawk industry mhk gap be trading higher time high also report good quarter intuit intu jump serve fiscal second quarter report late thursday maker turbotax quicken quickbook software product report narrower expect loss earning growth consensus forecast stock have retake week move average be work right side shallow month consolidation
306,AGN,nordisk nvo stock rise sharply friday danish maker diabetes therapy say successfully complete phase trial new oral diabetes drug mark milestone diabetes therapy
307,AGN,drug call og be used type diabetes be oral version semaglutide once weekly glp glucagon peptide analogue drug work promote body natural production insulin way help patient lose weight relieve type diabetes symptom
308,AGN,industry fiercebiotech note friday morning report week patient trial be design determine ideal dose drug
309,AGN,diabetic take mg og highest dose chart reduction blood be marker glucose level report say comparison mg weekly inject semaglutide lead reduction placebo lower
310,AGN,say press release semaglutide appear have safe well tolerate profile trial most common adverse event be related system primarily nausea vomit diminish time
311,AGN,be very pleased result trial confirm potential semaglutide treat type diabetes once weekly subcutaneous injection once daily tablet mad krogsgaard thomsen executive vice president chief science officer say statement clinical proof concept mark important milestone oral peptide therapy field diabetes
312,AGN,base result initiate talk regulatory authority decision be make progress og phase development
313,AGN,nordisk stock be morning trading stock market today more month high stock have be volatile past several month touch record high drop low jan feb
314,AGN,have good not great ibd composite rating be part ibd medical ethical drug group rank industry track
315,AGN,top rate stock group include allergan agn be be acquire actavis act actavis wednesday post better expect earning sale announce take allergan name acquisition be finalize
316,AGN,other group member include salix pharmaceutical slxp company slate release earning tuesday valeant pharmaceutical vrx jazz pharmaceutical jazz nordisk nvo stock rise sharply friday danish maker diabetes therapy say successfully complete phase trial new oral diabetes drug mark milestone diabetes therapy drug call og be used type diabetes be oral version semaglutide once weekly glp glucagon peptide analogue drug work promote body natural production insulin way help patient lose weight relieve type diabetes symptom industry fiercebiotech note friday morning report week patient trial be design determine ideal dose drug diabetic take mg og highest dose chart reduction blood be marker glucose level report say comparison mg weekly inject semaglutide lead reduction placebo lower say press release semaglutide appear have safe well tolerate profile trial most common adverse event be related system primarily nausea vomit diminish time be very pleased result trial confirm potential semaglutide treat type diabetes once weekly subcutaneous injection once daily tablet mad krogsgaard thomsen executive vice president chief science officer say statement clinical proof concept mark important milestone oral peptide therapy field diabetes base result initiate talk regulatory authority decision be make progress og phase development nordisk stock be morning trading stock market today more month high stock have be volatile past several month touch record high drop low jan feb have good not great ibd composite rating be part ibd medical ethical drug group rank industry track top rate stock group include allergan agn be be acquire actavis act actavis wednesday post better expect earning sale announce take allergan name acquisition be finalize other group member include salix pharmaceutical slxp company slate release earning tuesday valeant pharmaceutical vrx jazz pharmaceutical jazz
317,AGN,earning season be still chug past president day several major drugmaker technology company yet disclose eagerly anticipate result
318,AGN,today ibd roundup take peek hot biotechs laser focuse tech firm report week
319,AGN,actavis act have already offer early view result dublin headquarter specialty pharmaceutical company hyped figure last month say earning exceed then consensus estimate lead strong international sale growth fda approval alzheimer drug namzaric
320,AGN,wall street now anticipate share earning year year increase jump revenue drugmaker report wednesday
321,AGN,ep advance mark sharp slowdown past year actavis have register least earning growth previous consecutive quarters
322,AGN,friday actavis say have agree divest aptalis pharmaceutical technology business private equity firm tpg undisclosed term news follow monday announcement divest right doryx brand acne treatment mayne pharma approximately
323,AGN,sell off actavis have be buy spree recent year acquire irish pharma warner chilcott forest laboratory last year november secure deal take botox maker allergan agn lengthy bidding war valeant pharmaceutical vrx
324,AGN,medicine maker pharmacyclic pcyc also report close wednesday analyst expect earning decline cent rise revenue
325,AGN,share sunnyvale calif base biotech shot day pharmacyclic announce preliminary result jan stock easily retook day line have continue march higher then
326,AGN,management say company product revenue be consensus estimate predict blood cancer drug imbruvica rake jan fda approve medication treatment type lymphoma
327,AGN,handful other ibd biotechs also report future include valeant jazz pharmaceutical jazz feb akorn akrx feb
328,AGN,ipg photonic ipgp be stranger ibd best list bolt relative strength line worth brag
329,AGN,maker fiber optic laser amplifier also provide sneak peek result feb disclose preliminary share earning guidance cent revenue prior guidance
330,AGN,number easily surpass analyst expectation ep revenue ipg photonic have make double digit earning advance straight quarters report full result friday
331,AGN,stock find support day line late january have be climb ever
332,AGN,related hot medical stock report earningsearning season be still chug past president day several major drugmaker technology company yet disclose eagerly anticipate result today ibd roundup take peek hot biotechs laser focuse tech firm report week actavis act have already offer early view result dublin headquarter specialty pharmaceutical company hyped figure last month say earning exceed then consensus estimate lead strong international sale growth fda approval alzheimer drug namzaric wall street now anticipate share earning year year increase jump revenue drugmaker report wednesday ep advance mark sharp slowdown past year actavis have register least earning growth previous consecutive quarters friday actavis say have agree divest aptalis pharmaceutical technology business private equity firm tpg undisclosed term news follow monday announcement divest right doryx brand acne treatment mayne pharma approximately sell off actavis have be buy spree recent year acquire irish pharma warner chilcott forest laboratory last year november secure deal take botox maker allergan agn lengthy bidding war valeant pharmaceutical vrx medicine maker pharmacyclic pcyc also report close wednesday analyst expect earning decline cent rise revenue share sunnyvale calif base biotech shot day pharmacyclic announce preliminary result jan stock easily retook day line have continue march higher then management say company product revenue be consensus estimate predict blood cancer drug imbruvica rake jan fda approve medication treatment type lymphoma handful other ibd biotechs also report future include valeant jazz pharmaceutical jazz feb akorn akrx feb ipg photonic ipgp be stranger ibd best list bolt relative strength line worth brag maker fiber optic laser amplifier also provide sneak peek result feb disclose preliminary share earning guidance cent revenue prior guidance number easily surpass analyst expectation ep revenue ipg photonic have make double digit earning advance straight quarters report full result friday stock find support day line late january have be climb ever related hot medical stock report earning
333,AGN,pharmacyclic pcyc stock soar time high wednesday medium report biotech be consider selling big pharmaceutical company pharmacyclic only market product be imbruvica blood cancer drug have draw interest johnson johnson jnj novartis nvs accord report bloomberg cite unidentified source knowledge matter
334,AGN,respite former leader salix pharmaceutical rejoin sector leader wednesday issue salix slxp stock have be build right side unusually steep base help few big day recent week still high start shape deep pattern salix rise tuesday
335,AGN,past week several top rate ibd stock see big gain notable news
336,AGN,watch video more information
337,AGN,stock mentioned include valeant pharmaceutical vrx salix pharmaceutical slxp allergan agn actavis act ulta beauty ulta dollar tree dltr family dollar fdo dollar general dg
338,AGN,follow alissa william twitter ibd_awilliam
339,AGN,related valeant mull higher salix bid don expect past week several top rate ibd stock see big gain notable news watch video more information stock mentioned include valeant pharmaceutical vrx salix pharmaceutical slxp allergan agn actavis act ulta beauty ulta dollar tree dltr family dollar fdo dollar general dg follow alissa william twitter ibd_awilliam related valeant mull higher salix bid don expect
340,AGN,generic drug maker spotlight screen remain buy point market recent turbulence akorn akrx have be seesaw early buy point irregular pattern stock clear entry jan volume be light go sideway investor probably stock clear
341,AGN,merger mania be heating again ethical drug firm rush acquire other expand portfolio salix pharmaceutical slxp be target latest potential bidding war stock surge heavy trade feb report valeant pharmaceutical vrx be talk buy drug maker rise thursday
342,AGN,stock future deepen early loss ahead tuesday open weaker expect september durable good report dow future trade point be fall future slip point
343,AGN,nasdaq future have pare loss past hour reversed fall point fair market value
344,AGN,stock market today face busy session federal open market committee swing day meeting washington policy announcement due wednesday afternoon
345,AGN,great many investor be tune aftermarket session apple aapl be schedule report fiscal result
346,AGN,economic news open durable good order slip september accord commerce department be bit projection decline department also revise august decline transportation order dip august flat performance deeper project slip
347,AGN,case shiller report city composite home price index august et researcher markit release preliminary purchasing manager index estimate service conference board plan report october consumer confidence index
348,AGN,earning action be thick heavy roll tuesday open
349,AGN,beleaguered german chip equipment maker aixtron aixg spiked base big oil play bp bp add almost big pharma name merck mrk pfizer pfe rolled gain report better expect result
350,AGN,downside frac sand quarrier crush partner hclp implode miss earning forecast suspend cash distribution rent center rcii post premarket meltdown miss revenue expectation lower full year earning guidance ford slip unite parcel service up dim
351,AGN,alibaba baba rumble bell launch premarket rally many china base stock china base diversify internet play report ep gain rise revenue fiscal easily top consensus forecast mobile revenue rise cloud compute internet infrastructure revenue rise
352,AGN,company also announce security exchange commission give notice conclude inquiry enforcement action be recommend alibaba share end monday day move average stock have climb late september low leave still nov high ipo price
353,AGN,yahoo yhoo ahead early tuesday investor account increase value yahoo stake alibaba yahoo remain deep month consolidation
354,AGN,other china base internet play catch alibaba premarket heat jd com jd com wbai pop jumei international jmei vipshop vip jump apiece
355,AGN,chip developer marvell technology mrvl tank announce late monday have resign company accounting firm marvell september announce internal investigation revenue be recognize earlier have be marvell share have be steep correction february
356,AGN,cummin cmi dive miss expectation earning revenue line management lower full year revenue outlook flat vs prior guidance gain columbus ind base diesel engine maker also announce lay worker share have be deepen decline june
357,AGN,leader ibd stock be relatively quiet more group unmoved premarket trade
358,AGN,gainer cirrus logic crus rise topple heavy trade monday stock post decline more stock future deepen early loss ahead tuesday open weaker expect september durable good report dow future trade point be fall future slip point nasdaq future have pare loss past hour reversed fall point fair market value stock market today face busy session federal open market committee swing day meeting washington policy announcement due wednesday afternoon great many investor be tune aftermarket session apple aapl be schedule report fiscal result economic news open durable good order slip september accord commerce department be bit projection decline department also revise august decline transportation order dip august flat performance deeper project slip case shiller report city composite home price index august et researcher markit release preliminary purchasing manager index estimate service conference board plan report october consumer confidence index earning action be thick heavy roll tuesday open beleaguered german chip equipment maker aixtron aixg spiked base big oil play bp bp add almost big pharma name merck mrk pfizer pfe rolled gain report better expect result downside frac sand quarrier crush partner hclp implode miss earning forecast suspend cash distribution rent center rcii post premarket meltdown miss revenue expectation lower full year earning guidance ford slip unite parcel service up dim alibaba baba rumble bell launch premarket rally many china base stock china base diversify internet play report ep gain rise revenue fiscal easily top consensus forecast mobile revenue rise cloud compute internet infrastructure revenue rise company also announce security exchange commission give notice conclude inquiry enforcement action be recommend alibaba share end monday day move average stock have climb late september low leave still nov high ipo price yahoo yhoo ahead early tuesday investor account increase value yahoo stake alibaba yahoo remain deep month consolidation other china base internet play catch alibaba premarket heat jd com jd com wbai pop jumei international jmei vipshop vip jump apiece chip developer marvell technology mrvl tank announce late monday have resign company accounting firm marvell september announce internal investigation revenue be recognize earlier have be marvell share have be steep correction february cummin cmi dive miss expectation earning revenue line management lower full year revenue outlook flat vs prior guidance gain columbus ind base diesel engine maker also announce lay worker share have be deepen decline june leader ibd stock be relatively quiet more group unmoved premarket trade gainer cirrus logic crus rise topple heavy trade monday stock post decline more
359,AGN,jazz pharmaceutical rejoin sector leader list thursday work new base couple fail breakout drugmaker be shape cup type base potential buy point be jazz jazz rely heavily single drug xyrem be used treat sleep disorder narcolepsy account third
360,AGN,beleaguered specialty drugmaker salix pharmaceutical slxp pop tuesday afternoon word explore possible sale company cite anonymous source reuter report salix hire centerview partner explore option have not yet definitely decide sell wouldn be first time such report surround company august allergan ticker
361,AGN,recent flurry deal make drug sector have put spotlight other top rate drugmaker have grow help savvy merger acquisition just past week abbvie abbv agree buy pharmacyclic pcyc beating johnson johnson jnj mallinckrodt mnk announce deal acquire privately
362,AGN,wonder put dollar bill work stock market year service health care technology consumer discretionary be sector largest project percentage increase earning growth year compare say dow jone index
363,AGN,earning be rise stock market stock price increase usually follow
364,AGN,so stock mutual fund manager other investor be pay close attention earning season play
365,AGN,forecast whopping jump earning telecom stock equally whopping decline estimate be feb company have report result
366,AGN,health tech consumer discretionary be expect post gain
367,AGN,allergan agn earning contribute sector result rise year year beating consensus estimate
368,AGN,earning mallinckrodt mnk drugmaker be also upside surprise
369,AGN,tech apple aapl earning be also better expect
370,AGN,pocket strength be visible even sector investor expect weakness
371,AGN,dollar get stronger think impede unit volume higher value add good airplane turbine machinery say jim swanson mfs investment management chief investment strategist unit volume be hold revenue be rise not spectacularly
372,AGN,take flight
373,AGN,earning lockheed martin lmt be also exceed expectation
374,AGN,several segment have grow pricey social medium stock have achieve nosebleed valuation swanson say find datum storage cloud software more attractively price
375,AGN,health care hospital rehabilitation facility benefit expansion insurance coverage affordable care act
376,AGN,yet congressional intervention supreme court decision threat aca say brad sorensen charle schwab director market sector analysis biotechs have grow pricey long run add
377,AGN,other hand be bipartisan support possible rollback tax certain medical device benefit equipment maker sorensen say
378,AGN,currency fluctuation be risk company foreign sale say margaret vitrano co manager clearbridge large cap growth fund
379,AGN,impact large cap drugmaker say have little impact centric name cvs health cvs amgen amgn add
380,AGN,company unitedhealth unh celgene celg biogen idec biib have strong franchise protect pricing foreign exposure say
381,AGN,microsoft msft other software maker have fx exposure vitrano caution
382,AGN,other tech company benefit secular tailwind more make fx risk add
383,AGN,facebook fb be monetize instagram help stablemate atla be gain advertising dollar akamai akam benefit increase demand online security online video wonder put dollar bill work stock market year service health care technology consumer discretionary be sector largest project percentage increase earning growth year compare say dow jone index earning be rise stock market stock price increase usually follow so stock mutual fund manager other investor be pay close attention earning season play forecast whopping jump earning telecom stock equally whopping decline estimate be feb company have report result health tech consumer discretionary be expect post gain allergan agn earning contribute sector result rise year year beating consensus estimate earning mallinckrodt mnk drugmaker be also upside surprise tech apple aapl earning be also better expect pocket strength be visible even sector investor expect weakness dollar get stronger think impede unit volume higher value add good airplane turbine machinery say jim swanson mfs investment management chief investment strategist unit volume be hold revenue be rise not spectacularly take flightq earning lockheed martin lmt be also exceed expectation several segment have grow pricey social medium stock have achieve nosebleed valuation swanson say find datum storage cloud software more attractively price health care hospital rehabilitation facility benefit expansion insurance coverage affordable care act yet congressional intervention supreme court decision threat aca say brad sorensen charle schwab director market sector analysis biotechs have grow pricey long run add other hand be bipartisan support possible rollback tax certain medical device benefit equipment maker sorensen say currency fluctuation be risk company foreign sale say margaret vitrano co manager clearbridge large cap growth fund impact large cap drugmaker say have little impact centric name cvs health cvs amgen amgn add company unitedhealth unh celgene celg biogen idec biib have strong franchise protect pricing foreign exposure say microsoft msft other software maker have fx exposure vitrano caution other tech company benefit secular tailwind more make fx risk add facebook fb be monetize instagram help stablemate atla be gain advertising dollar akamai akam benefit increase demand online security online video
384,AGN,special report best mutual fund february performance report nation top rate mutual fund past month have be big buyer large medical name such allergan agn latest report period ibd biotech biomedical group be rank industry tuesday other do well group be biogen idec biib pharmacyclic pcyc
385,AGN,big cap biotech celgene celg provide preliminary fourth quarter earning report monday top estimate warn foreign exchange currency impact year ahead result be present prior presentation early monday annual jpmorgan healthcare conference san francisco fourth quarter celgene forecast net product sale be approximately include
386,AGN,investor look find very best stock right now find several grade company start list ibd rise estimate screen day look top rate stock analyst have be raise earning estimate rise ep view signal improve growth prospect not only company also
387,AGN,valeant pharmaceutical jump new time high huge volume thursday issue bullish guidance stock be extend handle buy point also show higher entry past be buy range past entry early thursday valeant vrx host conference call provide update development
388,AGN,actavis have undergo multiple change past few year constant be growth acquisition back actavis act then know generic drug maker watson pharmaceutical buy swiss partner actavis change corporate name actavis then acquire irish pharma warner chilcott acquisition not only help actavis expand brand drug portfolio
389,AGN,generic drug maker lannett co recent quarters have surge price increase more recently volume gain key prescription medication other drug company news week lannett lci be hunt potential acquisition help expand offering extend global reach lower tax base philadelphia base firm develop
390,AGN,rapidly consolidate industry re hunter prey mylan be former mylan myl make generic brand drug treat illness cardiovascular central nervous system other disorder operate segment generic specialty generic unit make generic brand generic product tablet capsule injectable transdermal patch form active
391,AGN,clear buy point cup base october qualys qlys be bounce week move average
392,AGN,rebound week line be generally used point add share investor still use setup start new position stock have retreat mostly tame volume have find support level
393,AGN,demand gauge such stock accumulation distribution rating volume ratio remain level point strong buy fund ownership grow fourth quarter accord marketsmith year period
394,AGN,qualys be thin issue average daily volume share daily dollar volume have double year
395,AGN,redwood city calif base qualys provide cloud security compliance product more customer more country allergan agn best buy bby merck mrk be customer
396,AGN,qualys be smaller company highly rank computer security software group have market cap symantec symc check point software technology chkp have market cap respectively
397,AGN,smaller qualys have deliver much bigger earning gain compare industry giant recent quarters qualys profit grow latest quarters top line growth have accelerate straight period latest come new customer renewal upsell have help sale growth
398,AGN,qualys report fourth quarter result feb market close analyst poll thomson reuter see earning surge cent share sale be expect year company full year profit be expect cent share earning be slate rise cent clear buy point cup base october qualys qlys be bounce week move average rebound week line be generally used point add share investor still use setup start new position stock have retreat mostly tame volume have find support level demand gauge such stock accumulation distribution rating volume ratio remain level point strong buy fund ownership grow fourth quarter accord marketsmith year period qualys be thin issue average daily volume share daily dollar volume have double year redwood city calif base qualys provide cloud security compliance product more customer more country allergan agn best buy bby merck mrk be customer qualys be smaller company highly rank computer security software group have market cap symantec symc check point software technology chkp have market cap respectively smaller qualys have deliver much bigger earning gain compare industry giant recent quarters qualys profit grow latest quarters top line growth have accelerate straight period latest come new customer renewal upsell have help sale growth qualys report fourth quarter result feb market close analyst poll thomson reuter see earning surge cent share sale be expect year company full year profit be expect cent share earning be slate rise cent
399,AGN,be shape etfs not too bad thank shire shpg be buy nps pharma npsp maker rare drug roche johnson johnson jnj biogen idec biib have also announce deal zillow be likely merge trulium trla transaction ride coattail banner year
400,AGN,time year world be gear winter olympic sochi russia few thing put perspective contrast experience global market vast squander political capital follow sochi game send president vladimir putin economy desperate recession russia ukraine come rise
401,AGN,share shire shpg moved higher early thursday irish drugmaker better expect quarterly revenue upbeat outlook offset earning miss report open shire logged fourth quarter earning american depositary share year earlier period nickel consensus estimate analyst poll thomson reuter revenue climb
402,AGN,market sell early week investor retreat traditionally defensive area utility select sector spdr exchange trade fund xlu spark tuesday wednesday vanguard reit etf vnq gain ground monday wednesday want steer clear sector likely be hurt once federal reserve start nudge
403,AGN,drugmaker valeant pharmaceutical be work new base prepare issue financial outlook base cup handle pattern show potential buy point risky late stage pattern form stock have already enjoy strong advance canada base valeant vrx focus dermatology eye health neurology brand generic drug plan
404,AGN,longtime lead medical biotech stock be come fire shift be reflect sector leader gilead science gild jazz pharmaceutical jazz be monday screen drop tuesday edition alexion pharmaceutical alxn valeant pharmaceutical vrx remain be selling well alexion be threaten erase gain buy
405,AGN,surge stock robust economic growth strengthen job market have lift business confidence result thirst deal year continue analyst say target merger acquisition totale comprise global deal total accord datum provide
406,AGN,market look bit unsettled again last week sign strength nasdaq tech index gain higher volume jan be sign start wading back stock again underlie market health be question due distribution week be always instance stock
407,AGN,medical stock continue be solid performer latest market uptrend many score week high recent session friday sector leader screen stock hailed medical space most sector ibd track alexion pharmaceutical alxn be trading mostly sideway hit new high earlier month stock be
408,AGN,few ethical drug maker maintain presence ibd sector leader screen be show bullish action follow lose bid acquire allergan week thursday close valeant pharmaceutical vrx be heavy volume stock be nicely early handle buy point valeant price volume
409,AGN,valeant pharmaceutical vrx hasn miss beat fail takeover bid botox maker allergan agn valeant lose monday compete bid generic drugmaker actavis act say buy allergan yet valeant climb heavy volume day clear buy point handle long consolidation
410,AGN,stock finished higher tuesday dow jone industrial average make fresh time high nasdaq overcome monday weakness year high
411,AGN,volume be higher monday nyse slightly lower nasdaq accord preliminary datum
412,AGN,close chinese online retailer vipshop holding vip report earning beat street penny guide revenue analyst estimate ep jump cent share revenue soar stock be trading higher lose regular session
413,AGN,jack box jack be also trading higher hour report earning beat estimate announce board have authorize buy back additional stock
414,AGN,regular session actavis act ramp time high volume zoom more quadruple daily average stock close extend past buy point flat base monday drugmaker announce buy botox maker allergan agn cash stock
415,AGN,open wednesday census bureau release october housing start economist be forecasting annualize unit vs september
416,AGN,et energy information administration release weekly statement crude oil inventory federal reserve release minute oct meeting interest rate stock finished higher tuesday dow jone industrial average make fresh time high nasdaq overcome monday weakness year high volume be higher monday nyse slightly lower nasdaq accord preliminary datum close chinese online retailer vipshop holding vip report earning beat street penny guide revenue analyst estimate ep jump cent share revenue soar stock be trading higher lose regular session jack box jack be also trading higher hour report earning beat estimate announce board have authorize buy back additional stock regular session actavis act ramp time high volume zoom more quadruple daily average stock close extend past buy point flat base monday drugmaker announce buy botox maker allergan agn cash stock open wednesday census bureau release october housing start economist be forecasting annualize unit vs september et energy information administration release weekly statement crude oil inventory federal reserve release minute oct meeting interest rate
417,AGN,top rate medical stock such illumina ilmn be bullish jpmorgan healthcare conference san francisco week several talk earning sale prospect announce new takeover deal
418,AGN,ibd screen day be big cap leader top rate stock generally price market capitalization least today screen include large drug other medical stock proven track record
419,AGN,illumina outlook cautious
420,AGN,gene sequence equipment maker illumina monday say collaborate lockheed martin lmt develop next generation gene sequence gear envision advantage early national adoption country globe lower health care cost lockheed health life science vice president horace blackman say
421,AGN,monday jpmorgan conference illumina report preliminary revenue beating estimate full year guidance be conservative ibd leaderboard stock just clear flat base last week hit intraday peak friday stock fall monday tuesday fall close day move average
422,AGN,biogen buy convergence
423,AGN,cambridge mass base biogen idec biib develop treatment variety ailment include multiple sclerosis cancer autoimmune disease
424,AGN,sunday biogen agree buy privately hold base drugmaker convergence pharmaceutical milestone be meet expand biogen presence pain management drug convergence be develop drug treat chronic nerve pain
425,AGN,biogen rise high tuesday whisker time high set dec close
426,AGN,shire buy nps pharma
427,AGN,january ireland base shire shpg buy biotech viropharma specialize rare disease drug shire begin buyout bid nps pharmaceutical npsp biopharma focuse rare disease
428,AGN,shire share plunge more oct abbvie abbv withdraw buyout offer treasury department tighten rule limit tax inversion tax inversion be maneuver company buy company base country shift own headquarters country get lower tax rate
429,AGN,shire have partly re-cover stock fall monday stock close tuesday day line
430,AGN,actavis see exceptional sale
431,AGN,actavis act irish drugmaker recently agree buy botox maker allergan agn top hostile bid valeant pharmaceutical vrx pairing create global top drugmaker combine annual revenue more deal be expect close second quarter
432,AGN,actavis say monday jpmorgan conference expect ep top wall street estimate strong sale actavis consolidated late november monday rise time high touch intraday high tuesday pull back close
433,AGN,celgene bullish revlimid
434,AGN,monday conference summit base drugmaker celgene celg give generally bullish forecast flagship cancer fight drug revlimid account estimate sale
435,AGN,celgene expect overall sale climb
436,AGN,term celgene guide sale view partly negative currency effect preliminary ep top wall street target sale revlimid climb drug gain approval treat more type cancer
437,AGN,celgene stock form cup handle base january mid june buy point gap have rise tuesday stock rise hit new high rise monday celgene stock clear month consolidation too short be proper base be extend day day average
438,AGN,follow james detar twitter ibd_jdetar top rate medical stock such illumina ilmn be bullish jpmorgan healthcare conference san francisco week several talk earning sale prospect announce new takeover deal ibd screen day be big cap leader top rate stock generally price market capitalization least today screen include large drug other medical stock proven track record illumina outlook cautiousgene sequence equipment maker illumina monday say collaborate lockheed martin lmt develop next generation gene sequence gear envision advantage early national adoption country globe lower health care cost lockheed health life science vice president horace blackman say monday jpmorgan conference illumina report preliminary revenue beating estimate full year guidance be conservative ibd leaderboard stock just clear flat base last week hit intraday peak friday stock fall monday tuesday fall close day move average biogen buy mass base biogen idec biib develop treatment variety ailment include multiple sclerosis cancer autoimmune disease sunday biogen agree buy privately hold base drugmaker convergence pharmaceutical milestone be meet expand biogen presence pain management drug convergence be develop drug treat chronic nerve pain biogen rise high tuesday whisker time high set dec close shire buy nps pharmain january ireland base shire shpg buy biotech viropharma specialize rare disease drug shire begin buyout bid nps pharmaceutical npsp biopharma focuse rare disease shire share plunge more oct abbvie abbv withdraw buyout offer treasury department tighten rule limit tax inversion tax inversion be maneuver company buy company base country shift own headquarters country get lower tax rate shire have partly re-cover stock fall monday stock close tuesday day line actavis see exceptional salesactavis act irish drugmaker recently agree buy botox maker allergan agn top hostile bid valeant pharmaceutical vrx pairing create global top drugmaker combine annual revenue more deal be expect close second quarter actavis say monday jpmorgan conference expect ep top wall street estimate strong sale actavis consolidated late november monday rise time high touch intraday high tuesday pull back close celgene bullish revlimidon monday conference summit base drugmaker celgene celg give generally bullish forecast flagship cancer fight drug revlimid account estimate sale celgene expect overall sale climb term celgene guide sale view partly negative currency effect preliminary ep top wall street target sale revlimid climb drug gain approval treat more type cancer celgene stock form cup handle base january mid june buy point gap have rise tuesday stock rise hit new high rise monday celgene stock clear month consolidation too short be proper base be extend day day average follow james detar twitter ibd_jdetar
439,AGN,cancer therapy bullish earning forecast take spotlight monday open jpmorgan healthcare conference week san francisco largest annual biotech conference worldwide
440,AGN,celgene celg provide bullish forecast cancer drug revlimid generally positive preliminary result long term financial outlook bristol myer squibb bmy announce positive trial result lung cancer drug opdivo
441,AGN,celgene expect ep vs year earlier wall street see cent net product sale be include negative foreign currency shift dollar hit multiyear high vs euro yen
442,AGN,analyst have expect sale
443,AGN,be exceptional year celgene momentum core business position year outstanding execution say ceo bob hugin statement
444,AGN,celgene estimate ep product sale wall street have see ep sale
445,AGN,celgene long term outlook
446,AGN,forecast net product sale wall street estimate be strong dollar other currency shift hurt net product sale celgene forecast adjust ep consensus
447,AGN,sale core drug revlimid climb celgene gain wider approval treat more type cancer ongoing global expansion revlimid be used treat multiple myeloma type lymphoma
448,AGN,celgene expect total revenue ep hematology franchise top
449,AGN,celgene outlook be impressive write michael yee analyst rbc capital market report reason cite celgene beat narrowing guidance upper end most importantly long term guidance well previously publish estimate
450,AGN,opdivo superior survival
451,AGN,ahead jpmorgan event bristol myer squibb say sunday phase trial drug opdivo result superior overall survival lung cancer patient take pharma giant rise monday hit year high early
452,AGN,several sunday pharma announcement swiss drug giant roche rhhby say buy foundation medicine fmi foundation make genomic test cancer shot roche share rise
453,AGN,other jpmorgan news monday gene sequence equipment maker illumina ilmn report preliminary revenue estimate
454,AGN,illumina expect revenue rise ep slightly cautious vs wall street forecast ep sale growth
455,AGN,illumina share close trading low stock hit record friday
456,AGN,actavis act say expect gaap earning top wall street estimate cite exceptional sale drugmaker share rise hit record intraday
457,AGN,actavis recently win bidding war botox maker allergan agn offer trumping valeant pharmaceutical vrx valeant share shot new high last week give upbeat preliminary result cancer therapy bullish earning forecast take spotlight monday open jpmorgan healthcare conference week san francisco largest annual biotech conference worldwide celgene celg provide bullish forecast cancer drug revlimid generally positive preliminary result long term financial outlook bristol myer squibb bmy announce positive trial result lung cancer drug opdivo celgene expect ep vs year earlier wall street see cent net product sale be include negative foreign currency shift dollar hit multiyear high vs euro yen analyst have expect sale be exceptional year celgene momentum core business position year outstanding execution say ceo bob hugin statement celgene estimate ep product sale wall street have see ep sale celgene long term forecast net product sale wall street estimate be strong dollar other currency shift hurt net product sale celgene forecast adjust ep consensus sale core drug revlimid climb celgene gain wider approval treat more type cancer ongoing global expansion revlimid be used treat multiple myeloma type lymphoma celgene expect total revenue ep hematology franchise top celgene outlook be impressive write michael yee analyst rbc capital market report reason cite celgene beat narrowing guidance upper end most importantly long term guidance well previously publish estimate opdivo superior survival ahead jpmorgan event bristol myer squibb say sunday phase trial drug opdivo result superior overall survival lung cancer patient take pharma giant rise monday hit year high early several sunday pharma announcement swiss drug giant roche rhhby say buy foundation medicine fmi foundation make genomic test cancer shot roche share rise other jpmorgan news monday gene sequence equipment maker illumina ilmn report preliminary revenue estimate illumina expect revenue rise ep slightly cautious vs wall street forecast ep sale growth illumina share close trading low stock hit record friday actavis act say expect gaap earning top wall street estimate cite exceptional sale drugmaker share rise hit record intraday actavis recently win bidding war botox maker allergan agn offer trumping valeant pharmaceutical vrx valeant share shot new high last week give upbeat preliminary result
458,AGN,generic specialty drugmaker actavis agree acquire allergan more monday potentially create pharmaceutical giant annual sale market cap
459,AGN,actavis act pay actavis share share allergan agn equal base monday close price be appreciably hostile bid valeant pharmaceutical international vrx put june base valeant current valuation be worth share
460,AGN,actavis stock rise allergan climb
461,AGN,allergan board maintain valeant offer grossly undervalue company have achieve strong ibd ep rank sale flagship botox various other aesthetic dermatologic opthalmic product board also say valeant slash allergan research development budget destroy longer term value
462,AGN,valeant recently hint raise offer allergan valeant statement deal monday seem raise white flag
463,AGN,valeant justify price
464,AGN,have see announcement allergan actavis have make review such agreement determine course action valeant justify own shareholder pay price more share allergan valeant ceo michael pearson say
465,AGN,valeant stock rise
466,AGN,actavis say expect realize annual cost saving deal just be slate come less half cut valeant have propose conference call discuss merger allergan ceo david pyott say plan annual spending be real money believe actavis be commit
467,AGN,historically look spend actavis specialty brand business intensity have be pretty close our pyott say add actavis have opthalmology business present admire ceo brent saunder leadership contact lens giant bausch lomb saunder head
468,AGN,actavis deal offer double digit earning accretion first month deal close expect saunder expect annual organic revenue growth foreseeable future add revenue small acquisition recent deal furiex pharmaceutical durata therapeutic drtx set aspirational earning target share analyst consensus year
469,AGN,overlap synergy
470,AGN,saunder say call firm overlap area dermatology neurology urology latter lately have be provide new revenue botox have be approve treat migraine overactive bladder also believe actavis formidable primary care salesforce broaden market allergan opthalmology drug such restasis dry eye syndrome
471,AGN,source efficiency be tax rate allergan be base irvine calif actavis be domicile dublin thank tax inversion deal last year saunder say actavis also move allergan intellectual property offshore keep overall tax rate
472,AGN,rumor deal have be circulate wall street couple month most analyst speculate price more valeant less final offer
473,AGN,estimate deal allergan be meaningfully accretive act shareholder price synergy write sterne agee analyst shibani malhotra note monday price be somewhat higher synergy guidance be meaningfully higher estimate see management double digit year accretion expectation highly achievable
474,AGN,leerink jason gerberry agree be less convince ep own estimate be generic specialty drugmaker actavis agree acquire allergan more monday potentially create pharmaceutical giant annual sale market cap actavis act pay actavis share share allergan agn equal base monday close price be appreciably hostile bid valeant pharmaceutical international vrx put june base valeant current valuation be worth share actavis stock rise allergan climb allergan board maintain valeant offer grossly undervalue company have achieve strong ibd ep rank sale flagship botox various other aesthetic dermatologic opthalmic product board also say valeant slash allergan research development budget destroy longer term value valeant recently hint raise offer allergan valeant statement deal monday seem raise white flag valeant justify price have see announcement allergan actavis have make review such agreement determine course action valeant justify own shareholder pay price more share allergan valeant ceo michael pearson say valeant stock rise actavis say expect realize annual cost saving deal just be slate come less half cut valeant have propose conference call discuss merger allergan ceo david pyott say plan annual spending be real money believe actavis be commit historically look spend actavis specialty brand business intensity have be pretty close our pyott say add actavis have opthalmology business present admire ceo brent saunder leadership contact lens giant bausch lomb saunder head actavis deal offer double digit earning accretion first month deal close expect saunder expect annual organic revenue growth foreseeable future add revenue small acquisition recent deal furiex pharmaceutical durata therapeutic drtx set aspirational earning target share analyst consensus year overlap say call firm overlap area dermatology neurology urology latter lately have be provide new revenue botox have be approve treat migraine overactive bladder also believe actavis formidable primary care salesforce broaden market allergan opthalmology drug such restasis dry eye syndrome source efficiency be tax rate allergan be base irvine calif actavis be domicile dublin thank tax inversion deal last year saunder say actavis also move allergan intellectual property offshore keep overall tax rate rumor deal have be circulate wall street couple month most analyst speculate price more valeant less final offer estimate deal allergan be meaningfully accretive act shareholder price synergy write sterne agee analyst shibani malhotra note monday price be somewhat higher synergy guidance be meaningfully higher estimate see management double digit year accretion expectation highly achievable leerink jason gerberry agree be less convince ep own estimate be
475,AGN,most widely rumore deal pharma come fruition monday actavis act agree acquire allergan agn cash stock allergan stock be more actavis stock nearly early trading stock market today actavis agree pay cash
476,AGN,market stage follow thursday investor start buy lead stock again number top rate stock spotlight screen be form basis get support week line give investor buy opportunity technology avgo be putt finishing touch flat base buy point friday
477,AGN,chinese car information bitauto clear buy point friday continue outperform industry peer meanwhile prescription drugmaker valeant pharmaceutical vrx return sector leader try climb right side long base bitauto bita online automotive showroom help connect dealer car buyer clear buy point
478,AGN,stock be mixed afternoon trading tuesday many technology leader be shell past few day see initial sign rebound nasdaq composite suffer brunt tech sell lead increase today market solar semiconductor networking internet stock rise more explain tech heavy index be outperform be less erase gain dow jone industrial average be small cap russell drop be behave more calmly day marked volatility volume be run lower compare same time monday decliner lead advancer ratio board way stock behave day move average be good way judge health basis be encourage sign beaten technology stock red hat rht paypal pypl rise back day line make brief dip line adobe adbe cognex cgnx microsoft msft hold day line sharp decline microsoft be form flat base also arista network anet universal display oled make bullish price reversal touch week move average many other key techs remain day line include facebook fb nvidia nvda ipg photonic ipgp lam research lrcx atlassian team fact majority tech stock rise stock move be still day average nvidia have slide more prior high buyer step day short breakout revance therapeutic rvnc soar past buy point flat base huge volume company report good result study treatment wrinkle eyebrow news send allergan agn be work compete product busy trading nearly year low downside department store be cool rally group have surge past week be related fang stock other major techs rebound multiday sell offbroadcom earning get apple juice iphone production
479,AGN,drug industry rumor mill get fresh surge energy wednesday report emerge drug giant actavis act be near deal buy botox maker allergan agn least report company be talk have be leak couple month now subject be major unnamed topic
480,AGN,stock finished strong day nasdaq back other index also high volume run higher previous day accord preliminary datum nasdaq gain be dow jone industrial average lift stock market today netflix nflx rise sharply hour company issue upbeat report say total subscriber amount vs estimate stock close top long deep cup handle base energy stock be top performer oil rise nearly close barrel select retail group be day poorest performer market open thursday closely watch economic indicator housing start weekly claim unemployment be report housing start march be forecast be new unit compare february jobless claim be expect be week end april vs prior week
481,AGN,animal health giant zoetis zts offer guidance street consensus longer term financial goal analyst day tuesday brief halt trading early afternoon announcement stock be more afternoon trading stock market today zoetis say expect ep next year
482,AGN,drugmaker cluster top ibd stock move list tuesday afternoon actavis act ireland base maker generic brand drug shot more huge volume tuesday afternoon trading stock market today follow monday gain actavis announce acquire botox maker allergan agn more stock cash potentially create pharmaceutical giant market cap tuesday activist investor william ackman say cnbc interview support deal ackman persh square fund build stake have push valeant pharmaceutical vrx acquire allergan citigroup tuesday raise price target actavis cite potential synergy growth prospect actavis investor seem pleased valeant not have go merger process allergan take stock more more double usual volume rise nearly monday valeant deal ackman get profit persh square allergan hold allergan rise actavis higher stock price mean higher deal valuation valeant be also ibd list top rate stock now focus broad line drug mainly dermatology neurology eye health brand generic portfolio include antidepressant wellbutrin xl liposoniz thermage fraxel professional skin care sector gilead science gild climb higher volume european union grant company permission market harvoni first once daily single tablet regimen treat hepatitis highly infectious disease primarily affect liver lead cirrhosis potentially fatal disease combine blockbuster sovaldi drug israel base taro pharmaceutical taro continue recover drop day company nov report strong earning revenue gain end quarter partly price increase say also have marginal decline volume stock be track tuesday afternoon post third straight daily rise be trading more twice normal volume follow james detar twitter ibd_jdetar
483,AGN,stock remain mixed late monday afternoon investor weigh spate merger activity news japan fall recession
484,AGN,dow jone industrial average be nasdaq be volume be slightly lower stock market today nasdaq fall fraction nyse compare same time friday
485,AGN,allergan agn jump new high huge volume actavis act say buy botox maker cash stock
486,AGN,deal end hostile bid allergan valeant pharmaceutical vrx persh square capital management backed activist investor william ackman valeant rise
487,AGN,zillow be heavy volume report real estate list shut agentfolio service allow home shopper share listing friend real estate agent zillow clear converge day day move average
488,AGN,meanwhile halliburton hal plunge announce buy baker hughe bhi cash stock baker hughe be
489,AGN,linkedin lnkd slump report facebook fb be develop professional sell push stock back buy point cup base larger pattern linkedin have struggle breaking nov
490,AGN,larger economic news japan economy unexpectedly shrank second straight quarter putt world economy recession stock remain mixed late monday afternoon investor weigh spate merger activity news japan fall recession dow jone industrial average be nasdaq be volume be slightly lower stock market today nasdaq fall fraction nyse compare same time friday allergan agn jump new high huge volume actavis act say buy botox maker cash stock deal end hostile bid allergan valeant pharmaceutical vrx persh square capital management backed activist investor william ackman valeant rise zillow be heavy volume report real estate list shut agentfolio service allow home shopper share listing friend real estate agent zillow clear converge day day move average meanwhile halliburton hal plunge announce buy baker hughe bhi cash stock baker hughe be linkedin lnkd slump report facebook fb be develop professional sell push stock back buy point cup base larger pattern linkedin have struggle breaking nov larger economic news japan economy unexpectedly shrank second straight quarter putt world economy recession
491,AGN,stock be best level session tuesday afternoon news japan jump homebuilder confidence nasdaq rise earlier touch fresh year high climb time high meanwhile dow jone industrial average lag gain due weakness home depot hd report earning earlier session volume be still run mixed stock market today nyse trade be tracking higher nasdaq volume be run lower monday pace japan prime minister shinzo abe call early election seek approval economic policy japan have fall recession economist blame abe tax hike lead stock actavis act rally time high now past buy point flat base monday drugmaker announce buy botox maker allergan agn cash stock citigroup raise actavis price target tuesday valeant pharmaceutical vrx lose deal buy allergan climb month high stock clear buy point handle monday outside drug stock bitauto bita rise fast trade regain monday loss then bitauto be now past buy point late stage cup handle base clear friday downside vipshop holding vip reversed lower fall breach day move average chinese online retailer report third quarter result close analyst poll thomson reuter see profit surge cent share sale be estimate year
492,AGN,stock open hole then quickly turn mixed monday weak economic news flurry heavy merger activity center early trade
493,AGN,nasdaq narrow early loss dow jone industrial average shed thin loss post fractional gain
494,AGN,stock market today most global market feel early pressure disappointing third quarter gdp number japan new york federal reserve empire state manufacturing survey rise november also come weaker expect
495,AGN,nationwide industrial production slip october federal reserve report be downwardly revise gain september projection expansion utilization production capacity also contract more expect vs estimate flat performance
496,AGN,merger news drive swirl big stock move early trade baker hughe bhi surge halliburton hal dive dreamwork animation dwa plummet
497,AGN,upside hasbro have climb allergan agn jump
498,AGN,earning news tyson food tsn rise healthy fiscal fourth quarter result sturm ruger rgr slip wide miss earning revenue
499,AGN,tata motor ttm clear news drive move big volume gain crack stock past buy point month cup handle base
500,AGN,chip designer ambarella amba nxp semiconductor nxpi jump lead ibd list ambarella be extend just new high rebound week support nxp be just buy point week cup base
501,AGN,sawmill titan boise cascade bcc fall biggest drop ibd stock stock be still retake buy point early august stock open hole then quickly turn mixed monday weak economic news flurry heavy merger activity center early trade nasdaq narrow early loss dow jone industrial average shed thin loss post fractional gain stock market today most global market feel early pressure disappointing third quarter gdp number japan new york federal reserve empire state manufacturing survey rise november also come weaker expect nationwide industrial production slip october federal reserve report be downwardly revise gain september projection expansion utilization production capacity also contract more expect vs estimate flat performance merger news drive swirl big stock move early trade baker hughe bhi surge halliburton hal dive dreamwork animation dwa plummet upside hasbro have climb allergan agn jump earning news tyson food tsn rise healthy fiscal fourth quarter result sturm ruger rgr slip wide miss earning revenue tata motor ttm clear news drive move big volume gain crack stock past buy point month cup handle base chip designer ambarella amba nxp semiconductor nxpi jump lead ibd list ambarella be extend just new high rebound week support nxp be just buy point week cup base sawmill titan boise cascade bcc fall biggest drop ibd stock stock be still retake buy point early august
502,AGN,stock future trade lower steady ahead monday open oil price federal reserve test investor confidence dow future trade point fair market value future hung point line nasdaq future be mild point small cap be pressure russell future fall point stock market today open clear caution flag ahead wednesday policy decision federal reserve nasdaq drop last week slice support day day move average crumple also violate level support mean bet be market direction next day uncertainty oil price continue diving early monday west texas intermediate more barrel lowest mark more decade brent crude drop nearly weakest level benchmark have logged steady loss dec organization petroleum export country meeting group fail agree production quota permit member country continue current production level oil price slump be dupont dd apple aapl drag dow open dupont dip more apple trim premarket loss dive morgan stanley cut price target cite pressure international iphone price due oversupply outside china apple end friday well august low struggle retake week move average month consolidation jarden jah jump newell rubbermaid nwl slip more newell say pay cash stock deal acquire boca raton fla base maker sunbeam iron marmot outdoor gear crock pot cookware newell management say combination be target annualize cost saving be immediately positive earning close jarden rise last week merger speculation move stock right side month consolidation china base maker solar electrical component trina solar tsl spiked news report company have receive offer be take private share shanghai xingsheng equity investment management offer be friday close price edward lifescience ew be confuse brokerage datum collection system premarket trade prepared go live stock split today open be company first stock split overseas europe stock come lows midday london ftse reversed early loss wrestle narrowly positive territory frankfurt dax be loss cac paris ease loss asia market be widely mixed hong kong hang seng index dip shanghai composite jump nikkei tokyo stumble loss
503,AGN,stock index be have trouble get past start gate friday afternoon nasdaq grip gain be flat dow jone industrial average slouch volume rise previous session pace signature authentication product provider vasco datum security international vdsi surge volume average small cap stock first clear buy point wednesday then dip entry thursday now back buy point vasco carry best possible ibd composite rating company year earning stability factor be scale run calm wild composite rating combine ibd rating single number rating mean stock be top percentile big cap ebay ebay pop heavy volume make new week high stock break cup handle base clear buy point cup handle be bullish pattern ebay be tuesday big cap computer generate list best big cap fundamental technical other top price performer friday afternoon include super regional bank several stock group be threaten cross buy point include suntrust bank sti fifth third bancorp fitb bb bbt fundamental super regional bank however be spotty follow paul whitfield twitter ibd_pwhitfield
504,AGN,jazz pharmaceutical jazz briefly clear buy point wednesday get lift better expect earning report stock jump early session breaking past cup handle entry heavy volume jazz end buy point early gain fade action be disappointing jazz late tuesday beat wall street
505,AGN,generic specialty drug giant actavis beat wall street third quarter estimate raise guidance early wednesday send stock new high close actavis agn earning exclude time item rise year earlier quarter share beating analyst consensus cent accord thomson reuter revenue
506,AGN,big highly rate company such technology avgo be good candidate want start continue stock gain today screen day be big cap leader top rate company market value least be price second sort reveal top company strongest revenue
507,AGN,major average pare loss late morning slump end mixed big merger deal weak economic datum
508,AGN,dow jone industrial average close fractionally higher nasdaq fall volume run lower board stock market today accord preliminary datum
509,AGN,meat product staffing service toymaker be day top gainer industry group track ibd computer software oil explorer suffer biggest loss
510,AGN,tyson food tsn leap month high heavy trade near early buy point poultry processor report fiscal earning top estimate revenue roughly line view sale get boost june purchase hillshire brand
511,AGN,other chicken stock sanderson farm safm rise average volume pilgrim pride ppc have be bidding war tyson hillshire gain slow turnover
512,AGN,allergan agn jump record high big volume actavis act say acquire botox maker cash stock put end valeant pharmaceutical vrx persh square capital management bid allergan
513,AGN,michael co mik soar fast trade extend gain fifth straight session art craft store operator be expect post earning cent share report thursday last week morgan stanley forecast ep cent upgrade stock overweight
514,AGN,follow nancy gondo twitter ibd_ngondo major average pare loss late morning slump end mixed big merger deal weak economic datum dow jone industrial average close fractionally higher nasdaq fall volume run lower board stock market today accord preliminary datum meat product staffing service toymaker be day top gainer industry group track ibd computer software oil explorer suffer biggest loss tyson food tsn leap month high heavy trade near early buy point poultry processor report fiscal earning top estimate revenue roughly line view sale get boost june purchase hillshire brand other chicken stock sanderson farm safm rise average volume pilgrim pride ppc have be bidding war tyson hillshire gain slow turnover allergan agn jump record high big volume actavis act say acquire botox maker cash stock put end valeant pharmaceutical vrx persh square capital management bid allergan michael co mik soar fast trade extend gain fifth straight session art craft store operator be expect post earning cent share report thursday last week morgan stanley forecast ep cent upgrade stock overweight follow nancy gondo twitter ibd_ngondo
515,AGN,raise eyebrow lead decline stock price stock move today include salix pharmaceutical slxp embroil drama question accuracy honesty cloud drugmaker weak result be inventory accurate do cfo adam derbyshire resign share plummet stock market today hit lowest level
516,AGN,salix pharmaceutical slxp be show improve action trigger sell signal earlier month still have hurdle ahead oct stock erased gain past buy point flat base stock break follow report be potential buyout target allergan agn be fight hostile
517,AGN,big pharma firm such alexion pharmaceutical biogen idec continue outperform market develop market new treatment treat long time target such alzheimer well rare illness
518,AGN,today screen day be big cap leader top rate stock large market capitalization stock be price
519,AGN,today screen feature big drugmaker have report strong quarterly earning recently
520,AGN,alexion pharmaceutical alxn continue grow steady clip blockbuster drug soliris so call orphan drug used treat rare blood disease dose pricey effective widely used alexion stock jump more oct break month base strong third quarter result
521,AGN,earning call ceo leonard bell say alexion have complete last phase roll fda submission approval second drug alfa treatment genetic bone disease alexion rise fractionally tuesday trading stock market today
522,AGN,biogen idec biib say day earlier ep rise crush estimate cent sale rise line view
523,AGN,biogen lift full year earning guidance sale best selling treatment multiple sclerosis drug tecfidera fall short consensus share fall day stock have re-cover drop be trading day average just day average tuesday
524,AGN,jazz pharmaceutical jazz say tuesday market close iyd ep rise beating consensus cent sale climb more analyst expect
525,AGN,company lift full year profit outlook consensus view beat raise forecast come largely strong performance defitelio specialty drug treat rare condition afflict person undergo stem cell transplantation jazz acquire drug buy italian biotech gentium january
526,AGN,jazz share rise late tuesday close
527,AGN,celgene celg oct say ep climb cent beating analyst estimate cent share sale grow more wall street expect
528,AGN,biotech guide full year revenue prior year line analyst view trim outlook flagship cancer drug abraxane investor weren worry take celgene stock day celgene stock be ibd leaderboard list top rate stock fall tuesday
529,AGN,allergan agn buyout target lose round court tuesday bid defend takeover bid valeant vrx district judge david carter deny allergan motion sue valeant activist investor bill ackman persh square capital management insider trading bid block persh voting stake allergan special meeting slate dec
530,AGN,allergan share rise tuesday hit new high investor see greater chance valeant takeover
531,AGN,oct allergan report solid earning raise guidance ep rise beating estimate sale rise line guidance firm see ep vs year analyst consensus
532,AGN,bonus stock
533,AGN,actavis act be slate report financial result wednesday morning market open wall street expect ep jump surge revenue specialty drugmaker say oct be acquire biotech startup durata therapeutic cash
534,AGN,follow james detar twitter ibd_jdetar big pharma firm such alexion pharmaceutical biogen idec continue outperform market develop market new treatment treat long time target such alzheimer well rare illness today screen day be big cap leader top rate stock large market capitalization stock be price today screen feature big drugmaker have report strong quarterly earning recently alexion pharmaceutical alxn continue grow steady clip blockbuster drug soliris so call orphan drug used treat rare blood disease dose pricey effective widely used alexion stock jump more oct break month base strong third quarter result earning call ceo leonard bell say alexion have complete last phase roll fda submission approval second drug alfa treatment genetic bone disease alexion rise fractionally tuesday trading stock market today biogen idec biib say day earlier ep rise crush estimate cent sale rise line view biogen lift full year earning guidance sale best selling treatment multiple sclerosis drug tecfidera fall short consensus share fall day stock have re-cover drop be trading day average just day average tuesday jazz pharmaceutical jazz say tuesday market close iyd ep rise beating consensus cent sale climb more analyst expect company lift full year profit outlook consensus view beat raise forecast come largely strong performance defitelio specialty drug treat rare condition afflict person undergo stem cell transplantation jazz acquire drug buy italian biotech gentium january jazz share rise late tuesday close celgene celg oct say ep climb cent beating analyst estimate cent share sale grow more wall street expect biotech guide full year revenue prior year line analyst view trim outlook flagship cancer drug abraxane investor weren worry take celgene stock day celgene stock be ibd leaderboard list top rate stock fall tuesday allergan agn buyout target lose round court tuesday bid defend takeover bid valeant vrx district judge david carter deny allergan motion sue valeant activist investor bill ackman persh square capital management insider trading bid block persh voting stake allergan special meeting slate dec allergan share rise tuesday hit new high investor see greater chance valeant takeover oct allergan report solid earning raise guidance ep rise beating estimate sale rise line guidance firm see ep vs year analyst consensus bonus stock actavis act be slate report financial result wednesday morning market open wall street expect ep jump surge revenue specialty drugmaker say oct be acquire biotech startup durata therapeutic cash follow james detar twitter ibd_jdetar
535,AGN,several highly rate tech company drugmaker be set report earning wednesday here look analyst expect actavis act report result open specialty drug giant be project earn share jump last year revenue be see skyrocket botox maker allergan agn be fight
536,AGN,diversify stock fund gain november propel rally stock market push third strongest gain year be continuation rally begin mid october lead gain diversify fund month rebound be drive grow investor perception pullback
537,AGN,several big cap stock have recently break basis be still buy range be build new basis be good addition watch list alexion pharmaceutical alxn have pull back be buy zone stock break cup handle base oct double usual volume go
538,AGN,stock end mixed back forth session monday continue pattern mildly choppy action weakness energy stock rise new close high bounce back loss intraday tug war index close little change fifth straight session nasdaq trim deficit
539,AGN,mylan myl company president rajiv malik be name sweeping lawsuit tuesday state attorney general expand complaint charge drugmaker prosecutor call mind blow scheme fix generic drug price newly expand complaint allege drugmaker collude fix price pharmaceutical communicate trade show conference other event well email phone text message together company work together falsely inflate price drug treat glaucoma arthritis high blood pressure diabetes anxiety asthma well several other condition attorney general allege allege complaint defendant company collusion be so pervasive essentially eliminate competition market drug entirety connecticut attorney general george jepsen say prepared statement jepsen be lead charge describe conspiracy allege mind blow mylan say stand malik have find evidence price fix part mylan employee mylan say still wait attorney general share information intend substantiate new allegation mylan have deep faith integrity president rajiv malik stand fully firm say prepared statement mylan rajiv malik intend defend case vigorously look forward opportunity present full defense ibd take biotech stock have largely have mixed report quarter celgene sale miss lower expect sale otezla cause stock slide hard head ibd industry theme closer look earning season thus far generic drug sale be estimate today generic drug industry account prescription written mylan lawsuit also include generic giant teva pharmaceutical teva new complaint add actavis pharma acquire teva allergan agn dr reddy laboratory rdy novartis nvs sandoz unit close bell stock market today mylan topple broad generic drug group plunge collective generic firm name complaint lannett lci lead downward slide fall close mylan malik satish mehta chief executive manage director privately hold emcure pharmaceutical parent company heritage pharmaceutical be other individual name complaint earlier year former heritage executive admit price fix scheme april december involve generic antibiotic diabetes drug heritage be drugmaker name initial lawsuit late evercore analyst umer raffat expect series settlement have originally expect teva pay damage ultimately settle mylan pay related generic drugmaker crash perrigo search antitrust probecelgene ceo drug pricing debate hinge incentive innovationdoj charge pharma exec price fix teva mylan stock fall
540,AGN,allergan agn be advance hepatitis drug phase testing likely win get food drug administration approval analyst predict friday mizuho analyst irina koffler be still constructive allergan stock have buy rating price target close stock market today allergan lift finish disappointing datum drug call cenicriviroc treat be know nash nonalcoholic steatohepatitis phase trial cenicriviroc miss key goal course year patient treat cenicriviroc fail achieve statistically significant improvement fibrosis liver compare patient receive placebo datum include patient treat year cenicriviroc switch allergan drug year placebo patient higher fibrosis start cenicriviroc ultimately have better outcome year treatment period allergan plan release full result upcoming medical conference cenicriviroc prove be safe compare placebo firm say news release most common side effect be diarrhea headache fatigue ibd take allergan have ibd composite rating best possible meaning trade bottom half stock term key growth metric head ibd stock checkup look better rate drugmaker patient be enrolled phase trial have more serious fibrosis liver koffler say allergan plan follow patient year period goal be reduction fibrosis worsening nash year don see be realistic trial require liver biopsy year point be deem unethical local institutional review board koffler write note client koffler expect cenicriviroc disappointment be already baked allergan stock have topple more hit high late july allergan have trade well day move average early august bottom line here be molecule cenicriviroc be unlikely make approval say only upside be have very little model nash so be minimal impact valuation allergan still have promising portfolio migraine depression write evercore analyst umer raffat note allergan be expect provide datum phase phase trial drug treat chronic acute migraine first half related generic drug maker face pricing issue other pharma companiesteva mylan pressure rivalry loom key drugswhy allergan be stagnant beating view raise outlook
541,AGN,allergan agn stock tank monday federal judge invalidate patent cover eye drug restasis dispute pit allergan group generic drugmaker lead teva pharmaceutical teva mylan myl xby close bell stock market today allergan topple finish teva fall close mylan lift fraction end regular trading session judge william bryson say idea cover restasis patent be too obvious protect evercore analyst umer raffat write note client bryson tend agree allergan be case infringement patent be hold be valid allergan pledge news release appeal decision ruling invalidate patent restasis date none propose generic version restasis have receive approval none be able launch market firm note allergan remain commit vigorously defend intellectual property product allow continue invest develop bring forward new medicine million patient chief legal officer robert bailey say statement ibd take allergan have ibd composite rating meaning outperform just half stock track term key growth metric head ibd stock checkup list better perform drugmaker follow allergan move last month transfer right patent st regis mohawk tribe legal play be call creative controversial take advantage native american tribe sovereign status bryson have serious concern legitimacy tactic raffat say allergan purport have sell patent tribe reality have paid tribe allow allergan purchase perhaps more precisely rent tribe sovereign immunity say successful method give patent defendant new method defeat challenge raffat expect final decision base allergan appeal late suggest allergan seek injunction rival generic related allergan hepatitis drug likely win get fda approvalgeneric drug maker face pricing issue other pharmas don tteva mylan pressure rivalry loom key drug
542,AGN,allergan agn be already face public relation backlash transfer patent right restasis eye medication native american tribe judge monday then invalidate patent xnow allergan face battle regain credibility wall street credit suisse analyst vamil divan write note client cut price target allergan keep outperform rating generally have be fan allergan management team find challenge defend step be take patent agreement write note client believe take time management team regain credibility have lose process process involved transfer right restasis patent st regis mohawk tribe september avoid patent challenge native american tribe st regis mohawk have sovereign immunity play have be call creative well controversial monday judge invalidate patent cover restasis judge william bryson say idea cover patent be too obvious protect also expressed serious concern regard legitimacy transfer st regis mohawk ibd take allergan have ibd composite rating best possible lag top player abbvie cr meaning perform top stock term key growth metric head ibd stock checkup look other high ranking drug stock even monday allergan stock have lose value follow agreement divan write loss district court also do nothing erase public relation backlash company have suffer go agreement first place combine push food drug administration approve generic drug faster clip divan assume generic launch restasis drug mid earlier view mylan myl teva pharmaceutical teva be work generic version drug longer term investor divan see attractive entry point stock short term catalyst include third quarter earning nov potential guidance update generic restasis competition guidance be not provide nov call least high level investor likely have january time frame company guidance divan say datum readout include late stage trial treat acute migraine midstage trial drug prevent migraine first half class drug call cgrps teva amgen amgn eli lilly lly aldr be also work arena close bell stock market today allergan slip close end monday trade related allergan tank judge invalidate restasis patentswhy allergan hepatitis drug likely win get fda approvalgeneric drug maker face pricing issue other pharmas don
543,AGN,index other major average rise modestly record high apple aapl report strong earning guidance iphone launch facebook fb crushed view warn soar operate cost tesla tsla miss badly temper model goal production hell continue alibaba baba deliver huge growth symantec symc several security stock tumble oclaro oclr spur big fiber optic retreat president trump nominated new federal reserve chairman house gop finally unveil big tax cut plan job growth do not rebound much expect last month index dow industrial nasdaq extend weekly streak modest gain new high new wave earning president trump fed pick gop tax plan megacap apple give nice friday lift follow strong result facebook crushed view warn ll hike security spending russia tie political content reach nearly half american tesla report big loss burn cash push back model production path cut model model output alibaba have stellar result fiber optic several cybersecurity stock be hammer home depot hd homebuilder sell thursday house republican include measure slash mortgage interest deduction tax plan related stock buy watch top ipos big small cap growth stocksapple sell more iphone ipad mac computer expect fiscal fourth quarter apple earn share sale analyst expect china sale rise first time quarters december quarter typically conservative apple guide revenue slightly consensus ceo tim cook say be bullish apple prospect expect best holiday season yet thank iphone iphone handset iphone go sale friday share jump record high friday close related apple beat earning sale target guide sale higherapple give rare bullish outlook iphone hit storesfacebook report blowout earning snap quarter string decelerate revenue growth social medium giant say see faster growth expense facebook commit step spending improve security platform follow day congressional hearing role facebook google googl twitter twtr play russia misinformation campaign presidential campaign facebook share fall thursday close week fractional gain still buy zone related analyst hail blowout earning be facebook be downchina commerce leader alibaba report better expect fiscal second quarter result annual active consumer alibaba retail marketplace reach year end quarter mobile monthly active user previous quarter share have run several day record high head earning dip follow report alibaba earning revenue beat estimate strong third quarter adjust loss cash burn be much expect tesla reveal continue model rollout wo tesla now expect hit production rate model vehicle week late first quarter push back plan month tesla share fall thursday hit month low related tesla third quarter result show big miss model wo economy add job october less expect be notable upward revision prior month affected hurricane unemployment rate dip new cycle low average hourly wage be flat vs september meanwhile ism manufacturing index pull back longtime high still show factory activity be expand rapidly related jobless rate sink wage slip october payroll president trump tap federal reserve gov jerome jay powell succeed janet yellen chair central bank term expire february wall street breathe bit easier become clear powell get nod be expect follow yellen low interest rate path powell republican former investment banker serve george bush treasury department be somewhat more amenable yellen ease post crisis bank regulation trump priority yellen lead fed keep rate steady wednesday sign point december hike related federal reserve hold rate steady december hike bioscience nbix exelixis exel juno therapeutic juno rise demolish view clovis oncology clvs dove widely miss incyte incy report better expect metric expand cancer deal astrazeneca azn dow pfizer pfe allergan agn be soft revenue narrow full year sale outlook teva pharmaceutical teva earning miss drugmaker cut full year forecast cite challenge face copaxone generic drug add industry concern pricing tuesday sweeping antitrust lawsuit vs generic drugmaker be expand include total company president mylan myl meanwhile bluebird bio blue juno pop preliminary datum respectively sickle cell disease aggressive lymphoma related teva dife long road ahead earning miss guidance blood disease datum send biotech stock flyingdow pfizer fall legacy medicine exelixis juno stock rocket crush viewsshale operator generally show spending discipline third quarter investor shift focus production growth cash growth spending cash flow pioneer natural resource pxd boost capital spending outlook concho resource cxo devon energy dvn beat bottom line anadarko petroleum apc miss eog resource eog beat quarterly estimate announce new oil play together hold barrel oil equivalent crude future trade year high related eog resource beat view announce new premium oil playspioneer natural resource crush earning view laredo mixedshale earning concho resource devon energy beat anadarko blizzard atvi post better expect third quarter sale profit raise full year guidance thank game destiny call duty wwii guidance not have be strong enough activision reversed lower record high friday nintendo ntdoy nearly double profit outlook current fiscal year thank switch console exclusive game super mario odyssey nintendo now expect ship switch console financial year end march previous prediction ea ea stock fall publisher forecast lower expect sale holiday quarter prospect star war battlefront game remain big question mark december quarter related nintendo nearly double profit outlook switch hit home runbroadcom avgo deliver positive surprise thursday announce revenue fiscal fourth quarter end oct be higher end guidance range friday broadcom rise apple earning report be close deal buy fellow iphone chipmaker qualcomm qcom spiked meanwhile other chip company get mixed reaction third quarter result qorvo qrvo drop disappointing december quarter sale earning guidance cavium cavm beat wall street forecast sale earning september quarter share still fall cirrus logic crus also report better expect result quarter stock rise department justice sue block buy time warner twx say report analyst say leak reflect doj try increase leverage negotiating condition set deal condition involve access time warner content base analysis emerge internet video service pay tv market sprint owner softbank reportedly walk away merger talk involve mobile tmus parent deutsche telekom sprint valuation management control seem be stumbling block late week talk be say be back ford motor grow new car sale october consumer demand utility vehicle truck continue intensify series truck be especially brisk seller general motor gm see sale slide do better expect fiat chrysler fcau sale drop estimate slash low margin fleet sale annualize pace auto sale last month be accord autodata be september see strong post hurricane demand replacement vehicle ferrari race top earning view raise full year guidance share drop buy point related ford gm top october sale view fiat chrysler tumbleferrari raise earning revenue view tesla big flopoclaro oclr plunge december quarter guidance send share other optical device supplier include finisar fnsr lumentum hold lite neophotonic nptn weak demand china telecom gear maker have pressured fiber optic stock new worry involve datum center market internet company be shift purchase new type optical device inventory build slower part lumentum fall expectation apple aapl order more sensor iphone acacia acia also give december quarter guidance well estimate earning computer security software maker be mixed share qualys qlys cyberark software cybr jump report september quarter result investor hammer check point software technology chkp symantec symc fireeye feye analyst say shift cloud compute service be roil security market startup be take share incumbent casino operator la vegas sand lvs melco resort entertainment mlco wynn resort wynn mgm resort international mgm get lift month gross gaming revenue increase macau well positive datum nevada news gamble expansion pennsylvania share melco plunge thursday top earning sale forecast aetna aet object acquisition talk cvs health cvs grab center stage easily beat earning expectation soft top line result wellcare health plan wcg steal show leap buy zone earn rank ibd medical manage care industry group base earning revenue margin stock performance trend wellcare earning surge help strength medicaid medicare focuse acquisition aetna highlighted medicare primary growth driver report increase ep revenue fall molina health moh medicaid obamacare exchange insurer report better expect earning send share soar friday aetna add recent cvs tie gain mostly friday wellcare rocket record high cvs aetna finalize deal december reportaetna top earning view mum cvs wellcare health soarsshopify shop report first ever adjust profit beating view share commerce software maker fall high volume trading analyst call shopify battleground stock criticism short seller citron research paycom software payc report earning top expectation light revenue guidance send share maker human resource payroll process software constellation brand stz beer wine spirit producer say take stake canadian medical cannabis provider canopy growth move intend keep apace early stage consumer trend concern legalization impact booze sale molson coor tap say keep eye marijuana market cme group cme massive derivative marketplace say plan launch bitcoin future mark big step financial world acceptance still volatile cryptocurrency bitcoin soar new high mastercard beat third quarter earning revenue expectation raise year operate expense forecast largely due spending related investment masterpass digital wallet armour uaa cut full year target cent ep well view cent turn mixed result quarter share crumble tuesday multiyear lows
544,AGN,everyone know high prescription drug price be problem pharma stockholder few person realize price cut be ripple generic side industry take look recent event tumble generic drug price wipe billion dollar market value august like teva pharmaceutical teva mylan myl dr reddy laboratory rdy compound industry wo brutal second quarter earning season relatively small contingent pharma company produce cheaper version brand name drug be get broadside player distribution chain lead wholesaler be squeeze drugmaker lower price undercut battle pharmacy contract meanwhile group purchasing organization be consolidate grab more negotiating power represent hurdle generic comprise large chunk purchase analyst say be month price stabilize ever recover mean lower price patient drugmaker be take brunt battle price have clearly deteriorate aftermath contract negotiation evercore analyst umer raffat say aug audio report question really be do mean go forward say look way mylan teva stock have behaved look way estimate have be revise clearly suggest material worsening business teva stock lose august have re-cover month drugmaker market cap be close lose status july teva market value have fall nearly half comparatively mylan trail cap teva isn only feel pain selling pressure shave mylan market capitalization august share have topple begin august particularly disheartening quarterly report whole investor business daily generic drug industry group be year date near year low august rank group track ibd underlie cause price erosion stem back drugmaker spiked price base shortage monopoly other opportunity credit suisse analyst vamil divan tell ibd something be day see day re only make be competition say else produce have more flexibility price drug now card be go say ibd take teva have ibd composite rating best possible meaning perform bottom stock term key growth metric top rank generic drugmaker be ani pharmaceutical have middling cr visit ibd stock checkup look stock not only competition be more fierce also generic face adversary heavy scrutiny medium washington january then president elect donald trump accuse drugmaker get away murder pricing now aim use competition undercut price complicate matter drugmaker teva mylan perrigo prgo include be investigation department justice allege generic drug price fix last month member congress send letter maker multiple sclerosis drug probe rise drug price yet wrench generic story divan say investor be look cleaner story say too much unknown here teva mylan second quarter earning call project price erosion high single digit rest mylan specify erosion take place north american generic unit follow lackluster quarterly report mylan north american sale decline teva number be help acquisition actavis generic teva mylan cut forecast call executive company acknowledge increase generic approval food drug administration be champ sale new fda commissioner scott gottlieb be look speed generic approval even more help ease drug price be line trump vision quarter see increase competition result fda focus accelerate approval third fourth fifth generic mylan president rajiv malik say unfortunately have not see same first generic more complex niche product result mylan say delay launch generic version glaxosmithkline gsk asthma drug advair teva multiple sclerosis drug copaxone uncertain regulatory environment teva former interim chief executive yitzhak peterburg cite customer consolidation increase fda generic drug approval product be delay subject more competition accelerate price erosion decrease volume second quarter fda approval complication be cite second quarter report mizuho analyst irina koffler say aug report client generic approval be catch wind fda new goal complex generic molecular copy also have complex active ingredient formulation route device combination have be subject administrative delay koffler see mylan best position rebound tie challenged generic sector firm have pipeline complex generic biosimilar guidance be now more realistic less lever peer meaning pursue acquisition company stock have drop risk be pricing pressure not abate overall profitability company be decline expand lower margin international market now comprise greater percentage revenue say few drugmaker seemingly escap second quarter malaise report be somewhat mislead cfra analyst jeffrey loo tell ibd perrigo issue beat raise help stock fly day perrigo generic drug sale topple year year separate consumer health segment have smaller decline internationally respectively valeant pharmaceutical vrx crushed second quarter profit view sale come hair light firm also cut revenue target keep earning interest taxe depreciation amortization forecast lot person consider valeant generic play bulk business be now bausch lomb eye care product loo say quarter revenue bausch lomb well salix drug division represent total sale smaller generic unit other hand fall exclude valeant generic space perrigo none generic drugmaker really buck trend second quarter loo say think pressure group likely continue go forward next quarters teva lead generic drug sector also most pressure steven schoenfeld chief information officer bluestar index tell ibd bluestar index track israeli equity cybersecurity play check point software technology chkp be now bigger teva term market cap former teva chief executive erez vigodman step february bribery investigation then management have be shaky firm strategy have be kilter schoenfeld say follow loss several key patent protect ms drug copaxone january september teva name former lundbeck nordisk nvo veteran kare schultz new chief executive officer still teva be splitting focus generic brand drug schoenfeld say need strategy say need see want expand continue invest blockbuster drug ve now get early stage alzheimer asset other drug have decide re go be percentage generic so do profit go innovation meanwhile debt have rocket investor be longer sure teva paid acquire actavis generic allergan agn be good price say june teva have debt rise end march schultz teva recently avoid covenant violation debt teva say amend several term loan revolve credit facility provide teva greater flexibility financial leverage ratio covenant question forefront now be generic drug sector have hit bottom recent history mylan have come scrutiny pricing emergency allergy injection epipen turing pharmaceutical former chief executive martin shkreli draw criticism spiking price decade old hiv drug teva be be look ms drug price popular culture have turn bluestar schoenfeld say secular trend aren go go away market see pricing pressure have stock price worst teva be trading have major support time frame wouldn recommend anyone plunge teva most firm be now trading time earning cfra loo say continue price erosion see stock trading sideway next month note aren many drug go patent future cause somewhat roadblock new generic hope ve hit bottom say be not many catalyst go forward see buyer step buy share company time earning be awfully attractive valuation related biogen teva slip democrat launch ms drug pricing topple generic drugmaker be poise rebound fall generic drugmaker get analyst upgradegeneric drug be rebound teva mylan free fallperrigo beat raise lift generic drug buck teva mylan trend
545,AGN,teva pharmaceutical teva mylan myl stock rise tuesday sustain price target cut downgrade respectively follow lackluster second quarter report result haircut guidance xby close bell stock market today teva inched mylan gain still stock have trade well day move average month generic drug maker face pressure mizuho analyst irina koffler slash price target teva nearly half keep neutral rating see teva struggle bring gross debt year end face upcoming competition multiple sclerosis drug copaxone teva end second quarter debt likely struggle patch together combination asset sale operate cash flow allergan agn work capital settlement full dividend cut bring gross debt year initial debt hurdle be clear teva indicated be able push maturity bank debt refinancing koffler write note client help share wouldn solve teva problem generic version copaxone be likely come market erode already weak earning interest taxe amortization depreciation write longer term expect decline remain business don see anything brand pipeline change trajectory write teva eventually lose investment grade rating result further share deterioration be possibility longer term argus analyst jasper hellweg downgrade mylan hold rating buy cite weak outlook mylan guidance adjust income share imply decline midpoint firm also lower sale view ibd take top generic drug maker be poise rebound analyst say last week head ibd technology page deep dive drugmaker look stronger still mylan stock have be pressure year due controversy surround epipen pricing hellweg write note client earlier month mylan finalize settlement justice department epipen pricing medicaid justice department allege company have overcharge medicaid classify epipen generic rather brand product write drugmaker be able pay lower rebate government generic drug brand drug recently justice department reveal source information be sanofi sny separate antitrust suit sanofi allege mylan offer discount insurer pharmacy benefit manager make more difficult sanofi rival drug get medicaid reimbursement new york attorney general also be investigate mylan practice selling epipen school discount price exchange exclusive contract hellweg say mylan have eliminate exclusivity provision deal adamis pharmaceutical admp also be likely take share mylan epipen gain approval drug symjepi be market low cost alternative epipen hellweg write also prepare junior dose symjepi compete low dose epipen symjepi be smaller epipen potential advantage product be often carry time person life threaten allergy write look epipen benefit establish reputation many consumer be likely prefer epipen auto injector vs symjepi be self administer injection hellweg write related fall generic drugmaker get analyst upgradegeneric drug be rebound teva mylan free fallperrigo beat raise lift generic drug buck teva mylan trend
546,AGN,theravance biopharma tbph exelixis exel tick most acquisition box big pharma overview biotech merger picture analyst say friday acquisition biotech company pharma be important theme space needham analyst alan carr say note client believe late development stage commercial stage biotech company be particularly attractive acquisition target part due reduce risk company carr cover theravance attract big pharmas amgen amgn eli lilly lly teva pharmaceutical teva total carr count company be interested buy theravance base research area business development interest past acquisition theravance have approve drug antibiotic hard treat infection exelixis agio pharmaceutical agio bavarian nordic pharmaceutical bhvn progenic pharmaceutical pgnx be attract interest pharmaceutical apiece abbvie astrazeneca azn novartis nvs roche rhhby dow stock pfizer pfe johnson johnson jnj be most acquisitive base carr criterium have least potential target biotechs stand better chance be acquire vs other carr say january have be acquisition public biotech company involve payment more upfront more half already have approve drug have least phase datum carr write oncology be key target japanese pharmas rare disease play be likely be acquire later stage ibd take last month potential acquisition target jump ibd relative strength rating best possible today still have rating head ibd datum story closer look stock catalyst rare disease tend be interest mid specialty pharmas biotechs traditional drugmaker be likely avoid drug pricing controversy january only rare disease firm snatch be actelion pharmaceutical european pharma acquire more later stage biotechs vs less risk adverse japanese pharmas allergan agn big area interest include central nervous system rare disease oncology account acquisition respectively january have be new chemical entry approval food drug administration small midsize biotechs gain type approval have be acquire already have drug market time acquisition many oncology company few rare disease company be acquire say gilead science gild acquisition kite pharma kite break approval rule gilead announce plan spend buy kite month ahead expect approval date first drug blood cancer novartis rival treatment be approve day later related small biotech launch month high today here whyexelixi recover bristol inspire pitfall kidney cancerbristol dife still have chance kidney cancer analyst
547,AGN,dow jone component merck mrk remain credit suisse top pick head european society medical oncology conference october drugmaker allergan agn eli lilly lly also look strong brokerage say monday time merck be expect unveil result trial dub keynote testing immuno oncology drug keytruda chemotherapy previously untreated patient advanced lung cancer combo receive accelerate approval expect continue discussion potential used keytruda await top line datum confirmatory keynote study september october time frame expect be positive credit suisse analyst vamil divan say second quarter conference call july merck confirm cyberattack delay product year say full recovery cyberattack take time still merck be best position remainder divan say note client merck share end regular trading session investor seem prefer abbvie abbv bristol myer squibb bmy divan be place bet allergan lilly still be several month allergan be expect unveil datum migraine trial say lilly offer diverse pipeline more interest be nordisk nvo trial know sustain be look diabetes drug semaglutide vs lilly trulicity divan see trulicity safer drug lilly be expect unveil datum trial drug abemaciclib breast cancer upcoming oncology conference divan say lilly be also plan file application migraine drug be drive adoption new drug cancer plaque psoriasis ibd take biotechs have struggle lately be now rank seventh group track ibd fifth last week sector hit week low thursday hit month high july head ibd industry theme more happened meanwhile divan isn bullish commercial potential drug abbvie inflammatory disease immuno oncology also call relatively rapid erosion sale key drug humira once generic enter market likely bristol case rumor become takeover target have limit stock term early asset immuno oncology potential approval kidney liver cancer drive upside time divan argue credit suisse also reinstate coverage dow stock johnson johnson jnj july divan note valuation be limit investor interest likely change release datum compass trial european society cardiology meeting meeting be set later month be look ability anticoagulant xarelto prevent major adverse cardiac event include cardiovascular death heart attack stroke patient heart disease expect compass be star meeting have potential dramatically increase uptake xarelto come quarters something move needle even company size divan write divan also note downgrade pfizer pfe teva pharmaceutical teva neutral rating outperform quarter dow stock pfizer be struggle term catalyst lack acquisitive appetite potential tax reform teva other hand be range bound new leadership team be place strategy reduce debt be more certain more clarity potential generic version copaxone multiple sclerosis drug milligram be obtain write related pfizer cancer drug help grow merger generic drug be rebound teva mylan free fallperrigo beat raise lift generic drug buck teva mylan trend
548,AGN,botox maker allergan agn top wall street second quarter model thursday stock reaction be muted light sale eye drug restasis stagnant revenue fat strip drug kybella second quarter end june allergan report adjust income share sale respective vs year earlier period consensus expect adjust earning share sale allergan also raise guidance revenue adjust income share previously allergan have guide sale adjust earning share raise be unexpected view mizuho analyst irina koffler say note client koffler keep price target buy rating allergan stock stock be hold back mixed performance key product botox cosmetic revenue miss koffler estimate grow year year botox therapeutic bring top koffler view grow allergan cite trade buy pattern stable volume demand decrease sale eye drug restasis number also miss consensus view koffler say ibd take allergan lead medical aesthetic market rival hologic holx dow johnson johnson jnj valeant pharmaceutical vrx have piece sector head industry snapshot closer look layout unit sale linzess increase vs year earlier quarter widely miss street expectation koffler say follow destock first quarter sale kybella injection used improve appearance fat chin be flat juvederm collection sale climb coolsculpt sale be follow close zeltiq acquisition late april stock market today allergan inched less close july share top buy point flat base begin form february related biotech be head deal ceo take rein small biotech launch month high today here biotechs defy downtrend hit fresh high
549,AGN,be good short seller improve chance select best stock profit downside spending time search crumble fundamental need little extra time do such research such effort usually pay crumble be hard quantify give important earning be stock health be lookout
550,AGN,generic drug maker mylan myl continue free fall friday rival teva pharmaceutical teva manage briefly arrest slide broader generic lead eagle pharmaceutical egrx defy trend spiked higher third straight day xin afternoon trading stock market today ibd company generic drug industry group pop highest point aug day teva report second quarter earning sale miss cut guidance generic drug stock broadly trade consecutive day begin recover earlier week eagle aclaris therapeutic acrs lead group midday friday rise respective perrigo prgo offer quarterly beat raise week pop analyst expect perrigo generic drug business topple quarter follow disappointment teva mylan generic business do decline strength consumer drive business be enough help perrigo top expectation perrigo shot thursday second quarter report amazing good quarter do ub analyst marc goodman write research report have buy rating price target perrigo goodman note perrigo do unexpected increase net sale guidance generic drug unit perrigo bump expect generic sale earlier view due earlier expect launch new product significant move stock be also due solid upside consumer business combination cost cut execution be drive margin improvement appear be sustainable goodman say ibd take inflation have have part play earning miss head ibd economy page see teva other have be impact perrigo boost generic guide call year year erosion generic drug price second half year separate report goodman nearly halved price target teva keep neutral rating expect teva see generic competition multiple sclerosis drug copaxone first quarter lose several key patent earlier year more importantly have significantly lower generic number topline margin base management see new generic landscape write analysis suggest be not buy opportunity hence remain neutral stock goodman assume teva generic business likely decline average decrease be drive base erosion be partially offset new product launch say teva expect generic revenue decline look save money close manufacturing facility well synergy allergan agn generic deal teva acquire allergan generic business last august related perrigo beat raise lift generic drug buck teva mylan trendhow teva crash day be hurt generic pop report ceo win jump ship teva pharma
551,AGN,pfizer pfe be await clarification tax reform embark merger deal dow component say tuesday investor push acquisition second quarter sale decline again xinvestor have be clamore pfizer drugmaker market cap make more acquisition sale have fall past consecutive quarters early tuesday pfizer say second quarter revenue slip conference call follow report pfizer reaffirm be short term event marketplace such tax reform change asset value evercore analyst umer raffat say note client trump administration have make lofty promise regard tax reform include proposal cut corporate tax rate help domicile company render corporate inversion less desirable washington act tax reform business development acquisition be somewhat delay pfizer reportedly say need see tax reform absence tax reform then look business development activity ibd take president donald trump tax vision benefit biotechs drugmaker more other head ibd technology page breakdown look likely benefit most year pfizer chief method grow topline have be make big deal acquire medivation last year deal earlier year buy anacor pharmaceutical bind therapeutic bamboo therapeutic also walk away deal acquire allergan agn political controversy link allergan ireland tax domicile deal have let pfizer change tax domicile ireland thus pay less taxe legacy drug weigh pfizer quarter pneumonia drug prevnar see sale decline pristiq depression drug lose market exclusivity topple sale erectile dysfunction drug viagra fall meantime pfizer be putt effort further develop immuno oncology drug call bavencio approve treat form skin cancer bladder cancer drug be develop germany merck kgaa bavencio be pd inhibitor compete rival drug astrazeneca azn roche rhhby competitor space dow merck mrk bristol myer squibb bmy have pd inhibitor pfizer be look combine bavencio other drug pfizer acknowledge tuesday call astrazeneca recent failure combine immuno oncology drug imfinzi tremelimumab treat lung cancer doesn bode well similar combination trial indicate immuno oncology immuno oncology combination be more problematic term pfizer reportedly say pfizer note value have pd inhibitor purview still other be ahead stock market today pfizer fall share be yearlong consolidation buy point related generic chip away dow stock pfizer cancer unit be stabilize astrazeneca fail not once twice cancer drugswhy clovis regeneron be lead biotech deluge todayhow dow merck be benefit back astrazeneca bristol
552,AGN,here weekly investing action plan need know investor come week xapple aapl tesla tsla square sq grubhub grub headline busy week earning top shale producer weigh sign slow activity oil patch fresh set
553,AGN,sarepta therapeutic srpt stock pop time thursday speculation biotech be auction block announce hire new savvy chief executive xdougla ingram succeed ed kaye chief executive sarepta biotech say late wednesday ingram be allergan agn president front runner chief executive takeover actavis kaye remain advisor ingram also be credit corporate turnaround allergan include reduce cost increase earning growth north leerink analyst joseph schwartz say note client help fend takeover bid valeant pharmaceutical vrx ingram be chief executive privately hold chase pharmaceutical allergan formerly actavis acquire deal also include regulatory sale milestone corporate success biotech pharma company knowledge expertise disease make ideal appointment sarepta be seek solidify leadership duchenne muscular dystrophy space schwartz say ibd take sarepta stock have middling ibd composite rating meaning underperform more third stock term key growth metric head ibd stock checkup look strongest rate biotechs ingram hire also spike potential takeover analyst say rumor biotech be auction block have circulate drug treat duchenne muscular dystrophy exondys be approve last year follow kaye announcement first quarter step french drugmaker sanofi sny have often be cite potential acquirer sarepta takeover speculation layer premium company valuation schwartz say schwartz previously upgrade sarepta stock outperform rating likelihood commercial success exondys sarepta be set announce second quarter earning july prior quarters show exondys be gain momentum say rbc analyst matthew eckler see ingram benefit sarepta background neurology drug development duchenne muscular dystrophy be neurological disorder prior dealmake experience also help sarepta license drug eckler have outperform rating sarepta stock credit suisse analyst alethia young also keep outperform rating price target sarepta stock call ingram strong fit sarepta point stock market today sarepta stock lift much general market sellloff bring share close related sarepta pop consensus top revenue boost humana unite push back sarepta fda approve dmd drugsarepta costly muscular dystrophy drug flirt big pharma
554,AGN,allergan agn report better expect earning first quarter early tuesday strong demand aesthetic eye care product adjust income rise share revenue vs year earlier quarter beating expectation cent quarter end march sale grow year year top view allergan credit increase sale higher demand facial aesthetic botox therapeutic eye care birth control loestrin addition lifecell regenerative medicine business sale growth total medical aesthetic advanced quarter include facial aesthetic sale grow vs year period regenerative medicine lifecell add chunk revenue medical dermatology sale be sale juvederm advanced juvederm be injectable filler facial line fold meanwhile allergan generic medicine unit fall sale dementia drug namenda topple year year allergan blame promotional support conversion namzaric decline namenda sale namzaric sale grow birth control loestrin grow wasn enough offset decline sale birth control minastrin lose exclusivity march sale woman hormone cream estrace fall lower net pricing trade buy pattern revenue be lead linzess drug approve treat constipation grow sale asacol delzicol approve treat ulcerative colitis fall asacol be impact generic entry demand decline delzicol allergan see full year revenue adjust ep midpoint wall street expect revenue ep ibd take allergan have dominate presence medical aesthetic space look unlikely anyone keep few be try head industry snapshot deeper look botox breast implant ear pin new forecast include fat freeze firm zeltiq aesthetic allergan agree buy february chief executive brent saunder call pivotal year allergan start solid well execute first quarter say statement many key brand continue deliver significant year year growth lead botox juvederm collection filler regenerative medicine business linzess loestrin allergan share rise high reversed lower close stock market today allergan have potential buy point related stock buy range ahead earning report investing action plan
555,AGN,hologic holx stock topple week low thursday firm beat fiscal second quarter sale profit view report lag breast screening revenue note significant disruption cynosure unit late afternoon trading stock market today hologic stock be earlier fall much wednesday close hologic share be year date follow acquisition body sculpting firm cynosure cynosure sale fall year year full quarter hologic cynosure bring beat view canaccord analyst mark massaro modeled blip cynosure sale be due turnover time hologic acquisition company say cite leak deal create significant distraction then hologic have filled vacancy be look add skin tighten future hologic cynosure unit be expect be huge massaro say recent survey doctor core doctor be perform invasive aesthetic procedure today say offer procedure future ibd take hologic acquisition cynosure follow allergan agn acquisition zeltiq day cynosure zeltiq be rival aesthetic business allergan be pull ahead market analyst say head industry snapshot more allergan be dominate market management win quantify opportunity other state be huge write note massaro keep buy rating price target hologic stock note breast health unit stifle quarter hold better fear revenue breast health grow miss consensus view breast imaging used technique call tomosynthesis slow quarter hologic cite political unease decline management note hospital have slow spending base concern potential repeal healthcare reform needham analyst mike matson write note client breast health sale decline growth year earlier quarter international sale accelerate growth matson have buy rating price target hologic stock related hologic smash fiscal sale view beat profit cent
556,AGN,hologic holx crushed wall street fiscal second quarter revenue profit expectation late wednesday lead double digit growth molecular diagnostic gynecological surgery unit hour trading stock market today hologic stock pop close less share be year follow hologic acquisition body sculpting firm cynosure cynosure be rival zeltiq be recently acquire allergan agn second quarter end april hologic report adjust income cent share revenue earning grow year year basis top cent sale be beat view hologic molecular diagnostic segment lead quarter grow comprise total sale gynecological surgery revenue follow sale skeletal health fall ibd take allergan hold dominant position medical aesthetic market hologic make dent cynosure acquisition head ibd industry snapshot closer look setup quarter hologic sell blood screening business grifol grfs part quarter sale blood screening business bring medical aesthetic unit create cynosure acquisition account related hologic follow allergan buy body sculptor cynosure bil
557,AGN,allergan agn jazz pharmaceutical jazz be expect tuesday report grow first quarter profit allergan be likely see sale decline first time period sunnier view jazz share allergan jazz dip allergan lose jazz fall stock market today share allergan player so call medical aesthetic have be form flat base february jazz stock hit buy point cup handle formation april first quarter analyst expect allergan report adjust income share sale respectively year year basis profit fall past quarters sale have grow march wall street likely be key early tuesday allergan conference call more company nonalcoholic fatty liver disease steatohepatitis program last month allergan announce team novartis nvs arena follow several acquisition jazz be expect close tuesday report sale adjust earning share first quarter sale be earning share grow vs year earlier period ibd take anyone catch allergan medical aesthetic not look likely head industry snapshot closer look allergan be dominate space analyst be look strong sale xyrem narcolepsy drug jazz biggest moneymaker bring total sale revenue increase due strong sale xyrem defitelio anticoagulant jazz say investor keep close eye other narcolepsy med jazz drug know jzp last month jazz say drug have promising result study patient excessive sleepiness associate narcolepsy jazz plan submit application fda late year jzp obstructive sleep apnea narcolepsy related lilly outperform bigger rival strong diabetes med rival swipe jazz sleep business stock perk upjazz pharma isn doze stock break sleep apnea trial
558,AGN,here investing action plan tuesday need know investor come day fan favorite apple aapl facebook fb give current stockholder reason cheer be well buy range even apple bull warren buffett wouldn buy share again now be skittish amazon com amzn
559,AGN,regeneron pharmaceutical regn gilead science gild biogen biib benefit most biotechs president trump propose tax reform measure cut corporate tax rate trump proposal business size fortune mom pop shop freelancer live job job pay more business income taxe make corporate inversion unnecessary corporate tax rate be currently mean regeneron gilead biogen have guide adjust tax rate see serious boost cash trump proposal pass analyst say compromise beltway so rate be still air trump approval rating jump april gain ibd tipp presidential leadership index unveil tax reform proposal be first month month increase trump become president doesn mean big pharma biotech be totally sell trump proposal page document release april share biotechs drugmaker collectively lift less day generic drug stock pop gilead chief executive john milligan note uncertainty washington be norm so think ve kind learn filter focus thing be right company say gilead first quarter earning conference call be tax reform be repatriation count trump plan slash corporate tax rate benefit company consolidated tax rate remain well level consolidate taxe allow firm treat group wholly majority own company single entity tax purpose domicile drugmaker typically pay consolidated taxe canaccord analyst dewey steadman tell investor business daily company acquire foreign firm move tax domicile outside acquire company often lower tax homeland mylan myl acquire generic manufacturer abbott laboratory keep operational headquarters pennsylvania reincorporate netherlands march mylan say expect pay tax rate similarly allergan agn guide february adjust tax rate allergan corporate headquarters be ireland april pfizer pfe scrap attempt acquire allergan day treasury unveil new rule curb inversion former president barack obama call global tax avoidance huge problem urge congress close loophole good trump other hand say tax reform proposal make inversion unnecessary make america tax rate best world regeneron gilead biogen be biggest winner cut evercore analyst umer raffat say april report regeneron have guide effective tax rate gilead see first quarter biogen paid adjust taxe drugmaker pfizer eli lilly lly merck mrk bristol myer squibb bmy guide effective tax rate canaccord steadman mizuho analyst salim sy tell ibd everything politic be subject negotiation smaller biotechs say obviously positive future everyone be take see approach steadman say rate be probably go happen re not change capital expenditure organizational structure meantime ibd take look latest biotech drug news be sure bookmark ibd biotech pharma industry stock news page second facet trump plan allow time repatriation corporate cash park overseas discount tax rate be follow end deferral taxe corporate income earn abroad evercore raffat say amgen amgn benefit most drugmaker provision amgen have cash stash overseas money amgen use help boost war chest generic rivalry battle regeneron sanofi sny cholesterol front same be say gilead overseas cash be face dwindle sale hepatitis drug franchise gilead have be pressure month analyst chatter buy something bolster sale incyte incy be likely candidate analyst say accord raffat merck pfizer have respective cash outside lilly bristol celgene celg biogen abbvie abbv have park overseas cash be repatriate research development used fuel pfizer chief executive ian read offer similar view gilead milligan company first quarter earning conference call expect industry consolidation continue time political atmosphere remain major deterrent believe be simply too much redundancy fragmentation globally sector continually efficiently deliver medicine society say however be lack clarity potential tax reform health care policy uncertainty european market canaccord steadman doesn expect wave even trump tax reform pass muster congress need attempt pfizer allergan merger inversion purpose say appetite biotechs look healthy see decline big inversion type merger be not necessarily strategic see appetite biotech asset just tax picture look better say net result be actually decrease large merger maybe increase valuation biotech don think drife much more much still murky trump tax proposal analyst say general theme be tax reform be good thing biotech mizuho sy tell ibd don exactly know tax reform be go be be still lot piece move repatriation border tax don have component border tax be extreme drawback company manufacturing less expensive country such adjustment exempt export taxation tax import pwc analyst doug strang kathy michael write feb report january speech chamber commerce house way mean committee chairman kevin brady say tax eliminate tax incentive company move manufacturing overseas couple new lower gop tax rate local business end double taxation earning overseas establish america st century magnet new job technology breakthrough headquarters say gop tax plan be already drive company ask soon bring supplier back most company relocate operation back be paperwork nightmare canaccord steadman say current plan doesn include border tax provision nothing incentivize company bring operation back be enough keep newer smaller company re domicile overseas say probably entice future company not leave think core goal re try do say be domicile lower rate wouldn have leave cash foreign subsidiary cash be base encourage investment related do gilead just provide incyte potential deal dow pfizer top earning view sale come lilly new drug spark deeper rivalry pfizer novartis
560,AGN,generic drug stock crash wednesday news department justice have conduct search perrigo prgo office related widespread price fix investigation be also look teva pharmaceutical teva mylan myl early trading stock market today ibd company medical generic drug industry group fall collective week low lannett company lci perrigo stock lose most respectively lannett miss third quarter earning estimate late tuesday perrigo decline comment press release confirm authority execute search warrant perrigo corporate office have be previously disclose number company justice department antitrust division have be look industrywide pricing practice perrigo release say company be take investigation seriously be cooperate appropriate authority investigation center potential price collusion dozen company illegal company agree set price corporate discount perrigo case justice department be look price skin drug bloomberg report other drugmaker investigation be allergan agn impax laboratory impx covis pharma sun pharmaceutical mayne pharma taro pharmaceutical taro endo international endp subsidiary par pharmaceutical ibd take keep pharma news visit ibd biotech pharma industry stock news page mylan tell investor business daily last year receive subpoena regard doxycycline antibiotic hadn be ask information pricing tactic digoxin blood pressure drug be also search january jeffrey glazer jason malek former executive generic drug maker heritage pharmaceutical plead guilty price fix agreement other drugmaker related teva ceo step patent loss bribery settlement stock ionis outplay med sector perrigo tenet valeant diveperrigo share plunge plan sell ms drug royalty stream
561,AGN,oil major exxon mobil xom chevron cvx well slew energy company be gush best profit year yet crude price be plunge again level last see november clouding outlook dividend glimmer profit recovery trouble energy sector mean rush plow money back shareholder weakness oil price keep shareholder return muted first foremost oil price need improve energy sector dividend buyback return historical level say lindsey bell investment strategist cfra research energy earning be very highly correlated energy price oil price barrel be very hard stock perform grant engelbart portfolio manager cls investment agree rebound oil price be key energy company profitability therefore ability pay dividend buy back share same time note energy company have actually cut dividend earning season few include exxon phillip psx cabot oil gas cog actually raise dividend think dividend cut have probably come end company have mandate raise dividend continue do so engelbart say phone call latest report reveal energy company have do good job navigate new landscape cut back expenditure price bust hold massive outlay rebound add help cost cut royal dutch shell rdsa pump cash flow anglo dutch giant used cover dividend third straight quarter reduce debt yellow flag remain revenue exxon be expect first quarter chevron keep dividend unchanged even exxon raise payout company alone account nearly energy sector market cap energy sector also face tougher year year comparison course make earning growth less dramatic oil gas company flounder ugly commodity collapse early hope rebound yet materialize profit crater like conocophillip cop kinder morgan kmi anadarko petroleum apc chesapeake energy chk be force slash dividend payout case stock price plunge dividend yield spiked much even exxon world biggest oil company be force borrow money pay dividend smaller cap energy company struggle most increase maintain dividend payment share buyback form shareholder return be easier company turn dividend be pare back even more whole energy sector represent buyback vs accord dow jone index contribute dividend vs previous year fourth quarter combine dividend yield buyback yield energy sector be lowest sector exxon have grow dividend year row be now longer biggest dividend payer apple aapl start pay dividend have be hike payout aggressively be new king iphone maker hike quarterly dividend cent take annual dividend vs exxon still dividend yield energy stock be more attractive apple stock hit new high dividend yield be just less half exxon chevron apple also have replace exxon poster child buyback recent year accord howard silverblatt dow jone index apple buyback totale make second largest company buyback allergan agn meanwhile exxon do not even rank top have do very little way buyback late silverblatt write recently recent good news shareholder current price don bode well revenue payout crude price settle higher wednesday barrel datum show sharp drawdown inventory meanwhile opec top opec producer have suggest extend production cut end year possibly price get bump new aggressive move oil group partner further reduce global glut inventory likely be offset increase production company still top line remain challenged company improve bottom line cash flow focuse lower cost region permian basin producer have also be used new technology technique allow extract oil profitably even lower price related opec top shale play vow big output boost even sub oileog show apple oil gusher mobile apps dataeven latest idea opec not lift oil price shale loom
562,AGN,here weekly investing action plan need know investor come week facebook fb report dog mimic snapchat feature parent company snap snap release quarterly result first time march ipo hot chip stock lead nvidia nvda report
563,AGN,be just year formula seem right biogen biib fourth largest company industry mix biotechnology megamerger biogen multiple sclerosis franchise lineup drug include tecfidera tysabri be grow tecfidera biogen most important drug bring further hemophilia sale small grow just brand name drug eloctate alprolix spinraza spinal muscular atrophy drug grab fda approval just day christmas plot thicken biogen chief executive george scango resign july leave company susceptible takeout like merck mrk allergan agn eli lilly lly pfizer pfe takeout rumor abound biogen stock end make cheaper asset buy thought last year be really time happen leerink analyst geoffrey porge say biogen offer last year be relatively stable ms business be still grow robust cash flow scheme opportunity spinraza hemophilia franchise so acquirer say get fast forward today picture be entirely different biogen be see increase competition ms market payer be balk spinraza price company have already take hemophilia drug equation now only wall street see biogen potential takeout candidate accord mizuho survey porge say biogen probably have see deal roll ever think have become significantly less likely porge say so happened incredibly successful multiple sclerosis include launch zinbryta abbvie abbv biogen ms unit be face loom competition like roche rhhby celgene celg porge tell investor business daily note client april porge call roche ocrevus game changer ocrevus be approve late march treat relapse remit primary progressive form ms separate pack be only approve relapse remit form ms physician patient community have be eagerly await ocrevus launch porge say drug high efficacy reasonable safety profile convenient month dose schedule be major factor drug positive reception spell trouble biogen tecfidera have comprise total product sale well ms unit biogen be actually partner roche ocrevus royalty win be enough offset erosion own ms franchise analyst say porge expect ocrevus get primary progressive ms market year relapse remit ms market porge see erosion tysabri erosion tecfidera novartis nvs gilenya sale meanwhile celgene be work ms drug call ozanimod phase testing function ozanimod be closest novartis gilenya also rival tecfidera sanofi sny aubagio tecfidera gilenya aubagio respectively lead ms market term sale celgene want buy sale force have something overnight help sell ozanimod biogen be company porge tell ibd biogen likely suffer erosion roche competition ms look less probable silver line biogen win patent interference case forward pharma fwp tecfidera be settlement fee forward stock topple decision now lose major royalty biogen spinraza have different set trouble develop ionis pharmaceutical ion spinraza be first only drug approve rare neurological disorder cause muscle weakness wasting infant child wall street largely thought spinraza slam dunk have profound efficacy august study infant child drug be so effective biogen ionis end study early ionis chief executive stanley crooke tell ibd december spinraza be approve dec fairly broad label approve use child adult spinal muscular atrophy remain only drug approve disease crooke call catastrophic drug thing be rapidly adopt widely reimburse porge say have happened be appear be good fortune label have turn liability payer become concern too many patient start drug so restrict access mizuho analyst salim sy call largely spinraza story biogen be set report first quarter earning april be particularly tell follow launch spinraza earlier year analyst say payer be push back hard reimbursement drug insurer anthem antm humana hum be only reimburse patient spinraza most severe form disease type unitedhealth group unh have broader policy cover type patient be spinraza cost treatment first year subsequent year make pricey drug consensus be project first quarter spinraza sale sy say porge lower expectation spinraza sale result first quarter be especially tell tell ibd north patient drug be pretty good long re see continue start then biogen hemophilia drug lineup february biogen spun hemophilia franchise bioverativ bivv then bioverativ share be be great bioverativ company consider biogen takeover think again unit porge say ibd take bioverativ isn standard biotech startup head new america find bioverativ have yet announce quarterly result have only be public early february company be set release first quarter earning result last full quarter biogen hemophilia unit bring year year now porge say be smart biogen also spin multiple sclerosis unit turn focus alzheimer alzheimer biogen be follow eli lilly merck have notable failure december february biogen alzheimer play be strongest sector analyst say march rbc analyst michael yee tell ibd pfizer merck be likeliest player make bid biogen be interested more brand drug particularly alzheimer pipeline biogen be work class alzheimer drug work remove plaque buildup brain associate alzheimer call bace inhibitor eisai bace inhibitor aim prevent plaque buildup porge say biogen likely have see renew takeover interest biogen be expect release result phase trial aducanumab bace inhibitor elenbecestat be also phase trial result expect september eli lilly solanezumab work theory remove plaque buildup call beta amyloid brain merck verubecestat be bace inhibitor fail be only handful potential alzheimer drug development now meanwhile axovant science axon be work different theory treatment doesn involve beta amyloid expect have phase datum drug intepirdine later year too change alzheimer landscape potentially further dent biogen chance merger still biogen board place high premium alzheimer pipeline ever come acquisition table porge say everything else have fail development cost aducanumab elenbecestat have head billion dollar porge say re willing take risk alzheimer still make sense acquisition ve hear person industry be re struggle bridge gap say board want be paid alzheimer go work related roche game changer drug chip away biogen novartisbiogen dife takeover buzz fade drug hit small cap biotech take gilead celgene biogen alzheimer
564,AGN,allergan agn paratek pharmaceutical prtk stock pop tuesday announce strong result late stage trial acne drug plan file fda approval year end close bell stock market today allergan be paratek climb deutsche bank analyst gregg gilbert up price target allergan stock gilbert expect company acne drug sarecycline hit peak sale year slightly allergan view peak sale now model earning share first quarter full year gilbert still see allergan earning share penny consensus analyst poll thomson reuter gilbert model be unchanged year view boost spending first quarter sarecycline testing ibd take anyone catch allergan medical aesthetic not look likely be outside chance few nontraditional player head industry snapshot look fat freeze ear pin market sarecycline be narrow spectrum antibiotic mean avoid tract issue associate older oral medication acne gilbert say note client allergan expect file fda approval end phase trial sarecycline milligram dose daily week be superior drug placebo allergan say news release most common side effect be nausea cold headach only patient discontinue use gilbert keep buy rating allergan stock continue view allergan reasonably value stock attractive growth profile solid diverse franchise shareholder drive management team potentially pipeline write related lilly merck allergan top analyst view pharma
565,AGN,peter gassner launch veeva system veev didn expect outstrip revenue watch stock triple span less year expand arsenal product application instead gassner be survival mode begin have nothing have product customer person nothing say gassner time alum salesforce com crm have exactly so then have start hire person have make product get first customer add grand plan be sort interesting doesn mean anything hire first developer get first customer today veeva provide cloud backbone life science industry rival like medidata solution mdso count company pfizer pfe novartis nvs amgen amgn eli lilly lly customer drugmaker tackle challenge develop testing manufacturing lifesave drug veeva operate cloud system background dual role include organize doctor information pharmaceutical rep clinical trial datum graph company gassner call latter point veeva second act total veeva estimate total addressable market gassner expect nascent third act add become bigger better be exactly company alphabet googl ibm ibm cisco system csco do say important thing company be want keep go second act probably end be big bigger first act tell investor business daily company make second act bigger first act have long term ability reinvent veeva launch year single application help pharmaceutical rep organize drug datum make stronger doctor pitch today globe pharma sale rep use call veeva crm customer relationship management ipad application get drug company manager buy early wasn difficult gassner say ibd take veeva system stock have ibd composite rating best possible meaning outperform stock term key growth metric head ibd stock checkup list strong software leader think life science industry be more business outcome oriented say important thing ceo focus get drug approve get market effectively patent expire tool cloud not cloud help generally want fast forward veeva crm be part company commercial cloud business commercial cloud grow fiscal major crm win expansion top pharmaceutical firm veeva say earning news release business account third veeva sale gassner estimate veeva second act really have wall street key say veeva vault be launch single customer goal organize content involved clinical trial document video image datum record vault represent third veeva total sale target total addressable market gassner say see vault reason recent excitement veeva stock share be january march burst cup handle formation begin november top buy point deeper salesforce partnership stock be now more extend point bottom month veeva ipo time intraday high reach friday share gain nearly share ultimately retreat friday close be again monday gain close vault bring sale gassner say today vault annualize run rate be north whole veeva be aim top annualize run rate veeva be already tracking ahead say cornelio ash analyst william neil co affiliate investor business daily now vault be prep potential third act look opportunity outside life science first veeva gassner say veeva see additional opportunity take vault other manufacturing heavy industry chemical consumer packaging neil ash say success venture be game changer veeva be say be ve get lockdown step tell ibd then just become door do want knock potential be probably veeva stock continue trade premium gassner say veeva gain traction outside life science used same method employ launch major commercial cloud vault division company call veeva way method work life science veeva have estimate crm market sale clinical trial regulatory process match medidata medidata sale vs small grow chunk veeva brand become re good gassner say become good deliver value outside life science then think time ll become know end veeva be part collaboration include astrazeneca azn allergan agn biogen biib lilly novartis glaxosmithkline gsk pfizer other call align biopharma align be aim iron technological standard life science world veeva do same sector outside life science ash say literally get feedback horse mouth develop platform say be successful outside re go need same kind feedback other sector related ibd company break deepen salesforce tie upveeva help medicine go drug giant
566,AGN,acadium pharmaceutical acad intercept pharmaceutical icpt lexicon pharmaceutical lxrx be cusp be acquire analyst say friday examine historical merger pattern big pharma small midsize biotech company approve drug be attractive acquisition target due reduce development regulatory risk needham analyst alan carr write research report trio just grab first fda approval acadium nuplazid be approve april psychosis associate parkinson ocaliva intercept be approve liver disease lexicon xermelo get approval february carcinoid syndrome neurocrine bioscience nbix look likely get approval next month ingrezza drug aim treat involuntary movement associate long term use certain medicine disorder be know dyskinesia be number earlier stage company buy last year doesn tend be trend third small midsize company approval have be acquire carr write however acquire company have previously launch drug somewhere interpret risk mitigation acquire company say be acquire shortly first fda approval nearly year ibd take anyone catch beauty giant medical aesthetic least company be try read ibd industry snapshot biotechs half company acquire january more upfront cash have least approve market drug have phase datum drug fda review time announcement drugmaker target oncology infectious disease be ripest takeover then infection oncology have be acquire most rare disease company remain independent today allergan agn japanese pharmaceutical firm be most likely acquire earlier stage firm carr say overall allergan astella pharma daiichi sankyo sumitomo dainippon pharma collectively acquire company january today europe abbvie abbv merck mrk novartis nvs have acquire earlier stage company january related do beauty giant just solve acne challenge lilly merck allergan top analyst view pharma
567,AGN,conviction be vital manager parnassus fund parnx ian robert klaber lead portfolio manager jerome dodson have guide fund upper echelon large cap growth fund take big stake relatively few stock take average bet stock particularly top holding so better have do homework have high confidence pick pan top holding jan include charle schwab schw micron technology mu parnassus approach be work fine average annual return parnassus stablemate parnassus endeavor fund parwx have surpass past year well past year year year enough earn ibd best mutual fund award parnassus endeavor take top honor be top winner rank year average annual return category overall diversify equity well growth large cap fund parnassus fund be top growth large cap parnassus endeavor own just stock stablemate parnassus fund hold stock larger fund dodson have manage alone have asset invest top holding parnassus have be have embed top many growth fund hold stock smaller position seek control volatility greater diversification not parnassus be high conviction fund klaber say have high active share be bottom stock picker active share be measure much portfolio holding differ benchmark index aside focuse approach way fund stand be mandate invest good corporate citizen have exposure energy utility sector say be look company be best class environmental perspective social perspective governance perspective addition parnassus endeavor holding offer outstanding workplace multicap fund parnassus team have flexibility invest see opportunity be go anywhere domestic stock fund klaber say have market cap restriction so give pretty broad play field parnassus do have more endeavor small midcaps vs parnassus still favor large cap asset meanwhile large cap oriented endeavor have big cap fund aim control risk veer only so far benchmark index sector weighting parnassus conviction investing result heavy underweight sector jan parnassus fund have financial vs parnassus endeavor be close benchmark tech have outsize bet tech vs health care vs klaber note long term focus have be key fund success fund have turnover rate lower be bit more contrarian other parnassus fund say re willing wider range outcome short term indeed direct line top holding current fund performance isn always clear fund recent top holding show sign struggle include gilead science gild allergan agn week high parnassus screen potential holding relevance be look company be become increasingly relevant product service offer klaber say want own company be gain share sector industry focus relevance help avoid value trap value trap investor be attract stock low valuation investor buy stock fail rise wide moat be hallmark portfolio holding seek company sustainable competitive advantage klaber say feel provide protection market be store value important consideration parnassus be efficient capital allocation company invest go back year analyze management have allocate capital past klaber say then project think allocate capital future understand be good steward capital parnassus team create year forecast base bull bear scenario analysis potential new stock buy be look asymmetry klaber say want company moderate low downside risk significant upside asymmetric risk reward ratio be common feature holding historically endeavor fund have have tech bias klaber say end last year more fund be invest tech end january sector account approximately half parnassus fund sector perspective sector have be most overweight be financial say pro growth agenda new administration have be tailwind firm parnassus be weight financial service stock add progressive pgr first quarter endeavor also have stake auto insurance company see company online sale strategy disruptive force aren many company be go gain market share long see say see opportunity be go invest year progressive chip away gain market share market share now be auto insurance market go keep go time progressive share have gain begin year year parnassus be weight technology technology own collection wide moat business strong growth profile trade attractive valuation klaber say klaber cite ebay ebay prime example company wide moat be own parnassus endeavor source moat be strong network effect more seller bring more buyer vice versa say share ebay be year date past year break cup handle base february run have ease point ibm ibm be top tech hold portfolio be trading time earning discount market dividend yield so expectation be low klaber say think server business do better expectation strategic initiative group continue see growth accelerate ibm have climb so far year last week parnassus team see lengthy runway allergan pharmaceutical company be top hold parnassus top hold endeavor have dominant position many therapeutic area klaber say stock have own firm end be high be also buy aggressively end last year be company have drug phase enter phase allergan share have jump parnassus crew exhibit kind patience allergan many growth investor do not company earning have grow annual rate past year wall street analyst see growth slow year next year stock relative price strength rating ibd be just related contrarian pin oak equity rise top
568,AGN,fat freeze ear pin breast augment allergan agn isn make expansion medical aesthetic market easy rival hologic holx johnson johnson jnj valeant pharmaceutical vrx analyst say allergan have sunk north aesthetic space add skin cream double chin treatment most recently fat freeze business be just transaction
569,AGN,persh square capital management activist fund run bill ackman sell entire stake valeant pharmaceutical international vrx say billionaire leave board ackman fellow persh square representative steve fraidin stay company annual meeting not stand re election accord statement release monday investment represent persh square fund require large amount time resource statement say valeant share end trading monday then plunge nearly close jeffery group offer persh square valeant share apiece accord person familiar process ask not be identify discuss private information persh square first disclose investment valeant march earlier ackman fund have team valeant hostile bid allergan agn be thwart allergan agree be acquire actavis valeant ackman be face shareholder lawsuit allege insider trading involve fail deal allergan
570,AGN,drugmaker allergan agn smartphone king apple aapl member dow jone industrial average be leader stock buyback fourth quarter follow citigroup microsoft msft say report dow jone index overall company index spend stock buyback period third quarter year year time high be third quarter year company spend buyback buyback fall press release note last time issue reduce buyback payment consecutive year be buyback remain concentrated top issue account total fourth quarter expenditure share repurchase be popular way return capital shareholder tend boost stock share earning dividend put cash shareholder hand allergan spend buyback fourth quarter seventh largest quarterly purchase company apple dow stock come second apple be frequently biggest spender buyback dividend spend buyback last year citigroup be third then microsoft dow component be follow dow stock general electric ge exxon mobil xom buyback activity have slow steady growth dividend indicate positive development shareholder say howard silverblatt senior index analyst dow jone index allergan giant sum health care sector lead buyback spending fourth quarter second be information technology sector allergan share close stock market today apple climb retake buy point microsoft advanced find support day line related stock tumble again oil slide earning focus nike weigh dow
571,AGN,eli lilly lly merck mrk allergan agn stand outperform broad pharma stock credit suisse analyst say monday cite strong pipeline expect clinical datum year merck stock close stock market today share allergan dip lilly finished lower drug stock be broadly stay day move average credit suisse analyst vamil divan expect macro uncertainty pressure drug stock first half continue trend begin raucous election season drug stock end be january merck outperform keytruda immuno oncology drug divan say keytruda similar drug bristol myer squibb bmy roche rhhby patient immune system identify tumor cell immune system then destroy cancer keytruda go head head bristol myer squibb opdivo target specific protein body merck be team test keytruda incyte incy drug epacadostat epacadostat target protein ibd take jazz pharmaceutical top ibd company ethical drug industry group composite rating best possible score mean jazz outperform nearly third stock term key growth metric get rest leader list ibd stock checkup lilly pipeline be now derisked divan write note client see promise diabetes drug jardiance trulicity plaque psoriasis drug talz lartruvo soft tissue sarcoma baricitinib treatment eczema sentiment allergan be finally start thaw write cite further upside pipeline new drug linzess viberzi irritable bowel syndrome well vraylar bipolar disorder small midcap scene divan prefer aldr corvus pharmaceutical crvs aimmune therapeutic aimt be work migraine medicine base inhibit specific peptide body eliminate migraine corvus be peer player divan say related be first immune system cancer drug fdamerck bristol myer incyte race career market
572,AGN,drugmaker pfizer pfe boost value takeover bristol myer squibb bmy analyst say monday acknowledge bristol specific macro uncertainty limit likelihood still be common question give challenge bristol myer squibb be face activist involvement name credit suisse analyst vamil divan say question takeout center next month say note client pfizer commentary recent meeting management other investor conference make think be certainly look possibility come business development write overall credit suisse see bristol have positive impact pfizer return capital cash deal assume pfizer pay premium extract synergy lead value creation cent share pfizer opt cash stock deal dilution issue undervalue share offset initial value creation analyst write deal partially finance stock issuance be break even pfizer shareholder ibd take bristol myer have immuno oncology drug approve meaning compete other fda approve treatment roche merck head ibd technology page breakdown drug sector close bell stock market today bristol be fractionally pfizer tick share bristol have be pressure year be january activist investor carl icahn reportedly take stake bristol myer february icahn be know investment company paypal pypl xerox xrx allergan agn jana partner activist investor buy stake bristol fourth quarter compound add pressure like merck mrk roche rhhby be add macro uncertainty bristol myer february bristol lose share immuno oncology market merck roche remain flat month month basis related bristol myer partner hit month high immuno oncology dealmerck be near rival keytruda approvalincyte spike record high rumor gilead acquire
573,AGN,market early decline monday be head fake stock be poise handle bad news be good reason be comfort array industry dive sharp early loss heel friday stalemate attempt health care reform washington steel maker dive ryerson ryi steel
574,AGN,satisfy trump administration call deal high drug cost industry leader be propose president lead negotiation drugmaker restrain price allergan agn chief executive brent saunder cite tactic used president john kennedy decade keep steel price administration also waive federal antitrust rule currently prohibit drugmaker discuss pricing so put together guideline follow say voluntary agreement restrain price be very practical solution doesn view do anything impede innovation saunder say wednesday interview bloomberg headquarters new york convince fellow drugmaker agree however be challenge be difficult saunder say big pharma be intense pressure come way reduce price president trump accuse company get away murder threaten use government buy power force price saunder have be outspoken excessive price hike own industry allergan company product range wrinkle treatment botox stomach schizophrenia medicine ceo have implement social contract cap increase annually trump model something pharmaceutical industry maybe look something social contract saunder say easy suggest re already do just be transparent add ask target amount restraint agreement say low single digit rate inflation pharmaceutical giant include novartis nvs japan takeda pharmaceutical abbvie abbv also have take voluntary action cap price increase johnson johnson jnj merck mrk have take step increase transparency price industry have moved quite bit month month saunder say need big push saunder allergan have transform specialty pharmaceutical behemoth series acquisition sale generic business attempt merge pfizer pfe inc megadeal be abandon last year allergan have focuse smaller purchase allergan share be compare rest industry last month ve lose compare gain company standard poor pharmaceutical biotechnology life science index include allergan rather deal saunder be more interested build allergan main therapeutic area include medical aesthetic dermatology eye care central nervous system past month make acquisition worth combine add allergan aesthetic medicine cosmetic surgery line hair restoration skin quality be next frontier say company be currently do research area be huge unmet need say ask valeant pharmaceutical international vrx asset include bausch lomb eye care company once lead saunder say not interested not even piece valeant didn respond request seek comment
575,AGN,allergan agn be buy fat freeze company zeltiq aesthetic zltq botox maker say early monday send zeltiq stock record high offer price zeltiq flagship product coolscultp be fda approve remove unwanted fat cell affect surround tissue body sculpting be market become third pillar allergan global aesthetic company allergan say announcement zeltiq stock debut lift stock market today allergan offer come share allergan stock edge close month high deal be expect close subject approval zeltiq shareholder acquire zeltiq be immediately accretive allergan earning allergan say ibd take allergan promise last year not raise drug price more year social contract patient draw ire celgene ceo read mark alle response jpmorgan healthcare conference allergan say release monday aim marry plastic surgery regenerative medicine business body sculpting distinct complementary business converge create optimal customer experience company say coolsculpt offering plastic surgeon dermatologist aesthetic practitioner now extend largest fastest grow segment practice putt allergan unique position provide expand customer service help meet need patient ceo brent saunder say news release zeltiq be only most recent allergan acquisition december allergan say acquire lifecell specialist regenerative medicine follow announcement acquire chase pharmaceutical motus therapeutic september allergan announce deal worth total retrosense therapeutic vitae pharmaceutical tobira therapeutic akarna therapeutic tobira akarna allergan be boost liver include alcoholic steatohepatitis offering related intercept bound month high nash trial edit analyst splitallergan lead drug stock view crush guidanceendo resolve ftc antitrust suit allergan hang stock mixed
576,AGN,hologic holx announce plan acquire body sculpting firm cynosure cyno early tuesday day allergan agn say pay fat freeze zeltiq zltq investor be more forgive allergan purchase hologic stock fall stock market today touch month low cynosure stock lift purchase price share flirt time high cash transaction have enterprise value net cash company say be subject approval cynosure stockholder hologic leader woman health see cynosure ticket medical aesthetic market cynosure portfolio include more product body sculpting hair removal skin revitalization ibd take hologic have middling ibd composite rating meaning outperform nearly quarters stock term key growth metric sale performance only rank company medical system equipment industry group masimo stock lead cr head ibd stock checkup top performer cynosure go obstetric gynecological market make sale revenue be derive market vs traditional plastic surgery dermatology hologic have strong presence ob gyn market deal be expect be immediately accretive earning share ex item add cent grow cent hologic say press release transaction also fill hole left hologic divest blood screening business hologic estimate deal help grow revenue base point increase ep ex item double digit next several year year return interest exceed hologic cost capital company say have identify medical aesthetic attractive complementary growth opportunity strategic plan process be pleased have agree acquire cynosure best class company space hologic ceo steve macmillan say company news release medical aesthetic market be worth more annually globe hologic say monday allergan put price tag body sculpting alone announce plan buy zeltiq used technique freeze fat cell zeltiq stock hit time high response allergan stock close fraction rise tuesday share last week touch month high related hologic still buy get lofty price blood screening unitnew screening rule boost hologic sale growth
577,AGN,apple aapl general electric ge follow microsoft msft part dow jone industrial average spend more stock buyback dividend third quarter other company say latest tally factset research apple spend buyback general electric come microsoft be follow allergan agn mcdonald mcd dow industrial component say report factset apple lead pack shareholder dividend spending next come microsoft then ge share repurchase be popular way return capital shareholder tend boost stock share earning dividend put cash shareholder hand company total spend share buyback smallest quarterly total have be norm information technology sector be top spending group term dollar value buyback totale be follow financial sector aggregate buyback represent decline year quarter be largest year year decrease apple stock wednesday touch time high have be roll post december quarter beat jan rise cent stock market today ge stock fall microsoft rise microsoft stock touch record high jan related apple microsoft alphabet be king cash tech sector rulesapple exxon mobil lead dividend paid
578,AGN,stock open higher monday ahead busy week economic datum testimony capitol hill federal reserve chief janet yellen dow jone industrial average nasdaq climb rise open small cap also get early bid russell share apple aapl add help price target hike goldman sachs merger news allergan agn announce plan acquire zeltiq aesthetic zltq accord allergan body contour market be market grow news send zeltiq share higher more open allergan rise earning news electronic commerce payment provider first datum fdc report earning open earning share top expectation sale be tad light share jump nearly open first datum be buy range buy point support action week move average elsewhere dupont dd chemour cc settle teflon chemical exposure case dupont have be get consistent support week move average recent share dupont edge higher teflon maker chemour soar chemour recently clear cup shape base buy point volume be light earning be due wednesday close busy week economic datum report due wholesale consumer inflation january retail sale housing start manufacturing datum also fed chief janet yellen be capitol hill week testify senate committee tuesday house panel wednesday monetary policy new york mercantile exchange crude oil future be barrel gold ease ounce year treasury yield add basis point related yellen netease gold stock cisco lead investing action plan
579,AGN,intercept pharmaceutical icpt be likely succeed phase nonalcoholic steatohepatitis nash trial fda bless key change rbc analyst michael yee say friday company share rocket month high stock market today intercept stock lift earlier hit highest point november stock have be consolidate september remain far entry point trading day move average food drug administration allow intercept reduce number patient phase trial ocaliva nash enrollment be expect wrap mid week treatment period datum likely be ready year end ocaliva already be approve primary biliary cholangitis rare liver disease now intercept be grow throng company aim nash market novartis nvs allergan agn genfit be also work nash drug gilead science gild bow november ibd take intercept stock have low composite rating meaning underperform stock term growth metric sale earning power head ibd stock checkup see biotech biggest leader stack hint company have cr intercept stand good chance meeting endpoint phase trial yee write fda ocaliva only meet co endpoint improvement fibrosis nash resolution previously drug have meet endpoint fda also agree standard definition nash resolution improvement ballooning residual inflammation new definition ocaliva show phase statistically significant reduction fibrosis hit nash resolution patient change calculation be well overpower hit fewer patient yee write research report see chance success ocaliva approval nash leerink analyst joseph schwartz note questionable safety profile ocaliva wonder be reasoning slow enrollment ocaliva result itch patient primary biliary cholangitis meanwhile other genfit aren have problem fill trial schwartz be much more bearish intercept chance success trial have market perform rating intercept stock vs yee outperform rating be discourage enrolling patient cohort be unattainable timely manner be not convince raise probability success trial write research report related conatus pharma double novartis nash licensing dealallergan challenge intercept tobira nash drug
580,AGN,stock market correction begin major average lead stock show more weakness other index rebound solid weekly gain nvidia nvda plunge halter autonomous drive test just several negative headline tesla tsla facebook fb continue slide datum privacy furor amazon amzn tumble day move average lululemon athletica lulu rh rh rally strong earning retail remain relative source strength baidu bidu stream video unit iqiyi iq come public major average rebound monday trade war fear ease other index tumble tuesday trigger stock market correction fuel thursday rally dow jone rise week testing day move average nasdaq composite rise many tech giant be big loser nvidia nvda uber suspend self drive test tesla tsla nvidia supplier also face federal probe model involve autopilot system moody also cut tesla debt model production wo amazon com amzn tumble day line first time month fear president trump go commerce giant retail apparel remain relative bright spot quarter dow lose nasdaq add uber technology suspend self drive test federal probe recent fatal crash involve autonomous vehicle nvidia nvda also say halt test share chipmaker plunge help trigger stock market correction tesla tsla used nvidia chip fall sharply bad news national transportation safety board say be probe fatal crash march involve model moody downgrade tesla credit rating concern cash burn model production delay alphabet googl unit waymo be sticking plan roll commercial robotaxi service phoenix year waymo also plan order many luxury autonomous electric car jaguar land rover subsidiary india tata motor ttm waymo jaguar plan move production crossover sport utility daimler bmw announce combine self drive service asset form joint venture structure facebook chief executive mark zuckerberg be expect testify congress pressure mount datum privacy scandal have roil company stock congressional hearing be prompt revelation datum consultancy cambridge analytica have wrongfully obtain personal information million facebook user knowledge facebook beef privacy control say halt selling datum third party broker facebook share initially tumble rise modestly week amazon fall wednesday undercut day line report president trump want go commerce giant trump have long be critical amazon perhaps part ceo jeff bezos own washington post white house deny plan target amazon trump tweet concern regard amazon thursday amazon initially fall thursday close fellow fang netflix nflx find support day line share lululemon lulu soar record high week athletic apparel maker retailer beat estimate board raise full year guidance ep rise revenue grow nearly north america peer nike nke have struggle lululemon sale grow low single digit online sale pop constant currency top prior year growth analyst say new product improve marketing investment fuel quarterly apparel maker retailer be pocket market strength linux open source software provider earning growth accelerate fiscal fourth quarter revenue rise gradually accelerate fourth straight quarter top view red hat rht guide low earning see full year earning revenue consensus red hat push container software cloud compute workload drive growth analyst say red hat share initially soar tuesday settle fractional gain share rise week concho resource cxo buy rsp permian rspp stock deal worth takeover create largest drill completion operation permian concho share tumble crude inventory rise barrel more expect energy information administration say production hit new high barrel day saudi crown prince moham bin salman tell reuter opec be look extend oil production cooperation russia year baidu bidu video stream unit iqiyi iq fall nearly thursday trading debut selling share apiece line expect range raise ipo be just shy january ipo pagseguro digital pag call netflix nflx china iqiyi have licensing deal netflix subscriber iqiyi have market share china rival alibaba baba tencent tcehy have own stream service hotly contest battle viewer fed favorite inflation gauge core personal consumption expenditure price index show slight uptick february annual inflation rate edge month high inflation be far fed target enough doubt corporate pricing power so inflation have rise further pressure fed policymaker hike rate more time year commerce department datum thursday show disposable personal income rise february spending rise modest suggest person initially be save tax cut consumer end strong note fourth quarter gdp be revise biotech stock collectively rise sixth group track ibd last week news be more mixed big mover monday celgene celg lift nearly analyst suggestion be settlement dr reddy laboratory rdy generic version cancer drug revlimid same time pharmaceutical bhvn tank unveil late stage trial migraine drug lag result rival drug allergan agn tesaro tsro slip tuesday split view combination zejula merck mrk blockbuster keytruda ovarian cancer patient also tuesday anaptysbio anab topple result peanut allergy drug study celgene celg bluebird bio blue agree jointly market advanced cancer treatment know bb expand deal sport retail giant jd sport pay athletic apparel chain finish line finl soar slightly share offer finish line pull back thursday follow mixed result build material company usg usg have rebuff buyout offer germany knauf offer get support warren buffett berkshire hathaway brkb be usg top shareholder usg share shot speculation provider wall ceiling flooring roofing product be have higher price shire pharmaceutical shpg shot confirm japan takeda make offer finally audio communication firm plantronic plt agree wednesday acquire company polycom polycom be buy private equity firm siris capital same price just year glaxosmithkline gsk agree buy stake consumer health unit novartis nvs blackberry bb report fiscal adjust profit cent share top expectation break even revenue fall line view rh rh formerly know restoration hardware report profit leap share sale growth top forecast home furnishing retail guide high signale more aggressive expansion plan design gallery share soar nearly week blast day day line constellation brand stz earning share rise revenue climb beating beer sale grow constellation brand increase quarterly dividend cent share rise close recent buy point cross intraday apple aapl introduce lower price ipad chicago high school company seek regain ground lose google owner alphabet microsoft education market new inch retina display ipad have start price gigabyte wi fi model discount school
581,AGN,dozen drug launch heavy hitter roche rhhby gilead science gild johnson johnson jnj be expect reach blockbuster status end analytic firm say clarivate analytic describe year blockbuster drug have launch be expect launch eventually bring north sale year period biggest number clarivate begin make forecast set be exciting year see valuable addition exist treatment well disruption certain market first class treatment option disease firm say report issue late thursday end drug roche gilead nordisk nvo be expect top annual sale remain likely account year revenue analyst say get newsletter deliver inbox more info product service privacy policy term be diabetes drug food drug administration approve medicine derive cannabis plant first series drug expect prevent migraine patient dozen drug be project collectively top sale roche hemlibra treatment patient hemophilia top list be expect generate north sale only hemophilia patient world roughly eligible hemlibra treatment cost first year year drug be approve month early launch december sale be forecast drug set reach blockbuster status forecast hemlibra be expect take share shire shpg feiba nordisk novoseven hemlibra also compete bioverativ bivv eloctate shire advate eloctate be forecast be blockbuster advate continue be market leader estimate sale however advate sale be forecast decline further thereafter clarivate report say gilead biktarvy grab approval february target estimate person globally live hiv be receive antiretroviral therapy suppress viral replication allow immune system strengthen biktarvy add gilead hiv franchise have long rivale glaxosmithkline gsk have trade market share gilead first enter market atripla gilead hiv drug be featured clarivate drug watch report biktarvy become blockbuster generate sale spiking decline report say trajectory be similar gsk drug triumeq be expect bring year year launch round top nordisk get approval diabetes drug ozempic december drug help stimulate body own insulin release limit much sugar get blood liver slow quickly food leave stomach ozempic be expect become blockbuster revenue way immuno oncology treatment novartis nvs gilead grab headline ability revolutionize treatment disease report say more half drug potential blockbuster list be cancer therapy just drug list expect blockbuster be cancer treatment erleada product dow jone component johnson johnson be approve february treat castration resistant prostate cancer hasn spread body fellow dow jone component pfizer pfe have drug treat same cancer once spread zytiga xtandi battle expand market share include market patient metastatic disease second generation oral androgen erleada become first approve set mid february clarivate say drug be project bring rise also be expand treat other form prostate cancer combination zytiga contribute blockbuster potential gsk shingle vaccine call shingrix rare disease drug alnylam pharmaceutical alny know patisiran be expect join blockbuster list sale respectively revenue be expect hit respective gw pharmaceutical gwph be expect grab approval summer first cannabidiol drug derive cannabis plant treat patient seizure disorder drug call epidiolex be expect generate sale approve epidiolex likely encounter bureaucratic barrier distribution political hurdle associate cannabis derive medicine particularly strict guideline use medicinal cannabis exist report say biotech isn alone market cara pharmaceutical cara insys therapeutic insy zynerba pharmaceutical zyne be also work treatment base cannabis plant migraine drug amgen amgn novartis aimovig be project bring sale spiking sale drug other seek prevent migraine block specific peptide group amino acid approve aimovig be first drug know cgrp market ahead teva pharmaceutical teva aldr eli lilly lly allergan agn also be work area first class mover advantage be crucial aimovig competition other subcutaneously administer monoclonal antibody target cgrp be not far clarivate say lilly teva file fda approval drug late last year meanwhile be phase testing drug analyst be worry falter submit application fda co founder randall schatzman unexpectedly step chief executive role tuesday other area shire lanadelumab treatment swell disorder be forecast bring next be abbvie abbv elagolix treatment painful symptom associate menstruation round list pfizer merck mrk diabetes drug steglatro indivior opioid dependence drug sublocade be forecast become blockbuster sale respectively related chart read basic buy point mark time real much money do need start investing build long term profit stock take many gain
582,AGN,aldr successfully compete larger rival amgen amgn eli lilly lly teva pharmaceutical teva prevent chronic migraine pair analyst say tuesday comment come wake result last week phase trial chronic migraine more patient see reduction day re afflict migraine company also say resolve patent dispute drug eptinezumab teva find equity financing be turn thing needham analyst danielle brill say note client have buy rating price target stock bullish note topple close stock market today share rocket day reveal result phase eptinezumab trial jan stock break cup formation buy point jan eptinezumab be be develop intravenous treatment prevent chronic migraine belong class drug call cgrps compete rival drug amgen lilly teva phase trial patient treat eptinezumab have migraine month third patient achieve greater reduction migraine day baseline month see migraine day cut least half time believe datum also showcased intravenous eptinezumab differentiate profile brill say rapidity onset magnitude benefit intravenous eptinezumab be clearly distinguish subcutaneous injection competitor datum ibd take stock rise ibd relative strength rating best possible last week have fall visit ibd datum story go rs rating prompt spike specialist cite credit suisse analyst vamil divan prefer intravenous route eptinezumab lead regular office visit patient monitor progress ensure proper compliance therapy be likely be fourth market cgrp divan say note client analyst have worry put disadvantage larger rival needham brill divan see eptinezumab differentiate still rival face same insurer obstacle competition likely less costly treatment allergan agn botox say botox sale come use chronic migraine base cost novel therapy be possible payer push patient try older label therapy well botox patient be give access cgrp antibody divan say time assume new patient patient be not have satisfactory response botox move cgrp antibody share teva dove close lilly dip finish amgen lose be fraction close related amgen have edge rival prevent cruise upgrade drugmaker miss boatwhy biotech suffer day headache rare disease trial
583,AGN,index dow industrial nasdaq composite suffer worst day weekly loss year lead stock suffer major damage stock market moved correction nvidia nvda snap snap twitter twtr rally strong earning grubhub grub shot big deal kfc taco bell parent yum brand yum tesla sell line result world publicity stunt major average many lead stock tumble intensify loss prior week big loss stock market moved uptrend pressure correction chip energy china name be big loser stock market retreat be broad deep stock do stage nice rebound test day move average take more good day snap downtgrend facebook rival snap snap twitter twtr have stellar result nvidia deliver blowout earning bullish guidance year treasury yield hit year high unnerve stock market backed graphic chip maker nvidia nvda earning swell share sale quarter end jan analyst expect current nvidia expect revenue wall street be look share soar friday meanwhile broadcom avgo raise bid buy wireless chip maker qualcomm qcom share say be best final offer qualcomm reject deal value broadcom be seek replace qualcomm board ibd take stock market be now correction read cover story stock sell do now tesla beat fourth quarter revenue earning estimate maintain production target model sedan tesla still see weekly model production rate end first quarter end second quarter again warn difficulty accurately forecasting specific production rate specific point time cash burn decline analyst say special factor suggest improvement win continue spacex falcon heavy rocket most powerful rocket use factor successfully lift maiden flight booster return safely rocket show satellite insertion technique air force position future military launch small potentially lucrative market then send ceo elon musk tesla roadster elliptical orbit sun twitter share report first ever gaap profit adjust earning easily beating view first quarter guidance estimate share shot week meanwhile snap catapult wednesday snapchat operator deliver strong fourth quarter revenue user growth smaller expect loss grubhub grub sky-rocket announce partnership fast food behemoth yum brand yum parent taco bell kfc pizza hut report better expect fourth quarter earning already top provider online order food delivery service grubhub now be exclusive online delivery partner yum brand taco bell kfc yum brand be buy grubhub stock video game publisher activision blizzard atvi modestly beat wall street consensus estimate holiday sale quarter thank hit game call duty wwii industry peer take interactive software plunge holiday earning top sale revenue guidance disappoint fireeye feye swung adjust profit cent share revenue rise top fireeye forecast march quarter revenue estimate fortinet ftnt top earning sale view give weak operate margin guidance march quarter fortinet cfo be leave citrix system ctxs proofpoint pfpt top earning view march quarter profit guidance be light proofpoint announce third recent acquisition wombat security paycom software payc report fourth quarter result beat consensus estimate revenue earning paycom leader cloud base human resource management tool also present first quarter revenue guidance line consensus estimate general motor gm post record profit top fourth quarter estimate help part boom crossover sale ep jump revenue fall reflect key divestiture fellow auto giant toyota motor tm see operate profit grow fiscal third quarter lift full year profit forecast gilead science gild top fourth quarter expectation adjust profit share sale sale guidance be light bristol myer squibb bmy glaxosmithkline gsk allergan agn alexion pharmaceutical alxn regeneron pharmaceutical regn teva pharmaceutical teva top expectation bristol share fall confusion regard immuno oncology trial opdivo lung cancer alexion teva topple weak guidance sanofi sny miss ep sale view bitcoin tumble early tuesday top financial regulator senate banking commerce hearing be not negative fear investing digital currency bitcoin rebound be still less half december time high meanwhile goldman sachs global investment chief predict most not current cryptocurrency end lose value cboe global market cboe crash day move average tuesday trading be halter several inverted volatility product raise concern trading volume profit option exchange friday cboe miss earning revenue estimate fidelity say bar client buy inverted volatility instrument cboe fall week walt disney surpass expectation ep jump sale grow theme park resort segment lead revenue gain offset weakness studio consumer product medium network subscription stream service espn debut spring month mlb mls nhl game sport tennis boxing golf rugby cricket share fall week line major avearage handbag brand michael kor kor post surprise profit growth share sale gain comp slide less anticipate upscale parka maker canada goose goos beat yet again share plunge ostensibly due high expectation coach kate spade parent tapestry tpr turn solid beat kor fall week canada goose nearly tapestry gain wynn resort wynn ceo steve wynn resign wall street journal report detailed allegation sexual misconduct spur stock sell regulatory probe wynn share rise wednesday edge lower week well fargo wfc share tumble federal reserve feb bar bank expand balance sheet demand board shake wake well sham account scandal chipotle grill cmg share nose dive fast casual chain signale continue weaker sale traffic trend more spending year improve restaurant boee ba reportedly present compromise plan brazil government let take stake joint venture commercial jet business embraer erj meanwhile wwd deny report talk boee takeover chip gear maker ichor holding ichr top estimate fourth quarter earning share penny miss view penny outlook current quarter send share sharply lower laser system maker coherent cohr fall hard post slightly better expect december quarter result disappoint profit margin outlook share crash extreme network extr report fiscal revenue miss adjust profit edge view march quarter guidance include asset acquire brocade be slightly estimate share fall netgear ntgr report earning beat expectation miss revenue company plan spin fast grow arlo security camera business hold ipo share fall zendesk zen narrow quarterly loss year earlier revenue also top view send share higher zendesk forecast revenue consensus estimate share gain match group mtch report revenue top estimate soar growth tinder date app adjust profit miss rise investment match add tinder subscriber december quarter give overall yelp yelp report fourth quarter earning top consensus view provider crowdsource online reviews advertising growth amazon amzn rolled same day hour delivery whole food grocery order include produce meat dairy seafood certain alcohol product austin cincinnatus dalla virginia beach challenge grocer staking territory supermarket turf war amazon aim expand service other city year amazon also reportedly be plan launch own mail delivery service hit share fedex fdx unite parcel service up
584,AGN,here weekly investing action plan need know investor come week earning season be here again give top company chance provide more detail tax cut recently sign law change guidance profit come year delta air line dal
585,AGN,clovis oncology clvs sage therapeutic sage puma biotechnology pbyi stoke acquisitive appetite large cap biotechs struggle slow growth major patent cliff analyst say tuesday deal make have slow hit record high rbc analyst say note client number deal value hit year year have be merger include gilead science gild takeover kite pharma investor have expect gilead major buy stoke more acquisition didn come fruition biotech stock suffer pent demand prompt merger acquisition play next year analyst say many large cap company generate share overall revenue handful blockbuster drug many be face impending patent cliff come year rbc note say need make lose source revenue stimulate growth encourage future gilead buy kite suffering major decline hepatitis drug unit hiv drug tenofovir alafenamide be likely lose patent protection celgene celg cancer drug revlimid be face patent cliff amgen amgn inflammatory enbrel be likely lose protection also have most cash hand recent update amgen report celgene have gilead note remainder large cap biotech realm have ibd take analyst say monday large cap biotech franchise feel pain competition speeding number rival brand generic drug approval head ibd industry theme more mean like vertex pharmaceutical gilead amgen overall cash position be near year high analyst say tax reform help most recent proposal company repatriate earning tax rate amgen bristol myer squibb bmy dow johnson johnson jnj have excess cash currently overseas however think unlikely majority overseas cash be repatriate immediately institution tax reform rbc analyst say celgene instance have suggest chunk foreign earning be expect be reinvest permanently outside analyst also note average project revenue next year mid cap biotechs be likely do little offset loss patent cliff performance acquirer past year have be poor industry check also indicate large deal be out gilead kite be exception still expectation be high merger acquisition analyst say recent survey investor cite biggest tailwind group drug pricing be expect be biggest headwind rbc analyst be slightly bullish slightly bearish drug pricing expectation high major tailwind sector do not materialize first half see broad downside rbc say credit suisse analyst vamil divan too note be important big pharma group likely come result change tax rate repatriation top pick be also expect dow merck mrk allergan agn rebound additional fund dividend growth share repurchase also boost overall outlook sector investor perspective say see regulatory environment remain generally favorable provide more rapid path market product bring real innovation related beware price war big pharma biotech company biotech stock see cheapest rival cancer drugsgeneric drug maker face pricing issue other pharmas don
586,AGN,british billionaire reportedly be consider buy stake teva pharmaceutical teva prod share israeli drugmaker pop monday price target cut follow lackluster quarter xby close bell stock market today teva jump close allergan agn also sustain price target cut follow mixed report last week share dip close len blavatnik be look acquire stake teva accord reuter cite report israeli outlet weekend teva have market cap share hit year low last week third quarter earning miss teva cut guidance blavatnik acquire stake teva private stock list scoop allergan stake allergan receive teva part deal last year sell generic business teva last week allergan say be look sell stake credit suisse analyst vamil divan trim price target teva keep underperform rating expect stock continue languish investor await update strategic plan new chief executive kare schultz teva left lot question unanswered conference call divan say note client be understandable new ceo just joined company day lack insight be still frustrate ibd take least biotech have alarm result earning be mixed most head ibd industry theme breakdown industry group thus far third quarter earning season teva maker generic drug now find flip side coin mylan myl just launch generic version copaxone multiple sclerosis drug teva now divan see teva pull copaxone sale next year year year mylan come market immediately price be lower teva expect say question also remain allergan divan say separate report cut price target allergan keep outperform rating teva allergan be soon face generic competition restasis eye drug see competition january july base case now assume restasis generic entry start instead mid say base ep be previous large part change assume be relatively rapid erosion sale generic also pressure namenda ex extend release estrace delzicol aczone drug treat dementia menopausal side effect ulcerative colitis type acne respectively divan also lower estimate kybella drug reduce fat chin give limit commercial progress product have make now see peak sale related epipen rivalry slug mylan result sale outlook beat viewsallergan soft revenue earning top nordisk mixedteva dife long road ahead earning miss guidance cut
587,AGN,stock pare loss be still lower early action tuesday healthy reading service sector shed nasdaq trim dow lose turnover be mixed stock market today volume nyse lower nasdaq relative action same time monday european market be pressure wave weak economic news researcher markit report service sector toggle back growth mode march lift service purchasing manager index vs read february tally indicate economic contraction institute supply management corroborate read place march manufacturing index february consensus projection read labor department job opening labor turnover survey show available unfilled job position february be slightly department initial estimate january revise total oil future ease west texas intermediate continue trade barrel gold climb more ounce drug maker be highly active early trade allergan agn tumble widest loss issue pending federal rule change aim tax inversion deal affect allergan plan merger new york base pfizer pfe pfizer share rise valeant pharmaceutical vrx pop announce internal review accounting issue mail order pharmacy philidor rx service find additional issue quebec canada base drug maker announce last month restate revenue find irregularity marvell technology mrvl spark bermuda base outfit announce chief executive sehat sutardja wife president weili dai resign executive position immediately hold board seat earlier audit committee investigation find management tone have lead company accounting issue walgreen boot alliance wba slip serve mixed fiscal result pharmacy chain say expect acquisition rite aid rad close second half year ibd stock chip maker maxlinear mxl fall lead manufacturer universal display oled drop more maxlinear have be struggle early march get distance cup base buy point universal be hold just cup handle buy mark wesson holding swhc sturm ruger rgr top ibd group rebound sharp loss monday
588,AGN,stock open sharply lower tuesday follow lead overseas market slip nasdaq lose dow jone industrial average give stock market today appear pull premarket cue europe stock be pressure raft unexpectedly soft economic datum cac paris frankfurt dax trade more ftse london show loss afternoon trading market receive dose service sector datum later morning london base researcher markit release march service purchasing manager index et institute supply management deliver march index labor department report job opening labor turnover survey february early report show trade gap widen slightly february upwardly revise january commerce department report economist consensus have forecast milder uptick oil price dip slightly left west texas intermediate bob barrel natural gas jump more gain last week monday gold future climb more ounce dollar be mixed bond blipped higher send year yield basis point dow stock slide almost unanimously lower cisco system csco lead downside fall early outperformer include pfizer pfe procter gamble pg johnson johnson jnj pfizer report positive result psoriatic arthritis treatment phase clinical trial federal regulator announce pending rule change affect potential inversion merger rule directly affect pfizer allergan deal set close later year share ireland base allergan agn crumble tesla motor tsla lag nasdaq fall late monday company give delivery count mentioned model part shortage nearly ibd stock be flat start regular trade edward lifescience ew backed suggest well earn pause monday price spike wesson swhc show sign life sell monday japan tokyo nikkei dive week low yen continue gain strength disappointing industry forecast send iron steel issue tumble china market end mixed shanghai composite hong kong hang seng index stock india skid lower reserve bank india cut interest rate basis point line consensus expectation market have already price react cue global market bloomberg report send mumbai benchmark sensex index image provide shutterstock
589,AGN,allergan agn tumble new tax inversion rule tesla motor tsla skid weak delivery walt disney retreat key executive exit raise doubt be eventual successor ceo bob iger allergan stock fall treasury department issue new rule curb so call tax inversion include step curb earning strip method used reduce taxe inversion pfizer pfe ireland base allergan plan merge pfizer takeover structure reduce tax liability pfizer stock edge higher late close allergan have close higher tesla motor say deliver vehicle nearly vs year earlier company february forecast tesla blame severe part shortage model crossover own hubris tesla share fall late erase nearly regular session gain huge preorder model model be suppose go production late total vehicle production hit walt disney say close coo thomas stagg be see possible successor ceo bob iger be leave stagg serve special advisor iger disney stock fall close meanwhile salesforce com crm agree buy artificial intelligence startup metamind undisclosed term latest big tech step ai takeover investment salesforce ceo marc benioff invest metmind back december salesforce stock be little change late
590,AGN,drugmaker allergan agn get price target cut canaccord genuity thursday company hit delay merger pfizer pfe other issue analyst corey davis note wednesday federal trade commission ftc have ask additional information pfizer allergan merger be first announce november company also have allergan finish divest generic drug business teva pharmaceutical industry teva hit delay month cause teva push expect close date june pfizer allergan still expect close merger second half year meanwhile be lower estimate ep drop always weakest quarter specialty pharma feel rest street be also too high davis write research note lower price target allergan stock have be trend past several year be partly reset medicare part davis add merger target tgt cvs health cvs hit allergan distribution business tune year launch bowel disease drug viberzi have increase spending davis write be nonetheless maintain buy rating due high likelihood deal close have be skepticism investor pfizer allergan deal be go close year signal allergan fall stock price buy side survey evercore isi analyst mark schoenebaum month find fifth respondent place odd less ftc backlog concern incoming president congress do something limit tax inversion deal candidate have threaten do pfizer leadership wall street analyst have be more confident however march deutsche bank analyst gregg gilbert write gap pfizer offer price allergan stock price then present buy opportunity likely narrow deal close near allergan stock be fraction morning trading stock market today
591,AGN,small biotech aldr soar more month high early trading monday migraine drug candidate succeed mid stage trial position compete giant rival say single intravenous infusion monoclonal antibody ald have significantly reduce migraine day week period compare placebo depend dose patient experience reduction migraine day experience reduction evaluation ald continue exhibit potential best class profile include immediate significant durable migraine prevention infrequent quarterly dose ceo randall schatzman say statement commitment accelerate development ald reinforce today positive result look forward advance development plan assume fda approval independently marketing ald meet critical medical need patient nationwide be candidate migraine prevention therapy decision market drug big pharma partner unusual small biotech pit very big competitor develop similar drug ald be calcitonin gene related peptide cgrp antibody similar migraine candidate be develop amgen amgn teva pharmaceutical industry teva eli lilly lly drug be distinguish infrequent dose amgen teva drug be inject once month lilly be biweekly also be compete allergan agn botox be also quarterly involve separate shot credit suisse analyst vamil divan write ald result seem roughly equivalent teva term effectiveness do note be significant improvement placebo number patient experience reduction migraine day patient drug achieve be rather lower have be headache free previous trial stock so many other biotech stock have lose more half value touch time peak july early trading stock market today share be be image provide shutterstock
592,AGN,delaware select growth fund dveax pull stop search growth go anywhere fund invest company size look name be expect grow faster economy long term asset fund be sub advise team manager san francisco base jackson square partner year date go tuesday fund be vs average decline peer large growth fund track morningstar last decade delaware select growth have churn annual average return vs large growth category fund hold stock feb spread vary market cap category fund count technology consumer discretionary health care be top weighting fund have annual turnover rate versus category average delaware select growth primarily bet company asset invest top holding paypal pypl be top holding fund better recent performer digital mobile payment provider be so far year stock be top hold feb earning share rise past quarter vital signsat end february fund top hold be company celgene celg january company report fourth quarter earning share growth jump revenue celgene top line have benefit strong sale top selling cancer drug revlimid share celgene be year date earlier month biotech release drug trial datum disappoint investor celgene report phase disappointing result experimental oral treatment psoriasis delaware select position have also be make gain pharmaceutical space allergan agn be come impressive own botox be company top revenue generator quarter figure amount total revenue november company agree blockbuster merger pfizer pfe allergan have see stock price slide begin year ep growth have decelerate grow past quarters qualcomm qcom be fund third largest hold have be portfolio delaware select growth team state commentary believe company mobile chip business bounce back product cycle issue be unlikely recur show strength company recently up dividend qualcomm have see stock price rise zebra technology zbra be add delaware select growth portfolio company sell tracking computer printing technology such barcode scanner specialty printer zebra recently say be project full year net sale growth also expect pay least debt principal zebra share have decline so far year commentary delaware select growth team note progress microsoft msft top hold shift cloud base technology believe transition be beneficial software be better utilize multiple platform team write share microsoft have tick so far year
593,AGN,bloodbath january miss february market finally get right march advanced last month diversify stock mutual fund tack average accord lipper inc wasn enough pull stock mutual fund black entire first quarter lose gain be tale half say anthony valeri investment strategist lpl financial largest independent broker dealer top custodian register investment advisor summarize quarter stock market news first half investor worry interest rate rise oil price slumping china economy cramp flat fear penalize stock inordinately valeri say second half investor fear ease mid february lot bad news be price stock datum start get better valeri say mid march market get tailwind federal reserve suggest be likely raise rate twice year not time click here view list mutual fund month leadersweekly jobless roll fall retail sale january be stronger expect upward revision december even manufacturing datum sore spot previously improve march housing datum show resilience do leave anything oil price stabilize valeri say be big dollar ease help exporter stock general click here see list mutual fund category performancelike wildcatter flock rich oil field boom time investor pour natural resource fund commodity energy fund drive respectively march commodity general do well last month precious metal fund gain padding overall gain big top sector quarter commodity prominent value oriented mutual fund midcap value fund be top perform category diversify fund group gain not far be equity income fund gain click here see list mutual fund quarterly leaderstop diversify stock fund include small cap equity gsxax return top small cap growth peer management team include ralph bassett jason kotik be also eighth best perform diversify stock fund overall year end march foreign stock fund fared better stock fund lose less just average taxable bond fund lose tax exempt bond fund gain term good reason think oil have stop go dollar have stop go say bob doll chief equity strategist asset management case market get better second half year doll caution oil have never stage sharp rally commodity general oil particular have never make bottom say decline ve often have multiyear period go other side price formation late march barrel price benchmark light sweet crude oil have pull back slightly also china economic growth be still not expand china be consciously reorient economy away huge dependence export capital investment longer term sustainable economy base consumption doll say global economic uncertainty stock appear likely remain safe haven attraction investor technology financial sector appeal most doll financial be cheapest cyclical market doll say have big bear market first week year now re back spdr financial etf xlf fall feb rally march sluggish market stock picker outperform index hugger doll say investment return year time year blood street buy equity doll say thing improve other investor get complacent let go take profit doll say keep stock portfolio want defense say instead not utility be also defensive pay dividend re expensive now telecom be better value doll say also have more appetite consumer discretionary staple discretionary have better valuation say staple tend be more global therefore face more risk currency headwind valeri have similar view sector re still focuse area benefit further expansion say mean more cyclical sector consumer discretionary tech also have more modest overweight industrial fidelity select consumer discretionary portfolio fscpx recent top holding be amazon amzn follow home depot hd walt disney nike nke add health care be defensive sector be focus earning clarity be fairly good allergan agn bristol myer squibb bmy unite healthcare unh be recent top holding vanguard health care fund vghcx wield asset doll valeri be lean away utility consumer staple doll also lean away telecom expectation be improve economic growth say so sector win necessarily benefit much utility telecom be rate sensitive think rate move gradually higher year so headwind sector valuation be generally expensive image shutterstock
594,AGN,allergan agn stock dive tuesday treasury ir announce plan new rule aim curb tax inversion practice allow company avoid taxe buy foreign company move headquarters overseas impact pending deal pfizer pfe ireland base allergan set close year latter be result several recent inversion company say statement late monday be conduct review department treasury action announce today prior complete review win speculate potential impact allergan fall nearly premarket trading be lowest level october pfizer rise nearly latest treasury action limit ability inverted company lend money american subsidiary create deductible interest reduce taxable income treat certain debt issuance stock serial inverter be also target new rule year limit foreign company bulk asset avoid ownership requirement later inversion deal be third set inversion curb rule issue treasury secretary jacob lew last few year lew say office be continue explore additional way limit inversion america corporate tax system give company strong incentive shift headquarters overseas combine federal state corporate rate be highest industrialize world america most nation taxe overseas earning inverted company still have pay tax rate american profit be get relief earning elsewhere other notable recent inversion involved mylan myl medtronic mdt burger king now call restaurant brand qsr deal have already close
595,AGN,big biotech gilead science gild hit month high monday analyst deliver bullish outlook company sunday rbc capital market analyst michael yee lift ep estimate due stock buyback note several recent piece incremental good news cite late friday successful patent suit merck mrk ionis
596,AGN,big pharma player allergan unveil expect be final full year operation independent drug maker merge pfizer report fourth quarter earning beat expectation revenue barely top wall street estimate market open allergan agn say gaap earning rise share revenue gain metric exclude discontinue operation notably allergan global generic business agree sell july global generic unit carry old actavis name generic drug line business actavis have purchase specialty drug botox maker allergan deal close march rename allergan allergan stock rise stock market today time high touch july pfizer pfe stock rise monday nearly year high set july analyst poll thomson reuter expect ep item revenue analyst number apparently be not uniformly adjust discontinue operation allergan present pro year earlier number adjust ep revenue full year allergan say gaap ep continue operation increase revenue continue operation vary adjustment full analyst expect share item sale allergan report gaap loss continue operation share compare gaap loss continue operation share prior year period say full gaap result be impact amortization acquisition expense license agreement impairment severance related mainly acquisition allergan march kythera oct well research development expense result purchase asset mimetogen allergan have decline freshen guidance issue performance nov cite early merger discussion pfizer back then monday guide revenue material change gross margin current level gaap tax rate normalize management didn specify ep year offer guidance other suggest performance be weakest year fall result allergan result be analyst challenge influenced extraordinary dance card begin discontinue operation rename actavis generic line agree sell teva pharmaceutical teva july nov allergan board agree pfizer offer pfizer share allergan share then value allergan share entire deal expect take month close ceo brent saunder tell analyst conference call follow earning release still expect pfizer buyout close second half be second largest acquisition ever sale vodafone airtouch mannesmann dell october offer buy emc emc be value pfizer acquisition allergan be thin number tax inversion deal allow american company domicile ireland allergan home base buyer enjoy lower tax base obama administration have criticize practice throw speed bump not road block feb pfizer say plan reorganize broad line business merger allergan be complete allergan cfo tessa hilado tell analyst debt stand dec be paid close teva sale put revenue top seller botox eye drug restasis namenda xr say cvs cvs purchase target tgt pharmacy have effect revenue didn wouldn impact earning
597,AGN,valeant pharmaceutical vrx share climb much tuesday drug maker say expect restate earning not much overall help clear air congressional investigation raise question company former relationship distributor philidor rx service question pricing practice specialty drugmaker valeant say written statement late monday evening internal review additional analysis identify certain sale philidor have be recognize product be dispense patient rather delivery philidor valeant say currently believe net revenue be include second half have be book later correct misstatement be expect reduce report gaap earning share cent valeant say increase gaap ep roughly cent base analyst consensus lift ep roughly valeant share close stock market today share have fall friday monday well fargo warn unanswered question company accounting strategic direction stock fall hour monday wall street journal say earning restatement be likely stock plunge aug intraday high questionable number come light low nov statement valeant note sale occur prior earlier bid acquire philidor specialty pharmacy philidor be suspect fill prescription valeant alter doctor order raise insurer reimbursement bloomberg say oct report cite former employee internal document oct valeant say be sever ty philidor subsequently begin wind operation interim chief executive howard schiller say statement company also expect delay filing complete review related accounting matter ad committee determination need delay filing be very disappointing necessary schiller say add remain commit improve report procedure internal control transparency investor schiller be name post interim basis jan fill ailing ceo michael pearson be be treat severe pneumonia complication valeant release unaudited result feb private label counter prescription generic drugmaker perrigo prgo share have be batter too fall lowest point year monday perrigo lose session report weak fourth quarter earning last thursday be downgrade analyst earning perrigo close big pharma allergan agn report hike ep jump revenue monday rise monday finished tuesday allergan agree november be acquire pfizer pfe deal be expect close year
598,AGN,disgrace drugmaker valeant pharmaceutical vrx continue sell rest medical sector thursday report surface creditor be demand new term company default massive debt reuter cite anonymous source say early talk lender be ask higher interest payment pledge pay larger amount bank loan proceed valeant asset sale valeant have be breach report covenant tuesday miss filing deadline have day resolve however doesn file march also be default bank creditor have only day resolve default valeant be debt year long buy spree culminate fail attempt buy allergan agn last year allergan subsequently merged actavis be now process be buy pfizer pfe late afternoon stock market today valeant stock lose medical group track ibd even unrelated drug account worst perform group ibd industry generic drug group lead slide decline hardest hit individual stock be valeant fellow specialty drugmaker have consciously follow valeant business model mallinckrodt mnk authorize stock buyback be endo international endp be head former valeant executive rajiv silva hit year low trading horizon pharma hznp have be criticize pricing policy much valeant have be selling last day major drugmaker eli lilly lly tumble eli lilly fall intraday lowest level late
599,AGN,something everyone vast universe sector fund consumer staple health care technology sector be favor fund rack big return also be prone bigger decline re more concentrated specific area diversify fund ibd run screen actively manage fund least asset have beaten benchmark past year sector be clear winner best sector fund rank year performance focus biotech health science see full list best sector mutual fund highlight best mutual fund top perform sector best best list ibd best mutual fund award winner include top fund sector click here view table top perform mutual fund select biotechnology portfolio fbiox come top year average annual return well ahead fund hold net asset feb expense ratio be rajiv kaul have manage fund october most sector biotech have see fair share volatility not necessarily negative next year go be renaissance industry term golden age innovation kaul tell ibd not go be straight line biotech be volatile investor amazing opportunity happen jan biotech stock make portfolio pharmaceutical fidelity select biotech hold stock top holding end include alexion pharmaceutical alxn regeneron pharmaceutical regn vertex pharmaceutical vrtx gilead science gild celgene celg stock ibd biotech industry group surge more november low july peak turnover fund tend run fairly low be high barrier entry biotech field include expertise capital regulatory hurdle kaul point do get major breakthrough medication really improve person life help save cost health care system do kaul pick stock fund have understand management be track record success say have kind historical understand depth understand industry individual player equally important be ability company access capital low cost want company be self reliant top biotech fund own big cap biotech soliris maker alexion recently report quarters fund also hold biotechs celgene gilead focus cancer hepatitis respectively generic drug maker track ibd soar more march july ethical drug stock rally nearly march august rowe price health science prhsx take second place biotech fund year return fund have net asset have be close new retail investor june feb portfolio hold stock service account asset follow biotech pharmaceutical product device life science top holding include aetna aet alexion pharmaceutical allergan agn becton dickinson bdx cigna ci focus innovative medicine diagnostic device business model have be core driver success taymour tamaddon have manage fund february say mail past year strength have be broad base biotech likely have highest level performance fund expense ratio be prudential jennison health science phlax return past year have be close new investor end june fund have total net asset expense ratio david michael del balso debra netschert manage fund biotech make biggest weighting jan asset pharmaceutical account health care provider service be health care equipment supply be life science tool service be biggest holding stock portfolio include celgene biomarin pharmaceutical bmrn bristol myer squibb bmy shire shpg allergan remain focuse longer term outlook fund believe continue be very positive base range industry trend health care reform advent oncology active immune therapy manager say jan fund commentary realization company value encounter intermittent setback believe market recognize reward longer term franklin biotechnology discovery fbdix total net asset feb have year return biotech stock make portfolio follow pharmaceutical nearly life science tool service focus biotechnology generally have limit exposure other area health care evan mcculloch senior vice president lead portfolio manager fund say avoid more traditional large cap pharmaceutical company have less favorable growth prospect do not show same level innovation see biotechnology celgene gilead science biogen biib amgen amgn regeneron pharmaceutical be top position stock fund fund close new investor july have expense ratio overall believe be strong fundamental underlie biotechnology sector recent growth have also help fund mcculloch say innovation remain very strong promising new treatment area immuno oncology gene therapy alzheimer disease gi disorder central nervous system disease other rydex biotechnology ryoax round top sector fund year return expense ratio be biotech account net asset feb pharmaceutical life science tool service top holding march include gilead amgen celgene biogen regeneron health care clearly dominate sector fund past decade other fund lead respective category rowe price global technology prgtx net asset end february lead tech sector fund year average annual return medium semiconductor software make biggest weighting stock fund top holding include alphabet googl amazon com amzn jd com jd have expense ratio lead consumer cyclical sector be fidelity select retail portfolio fsrpx asset feb year average annual return expense ratio be internet retail home improvement retail apparel retail account top subindustry end january amazon home depot hd netflix nflx be top holding rowe price medium prmtx top communication sector average annual return fund have net asset feb expense ratio be medium telecom service software be biggest investment area alphabet amazon american tower amt stock portfolio recent top holding rydex consumer product rycix average annual return expense ratio lead consumer defensive sector food product beverage household product account more half net asset procter gamble pg coca cola ko philip morris international pm be recent top holding burnham financial service burkx hold asset head financial sector average annual return yadkin financial ydkn bnc bancorp bncn atlantic capital bancshare acbi be fund top holding jan fund gross expense ratio be net expense ratio be
600,AGN,valeant pharmaceutical vrx perrigo prgo share continue tumble monday generally pull drug sector allergan agn be exception rise strong earning valeant late monday tumble low be lowest march dow jone report valeant pharmaceutical likely restate earning hour later valeant say restatement earning be expect related sale drug ex distributor philidor valeant say sale late have be recognize later valeant expect earning be lower cent share ep lift cent regular session valeant share close stock market today extend loss bearish report well fargo friday valeant share dive nearly day well fargo initiate coverage maker brand drug treat eye disease acne depression other ailment underperform say be unanswered question accounting method strategic direction earlier monday drugstore giant cvs health cvs say plan restrict use valeant jublia toenail fungus drug part initiative cut cost dermatology treatment jublia retail milliliter bottle accord goodrx valeant stock price have plunge intraday high double digit quarterly earning revenue growth nearly year bill ackman persh square hedge fund be significantly year partly fund large stake valeant valeant have already be batter series event include absence ceo michael pearson be be treat severe pneumonia complication jan valeant board name board member former chief financial officer howard schiller interim ceo earlier month valeant interim ceo schiller be call congress explain company decide increase price cardiac drug schiller promise end era sharp price hike perrigo business model be divide private label counter prescription generic drug fall monday lowest level late stock have lose session perrigo report weak fourth quarter result thursday subsequently have negative report jeffery friday goldman sachs monday jeffery cut price target maintain buy rating goldman sachs however downgrade stock neutral sell price target report say perrigo report ep time item cent estimate be company first earning miss quarters revenue grow analyst expect mylan myl last year make offer perrigo perrigo shareholder mid november reject mylan rise monday big pharma allergan agn report expect be final full earning report independent drug maker agree november be buy pfizer pfe allergan ep ex item rise hike revenue wall street expect ep revenue allergan share climb pfizer rise ibd generic drug ethical brand drug group be rare loser otherwise strong day stock
601,AGN,big pharma pfizer pfe announce monday close acquisition allergan agn plan reorganize unit pending possible split back pfizer reorganize operation business unit innovative product establish product vaccine oncology consumer healthcare voc be widely view preparation split company pending buyout allergan pfizer be add large number drug include wrinkle treatment botox variety eye care skin care product monday pfizer say plan combine innovative product voc business include new subdivision call global specialty consumer brand include most allergan product larger innovative product business be head current voc head albert bourla replace geno germano leave company new global specialty consumer brand division be head allergan executive bill meury establish product business continue be lead john young allergan current ceo brenton saunder meanwhile be set become next president chief operate officer pfizer be generally expect wall street land high ranking position so be ready succeed present pfizer ceo ian read pfizer announce allergan buyout last year say decision split not be make be couple year later previously expect read reiterate monday announcement be design combine company preserve enhance option potentially separate innovative establish business separate company future continue expect make decision potential separation later end read say statement pfizer stock be midday trading stock market today allergan be
602,AGN,mark finn never see market sell didn portfolio manager rowe price value fund trvlx finn often used dip set long term position mutual fund recent december january stock market pullback present own set opportunity finn have be gdp scare sell say person be worry economy tip back recession so cyclicality be sale right now be look particular be company get really attractive dividend yield generate lot free cash flow have be cheapen re perceive be cyclical business finn be ready pick spot more pullback occur month ahead be not overly optimistic market overall say end year flat begin think be expect interim get chance buy really good company dividend yield close be trading multiple time rowe price value be year date go thursday vs decline large cap value peer track morningstar inc past year mutual fund have return annual average beating peer trail fund carry ibd month performance rating meaning top mutual fund year performance finn rely robust team research analyst help fundamental stock pick be try identify invest quality company be face controversy perceive controversy have determine be trading intrinsic value say have good idea make big position accrue benefit shareholder end general electric ge be rowe price value top hold finn be optimistic ge renew focus industrial business help increase margin time have be best perform industrial company last year say think ge be go continue relatively outperform industrial have really figured mission be ge have see stock price climb past year share be almost stock market today pfizer pfe top hold have sunk week high have fall back allergan agn acquisition pfizer be phenomenal company really nice pipeline product now have really good yield finn say pfizer be year sport dividend yield energy sector finn have favorable outlook exelon exc have great dividend yield look be cyclical bottom come energy say share exelon yield have gain so far year holding finn see undervalue also include international paper ip aes aes be company trading dividend yield market perceive be cyclical risky really don say
603,AGN,san francisco jpmorgan healthcare conference continue yield mixed result investor second day tuesday several company tweak guidance big pharmas offer incremental update specialty drugmaker horizon pharma hznp have best day share rise company update guidance ahead presentation wednesday horizon say
604,AGN,past few year be big year health care merger controversy pfizer pfe agree buy ireland base allergan agn last month bring new plan treasury department presidential candidate curb tax inversion deal company relocate lower tax country device
605,AGN,big pharma pfizer fulfilled week rumor monday announce deal buy specialty drug giant allergan stock swap value heating political debate tax inversion deal pfizer pfe agree provide allergan agn shareholder pfizer share allergan share base friday close price value allergan share price be somewhat lower last week anonymously source press report peg price share be still premium allergan friday close price make deal second largest ever say thomson reuter only mannesmann acquisition vodafone airtouch more twice value largest tech couple ever merger dell emc emc announce october term disappoint investor allergan stock fall pfizer fall monday pfizer drop lower value deal allergan share expect deal allow pfizer perform tax inversion domicile allergan official homeland ireland lead pfizer rename pfizer plc expect close deal month pfizer say inversion result pro tax rate cut more company tax bill overall pfizer expect cost saving first year combination doesn forecast earning accretion allergan shareholder end own combine company steer clear last week new treasury guideline attempt tighten rule such tax inversion deal rule target more lopsided deal acquirer try redomicile still own more company full tax benefitson conference call analyst monday morning discuss merger pfizer ceo ian read say expect realize full benefit tax inversion hasten add trimming tax bill wasn only reason deal say pleasant surprise pfizer due diligence be discover strength allergan drug franchise say pfizer further expand abroad thank vast global infrastructure allergan expand leadership position bring very strong franchise aesthetic dermatology eye care gi disease woman health urology infective read say remember several year pfizer decide exit prioritize area not be unattractive do not have scale expertise market lead position be competitive allergan gain access expertise market lead product area read say lack overlap company product line be reason projection cost saving be somewhat lower analyst expect say pfizer plan keep most allergan operation employee southern california be originally headquarter bring irish domicile imply not be big layoff evercore isi analyst mark schoenebaum theorize webinar client preserve job also be way deflect criticism deprive tax income so didn entirely work democratic presidential candidate hillary clinton bernie sander criticize deal monday week ahead propose specific step prevent kind transaction take advantage loophole litter tax code distort incentive investment disadvantage small business domestic firm game international tax system clinton say statement buyout deal include breakup fee likely real change legal regime come only new president congress be swear early be deal be expect close say analyst edison investment analyst maxim jacob however say federal trade commission look askance such enormous entity even pass treasury restriction pfizer allergan deal appear have be consummate be attractive side regulatory reaction very high profile merger remain unknown very well be negative due size tax inversion jacob write email read remain chairman ceo combine company allergan ceo brent saunder become president chief operate officer arrangement seem support pre deal speculation saunder be be view potential successor read year older saunder pfizer also say delay make decision splitting innovative establish old generic product business move have be expect next year analyst call weren happy delay leerink analyst seamus fernandez say still expect split happen eventually ultimately cash flow combine entity likely quickly exceed split believe overall operational complexity be likely be too high drive innovative growth fernandez write research note
606,AGN,dow chemical dow dupont dd be advanced talk create chemical giant accord multiple report cap record year merger activity include last month deal pfizer pfe buy allergan agn merged dow dupont firm then split separately trade company accord wall street journal cnbc david faber firm be agriculture material service specialty product dow chemical close tuesday market cap dupont be value dow ceo andrew liveris be expect become executive chairman merged firm dupont ceo edward take only october be expect hold same position post merger faber report merger deal be likely thursday company have be pressure shed slower growth unit dupont reportedly have seek merge agricultural asset syngenta syt syngenta have rebuff overture activity have top eclipse old record set pfizer tax inversion deal allergan be largest year big drug takeover ever
607,AGN,share drug giant allergan rise friday analyst say new treasury guideline tax inversion deal shouldn hinder possible acquisition pfizer new york base pfizer pfe have be talk ireland base allergan agn late last month possibility buyout allow pfizer relocate allergan lower tax home wall street generally
608,AGN,stock future point sharply higher be early high ahead wednesday start trade follow mixed early economic news market rally europe
609,AGN,dow future steer point nasdaq future trade point fair market value future show point gain small cap be positive steady russell future hold point gain
610,AGN,stock market today open day rally belt nasdaq end higher trading range tuesday index remain day move average nasdaq be position possible test line week
611,AGN,personal spending rise november commerce department say welcome improvement october gain show line economist expectation personal income rise tad october gain better view advance
612,AGN,durable good order be flat month sharply october downwardly revise gain better contraction project economist consensus transportation order dip vs estimate change
613,AGN,et university michigan be schedule report final consumer sentiment estimate december commerce department give new home sale number november
614,AGN,dollar be mixed early wednesday vs euro yen bond slip send year yield basis point
615,AGN,crude price moved higher brent crude west texas intermediate benchmark trading tandem just barrel crude price see effect weekly inventory datum energy information administration due et metal agricultural commodity be mixed
616,AGN,mining company appear poise rally day bhp billiton bbl rio rio freeport mcmoran fcx vale vale jump bounce oil mining issue trip rally european market send london ftse more cac paris frankfurt dax nearly much midday trade
617,AGN,stock nike nke vault nearly lead dow well ibd list premarket action athletic wear maker report late tuesday fiscal second quarter earning top consensus forecast revenue rise just shy expectation gross margin increase more forecast primarily due higher selling price stock have be testing support week move average just flat base buy point
618,AGN,devon energy dvn spiked devon have be highly active acquisition front month pay asset anadarko powder river basin sell san juan river holding new mexico bp bp
619,AGN,celgene celg muster gain open drug maker announce settlement litigation vs india natco pharma partner arrow international subsidiary allergan agn pertain patent oral cancer drug revlimid celgene share have be consolidate july
620,AGN,micron technology mu tank hurt fiscal earning result deliver late tuesday idaho base chip maker score narrow earning beat revenue miss analyst target management guide revenue earning consensus forecast stock future point sharply higher be early high ahead wednesday start trade follow mixed early economic news market rally europe dow future steer point nasdaq future trade point fair market value future show point gain small cap be positive steady russell future hold point gain stock market today open day rally belt nasdaq end higher trading range tuesday index remain day move average nasdaq be position possible test line week personal spending rise november commerce department say welcome improvement october gain show line economist expectation personal income rise tad october gain better view advance durable good order be flat month sharply october downwardly revise gain better contraction project economist consensus transportation order dip vs estimate change et university michigan be schedule report final consumer sentiment estimate december commerce department give new home sale number november dollar be mixed early wednesday vs euro yen bond slip send year yield basis point crude price moved higher brent crude west texas intermediate benchmark trading tandem just barrel crude price see effect weekly inventory datum energy information administration due et metal agricultural commodity be mixed mining company appear poise rally day bhp billiton bbl rio rio freeport mcmoran fcx vale vale jump bounce oil mining issue trip rally european market send london ftse more cac paris frankfurt dax nearly much midday trade stock nike nke vault nearly lead dow well ibd list premarket action athletic wear maker report late tuesday fiscal second quarter earning top consensus forecast revenue rise just shy expectation gross margin increase more forecast primarily due higher selling price stock have be testing support week move average just flat base buy point devon energy dvn spiked devon have be highly active acquisition front month pay asset anadarko powder river basin sell san juan river holding new mexico bp bp celgene celg muster gain open drug maker announce settlement litigation vs india natco pharma partner arrow international subsidiary allergan agn pertain patent oral cancer drug revlimid celgene share have be consolidate july micron technology mu tank hurt fiscal earning result deliver late tuesday idaho base chip maker score narrow earning beat revenue miss analyst target management guide revenue earning consensus forecast
621,AGN,pharmaceutical etfs pop friday news pfizer pfe takeover irish drugmaker allergan agn reportedly biggest tax inversion deal history largest ever health sector allow pfizer new york base pharma giant redomicile ireland have much lower corporate tax rate exchange trade fund track major index stumble investor eye gdp inflation datum due later week spdr pharmaceutical xph jump stock market today etf equal weight stock holding include pfizer allergan stock holding fall today investor soured term deal prestige brand holding pbh lead upside xph holding gain xph have gain momentum recent week be july high powershare dynamic pharmaceutical pjp nose etf provide broad exposure stock include highly rate ibd stock allergan gilead gild celgene celg etf select weight holding base various fundamental risk factor allocate roughly asset allergan pfizer combine pjp have rally significantly september interim low post gain last week retake line move average even trade july high year date pjp be nearly vs xph loss gold price fall again monday dollar rise fraction major world currency etfs backed physical gold have peg straight weekly loss stagnate multiyear lows higher expectation interest rate hike december be weigh precious metal bear yield bellwether etfs here look major exchange trade fund tracking various asset class perform today follow daily etf market action be key successful investing spdr spy rs powershare qqq qqq rs spdr dow jone industrial average dium rs ishare core mid cap ijh rs ishare russell iwm rs ishare msci eafe efa rs vanguard ftse emerge market vwo rs spdr gold share gld rs ishare core aggregate bond agg rs powershare db bullish uup rs follow aparna narayanan twitter ibd_anarayanan
622,AGN,pfizer pfe announce takeover monday morning buy botox maker allergan agn more accord multiple report make biggest tax inversion deal history pfizer board sign deal sunday report say monday announcement plan pfizer pay share small cash component
623,AGN,talk possible merger dupont dd dow chemical dow be icing very large cake have already set record be time biggest year merger acquisition wednesday be announce deal worldwide act prom queen
624,AGN,pharmaceutical aren just source relief physical ailment oft steady dividend provide comfort even stock underperform today ll look drug stock dividend leader screen yield beat average pfizer pfe monday raise quarterly payout cent
625,AGN,massive pfizer pfe allergan agn merger deal week make clear irish economy be not shy away inversion deal free corporation domestic tax burden be still likely be headquarter new york pfizer save more now paid taxe first year
626,AGN,stock market close lower monday retailer have bumpy session nasdaq dow jone industrial average fall slip volume rise be surprise friday half session decline stock lead advancer nyse nasdaq stock market today transportation medical retail industry group be weakest monday energy mining stock be strongest lululemon athletica lulu gap loss sink right back day move average analyst fbr capital market downgrade lululemon underperform market perform cut price target investor grow pessimistic early holiday shopping indication other retailer sell heavy trading include ulta beauty ulta urban outfitter urbn regeneron pharmaceutical regn have worst loss ibd bid past buy point have unraveled close unitedhealth group unh say be back forecast earning share revenue be project be health insurer warn nov earning hit obamacare exchange related business cite higher medical cost individual market customer soft enrollment outlook unitedhealth share rise slightly extend trading several economic report be due tuesday manufacturing report purchasing manager institute supply management be due morning automaker report november sale earning report tuesday include fifth street finance fsc guidewire software gwre follow juan carlos arancibia twitter ibd_jarancibia
627,AGN,stock hold narrow open gain monday pair weaker expect economic report nasdaq gain be ahead dow jone industrial average show gain
628,AGN,stock market today rolled soft trade not surprising give option expiration boost trade friday week many investor be already book thanksgiving plan volume drop nasdaq nyse vs action same time friday
629,AGN,manufacturing growth slow november accord preliminary read research markit markit put purchasing manager index month october lowest read month analyst have expect uptick
630,AGN,sale exist home slow october annualize rate accord national association realtor home sell rate september economist have forecast october slowdown
631,AGN,stock tyson food tsn cook advance arkansa base meat packer fiscal fourth quarter earning miss target revenue beat estimate management full year revenue guidance top expectation big volume gain lift share back flat base buy point
632,AGN,ireland mallinckrodt mnk pop work seventh straight advance climb floor deep month correction drugmaker report strong fiscal revenue earning beat
633,AGN,gamestop gme topple lowest mark february weak result
634,AGN,leader list constellation brand stz pump lead ibd list climb past buy point flat base cowen co upgrade stock outperform market perform
635,AGN,ibd stock grupo financiero galicia ggal reversed open gain dive back buy range buy point argentina base stock be busy early monday react sunday election center right candidate mauricio macri defeat leftist contender daniel scioli country presidency bueno aire benchmark merval index open
636,AGN,ibd weekly review list argentina base bbva banco france bfr also dump worst loss list drop drag share friday new high back cup base buy point
637,AGN,upside weekly review stock prestige brand pbh leap almost announce acquire privately hold dentek oral care dentek specialize floss pick brace care other oral hygiene good sell wal mart wmt target tgt other gain better double stock average daily volume break share past buy point cup handle base
638,AGN,ibd drugmaker allergan agn drop nearly agree combination pfizer pfe allergan share gain october anticipation deal pfizer share slip early monday stock hold narrow open gain monday pair weaker expect economic report nasdaq gain be ahead dow jone industrial average show gain stock market today rolled soft trade not surprising give option expiration boost trade friday week many investor be already book thanksgiving plan volume drop nasdaq nyse vs action same time friday manufacturing growth slow november accord preliminary read research markit markit put purchasing manager index month october lowest read month analyst have expect uptick sale exist home slow october annualize rate accord national association realtor home sell rate september economist have forecast october slowdown stock tyson food tsn cook advance arkansa base meat packer fiscal fourth quarter earning miss target revenue beat estimate management full year revenue guidance top expectation big volume gain lift share back flat base buy point ireland mallinckrodt mnk pop work seventh straight advance climb floor deep month correction drugmaker report strong fiscal revenue earning beat gamestop gme topple lowest mark february weak result leader list constellation brand stz pump lead ibd list climb past buy point flat base cowen co upgrade stock outperform market perform ibd stock grupo financiero galicia ggal reversed open gain dive back buy range buy point argentina base stock be busy early monday react sunday election center right candidate mauricio macri defeat leftist contender daniel scioli country presidency bueno aire benchmark merval index open ibd weekly review list argentina base bbva banco france bfr also dump worst loss list drop drag share friday new high back cup base buy point upside weekly review stock prestige brand pbh leap almost announce acquire privately hold dentek oral care dentek specialize floss pick brace care other oral hygiene good sell wal mart wmt target tgt other gain better double stock average daily volume break share past buy point cup handle base ibd drugmaker allergan agn drop nearly agree combination pfizer pfe allergan share gain october anticipation deal pfizer share slip early monday
639,AGN,stock future struggle hold narrow gain monday market prepared holiday shorten week trade dow future be point point gain hour earlier
640,AGN,nasdaq future slim advance point fair market value future hover slim point gain small cap lag russell future slip point
641,AGN,stock market today start week mixed signal nasdaq post strong gain last week retook support day move average nasdaq also hold distribution day stall friday raise distribution day count measure show high level institutional selling show large investor be degree work be currently confirm uptrend
642,AGN,volume typically fade move thanksgiving holiday thursday stock bond market reopen friday only short session market london paris frankfurt hong kong shanghai be open week tokyo market restart tomorrow trade remainder week follow labor thanksgiving break today
643,AGN,economic news researcher markit be tap release november manufacturing purchasing manager index et national association realtor report october exist home sale
644,AGN,crude oil continue recent split trade benchmark west texas intermediate more just barrel europe brent crude rise fraction gold slip silver fall more copper drop almost
645,AGN,stock pfizer pfe allergan agn agree combination deal have be highly anticipate send allergan share only fraction higher pfizer nearly
646,AGN,peabody energy btu rumble st loui base miner announce sell coal asset colorado new mexico bowie resource partner cash deal
647,AGN,chipotle grill cmg slump still pressure dive friday trigger center disease control prevention announcement additional case coli contamination have be link restaurant chain
648,AGN,argentina base issue be motion center right candidate mauricio macri win country run presidential election narrow margin ibd stock grupo financiero galicia ggal jump more stock end friday new high extend buy point oil gas producer ypf sociedad anonima ypf jump global msci argentina argt exchange trade fund leap more
649,AGN,pace quarterly report slow significantly week ireland base drugmaker mallinckrodt mnk punch revenue earning clear analyst consensus estimate fiscal fourth quarter
650,AGN,capital bank financial cbf ibd current weekly review stock jump premarket action thinly trade stock finished friday still buy range flat base buy point
651,AGN,follow alan elliott twitter ibd_aelliott stock future struggle hold narrow gain monday market prepared holiday shorten week trade dow future be point point gain hour earlier nasdaq future slim advance point fair market value future hover slim point gain small cap lag russell future slip point stock market today start week mixed signal nasdaq post strong gain last week retook support day move average nasdaq also hold distribution day stall friday raise distribution day count measure show high level institutional selling show large investor be degree work be currently confirm uptrend volume typically fade move thanksgiving holiday thursday stock bond market reopen friday only short session market london paris frankfurt hong kong shanghai be open week tokyo market restart tomorrow trade remainder week follow labor thanksgiving break today economic news researcher markit be tap release november manufacturing purchasing manager index et national association realtor report october exist home sale crude oil continue recent split trade benchmark west texas intermediate more just barrel europe brent crude rise fraction gold slip silver fall more copper drop almost stock pfizer pfe allergan agn agree combination deal have be highly anticipate send allergan share only fraction higher pfizer nearly peabody energy btu rumble st loui base miner announce sell coal asset colorado new mexico bowie resource partner cash deal chipotle grill cmg slump still pressure dive friday trigger center disease control prevention announcement additional case coli contamination have be link restaurant chain argentina base issue be motion center right candidate mauricio macri win country run presidential election narrow margin ibd stock grupo financiero galicia ggal jump more stock end friday new high extend buy point oil gas producer ypf sociedad anonima ypf jump global msci argentina argt exchange trade fund leap more pace quarterly report slow significantly week ireland base drugmaker mallinckrodt mnk punch revenue earning clear analyst consensus estimate fiscal fourth quarter capital bank financial cbf ibd current weekly review stock jump premarket action thinly trade stock finished friday still buy range flat base buy point follow alan elliott twitter ibd_aelliott
652,AGN,let take look stock ibd stock move screen be see big volume action chipotle grill cmg dycom industry dy fitbit fit pfizer pfe allergan agn chipotle be rebound today loss more friday fast casual chain have be suffering coli outbreak
653,AGN,ahead thanksgiving day stock inched higher wednesday quiet volume dow jone industrial average nasdaq rise tick fraction volume nyse nasdaq be tracking well tuesday level stock market today pfizer pfe be best performer dow rise recently announce plan buy allergan agn economic news personal income rise october line estimate spending come bit short rise commerce department also say durable good order jump october double expectation exclude transportation order rise tad better expect earning news pc printer manufacturer hp hpq tumble report sluggish earning issue weak guidance hewlett packard enterprise hpe spun hp earlier month rise nearly report solid result late tuesday ibd euronet worldwide eeft be get support week move average recent share rise edward lifescience ew garner more strength buy point share rise nearly new york mercantile exchange wti crude oil future fall cent barrel stock market be close thursday thanksgiving be open half session friday close et follow ken shreve twitter ibd_kshreve facebook
654,AGN,justice department decision tuesday not rule halliburton baker hughe deal reflect obama administration increasingly wary approve mammoth takeover halliburton hal offer clear way baker hughe bhi takeover reportedly haven impressed antitrust official oil service giant say tuesday don expect deal close year
655,AGN,expect treasury department late thursday issue tougher rule govern tax inversion company buy overseas firm then move headquarters country get more favorable tax treatment wasn clear immediately new rule impact possible pfizer pfe acquisition ireland base allergan agn deal value
656,AGN,pfizer pfe be massive deal buy allergan agn redomicile ireland multiple report say even treasury department plan impose new restriction tax inversion pfizer be discuss deal pay share botox maker allergan bloomberg reuter report late wednesday allergan rise wednesday retreat hour follow news inversion rule allergan trade low oct pfizer allergan deal buzz picked pfizer rise wednesday be little change late wednesday share be takeover largest health care deal ever biggest takeover kind year bloomberg say company want announce deal soon monday reuter say announcement be not necessarily imminent say treasury wednesday announcement issue target tax inversion guidance later week affect timing agreement acquire irish drugmaker pfizer be able limit exposure punitive corporate tax system america corporate rate be highest industrial world country taxe company overseas profit be repatriate treasury issue restriction tax inversion september stop abbvie abbv acquisition deal involve burger king now restaurant brand qsr medtronic mdt mylan myl go ahead unclear new limit treasury impose obama administration ban inversion addition inversion benefit pfizer beef brand name drug boost pipeline treatment mid late stage trial pfizer use allergan deal lead pfizer breakup company follow ed carson twitter ibd_ecarson facebook
657,AGN,big pharma pfizer pfe be reportedly deal acquire ireland base allergan agn thursday even treasury department say put new guidance cut economic benefit such deal pfizer allergan confirm rumor be such talk late last month detail such price be left wall street speculation late wednesday however bloomberg reuter report price have be set range share total bloomberg say deal be announce soon monday cnbc say thursday announcement be expect follow monday come just hour treasury secretary jacob lew send letter senate finance committee criticize tax inversion deal company acquire smaller company lower tax domicile sort reverse acquisition allow company relocate cut tax bill pfizer already try do last year acquire british drug giant astrazeneca azn be rebuff so pursuit dublin base allergan be generally see alternative inversion deal lew say letter later week treasury issue target guidance reduce further economic benefit corporate inversion treasury have previously issue guideline effect back september evercore isi policy analyst terry haine point never result actual change rule guidance say treasury never do propose new regulation combat hopscotch loan prevent restructure foreign subsidiary prevent inverted company transfer cash property controlled foreign corporation avoid tax strengthen interpretation ownership rule haine write email client treasury also say intend take comment earning strip also be not do just treasury do letter lew boast guideline do slow previously torrid rate tax inversion deal indeed torpedo abbvie abbv plan takeover shire shpg abbvie decide pay hefty termination fee rather take risk rule materializing haine evercore colleague specialty drug analyst umer raffat write separate email lew follow actual guideline time address issue earning strip inverted company foreign hq issue intercompany loan subsidiary charge tax deductible interest prior conversation legal expert treasury not have mandate change cap interest expense deduction raffat write be very interesting see treasury come change threshold guidance let concern party litigate hope timeline litigation be long enough prevent inversion transaction raffat add treasury also propose modify definition debt exclude such intercompany loan guideline come allergan ceo brent saunder say seem most plausible avenue attack worst case scenario hit company tax rate tune basis point allergan then call actavis be product tax inversion have large presence credit suisse analyst vamil divan write hard tell much tax pfizer save current inversion rule deal price now table still yield accretion pfizer modeled conservative tax benefit go forward anticipate tax rate subsequently drop divan write research note initial cost synergy assumption be also relatively conservative assumption cost synergy realize be possible pfizer be able extract greater cost synergy deal incremental synergy represent additional cent yearly ep midmorning trading stock market today allergan stock be pfizer be more follow amy reeve twitter ibd_areeve facebook
658,AGN,stock surge session high little hour left regular trading session nasdaq lead gain rise dow jone industrial average be volume be mixed run higher nasdaq lower nyse vs same time tuesday big gainer stock market today include apparel maker automaker generic drug maker energy stock be weak crude oil price slide winner swamp loser nyse nasdaq tesla motor tsla gain slow trade stock be still day day move average line be work new base high electric carmaker be talk germany build battery factory country accord report tuesday wednesday fortune magazine say fortune crystal ball apple aapl build electronic car well target buy tesla meantime apple rise lead dow retook day line goldman sachs add iphone maker conviction buy list still well day line april intraday high generic drug stock allergan agn advanced heavy volume stock work handle cup base buy point ibd light product maker acuity brand ayi jump new high share be extend past buy point early entry inogen ingn sank slice day line heavy trade slightly undercut bottom consolidation start mid september follow nancy gondo twitter ibd_ngondo
659,AGN,large cap mutual fund trail small midcap fund year performance large cap fund be hold better so far year investment average large cap mutual fund have grow nov year same investment have grow average midcap fund average small cap fund so far year large cap mutual fund be vs decline midcap fund small cap fund be flat alger spectra have generate average annual return past year vs so far year spectra have handed investor gain nearly alger spectra have be manage patrick kelly ankur crawford joined co fund manager year large cap growth fund recent top holding be familiar growth stock investor apple aapl facebook fb alphabet googl allergan agn amazon com amzn be form basis be extend recent breakout allergan stock be work first stage base have undercut previous base time high form cup handle base buy point much base be form day move average bearish sign handle be line company be discuss merge pfizer pfe allergan make generic drug include botox treatment hypertension sleep disorder pain earning have grow annual pace past year analyst poll thomson reuter see profit rise current year slow next year apple be also consolidate recent gain trading time high also trading day move average testing support week line maker iphone ipad apple watch have grow earning annual clip past year net growth be see slow current fiscal year end september facebook stock clear buy point stock market september run pull back past week remain extend buy point social network company be see grow earning year next year alphabet have slip recent high remain buy point amazon be past latest buy point clear september online retail giant be expect post earning share year represent gain loss cent last year net be see climb next year follow doug roger twitter ibd_droger
660,AGN,war word heated generic drug maker mylan myl perrigo prgo week company strive shareholder vote set friday mylan hostile takeover attempt mylan first propose buy perrigo back april cash mylan share perrigo share later lift
661,AGN,normally quiet week trading ahead thanksgiving holiday be just monday major average be mixed mostly unchanged early afternoon trading nasdaq picked add dow jone industrial average gain less volume nyse nasdaq be tracking friday level stock market today new york mercantile exchange wti crude oil future rally more barrel saudi arabia say willing do part stabilize oil price merger news pfizer pfe allergan agn agree stock merger deal have be highly anticipate share pfizer allergan fall meanwhile prestige brand pbh clear buy point company announce plan acquire dentek oral care cash early gainer nasdaq include monster beverage mnst plenty breakout have emerge follow day oct monster be next work cup handle base buy point clear first stage base earlier month stamp com stmp continue trade tightly high share rise nearly ibd meat product industry group be day best percentage gainer help strength tyson food tsn meat processor soar new high investor like see tyson quarterly earning report earning share miss expectation company forecast fiscal earning compare consensus estimate tyson say chicken business be benefit rise demand decline feed cost couple top rate growth name be set report close today earning ibd name dycom dy be see rise year share profit palo alto network panw be forecast rise cent share palo alto be trading week move average second stage consolidation follow ken shreve twitter ibd_kshreve facebook
662,AGN,stock be mixed mostly unchanged head noon hour thursday highly anticipate ipos come market nasdaq dow jone industrial average add add
663,AGN,volume nyse nasdaq be tracking slightly higher wednesday level stock market today
664,AGN,manage care hospital stock underperform so do oil gas name december wti crude oil future fall barrel
665,AGN,insurer unitedhealth unh be drag dow fall company lower earning guidance cite lower expect activity health exchange set obamacare
666,AGN,also dow pfizer pfe lose close reuter report wednesday company talk allergan agn merger be accelerate share allergan give
667,AGN,economic news philadelphia federal reserve manufacturing index mid atlantic district rise november october september economist have expect read just break even
668,AGN,ipo news square sq match mtch have solid debut concern valuation square price last night propose range share be recently trading match meanwhile price low end propose range share be recently trading
669,AGN,elsewhere small cap universal display oled continue work right side deep cup shape base share jump cfo sidney rosenblatt hold session goldman sachs emerge cap growth conference et universal display be know organic light emit diode technology display light industry straight quarters decline earning sale growth nov result impressed quarterly profit year sale rise
670,AGN,other earning winner include keurig green mountain gmcr salesforce com crm china base online travel firm ctrip com ctrp
671,AGN,follow ken shreve twitter ibd_kshreve facebook stock be mixed mostly unchanged head noon hour thursday highly anticipate ipos come market nasdaq dow jone industrial average add add volume nyse nasdaq be tracking slightly higher wednesday level stock market today manage care hospital stock underperform so do oil gas name december wti crude oil future fall barrel insurer unitedhealth unh be drag dow fall company lower earning guidance cite lower expect activity health exchange set obamacare also dow pfizer pfe lose close reuter report wednesday company talk allergan agn merger be accelerate share allergan give economic news philadelphia federal reserve manufacturing index mid atlantic district rise november october september economist have expect read just break even ipo news square sq match mtch have solid debut concern valuation square price last night propose range share be recently trading match meanwhile price low end propose range share be recently trading elsewhere small cap universal display oled continue work right side deep cup shape base share jump cfo sidney rosenblatt hold session goldman sachs emerge cap growth conference et universal display be know organic light emit diode technology display light industry straight quarters decline earning sale growth nov result impressed quarterly profit year sale rise other earning winner include keurig green mountain gmcr salesforce com crm china base online travel firm ctrip com ctrp follow ken shreve twitter ibd_kshreve facebook
672,AGN,treasury department say wednesday announce target guidance intend discourage so call tax inversion deal used business relocate lower tax nation
673,AGN,later week intend issue additional target guidance reduce further economic benefit corporate inversion treasury secretary jack lew say letter senior lawmaker further detail be unavailable
674,AGN,be important emphasize however treasury stop inversion new statutory authority lew say congress act creative accountant lawyer continue find new way company move tax residence overseas avoid pay taxe here home
675,AGN,share allergan agn ireland base drugmaker have be mull inversion deal pfizer pfe pfizer be little change hour allergan fall late trade nearly wipe regular session gain allergan be still sharply late october level pfizer buzz begin
676,AGN,treasury department first begin attempt crack tax inversion september follow series inversion attempt particularly pharmaceutical business rule stop abbvie abbv acquisition deal involve burger king now restaurant brand qsr medtronic mdt mylan myl go ahead
677,AGN,tax inversion company seek move be technically be acquire practice relocate company run combine business
678,AGN,many say deal deplete tax revenue allow company much operation dodge taxe many business community say inversion wouldn be need corporate tax rate be lower have world highest tax rate industrial world taxe overseas profit be repatriate here
679,AGN,follow bill peter twitter ibd_bpeter treasury department say wednesday announce target guidance intend discourage so call tax inversion deal used business relocate lower tax nation later week intend issue additional target guidance reduce further economic benefit corporate inversion treasury secretary jack lew say letter senior lawmaker further detail be unavailable be important emphasize however treasury stop inversion new statutory authority lew say congress act creative accountant lawyer continue find new way company move tax residence overseas avoid pay taxe here home share allergan agn ireland base drugmaker have be mull inversion deal pfizer pfe pfizer be little change hour allergan fall late trade nearly wipe regular session gain allergan be still sharply late october level pfizer buzz begin treasury department first begin attempt crack tax inversion september follow series inversion attempt particularly pharmaceutical business rule stop abbvie abbv acquisition deal involve burger king now restaurant brand qsr medtronic mdt mylan myl go ahead tax inversion company seek move be technically be acquire practice relocate company run combine business many say deal deplete tax revenue allow company much operation dodge taxe many business community say inversion wouldn be need corporate tax rate be lower have world highest tax rate industrial world taxe overseas profit be repatriate here follow bill peter twitter ibd_bpeter
680,AGN,action camera maker gopro gpro get price target cut monday embattled restaurant chain chipotle grill cmg suffer series downgrade price target cut own
681,AGN,analyst also make call biotech startup bluebird bio blue teva pharmaceutical teva new issue ferrari race
682,AGN,jpmorgan trim gopro target friday robert baird downgrade gopro neutral outperform slash price target share be hit last week chip supplier ambarella amba give weak guidance due part soft sale action camera
683,AGN,gopro share lose stock market today ambarella give
684,AGN,cowen co guggenheim security downgrade chipotle former market perform latter neutral maxim group lower price target stock
685,AGN,report say friday coli outbreak chipotle have expand state outbreak have sicken dozen customer force closure restaurant
686,AGN,chipotle share sank year low early monday recover later session stock close
687,AGN,bluebird bio stock price tumble be downgrade neutral buy roth capital have price target chopped nearly half weekend bluebird present disappointing gene therapy datum american society hematology annual meeting
688,AGN,teva stock price rise be initiate buy rating mizuho security last week reuter report generic drugmaker be divest worth asset address antitrust concern deal buy allergan agn generic drug business
689,AGN,share home depot hd fall even price target be raise telsey advisory group have outperform rating stock
690,AGN,sport luxury car manufacturer ferrari have initial public offer october be initiate overweight give price target morgan stanley ferrari share rise monday be still more close price first day trading
691,AGN,abbott laboratory climb be upgrade buy jeffery give price target
692,AGN,share big pharma firm eli lilly lly lose score upgrade buy deutsche bank follow upgrade overweight barclay last week
693,AGN,follow vance cariaga twitter ibd_vcariaga action camera maker gopro gpro get price target cut monday embattled restaurant chain chipotle grill cmg suffer series downgrade price target cut own analyst also make call biotech startup bluebird bio blue teva pharmaceutical teva new issue ferrari race jpmorgan trim gopro target friday robert baird downgrade gopro neutral outperform slash price target share be hit last week chip supplier ambarella amba give weak guidance due part soft sale action camera gopro share lose stock market today ambarella give cowen co guggenheim security downgrade chipotle former market perform latter neutral maxim group lower price target stock report say friday coli outbreak chipotle have expand state outbreak have sicken dozen customer force closure restaurant chipotle share sank year low early monday recover later session stock close bluebird bio stock price tumble be downgrade neutral buy roth capital have price target chopped nearly half weekend bluebird present disappointing gene therapy datum american society hematology annual meeting teva stock price rise be initiate buy rating mizuho security last week reuter report generic drugmaker be divest worth asset address antitrust concern deal buy allergan agn generic drug business share home depot hd fall even price target be raise telsey advisory group have outperform rating stock sport luxury car manufacturer ferrari have initial public offer october be initiate overweight give price target morgan stanley ferrari share rise monday be still more close price first day trading abbott laboratory climb be upgrade buy jeffery give price target share big pharma firm eli lilly lly lose score upgrade buy deutsche bank follow upgrade overweight barclay last week follow vance cariaga twitter ibd_vcariaga
694,AGN,stock be modestly higher midday monday shorten week trading kick much fanfare nasdaq lead way rise early gainer nasdaq include autodesk adsk jd com jd biogen biib monster beverage mnst
695,AGN,add dow jone industrial average gain less volume nyse nasdaq be tracking well friday level stock market today
696,AGN,merger news pfizer pfe allergan agn agree combination deal have be highly anticipate share pfizer allergan fall more
697,AGN,china base online direct sale company jd com add gain heel last week earning report share rise clear key resistance level
698,AGN,meanwhile buyer be netease nte again buy point share rise almost netease operate interactive online community china also report strong earning last week
699,AGN,ibd meat product industry group be day best percentage gainer help strength tyson food tsn pilgrim pride ppc meat processor tyson food soar new high investor weigh quarterly report earning share miss expectation company forecast fiscal earning compare consensus estimate tyson say chicken business be benefit rise demand decline feed cost group peer pilgrim pride jump
700,AGN,chipotle cmg reversed higher crash friday more coli problem share rally
701,AGN,couple top rate growth name be set report close today earning ibd name dycom dy be see rise year share profit palo alto network panw be forecast rise cent share
702,AGN,follow ken shreve twitter ibd_kshreve facebookstock be modestly higher midday monday shorten week trading kick much fanfare nasdaq lead way rise early gainer nasdaq include autodesk adsk jd com jd biogen biib monster beverage mnst add dow jone industrial average gain less volume nyse nasdaq be tracking well friday level stock market today merger news pfizer pfe allergan agn agree combination deal have be highly anticipate share pfizer allergan fall more china base online direct sale company jd com add gain heel last week earning report share rise clear key resistance level meanwhile buyer be netease nte again buy point share rise almost netease operate interactive online community china also report strong earning last week ibd meat product industry group be day best percentage gainer help strength tyson food tsn pilgrim pride ppc meat processor tyson food soar new high investor weigh quarterly report earning share miss expectation company forecast fiscal earning compare consensus estimate tyson say chicken business be benefit rise demand decline feed cost group peer pilgrim pride jump chipotle cmg reversed higher crash friday more coli problem share rally couple top rate growth name be set report close today earning ibd name dycom dy be see rise year share profit palo alto network panw be forecast rise cent share follow ken shreve twitter ibd_kshreve facebook
703,AGN,specialty drug giant allergan agn beat analyst estimate wednesday ceo brent saunder dodge question buyout talk pfizer pfe defend company drug pricing strategy distancing model peer valeant pharmaceutical international vrx allergan sale rise year earlier quarter analyst consensus accord thomson reuter earning
704,AGN,do high quality stock big dividend yield top way be company increase cash payout here be stock yield better double digit dividend growth rate fast stock dividend rise year calculate ibd cisco system csco pay
705,AGN,big pharma pfizer specialty drug giant allergan affirm thursday re preliminary buyout talk much speculate move pfizer hunt new catalyst allergan agn stock soar pfizer pfe retreat allergan plc today confirm have be approach pfizer inc be preliminary friendly discussion regard potential business combination transaction say
706,AGN,stock market today continue trim early loss afternoon trade aid bounce oil price re-cover gain dip nasdaq whittle decline dow swung earlier loss rise exxon mobil xom pfizer pfe chevron cvx do much heavy lift oil related group post best gain industry oil price rebound rise tension middle east stock dollar tree dltr sprang ahead report mixed result first full quarter acquire peer family dollar stock be work seventh straight daily gain testing resistance day move average analog device adi keurig green mountain gmcr also rise more ibd list be nearly evenly split advancer decliner technology avgo allergan agn skywork solution swks top list signet jeweler sig cal maine food calm drop apiece
707,AGN,ibd stock be advance thank sale growth latest quarter company list report revenue gain minimum gain historically have characterize successful stock average sale growth rate be less be skewer company more double sale allergan agn heritage insurance hrtg allergan have make big acquisition say revenue pro basis rise dozen ibd company have single digit sale growth breakdown be do base last monday list poor sale have hit consumer medical technology transportation other sector ibd fact sale weakness be pretty much endemic second quarter revenue fall share year year basis accord capital iq slumping oil sector have much do drop wasn only reason yes energy have be key reason sale earning weakness lindsey bell senior analyst capital iq tell ibd exclude energy sector sale growth have be say bell note growth ex energy be still year average strength dollar be weigh heavily top line growth see decline consumer staple sector post quarter indeed company currency exposure such hawaiian holding revenue cambrex cbm global payment gpn exclude foreign exchange cite currency factor earning filing revenue slump be expect continue factset estimate sale decline third quarter energy sector be expect report largest year year decrease sale sector telecom service health care sector be expect report largest growth sale sector quarter report senior earning analyst john butter note earning company be expect drop factset say single digit sale don necessarily limit stock performance nike nke roar base friday beat expectation quarter see sale rise only
708,AGN,stock trade bit lower yesterday wednesday fed induced rally trader consider language odd december rate hike selling be subdue be get here tone action
709,AGN,mkt pause really investor now thought latest gdp report come great be positive compare qtr look bit pale yesterday report be more drop qtr qtr time fed suggest economy be poise explode rate rise december
710,AGN,addition yesterday report be disappointment consider year year growth last year rd qtr growth rate be so say be economy continue be hold hostage dynamic weakness home abroad journal point economy slog soft patch consumer spending business spending home build contribute positive report face headwind abroad
711,AGN,do not be blindside consumer spending be mislead include consumer spend healthcare be not something many person consider read story health consumer spending consumer healthcare represent gdp bil gov include head consumer spending make appear consumer spending be stronger reality prove otherwise remember spending healthcare be not really option family budget so get file pay budget line mean discretionary spending get cut back semantic really far obama be concern consumer spending matter be still consumer spending so good
712,AGN,now other news break corporate tax structure have create opportunity huge merger pfizer pfe allergan agn consider hook avoid taxe see allergan be base ireland ireland be bit friendlier big corporation so pfizer get bed allergan ireland cut corporate tax liability be know inversion trade company buy smaller foreign rival then move corporate headquarters abroad boom just cut tax obligation million dollar make point pfe ceo ian read make bone say corporate tax rate have put company disadvantage foreign rival be fight hand tie back pfizer be do need do ensure continue innovate
713,AGN,washington wake many more inversion trade see bozo congress recognize be nothing bunch clown evidence new yr budget deal lift debt ceiling even higher roll back fiscal austerity remove risk debt limit default risk yr so mkt embrace
714,AGN,other pharma story continue keep glue seat valeant pharma vrx continue make headline cvs health corp cvs express script esrx unite health be cut ty philidor rx pharmacy have help propel vrx international fame stock close pt be now pt early pre mkt trading remember old quote smoke fire question now be be fire just log whole house
715,AGN,future be pt global mkts be bit pressure boj bank japan do not increase qe program catch surprise do not cause negative mkt reaction europe eu eco datum be mixed cpi do rise german retail sale miss expectation inflation figure be better still low have impact ecb plan more stimulus
716,AGN,be last day month so sure have window dressing undress take place asset manager close book october earning continue weigh stock overall season be not bad originally expect so nervousness permeate mkts early october seem have subside expect see mkt challenge today then back churn line eco datum today derail doubt pers income pers spend ism milwaukee chicago purch manager
717,AGN,earning front look oil chevron cvx exxon mobil xom phillip psx cvs health corp cvs colgate palmolive cl weyerhaeuser co wy
718,AGN,have good weekend take good care kp
719,AGN,kenny polcari be vice president director nyse floor operation behalf neil security inc sister company investor business daily market commentary be opinion author be base decade industry market experience however guarantee be make imply respect opinion commentary be not be intend be rely authoritative take substitution exercise judgment comment note herein not be construe offer sell solicitation offer buy sell financial product official statement endorsement neil security incorporate affiliate stock trade bit lower yesterday wednesday fed induced rally trader consider language odd december rate hike selling be subdue be get here tone action mkt pause really investor now thought latest gdp report come great be positive compare qtr look bit pale yesterday report be more drop qtr qtr time fed suggest economy be poise explode rate rise december addition yesterday report be disappointment consider year year growth last year rd qtr growth rate be so say be economy continue be hold hostage dynamic weakness home abroad journal point economy slog soft patch consumer spending business spending home build contribute positive report face headwind abroad do not be blindside consumer spending be mislead include consumer spend healthcare be not something many person consider read story health consumer spending consumer healthcare represent gdp bil gov include head consumer spending make appear consumer spending be stronger reality prove otherwise remember spending healthcare be not really option family budget so get file pay budget line mean discretionary spending get cut back semantic really far obama be concern consumer spending matter be still consumer spending so good now other news break corporate tax structure have create opportunity huge merger pfizer pfe allergan agn consider hook avoid taxe see allergan be base ireland ireland be bit friendlier big corporation so pfizer get bed allergan ireland cut corporate tax liability be know inversion trade company buy smaller foreign rival then move corporate headquarters abroad boom just cut tax obligation million dollar make point pfe ceo ian read make bone say corporate tax rate have put company disadvantage foreign rival be fight hand tie back pfizer be do need do ensure continue innovate washington wake many more inversion trade see bozo congress recognize be nothing bunch clown evidence new yr budget deal lift debt ceiling even higher roll back fiscal austerity remove risk debt limit default risk yr so mkt embrace other pharma story continue keep glue seat valeant pharma vrx continue make headline cvs health corp cvs express script esrx unite health be cut ty philidor rx pharmacy have help propel vrx international fame stock close pt be now pt early pre mkt trading remember old quote smoke fire question now be be fire just log whole house future be pt global mkts be bit pressure boj bank japan do not increase qe program catch surprise do not cause negative mkt reaction europe eu eco datum be mixed cpi do rise german retail sale miss expectation inflation figure be better still low have impact ecb plan more stimulus be last day month so sure have window dressing undress take place asset manager close book october earning continue weigh stock overall season be not bad originally expect so nervousness permeate mkts early october seem have subside expect see mkt challenge today then back churn line eco datum today derail doubt pers income pers spend ism milwaukee chicago purch manager earning front look oil chevron cvx exxon mobil xom phillip psx cvs health corp cvs colgate palmolive cl weyerhaeuser co wy have good weekend take good care kpkenny polcari be vice president director nyse floor operation behalf neil security inc sister company investor business daily market commentary be opinion author be base decade industry market experience however guarantee be make imply respect opinion commentary be not be intend be rely authoritative take substitution exercise judgment comment note herein not be construe offer sell solicitation offer buy sell financial product official statement endorsement neil security incorporate affiliate
720,AGN,major average lose ground thursday tech stock lag loss weren ominous less hour remain session nasdaq lose dow jone industrial average fall ease volume nyse nasdaq be tracking slightly lower wednesday level stock market today economic news first look gdp show growth tad consensus estimate sharp slowdown growth meanwhile weekly jobless claim fall more expect pending home sale september miss badly top rate homebuilder slump weak housing datum horton dhi lennar len lgi home lgih show loss range health care space allergan agn jump drugmaker confirm early talk pfizer pfe merger share pfizer fall ellie mae elli be big winner ibd share jump company report strong earning late wednesday share be so far week ellie mae be back week move average approach time high downside nxp semiconductor nxpi crash chip designer report sharp deceleration earning growth flat sale buffalo wild wing bwld be casualty crater late wednesday report ep share cent consensus estimate revenue also miss starbucks sbux lose ahead earning report close former leader baidu bidu linkedin lnkd be also set report follow ken shreve twitter ibd_kshreve facebook
721,AGN,stock battle narrow loss early action thursday investor respond busy morning earning economic news dow jone industrial average dip nasdaq slip
722,AGN,volume increase nasdaq nyse relative wednesday morning trade
723,AGN,weaker expect gdp estimate knock stock market today positive premarket stance expect unemployment claim do little counter effect
724,AGN,pending home sale also pressed button slip september accord national association realtor be sharp step august decline more double decline expect consensus
725,AGN,third dow moved lower intel intc pfizer pfe staking low ground loss nearly
726,AGN,pfizer reversed premarket gain follow news report be early stage discussion regard possible merger allergan agn allergan confirm report early thursday share flattened premarket gain fractional advance open
727,AGN,hanesbrand hbi stretched gain strong report late wednesday network ffiv drop report also deliver wednesday close
728,AGN,chipmaker face broad selling pressure early action feel drawdown nxp semiconductor nxpi dive nxp report weaker consensus revenue cite slow customer order rise industry inventory
729,AGN,philadelphia semiconductor index be less week rally prior week
730,AGN,cirrus logic crus cavium cavm fabless chipmaker ibd list drop report earning late wednesday cirrus score clear revenue earning cavium result just meet expectation
731,AGN,technology avgo shed singapore base chipmaker be have mixed success fight gain ground vs day move average be seventh week cup handle base form longer consolidation
732,AGN,high side ibd ellie mae elli climb top third quarter consensus revenue earning expectation number user mortgage lease provider online encompass service rise year year increase user revenue management earning guidance be consensus forecast stock be back day move average work fourth straight advance build right side month base
733,AGN,reilly automotive orly pop report strong result late wednesday auto part chain also beat revenue earning line guide ep consensus estimate big volume gap gain send share new high leave extend buy point stock battle narrow loss early action thursday investor respond busy morning earning economic news dow jone industrial average dip nasdaq slip volume increase nasdaq nyse relative wednesday morning trade weaker expect gdp estimate knock stock market today positive premarket stance expect unemployment claim do little counter effect pending home sale also pressed button slip september accord national association realtor be sharp step august decline more double decline expect consensus third dow moved lower intel intc pfizer pfe staking low ground loss nearly pfizer reversed premarket gain follow news report be early stage discussion regard possible merger allergan agn allergan confirm report early thursday share flattened premarket gain fractional advance open hanesbrand hbi stretched gain strong report late wednesday network ffiv drop report also deliver wednesday close chipmaker face broad selling pressure early action feel drawdown nxp semiconductor nxpi dive nxp report weaker consensus revenue cite slow customer order rise industry inventory philadelphia semiconductor index be less week rally prior week cirrus logic crus cavium cavm fabless chipmaker ibd list drop report earning late wednesday cirrus score clear revenue earning cavium result just meet expectation technology avgo shed singapore base chipmaker be have mixed success fight gain ground vs day move average be seventh week cup handle base form longer consolidation high side ibd ellie mae elli climb top third quarter consensus revenue earning expectation number user mortgage lease provider online encompass service rise year year increase user revenue management earning guidance be consensus forecast stock be back day move average work fourth straight advance build right side month base reilly automotive orly pop report strong result late wednesday auto part chain also beat revenue earning line guide ep consensus estimate big volume gap gain send share new high leave extend buy point
734,AGN,stock future shed thursday premarket gain reversed moderate loss mixed report unemployment claim gdp growth
735,AGN,dow future drop point fair market value point advance hour earlier nasdaq future shed point gain drop point future also reversed trading point
736,AGN,stock market today receive boost federal reserve wednesday left nasdaq so far week show gain index be work be fifth straight weekly advance
737,AGN,more important growth investor small cap be have strong week russell surge wednesday strongest session dec lift small cap gauge clear day move average put ahead week even so index remain well next test resistance day line
738,AGN,ibd index pop wednesday be easily outpace market gain week
739,AGN,big day economic news be mixed start preliminary estimate commerce department putt gdp growth less half jump just forecast increase price inflation also softened gdp price index rise shade view advance
740,AGN,unemployment claim inched fractionally higher week end oct labor department report be better uptick claim forecast economist prior week tally be claim week move average dip sixth straight decline
741,AGN,atlanta federal reserve bank president dennis lockhart be schedule speak washington et national association realtor report september pending home sale datum
742,AGN,big oil company get earning ball roll royal dutch shell rdsa total tot conocophillip cop report result oil price backed west texas intermediate barrel surge more wednesday
743,AGN,drug maker pfizer pfe climb allergan agn soar news report company be explore possible merger wall street journal quote unnamed source say talk be early stage detail be unclear pfizer end wednesday week less buy point cup handle base
744,AGN,premarket session move identity security firm lifelock lock soar healthy result report late wednesday news have settle federal trade commission lawsuit digital video camera maker gopro gpro dive weaker forecast sale earning also report wednesday close
745,AGN,lead stock reilly automotive orly jump tesoro tso rise ellie mae elli be flat report reilly end wednesday session buy range less buy point tesoro be buy point cup handle base
746,AGN,nxp semiconductor nxpi dive netherlands base chip maker report earning stronger expect revenue rise less weaker estimate management expand stock buyback initiative share nxp finished wednesday just week move average have be work climb right side month consolidation
747,AGN,cavium cavm take hit report line earning revenue late wednesday chip maker have be chop uneven consolidation fight hold support june
748,AGN,follow alan elliott twitter ibd_aelliott facebook stock future shed thursday premarket gain reversed moderate loss mixed report unemployment claim gdp growth dow future drop point fair market value point advance hour earlier nasdaq future shed point gain drop point future also reversed trading point stock market today receive boost federal reserve wednesday left nasdaq so far week show gain index be work be fifth straight weekly advance more important growth investor small cap be have strong week russell surge wednesday strongest session dec lift small cap gauge clear day move average put ahead week even so index remain well next test resistance day line ibd index pop wednesday be easily outpace market gain week big day economic news be mixed start preliminary estimate commerce department putt gdp growth less half jump just forecast increase price inflation also softened gdp price index rise shade view advance unemployment claim inched fractionally higher week end oct labor department report be better uptick claim forecast economist prior week tally be claim week move average dip sixth straight decline atlanta federal reserve bank president dennis lockhart be schedule speak washington et national association realtor report september pending home sale datum big oil company get earning ball roll royal dutch shell rdsa total tot conocophillip cop report result oil price backed west texas intermediate barrel surge more wednesday drug maker pfizer pfe climb allergan agn soar news report company be explore possible merger wall street journal quote unnamed source say talk be early stage detail be unclear pfizer end wednesday week less buy point cup handle base premarket session move identity security firm lifelock lock soar healthy result report late wednesday news have settle federal trade commission lawsuit digital video camera maker gopro gpro dive weaker forecast sale earning also report wednesday close lead stock reilly automotive orly jump tesoro tso rise ellie mae elli be flat report reilly end wednesday session buy range less buy point tesoro be buy point cup handle base nxp semiconductor nxpi dive netherlands base chip maker report earning stronger expect revenue rise less weaker estimate management expand stock buyback initiative share nxp finished wednesday just week move average have be work climb right side month consolidation cavium cavm take hit report line earning revenue late wednesday chip maker have be chop uneven consolidation fight hold support june follow alan elliott twitter ibd_aelliott facebook
749,AGN,pfizer pfe allergan agn be consider massive drug merger worth more wall street journal report late wednesday cite source make biggest deal year least pfizer recently reach irish drug giant wsj report combine pfizer market cap allergan forge
750,AGN,doctor be not just ask unite health care unh ceo stephen helmsley obama care have make sick be not willing continue suffer loss go right yesterday company announce mil loss exchange business include advance recognition loss announcement cause cut earning projection sh share
751,AGN,announcement do not include expect additional mil loss result investor take stock point yesterday hear news biggest health insurer have suffer major loss policy sell affordable care act aca exchange consider withdraw
752,AGN,hark hear hear other herald angel sing aetna aet humana hum cigna ci anthem antm chime singing same tune insurer focus medicaid population molina moh don seem be have same problem low income consumer be subsidize gov result be now see effect poorly design piece signature legislation anyone see nancy pelosi recently do ever read legislation insurer be raise premium cut product offering choice health care provider consumer be see least desirable silver plan increase rate avg better plan be see increase more higher deductible higher co pay just econ taught higher cost discourage buyer case healthy buyer then only drife cost even higher remain consumer be sicker need more healthcare vicious circle know death spiral
753,AGN,now republican be quick jump bandwagon say premium be healthcare be more expensive consequence see hastily conceive legislation be entirely foreseeable not surprising expect democrat lead obama be quick point law be work well well boy have way so be be aca work not sound ceo helmsley clearly have view maybe democrat need talk insurer see doctor be not
754,AGN,move healthcare industry yesterday bring news pfizer pfe be press ahead fight save corporate taxe get bed ireland base allergan agn putt gov company collision course be know inversion trade here democrat want prevent company strategically relocate take advantage break corp tax structure pile more regulation red tape republican say real problem here be break corp tax structure call complete overhaul tax code thereby eliminate need incentive invert
755,AGN,now back mkts broader mkt show lack direction yesterday wednesday surge cause tease side unchanged least time lack real significant change come trader investor take breath technical underpinning mkt continue argue only few company continue dominate major index so many continue drag biggest company largest capitalization have push dow nasdaq closer annual high broader index wilshire russell be still struggle
756,AGN,wilshire total mkt index measure performance stock readily available price datum most person do not follow even know wilshire be medium only talk dow nasdaq be heavily weight large cap company average investor know fact wilshire be much truer measure real health economy whole just sayin short term basis market be try work last week sharp selloff so far appear be do just need continue watch crude oil price do crude be now trading barrel need hold here rally oil certainly help support mkt be still difficult call give fundamental strengthen dollar be short term oversold condition so bounce not be question cause bargain hunter go shopping spree
757,AGN,overnight asian mkts finished week strong japan hong kong china asx europe mkts be churn even draghi hint more stimulus mali hostage crisis morning be raise concern global security cause focus once again turn isis recent event france end mkts need digest action late move weekend ftse cac dax eurostoxx spain italy future be point higher currently pt keep still trading range get load fed speaker today st loui fed pre bullard ny dudley speaking economy believe hammer home message normalization come theater december eco front look report form kansa city fed survey say take good care kp
758,AGN,kenny polcari be vice president director nyse floor operation behalf neil security inc sister company investor business daily market commentary be opinion author be base decade industry market experience however guarantee be make imply respect opinion commentary be not be intend be rely authoritative take substitution exercise judgment comment note herein not be construe offer sell solicitation offer buy sell financial product official statement endorsement neil security incorporate affiliate doctor be not just ask unite health care unh ceo stephen helmsley obama care have make sick be not willing continue suffer loss go right yesterday company announce mil loss exchange business include advance recognition loss announcement cause cut earning projection sh share announcement do not include expect additional mil loss result investor take stock point yesterday hear news biggest health insurer have suffer major loss policy sell affordable care act aca exchange consider withdraw hark hear hear other herald angel sing aetna aet humana hum cigna ci anthem antm chime singing same tune insurer focus medicaid population molina moh don seem be have same problem low income consumer be subsidize gov result be now see effect poorly design piece signature legislation anyone see nancy pelosi recently do ever read legislation insurer be raise premium cut product offering choice health care provider consumer be see least desirable silver plan increase rate avg better plan be see increase more higher deductible higher co pay just econ taught higher cost discourage buyer case healthy buyer then only drife cost even higher remain consumer be sicker need more healthcare vicious circle know death spiral now republican be quick jump bandwagon say premium be healthcare be more expensive consequence see hastily conceive legislation be entirely foreseeable not surprising expect democrat lead obama be quick point law be work well well boy have way so be be aca work not sound ceo helmsley clearly have view maybe democrat need talk insurer see doctor be not move healthcare industry yesterday bring news pfizer pfe be press ahead fight save corporate taxe get bed ireland base allergan agn putt gov company collision course be know inversion trade here democrat want prevent company strategically relocate take advantage break corp tax structure pile more regulation red tape republican say real problem here be break corp tax structure call complete overhaul tax code thereby eliminate need incentive invert now back mkts broader mkt show lack direction yesterday wednesday surge cause tease side unchanged least time lack real significant change come trader investor take breath technical underpinning mkt continue argue only few company continue dominate major index so many continue drag biggest company largest capitalization have push dow nasdaq closer annual high broader index wilshire russell be still struggle wilshire total mkt index measure performance stock readily available price datum most person do not follow even know wilshire be medium only talk dow nasdaq be heavily weight large cap company average investor know fact wilshire be much truer measure real health economy whole just sayin short term basis market be try work last week sharp selloff so far appear be do just need continue watch crude oil price do crude be now trading barrel need hold here rally oil certainly help support mkt be still difficult call give fundamental strengthen dollar be short term oversold condition so bounce not be question cause bargain hunter go shopping spree overnight asian mkts finished week strong japan hong kong china asx europe mkts be churn even draghi hint more stimulus mali hostage crisis morning be raise concern global security cause focus once again turn isis recent event france end mkts need digest action late move weekend ftse cac dax eurostoxx spain italy future be point higher currently pt keep still trading range get load fed speaker today st loui fed pre bullard ny dudley speaking economy believe hammer home message normalization come theater december eco front look report form kansa city fed survey say take good care kpkenny polcari be vice president director nyse floor operation behalf neil security inc sister company investor business daily market commentary be opinion author be base decade industry market experience however guarantee be make imply respect opinion commentary be not be intend be rely authoritative take substitution exercise judgment comment note herein not be construe offer sell solicitation offer buy sell financial product official statement endorsement neil security incorporate affiliate
759,AGN,embattled drugmaker valeant pharmaceutical vrx tumble nearly wednesday year low close short selling outfit citron research charge complex fraud involve multiple specialty pharmacy valeant respond report be base erroneous assumption citron refer report southern investigative report foundation sirf probe lawsuit small california base pharmacy valeant allege valeant have charge drug have not actually buy sirf say piece apparently hadn do business valeant have do business philidor specialty pharmacy sirf find little information sirf eventually conclude valeant be sole provider drug philidor have economic relationship philidor have not disclose lead valeant lawyer seek payment behalf conference call analyst discuss monday earning valeant ceo michael pearson say company normally didn discuss relationship specialty pharmacy competitive advantage do not disclose competitor however do say have contractual relationship philidor late last year purchase option acquire philidor so choose citron find mighty suspicious write citron option acquire company be only customer valeant major big cap pharma darling hedge fund crowd suitor allergan agn aggressive acquirer pharmas salix bausch lomb etc etc be secretly maneuvering buy little know pharmacy dubious ownership structure citron say dig paperwork have conclude philidor actually own say find several other small pharmacy domain be register same day share same privacy officer phone number citron conclude be set valeant purpose phantom sale stuff ing channel avoid ing scrutiny auditor valeant fire backin early afternoon wednesday valeant issue press release dispute several point citron report valeant say reason pharmacy use same phone number be philidor provide back end service include call center claim adjudication logistic support well compliance hipaa regulation guidance other pharmacy include pharmacy valeant also say do not record shipment philidor other specialty pharmacy revenue drug be dispense patient imply be therefore not used stuff channel say have charge be also not record revenue timing revenue recognition selling philidor pharmacy network be actually delay compare selling traditional wholesaler channel valeant say afternoon trading stock market today valeant stock fall almost low more time high touch aug valeant close wednesday tuesday close price other specialty drugmaker be also affected endo international endp ceo used be president valeant have be re create valeant business model endo last year fall allergan release statement say only sale go specialty pharmacy allergan stock close follow amy reeve twitter ibd_areeve facebook
760,AGN,here weekly investing action plan investor need know come week quickly soar dow jone industrial average take breather other stock index market look follow week central bank meeting oil price dow energy stock exxon mobil xom be catalyst top executive
761,AGN,allergan agn stock outplay ibd company ethical drug industry group wall street crush metric well guidance lead glaxosmithkline gsk sanofi sny stock follow earning report afternoon trading stock market today allergan stock jump close firm release earning share sanofi be glaxosmithkline stock be drugmaker be ibd ethical drug group be fraction midday wednesday follow affirmation press secretary sean spicer late tuesday president trump support allow federal government negotiate drug price behalf medicare botox maker allergan report sale vs year earlier quarter top view allergan also post earning share ex item crush expectation total sale rise ep ex item rise cent ibd take allergan social contract patient promising keep annual drug price increase draw ire jpmorgan healthcare conference last month do celgene ceo have say guidance sale ep item top consensus analyst poll thomson reuter midpoint allergan outlook sale ep be expect grow respectively result be mixed sanofi glaxosmithkline sanofi sale come euro base quarter end exchange rate miss consensus analyst poll thomson reuter ep ex item euro be light penny glaxosmithkline report euro beating consensus view core ep cent top consensus cent related endo resolve ftc antitrust suit allergan hang stock mixedallergan pop guidance survive alzheimer rivalry allergan outlook improve good trial colon drug credit suisse
762,AGN,activist investor carl icahn have reportedly take stake cancer biotech bristol myer squibb bmy follow investment jana partner accord source cite wall street journal hour trading rumor break bristol myer stock edge fraction share rise fraction tuesday regular session re last month investor worry merck mrk have upper hand lung cancer market merck keytruda bristol opdivo class immuno oncology drug target pd checkpoint patient immune system roche rhhby astrazeneca azn incyte incy be also work drug target array checkpoint last month food drug administration accept merck supplemental filing keytruda chemo advanced lung cancer bristol say wouldn accelerate approval opdivo yervoy combo same market yervoy be drug target ctla checkpoint ibd take market grow barclay analyst geoffrey meacham estimate be just indication know dive world game change potential ibd technology page bristol decline comment ibd regard icahn rumore stake insider reportedly say icahn see bristol myer potential takeover candidate wsj report bristol myer be ninth largest biotech market cap value icahn be know investment household name paypal pypl xerox xrx last year make big bet allergan agn slash stake november share lose time purchase end november jana partner activist investor buy stake bristol myer tuesday bristol say buy back stock part agreement jana company also add robert bertolini matthew emmen theodore samuel board director temporarily expand board election related be first immune system cancer drug fdamerck keytruda sale lag defer revenuebristol myer dife opdivo setback get keytruda royalty
763,AGN,endo international endp agree year settlement ftc monday resolve antitrust suit file pennsylvania allege part endo paid allergan agn prevent launch generic version lidoderm joint motion ftc endo be file monday california federal court include ftc original complaint allergan endo stipulate order resolve dispute ftc have endo related patent settlement last march endo settle patent litigation involve local anesthetic lidoderm pain management drug opana ftc allege certain aspect opana lidoderm settlement constitute unfair method competition violation federal law endo say press release ftc voluntarily dismiss lawsuit october commission state plan refile elsewhere happened monday joint motion also include stipulate order dismiss claim endo ibd take other struggle incyte be likely outperform broader biotech market grab deeper dive ibd new america endo didn admit wrongdoing win have make payment rather endo agree prohibition agreement prevent marketing authorize generic product involve payment generic manufacturer connection delay market entry product span year lawsuit seek restitution disgorgement accord reuter allege allergan then watson pharmaceutical accept payment endo hold launch generic version lidoderm september allergan representative decline comment ibd endo rep didn return email close bell stock market today allergan stock finished endo stock be allergan have be trading day support line month endo past month related generic drugmaker crash report doj plan collusion chargesallergan pop guidance survive alzheimer rivalry allergan outlook improve good trial colon drug credit suisse
764,AGN,allergan agn stock pop week high thursday drugmaker issue guidance line broader wall street expectation afternoon trading stock market today allergan stock lift share have rise past trading day last week move day move average zero day average allergan stock plummet raucous drug pricing debate allergan see mid single digit gaap top line net revenue growth double digit growth earning share item compare consensus analyst poll factset sale growth earning growth say mizuho analyst irina koffler ibd take drug stock survive donald trump break republican seek curb rise drug price koffler maintain buy rating price target allergan stock follow announcement see allergan pull sale growth ep item growth executive likely provide more specific guidance company earning conference call february say allergan also guide stable restasis sale continue erosion namenda xr sale restasis be used treat rheumatoid arthritis psoriasis namenda xr be alzheimer drug generic version expect launch erode allergan sale related allergan outlook improve good trial colon drug credit suissedrastic drug price action trump card say needhamconatus pharma double novartis nash liver drug licensing deal
765,AGN,large cap growth opportunity fund figwx recent surge election federal reserve december rate hike have give retirement account other investor reason cheer trail month go thursday fund gain top large cap growth peer track morningstar inc averaged advance broad market measure gain fund way better mere direct rival outpaced past month not so shabby return difference now earlier period overall investment approach fund manager harold goldstein david chalupnik favore stock likely get extra tailwind election rise rate have be stock fit basic approach be pursuit stock think have faster earning growth market expect paid cut stable defensive consumer staple stock fourth quarter consumer discretionary stock fund fourth quarter commentary note manager pump financial mostly day election boost technology energy begin position signature bank sbny svb financial sivb raymond james rjf td ameritrade amtd newcomer have very strong composite rating ibd high composite rating start run combine ibd performance rating stock poise move higher often have comp rating higher addition sterling comp rating svb financial be rank bank ibd superregional industry group thank growth metric year row earning share ep growth annual pretax margin ibd take svb financial be rank rate bank super regional group see superregional bank be financial stack easy understand fundamental technical datum ibd stock checkup bank be headquarter silicon valley hotbed innovation nonbanking business include asset management private wealth management brokerage investment service fund management business valuation service raymond james be ibd finance investment bank banker group be propel factor fourth quarter ep growth straight quarters increase ownership mutual fund tech fund open position broadcom avgo chipmake company ep growth have accelerate quarters ibd leaderboard company make analog digital semiconductor system wireless communication communication goldstein chalupnik semiconductor space economic sensitivity broadcom role leader consolidation industry energy fund add new position concho resource cxo parsley energy pe add stake pioneer natural resource pxd add exposure several growth oriented exploration production firm result generally improve outlook oil pricing supply manager write health care fund overall weight stay basically unchanged immediate postelection period fund make individual stock move start stake incyte incy manager call fast grow young biotech firm exciting pipeline cancer fight treatment pay incyte fund used proceed sale drugmaker allergan agn bristol myer squibb bmy have own long time manager think allergan have grow so large longer grow much faster industry sell bristol meyer test result dim outlook lung cancer therapy be develop manager summarize approach way portfolio continue be reasonably balanced sector standpoint well measure other factor fund largest overweight be area company high growth potential believe perform well somewhat independent economic cycle be always look exceptional growth company believe have solid improve fundamental reasonable valuation approach catalyst related victory munder fund like semiconductor gear maker obamacare health stockswhere mutual fund bigwig expect see stock gain
766,AGN,major market average rally fresh time high early monday caterpillar cat boee ba goldman gs lift dow apple aapl tesla tsla boost nasdaq dow jone industrial average lead gain nasdaq composite rise add volume be tracking higher nyse lower nasdaq vs same time friday steel maker automaker build related issue outperformed stock market today gold miner discount retailer gaming software maker lag west texas intermediate crude slide barrel gold future fall ounce organization petroleum export country double full year supply growth outlook opec producer due rise drill activity investment caterpillar rally nearly heavy trade regain flat base buy point first clear jan share be still buy range entry boee goldman sachs also weigh gain more blue chip be trading record high boee have advanced thursday confirm singapore airline commit order widebody jet apple rise more be just shy time high stock be well extend cup handle buy point clear early january goldman sachs raise price target cite grow confidence upgrade cycle iphone due later year have buy rating stock tesla cruised new week high fast trade now buy range cup handle entry clear last week restaurant brand international qsr pop busy turnover track fifth straight session share be top buy range flat base entry burger king tim horton international parent report better expect result profit growth be highest quarters body contour system maker zeltiq aesthetic zltq gap soar time high news be acquire allergan agn allergan make wrinkle treatment botox climb related boee confirm singapore air deal bigger airbus doubtapple target raise weibo momo be buy nucor upgrade
767,AGN,major market index surge fresh high third straight session caterpillar cat apple aapl boost dow jone industrial average tesla tsla lift nasdaq nvidia nvda weigh dow rally nasdaq composite rise volume be flat nyse lower nasdaq vs friday accord preliminary number fiber optic automaker steel producer lead upside today stock market action discount retailer international oil explorer apparel maker lag steel surge clear cup base entry busy trade share be still buy range steel maker be expect benefit president donald trump protectionist policy caterpillar rise more heavy trade regain flat base buy point first clear jan share be still buy range entry apple rise nearly time close high stock be well extend cup handle buy point clear early january goldman sachs reiterate buy rating raise price target cite grow confidence upgrade cycle iphone be expect be release fall goldman also raise fiscal ep outlook well street consensus tesla cruised month high fast trade now buy range cup handle entry clear last week share pop thursday heavy volume report electric car maker be plan start test production model month ahead july mass production goal merger news zeltiq aesthetic zltq gap soar time high news body contour system maker be be acquire allergan agn allergan make wrinkle treatment botox edge fractionally higher ibd interdigital idcc western alliance bancorp wal stage breakout gain interdigital clear flat base buy point western climb past flat base entry average volume downside nvidia sank active turnover extend slide fourth straight session stock have head south rise buy point intraday tuesday tepid trade economic datum tap tuesday include producer price index january national federation independent business small business optimism index also january fed janet yellen jeffrey lacker dennis lockhart robert kaplan be slate speak earning be due agilent technology diamondback energy fang dr pepper snapple dps martin marietta material mlm mobile related apple get price target hike ar enabled iphone allergan buy fat freeze zeltiq bil zeltiq hit record high
768,AGN,dow jone industrial average index nasdaq composite hit fresh record high president trump say ll have phenomenal news tax cut soon nvidia nvda crushed earning view share fall raft earning twitter twtr growth have come standstill whole food market wfm plan close store lockheed martin lmt other defense firm mull deal tweeter chief dow jone industrial average index nasdaq composite rally fresh time high fuel trump pledge airline executive ll announce big news taxe few week earning be still heavy nvidia headline several highly rate chipmaker yum brand yum restaurant report well cybersecurity fiber optic play gold price rise year treasury yield fall once again find support day line semiconductor company nvidia nvda maxlinear mxl microchip technology mchp inphi iphi top wall street target december quarter result nvidia earn share ex item year year january sale rise straight quarter accelerate revenue growth analyst have expect cent ep sale nvidia guide line sale slightly lower gross profit margin nvidia share initially rally friday morning reversed finish session maxlinear guide sale slightly analyst target microchip inphi guide sale earning estimate higher current quarter intel intc say expect datum center profit margin decline time send share thursday month low trading day line recent session day earlier white house intel announce investment arizona plant related nvidia earning sale crush view guidance be so socrude price rise cent barrel international energy agency say opec compliance output cut be more qatar say opec extend production curb midyear gasoline supply unexpectedly fall latest week crude stockpile rise far more expect domestic production picked parsley energy pe announce be buy net acre permian basin second acquisition lucrative shale region month bp bp swung profit fall short analyst view company expect spend more oil major overall have give mixed capital spending outlook year related struggle expand power user base face competition facebook fb snapchat other twitter twtr report growth have essentially stall adjust earning be flat do top view revenue rise just far analyst estimate sale growth decelerate straight quarter ad revenue actually dip election year donald trump headline grab daily tweeting twitter also give dismal guidance share tumble thursday friday related president trump meet airline executive white house thursday discuss cut regulation modernize air traffic control system obsolete aviation infrastructure also tease announcement come next week be phenomenal term tax airline related group praise trump understand support airline industry delta air line dal american airline aal other take follow meeting overall market earlier week alaska air group alk beat view forecast flat unit cost even industry face higher expense due new labor agreement related lumentum lite report gaap fiscal earning beat view revenue miss expectation also give mixed guidance share lumentum core business be optical communication surge week ceo discuss emerge sensor market opportunity not include company guidance analyst speculate apple iphone design apple have multiple device supplier fabrinet fn provide optical packaging assemble optical electronic device other manufacturer report fiscal earning growth revenue better expect be second straight quarter accelerate profit growth best ep gain year fabrinet gain more related president trump be major topic cowen aerospace defense industrial conference lockheed martin lmt cfo bruce tanner say official fill key acquisition spot pentagon have bigger impact demand trump involvement deal northrop grumman noc say contract negotiation lockheed drive price haven change trump blast plane high cost raytheon rtn be wait see trump do corporate tax plan regard export boee ba ceo dennis muilenburg be still bullish deal sell airplane iran trump threaten reverse nuclear deal company confirm commitment singapore airline good sign post broader widebody market related yum brand yum parent kfc taco bell pizza hut report mixed result company say bring outside expert evaluate pizza hut chain turn disappointing not acceptable result instinet analyst mark kalinowski say be time pizza hut be divest yum rise nearly week breaking month high buffalo wild wing bwld result badly miss view analyst point loyalty program delivery test future positive activist investor want sport centric chain refranchise more also boost share buffalo wild share rally sharp weekly loss solid weekly gain yum china yumc recent spin yum china business report mixed result do panera bread pnra yum china stock fall panera share shot more bust base record high dunkin brand dnkn report better expect earning sale send share higher online food delivery service provider grubhub grub report ep cent miss consensus cent face increase competition amazon other grubhub revenue rise slightly beating more consumer use service year year grubhub stock skid nearly week fall day line entertainment heavyweight walt disney turn mixed result tuesday better expect ep decline surprise revenue drop espn abc parent also say expect debut stream sport service year address chatter surround succession plan ceo bob iger say do be best interest company be open stay top spot june expiration contract disney share fall hasbro have report earning jump share analyst view revenue climb also beating view disney princess frozen toy be bright spot sluggish holiday season retail sector hasbro stock rise more time high ibd tipp economic optimism index hit year high february rise tenth point sign confidence trumponomic reading signal optimism economist be still unsure growth live rise confidence least term positive sign come drop initial jobless claim week end feb second lowest level year related gilead science gild top revenue adjust ep share crash month low light hepatitis drug sale guidance segment slip year year allergan agn beat expectation crushed view sanofi sny result be mixed ep lag penny mallinckrodt mnk top analyst model guidance specialty generic be light regeneron regn ep just beat sale lag eylea guidance be light federal judge stay halt sale praluent pending appeal regeneron partner sanofi patent ruling favor amgen cholesterol fighter repatha related system reseller cdw cdw earn cent nickel view sale rise just slightly view share still shot akamai technology akam earn cent share flat vs year earlier revenue climb top view share tumble content delivery network specialist plan heavy spending beef global server internet infrastructure whole food market wfm meet view ep decline natural food grocer sale rise less expect same store sale fall again whole food also give weak guidance announce plan cut store count first time whole food share rebound rise nearly qualys qlys earn cent view sale just view tech security firm give weak full year earning revenue guidance qualys share fall nearly so far week flirt buy point twilio twlo unexpectedly break even revenue rise also view twilio give weak ep guidance twilio cloud base software provide real time messaging service business alert client brink bco earn cent share year earlier cent view armored car service revenue grow best year vs estimate brink stock shot coherent cohr spiked so far week hit fresh time high laser maker report ep gain revenue rise accelerate growth easily beating view vulcan material vmc earning fall cent share cent estimate revenue rise vs view gain vulcan material also give ebitda guidance be slightly view construction aggregate firm have rally follow donald trump election hope infrastructure boom stronger economic growth lower taxe fall nearly friday morning zillow earn cent share revenue beating view real estate information web site sale guidance have midpoint be slightly consensus zillow zg class share tumble close day average
769,AGN,here weekly investing action plan need know investor come week nvidia nvda disney grubhub grub general motor gm highlight earning news report season slow meanwhile boee ba lockheed martin lmt other giant defense aerospace appear conference time fraught
770,AGN,san francisco celgene celg ceo mark alle parry back tuesday so call social contract patient allergan agn face drug pricing debate spiked last year mylan myl epipen turing pharmaceutical hiv medication debate be not new just new social medium say many pharma company have become public proclaim free access program interesting principle have be play celgene year speaking medium panel tuesday morgan healthcare conference san francisco alle outlined series program celgene offer less expensive free access revlimid key chemotherapy treat multiple myeloma myelodysplastic syndrome mantle cell lymphoma alle estimate celgene medicine go patient free year subsidize well reinvest cfo peter kellogg say celgene reinvest north accounting partnership company hike price year ibd take celgene stock have ibd composite rating meaning have outperformed stock key metric past month rank company ibd medical biom biotech industry group see company lead sector visit ibd stock checkup person think lower price be answer drug pricing debate say meant longer have threshold provide access patient don have safety net trouble be celgene isn alone annual price hike last july wall street journal find drug price have jump vs year earlier figure alle say number factor be play complicate matter consumer generally don understand costly drug development process instance run pivotal late stage trial cost average drug fail firm be million alle say welcome comprehensive transparency look forward evolve say incentive have exist company take risk create return biopharmas generic alike simply agree price illegal alle note late monday pair former heritage pharmaceutical executive admit price fix scheme april december involve generic antibiotic diabetes drug accord philly com ex ceo jeffrey glazer jason malek former senior vice president commercial operation plead guilty federal court philadelphia conspire manipulate drug price federal investigator be also look mylan teva pharmaceutical teva other drugmaker suspicion price fix do industry person want do alle say assured be pay list price drug celgene share fall stock market today celgene work consolidation buy point rise monday raise profit forecast
771,AGN,credit suisse reiterate outperform rating allergan agn stock friday company late thursday release positive trial result colon drug treat irritable bowel syndrome give current valuation see potential significant upside agn expectation be properly reset new product continue deliver investor begin
772,AGN,appreciate value see agn pipeline credit suisse analyst vamil divan write research note allergan stock rise stock market today year nov touch nearly year low be tough year general maker generic drug allergan receive department justice subpoena seek information actavis generic unit liability transfer teva teva acquire actavis august part ongoing wide range doj investigation possible price collusion generic field month doj charge former heritage pharmaceutical ceo jeffrey glazer president jason malek felony count related conspire fix price diabetes drug antibiotic drug next day attorney general state sue mylan myl teva heritage other maker generic drug price fix allegation ibd take allergan have be worst perform stock year other end scale drugmaker be celgene learn company make ibd leaderboard top stock breakout ironwood stock rise friday buy point flat base touch month high nov dublin ireland base allergan partner ironwood pharmaceutical irwd be base cambridge mass announce call positive top line datum phase clinical trial evaluate linaclotide colonic release cr colonic release cr formulation adult patient irritable bowel syndrome constipation ib constipation ib aim work fda start phase iii trial second half cr second phase iib trial cr patient constipation linaclotide ir immediate release brand name linzess be currently fda approve available treatment adult ib chronic idiopathic constipation cic new formulation linaclotide aim treat distal small intestine colon trail patient not experience constipation majority abdominal pain associate ib be believe originate allergan ironwood say news release abdominal pain be usually most difficult symptom treat patient ib pain be not treat sufficiently then drife patient back office again again dr philip schoenfeld chief section john dingell va medical center adjunct professor medicine university michigan school medicine say allergan news release encourage initial datum new formulation linaclotide produce additional relief abdominal pain patient ib related trump break republican push major drug price reform drastic drug price action trump card needhammylan epipen settlement remove concern
773,AGN,president elect trump have promise action high drug price prospect government take control drug pricing have largely subside thank trump victory hillary clinton needham say bullish research report thursday specialty pharma sector furthermore trump state plan lower corporate taxe lessen tax burden company look bring cash back spark drug industry needham analyst serge belanger write research report belanger name acad pharmaceutical acad tiny corium international cori top pick specialty pharma coverage area interview time early month be name magazine man year trump give most definitive statement yet long simmer issue escalate drug price go bring drug price tell time don have happened drug price ibd take drug stock haven be boom see health care industry related company make latest ibd ranking stock have perform best past week emphasis most recent month comment hurt drug stock drug pricing remain issue trump didn expand comment interview subsequently belanger tell ibd email ask analyst amplify report even trump comment idea federal government negotiating drug price rather insurer seem far fetch now belander say email assume pricing scrutiny generic old drug continue pbm payer pharmacy benefit manager health insurer have be active area have previously be talk democrat have medicare other agency negotiate own drug price much va medicaid do now pricing control newly approve drug seem less issue now republican have board control mylan myl valeant pharmaceutical vrx be few company have receive most heat consumer lawmaker escalate drug price justice department be investigate possible price collusion maker generic drug company such mylan allergan agn teva pharmaceutical teva endo international endp be investigate first charge investigation doj month charge former heritage pharmaceutical ceo jeffrey glazer president jason malek felony count related conspire fix price diabetes drug antibiotic drug next day attorney general state sue mylan teva heritage other drugmaker price fix allegation less threat drastic drug price action belanger see much improve climate merger acquisition sector driver increase activity be likely be propose tax policy change new
774,AGN,administration write report also say trump effort ease repatriation overseas cash balance likely re energize entire health care sector big pharmas be company most overseas cash biggest tech company such apple aapl microsoft msft alphabet googl belanger cite amag top pick hit maternal health product development corium alzheimer drug amag stock be extend buy point first touch nov even fall stock market today corium stock fall small cap have partner teva have trade past month amag corium be part ibd huge company medical biom biotech industry group jump day follow surprise trump election have fall then group fall thursday related doj charge pharma exec price fixingwill trump break republican push major drug reform state sue mylan teva other price fix allegation
775,AGN,san francisco less hour president elect donald trump wednesday refer drug industry disastrous aldr ceo randall schatzman classify tone annual jpmorgan healthcare conference cautiously optimistic wide departure event time say sentiment be decidedly pessimistic enter turn be raucous election year drug pricing debate be alive biotech sentiment be grow stronger year schatzman tell ibd interview conference drug industry major event hold week san francisco talk biotech industry whole think finally come maturity say last year almost drug have be approve have come innovation biotechnology not large pharma so dollar be really pay back re see real game changer schatzman include cgrp migraine drug compete directly similar med eli lilly lly teva pharmaceutical teva amgen amgn migraine market be big enough grab sizable share drug hit shelve likely acknowledge trump comment didn help stock price hold phone schatzman pull screen biotech stock red arrow indicate descent point ishare nasdaq biotechnology index ibb exchange trade fund fall wednesday rise fraction thursday friday ibd take trump commentary send drug stock tailspin wednesday get deep dive mean drug biotech pick ibd industry theme so rally wall street expect jpmorgan event didn unfold here be key takeaway investor note trump take office drug firm look sidestep lilly alzheimer flop get early start trump isn alone fixation drug price celgene celg ceo mark alle parry back reporter question biotech follow allergan agn footstep apply so call social contract not raise price more annually celgene have offer free access program year alle say estimate biotech give away drug year free drug price increase help fund new drug add cfo peter kellogg estimate celgene reinvest fund accounting partnership alle say celgene go thoughtful process accounting innovation spending bring drug market price new med schatzman used same word describe plan price cgrp drug once near fda approval head market healthprize technology ceo tom kottler call pricing spike easy way drug company healthprize be software service firm marry behavioral economic consumer marketing analyze improve patient adherence prescription pharma leave worldwide revenue table year not push patient take med kottler tell ibd bridge gap company bring new product market prompt doctor more prescription raise price typically choose latter re miss easy money kottler say raise price be easiest thing say drugmaker merck mrk announce immuno oncology io drug keytruda combination chemo eli lilly alimta have win priority review fda small cell lung cancer have prescription drug free user act pdufa date meanwhile merck incyte incy be move keytruda epacadostat phase trial tumor type small cell lung cancer renal cell carcinoma bladder cancer squamous cell carcinoma head neck incyte stock jump jan news bristol myer squibb bmy be merck tail analyst say bristol myer be testing combination opdivo yervoy io therapy nsclc analyst expect bristol myer readout first half io combo be likely be more effective durable io chemo say monday japan takeda pharmaceutical put share bid ariad pharmaceutical ariad oncology firm base massachusett ariad stock fly news help share oncology firm tesaro tsro lift tesaro stock ipos lead ibd company medical biom biotech industry group stock see triple digit gain tesaro jump group overall fall painful election cycle now analyst wonder tesaro success oncology mind atmosphere reiterate takeda offer ariad garner bid tesaro leerink analyst seamus fernandez see potential takeout price share tesaro stock close friday rise tesaro remain well position grow independently validate parp inhibitor niraparib ovarian cancer drug still development offer durable strategically important product opportunity multiple suitor fernandez write research report jan regeneron regn sanofi sny be ask federal judge stay ban ldl bust drug praluent aftermath patent battle land biotech amgen praluent infringe amgen patent pcsk inhibitor repatha judge say meanwhile ldl buster alnylam pharmaceutical alny medicine co mdco be slowly advance jan medicine co announce day interim analysis study examine pcsk inclisiran datum show inclisiran significantly lower ldl day rbc analyst adnan butt expect month datum be similar efficacy safety detail be expect american college cardiology conference march washington inclisiran do well strong datum patent litigation amgen regeneron sanofi inclisiran be differentiate have patent litigation overhang butt say research report wednesday axovant axon ceo vivek ramaswamy say biotech drug industry have utterly fail alzheimer oncology inflammation cardiology ve see significant advancement last year disease alzheimer dementia include lewy body haven say don find treatment major threat society tell ibd interview wednesday be single area health care have fail deliver major advancement last decade ramaswamy say be root eli lilly december lilly highly laud solanezumab fail meet primary endpoint late stage trial cause lilly stock plunge day announcement lilly drug drug development biogen biib work remove plaque buildup brain associate alzheimer silver bullet theory ramaswamy doesn buy instead see necessary treat various behavioral psychological neurological piece alzheimer dementia axovant be aim build new therapy top older one axovant be next be alzheimer field deliver readout datum be slate say ramaswamy be look just major piece news alzheimer advancement say ramaswamy rise tide lift boat
776,AGN,first news conference surprise president elect trump wednesday indicated issue escalate drug price be priority used harsh word describe situation drug industry have be disastrous say trump drugmaker be subject new bidding procedure re get away murder say hit issue already have be get increase attention federal state lawmaker mylan myl ceo heather bresch be skewer house committee september plenty other have be heavily criticize include valeant pharmaceutical vrx teva pharmaceutical teva mylan teva acquire generic drugmaker actavis last year allergan agn be publicly trade company company december be sue attorney general state price fix charge field generic drug day earlier first action similar investigation justice department charge former ceo president privately hold heritage pharmaceutical price fix ibd take event such news conference president elect move stock see ibd stock move learn latest big mover number drugmaker currently move list interview time name magazine man year trump pledge bring high drug price wednesday marked first substantive comment subject pharma have lot lobby lot lobbyist lot power very little bidding drug say news conference re largest buyer drug world yet don bid properly re go start bidding re go save billion dollar period time actavis have boost price hydrocortisone tablet number year mylan epipen treat allergic reaction see price increase year end last year product treat potentially life threaten situation ishare nasdaq biotechnology ibb etf fall stock market today fall back day line already depress share mylan teva fall respectively wednesday valeant tumble ibd company biotech industry group fall again fall day day line larger biotech stock aldr fall spark therapeutic once plunge unite therapeutic uthr fall larger drugmaker amgen amgn end day regeneron pharmaceutical regn fall gilead science gild fall biogen biib tumble related trump drugmaker get away murder mylan teva sue allege price fix
777,AGN,supernus pharmaceutical supn break monday help ibd biotech group rise key support line supernus maker drug treat central nervous system disease adhd see share spike stock market today hit record intraday share break cup handle base buy point week supernus announce court appeal federal circuit affirm lower court decision actavis have infringe supernus patent supernus patent be valid teva pharmaceutical teva acquire actavis allergan agn year supernus stock rise news monday bigger jump come apparent news ibd take ibd biotech industry group have not be leader late ibd industry snapshot industry theme feature provider deeper dife group be hotter help trump election many factor ibd company medical biom biotech industry group meanwhile rise much day close nearly monday group briefly retook day line intraday close just day move average biotech stock first get boost surprise presidential election donald trump thought focus less issue high drug price opponent hillary clinton trump interview time publish month magazine name man year say go bring drug price don have happened drug price send drug stock fall biotech group have be trading day average month group rank group quarter rank trump also aim speed drug approval process be catalyst drug stock bigger biotech stock supernus clovis oncology clvs be lead charge monday clovis be monday afternoon get big fda drug treat ovarian cancer trading resume early afternoon be temporarily halter related trump break republican push major drug pricing reform clovis rocket cancer
778,AGN,conatus pharmaceutical cnat share more double early tuesday announce licensing deal novartis nvs late monday conatus get immediately further payment collaboration royalty deal pharmaceutical giant liver treatment emricasan novartis pay conatus phase emricasan development cost expense phase trial conatus say statement emricasan be be evaluate use treatment nash cirrosis nash fibrosis stand alone treatment part combo therapy conatus share shot morning trade stock market today hit month high intraday be month high micro cap biotech have have virtually revenue novartis edge higher intraday several drugmaker be work treatment nash stand nonalcoholic steatohepatitis fatty liver disease include liver specialist such intercept pharmacetical icpt genfit do not trade exchange intercept have advantage nash drug recently winning tentative european approval liver disease big biom nash player gilead science gild have candidate trial allergan agn make acquisition september enter nash development field intercept gilead allergan fall intraday related biogen name insider new ceo month search stock fallsclovis stock rally astrazeneca rivale ovarian cancer
779,AGN,promise mylan myl announce friday generic version own epipen injector cost half price exist epipen reach pharmacy next week mylan epipen have become last poster boy issue rapidly escalate drug price mylan ceo heather bresch get skewer house committee hearing september lawmaker ask question bresch own pay use private plane travel hearing bresch be daughter sen joe manchin va cost pen epipen pack have rise used treat often life threaten allergic reaction cause insect bite food drug more american be rightfully concern rise drug price now more ever patient family country be standing pharmacy counter struggle pay medication bresch say company announcement friday ibd take pricing issue have weigh drug stock group be do well find group be upswing regularly check ibd depth industry snapshot feature issue remain front burner president elect trump have not be expect focus drug pricing much ease drug approval process say time magazine interview publish month go bring drug price don have happened drug price thursday mylan be drugmaker sue state attorney general allegation fix price generic drug teva pharmaceutical teva also be sue teva mylan be largest generic drug maker market cap statement news mylan say date know evidence mylan participate price fix thursday news follow wednesday announcement department justice have charge former ceo former president new jersey base heritage pharmaceutical collude fix generic drug price charge be first year doj investigation drug price fix doj be look mylan teva group company include allergan agn endo international endp have disclose receive subpoena ag suit reveal thursday have name heritage principal architect ringleader conspiracy mylan stock year rise stock market today teva nearly year lose bresch mylan announcement friday say problem remain pharmaceutical pricing system be re-form address increase shift cost directly consumer pharmaceutical pricing be too far remove patient pharmacy counter not design today increasingly consumerize health care system authorize generic epipen auto injector have wholesale acquisition cost pack mylan say release generic version vs company own product be unprecedented action so anyone choose more expensive nongeneric epipen depend several factor example patient health insurance pocket cost epipen auto injector be more affordable option mylan spokeswoman julie knell tell ibd email mylan continue offer option patient so work health care professional determine best least expensive option related mylan teva sue allege price fixingdoj charge pharma exec price fix
780,AGN,drugmaker actavis face fine raise cost hydrocortisone tablet more british antitrust regulator say friday continue crackdown excessive pricing pharmaceutical industry division teva pharmaceutical industry teva break competition law charge excessive unfair price competition market authority say statement example company raise price milligram pack roughly cent currency teva acquire actavis allergan agn earlier year say defend allegation be lifesave drug rely thousand patient national health service nhs have choice continue purchasing say andrew grove cma senior responsible officer allege company have take advantage situation removal drug price regulation leave nhs ultimately taxpayer foot bill substantial price rise cma send actavis statement objection layer concern wider crackdown unfair drug pricing dec cma fine pfizer pfe flynn pharma record amount abuse dominant position charge unfair price unbranded version epanutin epilepsy drug regulator fine pfizer roughly flynn pharma increase price much september price increase occur pfizer transfer distribution right flynn sell medicine generic name phenytoin sodium teva be already process selling actavis operation inta pharmaceutical ltd say cma probe raise broader question regulation generic medication pricing actavis product investigation be never teva effective control teva believe intervention cma price generic medicine raise serious policy concern regard role cma department health teva say generic medicine continue be affordable alternative brand therapy statement objection often lead fine order change business practice regulator have power fine company find have abused dominant market position annual revenue hydrocortisone tablet be used primary replacement therapy person adrenal gland do not produce sufficient amount natural steroid hormone result condition such addison disease tablet be also used treat condition such arthritis blood hormone immune system disorder skin eye condition breathe problem cancer severe allergy actavis also increase price milligram hydrocortisone tablet nearly result charge nhs pack march cma say nhs have previously paid equivalent pack april nhs spend pound year hydrocortisone tablet nhs spend tablet have rise year steep price hike have put string drugmaker microscope company mylan myl valeant pharmaceutical international vrx bearing brunt public outrage president elect donald trump have be cite boon free market health care also declare opponent high drug price interview time magazine
781,AGN,allergan agn mylan myl teva pharmaceutical teva stock fall wednesday department justice accuse former pharmaceutical executive collude fix generic drug price former heritage pharmaceutical ceo jeffrey glazer jason malek ex president be charge wednesday philadelphia conspire fix price antibiotic diabetes med felony doj say release be fire heritage august accord bloomberg report cite lawsuit file last month new jersey heritage accuse glazer malek steal ten million dollar siphon profit various racketeering scheme fbi be prepared go pharma company violate antitrust law say special agent charge michael harpster statement filing charge drug price collusion skews market flout common decency say sad state affair pharmaceutical executive be determine further pad profit back person health depend company drug say ibd take biotechs have nearly return pre election level recent commentary donald trump work cut drug price wednesday teva stock fall mylan allergan ibd company medical generic drug industry group fall charge be first year investigation generic drugmaker include allergan mylan teva lannett lci impax laboratory ipxl covis pharma sun pharmaceutical mayne pharma taro pharmaceutical taro endo international endp email statement edison base heritage pharma say august follow internal investigation reveal variety serious misconduct individual charge today heritage pharmaceutical terminate be fully cooperate aspect department justice continue investigation recently heritage initiate own legal action same individual seek redress elaborate embezzlement self deal scheme be deeply disappoint misconduct be commit ensure do not happen again last month allergan sun pharma decline comment ibd mylan say have disclose subpoena regard antibiotic doxycycline be subpoena information pricing tactic digoxin blood pressure med ceo drug biotech market have comment rise drug price light recent commentary president elect donald trump go bring drug price hillary clinton be often see tougher drug price earlier wednesday express script esrx ceo timothy wentworth joined fracas say doesn see major impact business affordable care act be repeal say guidance call analyst overarch drug price conversation isn go away be question mind conversation be not go go away need demonstrate used tool client voice well demonstrate say accord marketwatch share pharmacy benefit management company tank much wednesday end day day line express script affirm earning share ex item view deliver line sale view related drugmaker mylan slate growth follow price fix fracasincyte recoup loss price fix fracas strong chemo result
782,AGN,thanksgiving week see shire shpg xiidra lose ground rival allergan agn dry eye market broader sector continue grow wake xiidra launch august rbc analyst dougla miehm say friday xiidra market share decline prior week miehm say total xiidra prescription dip underperform allergan restasis decline decline be expect short week miehm write research report xiidra do better week total prescription climb total restasis prescription rise just ibd take other sector leader be face biotech world boston scientific acquire neovasc asset take medtronic edward lifescience transcatheter aortic valve replacement market meanwhile new xiidra prescription fall thanksgiving week wipe increase prior week miehm write still xiidra new prescription market share remain robust say slightly week earlier broad dry eye market miehm say be grow year base week average total prescription estimate year year growth xiidra entrance market reiterate outperform rating price target shire stock be more close stock market today share last month fall day day move average allergan stock trading year lows be fraction related shire rout incumbent allergan boom dry eye market rbc
783,AGN,stock buyback apple aapl qualcomm qcom verizon communication vz intel intc comcast cmcsa slow month end tech telecom stock have thing common re just same apple september quarter share repurchase be still top company ahead microsoft msft general electric ge allergan agn citigroup even fall apple buyback year earlier period fiscal end apple buyback slip previous year say standard poor comcast buy back own stock month end comcast buy back stock year earlier period qualcomm buy back stock intel repurchase say month end share repurchase be respectively year earlier period ibd take broadcom burlington store martin marietta be stock ibd leaderboard leaderboard follow top stock work form basis breakout post action point start top leader be constantly monitored verizon have not repurchase share phone company have prioritize debt repayment buy vodafone group vod stake verizon wireless month end verizon buy back own stock say slowdown buyback name company stock gain thursday close apple stock be year apple stock flat stock market today have form cup pattern buy point comcast stock fraction thursday be year qualcomm rise thursday year qualcomm stock have form cup handle pattern buy point intel stock have edge rise small fraction thursday stock have form cup handle base buy point verizon stock thursday have gain also form cup base buy point tech company big buyback general electric buy back own stock ge be track repurchase own stock next year ge plan stock buyback range related apple general electric microsoft lead field stock buyback
784,AGN,interview time selection news magazine man year bring president elect trump most definitive statement date drug price go bring drug price don have happened drug price incoming president have be short detail many observer say bigger focus be streamline food drug administration drug approval process effort get boost wednesday same day trump time interview be publish senate approve bill aim speeding approval drug medical device president obama be expect approve so call st century cure bill just action trump take remain unknown resolution issue drug price time jump exponentially critical need patient trump have vow repeal president obama affordable care act promise drain swamp special interest washington help contribute rise big pharma time interview hadn broach drug pricing issue just election boost drug stock ishare nasdaq biotechnologg etf ibb jump day nov election fall ibd company biom biotech industry group jump nov generic ethical drug group rise respectively group have give back gain trump ignore rise drug price say trevor william penn mutual asset management manage director trouble be businessman reality tv star be relative political enigma william tell ibd hard see be champion lower drug price same sense hillary have be so focuse dismantle aca william say trump not have political history really difficult telegraph go go policy proposal be tell trump pledge contract american voter fully repeal aca better know obamacare first day office replace health saving account vein say ll cut fda red tape be drug await approval especially want speed approval life save medication trump write contract trump crack fda be nothing new say credit suisse analyst vamil divan yet recent year fda have work expedite sorely need drug fast track designation prescription drug user fee act help fund drug quickly still be backlog approval generic drug divan tell ibd many proposal work have target make approval process generic drug cheaper drug similar drug long enough ve lose patent protection much easier trump platform remove barrier entry safe reliable cheaper product trump also allow broader label use number drug penn william say replacement plan aca remain somewhat ambiguous trump have backed earlier promise fully repeal act say ll maintain provision require insurer cover patient pre exist condition let parent cover child age obama didn touch pharmaceutical much obamacare legislative centerpiece say divan outside require drugmaker pay expand health care coverage trump completely do away aca be unlikely divan say fee disappear backroom negotiation aca let company come reasonably well divan say repeal aca put cash fee back drugmaker pocket yet wall street be anything reasonably sure trump care affect biotech drug firm trump doesn appear have vendetta pharmacy benefit manager pbms drugmaker pbm tactic undercut amgen amgn eli lilly lly prompt stock topple late october amgen offer dim view eli lilly see diabetes sale take hit pbms be third party administrator commercial government medicare health plan pbms use discount competition keep drug price low help patient raise conflict drugmaker amgen stock topple nearly oct sale enbrel come flat firm say doesn expect net selling price increase business be drive volume amgen executive anthony hooper say company earning conference call ibd take rebate chip away amgen enbrel sale do mean broader industry grab ibd industry theme deeper look eli lilly stock oct sale diabetes drug humalog fall higher volume be more offset lower realize price company say earning conference call ep revenue miss wall street target trump lack commentary pbms be tell divan tell ibd stand government be not involved drug price negotiation trump work change order lower drug price not be focus republican divan say trump be not typical republican question say be new administration willing go something big pharma politically score point general public drug company have own view course merck mrk ceo ken frazier month bloomberg interview say company have be restrain raise price always be individual drug individual year point say look large relation other look whole portfolio see merck have tend be rather restrain come drug price bloomberg report frazier say bloomberg also report month allergan agn ceo brent saunder say trump be more vicious more focuse take do something again term spiking price drug drug bloomberg have interview saunder frazier appear forbe healthcare summit new york dec question patient have have high drug price kaiser foundation find september american last year believe drug price be too high american generally support require firm release information price be set allow government negotiate drug price kaiser survey follow drug pricing controversy erupt september mylan myl boost price pair epipen ceo heather bresch be subject tough question house committee hearing last year similar controversy prompt capitol hill hearing involved turing pharmaceutical former ceo martin shkreli involve big hike decade old hiv drug valeant pharmaceutical vrx have also impose huge hike drug price justice department be investigate be expect file charge generic drug company price collusion year end yes analyst divan say don think issue be go away also say see fewer chance big change drug pricing policy trump related pfizer sale challenged eli lilly novartis breakup busteli lilly topple alzheimer darling sola fail biogen merck downcelgene kite spark look sidestep lilly alzheimer flopalder keel sixth day eu uphold teva migraine patent
785,AGN,have be norm apple aapl lead stock buyback third quarter information technology sector overall lead field say report factset research firm overall spend share buyback be year year smallest quarterly total top spender apple repurchase worth share follow apple second place be general electric ge then microsoft msft allergan agn mcdonald mcd apple general electric microsoft lead stock buyback well month microsoft say director have authorize new stock buyback program much company reaffirm be track complete current buyback authorization year end ibd take share repurchase be popular way return capital shareholder tend boost stock share earning reduce number share outstanding also move company make begin transition rapid growth middle age have be norm index information technology sector be top spending group term buyback be year year several major contributor be smaller repurchase oracle orcl intuit intu apple financial sector be second top spending group worth stock be repurchase apple share rise stock market today related apple exxon mobil lead dividend paidapple alphabet microsoft cisco be king cash
786,AGN,valeant pharmaceutical vrx sale force expansion stomach drug signal fail negotiation sell salix pharmaceutical unit mizuho analyst irina koffler say wednesday similar report wall street journal acquisition talk valeant japanese firm takeda pharmaceutical break hour price disagreement source tell wsj valeant official didn immediately return request comment ibd takeda have paid roughly salix business valeant buy winning bidding war rival endo international endp salix be largest independent gi drug company world acquisition then valeant have accrue nearly long term debt accord earning release struggle include allegation relationship shutter philidor mail order pharmacy complaint price hike drug naming new ceo valeant stock have topple peak august valeant stock close stock market today tuesday valeant say plan expand sale force primary care physician pcp prescriber xifaxan irritable bowel syndrome diarrhea relistor opioid induced constipation cost do so be already include guidance valeant say ibd take valeant stock have go low most stock do worst possible composite rating meaning underperform stock term key growth metric gauge better drug company bet stock checkup mizuho koffler reiterate underperform rating price target wednesday valeant stock xifaxan be antibiotic only take week time write research report product allergan agn viberzi be take chronically koffler say see competition horizon too cosmo pharma be plan submit new drug application food drug administration first half zemcolo zemcolo recently have success phase trial treat traveler diarrhea think expansion be reasonable ultimately futile reaction xifaxan slow growth evidence year year growth milligram total prescription average year year decline mg new prescription past week period koffler write related mallinckrodt earning top stock dife guidancevaleant official charge connection kickback house say be eyee buyout valeant divisionvaleant crash sale ep miss slash guidance
787,AGN,acorda therapeutic acor stock nose dive monday firm scrap development drug treat walking impairment stroke patient defy otherwise upbeat day biotech stock stock market today acorda stock topple share be half year vs dip ibd company medical biom biotech industry group share group be small fraction monday afternoon rbc analyst michael yee maintain outperform rating acorda stock note low prior expectation ampyra use stroke victim walking impairment ampyra be muscle strengthener be used treat multiple sclerosis acorda begin enrolling patient phase post stroke walking deficit trial ampyra december study be stop early pre specify interim analysis due lack efficacy week patient receive milligram mg dose respectively show least improvement minute walking test wasn much better patient placebo show same improvement ibd take acorda stock have poor ibd composite rating meaning underperform stock term key growth metric find better bet stock checkup investor remain leery ampyra patent face continual pressure yee write patent trial appeal board be due make decision pending petition march acorda allergan agn recently reach settlement ampyra patent dispute bottom line stock currently remain cheap give fact still only price civita program cvt nothing else yee write discontinue development be small disappointment add related amgen biogen celgene eye trump pro biotech world
788,AGN,allergan agn stock plunge month low wednesday drugmaker report third quarter sale earning miss wall street view cut full year guidance lag demand asacol namenda drug stock market today allergan stock fall meanwhile ibd company medical ethical drug industry group slip fraction third quarter allergan report sale earning share ex item respectively vs year earlier quarter metric miss consensus analyst poll factset sale ulcerative colitis drug asacol fall grow generic rivalry namenda sale dip sale namenda dementia drug fall unfavorable rate currency exchange foreign nation allergan say release allergan also slash full year profitability guidance adjust earning vs earlier expectation midpoint guidance adjust earning be vs year earlier quarter firm also keep full year sale view be vs ibd take fellow drugmaker amgen biogen be also struggle angst fraught political environment take look ibd industry theme key company sector relatedpfizer end cholesterol drug development lower ep guidancegilead nash drug active promising lag interceptshire rout incumbent allergan boom dry eye market rbc
789,AGN,president elect donald trump republican congress likely seek faster drug pipeline buoy medidata solution mdso other medical software firm keybanc analyst donald hooker say monday drug stock rise again emphasis faster pipeline come reduce drug pricing scrutiny trump plan incentivize repudiate cash credit suisse analyst kennen mackay write separate research report predict trump presidency likely keenly boost biotech sector stock market today medidata stock help lead ibd company computer software medical industry group be medidata stock be seventh straight gain hooker have overweight rating price target share say macro backdrop have improve medidata follow trump election ibd take biotech drug stock have fly trump uncertainty exist intention affordable care act check ibd industry theme full skinny rise drug price have become major political issue year hooker write research report monday instead price control suspect republican solution more likely involve regulatory reform speed approval new drug create greater competition trump make drug development great again quip hooker see organic growth medidata give likely improve regulatory legislative landscape information technology drug development medidata have enterprise deal bristol myer squibb bmy celgene celg biogen biib boehringer ingelheim ibd biotech industry group rise day election fall thursday friday company group be monday ibd company generic drug group have rise day election be monday hope trump regulation help industry democratic nominee hillary clinton be see tougher runaway drug price september biotech industry see stock tumble clinton call former turing pharmaceutical ceo martin shkreli boost cost decade old hiv pill september mylan myl draw national ire raise price pair epipen mylan allergan agn teva pharmaceutical teva be handful drugmaker currently investigation department justice allege price collusion trump likely win push back drug pricing mackay say investor be more bullish sector give trump proposal incentivize return cash still caution health care pricing be area mr trump make concession democrat write research report seattle genetic sgen stock react richly trump election note related incyte recoup loss price fix fracas strong chemo resultsmylan third quarter earning fall short stock steady
790,AGN,pfizer pfe stock pop thursday report drugmaker be consider selling consumer care business less month firm opted long rumore corporate breakup evercore analyst john scottus expect potential transaction garner cent earning share midpoint forecast assume tax proceed sale be used share buyback potential sale make sense scottus write research report thursday pfizer reassess future pfizer walk away merger ireland base allergan agn april lawmaker look crack tax inversion deal company be set headquarters lower tax region such ireland pfizer also have long mulled corporate breakup splitting innovative essential health division scrap idea september johnson johnson jnj buy pfizer then consumer care business pfizer build unit back acquisition wyeth later pfizer sell nutrition business nestle spun animal health business zoetis zts thus sale current portfolio consumer product appear be logical next step allow pfizer focus core competency develop selling innovative drug scottus write ibd take trump presidency affect drug biotech stock get full skinny ibd industry theme reuter first report potential customer care sale late wednesday cite anonymous source unit pull sale annually scottus liken bayer acquisition merck mrk consumer care business annual unit stock market today pfizer stock climb day line ramp second consecutive day follow election president elect donald trump share rise wednesday drug biotech stock have rebound trump election trump be see less likely challenge drug price vs democrat hillary clinton unveil plan last year cut spiraling price tag drug trump have promise tackle affordable care act obamacare investment bank rbc say tuesday cause dip biotech stock uncertainty new not yet outlined national health care editor note correct fourth graph show zoetis be spinoff related pfizer likely overpay post allergan breakup flop twist pfizer scraps breakup follow dead allergan merger
791,AGN,drugmaker mylan myl be slate report rise sale earning close wednesday just day fellow drug leader teva pharmaceutical teva allergan agn plummet news federal probe allege price collusion mylan be expect report earning share ex item sale respective vs year earlier quarter be mylan consecutive quarter sale ep growth ep be expect decelerate growth sale be see speeding growth prior quarter mylan have beat meet ep view consensus analyst poll thomson reuter past quarters sale have only beat twice ibd take mylan have ibd composite rating meaning perform middle stock term key growth metric get stock checkup see stock be better rate mylan stock be past week touch year low thursday company have attract national ire epipen price september ceo heather bresch be grilled congressional committee high price pack epipen price epipen be used treat severe allergic reaction insect sting bite food same time period ibd company medical generic drug industry group have fall include nose dive last thursday report emerge department justice investigation potential price collusion generic drugmaker close bell stock market today mylan stock end trading more related incyte recoup loss price fix fracas strong chemo result
792,AGN,share drug giant pfizer pfe fall tuesday company say end development cholesterol lower drug project be blockbuster reduce earning outlook current quarter post ep just miss wall street expectation pfizer stock fall stock market today member dow jone industrial be trading nearly month low touch year high aug cease work injection drug call bococizumab be unexpected company say prove have unexpected side effect be become less effective wall street have modeled peak annual sale bococizumab evercore isi analyst john scottus say note client pfe be clear do not see attenuation benefit competitive datum amgen amgn regeneron regn write problem appear be bococizumab specific scottus say ibd take pfizer megadeal buy allergan go bust april takeover time warner go same direction drugmaker say revenue rise year earlier quarter earning share inched cent revenue meet view ep miss penny accord evercore isi analyst john scottus pfizer now guide ep earlier guidance sale vs earlier guidance pfizer attribute miss higher expect cog cost good sell tie foreign exchange rate scottus say sale breast cancer drug ibrance be marginally consensus scottus say prevnar deliver small beat sale prevnar pneumococcal conjugate vaccine miss forecast innovative health business execute strongly latest product launch recent acquisition medivation anacor be provide new term opportunity potentially drive incremental growth business product pipeline continue mature pfizer ceo ian read say earning release see business highly focuse therapeutic area be best position deliver value patient maintain overall high level financial flexibility discipline be strong position support strategic initiative business remain opportunistic business development activity addition continue actively manage cost structure august pfizer announce agreement acquire medivation maker prostate cancer drug xtandi come new york base pfizer ireland base allergan agn april call plan merger have be industry largest ever regulator set roadblock so call tax inversion merger company look set headquarters lower tax region such ireland september pfizer say not split separate company move have mulled several year have be expect separate essential health business consist older patent medication innovative health business be dedicate newer drug related surprise twist pfizer win split uplilly abbvie lead ranking pfizer challenged
793,AGN,gilead science gild cut loss tuesday fibrosis drug still plan send potential treatment fatty liver disease phase testing needham analyst say wednesday biotech earning report needham analyst alan carr keep hold rating gilead stock follow report late tuesday stock market today share dip share be year match decline ibd company medical biom biotech industry group gilead report sale earning share ex item respective vs year earlier quarter sale top consensus analyst poll factset ep miss cent ibd take gilead report follow amgen biomarin be similarly struggle volatile election season keep tab industry theme more evercore isi analyst john scottus attribute sale beat hiv drug genvoya bring more expect be partly offset miss hepatitis drug sale sale hep drug have be impact medicaid restrict access most seriously ill patient gilead hep unit be comprise harvoni sovaldi epclusa trio bring sale vs year earlier period gilead attribute decline lower demand harvoni sovaldi epclusa launch june july europe respectively rbc analyst michael yee expect term challenge gilead stock low visibility hepatitis sale europe keep outperform rating gilead stock cut price target gilead also announce discontinue testing fibrosis drug simtuzumab fail show efficacy phase trial nash nonalcoholic steatohepatitis primary sclerosing cholangitis psc instead firm be look send single agent phase testing have plan combination trial nash battle meanwhile continue heat intercept pharmaceutical icpt novartis nvs allergan agn be buy tobira therapeutic tbra purpose gilead mix nash affect american year liver disease be area opportunity needham carr write research report related allergan stock topple miss slash outlook
794,AGN,amazon amzn chevron cvx twilio twlo allergan agn godaddy gddy be wall street microscope tuesday axiom capital up price target commerce titan amazon fall far short third quarter earning forecast last week report line revenue figure period share tumble key day line friday have yet recover share fall stock market today chevron get more analyst love time morgan stanley just day goldman sachs upgrade stock conviction buy neutral morgan stanley give upgrade overweight price target follow solid earning report last week chevron rise general retreat stock price oil future oppenheimer start coverage new issue outperform rating price goal twilio begin trading june peaked late september have plummet less half price announcement follow stock offer share jump mizuho give allergan price target haircut still have buy rating rbc say several week shire shpg xiidra treatment be nipping away allergan restasis market share share fall intraday allergan report earning wednesday monness crespi hardt aren call domain name company buy anymore downgrading stock neutral early october summit redstone initiate coverage stock buy rating strength competitive advantage share fall related shire rout incumbent allergan boom dry eye market rbctwilio downsize price secondary stock offer share fallamazon earning fall short stock slumpsgodaddy start buy share taker brand scale
795,AGN,gilead science gild nonalcoholic steatohepatitis nash drug be clearly active promising intercept pharmaceutical icpt remain year ahead rbc analyst michael yee say gilead biotech market cap unveil promising efficacy datum gilead selonsertib aim inhibit apoptosis signal regulate kinase protein tie nash diabetic kidney disease pulmonary arterial hypertension patient enrolled gilead week phase study show least improvement fibrosis company say jibe result intercept earlier nash study patient have positive response vs placebo track yee write tobira therapeutic tbra be be acquire allergan agn also be active nash market recent study see improvement fibrosis used tobira drug intercept have healthy lead gilead tobira allergan yee say be vie nash market worth potential intercept see key datum rival likely have say competitive landscape be not shocking be nash drug be start show promise move late stage yee write intercept be still year ahead have datum thursday news do little gilead stock friday stock market today gilead fall cent share be year ibd company medical biom biotech industry group have fall ibd take gilead be tap report earning nov biotechs be deck next week include biogen celgene amgen check investing action plan potential mover next week earning season kick earnest related allergan challenge intercept tobira nash drugwhich biotechs set big boost drug trial result gilead allergan see trail intercept nash battle
796,AGN,shire shpg xiidra be rout allergan agn dry eye drug market share rbc analyst dougla miehm say friday nearly triple expectation sale shire xiidra close bell stock market today allergan stock fall shire stock drop miehm have outperform rating price target shire stock shire stock break flat base entry point go nowhere share be now buy point area investor be advise sell drug stock have be hit volatile election season high drug health care price always big issue ibd take biotech stock be worst perform group wednesday have slip company medical biom biotech industry group topple group track past week climb wall worry first week october shire dry eye drug pull total prescription week week compare incumbent restasis allergan see total prescription fall increase prior week shire total market share grow prior week miehm write total dry eye drug market be nearly prescription almost past week follow xiidra launch aug trend play well rbc outlook miehm say hike expectation xiidra sale see sale respectively forecast nearly triple vs earlier view related pfizer likely overpay asset post allergan breakup flop slam politic eli lilly pfizer challenge intercept tobira nash drug
797,AGN,stock turn mixed soft start wednesday wall street digest news trump plunge more point overnight dow jone industrial average be mostly unchanged nasdaq lose ease early leader dow include pfizer pfe caterpillar cat merck mrk jpmorgan jpm goldman sachs gs also outperformed ibd take election result be describe shocking upset ibd tipp presidential tracking poll ultimately have right year treasury yield soar basis point december gold rally ounce drugmaker campaign target democrat hillary clinton due pricing trade generally higher pfizer industry group mallinckrodt mnk shire shpg allergan agn lead gain more hospital operator stand lose president elect trump act promise repeal affordable care act dove deeper early loss tenet healthcare thc topple hca holding hca skid universal health service uhs drop coal mining stock soar consol energy csx arch coal arch add cement construction aggregate supplier surge possibly early commitment infrastructure other large scale project trump vulcan material vmc martin marietta mlm higher martin marietta gap cup shape base buy point vulcan gap cup shape base buy point stock be still buy range early trading early gainer ibd include healthequity hqy eagle material exp gain pra health science prah morgan stanley ms add related clinton vs trump ibd tipp presidential election tracking pollafter initial fall stock rally trump victory agenda
798,AGN,drugmaker pfizer pfe become acquisitive post breakup flop likely overpay asset say jeffry analyst jeffrey holford downgrade pfizer stock thursday cite lack catalyst stock market today pfizer stock fall nearly third consecutive day share dip flat base form nearly month be now possible entry point ibd take biotechs topple hard wednesday political angst thursday player supernus pharmaceutical rebound find day big mover ibd stock move holford downgrade pfizer stock hold rating buy cut price target key driver originally drive upgrade have play fail materialize write research report ibrance pfizer treatment metastatic breast cancer be grant accelerate fda approval early strong ramp enjoy have peter rival add pressure even pfizer prepare european launch note recent prescription trend indicate opportunity be become saturate patient be begin roll treatment rapidly new one be recruit write european launch reinvigorate growth similarly holford be previously bullish pfizer prevnar drug combat pneumococcal pneumonia much adult catch opportunity be now penetrate write pfizer biggest potential catalyst be engage holford see likely next month pfizer walk away merger allergan agn tax rule change april last month scrap year old plan break separate company help pfizer drive stronger growth profile risky write whilst management find attractive target acquire believe environment be very competitive right now be high risk pfizer overpay asset write related prothena slam politic eli lilly pfizer topple bristol myer lung cancer drug winregeneron sanofi beat pfizer roche astrazeneca eczema
799,AGN,just past year half antitrust concern have undo jeopardize several merger deal add doubt consummate takeover time warner twx agree pay share time warner medium giant stock fall stock market today well bid price indication investor be skeptical deal go fall still company see deal close late obama administration have become more aggressive merger acquisition lately sue block demand condition be too onerous donald trump have say block time warner deal president hillary clinton have voiced concern february comcast cmcsa agree buy time warner cable combine top cable provider federal communication commission raise concern consumer group netflix nflx also object regulator expect block deal comcast give april charter communication chtr moved agree buy twc deal close november pfizer pfe reach deal buy allergan agn so call tax inversion ve allow pfizer change domicile ireland slash tax bill deal ve create world largest drugmaker come time politician be already bash tax inversion treasury department introduce series new rule make inversion less attractive april pfizer walk away deal cite treasury rule related forget allergan pfizer have sight cancer drugmaker allergan pfizer strike separate path merger kill crude price be collapse november oilfield service provider halliburton hal agree buy rival baker hughe bhi deal be worth time also ve put combine company schlumberger slb prompt regulator duopoly halliburton scramble find buyer asset seek shed regulatory approval justice department reportedly push halliburton sell more asset single buyer then april doj file lawsuit block merger company call deal then be worth related halliburton fail buyout actually hurt eye new deal end baker hughe bid february staple spls agree buy office depot odp retailer face pressure commerce rival amazon amzn be second attempt earlier be block federal trade commission staple office depot say time be different industry landscape be completely different cite amazon other competitor ftc disagree sue december judge side federal government september general electric ge inked agreement sell home appliance business electrolux eluxy industrial conglomerate seek shed noncore asset focus area aviation power system oil gas doj sue july say merger hurt consumer judge rule lawsuit ge walk away december next month ge sell unit china haier december top food distributor sysco syy agree buy rival food february ftc sue argue merger player market result higher price restaurant hotel other company buy food related supply june sysco abandon deal judge rule favor ftc july anthem antm say buy cigna ci create largest health insurer membership come just week aetna aet reach deal acquire humana hum consolidation effort come health sector struggle find saving address higher anticipate cost associate obamacare mandate july doj file lawsuit block deal say much health insurance market be controlled just company august doj signale be willing reach settlement anthem cigna allow merger october walgreen boot alliance wba say plan buy rite aid rad bring together drugstore chain leapfrog cvs health cvs walgreen have be look buyer help company offload store pass regulatory muster management be also talk ftc appear be make progress summer kroger kr seem unwilling buy hundred store walgreen rite aid be try divest kroger have be interested want close location reopen grocery store ftc want preserve stand alone drugstore source tell new york post
800,AGN,biotech stock climb third consecutive day tuesday mid cap tesaro tsro forge way largest company amgen amgn gilead science gild celgene celg be buyable now say mizuho analyst salim sy sy initiate coverage tuesday amgen gilead celgene stock buy rating also initiate biogen biib neutral rating lack medium term catalyst uncertainty former ceo george scango resign july be clear still think biogen have good program be matter time get excited again just not right now sy write research report have price target biogen stock slip cent tuesday ibd company medical biom biotech industry group lift fraction stock market today volatile election season have strangle share cause group topple past week ibd take sy have neutral rating biogen stock share be look better biogen ionis announce early efficacy phase testing spinal muscular atrophy drug check industry theme full take sy liken amgen jogger have price target stock fraction tuesday amgen most recent call thought amgen largely hum steady stock jogger write however amgen call week stock have come enbrel commentary call spook investor say sale be flat give contract negotiation amgen expect relatively little benefit net selling price change enbrel wall street have be predict decline amgen legacy business time sy see silver line new drug amgen repatha cholesterol bust pcsk rival sanofi sny regeneron regn praluent repatha already have food drug administration approval sale have suffer restrict access sy write repatha be currently phase testing treat cardiovascular outcome september meet primary secondary endpoint phase test coronary artery disease cv datum be expect sy call most important datum event amgen positive event pull amgen stock dump share hit year low friday manage close fractionally day gilead manage impossible launch hepatitis hcv drug sovaldi harvoni triple revenue become company sy write separate report duo be cure hcv therefore win last forever flip side develop cure be eventually disease be eradicate write great patient mean decline revenue time have be weigh gilead stock answer slope decline isn exactly clear gilead hep trio sovaldi harvoni epclusa bring sale vs year earlier quarter epclusa launch june july europe help offset decline sovaldi harvoni sy model year year decline hcv sale gilead gilead be work next leg growth sy say have price target gilead stock nonalcoholic steatohepatitis nash hepatitis hbv drug be still too early pipeline gilead be face nash competition intercept pharmaceutical icpt allergan agn gilead isn table pound buy stock be undervalue company likely perform time reward patient investor sy write gilead stock rise cent tuesday celgene be castle chemotherapy drug revlimid be moat sy say revlimid sale grow vs last year drive new market share gain increase duration revlimid be used treat myelodysplastic syndrome mds multiple myeloma mantle cell lymphoma mcl revlimid allow celgene grow next source revenue sy write separate report revlimid be still grow part business value add celgene part business be fairly well establish mature moat celgene have cancer drug durvalumab car conjunction astrazeneca azn juno therapeutic juno respectively celgene be also work next generation replacement revlimid be expect go generic be fully generic core celgene have ozanimod currently phase testing multiple sclerosis ulcerative colitis ged investigational crohn disease drug be central celgene investment thesis say sy have price target celgene stock rise tuesday related biotechs be derisked buyable ahead election day amgen gilead eli lilly eat abbvie humira sale analystgilead nash drug active promising lag challenge intercept tobira nash drug
801,AGN,biotechs drugmaker rally friday follow big drop thursday news department justice be investigate dozen company suspect price collusion include industry leader teva pharmaceutical teva mylan myl plunge thursday month low ibd company medical generic drug industry group rise stock market today group be second best performer group ibd company medical biom biotech industry group meanwhile rise be third best performer price collusion be new challenge industry already wrack controversy spiraling price illegal company agree set price coordinate discount september mylan ceo heather bresch be grilled congressional committee sixfold price increase epipen last year former turing pharmaceutical ceo martin shkreli draw national ire raise price aids medication factor prosecutor file first charge year end accord anonymous source cite bloomberg biotech drug stock plunge thursday follow report year investigation span more dozen company include teva mylan lannett lci impax laboratory ipxl covis pharma sun pharmaceutical mayne pharma taro pharmaceutical taro endo international endp subsidiary par pharmaceutical teva actavis unit acquire allergan august also have be implicate ibd take spdr biotech etf get nice boost friday rise buyback follow slump thursday other etfs wobble election season aim dynamic close next week etfs be proxy broad market see winning ibd etfs fund page several company have acknowledge doj investigation security exchange commission filing allergan agn receive doj subpoena request information generic business liability have be transfer teva acquire allergan generic business actavis august teva twice disclose subpoena doj connecticut attorney general allergan decline comment previous disclosure liability transfer teva spokeswoman denise bradley tell ibd teva be not aware fact give rise exposure company respect subpoena mylan have already disclose subpoena regard antibiotic doxycycline be subpoena information regard pricing tactic digoxin blood pressure drug mylan mayne par actavis sun lannett make digoxin covis make lanoxin brand version mylan be have always be commit cooperate antitrust division investigation spokeswoman lauren kashtan tell ibd email date know evidence mylan participate price fix sun pharma decline comment say continue cooperate doj lannett impax covis mayne taro endo didn immediately return request comment credit suisse analyst vamil divan didn immediately see news create long term damage outside term overhang stock allergan stock lose thursday teva fall allergan stock rise friday teva rise mylan drag allergan be inappropriate consider actavis sale write research report teva case sharper deluge be likely overreaction say acknowledge investigation likely be overhang teva generic space have more clarity outcome understand potential financial criminal penalty be impose divan write related generic drug maker crash report doj plan collusion chargeseagle pharma teva pharma diverge surprise leukemia drug winteva pharma have generic trick ahead valuation treat mylan jump doj settlement remove linger concern ariad follow gilead mylan route drug price battle
802,AGN,prothena prta stock nose dive friday political volatility be buy opportunity say rbc analyst michael yee see biotech landing partnership like eli lilly lly pfizer pfe psoriasis drug investor haven be bullish prothena stock rival wednesday ibd company medical biom biotech industry group be worst perform group track share plunge dip day move average ibd take company group be rank group track rise just week share be rake coal wednesday prothena supernus topple markedly check ibd industry theme get idea better stock bet yee chalk weak drug stock late political angst have outperform rating price target prothena stock prothena share close stock market today intraday have fall more entry point touch consolidation investor be advise sell stock fall buy point key take away be recent pullback think be mostly due political uncertainty house senate race be opportunity view company be track very busy full pipeline write research report thursday prothena have key drug line be currently enrolling patient phase phase trial neod drug treat amyloidosis amyloidosis occur normally soluble protein mis fold accumulate become toxic organ yee have confidence neod chance see potential upside price target phase pronto trial show positive datum prothena prx prx be wall street consensus yee say expect duo provide additional upside opportunity prx aim treat parkinson partnership roche rhhby prx be prothena drug psoriasis latter be key consider big pharma interest inflammation drug evidence number allergan agn deal pharma be interested include pfizer eli lilly write think prothena land nice partnership asset phase ii datum summer design also be novel say prothena prx be build science inhibit cell il cytokine be tie inflammatory disease method be used amgen amgn eli lilly novartis nvs psoriasis drug related allergan challenge intercept nash drugeli lilly look coral more animal health business zoetis
803,AGN,allergan agn be take gilead science gild intercept pharmaceutical icpt acquisition tobira therapeutic tbra mizuho analyst irina koffler like deal say key tobira drug have solid chance approval tobira cenicriviroc cvc drug battle nonalcoholic steatohepatitis fail meet primary endpoint year study end july drug however do show efficacy improve fibrosis worsening nash regulatory endpoint nash drug continue change koffler write research report last year fda outlined surrogate endpoint improvement fibrosis worsening nash complete resolution steatohepatitis worsening fibrosis genfit intercept be used surrogate endpoint interim analysis week allergan follow path tobira acquisition be final expect late year likely cvc get fda nod koffler write koffler trim price target tuesday allergan stock base expense expect buyback allergan have be buy spree recently agree acquire vitae pharmaceutical akarna pharmaceutical addition tobira midday trading stock market today allergan stock fall close continue trade day line koffler expect sweeping beat allergan report earning date hasn yet be schedule koffler predict sale vs earning share ex item analyst consensus model sale ep ex item accord thomson reuter koffler keep buy rating allergan stock also lower sale expectation restasis allergan dry eye drug follow impressive launch rival shire shpg xiidra see sale vs earlier call also give viberzi forecast haircut ibd take allergan isn only drugmaker battle rival bristol myer squibb stock topple year low monday positive phase trial news competitor merck get more industry theme related unexpected twist pfizer scraps breakup follow dead allergan mergeramgen biogen pit scenario acadium draw interestgilead allergan see trail intercept ongoing nash battle
804,AGN,biggest breakup drug industry history isn happen pfizer pfe win split half year pharmaceutical giant call extensive evaluation decision follow collapse pfizer attempt merger allergan agn year deal have shift company tax address overseas bulk unit split recent month new york base pfizer have signale stay together operate separate autonomous unit pfizer be already access many potential benefit split sharper focus increase accountability greater sense urgency also retain operational strength efficiency financial flexibility operate single company chief executive officer ian read say statement question now be next biggest drugmaker pfizer statement say be poise grow business drugmaker most recently agree deal acquire medivation mdvn cancer treatment investor have be wait decision goldman sachs analyst suggest company soon pfizer begin reorganize business eventually become distinct unit cash generate business older patent medicine growth focuse operation product dependent more recent research development ibd take biotech stock have be healthier stock recent week takeover talk have be key factor amgen biogen be most likely buyer investor see slew potential takeover target share fall percent et stock market today pfizer stock have gain percent march drugmaker indicated meeting goldman sachs analyst be willing consider breakup comparable percent increase standard poor index same period well percent jump health care sector index decision doesn affect financial guidance pfizer reaffirm unit have deliver solid year year performance course past year demonstrate ability compete standalone basis pfizer say
805,AGN,election year have add pressure hit biotechnology stock hard look hood sibling biotech etfs be reveal show more speculative company extremely heterogeneous industry cause much hurt bioshare biotechnology product bbp be year date oct invest establish company have bring least drug market stock holding exchange trade fund include biogen biib amgen amgn celgene celg gilead science gild regeneron regn ibd take largest cap weight biotech etfs stand benefit most top company climb wall worry have build industry bioshare biotechnology clinical trial bbc be so far invest young smaller company drug be experimental testing stage portfolio include sarepta therapeutic srpt share rocket september fda approve drug treat duchenne muscular dystrophy approval mean sarepta move bbp portfolio bioshare etfs next rebalance december etf pair allow investor decide much mix term combine more risky less risky biotechs say paul yook founder bioshare bbp focus household name make relatively less volatile fund contrast bbc hold riskiest biotechs highflying company share double triple overnight crash burn just well yook describe bbp bbc only exchange trade fund separate clinical trial company product company distinct stand alone investment investor don seem much enamored idea custom tailor risk fund be extremely small thinly trade nearly year debut have however see combine net inflow first quarters bbp fund be best performer biotech etfs so far year bbc worst meanwhile bellwether ishare nasdaq biotechnology ibb have give year date sit december high biotechnology etfs crumble past year come pressure lackluster earning well negative scrutiny health care peer valeant pharmaceutical vrx mylan myl politically charge season wall worry industry group least analyst have favorable outlook biotechs nov presidential election yook point promising sign pickup mouthwater sticker price target company allergan agn announce september acquire vitae pharmaceutical vtae roughly premium share biotechs be attractively price too be rare corner stock market valuation be cheaper have be historically yook tell ibd phone interview many etf investor be wait buy biotechnology stock november election believe fear hillary clinton presidency be price democratic presidential contender remark drug price gouge have trigger sharp biotech decline yook add most political scrutiny be face specialty pharmaceutical company such valeant mylan horizon hznp bioshare fund avoid related top biotechs climb wall worry rbc call rally
806,AGN,share tobira therapeutic tbra multiply more fold tuesday allergan agn agree buy liver drug maker much allergan seek gain late stage experimental drug treat liver disease most anticipate category biotechnology pay share tobira cash accord statement tuesday base number share outstanding allergan also agree pay share tobira hit certain sale regulatory goal even tobira fail hit goal lower price be time close price monday close tobira share have catapult nearly near share share continue climb hour gain nearly recent action allergan end trading day tobira base south san francisco be develop several treatment nonalcoholic steatohepatitis know nash severe type nonalcoholic fatty liver disease hefty premium show important therapy disease have become biotech company gilead science gild intercept pharmaceutical icpt work experimental therapy treat
807,AGN,eli lilly lly abbvie abbv top credit suisse evaluation pharmaceutical company head leave more challenged pfizer pfe astrazeneca azn nordisk nvo dust pharmavalue list do little ibd company medical ethical drug industry group fall fraction stock market today fifth consecutive day group be more year touch month low monday be trading day move average ibd take biotech pharmaceutical stock have be trample last month earning report come climb wall worry credit suisse rank big pharma stock factor enterprise value net present value pricing replacement power sale growth overall eli lilly top list europe base sanofi sny novartis nvs trail closely abbvie rank highest fundamental investor likely assume long life span humira credit suisse analyst write research report humira be brand name adalimumab abbvie drug treat arthritis plaque psoriasis ankylose spondylitis crohn disease ulcerative colitis abbvie stock slip small fraction monday lilly stock fall nearly meanwhile pfizer be weak board astrazeneca have high ev npv enterprise value net present value nordisk be expose pricing pressure astrazeneca investor be potentially factor oncology pipeline credit suisse say recent result other demonstrate significant risk teva pharmaceutical teva score well ev npv valuation most sale power drive generic division gilead science gild incyte incy vertex pharmaceutical vrtx be trading discount vertex only need minimal further pipeline success justify current valuation report say biotechs vertex top credit suisse list amgen amgn flail bottom pharmaceutical ibd company medical biom biotech industry group have be month group fall fraction monday ethical drug group also fall fifth straight trading day fall seventh day past trading day bottom overall astrazeneca score well term pricing power shift oncology product nordisk be eye diabetes rebate storm credit suisse say pricing power credit suisse analyst note be important help company resist discount pressure formulary manager government regard allergan agn be clear winner only shire shpg rivale dry eye market alexion pharmaceutical alxn focus rare disease be most exceptional biotech analyst say biomarin bmrn incyte vertex also get high mark be unique bristol myer squibb bmy eli lilly beat cohort productivity ability drive current pipeline follow dramatic seesaw bristol myer squibb merck mrk bristol myer lung cancer drug opdivo fail meet key endpoint eli lilly score well launch trulicity diabetes taltz psoriasis
808,AGN,unexpected twist pfizer pfe decide splitting monday end year analyst speculation have be biggest corporate breakup history decision follow extensive evaluation speculation begin goldman sachs suggestion pfizer consider breakup accord bloomberg follow year pfizer begin reorganize become essential health innovative health business unit pfizer stock close stock market today tug ibd company medical ethical drug industry group fall pfizer market cap make second largest company group value roche rhhby pfizer be trading month low touch share hit year high aug ibd take biotech fodder be head just recent story ibd industry theme column new tax rule april force pfizer scrap merger allergan agn new rule pfizer wouldn have be allow shift tax address overseas do so have help pfizer bulk ahead expect breakup pfizer ceo ian read say monday statement pfizer be already reap benefit split sharper focus increase accountability greater sense urgency also retain operational strength efficiency financial flexibility operate single company innovative health essential health unit have deliver year solid year year performance pfizer say august earning announcement pfizer say innovative health sale rise year year essential health grow overall pfizer report growth sale first explore trap value question several year market valuation other company suggest business be worth more separate company be together single company say pfizer cfo frank amelio statement then gap have close say essential health be focuse older patent medication innovative health drife spending growth oriented product pfizer expect duo become market leader end acquire anacor innovative unit recently add hospira innopharma essential unit work close acquisition medivation mdvn astrazeneca azn small molecule infective business pfizer reiterate outlook plan begin give guidance indirect expense incur business unit related axovant confidence not sway rival alzheimer drug failsliver disease get attention several major biotech companiesaerie pharmaceutical skyrocket eye drug news
809,AGN,ibd company medical biom biotech industry group drop past week rbc analyst michael yee expect stock rally lackluster earning election season wrapped sector still have nearly week choppiness nov election recent blowout have have investor take profit yee suggest recent video buy dip biotechs climb wall worry earning not be hugely great biotechs combination uncertainty election understand trade choppy spdr biotech etf xbi get clarity election say ibd take biotechs be worst perform group wednesday ibd track group last month biotechs be major roll keep tab industry theme sector grab attention company group share spdr biotech etf have plunge dramatically month past week thursday share be flat entry point flat base biggest biotech player yee be most confident amgen amgn biogen biib respectively no market cap stock market today amgen biogen rise fraction respectively consensus analyst poll thomson reuter expect amgen report sale earning share ex item flat respectively vs year earlier quarter analyst model biogen report sale ep ex item biogen be stock own next month yee say chance biogen get take still lack ceo company announce july rumor george scango step yee also see chance eli lilly lly alzheimer drug trial yield positive result tug rival biogen other catalyst include biogen partnership ionis pharmaceutical ion drug treat type muscular dystrophy spinal muscular atrophy sma ionis be enrolling infant child phase trial sma wall street underappreciate catalyst yee say celgene celg too have number trial stoke stock yee say analyst model jump sale ep ex item celgene share be rise small fraction thursday yee only expect line quarter early next year celgene be expect release result trial drug treat muscular dystrophy crohn disease ulcerative colitis be likely stock catalyst gilead gild biotech market cap be rough quarter shadowy visibility hepatitis drug yee say drug epclusa win fda approval june be used pill form treat type hep lack greater visibility gilead stock be range bound yee say consensus expectation be too high hep sale ep write research report consensus analyst poll thomson reuter model ep ex item yee estimate be broadly analyst be bearish gilead forecasting sale dip ep item share be past week end thursday flat smaller intercept pharmaceutical icpt market cap likely print board beat yee predict share have be pressured recently gilead novartis nvs allergan agn be jump nash alcoholic steatohepatitis train nash drug have make big headline past month allergan buy tobira therapeutic tbra bulk nash battle say yee intercept drug belong class call fxr agonist be more potent intercept drug get liver activate fxr farnesoid receptor liver say other don get much fxr effectivity liver just do gut not potent intercept yee also call prothena prta own likely positive parkinson drug psoriasis drug datum spring respectively prothena stock be sell zone thursday entry point achieve rise nearly thursday related gilead try buy next poll offer incyte prothena build psoriasis science arthritis treatmentincyte stoke fire deep durable melanoma drug result
810,AGN,medical behemoth amgen amgn biogen biib square acquire muscle biologist cytokinetic cytk more dozen potential player prep donnybrook small cap pharmaceutical adms needham analyst suggest friday biotech fodder heated week allergan agn announce back back deal acquire vitae pharmaceutical vtae tobira therapeutic tbra tobira deal give allergan leg battle nonalcoholic steatohepatitis nash gilead gild intercept icpt pharmaceutical also compete ibd company biotech industry group have climb group track just week collectively group have market cap group group fall friday first decline past trading day group be week needham analyst review pipeline business development area interest activity large company gauge interested big pharma be biotechs important theme biotech space write research report allergan amgen bristol myer squibb bmy johnson johnson jnj merck mrk pfizer pfe roche rhhby shire shpg valeant vrx have be most acquisitive buy prep buy more company collectively shire have be most active acquisition believe late development stage commercial stage biotech company be particularly attractive acquisition target write research report title do big pharma want buy peak area interest include oncology cardiovascular needham research show not be big pharma take beaucoup buck needham analyst suggest central nervous system cns player acadium pharmaceutical liver disorder drugmaker intercept be prime acquisition interest firm overlap potential interest acadium abbvie abbv allergan eli lilly lly lundbeck merck novartis pharmaceutical nvs teva pharmaceutical industry teva takeda pharmaceutical needham list potential acquirer allergan make particular sense consider duo already partner next generation formulation memantine fix dose combination product namzaric battle alzheimer year end plan file new drug application food drug administration ad treatment levodopa induced dyskinesia involuntary movement parkinson disease patient multiple sclerosis walking impairment needham write meanwhile acadium potential suitor be interested nuplazid drug ease psychosis associate parkinson launch earlier year needham suggest acadium be look expand label other used similarly intercept draw interest nearly dozen potential buyer include gilead biotech market cap thursday rbc analyst posit intercept continue lead gilead allergan battle nash ibd take biotech stock notch higher week last week check ibd industry theme
811,AGN,medical behemoth gilead gild be trail intercept pharmaceutical icpt battle nonalcoholic steatohepatitis nash liver disease credit suisse analyst alethia young say thursday day botox maker allergan agn jump agreement acquire tobira therapeutic tbra larger gilead allergan market cap be later nash race intercept market cap intercept begin enrolling phase trial september expect complete enrollment early next year ibd take shove stick eye avoid daily eye drop treat glaucoma glaukos help check ibd new america intercept handful rival be attempt treat nash target fxrs farnesoid receptor class protein find liver intestine fxrs be stoke regulate carbohydrate lipid metabolism bile acid homeostasis fibrosis tie nash newer player be look used bile acid fxrs departure intercept chemistry still intercept phase flint trial be most mature datum set space show significance fibrosis liver histology base pre specify parameter young write research report long term young see room nash space many player intercept be more successful gilead success rate vs respectively predict intercept also have contend novartis nvs encanta now allergan allergan enter race tuesday plan acquire tobira get leg nash treatment yet tobira cvc cenicriviroc miss goal improve nonalcoholic fatty liver disease naflad activity score activity score be severity measurement patient likely have nash tobira cvc successfully reduce fibrosis worsening nash patient vs treat placebo comparatively intercept phase trial ocas obeticholic acid improve fibrosis patient vs receive placebo now allergan expect combine tobira cvc diabetes treatment preclinical bile acid fxr akarna encanta have bile bile fxrs likely slate human trial soon combine treatment be key young predict think combination regimen be important part treatment paradigm think intercept be position well here long term young write have outperform rating price target intercept stock afternoon trading stock market today intercept stock rise be nearly so far month share be buy zone third consecutive day pivot buy point double bottom base gilead science share fall allergan climb
812,AGN,be call silent epidemic slowly wasting away liver million american doctor have paltry understand disease approve treatment now alcoholic steatohepatitis nash be sight more dozen drugmaker allergan agn become latest tuesday announce deal acquire nash treatment less hour race company startup intercept pharmaceutical icpt giant include gilead science gild pfizer pfe reach untapped market be worth year accord estimate rbc capital market corp analyst michael yee drugmaker still be try determine different component disease inflammation scarring metabolic change interact be experiment variety treatment mechanism so many company pile field ll have work distinguish re look something get factor say alex depaoli chief medical officer closely hold ngm inc have nash partnership merck co mrk want develop something pop eye nash occur fat accumulate liver inflammation damage much quarter population have precursor condition call alcoholic fatty liver disease ailment develop slowly patient often don show symptom liver be heavily damage most common person be overweight have diabetes doctor mainly prescribe diet change weight loss ibd take medical biom biotech sector be run hot rank eighth ibd industry group sector be lead supernus pharmaceutical supn more be find here doctor need perform biopsy diagnose nash person alone be estimate have condition go develop life threaten cirrhosis nash be lead cause liver transplant accord allergan drug treat likely command high price elizabeth krutoholow analyst bloomberg intelligence say head race be intercept french biotech firm genfit large trial underway tobira therapeutic tbra allergan agree buy tuesday much be prepare recruit patient final stage study investor also be watch result gilead mid stage trial be expect be present year acquisition news tobira share soar more tuesday share be afternoon trade wednesday intercept be testing ocaliva already approve treat rare liver disease call primary biliary cirrhosis nash enrollment final stage trial person be expect be complete next year interim result due potential concern be earlier trial patient experience itch take drug case so severe interfere basic activity chief executive mark pruzanski say interview hope ocaliva become backbone treatment used combination other drug genfit be develop once day treatment raise fat metabolism fight inflammation treat underlie cause fibrosis dean hum genfit chief scientific officer say interview fail meet primary goal mid stage trial last year show promise subset patient moderate severe form disease final stage trial moderate severe patient be underway company have datum late startup biotechs biggest company be pay attention ready do deal merck say pay much partnership ngm gilead maker blockbuster hepatitis drug sovaldi harvoni buy nash drug nimbus therapeutic llc include milestone payment gilead also buy drug phenex pharmaceutical ag much gilead now have nash candidate portfolio have datum later year drug target different aspect disease be develop individually be used potent cocktail allergan tobira be biggest nash deal so far tuesday company also announce purchase akarna therapeutic ltd developer nash treatment pfizer biggest drugmaker be future acquirer have nash drug trial more be test human end year nash be major priority say morris birnbaum chief scientific officer cardiovascular metabolic disease company be try treat disease early stage win be easy genfit tobira mid stage trial fail raptor pharmaceutical rptp end program datum be start come study lot confidence be build lose say jay luly chief executive enanta pharmaceutical enta begin testing experimental treatment patient year same expect happen money
813,AGN,drugmaker allergan agn get upgrade mizuho friday base expectation solid product sale lower guidance analyst irina koffler write consensus estimate now reflect allergan guidance cut earning report month give stock potential upside add individual product sale include botox new double chin treatment kybella show management guidance organic sale growth be feasible strong fall push kybella dtc direct consumer promotion also drive increase utilization botox dermal filler view write upgrade note key say be execution be hard part write management need contain cost launch new product advance pipeline koffler upgrade rating buy neutral price target allergan stock edge close stock market today allergan stock remain day line carry weak relative price strength rating just putt performance lower fifth stock past month ibd take analyst trim allergan forecast guidance cut be reflect ibd estimate revision metric now show warning red stock checkup editor note story note new price target analyst koffler issue correction earlier research note
814,AGN,opec member agree production cut essentially give drive shale producer european bank wo briefly rattle financial market number possible twitter twtr buyer expand nike nke beat earning view give weak guidance order major average rise modestly week due friday solid gain deutsche bank db concern ease close just day move average trading key level most friday oil price surge opec deal cut output give big boost shale producer other energy stock biotech fiber optic several retail group fall fall september rise third quarter nasdaq advanced september organization petroleum export country say cap output barrel day essentially give year effort drive shale production cartel win enact cut november full detail individual production quota be likely be firm official opec meeting august opec production be barrel day energy information administration say inventory fall barrel vs barrel increase analyst expect fall fourth straight week production slide gasoline stockpile rise barrel number oil rig operation rise yet again week month high oil future rise barrel week fuel shale stock oil price dip quarter related oil hit month high opec blink vs shale deal fraysdeutsche bank db sank fresh record lows thursday grow capital concern report hedge fund be longer willing act counterparty european banking giant share rebound friday close week higher report deutsche bank justice department be settlement commerzbank say cut thousand job credit suisse cs warn difficult third quarter speaking congress fed chief janet yellen say politic do not factor interest rate policy contrary accusation make gop presidential nominee donald trump also discuss potential plan boost big bank capital requirement annual stress test well fargo wfc ceo john stumpf give stock award fight save job next day house panel skewer bank cross selling scandal week senator do same well share fall lowest level february other big banking stock test support day move average related banking giant gain deutsche bank european financial teeterconcern mount deutsche bank hedge fund withdraw cashwell fargo ceo stumpf ex top exec give stock award beat top bottom line sank month low expect future order product schedule delivery retailer particularly light north america future be fuel concern competition armour ua adida nike plan give figure less prominence future order revenue correlation decline related nike pepper red flag armour adida take big merger be discuss latest week few formal takeover related play cbs viacom courtship scenario twitter acquisition chatter get twitter treatmentnxp semiconductor rocket qualcomm acquisition reportadobe microsoft forge cloud partnership be full merger next pfizer scraps breakup follow dead allergen mergerspacex tesla motor tsla ceo elon musk describe fleet spacecraft be used colonize mar estimate investment realize project annual international astronautical congress guadalajara mexico musk also say hope complete developmental spaceship year spacex isn publicly trade event come musk try rally support tesla acquisition bid sister company solarcity scty critic see mar plan distraction tesla be already surround doubt ambitious car production target september consumer confidence index rise best level august last recession start economy rise upwardly revise annual rate still weak help less negative read business investment structure august durable good order be flat core capital good order edge higher new home sale fall sharply august less expect hit cycle high july pending home sale fall lowest level january next week ll get reading manufacturing well monthly job report related consumer confidence rise year high home sale fall lowest level januaryvail mtn report loss share narrower year loss share share loss analyst have expect vail revenue rise view get boost epic discovery summer park activity vail share fall find support day line carnival ccl say earning exclude fuel hedge other item rise share beating analyst view cent revenue climb view cruise line operator see ep cent midpoint analyst view cent carnival share initially fall report rebound close week day line rv maker thor industry tho earn share vs year earlier crush view revenue climb beating estimate be best sale gain quarters thor industry rise hit new high
815,AGN,allergan agn acquire gene therapy eye disease tuesday ceo separately criticize predatory drug pricing pledge limit company price increase allergan agree pay upfront acquire retrosense therapeutic unspecified future milestone payment tie success rst gene therapy eye disease retinitis pigmentosa spark therapeutic once have gene therapy same disease late stage development platform take different approach note evercore isi analyst umer raffat spark gene therapy be only aim specific defect however retinitis pigmentosa be cause very heterogeneous set mutation encompass gene raffat write email client simple word allergan approach theory address heterogeneous disease irrespective mutation cause ibd take spark therapeutic stock have be hover buy point breaking cup handle base early last month learn more basis see ibd buy stock allergan stock rise stock market today still more year spark stock fall more year also tuesday allergan ceo brent saunder write blog post drug pricing lately have be tremendous focus cost medicine have be very appropriately target outlier have take dramatic price increase write naming name doubt refer political outcry mylan myl epipen last couple week saunder go detail see social contract drugmaker public say such price increase violate other thing make specific promise regard allergan price increase increase price brand therapeutic medicine take price increase more once year do be limit single digit percentage increase expectation be overall cost drug net rebate discount not increase more low mid single digit percentage year slightly current annual rate inflation saunder also say allergan stop increase price be corresponding increase cost practice often take drug near patent expiration practice allergan have take past admit related allergan carve middle path spending open science be epipen price fda fault
816,AGN,federal reserve say case rate hike have strengthen stock rally policymaker indicated path increase be even slower congress grilled big ceo federal government announce autonomous drive guideline yahoo yhoo facebook fb make embarrass disclosure nasdaq climb time high fuel fed decision further lower likely rate hike trajectory rise close day retake key support thursday oil metal mining stock fared well retail group struggle federal reserve hold interest rate steady wednesday signale hike key rate december still market be pleased fed member own projection point just hike meanwhile bank japan say intervene keep year government bond yield roughly say now aim overshoot inflation target neither move currency impressed investor yen rise close year high boj meeting divide fed hold rate hike see slower tighten pathnote fed job market just take wrong department transportation unveil long await federal autonomous vehicle guideline new rule provide tesla motor tsla ford motor alphabet googl general motor gm other be develop self drive car framework safety guideline pre empt state law dot say new guideline be root view automate vehicle hold enormous potential benefit safety mobility sustainability alphabet be early pioneer self drive car tesla have be most aggressive push technology tesla update autopilot driver assistance technology greater emphasis radar apple aapl reportedly have hit brake develop car house have approach mclaren technology group british luxury car maker possible acquisition financial time report new york time report apple have hold talk mclaren investment company mclaren deny report say company be not discussion apple respect potential investment related tesla just make big move be key futureapple talk buy luxury car maker mclaren reportyahoo yhoo disclose confidential information be take least user account late likely state sponsored actor password be steal not payment information yahoo urge user change password security question haven be update unclear affect sale yahoo core operation verizon vz include regulatory legal issue yahoo share fall week twitter twtr share spiked friday report struggle social network be mull putt sale salesforce crm alphabet googl possible buyer facebook fb disclose late thursday give advertiser inflate figure long person watch video year facebook fall move slightly buy point be good week initial public offering most active week year winner be apptio apti cloud provider information technology management tool pop first trading day friday tech winner digital ad company trade desk ttd jump first trading day wednesday low cost cosmetic provider beauty surge trading debut thursday cloud vendor twilio fiber optic company acacia communication acia japanese messaging firm line ln have help boost outlook ipos be forecast shift high gear rest year ipos earlier year have see strong gain twilio twlo hit new high week largest ipo week be valvoline vvv quick lube chain auto lubricant maker raise adobe system adbe late tuesday say earn cent share exclude item year year sale fiscal third quarter end current quarter medium marketing software company expect gaap earning share cent sale top view adobe share rise nearly record high enterprise software provider red hat rht wednesday also beat view earn cent share item sale fiscal end aug give guidance top wall street expectation share rise more shipping giant raise full year ep outlook exclude tnt express related acquisition cost previous guidance slower economic growth prospect say integration dutch company be go smoothly fedex fdx report fiscal ep jump beating estimate revenue climb top view company also reiterate boost shipping rate service fedex share jump nearly gapping day average hit highest level june exist home sale unexpectedly fall second straight month august housing start decline more expect builder sentiment gauge rise year high meanwhile kb home kbh report better expect earning lennar len also top earning order margin fall lennar also buy wci community wcic fed slower rate hike path also be good news housing sector related exist home sale unexpectedly fall august ratebotox maker allergan agn jump tuesday battle nonalcoholic steatohepatitis nash announce plan acquire tobira therapeutic tbra tobira stock shot tuesday later day allergan paid akarna therapeutic nash developer nash avenue allergan compete gilead gild intercept icpt novartis nvs enanta enta also last week allergan announce plan buy vitae pharmaceutical work combat psoriasis eczema autoimmune disorder ophthalmology gene therapist retrosense various opec member hint support output curb ahead informal meeting top opec opec producer algerium week other downplay likelihood decision oil price rise barrel week drop friday energy information administration say wednesday crude stockpile fall barrel barrel month low gasoline inventory fall barrel pioneer natural resource pxd chief executive scott sheffield tell bloomberg oil rig be add permian next year join eog eog diamondback energy fang chevron cvx other bullish texas play france total tot say cut overall investment year related texas shale leader see permian boom french oil major cut backmylan myl ceo heather bresch be lambaste wednesday congressional meeting probe company price tag pack lifesave epipen used allergy treatment bresch argue mylan only profit pack republican democrat alike criticize benefit facto monopoly epipen still mylan stock rise fractionally week well fargo wfc ceo john stumpf become senate panel punch bag tuesday sen elizabeth warren mass urge resign bank cross selling scandal stumpf say learn issue say be deeply sorry sale practice bank say be end retail banking sale goal authority say well employee start least open unauthorized consumer account attempt hit sale target analyst say financial fallout fine regulator investigation intensify appear limit now share rise week drop nearly prior week goldman sachs communacopia medium conference big medium seem unworried cord cut cbs cbs chief moonfe say netflix nflx star trek licensing right deal paid cost cbs new star trek series disney ceo bob iger be already think star war film slate time warner twx st century fox foxa exec wave less well receive summer movie related netflix lose key support subscriber churn concernsnetflix star trek deal help cbs chief moonfe sleep nightdisney already look star war film next decade
817,AGN,cloud juggernaut adobe system adbe win slew price target hike wednesday raymond james downgrade american airline group aal stifel upgrade puma biotechnology pbyi raise price target clovis oncology clvs adobe late tuesday beat wall street fiscal third quarter target raise fourth quarter guidance forecast creative cloud juggernaut deliver upside growth subscription revenue say brent bracelin pacific crest analyst report pacific crest hike price target piper jaffray increase price target rbc capital rw baird pivotal research canaccord genuity also hike price target adobe share jump more record high close wednesday raymond james downgrade american airline market perform raymond james upgrade latam airline group lfl market perform lower fuel price boost ibd transportation airline group now rank industry group american stock lose close related american follow unite capacity outpace trafficamid acquisition spree biotech sector stifel upgrade puma biotech buy hold raise price target stifel hike clovis oncology price target cowen co upgrade clovis outperform price target allergan agn acquire tobira tbra tuesday surge more tuesday puma be close wednesday clovis add finish score more gain tuesday related sarepta muscular dystrophy drug cost acquisition target mizuho security initiate coverage splunk splk neutral rating price target share rise close company capitalize differentiate product strong customer momentum ample runway growth give large market opportunity however give model transition see risk term license revenue trajectory well profitability gain management aggressively invest growth say analyst lamba report other analyst move william blair initiate coverage boston beer sam outperform rating cowen co downgrade beer maker underperform morgan stanley downgrade skecher skx equal weight jpmorgan downgrade wix com wix neutral
818,AGN,recent wall street darling sarepta therapeutic srpt isn only potential takeover candidate hot potentially hot biotech company say rbc capital market research report wednesday rbc analyst list ariad pharmaceutical aria spark therapeutic once biomarin pharmaceutical bmrn aerie pharmaceutical aeri intra cellular therapy itci tesaro tsro incyte incy puma biotechnology pbyi well sarepta top takeover contender late stage fda approve blockbuster franchise sarepta stock rocket monday fda approve drug treat duchenne muscular dystrophy first drug approve treat rare disease sarepta stock hit time high wednesday first time march sarepta close stock market today close sarepta announce plan offer stock finance further trial production other drug effort share be little change late ibd company medical biom biotech industry group rise wednesday sixth straight gain touch month high intraday group rank group track just week second half be likely prove rally point biotech stock rbc analyst say biotech sentiment continue improve investor climb wall worry get year past election believe have be mostly base political rhetoric analyst write ibd take many biotechs fair number stock overall have recently hit week high check stock list composite rating ibd new high list be good feature check winning stock furor have be heating biotech sector past month biotech acquisition value have be announce rbc say smattering smaller deal tuesday allergan agn announce agreement acquire liver disease drugmaker tobira therapeutic tbra much big deal pending pfizer pfe be buy medivation mdvn june buy anacor pharmaceutical also abbvie abbv be acquire privately hold stemcentyrx shire shpg baxalta complete merger june related sarepta soar fda approve drug treat muscular stock hot sarepta provide shot arm
819,AGN,ibd medical biom biotech industry group rise tuesday month high third straight trading day outperform wishy washy overall market await fed announcement wednesday end day meeting company group ibd second biggest finance etf be early afternoon trading stock market today touch highest price jan group rank week week week ibd take look depth report top perform industry group ibd industry snapshot be first port call fiber optic mining be industry recently profile sarepta therapeutic srpt continue help spark group rise second day fda approval early monday drug treat duchenne muscular dystrophy dmd send share soar sarepta stock end trading tuesday nearly ptc therapeutic ptct also work dmd treatment fall close jump month high monday amphastar pharmaceutical amph jump record high gain nearly news join smallcap index replace cirrus logic crus apple aapl chip supplier be move midcap puma biotechnology pbyi finished day company say fda have accept new drug application breast cancer treatment neratinib big mover be intercept pharmaceutical icpt jump close allergan agn announce have agree buy small tobira therapeutic tbra time market value tobira intercept be develop drug treat nonalcoholic steatohepatitis nash common liver disease lead cancer diabetes related sarepta see possible takeover target drug approvalcelgene kite vertex make move september
820,AGN,number biotech stock rise wednesday biotech be few group hold well time market uptrend be pressure sarepta therapeutic srpt stock jump wednesday month high be recover huge decline early year last week food drug administration staff member have argue approval key sarepta drug left fda job private sector raise hope drug approval multiple medium source report wednesday sarepta drug be eteplirsen treat duchenne muscular dystrophy fda continue review drug exit fda staff member dr ron farkas be sarepta drug not biggest needham analyst chad messer say research note wednesday hike price target sarepta stock farkas be not only skeptic frankly do not believe personally hold enough power be decide factor messer write instead messer say company likely provide desire trial result support approval drug sarepta have plenty company upswing wednesday ultragenyx pharmaceutical rare get bullish report credit suisse wednesday ahead friday start annual meeting american society bone mineral research credit suisse expect ultragenyx report solid trial result drug treat xlh bone disease symptom include leg bow childhood dental abscess long term medical therapy be usual diagnosis disease ultragenyx stock rise stock market today touch month high remain deep price consolidation ibd company biotech industry group rise wednesday group have be move now ranking group week week week ibd take group be rise almost surely soon be featured ibd weekly industry snapshot not already good idea regularly check feature deep dive best perform industry group ishare nasdaq biotechnology etf ibb rise monday gain biggest day jump june etf be form base buy point ariad pharmaceutical aria rise extend july seattle genetic sgen jump also extend july bluebird bio blue soar month high try recover severe decline rise send exelixis exel soar year high too be extend research note wednesday rbc capital market point related group say select pharma name be begin show sign stabilize bottom mnk agn allergan agn stock rise wednesday mallinckrodt mnk rise related top new issue patheon help turn new idea realitycelgene kite vertex be biotechs watch september
821,AGN,drug industry merger acquisition continue wednesday pharma company sell core asset british giant astrazeneca azn agree sell small molecule biotech antibiotic pfizer pfe upfront payment january milestone payment depend drug still pipeline make market portfolio include already commercialize drug merrem zinforo zavicefta treat range serious infection well late stage pipeline candidate drug resistant infection allergan agn hold north american right zavicefta zinforo continue do so pfizer acquire international right ibd take pfizer size patent loss have keep be big growth stock lately lead dividend stock outlined recently ibd column income investor move fit astrazeneca strategy focuse choose area oncology respiratory autoimmunity cardiovascular metabolic disease pfizer add exist portfolio more infective continue reshape essential health portfolio be focuse area further address global public health need complement core capability experience therapeutic area john young head pfizer essential health say statement deal be expect close pfizer stock close lower stock market today astrazeneca stock fall meanwhile specialty drugmaker mallinckrodt mnk say selling diagnostic nuclear imaging business belgium base iba molecular fact mallinckrodt have not especially related business specialty drug imaging come peculiar history be more diversify company tyco international tyc buy tyco spun medical business covidien now part medtronic mdt then covidien spun mallinckrodt other division be strip spinoff drug business have be grow much faster imaging business so sale have be widely expect deal have clear unusual regulatory hurdle include approval nuclear regulatory commission committee foreign investment unite state so company say close first half mallinckrodt stock drop set month high intraday related pfizer medivation deal reignite biotech buyout speculation more drugmaker beat estimate guidance mixed
822,AGN,here investing action plan thursday need know investor come day oracle orcl report quarterly earning close tomorrow precede datum dump key economic indicator meanwhile share casino giant la vegas sand lvs wynn resort wynn mgm resort mgm well several medical stock
823,AGN,share valeant pharmaceutical international vrx be rise monday company continue fill new management lineup appoint new chief financial officer valeant nab paul herendeen animal health company zoetis zts have be executive vice president last year also be cfo number year warner chilcott buyout company eventually become allergan agn valeant current cfo robert rosiello become head corporate development strategy role cfo be crucial valeant recent accounting scandal result company restate last couple year earning rosiello wasn implicate trouble really happened june appointment previous cfo howard schiller take most heat valeant audit committee produce report march same time ceo michael pearson quit ibd take valeant become poster child drugmaker rely price increase goose revenue learn much other big cap drugmaker be rely price vs demand rbc capital market analyst dougla miehm write change be probably due match talent job view new role mr rosiello favorably work mckinsey year have advise company health care consumer product technology sector venture operational strategic initiative miehm write research note valeant stock rise stock market today just second day past month rise also have be fuel wider bounce drug stock view buyout target light pfizer pfe buyout medivation mdvn valeant earning call ceo joseph papa say be prepared sell worth asset wall street have wonder buyer acquire entire company now week high related
824,AGN,wal mart wmt apply material amat score price target increase friday strong earning thursday allergan agn be upgrade buy wal mart price target be raise telsey advisory rbc capital market thursday discount giant report earning sale view strong sale home toy sporting good earlier month wal mart agree buy jet com try compete online sale amazon com amzn wal mart share finished lower stock market today wal mart hit month high thursday apply material price target be raise rbc capital cowen late thursday chip gear maker report record earning issue guidance beat view share jump close allergan be upgrade buy have price target raise mizuho cite improve outlook less risk allergan share edge brand lb be upgrade sector perform underperform rbc capital have price target raise telsey advisory fbr capital operator victorium secret bath body work store top quarterly estimate wednesday brand share dip ibd take brand be weaker apparel retailer several name have break earning include ross store lululemon athletica compare brand other retail group stock checkup buffalo wild wing bwld be downgrade underperform longbow research share fall related
825,AGN,allergan agn share fall monday specialty drugmaker report mixed quarter guidance allergan result be complicate recent activity last week announce selling generic drug distribution business teva pharmaceutical industry teva thus exclude segment discontinue operation report analyst consensus have not yet adjust allergan spokesman tell ibd shave sale cent ep adjustment top bottom line come slightly ahead expectation represent operate growth year earlier quarter respectively however allergan also slightly lower full year guidance sale brand drug previously have say monday set range also give full year ep guidance first time midpoint low side wall street number ibd take allergan busy history have not only complicate financial have also drive many stock move such drop april pfizer end buyout deal company ibd prefer judge stock fundamental describe slim investing system foreign exchange headwind drive allergan revenue guidance decrease leerink analyst jason gerberry write fundamental be look good biggest driver top line outperformance be restasis dry eye legacy woman health product estrace cream loestrin gerberry write research note overall quality result be strong botox dermal filler achieve mid teen year year growth allergan exit quarter strong balance sheet recent divestiture generic distribution business have bring increase focus business allergan stock close stock market today
826,AGN,usual specialty generic drugmaker come fore earning season near end several interesting stock deck allergan agn report early monday have somewhat complicate financial just sell huge generic business teva teva have be count discontinue operation deal lengthy approval process exclude consensus sale estimate be flat vs year earlier quarter ep estimate share be modestly accord leerink ibd take outfit look acquire biogen have pay pretty price biogen boost buyout rumor be latest ibd big cap screen company deliver big gain have less volatility smaller stock teva deal close aug leave allergan fat wad cash fuel buyout speculation already anonymously source report have company explore acquisition biogen biib allergan stock trade mostly flat week close friday fraction valeant pharmaceutical vrx be look shrink quarter report early tuesday continue recent wo pricing pressure profit be see fall share sale drop company accept broad price cut partnership year walgreen wba stock rise july walgreen make positive comment deal own earning report valeant be start launch oral version constipation drug relistor be near possible launch psoriasis drug brodalumab have skeptic wall street valeant stock more week high close week fraction lower jazz pharmaceutical jazz report close tuesday be still growth train sale expect climb profit share jazz stock be still elevated rise nearly july patent board reject competitor request review patent jazz lead drug xyrem have be subject increase patent challenge age overall share be high however end week fraction also late tuesday generic drug giant mylan myl be expect record sale growth profit gain share company launch new generic drug alone pricing pressure space have be issue last few quarters mylan close buyout swedish rival meda friday deal be not hugely popular investor be announce february combine earning miss drive stock re-cover somewhat then friday mylan stock close week
827,AGN,yahoo yhoo nike nke be largest stock purchase make hedge fund manager second quarter apple aapl netflix nflx be top sale say analysis factset research top hedge fund sell worth netflix stock more other company say factset selling be lead vike global investor reduce stake tiger global exit stake worth netflix stock fall be roughly quarter netflix stock dip stock market today hover just day move average apple be stock sell second most hedge fund last quarter be top sale factset say top hedge fund reduce position apple tiger global greenlight capital adage capital cut stake apple apple stock fall be be then apple stock ease wednesday end ibd take apple be battle retake short term day line day line be area swing trader other short term investor focus apple have be run day line late july gap monday begin struggle stay line learn more find evaluate stock ibd university
828,AGN,microsoft msft be most widely hold stock top hedge fund second consecutive quarter say factset facebook fb allergan agn be other widely hold stock top hedge fund hold position factset say top hedge fund add total worth yahoo stock more other company buy be lead tci fund management increase ownership stake quarter yahoo purchase be make rumor circulate several company be interested acquire core operate business yahoo month verizon communication vz confirm acquire yahoo yahoo stock rise be quarter core internet business yahoo own big stake china alibaba group baba yahoo japan be trade tokyo exchange yahoo stock fall wednesday factset note yahoo be part software service industry group be largest aggregate purchase industry group group top hedge fund also buy stock facebook activision blizzard atvi be fifth eighth largest aggregate purchase respectively nike be second largest purchase top hedge fund add worth nike stock aggregate hedge fund portfolio nike stock fall be then nike stock rise wednesday related netflix pace top subscriber worldwide apple smartphone profit share slip vs samsungyahoo stock rise alibaba stake be tax efficient deal doable
829,AGN,pfizer pfe announce deal monday morning buy medivation mdvn share enterprise value move follow month takeover speculation cancer drugmaker well widespread report sunday imminent pfizer medivation deal medivation rise nearly soon open bell stock market today pfizer fall cent propose acquisition medivation be expect immediately accelerate revenue growth drive overall earning growth potential pfizer pfizer ceo chairman ian read say statement pfizer say deal boost earning share cent first year close additional gain medivation close friday market valuation be slightly extend buy point flat base medivation trade low feb be subject widespread buzz possible buyout biotech earlier year reject share offer france sanofi sny last week report have pfizer merck mrk gilead science gild celgene celg sanofi possible medivation buyer ibd take biotechs deliver great growth be generate profit revenue gain higher sale volume price increase here hunt biotech stock medivation make xtandi prostate cancer drug annual sale rate already have other cancer fighter development pfizer attempt buy allergan agn fall apart earlier year obama administration change rule make tax inversion merger deal less attractive related medivation affirm guidance earning growth make case leadership be convince
830,AGN,share biogen biib shot tuesday report big drugmaker be explore possibility buy company wall street journal say anonymously source report merck mrk allergan agn have talk biogen possibility talk be informal preliminary biogen stock have be slightly day then jump close stock market today hit year high wall street have be toss possibility biogen takeout time rumor start heat ceo george scango announce retirement last week rbc capital market analyst michael yee note video last weekend leave biogen vulnerable takeover especially investor have get restless slowdown company multiple sclerosis franchise risky pipeline most talk pipeline drug be aducanumab alzheimer disease explain merck interest merck be work different class alzheimer treatment call bace inhibitor be think eli lilly lly disease ultimately be treat combination drug allergan inherited drug treat alzheimer symptom acquisition forest laboratory few year so presumably leverage sale force other company be name yee opined roche rhhby also be logical buyer give already have partnership biogen selling lymphoma drug gazyva merck fall tuesday allergan lose roche climb
831,AGN,drugmaker thursday dividend leader have plenty go re not screamer mean be grow nicely compelling pipeline solid dividend yield pfizer pfe look poise clear long consolidation last month share slump nearly week end aug report second straight quarter double digit earning
832,AGN,amazon com amzn price target be hike wedbush security ahead earning citigroup upgrade hewlett packard enterprise hpe buy jpmorgan cut price target general electric ge credit suisse initiate allergan agn suntrust robinson humphrey downgrade cubesmart cube neutral wedbush analyst michael pachter raise price target amazon amazon report earning late thursday year uneven profit amazon finally appear poise deliver substantial earning growth write pachter report expect continue ep growth amazon first outsized earning beat expect revenue high end guidance amazon fall stock market today jpmorgan chase cut price target general electric ge friday report better expect earning thank notable item exclude adjust ep organic industrial revenue dip industrial order tumble ge fall friday just buy point ge stock fall credit suisse initiate coverage allergan outperform rating target price allergan stock fall citi analyst jim suva upgrade hewlett packard enterprise stock buy neutral appreciate free cash flow generation set price target be many move part business divestiture accelerate restructure separation payment believe investor be appreciate fcf free cash flow generation net cash improvement say hewlett packard enterprise rise needham raise price target fiber optic part maker lumentum holding lite oclaro oclr neophotonic nptn strong buy buy ibd telecom fiber optic group be rank industry group needham hike price target lumentum lumentum shot blast buy point ibd take lumentum be work second base come public august hit buy point monday just several strong tech ipos past year check hot new technology issue latest tech leader column suntrust robinson humphrey downgrade cubesmart extra space storage exr neutral buy real estate investment trust reit stock have run grow investor demand dividend pay stock global interest rate have fall cubesmart fall other analyst move pacific crest security initiate coverage level communication lvlt zayo group holding zayo sector perform rating deutsche bank downgrade tableau software datum hold buy credit suisse initiate coverage allergan agn outperform rating price target
833,AGN,stock moved sideway time high week week be packed market move news alibaba baba break growth accelerate acacia communication acia explode fiber optic ipo growth name spark macy trigger huge relief rally wal mart wmt buy jet com better compete vs amazon amzn oil price rebound solar stock crash week dow industrial hit time high nasdaq eclipse peak major index rise fractionally week nasdaq dow close climb point more quality breakout appear retailer energy play hot growth stock lead market earning report higher oil price solar stock tumble weak sunpower spwr guidance reit struggle investor seek growth name worry store closure alibaba report revenue beating wall street consensus estimate revenue rise local currency term best gain alibaba september ipo ep rise cent beating consensus cent jd com report revenue slightly consensus local currency report earning share cent double cent consensus revenue estimate fall short projection company show strong growth mobile user alibaba stock soar week breaking base highest level january jd com leap nearly next week messaging giant tencent tcehy perhaps alibaba biggest chinese rival report earning so do mobile gaming portal netease nte flash commerce seller vipshop vip ibd take market record high many growth name large small be breaking get depth look alibaba acacia other top rate stock fare vs rival go ibd stock checkup develop watch list saudi energy minister khalid al falih hint production freeze come meeting sideline international energy forum next month russia energy minister say didn see reason renew talk international energy agency say oil glut have disappear warn weaker demand dimmer macroeconomic outlook opec say saudi arabia pump record amount crude oil july cartel left demand outlook unchanged barrel day energy information administration say stockpile rise barrel week end aug production fall barrel second straight week decline oil rig operation rise week end aug baker hughe say seventh straight weekly gain highest level late february still crude oil price close week barrel wal mart store look keep pace amazon agree buy jet com wal mart have sizable online sale growth have be decelerate wal mart also put jet com ceo marc lore charge wal mart commerce operation jet com remain separately lore previously founder quidsi parent diaper com amazon buy wal mart stock rise hit month high week solar stock sunpower cut guidance inverter supplier solaredge sedg cite slowdown installer sunpower revenue growth adjust loss top estimate sunpower see revenue just vs consensus demand utility scale solar project tumble sunpower also cut view miss analyst view solaredge fiscal sale miss analyst expectation cent ep item beat nickel midpoint current quarter sale guidance trail consensus ep miss penny solarcity scty have agree takeover deal tesla tsla top analyst projection adjust loss revenue current quarter view revenue lag consensus sunpower stock crash year low chipmaker nvidia nvda involved everything gaming autonomous drive ai rise week fresh high tesla partner report sale cent earning share top consensus cent be respectively vs last year nvidia see current quarter sale beating analyst model china telecom datum center spending heavily higher speed connection maker fiber optic component be see huge demand hot ipo acacia communication say revenue rise adjust earning soar lumentum lite inphi iphi also report stronger expect figure neophotonic nptn sale growth fall short due sluggish demand older part production gigabit gear be ramp ibd company telecom fiber optic industry group hit year high thursday rank group acacia rise friday nearly week blast new high lumentum rise more inphi also new high neophotonic climb clear buy point friday related ibd take acacia communication be several tech leader have rise past buy point putt profit take zone sell top stock ibd latest tech leader column explain hold winning stock rule apply acacia weibo other right now recent ipo twilio twlo communication software firm report narrower expect gaap loss revenue jump vs wall street estimate sale top customer facebook fb own whatsapp fall year year twilio full year guidance edge consensus estimate twilio share surge week hit new high medpace holding medp soar thursday debut pricing high end expect ipo range share edge friday medpace provide outsourced clinical development service drug medical device company specialty drugmaker end have be strong season drug industry more ambiguous note allergan agn freshly divest generic business beat expectation slightly trim sale guidance share fall week valeant pharmaceutical vrx miss number affirm guidance reorganize say deal walgreen wba be finally turn profitable be willing sell worth core asset stock soar tuesday pare weekly gain report valeant face criminal charge defraud insurer medivation mdvn report hum quarter profit likely be flat expect market expansion drug xtandi share rise month high just barely buy range entry jazz pharmaceutical jazz miss ep estimate lower guidance partly due change tax report partly due higher cost stock drop mylan myl beat profit estimate slightly affirm guidance controversially high price epipen make light generic drug sale mylan close week unchanged walt disney top wall street estimate late tuesday say have buy stake stream company bamtech vie remain competitive digital medium conglomerate plan launch espn brand top service not include current espn content ep rise revenue growth share be week fail hold day line southwest luv cut third quarter unit revenue outlook say expect higher unit cost due flight cancellation july single router failure blac much technological infrastructure guidance come delta air line dal spend much week try recover own flight cancellation cause outage early monday american airline aal meanwhile forecast improvement unit revenue southwest delta share fall american air climb macy kohl kss report lower sale macy also have decline earning say cut store top forecast week bad news consumer stock such ford mcdonald mcd so macy kohl sky-rocket respectively week jwn jcpenney jcp top earning miss revenue share also soar week overall retail sale be flat july exclude auto accord commerce department home depot hd lowe low wal mart ross store rost be retailer report come week ibd tipp economic optimism index rise month high august climb point still neutral level
834,AGN,drug giant teva pharmaceutical industry teva raise guidance tuesday say wednesday morning offer long term guidance include buyout allergan agn generic drug business teva add topline estimate now roughly same year earlier quarter ep range be now share few cent previous guidance last year teva stock be hour trading rise tuesday regular session close month close high company also say give guidance include actavis allergan global generic business et conference call last earning report company have promise do so once deal close expect happen june process have drag teva have sell various product meet federal trade commission requirement teva have apparently decide give guidance deal be await ftc clearance accord teva press release allergan stock rise fraction tuesday regular session be flat hour
835,AGN,british drugmaker shire shpg be early tuesday win unexpectedly early food drug administration approval late monday dry eye drug fda approve lifitegrast newly brand xiidra sign symptom dry eye disease broader label have get accord evercore isi analyst umer raffat recall be big controversy only phase show efficacy sign endpoint raffat write email client doc call docs seem really care drug do sign endpoint leerink analyst jason gerberry write differentiate xiidra chief competitor allergan agn restasis difference be package mention study show xiidra bring significant improvement early week typical onset restasis be week shire allergan however not be sum game base ophthalmologist kol key opinion leader check be significant number eligible patient have fail adhere restasis due tolerability slow onset be pent demand new topical inflammatory last drug approve space be gerberry add research note expect xiidra approval expand dry eye category current currently forecast lifitegrast sale respectively fda have july decide approve xiidra so come earlier expect shire say win launch drug third quarter however wednesday morning hadn announce price shire stock close stock market today still nearly year shire carry not so great ibd composite rating be highest allergan rise tuesday
836,AGN,vote leave european union brexit be dazzling open ceremony olympic instead be uplifting brexit firework come form stock market devastation yet now little more month later many stock be rise game firework rio janeiro take look top perform growth stock mutual fund june post brexit low rank olympic class sprinter include driehaus micro cap growth dmcrx span other join otc medal stand elite runner circle be fidelity otc focpx primecap odyssey aggressive growth poagx tocqueville opportunity toppx harbor small cap growth opportunity hasox click here see list top holding top perform growth next top performer gain range be lord abbot micro cap growth lmiyx jpmorgan dynamic small cap growth vscox primecap odyssey growth pogrx well fargo emerge growth wfgdx jpmorgan small cap growth pgsgx power gold medal fund top holding include familiar name alphabet googl amazon amzn apple aapl facebook fb name gain amazon case alphabet month brexit low whole bunch additional growth stock be also championship fund top holding do even better be household name be less well know lead pack be acacia communication acia soar june low acacia account driehaus fund asset latest disclosure be fraction much just brexit acacia have composite rating ibd smr sale profit margin roe rating composite rating start run combine ibd performance rating include ep relative price strength rating stock poise move higher often have high composite rating look stock rating be higher mean ve outperformed other stock term composite rating smr rating be best acacia be cloud infrastructure tech firm be top rank stock ibd telecom fiber optic industry group group be rank now week stock share price have more double stock go public mid leave share price extend most recent quarterly report have show earning share skyrocket triple digit pace medivation mdvn rebound brexit have be more modest be still more twice good broad market leave maker cancer drug still buy range trading friday morning be less past flat base entry have comp rating smr rating ep growth be slow have grow past quarters ibd take medivation be takeover target ibd ken shreve report sanofi be suitor medivation blockbuster drug be prostate cancer treatment xtandi
837,AGN,mobileye mbly be brexit company be leader driver assistance system such automatic brake have comp rating smr rating trading share be alternate handle entry share gap july company say continue relationship tesla tsla not supply additional technology component investor have be assess tesla other firm produce driverless technology threaten mobileye ibd take paul gordon lead manager mfs mid cap growth fund tell ibd week be not worry tesla tesla be many mobileye customer say paul gordon lead manager mfs mid cap growth fund otcix be not significant percentage sale currently mobileye july pullback be due investor fear tesla have find supplier provide autonomous drive chip lower price gordon doubt case more difficult imagine ford gm gm even bmw bmwyy do mobileye paycom software payc be big gainer post brexit then paycom provide cloud base human capital management software be top hold tocqueville fund stock have comp rating smr rating trading share be extend entry paycom have comp rating smr rating big winner brexit be biogen biib top hold top perform fund vanguard capital opportunity vhcox notch gain also be hold primecap odyssey aggressive growth biogen be brit brew market meltdown leave slightly extend recent buy point cup handle base weighting biogen be top hold sixth best perform growth stock mutual fund vanguard capital opportunity vhcox notch gain biogen have comp rating smr rating ep grow quarters be stock medical biom biotech industry group group be rank now week back merger acquisition be roil pharmaceutical biotech water early week wall street journal say merck mrk allergan agn be check biogen fox business say allergan not afford make run biogen biogen merck product line be so different such hookup offer synergy merck
838,AGN,here investing action plan need know investor come week alibaba baba walt disney nvidia nvda headline quarterly earning report tech leader facebook fb alphabet googl microsoft msft start week buy range more drugmaker report top department store chain signal more trouble
839,AGN,job report push stock fresh time high busy week tesla motor tsla announce deal buy solarcity scty tech be strong general motor gm ford fuel sell consumer related stock oil price briefly undercut barrel also bank england cut rate revive bond buy major average be little change thursday rally friday strong job report nasdaq climb week record close friday just point july intraday peak rise hit fresh intraday best dow jone industrial average advanced energy stock fall oil undercut early week rally crude re-cover somewhat economy add job july second straight month much better expect hire allay fear economy ism manufacturing index index fall little more forecast still point growth strong hire wage gain support consumer spending housing demand many consumer related firm report stall demand tesla take step closer acquire solarcity special committee independent disinterested solarcity board member evaluate proposal alternative state approval merger deal still need be approve shareholder regulator tesla report earning miss estimate show improvement electric car production production be track support delivery second half reaffirm previous guidance electric car company loss balloon share cent year earlier figure much greater cent loss estimate tesla report gaap revenue miss consensus tesla fall week solarcity lose more ride hail giant uber technology be selling chinese operation apple aapl backed rival didi chux technology capitulate expensive battle foothold china deal have uber swap chinese business stake didi make former foe largest stakeholder didi turn didi become facto ride hail leader china value more uber most recent valuation put north verizon communication vz agree buy fleetmatic fltx vehicle tracking system maker share acquisition expand verizon push web connect vehicle part internet thing ireland base fleetmatic mobile software platform let business manage commercial fleet provide datum vehicle location fuel usage speed mileage verizon fall week drop buy point day move average fleetmatic jump time warner twx st century fox foxa turn mixed result time warner move buy stake netflix nflx rival hulu join current co owner walt disney fox comcast cmcsa steal headline viacom viab report better expect earning revenue do lion gate lgf post surprise profit oil price fall barrel early week follow july tumble opec production climb strong output nigeria iraq saudi arabia continue pump oil record high crude stockpile rise latest week accord energy information administration production dip gasoline supply fall shale producer continental resource clr oasis petroleum oas laredo petroleum lpi lift output forecast oil close week higher bristol myer squibb bmy plunge friday cancer drug opdivo end string clinical trial success failure trial single therapy newly diagnosed lung cancer patient merck mrk have succeed similar patient group trial compete drug keytruda be aim smaller potential market merck stock jump hit highest level june earlier merck be report be talk biogen biib possible biogen buyout be allergan agn further boost biogen stock day partner ionis pharmaceutical ion announce unexpected success clinical trial nusinersen treatment rare spinal disease blockbuster potential biogen rise nearly week meanwhile specialty drugmaker mallinckrodt mnk shire shpg rise respectively beat estimate raise guidance pfizer pfe nordisk nvo regeneron pharmaceutical regn slip beat number issue so so guidance animal health company zoetis zts also rise beating raise general motor gm ford lead auto stock lower report slower sale month july ford project industry sale fall year big gain department store grocery store restaurant airline also decline re-cover somewhat week end sell consumer stock trigger warning broader economy fall business investment homebuilder spending consumer spending rise strong annual rate falter economy not be able match anemic gdp growth texas roadhouse txrh beat earning estimate ep cent revenue growth miss view steakhouse chain also say early same restaurant sale growth have slow outlook come grow worry restaurant sector overall starbucks sbux mcdonald recently report weak comp warning analyst retail sector pizza delivery chain include papa john pzza be buck trend papa john say ep jump cent top view raise guidance rest year also chicken theme el pollo wingstop wing rally result jack box jack soar earning separately monster beverage mnst report weaker expect earning growth top revenue forecast monster beverage leaderboard stock rally friday hit new high ibd take investor look growth stock clear proper buy point ibd leaderboard be premium service provide detailed chart analysis lead stock see other top rate growth name be buy point bank england cut interest rate quarter point expect economy slow reaction brexit vote policymaker go further revive government bond purchase announce boe buy corporate debt also signale rate cut be likely year end boe gov mark carney say opposed negative rate helicopter money martin marietta material mlm make crushed stone sand other aggregate used construction fall short second quarter forecast rival aggregate supplier vulcan material vmc also badly miss related ready mix concrete market concrete uscr report ep plunge cent miss cent revenue rise also miss blame bad weather say expect better result second half martin marietta ceo nye cite record record rainfall attendant effect many key market share trio fall hard earning miss re-cover lose ground end week delta air line dal report decrease passenger unit revenue july say drop be line expectation investor appear worry tone result set third quarter delta say key metric operate efficiency fall german carrier lufthansa warn terror attack economic uncertainty affect travel also hurt sector delta stock fall american airline aal jetblue jblu also sank unite airline ual southwest luv close week higher aetna aet humana hum wellcare wcg put estimate beating quarterly result week however aetna say abandon expansion plan obamacare exchange humana recently say exit most obamacare exchange market next year follow unitedhealth unh aetna humana try overcome antitrust objection merger safety security concern person mind wake series officer involved shooting polouse officer polouse unarmed civilian sale sturm ruger rgr firearm grow second quarter rise earning climb share fbi report firearm background check see indicator future gun sale rise july june be july share fall day earning ruger ceo say be step close week only meanwhile taser international tasr say ep fall cent share cent year beat forecast cent share sale pop easily top view stun gun maker say booking axon body camera soar taser stock rise hit year high
840,AGN,israeli drug giant teva pharmaceutical industry teva be rise wednesday offer largely bullish outlook business acquire allergan agn generic drug business still not clear be late tuesday teva raise guidance ahead wednesday morning conference call give financial guidance expect sale growth low teen year next year flatten year be wall street have expect accord thomson reuter teva guide drop ep year expect guidance ep be consensus range subsequent year call modest growth be high side analyst estimate sec filing wednesday morning state close date teva buyout actavis allergan generic drug business have be push july oct teva allergan have originally hope close federal trade commission have subject deal lengthy review process make company sell product meet antitrust guideline nonetheless conference call analyst wednesday teva ceo erez vigodman say expect deal close time now evercore isi analyst umer raffat note revenue ebitda guidance be bit lower company have predict last july teva attribute delay deal close pipeline analyst be already lowbal company guidance year raffat also note guidance imply erosion sale best selling multiple sclerosis drug copaxone year copaxone have lose patent protection novartis nvs partner momenta pharmaceutical mnta launch generic version last year teva stock jump much early stock market today end session allergan stock be
841,AGN,major equity average edge higher early wednesday busy day headline flow goldman sachs gs walt disney apple aapl outperformed dow gain more nasdaq barely rise dow jone industrial average climb suffer third distribution day trading session tuesday raise count nasdaq composite currently show ibd take increase sign distribution higher volume decline index cause cause problem market uptrend learn more institutional selling impact market check lesson ibd university economic news private sector job be add july accord adp national employment report datum come ahead friday official job report economist expect july nonfarm payroll rise unemployment tick lower stock market today time warner twx buck trend rise nearly company report earning announce be take stake stream service hulu electronic art ea have be show support action week move average ahead earning rise adjust earning cent share fall year earlier handily top consensus estimate loss cent sale rise result be help strength digital download elsewhere biogen biib fall surge tuesday report merck mrk allergan agn be potential suitor ibd strong earning raise sale guidance late tuesday help cause paycom payc share rise almost provider workforce management software also get upgrade buy price target hike west texas intermediate crude oil september delivery rise barrel briefly top energy information administration say crude supply rise barrel last week gasoline inventory fall barrel crude production also fall close tesla motor tsla herbalife hlf be quarterly result tesla be flat fall prior day wake deal buy solarcity scty herbalife stock lose ahead earning stock have be volatile surge nearly week end july still hold buy point
842,AGN,ibd biotech industry group have rally february low move group be filled leader right be group house more stock only have composite rating higher tuesday session still noteworthy group have jump
843,AGN,generic drugmaker sagent pharmaceutical sgnt pop stock market today say be acquire japan nichi iko pharmaceutical agree pay share cash company premium friday close price nichi iko say deal provide platform commercialize biosimilar drug market give sagent access sophisticated manufacturing infrastructure industry lead quality control system sagent close news follow sagent own acquisition last month generic drug await approval teva pharmaceutical industry teva lengthy process close teva purchase allergan agn generic business first time least year sagent revenue fall year year past quarters drive price pressure weak cold flu season much business be infective product stock hit time low have gain buyout be announce other generic drug news lannett lci be hit month high lannett say fda have approve generic version paxil glaxosmithkline gsk popular antidepressant stock also probably receive lift lannett ceo arthur bedrosian comment paxil press release fiscal begin july be currently exceed expectation
844,AGN,sale allergan agn generic drug business teva pharmaceutical industry teva clear hurdle tuesday impax laboratory ipxl announce pay acquire product firm be require divest competitive reason impax wasn allow name product june deal close apart teva portion generic version johnson johnson jnj attention deficit drug concerta firm have be develop partnership allergan already have own generic concerta market so have be expect have go teva allergan announce deal last july remain product impax acquire include be already market approve strength not yet launch await approval development also drug different strength exist product await approval impax say together product generate sale gross profit last year impax say acquisition add top line second half year double full year earning growth impax also hike full year interest expense guidance slightly increase gross profit guidance low range impax ceo fred wilkinson say conference call analyst timing be highly opportune impax be face difficult second half financially last quarters bring triple digit earning growth thank company inflammatory diclofenac sodium gel new competition be expect shrink bottom line growth single digit move red wilkinson say federal trade commission have marked unnamed product divestiture face limit competition manufacturing difficulty intellectual property barrier difficulty meeting standard last issue have torpedo house version concerta impax have develop be fda review then agency update guideline way exclude impax drug well mallinckrodt mnk already market product impax teva come current drug acquisition leerink analyst jason gerberry however doesn guidance imply base business absent acquisition new guidance imply downside relative current factset consensus sale forecast gerberry write research note guidance revision base biz be due increase competition high margin generic relative update add get full right concerta help still have more year go get market market seem agree assessment impax stock tumble close stock market today teva stock lose allergan give back
845,AGN,back specialty drug maker allergan be fend hostile takeover bid valeant pharmaceutical main reason resistance be claim valeant decimate research development capability indeed time valeant boast have figured way spend far less other large drugmaker still crank new drug year later scene look very different valeant vrx plague scandal financial trouble be reworking business model ireland base allergan agn be tout approach call open science follow merger actavis merger pfizer pfe have be industry largest be scuttle april change tax rule concern company look locate headquarters lower tax country valeant botox maker allergan doesn have own internal research infrastructure spend less typical big pharma still spend more valeant other low cost specialty pharmas collaboration host small biotechs other external developer quest lead drug allergan ceo brenton saunder chief david nicholson recently speak ibd explain more open science mean help allergan grow ibd lot company acquire license externally develop drug so be open science differentiate saunder maybe start give perspective open science think prefer model allergan start premise innovation investment be crucial success allergan mission be help person live life better find cure treatment unmet medical need so therefore need be innovation business look do participate most efficient effective way believe open science be most effective construct allergan be focuse therapeutic area try be leader build scale discovery platform be potentially look innovation come innovation health care be best accomplish believe be better tap very vast ecosystem innovator be academic research center re venture backed startup company re private company re base public company re research spinout large pharmaceutical company look totality universe much larger anything ever build own also provide additional advantage be provide ability pursue best idea best probability success potential meet most unmet need re not wed internal program have make significant investment have justify cancele bypass order chase idea believe be better think also create attitude difference don have team person here be opposed go outside fresh idea don have not invented here syndrome depend open science sustain innovation flow so need be good partner licensing acquire asset so ve develop core capability now order be good partner part open science mean need be development powerhouse also commercial powerhouse generally person don want give idea have extreme confidence finish have requisite skill research development pharmaceutical science clinical development regulatory affair get science become drug generally want take royalty milestone payment regard commercial success so want believe hand approve drug become commercial success well nicholson advantage don have internal research organization be don need do technology base collaboration feed research have collaboration be exquisitely focuse product therapeutic area open science model be collaboration huge resource external world biotech industry open science model be focuse exquisitely novel innovative product opportunity therapeutic area think make almost unique industry ibd so say don have license technology be talk platform delivery technology something nicholson talk technology platform talk very very fundamental research technology discovery technology clearly be interested technology be utilize development novel pharmaceutical science technology instance do deal anterio recently give access technology let get large molecule dermal barrier don do discovery research don have have pure technology base discovery collaboration have collaboration early space technology be already deliver development project saunder have deep discovery platform technology take away flexibility purse novel interesting new technology ve make such investment capability almost fix investment ibd many company be look drug acquire license competitive be scene saunder area remain incredibly competitive good example be oncology really be arm race occur large pharma acquire much technology possible particularly technology be explode see dealmake price dealmake lately cancer arena therapeutic area compete be competition generally be pound gorilla area pride reputation be easy do business be commit strong productive partnership skill something believe be competitive advantage something take quite seriously ibd appropriate spending level be much debate late do decide appropriate level saunder view spending dollar be very practical invest believe investment target unmet medical need innovative probability success meet certain criterium have capability make successful so very differently most rest industry don target spend base revenue number spend program think make difference nicholson be part open science model don have fix cost be normally associate run discovery organization make certain have development powerhouse certain proportion flexible spend therefore flex amount cash spend depend pipeline need ibd preference stage development enter process external program saunder best keep secret allergan be enter agreement collaboration stage development early mid late ve do quite successfully drug just launch schizophrenia bipolar mania vraylar enter collaboration year really develop drug phase way approval be quite complex pharmaceutical science development person tend talk bring later stage seem more real right closer time reality be be very open mind enter collaboration related structure time continuum so long meet criterium meaningful innovation probability success fit capability ibd course probability success be more difficult gauge earlier get do gauge saunder lot time manage structure example have structure deal company call rhythm health really be impressed work rhythm health be do condition call diabetic gastroparesis really hasn be meaningful pharmaceutical advance diabetic gastroparesis year david team allergan evaluate science work be be do rhythm early thought be incredibly innovative so sign option agreement rhythm finish phase study read few month positive have option bring allergan phase finish development do same thing company call trevena trvn acute heart failure drug report result few week study fail therefore didn exercise option don have size fit do deal stage development depend preference partner conviction science side make sense thing be hallmark allergan be be open flexible principle mutuality do create inventor idea person be responsible bring conclusion re always look mutuality deal create scenario make everyone feel good remain constructive productive bring fruition
846,AGN,nyse index be modest selling pressure afternoon trading tuesday mostly quiet session memorial day weekend seller have generally be keep bay recent day nasdaq flirt stock market today nasdaq edge higher dow jone industrial average give lose volume nyse nasdaq be tracking higher friday level turnover be light friday ahead memorial day weekend boee ba lag dow fall late last week company announce delay deliver initial batch kc aerial refueling tanker air force stock market today allergan agn gap give back good chunk gain news carl icahn stake share rise nearly early gain fade afternoon trading other mover include retailer big lot big share jump friday earning inspire leader be emerge ibd retail discount variety group see other be ibd stock checkup ibd china base netease nte continue attract buyer work right side cup shape base share rise meanwhile ibd component acuity brand ayi clear flat base entry share rise economic news consumer spending april rise most almost year meanwhile consumer confidence fall unexpectedly accord conference board new read miss consensus estimate be also april upwardly revise read new york mercantile exchange wti crude oil july delivery add just barrel ahead thursday opec meeting
847,AGN,load player gap be rather subtle large cap beat small cap tuesday overall stock market trudge higher lower volume unfazed comment federal reserve chair janet yellen reaffirm investor belief longer see urgent move raise cost money stock fall last week fed decide stay
848,AGN,injectable drug specialist eagle pharmaceutical egrx stock be sharply monday get downgrade mizuho say thesis have play eagle stock jump june teva pharmaceutical industry teva win patent case several generic drugmaker include pfizer pfe hospira unit sagent pharmaceutical sgnt be try launch generic version blood cancer drug treanda january teva eagle launch low volume faster act version treanda call bendeka say expect replace treanda market eventually mizuho analyst irina koffler write research note expect company retain market exclusivity bendeka say other catalyst be slow come treanda bendeka switch be genuine success story eagle other hospital launch ryanodex docetaxel have be more challenge koffler write downgrade stock neutral buy be remind cost be still critical set insight have influenced longer term outlook bendeka rest eagle portfolio koffler note eagle be prepare file approval version eli lilly lly lung cancer drug alimta be alter way similar bendeka reformulation treanda doubt be lucrative teva deal be concern competition other filer allergan agn have already launch type product eu write reason think replicate bendeka agreement be challenge here eagle turn first annual profit last year cent share analyst expect jump year help bendeka launch stock nonetheless have single digit relative strength rating end trading stock market today
849,AGN,specialty drug giant allergan agn get conflict message wall street friday goldman sachs put stock conviction buy list mizuho lower price target due differ opinion company term strategy goldman analyst jami rubin write research note meeting top executive believe company be track deliver sustainable double digit top line growth margin expansion rubin add term catalyst include close allergan sale generic business teva pharmaceutical industry teva teva allergan confirm week happen next month well potential share buyback allergan unveil earning report tuesday rubin allergan decision scale back acquisition strategy favor stock buyback make sense believe allergan management be listen shareholder place capital deployment priority unlock value investing most attractive asset available allergan share rubin write mizuho analyst irina koffler however find shift less inspiring aside large share buyback management be not pursue change business expect be less excited execution story write research note lower price target affirm neutral rating market now side goldman allergan stock rise stock market today allergan share be still nearly year plunge april company pfizer pfe call marriage treasury department issue new rule discourage merger enable company move headquarters lower tax country such allergan home base ireland
850,AGN,specialty drug giant allergan agn report mixed first quarter affirm guidance announce massive share buyback tuesday lift batter stock allergan stock be already boost monday teva pharmaceutical industry teva say report buyout allergan generic unit actavis be track close next month have be delay various regulatory issue render moot worry generic drug pricing drive stock year low friday have already be hammer break merger pfizer pfe stock be early trading stock market today allergan report operate earning share year earlier quarter beating analyst consensus cent accord thomson reuter sale climb wall street average estimate allergan affirm full year revenue guidance vs last year number exclude actavis company say use part roughly proceed teva deal buy back stock plan buy next month say condition allow consider extend program much allergan stock once resident ibd still hold excellent ep rank actually decline less group whole drug stock sell august february high profile dissolution pfizer deal early april push stock single digit relative strength rating lead mediocre composite rating
851,AGN,stock turn lower afternoon trading friday bigger expect increase retail sale dow jone industrial average fall fall day move average neither have close day line feb nasdaq have be key support level volume stock market today be tracking lower same time thursday drug stock be biggest gainer oil retail transport stock fall endo international endp rise heavy volume try stem sharp decline have see stock drop lowest level federal probe relationship company manage prescription benefit other company johnson johnson jnj merck mrk have be contact part investigation accord reuter recently valeant pharmaceutical vrx be force end ty pharmacy benefit manager philidor bill practice valeant be week high valeant rise friday intraday allergan agn hasn be name investigation rise more afternoon trading botox maker be part generic drug industry group be best performer friday department store retailer have bad day government report show retail sale rise more expect april jwn plunge profit drop cent share much wall street have expect also issue disappointing full year guidance jcpenney jcp be nearly mixed earning report brick mortar retailer be suffering shopper increasingly buy online site such amazon com amzn gaming related stock be bright spot friday nvidia nvda make graphic chip used computer game console mobile device jump more record high strong quarterly earning report nvidia be now breaking cup handle base march
852,AGN,generic specialty drug giant teva pharmaceutical industry teva beat analyst earning estimate guide line expectation monday send stock early trading teva earning exclude time item come share year earlier quarter cent analyst consensus revenue shrank more past consensus teva guide earning share year bracketing consensus forecast revenue decline slightly low side analyst teva stock be early trading stock market today perhaps relief rally whole industry get spook friday endo international endp comment pricing pressure generic drug drive slash full year guidance teva stock fall more month low friday teva decline offer guidance close buyout allergan agn generic unit actavis be expect happen next month guide do not suggest dramatic credit suisse analyst vamil divan do note however generic business make total revenue miss wall street estimate be balanced beat specialty side generic revenue decline year year mainly decline sale nexium pulmicort divan write research note specialty medicine revenue increase year year drive primarily higher sale cns central nervous system respiratory product allergan stock also sell friday be early trading monday endo stock be
853,AGN,here investing action plan tuesday need know investor come day walt disney allergan agn lgi home lgih planet fitness plnt electronic art ea report quarterly result tuesday investor also keep eye national federation independent business index small business optimism
854,AGN,biotech stock fall deepest crater history start last summer rumbling recovery be sound year bull run more quadruple value peak last july ibd medical biom biotech industry group plunge early february hurt backlash high drug price merger seek lower corporate taxe group have gain feb low lead stock have do better biotech stock buoy potential blockbuster drugsbiomarin pharmaceutical bmrn be feb low incyte incy have gain low point same week ligand pharmaceutical lgnd have climb medivation mdvn boost buyout talk be group be even more take hit past week negative earning news several industry player fund manager tell ibd rebound be here say spate bad news have already be factor stock price more see climate favore rejuvenate hot drug new product pipeline pricing power innovate product bottom line positive factor drive runup never go away say just get drown noise very key point be group be very high beta group particularly small midcap stock don have sale don have earning say tom vandeventer portfolio manager tocqueville asset management history group be elevated macro uncertainty definitely hit vandeventer say own opinion be group trade more sentiment fundamental time period vandeventer point trouble china emblematic macroeconomic concern hit biotech stock sentiment drive factor be politic many candidate presidential race have bash drugmaker high price have propose way clamp wall street have dismiss idea impossible ineffective seem be generate most concern be democrat proposal let medicare medicaid negotiate drug price be not allow do now already center medicare medicaid service have show tooth announce pilot program change reimbursement medicare part cover drug administer hospital clinic part reimbursement scheme be long criticize encourage use expensive drug reimburse health care provider entire cost drug top propose scheme reduce premium add flat fee unrelated price drug theory encourage doctor choose cheaper option front treasury department last month issue new guideline tax inversion deal derail have be drug industry biggest ever merger pfizer pfe allergan agn tax inversion have become popular way drugmaker boost bottom line get access cash allergan earlier merger be base ireland have low taxe think tax regulation call inversion bottom bad press associate health care industry create bottom mind say robert bombace senior portfolio manager frost investment advisor lot bad news have already be baked company fact number industry insider say breakup pfizer allergan merger turn be good biotech stock make acquisition target company allergan have long history acquisitiveness pfizer be think splitting innovative drug business other product evercore isi analyst mark schoenebaum say pfizer want bulk innovative business make valuable standalone pipeline be modest compare big pharma competitor schoenebaum have also say biotech board be balk buyout offer much valuation have drop so ve be unwilling sell market price suspect lead hostile takeover deal big player be willing do partly come fruition late april sanofi sny make unsolicited bid medivation rumor swirl astrazeneca azn pfizer be also interested medivation response reflect attitude schoenebaum speak market be underprice stock sanofi time proposal come period significant market dislocation several important term event company be design seize sanofi value rightly belong stockholder medivation founder ceo david hung say statement reject offer bombace however say biotechs reluctance be show think just bargaining chip say reality be most company have partner anyway larger pharma biotech name reach point pipeline be so dry force hand bombace see lot exciting biotechnology science go fill pipeline put re go model stage space shuttle stage decline name specific company point work biomarker include pd inhibitor such bristol myer squibb bmy opdivo merck mrk keytruda also cite work genetic mutation focus many rare disease firm such biomarin bluebird bio blue discovery be keep money flow biotechnology say leonard yaffe manage health care hedge fund kessef capital management tell ibd specialty drug largely biologic drug prescribe specialist opposed primary care doctor contribute only prescription last year dollar spend drug year earlier thing think drive biotech stock be look drug introduce last year revenue derive drug be biological yaffe say so most attractive sector pharmaceutical area also most publicly trade biotech stock don have earning have successfully launch drug remain highly profitable top biotechs market cap gilead science gild amgen amgn celgene celg biogen biib regeneron pharmaceutical regn have ibd ep rank range putt top stock ep growth regeneron have ep rank number however reflect pricing power biologic drug be precisely political attack day vandeventer say price uncertainty be biggest risk bull thesis group right now also point democratic presidential front runner hillary clinton attempt previous overhaul health care system back mid depress drug stock short term be follow late boom boom be drive first wave biotech innovation company amgen roche rhhby genentech prove biotechnology produce blockbuster vandeventer say innovation remain key maintain pricing power even political pressure point gilead portfolio hepatitis drug start late launch sovaldi much political criticism sovaldi high price stop drug be so superior anything else market company have do research ll continue get price increase say company be particularly rare disease orphan disease arena oncology space company have drug era target medicine have higher efficacy rather shotgun try hit disease be go have pricing power promise such drug still make small stock explode celator pharmaceutical cpxx have surge march favorable late stage trial result acute myeloid leukemia treatment company also see hedge fund take position stock attract favorable initial coverage analyst be sign even generalist investor think biotech stock have get cheap say yaffe first quarter common lament be biotech stock get punish bad news good news get reward biogen issue mixed earning report draw mostly negative reaction wall street april stock rise more biogen have fall even harder other big cap biotechs drop march high feb low so be ready bounce say yaffe overview comment be sector have correct point get level stock be very attractive say
855,AGN,less month pfizer pfe scrap takeover allergan agn new inversion rule drug giant reportedly be eyee possible bid medivation mdvn send cancer biotech stock higher pfizer have approach medivation talk accord reuter lead offer top bid medivation france sanofi sny last week medivation have reject sanofi share bid undervalue company be best know prostate cancer drug xtandi medivation share have be trading well sanofi offer price close tuesday medivation rise pre market trading stock market today reuter report pfizer stock edge lower open tuesday pfizer rise breaking consolidation pharmaceutical king report best quarterly earning share gain more year pfizer ep rise better expect benefit several time factor include recent hospira takeover
856,AGN,big pharma pfizer pfe rise tuesday beat wall street estimate raise guidance company moved allergan agn last month call mammoth merger open pfizer say earning exclude time item rise year earlier quarter cent share beating analyst consensus cent revenue increase beating consensus accounting be complicate several factor include acquisition generic drugmaker hospira look closely year year revenue growth be worth mention growth vs operational growth year year favorable fx foreign exchange rate contribute inclusion hospira contribute write evercore isi analyst mark schoenebaum email client exclude fx hospira pfizer stand alone revenue increase year year growth be also additional factor favorably contribute revenue due additional selling day quarter exclude impact operational year year revenue growth come be still very good growth pfizer relatively mature portfolio product still none factor foreign exchange contribute pfizer full year guidance increase company add revenue guidance now cent ep range now pfizer say revenue hike cent ep gain be due improve operate performance pfizer stock rise stock market today touch nearly month high number important drug also beat consensus include breast cancer treatment ibrance epilepsy drug lyrica pneumococcal vaccine prevnar enbrel amgen amgn rheumatoid arthritis drug pfizer market outside also beat expectation do domestically amgen report last week nonetheless investor mind be elsewhere write credit suisse analyst vamil divan research note expect investor view quarter positive maintain focus strategic outlook company follow fail allergan deal ahead decision potential split pfizer write pfizer allergan base low tax ireland call merger have be industry largest ever treasury unveil new rule curb tax inversion deal
857,AGN,drugmaker endo international endp plunge friday deliver hefty guidance cut drive weakness generic business drag nearly other generic drug stock endo actually beat analyst consensus cut full year earning guidance now share trim revenue outlook range company earning release ceo rajiv silva blame new competitive entrant include voltaren gel greater expect price erosion generic sector delay regulatory action related certain endo product ibd take healthy be share endo teva do stack vs rival find ibd stock checkupit be second factor rattle rest generic industry teva pharmaceutical industry teva stock fall hit month low allergan agn already staggering cancellation buyout pfizer pfe hit year low end day even selling generic business teva perrigo prgo cut own guidance last month fall smaller drugmaker akorn akrx much end day akorn have fall way accounting due internal issue late friday finally set date earning release respectively leerink analyst joseph schwartz write research note endo problem read most directly teva akorn perrigo more moderately allergan essentially do most price hike product represent more generic sale lately be most trouble refer industrywide datum im schwartz write base analysis akorn have take price increase match criterium im generic sale perrigo generic im sale endo take generic im sale teva meanwhile be due report own earning guidance monday morning allergan be due open follow day endo get least downgrade wall street analyst friday mostly neutral underweight end day year close low
858,AGN,generic drug biotech firm score top gain industry past week super regional bank lead bb bbt suntrust bank sti northern trust ntrs fifth third bancorp fitb be other fast rise group biotech group rise week gain be influenced thinly trade name particularly amphastar amph
859,AGN,top brass nvidia nvda apple aapl supplier skywork solution swks pfizer pfe comcast cmcsa mckesson mck headline week insider transaction co founder ceo jen hsun huang thursday report sale execute wednesday share company stock late thursday nvidia report jump earning share time item hike revenue figure top analyst consensus nvidia share gap friday time high end week executive chairman david aldrich year skywork veteran filing thursday report have sell share also thursday skywork announce aldrich guide company be form merger wireless technology company step ceo skywork name liam griffin new chief skywork share lose week chairman ceo ian read sell share share pfizer beat wall street estimate raise guidance company also call last month merger allergan agn treasury unveil new rule curb tax inversion deal pfizer share dip week chairman ceo brian robert thursday file sale comcast share share total largest cable provider soon have stronger contend charter communication chtr recently receive approval fcc california regulator buyout time warner cable twc comcast share edge chairman ceo john hammergren sell share share total earlier month mckesson report disappointing fiscal earning revenue company have earlier warn weak generic drug price recent customer consolidation rite aid rad agree last year be acquire walgreen boot alliance wba have distribution agreement abc mckesson fall week insider transaction don typically have major impact stock indicate major pending news rapid liquidation most insider holding however affect stock
860,AGN,walt disney macy gap gps kohl kss fossil fosl other report weak earning guidance trigger broad sell retail other consumer stock not share amazon amzn meanwhile apple aapl tumble year low fresh evidence iphone demand remain weak major index ultimately close modestly lower dow industrial fall key support major average fall third straight week most loss come friday dow fall close day move average first time feb nasdaq already key line retreat market uptrend remain pressure retail consumer group be big loser raft weak earning report guidance like walt disney macy oil price rise month high week retail sale rise april best gain more year couldn shake gloom surround retail consumer stock macy kohl jwn jcpenney jcp dd tumble dismal first quarter report guidance macy upscale slash outlook sharp ep decline kohl post same store sale drop be worst height great recession accord retail metric macy stock fall year low kohl fall nearly set year worst jcpenney lose respectively meanwhile watchmaker seller fossil collapse miss view slash guidance fossil hint competition apple watch other wearable gap say same store sale sank april comp ahead full result share plunge nearly worst late wal mart wmt home depot hd ross store rost also continue flood retail earning next week medium conglomerate deliver first earning miss year share profit grow revenue grow short consensus espn lose subscriber once again medium network segment didn appear disappoint wall street too badly studio revenue shot star war force awaken zootopia fanfare captain america civil war keep movie box office receipt high disney share tumble fall cup handle base well buy range disney close just day line apple stock fall last week new evidence apple supplier be see weak order upcoming iphone suggest apple sale wo continue quite time separately apple invest didi chux chinese ride hail service app apple stock fall lowest level june lose market cap crown barely google parent alphabet googl amazon intensified rivalry alphabet google launch new video stream service comparable youtube sanford bernstein analyst carlos kirjner tuesday raise price target amazon whopping wal mart wmt announce subscription service offer day free delivery vs day brick mortar retailer struggle amazon rise investor bet share consumer spending keep expand facebook release guideline reveal social medium giant rely far more person trend news topic contradict earlier company claim be largely drive computer algorithms earlier gizmodo suggest facebook be suppress news story conservative medium outlet facebook strongly deny allegation say have rigorous guideline place review team seek ensure consistency neutrality facebook ceo mark zuckerberg say meet conservative discuss facebook policy facebook stock rise week extend recent still buy range staple spls office depot odp call propose merger late tuesday federal judge agree federal trade commission deal have limit office supply competition big corporate customer staple crash office depot drop obama administration have block several megamerger recently include halliburton hal baker hughe bhi analyst say health insurance consolidation get hard look aetna aet seek buy humana hum anthem antm set acquire cigna ci treasury department tuesday call greater oversight nascent industry quick easy online payment lend solution threaten upend traditional banking have raise question safeguard potential abuse come day lend club lc say ceo renaud laplanche be step company find misconduct online lend platform relate loan sale lack financial oversight several large small bank halter work lend club share shed hit record low peer peer lend firm prosper recently announce large round layoff disappointing quarterly result ondeck ondk have prompt worry insufficient loan volume growth online gaming platform netease nte more double revenue beating estimate boost mobile game such fantasy westward journey newer release such kung fu panda ep also top share rise week move day line weibo wb twitter twtr social medium platform majority own sina sina fared well help mobile user growth strong ad revenue expansion major city share rise week online medium company sina also top view better sale narrower net loss expect strong weibo performance be key help ad revenue web portal segment lag share lose plunge day line close just day online retailer jd com jd report loss line expectation sale surge be just expectation revenue guidance be just shy analyst consensus share tumble lgi home lgih tuesday report surprisingly strong surge first quarter adjust earning share entry level homebuilder revenue fall short gross profit margin decline lgi home briefly flirted buy point fall trex trex world largest maker wood alternative decking railing product top view trex guide revenue consensus share reversed hard week gypsum wallboard related product maker continental build product cbpx profit climb share rise breaking base month high topbuild bld install build insulation also best wall street earning revenue estimate share july ipo rise prior week several housing report include housing start exist home sale april be tap next week solarcity scty torch wall street sale view late monday loss swell residential installer cut installation guidance booking fall short nevada cut net meter payment solar customer also monday rival vivint solar vslr report revenue rise still miss view loss widen installer sunrun run late thursday report surprise profit ex item revenue nearly double solarcity fall week vivint be nearly hit record lows sunrun be nearly even friday pop israeli giant teva pharmaceutical industry teva beat earning sale estimate guide slightly consensus teva say buyout allergan agn generic business be track close june earlier delay teva stock rise cent week allergan report mixed result earning beat sale miss drugmaker say ll buy stock allergan fresh fail takeover pfizer pfe signale ll focus more improve operation make big buyout future share rise third generic giant perrigo prgo hit year low report thursday issue guidance last month be few surprise perrigo fall week work fifth straight weekly loss smaller player jazz pharmaceutical jazz miss estimate stock rise news deal generic drugmaker not sell knock off lead drug xyrem end jazz share close meanwhile akorn akrx finally report number long accounting overhaul lift share more set report jab beech add krispy kreme doughnut kkd coffee empire pay share krispy kreme shot slightly offer price jab beech subsidiary jab hold own peet coffee tea stumptown coffee roaster caribou coffee einstein noah restaurant group intelligentsia coffee lead investor group buy keurig green mountain
861,AGN,major stock etfs turn modest gain tuesday open big win close bounce oil upbeat earning drugmaker allergan agn hearten investor energy lead advance sector oil future rise supply bottleneck china nigeria outweighed persistent concern global supply glut accord news report west texas intermediate crude june delivery settle nearly higher barrel guggenheim solar tan give extend last week loss teeter february low still performance underscored diversification benefit etfs hold basket stock solarcity scty top hold sank report larger expect quarterly loss late monday company slash outlook installation tan be now mired week high hold stock decision last year nevada regulator reduce net meter payment solar customer force company exit state have make customer reluctant install solar solarcity say solarcity be installation leader residential market top rival sunrun run report sunrun have also exit nevada hold first solar fslr continue reel miss sale view follow resignation ceo jim hughe stock hit week high mid march have now crater lowest level late october energy select sector spdr xle pop stock market today sit week high set year unite state oil uso commodity etf investing month wti crude oil future add ibd leaderboard spdr gold share gld eke gain gld sit buy point etf track price gold here look major exchange trade fund tracking various asset class rank average daily dollar volume perform today follow daily etf market action be key successful investing spdr spy rs ishare russell iwm rs powershare qqq qqq rs spdr gold share gld rs ishare msci eafe efa rs ipath vix short term future vxx rs spdr dow jone industrial average dium rs vanguard ftse emerge market vwo rs unite state oil uso rs ishare core aggregate bond agg rs ishare core mid cap ijh rs powershare db bullish uup rs
862,AGN,share valeant pharmaceutical international vrx rise sharply third day row thursday company come agreement creditor avoid default valeant say lender have agree amendment extend filing deadline annual financial report july previously be due end march agreement give valeant day file prevent default amendment also waive cross default valeant indenture be set company fail file march valeant be late filing review financial record start scandal erupt last fall surround relationship now defunct pharmacy philidor tuesday company say review be complete so expect file month new agreement give bit more breathe room valeant say amendment also affect capability term amendment restrict company ability make certain acquisition other investment pay dividend other restrict payment financial statement be file company achieve certain leverage ratio valeant statement say restriction be place company also be require apply substantially net asset sale proceed prepay term loan valeant have become highly lever series acquisition have quickly bulk company management put acquisition hold philidor scandal break asset sale have be announce wall street have be speculate company be slim even break wednesday several analyst reporter ask allergan agn ceo brenton saunder allergan acquire bausch lomb business valeant buy back saunder be run valeant stock rise much stock market today close thursday stock have rise week hit more year low monday investor have be hearten completion financial review well promise new ceo future
863,AGN,future merger big pharma pfizer ireland base allergan seem be unravele tuesday treasury department propose new rule take away tax benefit deal late monday treasury announce action design curb tax inversion deal company pfizer merge smaller foreign company allergan so relocate lower tax foreign domicile pfizer allergan agreement announce november be latest biggest series such deal past few year have draw increase criticism politician press briefing tuesday president obama voiced approval new rule ve be push year eliminate injustice tax system obama say so very pleased treasury department have take new action prevent more corporation take advantage most insidious tax loophole flee country just get pay taxe obama also urge congress pass legislation create more comprehensive solution include lower corporate tax rate level more other country many ceo inverted company have also urge allergan stock fall stock market today wall street analyst agree big downside surprise treasury action be propose rule regard ownership current law company merge foreign company end own more foreign company officially relocate foreign company home country way accounting work now pfizer allergan merger end pfizer own new company allergan own allergan be today be fairly new entity back new jersey drugmaker then know actavis acquire irish counterpart warner chilcott give coveted dublin address then have buy more company notably new york base forest laboratory california base allergan last year lead name change treasury guideline seem be aim squarely allergan purpose compute ownership percentage determine acquisition be treat inversion current law today action exclude stock foreign company attributable asset acquire american company year prior signing date latest acquisition say treasury statement create complication here allergan formerly actavis be byproduct acquisition forest legacy allergan actavis lead issuance estimate share allergan write leerink analyst jason gerberry seamus fernandez research note strip share pro pfizer allergan share count multiplier end pfizer own close new co analyst note buyout deal include provision change tax law change breakup fee be adverse change drop only lower probability deal close conclude nonetheless add pfizer ownership come shy fed also back share related warner chilcott deal view warner be original foreign entity be subsequent deal get backed ownership test however unidentified source tell reuter tuesday pfizer believe treasury have paint target so unlikely be escape route pfizer be aware treasury keep ruling solution come reuter quote source say tuesday afternoon pfizer have make formal decision only statement be brief late monday press release say company be conduct review say nothing complete treasury proposal also include provision attack earning strip foreign parent make loan subsidiary deduct interest payment earning analyst say be expect be not deal killer rule formally take effect april be not finalize first have go public comment period take month accord evercore isi policy analyst terry haine however treasury have edge rule aren final haine say provision expect be subject litigation affected company affected company be not likely quickly get court relief stay treasury proposal haine write treasury be carefully limit earn strip action propose regulation not even temporary regulation other action today proposal accord haine treasury be try do be avoid court scrutiny discourage inversion same time rule be only propose regulator court reject lawsuit government have not take final action definitely harm someone side pfizer investor evercore drug analyst mark schoenebaum say email client allergan deal doesn go move timeline pfizer long expect split company devote innovative drug development other establish product have be push future allergan deal be announce november schoenebaum speculate decision be make early year pfizer stock rise tuesday allergan doesn merge pfizer still be affected earning strip provision allergan ceo brenton saunder have say shave profit margin percentage point still analyst calculate tuesday stock drop bring allergan well stand alone value update guidance put downward pressure allergan stock price continue view company undervalue stand alone price think moat be wide buoy strong differentiate portfolio solid pipeline write morningstar analyst damien conover research note
864,AGN,april auto sale release tuesday be catalyst general motor gm ford motor fiat chrysler automobile fcau earning pfizer pfe mylan myl cvs cvs be also top list need watch gm ford fiat chrysler miss analyst estimate sale march expert projection industry sale level several year boom growth edmund com expect seasonally adjust annualize rate saar sale reach april march last april power lmc automotive joint forecast see sale saar month gm have shape cup handle base buy point find support day line currently trading buy point week high dip fraction monday ford be week high share be try find support downward slope day line ford add intraday trade fiat chrysler be trading day line day line share be week high monday drug giant pfizer mylan issue quarterly report tuesday morning pfizer earning be project rise cent share revenue increase pfizer scrap inversion buyout plan allergan agn last month treasury department issue new rule curb tax beneficial deal pfizer be able retake day line early april end session lose streak monday add share be trading week high meanwhile mylan be expect see earning rise cent share gain revenue last quarter mylan miss expectation stock crumble company also announce be buy sweden meda mylan breach day line last week snap straight session decline monday stock be trading week peak climb monday drugstore chain be expect see earning rise share report tuesday morning revenue be project jump cvs find support day line be able retake day line rise monday day recently crossed day stock performance have improve share be trading high reach last july continue consolidate
865,AGN,here investing action plan need know investor come week earning season remain remain busy report tesla motor tsla alibaba baba top shale producer april job report provide more clue federal reserve take interest rate tesla mobileye auto giant luxury electric vehicle
866,AGN,stock market turn solid performance wednesday release minute march federal reserve meeting didn do much overall bullish tone close nasdaq be add dow jone industrial average picked preliminary datum show volume nyse come slightly lower tuesday level nasdaq volume rise bit new york mercantile exchange west texas intermediate crude oil delivery jump barrel government report unexpected drop crude inventory biotechs do heavy lift nasdaq ishare nasdaq biotechnology etf ibb outperformed rise regeneron regn biogen biib be best performer nasdaq respectively nutshell fed minute show sentiment be run rate hike later month cme group fedwatch currently have odd rate hike year treasury yield add basis point stock market today fast grow homebuilder lgi home lgih jump nearly strong trade clear resistance work right side possible base late tuesday company say new home closing surge march most ibd stock be higher lead acuity brand ayi bolt more upward follow strong quarterly earning report stock rocket past alternate entry hesitate earlier entry cup handle base pfizer pfe allergan agn rise drugmaker abandon deal have shift pfizer headquarters ireland provide company overseas tax shelter allergan rise plunge almost tuesday follow treasury department unveil rule aim discourage such tax inversion deal pfizer gain meanwhile oil field service giant baker hughe bhi halliburton hal outperformed jump respectively justice department file lawsuit halt plan merger concern combine company stifle competition sector close watch earning retailer bed bath bbby small cap ollie bargain outlet olli
867,AGN,big pharma pfizer pfe contemplated splitting specialty drugmaker allergan agn campaign regain investor confidence wednesday company announce plan merger be pfizer early wednesday confirm rumor company have cancele merger day treasury department release new guideline have remove most tax benefit deal new york base pfizer stock tank tuesday allergan ceo go medium blitz promote company prospect stand alone conference call analyst wednesday morning allergan ceo brenton saunder maintain treasury action tax inversion have impact stand alone allergan redomicile ireland inversion deal warner chilcott year company retain corporate tax rate say also be free deploy capital however choose saunder also say allergan sale generic unit actavis teva pharmaceutical industry teva be unaffected spiking pfizer deal be track close june timeline buyout be delay original close date teva work way multus country regulatory clearance process saunder say company be determine get do teva be do lot work say saunder ve restructure company have name entire leadership few level include allergan executive move teva be great deal allergan also great deal teva allergan stock tuesday rebound wednesday teva stock rise close actavis sale give allergan big wad cash so many analyst question call related do money several seem be root share buyback give allergan stock be trading week low wake pfizer breakup saunder say option be table emphasize allergan growth pharma model mean constantly hunt growth asset say allergan business development team have stay active pfizer deal be announce right opportunity come announce tomorrow couple analyst raise name contact lens giant bausch lomb saunder have personal history head company be sell valeant pharmaceutical international vrx give valeant recent spectacular crackup many wall street have speculate again go sale allergan suitable buyer not only saunder also allergan large ophthalmology business saunder response seem be swipe valeant infamously opaque financial report sell year late stage pipeline program strong organic growth profile say tell thing today be still true base public information impossible tell worth more sell year pfizer meanwhile rise hit month high investor look possible major catalyst stock back company reorganize so be able split innovative drug development business establish product perhaps divide more piece necessary company have originally plan make decision year allergan buyout be announce issue be push next year pfizer press release announce end allergan deal however say decision date be back year bring more write evercore isi analyst mark schoenebaum recent acquisition hospira pfizer probably have critical mass transform global establish product business unit independent company innovative product business unit benefit additional asset acquire outside schoenebaum write email client prospect company go back hunt have be lift drug stock whole wednesday especially biotechs distressed big cap biotech biogen biib have be subject buyout speculation give trading high rise smaller anacor pharmaceutical anac rise likely late stage eczema drug be see fit allergan dermatology portfolio
868,AGN,stock be lower mixed volume midday tuesday follow mixed economic datum nasdaq lose dow jone industrial average give volume stock market today be run higher nyse lower nasdaq compare same time monday walt disney lead dow lower drop heavy volume follow surprise resignation thomas stagg see heir apparent ceo robert iger be expect retire meanwhile drugmaker take hit allergan agn plunge treasury department issue ruling aim discourage tax inversion deal move threaten allergan plan merger pfizer pfe allergan share undercut oct low now lie week high pfizer share rise most ibd stock be lower acuity brand ayi show strength rise retake buy point cup handle base volume be run average lead system specialist former ibd leaderboard stock be slate report quarterly result open wednesday earning be see rise share jump revenue earning share grow average past quarters economic news institute supply management index service sector activity rise point march beating wall street expectation reading indicate growth also tuesday labor department job opening labor turnover survey show unfilled job position february be slightly department initial estimate january revise total image provide shutterstock
869,AGN,stock wake wrong side bed tuesday stay grumpy day content follow lead most overseas equity market be also foul mood nasdaq be short stay day move average gap lose also fall
870,AGN,apple aapl get price target cut thursday alphabet googl acuity brand ayi get price target raise allergan agn get downgrade btig trim price target apple cite conservative stance next iphone upgrade cycle apple share close stock market today morgan stanley raise price target alphabet alphabet share end thursday susquehanna downgrade allergan positive neutral deutsche maintain buy rating giant drug company jpmorgan initiate coverage overweight allergan pfizer pfe terminate merger deal wednesday cite new tax inversion rule allergan share fall cannacord genuity raise price target acuity brand smart light maker report second quarter result handily top view wednesday still csla downgrade acuity rating outperform buy acuity share lose brean capital initiate coverage intel intc buy rating price target intel share fall stifel raise price target constellation brand stz still wine beer giant share retreat other action macquarie initiate coverage skecher usa skx outperform rating price target skecher share drop image provide shutterstock
871,AGN,stock turn decidedly higher midday wednesday ahead minute due later today federal reserve recent march meeting interest rate nasdaq be climb dow jone industrial average be volume be run lower stock market today compare tuesday level only mildly so nasdaq drugmaker oil stock be biggest gainer midday transportation stock lag pfizer pfe allergan agn rise drugmaker abandon deal have shift pfizer headquarters ireland provide company overseas tax shelter allergan rise more plunge tuesday treasury department unveil rule aim discourage such tax inversion deal pfizer also rise more meanwhile oil field service giant baker hughe bhi halliburton hal lead jump respectively justice department file lawsuit halt plan merger concern combine company stifle competition sector most ibd stock be higher lead build product stock acuity brand ayi bolt follow strong quarterly earning report stock rocket past alternate entry hesitate earlier entry cup handle base investor scour minute federal reserve march meeting due et clue central bank outlook interest rate
872,AGN,stock higher flat start wednesday enough lift nasdaq narrowly back day move average nasdaq rise add dow industrial tack gain stock market today volume be quiet nyse lower nasdaq relative action same time tuesday pfizer pfe run head dow more breaking takeover allergan agn nixing pfizer allergan inversion reportedly cost pfizer breakup fee avoid run afoul treasury department launch inversion regulation monday allergan stock also rise more uninverted drug medical play lead nasdaq celgene celg illmina ilmn vertex pharmaceutical vrtx jump more ibd stock acuity brand ayi padded early gain press higher big fiscal sale earning gain put share past cup handle buy point baker hughe bhi spiked halliburton hal pop justice department file antitrust lawsuit challenge plan acquisition baker hughe halliburton suit claim merger eliminate competition specific product service related oil gas field production
873,AGN,treasury department have squelch drug giant pfizer pfe bid take ireland base allergan agn etf investor needn fear new federal rule don ice broader merger market say sal bruno chief investment officer indexiq firm largest merger focuse etf pfizer allergan merger deal be widely see attempt large company move legal domicile overseas avoid america steep corporate tax rate new rule make so call corporate inversion more difficult potentially less profitable however tax inversion deal make small percentage total merger market bruno say most merger deal focus opportunity synergy growth add pfizer allergan kibosh hurt merger industry optic standpoint accord bruno tactic dodge corporate taxe have come flak recently president barack obama presidential candidate side political divide iq merger arbitrage mna dump tuesday follow news extend loss stock market today exchange trade fund invest global company be target publicly announce takeover rebalance monthly used liquidity base weighting method allergan be top stock hold exchange trade fund portfolio weighting mna have coast far less volatility benchmark past year gain first quarter come very volatile period equity market performance help cushion tuesday blow mna be still year april comparison spdr spy have add challenge merger etfs extend pfizer allergan debacle obama administration have take more aggressive stance big merger sue block merger oil major halliburton hal baker hughe bhi staple spls bid rival office supplier office depot odp be also scrutiny even more worrisome deal activity be show sign cool record year record deal cumulatively worth first quarter deal worth accord intelligence service mergermarket bruno believe pace remain brisk future interest rate remain low make easier borrow money buy other company low growth climate acquisition add growth company generate growth own corporate balance sheet cash flow be healthier have be decade ample deal flow bruno say have very positive outlook merger arbitrage whole most challenge perhaps etf investor continue be wary more niche product mna fall liquid alternative fund category aim diversify portfolio make mostly stock bond category hasn grow tremendously etf space bruno say mna debut hold asset proshare merger mrgr launch hold proliferation thematic new product plain vanilla etfs be dominant investor continue focus most time attention well very low cost broad very well diversify market exposure ben johnson director global etf research morningstar say recent interview however bruno expect liquid alt etfs take person get more comfortable diversification benefit see growth go forward say
874,AGN,new sheriff be en route hasn stop old sheriff swing corporate billy club town subject be company merger instance administration president barack obama promise reinvigorate federal antitrust enforcement campaign trail back be crack be pile week obama justice department sue block merger baker hughe bhi halliburton hal antitrust concern also week obama say treasury department have take further step curb tax inversion company buy foreign target then re domicile avoid higher taxe scuttle major acquisition wednesday drugmaker pfizer pfe allergan agn call deal also be several other instance recent week month administration have take aim big business so give be product last year robust environment see global deal announce symptom white house critic have accuse be business re definitely get more aggressive max jacob analyst london base investment research house edison say administration historically obama have be bit more liberal government intervention side thing take pfizer allergan merger deal have result base pfizer relocate headquarters low tax ireland benefit nation corporate tax rate do so have bypass rate highest industrialize world terminate deal have be work month pfizer now pay ireland base allergan breakup fee be political calculation here say dane hamilton editor mergermarket speaking tax inversion deal obviously obama administration stop company move overseas generate lot tax dollar still obama pending departure january not bring much relief term friendlier face come be dearth obvious presidential candidate moment hillary clinton democratic party front runner president want crack inversion fellow white house democratic hopeful sen bernie sander have call practice tax scam meanwhile republican front runner donald trump party rival sen ted cruz texas propose lower taxe inversion aren come support still clamp tax inversion win solve corporate tax code underlie problem say lisa simone professor accounting stanford university tax system very much put incentive place say add become more difficult get inversion deal do tax inversion aren only target vigilant antitrust watchman be obama administration have take aim elsewhere addition antitrust concern baker hughe halliburton deal combine world oilfield service firm justice department take electrolux eluxy trial late last year cause general electric ge back deal sell appliance unit federal trade commission have take office depot odp staple spls trial block deal biggest office supply chain more last year administration quash comcast cmcsa time warner cable twc merger have combine nation largest cable television company yet approve live nation entertainment lyv merger ticketmaster diana moss president american antitrust institute favor more aggressive antitrust law enforcement say size company merge raise red flag enforcer deal be still be strike politician griping major health insurer aetna aet humana hum combine deal anthem antm agree buy cigna ci last year world largest beer maker anheuser busch inbev bud sabmiller agree combine now old sheriff have free hand say edison jacob obama have benefit not have stand election say
875,AGN,pfizer pfe allergan agn confirm wednesday be end merger agreement treasury unveil new rule curb tax inversion deal monday ireland base allergan rise stock market today ceo brenton saunder tell cnbc allergan have bright future standalone firm allergan plunge tuesday hit lowest level late concern new rule imperil deal pfizer rise wednesday gain tuesday pfizer inc today announce merger agreement pfizer allergan plc have be terminate mutual agreement company drug giant say statement decision be drive action announce department treasury april company conclude qualify adverse tax law change merger agreement company have strong incentive redomicile overseas reduce exposure america unusually high corporate tax rate global reach pfizer board report vote scrap deal give longer be tax benefit saunder say new rule blindside allergan feel unfairly target compnay be not name specifically treasury set restriction serial inverter allergan have history inversion deal allergan be run new jersey have official headquarters dublin pfizer pay merger related expense pfizer ceo ian reed say statement drug giant go ahead corporate split plan make decision pursue potential separation innovative establish business later end obama administration have become more aggressive go big merger justice department be sue block merger halliburton hal baker hughe bhi say ll fight doj action baker hughe share rebound wednesday slide tuesday report doj take action halliburton pop intraday climb tuesday meanwhile ftc be midst court battle seek block staple spls buy office supply rival office depot odp
876,AGN,stock be mixed mostly unchanged early wednesday oil price mixed quarterly earning report drive good amount action nasdaq add dow jone industrial average ease barely budge stock market today head midweek session nasdaq tote loss week nasdaq maybe more important nasdaq head wednesday session day move average retake line support week dow remain comfortably day line small cap russell index week have trade day level august eastern release minute federal open market committee march meeting provide economic center point session energy information administration report weekly oil inventory datum pfizer pfe exxon mobil xom chevron cvx be early leader dow west texas intermediate climb barrel early wednesday gold edge ounce dollar gain bond slip trimming year yield basis point overseas market close narrowly mixed asia europe market show similar action midday pfizer allergan agn formally announce plan abandon deal have shift pfizer headquarters ireland provide company overseas tax shelter such tax inversion deal be focus treasury department rule unveil monday pfizer be concern effort salvage deal provoke new rule treasury accord reuter pfizer reportedly pay allergan termination fee allergan edge higher news pfizer add oil energy related stock post best gain stock ibd stock acuity brand ayi soar early trade atlanta base light distributor report heavy fiscal second quarter sale earning beat basis point increase gross margin stock end tuesday buy range less buy point cup handle base constellation brand stz tap gain fourth quarter revenue earning clear consensus expectation beer wine maker distributor end tuesday less cup base buy point lead light manufacturer cree cree lower early go durham light maker warn fiscal third quarter revenue be initial guidance put earning cent cent vs initial projection cent cent management cite product delay system conversion affect customer service stock have be fight climb november low deep month correction
877,AGN,perrigo shareholder reject hostile takeover bid fellow generic drug maker mylan friday morning send perrigo stock mylan long acrimonious battle end
878,AGN,mylan myl say press release et deadline perrigo prgo share have be validly tender miss require takeover succeed
879,AGN,grow alone
880,AGN,mylan management maintain statement be fine perrigo
881,AGN,mylan focuse approach organic inorganic growth have deliver compound annual growth rate adjust diluted earning share ep shareholder strategically consistently expand business say mylan ceo heather bresch recent financial result continue demonstrate power stand alone platform double digit growth legacy business well enhance double digit growth epd business
882,AGN,mylan shareholder seem agree stock rise close perrigo stock fall management claim victory
883,AGN,have say offer mylan be bad deal shareholder significantly undervalue durable business model industry lead future growth prospect perrigo ceo joseph papa say statement strong organic growth discipline approach transparent accessible corporate governance policy be foundation successful business strategy
884,AGN,mylan first propose buy perrigo back april cash mylan share perrigo share later lift share mylan share time
885,AGN,time mylan launch tender offer stock portion offer have lose considerable value result teva pharmaceutical industry teva abandon own hostile bid mylan buy generic business allergan agn also general drug stock sell perrigo stock have fall also however lead mylan argue perrigo shareholder still make money deal
886,AGN,perrigo leadership have steadfastly opposed mylan overture criticize offer mylan business mylan corporate governance same time ve seek mollify shareholder operational improvement share buyback plan latter papa say friday go ahead now vote be
887,AGN,accord anonymously source report perrigo buyout prospect be also hold mylan issue be resolve wall street journal report wednesday summer perrigo be talk endo international endp possible combination
888,AGN,not do deal
889,AGN,capital iq analyst jeffrey loo write expect more perrigo future
890,AGN,do not see many synergistic fit company now mylan issue be believe perrigo begin pursue acquisition likely consumer health care unit loo write research note maintain buy rating perrigo mylan
891,AGN,morningstar analyst michael also write see mylan stay hunt
892,AGN,generic drug industry still remain relatively fragmented view possible asset sale pfizer pfe sanofi sny provide mylan other opportunity merger acquisition especially asset have greater cost synergy potential perrigo mostly counter business write research note perrigo shareholder reject hostile takeover bid fellow generic drug maker mylan friday morning send perrigo stock mylan long acrimonious battle end mylan myl say press release et deadline perrigo prgo share have be validly tender miss require takeover succeed grow alonemylan management maintain statement be fine perrigo mylan focuse approach organic inorganic growth have deliver compound annual growth rate adjust diluted earning share ep shareholder strategically consistently expand business say mylan ceo heather bresch recent financial result continue demonstrate power stand alone platform double digit growth legacy business well enhance double digit growth epd business mylan shareholder seem agree stock rise close perrigo stock fall management claim victory have say offer mylan be bad deal shareholder significantly undervalue durable business model industry lead future growth prospect perrigo ceo joseph papa say statement strong organic growth discipline approach transparent accessible corporate governance policy be foundation successful business strategy mylan first propose buy perrigo back april cash mylan share perrigo share later lift share mylan share time time mylan launch tender offer stock portion offer have lose considerable value result teva pharmaceutical industry teva abandon own hostile bid mylan buy generic business allergan agn also general drug stock sell perrigo stock have fall also however lead mylan argue perrigo shareholder still make money deal perrigo leadership have steadfastly opposed mylan overture criticize offer mylan business mylan corporate governance same time ve seek mollify shareholder operational improvement share buyback plan latter papa say friday go ahead now vote be accord anonymously source report perrigo buyout prospect be also hold mylan issue be resolve wall street journal report wednesday summer perrigo be talk endo international endp possible combination not do deal capital iq analyst jeffrey loo write expect more perrigo future do not see many synergistic fit company now mylan issue be believe perrigo begin pursue acquisition likely consumer health care unit loo write research note maintain buy rating perrigo mylan morningstar analyst michael also write see mylan stay hunt generic drug industry still remain relatively fragmented view possible asset sale pfizer pfe sanofi sny provide mylan other opportunity merger acquisition especially asset have greater cost synergy potential perrigo mostly counter business write research note
893,AGN,biotech sucampo pharmaceutical scmp have have mostly good year prepare challenge future sucampo have enjoy strong sale profit growth past quarters thank constipation drug amitiza market partner takeda drug have drive sucampo stock strong ibd composite rating even recent drug stock hammer amitiza be face competition linzess fast grow rival drug giant allergan agn
894,AGN,next year fact cvs cvs drop amitiza prefer formulary favor allergan drug
895,AGN,
896,AGN,peter greenleaf
897,AGN,year old
898,AGN,ceo sucampo pharmaceutical
899,AGN,ba western connecticut state university
900,AGN,mba st joseph university
901,AGN,note chair venture fund authority encourage investment state
902,AGN,
903,AGN,sucampo have other product pipeline cobiprostone potential treatment oral mucositis nonerosive reflux disease ceo peter greenleaf wall street have say company need acquire more asset
904,AGN,aug sucampo launch tender offer worth cash stock japanese biotech tech ueno sucampo say acquisition boost financial profile pipeline recently greenleaf talk ibd acquisition mean sucampo future
905,AGN,ibd be rationale tech ueno acquisition company have relationship right
906,AGN,greenleaf have relationship insomuch founder sucampo be founder tech ueno hold ownership position company well
907,AGN,business relationship company be primarily manufacturing be exclusive manufacturer lead product amitiza historical product call rescula ophthalmology indication be really only available today japan pipeline product have development product call cobiprostone
908,AGN,have historical tie research development work pipeline development today have right asset weren currently engage specific research collaboration company
909,AGN,acquisition set accelerant grow transform company strategic benefit be really threefold
910,AGN,provide immediately accretive transaction third economic be outside accrue partner third economic accrue outside partner be acquire bring significant financial benefit company increase revenue enhance profitability free cash flow early projection still be adjust base final financing term call double ep income year follow
911,AGN,do give guidance financial result look net income ep adjust ebitda number be obviously significantly higher be today sucampo have ep cent
912,AGN,get full control supply chain manufacturing basically take sucampo company do research development produce revenue partner also have benefit control manufacturing help way give control help ensure have contiguous continuous supply chain help management risk second operationally provide opportunity renegotiate contract gain operational leverage hopefully continue reduce cost structure
913,AGN,lastly tech ueno have lot pipeline program transaction re gain several new asset multiple new indication least re initially very excited bring significant diversification value company
914,AGN,ibd elaborate pipeline
915,AGN,greenleaf tech ueno pipeline provide new asset multiple therapeutic area include ophthalmology element dermatology autoimmune disease oncology initial diligence have tell most asset not meet criterium develop further do have datum certain phase development mostly phase phase do not decide develop close appear synergy deal decide monetize way licensing other partner regional global
916,AGN,be program call vascular adhesion protein inhibitor currently be study oral iv formulation autoimmune disease cancer stroke copd chronic obstructive pulmonary disease be pre proof concept development be lot interest pharmaceutical sector pathway inhibitor real potential solution many autoimmune inflammatory disorder
917,AGN,have be couple deal most recently boehringer ingelheim actually license vascular adhesion protein inhibitor smaller company call pharmaxis same stage development upfront then earn out so show real interest large pharma space re excited prospect
918,AGN,ibd do have impact future deal be still hunt other asset
919,AGN,greenleaf sure ve say past continue say part strategy ll build company organically inorganically ll continue work strengthen pipeline well financial performance company so yes re still actively look opportunity pipeline commercial space
920,AGN,re process get lock hopefully get successful tender offer ve say publicly re used debt financing cash balance sheet finance so process go be matter debt financing look back end quickly deleverage
921,AGN,so many different way structure deal day not slow degree re digest start process get deal do integrate want do more deal re go try make success first don think take long time want first get deal do start base stage integration
922,AGN,do think go affect ability do other deal think lot come fact deal different size structure well deal bring be factor be very deal specific management have desire have slow future deal flow biotech sucampo pharmaceutical scmp have have mostly good year prepare challenge future sucampo have enjoy strong sale profit growth past quarters thank constipation drug amitiza market partner takeda drug have drive sucampo stock strong ibd composite rating even recent drug stock hammer amitiza be face competition linzess fast grow rival drug giant allergan agn next year fact cvs cvs drop amitiza prefer formulary favor allergan drug peter greenleaf year oldceo sucampo western connecticut state universitymba st joseph universityof note chair venture fund authority encourage investment state sucampo have other product pipeline cobiprostone potential treatment oral mucositis nonerosive reflux disease ceo peter greenleaf wall street have say company need acquire more asset aug sucampo launch tender offer worth cash stock japanese biotech tech ueno sucampo say acquisition boost financial profile pipeline recently greenleaf talk ibd acquisition mean sucampo future ibd be rationale tech ueno acquisition company have relationship right greenleaf have relationship insomuch founder sucampo be founder tech ueno hold ownership position company well business relationship company be primarily manufacturing be exclusive manufacturer lead product amitiza historical product call rescula ophthalmology indication be really only available today japan pipeline product have development product call cobiprostone have historical tie research development work pipeline development today have right asset weren currently engage specific research collaboration company acquisition set accelerant grow transform company strategic benefit be really threefold provide immediately accretive transaction third economic be outside accrue partner third economic accrue outside partner be acquire bring significant financial benefit company increase revenue enhance profitability free cash flow early projection still be adjust base final financing term call double ep income year follow do give guidance financial result look net income ep adjust ebitda number be obviously significantly higher be today sucampo have ep cent get full control supply chain manufacturing basically take sucampo company do research development produce revenue partner also have benefit control manufacturing help way give control help ensure have contiguous continuous supply chain help management risk second operationally provide opportunity renegotiate contract gain operational leverage hopefully continue reduce cost structure lastly tech ueno have lot pipeline program transaction re gain several new asset multiple new indication least re initially very excited bring significant diversification value company ibd elaborate pipeline greenleaf tech ueno pipeline provide new asset multiple therapeutic area include ophthalmology element dermatology autoimmune disease oncology initial diligence have tell most asset not meet criterium develop further do have datum certain phase development mostly phase phase do not decide develop close appear synergy deal decide monetize way licensing other partner regional global be program call vascular adhesion protein inhibitor currently be study oral iv formulation autoimmune disease cancer stroke copd chronic obstructive pulmonary disease be pre proof concept development be lot interest pharmaceutical sector pathway inhibitor real potential solution many autoimmune inflammatory disorder have be couple deal most recently boehringer ingelheim actually license vascular adhesion protein inhibitor smaller company call pharmaxis same stage development upfront then earn out so show real interest large pharma space re excited prospect ibd do have impact future deal be still hunt other asset greenleaf sure ve say past continue say part strategy ll build company organically inorganically ll continue work strengthen pipeline well financial performance company so yes re still actively look opportunity pipeline commercial space re process get lock hopefully get successful tender offer ve say publicly re used debt financing cash balance sheet finance so process go be matter debt financing look back end quickly deleverage so many different way structure deal day not slow degree re digest start process get deal do integrate want do more deal re go try make success first don think take long time want first get deal do start base stage integration do think go affect ability do other deal think lot come fact deal different size structure well deal bring be factor be very deal specific management have desire have slow future deal flow
923,AGN,share specialty drug giant allergan agn be seesaw tuesday company issue guidance late monday rest year follow sale generic business allergan say expect second half revenue ep include interest expense company say longer term expect
924,AGN,biotech acorda therapeutic acor say monday have reach settlement actavis generic drug arm allergan agn agree actavis generic version acorda drug ampyra win come acorda stock rise sharply allergan fall news be reveal only terse sec filing come big surprise wall street most have expect generic version acorda multiple sclerosis drug come sooner many investor have perceive acorda have little negotiating power generate favorable settlement write leerink analyst paul matteis research note monday agreement actavis market generic ampyra represent best case scenario settlement view ampyra provide virtually acorda current revenue run past month so acorda stock respond favorably spike afternoon trading stock market today allergan be teva pharmaceutical industry teva have agree acquire actavis business deal close early next year be ampyra franchise really do go have increase visibility anywhere then current ampyra business be worth more comparable time sale imply ampyra be equity value business share just ms indication alone write rbc capital market analyst michael yee research note course phase iii post stroke indication add significantly study be positive give potential double sale however matteis point be other generic drugmaker ve sue make generic version ampyra so business be hardly settle also write be possible teva acquisition influenced settlement more fundamental legal issue especially teva be other filer contest patent eliminate filing ampyra be strategic move ahead ftc review approval teva actavis deal be merely drive desire save money avoid redundant legal expense matteis write be case readthrough other filer be limit however be unsure be motivate factor follow amy reeve twitter ibd_areeve facebook
925,AGN,tesla motor tsla get downgrade friday lackluster model launch jazz pharma jazz allergan agn be initiate buy rating barclay downgrade tesla underweight cut price target luxury electric automaker launch event typically generate run event payback yet last week
926,AGN,facebook fb whole food market wfm st century fox be notable company report quarterly result wednesday here look expect
927,AGN,analyst expect social medium pioneer facebook third quarter earning share surge year cent revenue acceleration prior quarters
928,AGN,company past year have make public post searchable try recast more news centric site rapidly expand video user advertiser develop array new video feature deepen user engagement
929,AGN,site user be view video day jeffery say research note last month investment firm expect video ad become multibillion dollar business next year digital ad format become more expensive
930,AGN,video consumption explode fb massive user base think fb look well position capture increase portion tv ad budget marketer migrate datum drive highly target online video ad campaign jeffery say firm also say facebook app instagram beautiful visual layout highly engage audience make good advertising environment
931,AGN,share close stock market today
932,AGN,upscale grocery chain whole food have struggle whole paycheck reputation allegation overcharge consumer competition traditional grocery chain kroger kr have push more aggressively whole food turf offer higher quality fare
933,AGN,whole food september say lay worker partly keep price lower invest technology
934,AGN,whole food be try draw younger shopper less disposable income launch new chain store call whole food market store be set open next year
935,AGN,analyst expect whole food ep fall cent sale be see rise slow prior quarters share rise
936,AGN,medium giant report wednesday st century fox foxa time warner twx have be pressured rise online programming service netflix nflx amazon amzn prime video investor be tune company ad sale subscriber figure other sign ve adapt digitization television
937,AGN,analyst see st century fox ep slip cent revenue edge time warner ep be expect fall revenue
938,AGN,time warner share rise fox rise
939,AGN,pharmaceutical company regeneron pharmaceutical regn allergan agn also report wednesday
940,AGN,botox maker allergan ep be see fall cent street forecast sale rise gain strong pale comparison prior quarter sale jump actavis acquire company march
941,AGN,regeneron third quarter ep be expect leap sale lift
942,AGN,regeneron drug fail eyesight eyelea have propel company growth drug praluent injectable pcsk inhibitor co develop sanofi sa launch summer
943,AGN,special focus be expect be give initial figure praluent launch roth capital partner say regeneron upcoming quarterly result note previous note expect gradual launch eventually expect praluent repatha achieve blockbuster status believe doctor first look optimize statin therapy other modality merck mrk zetia vytorin move injectable therapy
944,AGN,regeneron share fall allergan fall
945,AGN,follow bill peter twitter ibd_bpeter facebook fb whole food market wfm st century fox be notable company report quarterly result wednesday here look expect analyst expect social medium pioneer facebook third quarter earning share surge year cent revenue acceleration prior quarters company past year have make public post searchable try recast more news centric site rapidly expand video user advertiser develop array new video feature deepen user engagement site user be view video day jeffery say research note last month investment firm expect video ad become multibillion dollar business next year digital ad format become more expensive video consumption explode fb massive user base think fb look well position capture increase portion tv ad budget marketer migrate datum drive highly target online video ad campaign jeffery say firm also say facebook app instagram beautiful visual layout highly engage audience make good advertising environment share close stock market today upscale grocery chain whole food have struggle whole paycheck reputation allegation overcharge consumer competition traditional grocery chain kroger kr have push more aggressively whole food turf offer higher quality fare whole food september say lay worker partly keep price lower invest technology whole food be try draw younger shopper less disposable income launch new chain store call whole food market store be set open next year analyst expect whole food ep fall cent sale be see rise slow prior quarters share rise medium giant report wednesday st century fox foxa time warner twx have be pressured rise online programming service netflix nflx amazon amzn prime video investor be tune company ad sale subscriber figure other sign ve adapt digitization television analyst see st century fox ep slip cent revenue edge time warner ep be expect fall revenue time warner share rise fox rise pharmaceutical company regeneron pharmaceutical regn allergan agn also report wednesday botox maker allergan ep be see fall cent street forecast sale rise gain strong pale comparison prior quarter sale jump actavis acquire company march regeneron third quarter ep be expect leap sale lift regeneron drug fail eyesight eyelea have propel company growth drug praluent injectable pcsk inhibitor co develop sanofi sa launch summer special focus be expect be give initial figure praluent launch roth capital partner say regeneron upcoming quarterly result note previous note expect gradual launch eventually expect praluent repatha achieve blockbuster status believe doctor first look optimize statin therapy other modality merck mrk zetia vytorin move injectable therapy regeneron share fall allergan fall follow bill peter twitter ibd_bpeter
946,AGN,most sector leader still work potential basis let not forget company fundamental top notch earning sale growth be key driver performance winning stock acadium healthcare achc allergan agn show accelerate top line growth buyout be help result company franklin tenn base acadium provide psychiatric chemical dependency treatment service network
947,AGN,drug stock take pound third quarter lead drug company pipeline have keep flow potentially blockbuster new drug here be key product merck shire gilead science expect be approve fda next month so friday merck mrk be expect hear
948,AGN,major index end top session range stock sharply pare loss close thursday dow jone industrial average fall nasdaq shed give be more much session volume be higher board stock market today accord preliminary datum loser edge winner margin nyse nasdaq economic front new home sale rise nearly well estimate jobless claim week end climb come forecast durable good order slip august line view construction gear maker be hardest hit caterpillar cat gap sank cut revenue outlook also expect cut more job drug stock be day worst performer amag pharmaceutical amag buck sell reverse sharply upward gain fast trade stock be mid july peak jeffery recently maintain buy rating price target cite potential catalyst include approval amag makena premature birth drug allergan agn also stage upward reversal climb average volume stock be midst new consolidation drugmaker amgen amgn say wednesday biosimilar version roche rhhby avastin cancer drug be successful late stage trial monster beverage mnst rise work new base potential buy point current pattern be first stage base low undercut prior base goldman sachs raise rating energy drink maker buy neutral price target ibd stock paycom software payc be biggest loser slumping heavy trade day move average first time month company provide cloud base payroll human resource software follow nancy gondo twitter ibd_ngondo
949,AGN,year facebook fb acquire instagram photo sharing site say tuesday hit user milestone reach span globe instagrammer live outside say today screen day feature big cap leader top rate institutional quality stock such facebook starbucks sbux valeant pharmaceutical vrx here be several big cap have seek maintain presence get even bigger facebook bring hundred million more international user fold acquisition messaging service whatsapp annex territory virtual reality space last year oculus rift buyout facebook share end session stock market today stock have ibd composite rating be trading day line retake support earlier month relative strength line track stock vs have be hit new highsjust facebook have expand presence abroad buyout starbucks have broaden appeal coffee drinker several nonjava acquisition tea seller teavana baked good purveyor la boulange juice maker evolution fresh additionally investing mobile payment technology have paid coffee giant starbucks reward program have member rbc capital market say last week mobile payment account starbucks august sale adoption new mobile order pay feature be see grow share close wednesday starbucks also tough recent selloff share remain day valeant pharmaceutical vrx have make acquisition merge biovail biotech fail beat actavis battle botox parent allergan agn have not stop shopping acquire drug maker salix pharmaceutical sexual health drug firm addyi year share take hit monday follow hillary clinton price gouge tweet say outline plan take high drug price specialty drug market valeant share rally remain day cybersecurity firm palo alto network panw rate stock announce acquisition cirrosecure software service saas securer last year palo alto also buy morta security tel aviv base cyvera recent spate hack cyberattack business government agency have boost interest network security infrastructure product share palo alto network be trading day line end session wednesday related biotech stock dive clinton price gouge tweetfacebook hit home run instagram monetize adsamazon facebook hold market sell offstarbuck mobile order pop android join applevaleant miss botox hit other buy
950,AGN,big drugmaker amgen amgn allergan agn announce wednesday biosimilar version roche rhhby blockbuster cancer drug avastin succeed late stage trial small cell lung cancer amgen allergan start collaboration back allergan be generic drug maker call watson pharmaceutical release few detail say drug abp have
951,AGN,biotech stock tumble monday presidential candidate hillary clinton say propose plan address high drug price tuesday
952,AGN,price gouge specialty drug market be outrageous clinton write twitter account monday morning tomorrow ll lay plan take clinton link new york time article daraprim drug price be hike more fold be acquire privately hold turing pharmaceutical
953,AGN,rbc capital market analyst michael yee write note other reason biotechs rough monday be confirmation progressive multifocal pml case associate biogen biib multiple sclerosis franchise also say biotechs have be trading inversely crude price jump monday
954,AGN,biotechs lead drug sell
955,AGN,ishare nasdaq biotech etf ibb fall monday biogen stock skid gilead science gild start day slightly report good drug trial news lose
956,AGN,regeneron regn fall amgen amgn regeneron partner sanofi sny amgen recently win separate approval new class cholesterol fighter
957,AGN,leader other drug group also fall allergan agn sank valeant pharmaceutical vrx drug pricing policy have draw criticism retreat
958,AGN,politician have be criticize drug cost year price have keep go especially specialty drug segment drug prescribe specialist instead primary care doctor gilead sovaldi be target such criticism march company price week round
959,AGN,have written extensively specialty drug segment account prescription dollar spend vs year leonard yaffe manage health care hedge fund kessel capital management write email give dramatic rise spending drug average annually past decade annual cost often excess year represent easy target criticism
960,AGN,clinton impact see limit
961,AGN,ultimately political furor sovaldi didn lead actual legislation wasn government drive sovaldi price competition abbvie abbv unveil rival regimen december company get rebate war
962,AGN,so clinton really make difference terry haine evercore isi policy analyst former washington lobbyist find unlikely
963,AGN,even democratic president be assume congress almost certainly not approve drug pricing regulation legislation haine write note client
964,AGN,still wasn drug stock need struggle recover ibd medical biotech group dive july high aug low broader macroeconomic valuation concern analyst yee write continue current environment
965,AGN,investor prepare drug pricing volatility noise go have say drug pricing noise turn due election year write biotech stock tumble monday presidential candidate hillary clinton say propose plan address high drug price tuesday price gouge specialty drug market be outrageous clinton write twitter account monday morning tomorrow ll lay plan take clinton link new york time article daraprim drug price be hike more fold be acquire privately hold turing pharmaceutical rbc capital market analyst michael yee write note other reason biotechs rough monday be confirmation progressive multifocal pml case associate biogen biib multiple sclerosis franchise also say biotechs have be trading inversely crude price jump monday biotechs lead drug sell ishare nasdaq biotech etf ibb fall monday biogen stock skid gilead science gild start day slightly report good drug trial news lose regeneron regn fall amgen amgn regeneron partner sanofi sny amgen recently win separate approval new class cholesterol fighter leader other drug group also fall allergan agn sank valeant pharmaceutical vrx drug pricing policy have draw criticism retreat politician have be criticize drug cost year price have keep go especially specialty drug segment drug prescribe specialist instead primary care doctor gilead sovaldi be target such criticism march company price week round have written extensively specialty drug segment account prescription dollar spend vs year leonard yaffe manage health care hedge fund kessel capital management write email give dramatic rise spending drug average annually past decade annual cost often excess year represent easy target criticism clinton impact see political furor sovaldi didn lead actual legislation wasn government drive sovaldi price competition abbvie abbv unveil rival regimen december company get rebate war so clinton really make difference terry haine evercore isi policy analyst former washington lobbyist find unlikely even democratic president be assume congress almost certainly not approve drug pricing regulation legislation haine write note client still wasn drug stock need struggle recover ibd medical biotech group dive july high aug low broader macroeconomic valuation concern analyst yee write continue current environment investor prepare drug pricing volatility noise go have say drug pricing noise turn due election year write
966,AGN,share biotech aerie pharmaceutical aeri vault much thursday get passel price target increase company announce late wednesday glaucoma drug have succeed late stage clinical trial
967,AGN,aerie say eye drop rhopressa have succeed lower intra ocular pressure sufferer glaucoma ocular hypertension goal be show once daily dose rhopressa be inferior timolol popular ingredient eye drop such allergan agn combigan merck mrk cosopt
968,AGN,aerie also test twice daily dose rhopressa say be slightly more effective also show higher rate side effect most common side effect be eye redness appear subject rhopressa
969,AGN,aerie say expect file fda approval mid
970,AGN,aerie stock jump month high stock market today close make market top percentage gainer day
971,AGN,big drop april
972,AGN,trial be phase study call rocket rocket rocket have fail meet inferiority endpoint whack stock price back april however june fda agree let aerie modify rocket endpoint look only patient relatively low level intra ocular pressure start millimeter mercury mmhg group have respond better rocket
973,AGN,adjustment lead accusation aerie dredge rocket make rhopressa seem more efficacious canaccord genuity analyst corey davis acknowledge research note however glaucoma patient have intra ocular pressure less mmhg think rhopressa approve have definitive place market davis raise price target stock
974,AGN,rbc capital market analyst adnan butt write result also bode well roclatan combination rhopressa latanoprost prostaglandin analogue pga sell separately pfizer pfe xalatan roclatan be also phase testing earlier process
975,AGN,roclatan demonstrate superiority component believe be little controversy roclatan be blockbuster drug butt write raise price target
976,AGN,needham analyst serge belanger raise price target note rhopressa be first new glaucoma treatment year
977,AGN,follow amy reeve twitter ibd_areeve facebook share biotech aerie pharmaceutical aeri vault much thursday get passel price target increase company announce late wednesday glaucoma drug have succeed late stage clinical trial aerie say eye drop rhopressa have succeed lower intra ocular pressure sufferer glaucoma ocular hypertension goal be show once daily dose rhopressa be inferior timolol popular ingredient eye drop such allergan agn combigan merck mrk cosopt aerie also test twice daily dose rhopressa say be slightly more effective also show higher rate side effect most common side effect be eye redness appear subject rhopressa aerie say expect file fda approval mid aerie stock jump month high stock market today close make market top percentage gainer day big drop trial be phase study call rocket rocket rocket have fail meet inferiority endpoint whack stock price back april however june fda agree let aerie modify rocket endpoint look only patient relatively low level intra ocular pressure start millimeter mercury mmhg group have respond better rocket adjustment lead accusation aerie dredge rocket make rhopressa seem more efficacious canaccord genuity analyst corey davis acknowledge research note however glaucoma patient have intra ocular pressure less mmhg think rhopressa approve have definitive place market davis raise price target stock rbc capital market analyst adnan butt write result also bode well roclatan combination rhopressa latanoprost prostaglandin analogue pga sell separately pfizer pfe xalatan roclatan be also phase testing earlier process roclatan demonstrate superiority component believe be little controversy roclatan be blockbuster drug butt write raise price target needham analyst serge belanger raise price target note rhopressa be first new glaucoma treatment year follow amy reeve twitter ibd_areeve facebook
978,AGN,valeant pharmaceutical find plenty company market misery last week drugmaker biotech stock sell hillary clinton accuse big pharma price gouge valeant vrx close nearly lower week biogen biib gilead science gild regeneron pharmaceutical regn amgen amgn allergan agn horizon pharma hznp also fall bloomberg report clinton plan
979,AGN,valeant pharmaceutical vrx be specialty drug maker biotech stock get clobber week hillary clinton send tweet accuse big pharma price gouge reaction democratic front runner comment valeant fall monday misery find plenty company biogen biib gilead science gild regeneron pharmaceutical regn amgen amgn
980,AGN,target deal announce so far year mark jump pace biggest month period ever domestic merger acquisition accord dealogic comprise half global totale year date monday sum be pace set
981,AGN,aggressive investor aren know patience yet be exactly current market require be reason be patient now first uptrend be pressure mean individual investor least be wary add exposure raise bit cash be prudent second breakout top stock be scarce breakout investor have
982,AGN,stock have come session lows be still mixed late monday nasdaq cut deficit tech laden index be much intraday edge dow jone industrial average outperformed gain volume be run mixed stock market today compare same time friday nyse trade be tracking sharply lower nasdaq volume be run pinch higher volume surge friday due quadruple witching biotechs other medical issue be session lows still hard follow tweet hillary clinton valeant pharmaceutical vrx turn gain loss reversal send back day line lannett lci drop breach day line stock appear be try support day move average elsewhere regeneron pharmaceutical regn illumina ilmn allergan agn shed allergan be featured monday sector leader review upside cyberark software cybr be session high still nearly be upgrade buy hold deutsche bank stock be stabilize tumble june record high red hat rht rise little more poke day line software maker report earning close analyst poll thomson reuter see profit rise cent share follow vincent mao twitter ibd_vmao
983,AGN,top rate drugmaker such valeant pharmaceutical international vrx celgene celg have be busy lab wall street take part big merger deal today ibd list feature top rate drugmaker addition valeant celgene list include regeneron pharmaceutical regn lannett lci allergan agn friday biogen idec biib price
984,AGN,antibiotic specialist tetraphase pharmaceutical ttph stock crash nearly get multiple downgrade wednesday company lead drug eravacycline fail clinical trial
985,AGN,late tuesday tetraphase say ignite phase clinical trial complicate urinary tract infection cuti eravacycline do not stack standard treatment levofloxacin better know johnson johnson jnj levaquin
986,AGN,plan further analyze datum provide update have discuss datum plan path forward regulatory agency tetraphase ceo guy macdonald say statement previously announce positive datum ignite phase clinical trial eravacycline administer intravenously complicate intra abdominal infection do meet primary endpoint demonstrate high cure rate prevalent gram negative pathogen favorable safety profile
987,AGN,tetraphase doesn have product market yet stock have be fly high touch record high july hold ibd relative strength rating putt top stock performance past month least stock strength seem be buyout speculation fellow antibiotic maker cubist durata be acquire merck mrk actavis now allergan agn respectively
988,AGN,midday trading stock market today tetraphase stock be month low
989,AGN,brean needham suntrust stifel nomura downgrade stock neutral equivalent analyst say be surprised outcome positive datum study last september nomura analyst ian somaiya write news not only cut cuti market raise question drug approval timeline complicate intra abdominal infection ciai
990,AGN,give negative result ignite believe tetraphase need run additional phase iii trial somaiya write downgrade note lower price target
991,AGN,guggenheim analyst louise chen lower price target maintain buy rating be more confident somaiya tetraphase win have run ciai trial
992,AGN,thing give confidence happen chen write research note
993,AGN,similar drug have be approve only phase datum accord tetraphase have more datum drug
994,AGN,base discussion fda achaogen akao expect plazomicin be approve cuti only successful trial
995,AGN,eu new antibiotic guidance require only trial approval iai uti be target infection note agency
996,AGN,follow amy reeve twitter ibd_areeve facebook antibiotic specialist tetraphase pharmaceutical ttph stock crash nearly get multiple downgrade wednesday company lead drug eravacycline fail clinical trial late tuesday tetraphase say ignite phase clinical trial complicate urinary tract infection cuti eravacycline do not stack standard treatment levofloxacin better know johnson johnson jnj levaquin plan further analyze datum provide update have discuss datum plan path forward regulatory agency tetraphase ceo guy macdonald say statement previously announce positive datum ignite phase clinical trial eravacycline administer intravenously complicate intra abdominal infection do meet primary endpoint demonstrate high cure rate prevalent gram negative pathogen favorable safety profile tetraphase doesn have product market yet stock have be fly high touch record high july hold ibd relative strength rating putt top stock performance past month least stock strength seem be buyout speculation fellow antibiotic maker cubist durata be acquire merck mrk actavis now allergan agn respectively midday trading stock market today tetraphase stock be month low brean needham suntrust stifel nomura downgrade stock neutral equivalent analyst say be surprised outcome positive datum study last september nomura analyst ian somaiya write news not only cut cuti market raise question drug approval timeline complicate intra abdominal infection ciai give negative result ignite believe tetraphase need run additional phase iii trial somaiya write downgrade note lower price target guggenheim analyst louise chen lower price target maintain buy rating be more confident somaiya tetraphase win have run ciai trial thing give confidence happen chen write research note similar drug have be approve only phase datum accord tetraphase have more datum drug base discussion fda achaogen akao expect plazomicin be approve cuti only successful trial eu new antibiotic guidance require only trial approval iai uti be target infection note agency follow amy reeve twitter ibd_areeve facebook
997,AGN,vast majority growth stock be still consolidate gain thing certain new basis form point yield powerful technical breakout process doesn happen overnight so important be patient setup emerge pull trigger too quickly bullish technical setup aren easy find
998,AGN,come buyout drugmaker hard keep valeant pharmaceutical vrx rapid pace acquisition canadian drugmaker have already make flurry acquisition year lead stock ethical drug maker group composite rating other highly rate player group include horizon hznp eli lilly lly jazz pharmaceutical jazz nordisk nvo abbvie abbv
999,AGN,group rank tuesday issue spot week
1000,AGN,outperform other drug group generic biotechs
1001,AGN,latest news valeant progenic tuesday say fda accept new drug application submission oral relistor
1002,AGN,last week valeant say buy synergetic usa deal value synergetic make surgical instrument used ophthalmology neurosurgery
1003,AGN,also last week valeant announce agreement pay astrazeneca azn licensing deal psoriasis drug candidate brodalumab amgen astrazeneca previous partner drug exit program several trial patient commit suicide valeant plan file fda approval
1004,AGN,august also strike deal buy pharmaceutical maker addyi libido pill woman fda reject drug twice approve august day valeant acquisition news first only drug market treat call hypoactive sexual desire disorder
1005,AGN,july valeant say acquire amoun pharmaceutical egypt biggest drugmaker
1006,AGN,major acquisition get away earlier year be botox maker allergan agn valeant offer target company go higher bid ireland base actavis then change name allergan
1007,AGN,many other health care stock valeant be attempt come back trigger multiple sell signal late august market take beating stock find support week move average have be find resistance week line
1008,AGN,also still flat base entry clear july point be best new pattern emerge
1009,AGN,valeant tuesday ibd have post double digit profit growth double digit better sale gain past quarters analyst expect earning gain higher revenue steady performance help earn earning share rating year earning stability factor scale most stable least stable however poor accumulation distribution rating volume ratio point weak recent demand share
1010,AGN,recent price performance weakness valeant be more year horizon nordisk have rally more respectively come buyout drugmaker hard keep valeant pharmaceutical vrx rapid pace acquisition canadian drugmaker have already make flurry acquisition year lead stock ethical drug maker group composite rating other highly rate player group include horizon hznp eli lilly lly jazz pharmaceutical jazz nordisk nvo abbvie abbv group rank tuesday issue spot week outperform other drug group generic biotechs latest news valeant progenic tuesday say fda accept new drug application submission oral relistor last week valeant say buy synergetic usa deal value synergetic make surgical instrument used ophthalmology neurosurgery also last week valeant announce agreement pay astrazeneca azn licensing deal psoriasis drug candidate brodalumab amgen astrazeneca previous partner drug exit program several trial patient commit suicide valeant plan file fda approval august also strike deal buy pharmaceutical maker addyi libido pill woman fda reject drug twice approve august day valeant acquisition news first only drug market treat call hypoactive sexual desire disorder july valeant say acquire amoun pharmaceutical egypt biggest drugmaker major acquisition get away earlier year be botox maker allergan agn valeant offer target company go higher bid ireland base actavis then change name allergan many other health care stock valeant be attempt come back trigger multiple sell signal late august market take beating stock find support week move average have be find resistance week line also still flat base entry clear july point be best new pattern emerge valeant tuesday ibd have post double digit profit growth double digit better sale gain past quarters analyst expect earning gain higher revenue steady performance help earn earning share rating year earning stability factor scale most stable least stable however poor accumulation distribution rating volume ratio point weak recent demand share recent price performance weakness valeant be more year horizon nordisk have rally more respectively
1011,AGN,valeant pharmaceutical vrx have get lot face time due stream recent acquisition include pharmaceutical maker female viagra addyi not only drugmaker shopping spree sector leader allergan agn have be busy too formerly know actavis firm change name allergan june trumping valeant
1012,AGN,market be still correction mean not best time buy never hurt keep eye top performer such hot drugmaker ibd valeant pharmaceutical vrx say start month shell psoriasis drug licensing
1013,AGN,stock market wasn look great early last week nasdaq plunge day move average heavy volume federal reserve come rescue again dovish policy statement bring buyer back sideline several sector leader have come back life market linkedin lnkd be recently bide
1014,AGN,specialty drugmaker allergan agn report solid result raise guidance monday hostile suitor valeant pharmaceutical international vrx say raise bid company again allergan earning rise year earlier quarter share exclude time item result be high end guidance
1015,AGN,stock future show moderate loss ahead monday open
1016,AGN,dow future be point fair market value drop nasdaq future be mild point future slip point
1017,AGN,stock market today open week fairly tame note regard quarterly earning report
1018,AGN,drug giant merck mrk be fraction deliver third quarter result
1019,AGN,allergan agn climb clear analyst earning revenue forecast third quarter guide fourth quarter earning consensus projection stock also have receive boost news report say valeant pharmaceutical vrx be prepared raise takeover offer nearly share prior offer
1020,AGN,allergan share end friday extend buy point quick pullback test support week move average
1021,AGN,chip equipment maker kla tencor klac pop premarket trade stock gain last week announce thursday borrow finance special dividend share
1022,AGN,brazil base stock be selling hard ahead open final presidential vote sunday re elect incumbent president dilma rousseff state own oil producer petrobra pbr tumble bank itau unibanco itub banco bradesco bbd be telecom tim participacoe tsu drop miner valevale fall
1023,AGN,elsewhere overseas china market close narrow loss tokyo nikkei bump europe news bank fail european central bank stress test exercise weekend help place european stock mild selling pressure midday failure do not broadly surprise analyst do not trigger new capitalization requirement
1024,AGN,dollar be vs euro yen commodity be oil hammer back just barrel
1025,AGN,national association realtor be schedule release september pending home sale datum et stock future show moderate loss ahead monday open dow future be point fair market value drop nasdaq future be mild point future slip point stock market today open week fairly tame note regard quarterly earning report drug giant merck mrk be fraction deliver third quarter result allergan agn climb clear analyst earning revenue forecast third quarter guide fourth quarter earning consensus projection stock also have receive boost news report say valeant pharmaceutical vrx be prepared raise takeover offer nearly share prior offer allergan share end friday extend buy point quick pullback test support week move average chip equipment maker kla tencor klac pop premarket trade stock gain last week announce thursday borrow finance special dividend share brazil base stock be selling hard ahead open final presidential vote sunday re elect incumbent president dilma rousseff state own oil producer petrobra pbr tumble bank itau unibanco itub banco bradesco bbd be telecom tim participacoe tsu drop miner valevale fall elsewhere overseas china market close narrow loss tokyo nikkei bump europe news bank fail european central bank stress test exercise weekend help place european stock mild selling pressure midday failure do not broadly surprise analyst do not trigger new capitalization requirement dollar be vs euro yen commodity be oil hammer back just barrel national association realtor be schedule release september pending home sale datum et
1026,AGN,specialty drugmaker shire face future stand alone company thursday abbvie director late wednesday vote plan acquisition
1027,AGN,investor analyst seem optimistic shire shpg stock be early trading stock market today
1028,AGN,leerink analyst jason gerberry write research note thursday shire be unlikely attract buyer point pfizer pfe allergan agn have be rumore be interested firm same potential change tax inversion rule kill abbvie abbv interest likely do same say
1029,AGN,additional cash likely break fee view shpg more likely buyer market expect ceo flem ornskov resume orphan asset roll gerberry write shire look buy drug treat rare medical condition
1030,AGN,add upcoming event boost stock price include potential approval next year drug lifitegrast dry eye disease potential blockbuster indication
1031,AGN,gerberry cut price target shire stock give stock be trading wednesday plunge see buy opportunity
1032,AGN,bank america graham parry echo point upgrade stock buy wednesday base price drop thursday note re emphasize buy opportunity give attractive entry price fundamental compelling stand alone investment case
1033,AGN,shire be already high rate stock abbvie deal jacked ibd relative strength rating be likely abbvie have raise offer time finally clinch deal summer even wednesday hit stock boast highest possible ibd composite rating
1034,AGN,follow amy reeve twitter ibd_areeve specialty drugmaker shire face future stand alone company thursday abbvie director late wednesday vote plan acquisition investor analyst seem optimistic shire shpg stock be early trading stock market today leerink analyst jason gerberry write research note thursday shire be unlikely attract buyer point pfizer pfe allergan agn have be rumore be interested firm same potential change tax inversion rule kill abbvie abbv interest likely do same say additional cash likely break fee view shpg more likely buyer market expect ceo flem ornskov resume orphan asset roll gerberry write shire look buy drug treat rare medical condition add upcoming event boost stock price include potential approval next year drug lifitegrast dry eye disease potential blockbuster indication gerberry cut price target shire stock give stock be trading wednesday plunge see buy opportunity bank america graham parry echo point upgrade stock buy wednesday base price drop thursday note re emphasize buy opportunity give attractive entry price fundamental compelling stand alone investment case shire be already high rate stock abbvie deal jacked ibd relative strength rating be likely abbvie have raise offer time finally clinch deal summer even wednesday hit stock boast highest possible ibd composite rating follow amy reeve twitter ibd_areeve
1035,AGN,valeant pharmaceutical battle marry allergan end be left altar jury be still outcome takeover fight drug giant have unfold poorly script soap opera valeant vrx monday hint ante botox
1036,AGN,specialty drugmaker allergan raise guidance thursday take opportunity say yet again valeant pharmaceutical hostile bid company be too low
1037,AGN,allergan agn stock nonetheless be flat morning trading stock market today
1038,AGN,allergan earning guidance be now share more cent higher firm previous guidance analyst consensus allergan say year year sale growth be more quarter compare analyst
1039,AGN,allergan full year ep guidance be now previous guidance beating street least cent sale growth be forecast growth vs consensus
1040,AGN,allergan also guide ep consensus guide be vs street vs
1041,AGN,today announce expectation third quarter update future outlook further demonstrate be vast value gap valeant offer intrinsic value allergan allergan ceo david pyott say pointedly company press release
1042,AGN,value valeant vrx bid be move target offer be partly stock deutsche bank analyst gregg gilbert point initiation report allergan wednesday
1043,AGN,current offer value share do not suggest upside expect vrx share appreciate boost agn share likelihood complete deal increase write
1044,AGN,gilbert initiate coverage allergan buy rating price target
1045,AGN,meanwhile jpmorgan analyst chris schott write allergan buyout probably wouldn close less share especially now actavis act be rumore be near bid allergan well
1046,AGN,allergan pre announcement ep guidance continue support company premium stand alone multiple view write research note thursday
1047,AGN,valeant stock be morning trading thursday actavis stock be fraction
1048,AGN,share salix pharmaceutical slxp have lately be rumore be buyout target allergan actavis be fraction
1049,AGN,follow amy reeve twitter ibd_areeve
1050,AGN,related
1051,AGN,salix actavis big cap pharmas merger mambo specialty drugmaker allergan raise guidance thursday take opportunity say yet again valeant pharmaceutical hostile bid company be too low allergan agn stock nonetheless be flat morning trading stock market today allergan earning guidance be now share more cent higher firm previous guidance analyst consensus allergan say year year sale growth be more quarter compare analyst allergan full year ep guidance be now previous guidance beating street least cent sale growth be forecast growth vs consensus allergan also guide ep consensus guide be vs street vs today announce expectation third quarter update future outlook further demonstrate be vast value gap valeant offer intrinsic value allergan allergan ceo david pyott say pointedly company press release value valeant vrx bid be move target offer be partly stock deutsche bank analyst gregg gilbert point initiation report allergan wednesday current offer value share do not suggest upside expect vrx share appreciate boost agn share likelihood complete deal increase write gilbert initiate coverage allergan buy rating price target meanwhile jpmorgan analyst chris schott write allergan buyout probably wouldn close less share especially now actavis act be rumore be near bid allergan well allergan pre announcement ep guidance continue support company premium stand alone multiple view write research note thursday valeant stock be morning trading thursday actavis stock be fraction share salix pharmaceutical slxp have lately be rumore be buyout target allergan actavis be fraction follow amy reeve twitter ibd_areeve related salix actavis big cap pharmas merger mambo
1052,AGN,market correction mode investor have watch stock set sell signal sector leader wednesday paper salix pharmaceutical slxp fleetcor technology flt stage round trip recent breakout round trip be sell signal take place stock give double digit gain clear buy point
1053,AGN,abbvie abbv late wednesday say board director recommendation shareholder reject plan buy shire pharmaceutical board cite new treasury rule issue make tax inversion deal less attractive abbvie say statement breadth scope change include unexpected nature exercise administrative authority
1054,AGN,term stock picker market be cliche certainly apply ibd name be work well other well not so much ibd capped fourth straight weekly gain friday gain time compare gain nasdaq ibd
1055,AGN,stock show resilience trade tightly be worth watch price action often yield new entry initial biotech stock rally broadly tuesday include sector leader alexion alxn still buy range clear buy point strong volume alexion be stock
1056,AGN,top stock mutual fund manager recent month have be feast mostly tech medical stock be top gainer november nation lead fund past month have be pour money apple aapl yahoo yhoo alibaba baba baidu bidu technology avgo latest report period medical big gun actavis act
1057,AGN,seller be stock market thursday concern resurface health global economy vix volatility gauge shot month high
1058,AGN,close nasdaq dow jone industrial average lose preliminary datum show nyse nasdaq volume come slightly lower wednesday level
1059,AGN,new york mercantile exchange november crude oil lose barrel lowest close december gold meanwhile jump ounce commodity reflect fear world economy
1060,AGN,oil gas producer driller field service firm be worst perform industry group fall more
1061,AGN,economic news weekly jobless claim fall fourth straight week week move average claim be now lowest february
1062,AGN,stock market today pepsico pep be strong early company report earning gain fade close rise more share end
1063,AGN,ipo news hubspot hub have strong debut online marketing software company price last night open share be recently trading company do revenue
1064,AGN,tesla motor tsla surrender early gain fall nearly ahead today product announcement et barclay think tesla announce driver assistance system dual motor model wheel drive capability
1065,AGN,allergan agn give back early gain bullish earning guidance share fall valeant vrx be try acquire allergan share earlier offer share seller be stock market thursday concern resurface health global economy vix volatility gauge shot month high close nasdaq dow jone industrial average lose preliminary datum show nyse nasdaq volume come slightly lower wednesday level new york mercantile exchange november crude oil lose barrel lowest close december gold meanwhile jump ounce commodity reflect fear world economy oil gas producer driller field service firm be worst perform industry group fall more economic news weekly jobless claim fall fourth straight week week move average claim be now lowest february stock market today pepsico pep be strong early company report earning gain fade close rise more share end ipo news hubspot hub have strong debut online marketing software company price last night open share be recently trading company do revenue tesla motor tsla surrender early gain fall nearly ahead today product announcement et barclay think tesla announce driver assistance system dual motor model wheel drive capability allergan agn give back early gain bullish earning guidance share fall valeant vrx be try acquire allergan share earlier offer share
1066,AGN,seller be stock market spade thursday day major average rally broadly higher volume response perceive dovishness minute last month federal reserve meeting
1067,AGN,little more hour remain session nasdaq dow jone industrial average lose nyse volume rise slightly wednesday level nasdaq volume fall bit
1068,AGN,stock market today hubspot hub have strong debut online marketing software company price last night open share be recently trading company do revenue
1069,AGN,apple aapl be few gainer nasdaq rise activist investor carl icahn say tech bellwether be worth share letter apple icahn also urge company step share buyback new flat base be place apple buy point be
1070,AGN,tesla motor tsla surrender early gain fall ahead today product announcement et barclay think tesla announce driver assistance system dual motor model wheel drive capability
1071,AGN,mobileye mbly be partner tesla share also turn lower early strength fall recent new issue develop software camera base advanced driver assistance system
1072,AGN,allergan agn give back early gain bullish earning guidance share fall valeant vrx be try acquire allergan share earlier offer share
1073,AGN,downside gap gps plunge weak september same store sale company also say ceo glenn murphy retire february ll be succeed art peck president gap growth innovation digital division
1074,AGN,economic news weekly jobless claim fall fourth straight week ve be week move average claim be now lowest february seller be stock market spade thursday day major average rally broadly higher volume response perceive dovishness minute last month federal reserve meeting little more hour remain session nasdaq dow jone industrial average lose nyse volume rise slightly wednesday level nasdaq volume fall bit stock market today hubspot hub have strong debut online marketing software company price last night open share be recently trading company do revenue apple aapl be few gainer nasdaq rise activist investor carl icahn say tech bellwether be worth share letter apple icahn also urge company step share buyback new flat base be place apple buy point be tesla motor tsla surrender early gain fall ahead today product announcement et barclay think tesla announce driver assistance system dual motor model wheel drive capability mobileye mbly be partner tesla share also turn lower early strength fall recent new issue develop software camera base advanced driver assistance system allergan agn give back early gain bullish earning guidance share fall valeant vrx be try acquire allergan share earlier offer share downside gap gps plunge weak september same store sale company also say ceo glenn murphy retire february ll be succeed art peck president gap growth innovation digital division economic news weekly jobless claim fall fourth straight week ve be week move average claim be now lowest february
1075,AGN,gopro action packed clientele stock bolt relative strength line be also move today screen day feature company bolt relative strength line rs line measure well stock be perform here be top base relative strength rating tal education xrs offer school tutor program
1076,AGN,stock future be squarely higher early peak ahead wednesday open
1077,AGN,dow future hold point fair market value nasdaq future be ahead point future show point gain small cap be weak spot russell future trading point fair market value
1078,AGN,stock market today open shade market correction banner nasdaq tuesday left immediate attempt retake day move average tuesday retreat do not undercut low last thursday upside reversal however leave current rally attempt effect
1079,AGN,investor attention be turn federal reserve release minute meeting schedule et
1080,AGN,energy issue be mixed ahead open fact oil future leane lower drop almost tuesday
1081,AGN,oil price be less so far week month contract undercut january low tuesday send future briefly lowest level june weekly oil inventory datum be due et energy information administration
1082,AGN,drugmaker be busy premarket trade biom chimerix cmrx pop company announce positive preliminary result antiviral brincidofovir phase trial involve patient adenovirus stock be take new high so far third straight weekly advance
1083,AGN,botox maker allergan agn climb report company have resist repeat takeover attempt valeant pharmaceutical vrx now be willing consider offer more share report also say actavis act be set enter discussion possibly acquire company valeant share rise more actavis share be not quite
1084,AGN,tech stock symantec symc surge bloomberg report company be consider split separate security program datum storage business symantec share have be mild uptrend march remain mired month correction
1085,AGN,overseas china market post mixed finish tokyo nikkei drop erase week gain
1086,AGN,european stock be lower midday major index show loss less
1087,AGN,dollar edge pause day pullback vs euro yen natural gas trade slightly lower early wednesday be bit more so far week gold rise fraction ounce friday settle stock future be squarely higher early peak ahead wednesday open dow future hold point fair market value nasdaq future be ahead point future show point gain small cap be weak spot russell future trading point fair market value stock market today open shade market correction banner nasdaq tuesday left immediate attempt retake day move average tuesday retreat do not undercut low last thursday upside reversal however leave current rally attempt effect investor attention be turn federal reserve release minute meeting schedule et energy issue be mixed ahead open fact oil future leane lower drop almost tuesday oil price be less so far week month contract undercut january low tuesday send future briefly lowest level june weekly oil inventory datum be due et energy information administration drugmaker be busy premarket trade biom chimerix cmrx pop company announce positive preliminary result antiviral brincidofovir phase trial involve patient adenovirus stock be take new high so far third straight weekly advance botox maker allergan agn climb report company have resist repeat takeover attempt valeant pharmaceutical vrx now be willing consider offer more share report also say actavis act be set enter discussion possibly acquire company valeant share rise more actavis share be not quite tech stock symantec symc surge bloomberg report company be consider split separate security program datum storage business symantec share have be mild uptrend march remain mired month correction overseas china market post mixed finish tokyo nikkei drop erase week gain european stock be lower midday major index show loss less dollar edge pause day pullback vs euro yen natural gas trade slightly lower early wednesday be bit more so far week gold rise fraction ounce friday settle
1088,AGN,tango have turn full hoedown several major pharmaceutical company continue change partner floor valeant pharmaceutical vrx persh square capital management reportedly up bid tuesday allergan agn share accord wall street journal new bid raise valeant bid
1089,AGN,actavis have make acquisition transform generic focuse drugmaker bigger player prescription drug now find enviable position thrive home base ireland expect generate revenue be now large diverse enough forge ahead international power pharmaceutical industry yet
1090,AGN,bausch lomb division valeant pharmaceutical international vrx announce positive late stage trial result new glaucoma drug thursday project sell more year valeant pop morning trading stock market today early afternoon be just bausch lomb license drug vesneo french biotech nicox be acquire valeant last year phase study compare vesneo standard treatment timolol maleate find vesneo be better reduce intraocular pressure excess fluid eyeball once daily twice daily dose company say plan submit drug fda approval middle next year press release valeant say drug peak annual sale pass worldwide make blockbuster valeant doesn normally give drug sale guidance approval be emphasize fide hostile takeover attempt allergan agn allergan main reason resist valeant overture apart valuation be fear valeant decimate allergan thursday allergan issue official response correspondence valeant allergan ceo valeant release press include valeant assertion result beat expectation allergan statement talk own financial say soldier face shareholder valeant partner william ackman lawsuit threat succeed buy salix pharmaceutical slxp spoil takeover attempt also thursday valeant say valueact capital ceo jeffrey ubben be join board oct underscored valueact commitment company valueact president mason morfit left board join board microsoft msft enable company sell valeant share thursday ubben say valueact have not reduce position valeant fact plan increase allergan stock pop new high thursday morning early afternoon be fraction wednesday close follow amy reeve twitter ibd_areeve
1091,AGN,valeant pharmaceutical vrx share pop upbeat guidance addition actavis act allergan valeant salix triangle lift valeant chance allergan takeover
1092,AGN,valeant say expect beat third quarter analyst view revenue own cash ep guidance report oct also see same store organic growth exceed bausch lomb segment deliver more organic growth
1093,AGN,meantime cnbc report actavis be talk buy salix pharmaceutical slxp potentially sink allergan strategy buy salix way fend valeant takeover
1094,AGN,share valeant rise stock market today low early august raise value cash stock bid allergan even richer
1095,AGN,valeant be offer cash share allergan share equal share wednesday close analyst have speculate be fair price
1096,AGN,allergan rise hit new high
1097,AGN,valeant also release correspondence ceo michael pearson allergan agn ceo david pyott valeant prove be prince charming continue aggressive courtship botox queen claim extend olive branch
1098,AGN,monday letter pearson initially try soothe allergan talk tak ing temperature constructive discussion mudslinging
1099,AGN,rebuttal allergan prompt pearson send letter wednesday call pyott concern unfounded disingenuous
1100,AGN,continue believe best interest shareholder team conduct due diligence business seem intent avoid constructive engagement cost pearson write pyott
1101,AGN,remain convince shareholder support combination company such combination create far more value alternative transaction standalone plan
1102,AGN,actavis share rise wednesday hit new high intraday
1103,AGN,salix initially rise wednesday fresh high reversed close stock rise tuesday takeover talk
1104,AGN,related video allergan ackman war reignite salix rumorsvaleant pharmaceutical vrx share pop upbeat guidance addition actavis act allergan valeant salix triangle lift valeant chance allergan takeover valeant say expect beat third quarter analyst view revenue own cash ep guidance report oct also see same store organic growth exceed bausch lomb segment deliver more organic growth meantime cnbc report actavis be talk buy salix pharmaceutical slxp potentially sink allergan strategy buy salix way fend valeant takeover share valeant rise stock market today low early august raise value cash stock bid allergan even richer valeant be offer cash share allergan share equal share wednesday close analyst have speculate be fair price allergan rise hit new high valeant also release correspondence ceo michael pearson allergan agn ceo david pyott valeant prove be prince charming continue aggressive courtship botox queen claim extend olive branch monday letter pearson initially try soothe allergan talk tak ing temperature constructive discussion mudslinging rebuttal allergan prompt pearson send letter wednesday call pyott concern unfounded disingenuous continue believe best interest shareholder team conduct due diligence business seem intent avoid constructive engagement cost pearson write pyott remain convince shareholder support combination company such combination create far more value alternative transaction standalone plan actavis share rise wednesday hit new high intraday salix initially rise wednesday fresh high reversed close stock rise tuesday takeover talk related video allergan ackman war reignite salix rumor
1105,AGN,more leader advanced time high friday market rally palo alto network panw gap rise clear week tight buy point heavy trade stock be now entry piper jaffray reiterate overweight rating raise price target computer security provider
1106,AGN,specialty drugmaker salix pharmaceutical slxp friday cancele buyout cosmo technology become first drugmaker pull plug tax inversion deal salix stock be more early trading stock market today
1107,AGN,salix agree buy cosmo tech irish subsidiary italian drugmaker cosmo pharmaceutical july stock swap company plan use deal relocate ireland take advantage lower corporate tax rate breakup announcement friday salix ceo carolyn logan say time have change
1108,AGN,announce agreement merge cosmo technology july believe combination generate significant value stockholder addition key product development pipeline more efficient corporate structure enhance profitability logan say then however change political environment have create more uncertainty regard potential benefit expect achieve
1109,AGN,logan be doubt refer treasury department rule discourage tax inversion apply such deal hadn close
1110,AGN,be unique circumstance particular deal be never popular shareholder salix stock actually fall day be announce leerink analyst jason gerberry say many shareholder thought price be too high
1111,AGN,more pressingly actavis act allergan agn be widely report be try acquire salix cosmo
1112,AGN,cosmo inversion be see investor potential roadblock sale company write sterne agee analyst shibani malhotra research note friday see today termination cosmo deal signal company be sale especially light last night bloomberg report actavis salix be engage merger talk
1113,AGN,medical device giant medtronic mdt meanwhile have stick deal buy irish counterpart covidien cov friday medtronic say be change method financing purchase company use external financing complete deal rather draw cash foreign subsidiary originally plan company say be somewhat more expensive be still worth give strategic financial benefit merger
1114,AGN,deal be announce june most analyst believe medtronic claim tax inversion be just side benefit merger medtronic tax rate be already pretty low compare peer however firm do cite access overseas cash perk probably explain change financing
1115,AGN,medtronic stock pop morning trading covidien stock be nearly
1116,AGN,follow amy reeve twitter ibd_areeve specialty drugmaker salix pharmaceutical slxp friday cancele buyout cosmo technology become first drugmaker pull plug tax inversion deal salix stock be more early trading stock market today salix agree buy cosmo tech irish subsidiary italian drugmaker cosmo pharmaceutical july stock swap company plan use deal relocate ireland take advantage lower corporate tax rate breakup announcement friday salix ceo carolyn logan say time have change announce agreement merge cosmo technology july believe combination generate significant value stockholder addition key product development pipeline more efficient corporate structure enhance profitability logan say then however change political environment have create more uncertainty regard potential benefit expect achieve logan be doubt refer treasury department rule discourage tax inversion apply such deal hadn close be unique circumstance particular deal be never popular shareholder salix stock actually fall day be announce leerink analyst jason gerberry say many shareholder thought price be too high more pressingly actavis act allergan agn be widely report be try acquire salix cosmo cosmo inversion be see investor potential roadblock sale company write sterne agee analyst shibani malhotra research note friday see today termination cosmo deal signal company be sale especially light last night bloomberg report actavis salix be engage merger talk medical device giant medtronic mdt meanwhile have stick deal buy irish counterpart covidien cov friday medtronic say be change method financing purchase company use external financing complete deal rather draw cash foreign subsidiary originally plan company say be somewhat more expensive be still worth give strategic financial benefit merger deal be announce june most analyst believe medtronic claim tax inversion be just side benefit merger medtronic tax rate be already pretty low compare peer however firm do cite access overseas cash perk probably explain change financing medtronic stock pop morning trading covidien stock be nearly follow amy reeve twitter ibd_areeve
1117,AGN,stock market today be set open lower mixed economic report china europe arab nation begin airstrike syrium islamic state
1118,AGN,nasdaq dow jone industrial average future be
1119,AGN,bombing islamic state force overnight marked escalation conflict first time ally have hit target syrium saudi arabia jordan other arab nation participate attack pentagon say
1120,AGN,manufacturing service sector slow europe private survey show china economy sputtering
1121,AGN,monday ibd market outlook go uptrend pressure main index particularly small cap lead stock be show languish action
1122,AGN,major world market early tuesday asian share be mainly lower nikkei fall hang seng index hong kong fall european bourse be lower also london ftse german dax be cac paris be
1123,AGN,wall street salix pharmaceutical slxp soar premarket trading report allergan agn have revive talk acquire company salix share be bell allergan be unchanged have be seek deal salix fend hostile bid valeant pharmaceutical vrx stock market today be set open lower mixed economic report china europe arab nation begin airstrike syrium islamic state nasdaq dow jone industrial average future be bombing islamic state force overnight marked escalation conflict first time ally have hit target syrium saudi arabia jordan other arab nation participate attack pentagon say manufacturing service sector slow europe private survey show china economy sputtering monday ibd market outlook go uptrend pressure main index particularly small cap lead stock be show languish action major world market early tuesday asian share be mainly lower nikkei fall hang seng index hong kong fall european bourse be lower also london ftse german dax be cac paris be wall street salix pharmaceutical slxp soar premarket trading report allergan agn have revive talk acquire company salix share be bell allergan be unchanged have be seek deal salix fend hostile bid valeant pharmaceutical vrx
1124,AGN,merger acquisition company year have exceed pre crisis peak accord report thursday mergermarket deal announce third quarter be value same period peak year researcher say activity energy mining utility top sector target deal be same period activity sector be lead separate transaction kinder morgan entity value include kinder morgan kmi pending buyout master limit partnership kinder morgan energy partner kmp buyout eliminate incentive distribution lower kinder cost capital accord separate report morningstar call energy pipeline terminal giant kinder granddaddy mlp large deal sector exelon exc pending takeover pepco holding pom value numerous other energy deal be overseas second most active sector be pharmaceutical medical biotech announce buyout value last year valeant pharmaceutical vrx hostile takeover bid allergan agn lead deal list value other big propose year comcast bid time warner cable twc directv dtv tobacco giant reynold american rai lorillard
1125,AGN,stock be still monday worst level earlier rebound effort have weaken nasdaq be respectively meanwhile dow jone industrial average fall volume be again tracking higher major exchange stock market today ctrip com ctrp slump lowest level late june stock have now erased nearly gain buy point cup deep handle mark sell signal salix pharmaceutical slxp lose putt pace fourth straight loss now past flat base have be nearly salix jump latter part august report be potential buyout target allergan agn be fight hostile takeover valeant pharmaceutical vrx upside synchronoss technology sncr rise more erase early weakness stock clear level have be resistance recent session synchronoss provide cloud service software base activation communication service provider be featured new america early month akorn akrx be session high still fast trade share drugmaker be much be upgrade outperform sector perform rbc capital market
1126,AGN,normal market common see more stock hit new high give day only dozen scale new peak tuesday market correction deepen many hit new high only reverse lower best perform stock come health care utility sector investor seek
1127,AGN,specialty drugmaker auxilium pharmaceutical say wednesday review unsolicited takeover bid endo international announce late tuesday board adopt shareholder right poison pill plan deflect hostile takeover attempt many analyst argue endo have pay more auxilium market seem be root
1128,AGN,specialty drugmaker auxilium pharmaceutical say wednesday review unsolicited takeover bid endo international announce late tuesday board adopt shareholder right poison pill plan deflect hostile takeover attempt many analyst argue endo have pay more auxilium market seem be root
1129,AGN,earning season be right corner so smart investor look company expect post strong earning gain fall
1130,AGN,ibd list be good place start rank best growth stock base top fundamental such strong relative price strength market
1131,AGN,biotechs pharmaceutical chinese tech firm dominate list top company highest expect earning growth quarter just end
1132,AGN,gilead science gild top list analyst expect jump earning drugmaker blockbuster drug sovaldi cure hepatitis new pill combine sovaldi drug be expect get approve end month
1133,AGN,sovaldi cost nearly pill week regimen cost major turn patient
1134,AGN,gilead have grant sovaldi license generic drugmaker datum suggest more hep patient have stop take sovaldi new treatment become available
1135,AGN,fbr capital analyst andrew beren recently raise estimate sovaldi sale say prescription be still tracking forecast
1136,AGN,last month gilead also report positive datum trial latest hiv drug analyst expect be blockbuster company plan file drug approval eu next quarter hiv medication account nearly revenue
1137,AGN,athm be second expect jump earning china lead auto content web company have be ride boom china new car market nearly new vehicle be sell china vs
1138,AGN,be outperform rival bitauto bita be also ibd list expect jump quarterly earning
1139,AGN,chinese internet stock recently hit rough patch worry slow growth china lack new stimulus measure beij
1140,AGN,alibaba baba hotly anticipate ipo last month restore buzz sector
1141,AGN,alibaba still have prove worth record ipo vipshop holding vip be already success story
1142,AGN,rank list expect jump earning chinese online clothing retailer have poor debut share have steadily rise then
1143,AGN,popularity apple aapl iphone china be help technology avgo earning be expect rise singapore base chipmaker component be featured smartphone
1144,AGN,iphone finally come china mobile chl largest wireless service provider country january chinese order new iphone reach whopping reservation china friday follow regulatory approval earlier week
1145,AGN,salix pharmaceutical slxp round top jump expect earning maker disorder drug be talk sell actavis act accord report bloomberg late thursday
1146,AGN,salix cancele propose tax inversion merger italy cosmo pharmaceutical government have be tighten regulation overseas deal deal cancellation be see clear way actavis acquisition
1147,AGN,salix be buyout talk botox maker allergan agn be fight takeover bid valeant vrx actavis now close salix allergan defense valeant be weaken
1148,AGN,follow gillian rich twitter ibd_grich earning season be right corner so smart investor look company expect post strong earning gain fall ibd list be good place start rank best growth stock base top fundamental such strong relative price strength market biotechs pharmaceutical chinese tech firm dominate list top company highest expect earning growth quarter just end gilead science gild top list analyst expect jump earning drugmaker blockbuster drug sovaldi cure hepatitis new pill combine sovaldi drug be expect get approve end month sovaldi cost nearly pill week regimen cost major turn patient gilead have grant sovaldi license generic drugmaker datum suggest more hep patient have stop take sovaldi new treatment become available fbr capital analyst andrew beren recently raise estimate sovaldi sale say prescription be still tracking forecast last month gilead also report positive datum trial latest hiv drug analyst expect be blockbuster company plan file drug approval eu next quarter hiv medication account nearly revenue athm be second expect jump earning china lead auto content web company have be ride boom china new car market nearly new vehicle be sell china vs be outperform rival bitauto bita be also ibd list expect jump quarterly earning chinese internet stock recently hit rough patch worry slow growth china lack new stimulus measure beij alibaba baba hotly anticipate ipo last month restore buzz sector alibaba still have prove worth record ipo vipshop holding vip be already success story rank list expect jump earning chinese online clothing retailer have poor debut share have steadily rise then popularity apple aapl iphone china be help technology avgo earning be expect rise singapore base chipmaker component be featured smartphone iphone finally come china mobile chl largest wireless service provider country january chinese order new iphone reach whopping reservation china friday follow regulatory approval earlier week salix pharmaceutical slxp round top jump expect earning maker disorder drug be talk sell actavis act accord report bloomberg late thursday salix cancele propose tax inversion merger italy cosmo pharmaceutical government have be tighten regulation overseas deal deal cancellation be see clear way actavis acquisition salix be buyout talk botox maker allergan agn be fight takeover bid valeant vrx actavis now close salix allergan defense valeant be weaken follow gillian rich twitter ibd_grich
1149,AGN,stock turn negative late morning trading new datum federal reserve show industrial production slip october
1150,AGN,nasdaq fall drop dow jone industrial average shed volume be tracking lower nasdaq slightly higher nyse stock market today
1151,AGN,ibd stock medical name post best gain alexion alxn valeant pharmaceutical vrx akorn akrx actavis act outperform earlier today actavis agree acquire allergan agn trumping earlier offer bill ackman backed valeant
1152,AGN,automaker tata motor ttm jump heavy trading retake buy point cup handle base
1153,AGN,auto part maker gentex gntx climb heavy volume be buy point long consolidation
1154,AGN,paycom software payc add average trading stock recently trigger ibd week hold rule climb less week breaking past cup base buy point recent new issue have highest possible composite rating
1155,AGN,downside linkedin lnkd drop heavy trading stock have struggle gain traction recent past be back buy point stock have be hurt report facebook fb be develop collaboration call facebook work stock turn negative late morning trading new datum federal reserve show industrial production slip october nasdaq fall drop dow jone industrial average shed volume be tracking lower nasdaq slightly higher nyse stock market today ibd stock medical name post best gain alexion alxn valeant pharmaceutical vrx akorn akrx actavis act outperform earlier today actavis agree acquire allergan agn trumping earlier offer bill ackman backed valeant automaker tata motor ttm jump heavy trading retake buy point cup handle base auto part maker gentex gntx climb heavy volume be buy point long consolidation paycom software payc add average trading stock recently trigger ibd week hold rule climb less week breaking past cup base buy point recent new issue have highest possible composite rating downside linkedin lnkd drop heavy trading stock have struggle gain traction recent past be back buy point stock have be hurt report facebook fb be develop collaboration call facebook work
1156,AGN,biotech stock be gainer stock market friday standout be rare drug company alexion pharmaceutical alxn shot
1157,AGN,biotech group rank group track investor business daily just week
1158,AGN,other medical group be ibd top include hospital ethical drug week
1159,AGN,hospital have benefit health care reform obamacare have see healthy share gain recent month group pull back last week rise nearly friday
1160,AGN,hca holding hca largest hospital group market capitalization rise nearly
1161,AGN,ethical drug group jazz pharmaceutical jazz jump friday botox maker allergan agn shopping acquisition get hostile bidder valeant pharmaceutical vrx back shot nearly jazz have be rumore possible candidate
1162,AGN,biotech group hepatitis drug maker gilead science gild regeneron pharmaceutical regn ibd leaderboard stock end have be disappointing week high note regeneron climb friday gilead nearly
1163,AGN,related jazz pharmaceutical used new cash buy growth biotech stock be gainer stock market friday standout be rare drug company alexion pharmaceutical alxn shot biotech group rank group track investor business daily just week other medical group be ibd top include hospital ethical drug week hospital have benefit health care reform obamacare have see healthy share gain recent month group pull back last week rise nearly friday hca holding hca largest hospital group market capitalization rise nearly ethical drug group jazz pharmaceutical jazz jump friday botox maker allergan agn shopping acquisition get hostile bidder valeant pharmaceutical vrx back shot nearly jazz have be rumore possible candidate biotech group hepatitis drug maker gilead science gild regeneron pharmaceutical regn ibd leaderboard stock end have be disappointing week high note regeneron climb friday gilead nearly related jazz pharmaceutical used new cash buy growth
1164,AGN,bill ackman persh square capital management plan raise new fund list euronext amsterdam stock exchange company say statement monday hedge fund have already secure cornerstone investor expect new fund call persh square holding have market capitalization
1165,AGN,just few year drug generate small slice revenue jazz pharmaceutical drug xyrem target small patient population narcolepsy sufferer person prone fall suddenly asleep middle day high price make sale effort worthwhile jazz pharmaceutical jazz keep raise price
1166,AGN,salix pharmaceutical jump new high stock market today news fellow specialty drugmaker allergan be probably buy however allergan largest shareholder threaten sue company make such deal late monday anonymously source news report say salix pharmaceutical slxp allergan agn
1167,AGN,stock advanced lows day friday go last hour trading look finish week major index nasdaq dow jone industrial average rise be volume be run slightly lower thursday pace exchange
1168,AGN,stock market today ibd stock be higher be lower unchanged top performer be jazz pharmaceutical jazz report say drugmaker be takeover target allergan agn allergan be
1169,AGN,china mobile game entertainment cmge rise have heavy upside volume past few day be downtrend past few month have turn report favorable earning aug blast day move average friday stock advanced lows day friday go last hour trading look finish week major index nasdaq dow jone industrial average rise be volume be run slightly lower thursday pace exchange stock market today ibd stock be higher be lower unchanged top performer be jazz pharmaceutical jazz report say drugmaker be takeover target allergan agn allergan be china mobile game entertainment cmge rise have heavy upside volume past few day be downtrend past few month have turn report favorable earning aug blast day move average friday
1170,AGN,specialty drug giant valeant pharmaceutical international vrx agree drop litigation hostile takeover target allergan exchange allergan allow originally schedule dec special shareholder meeting speed potential merger
1171,AGN,meeting go ahead make merger likelier bmo capital market analyst david maris report visit allergan agn executive still sound confident stay independent
1172,AGN,allergan mentioned not be surprised shareholder be elect participate special meeting actually vote favor allergan maris write research report tuesday base discussion several holder believe have independently confirm be holder participate meeting state intend vote valeant measure
1173,AGN,allergan be fraction morning trading stock market today valeant stock be fraction
1174,AGN,allergan shareholder william ackman persh square capital be collaborate valeant bid have be fight make meeting happen hope rally shareholder replace most allergan exist board have steadfastly resist valeant overture allergan part sue valeant ackman august say involvement amount abuse insider information
1175,AGN,analyst maris say allergan executive also discuss persistent rumor allergan evade buyout make large acquisition own preferably take lower tax locale reportedly try fail british drugmaker shire shpg eventually go abbvie abbv rumor mill have lately focuse jazz pharmaceutical jazz salix pharmaceutical slxp latter be subject fresh round twitter chatter tuesday be mentioned cnbc david faber salix stock be morning trading tuesday jazz stock be fraction
1176,AGN,maris write allergan executive didn discuss specific name potential buyout do say large tax arbitrage be likely not sustainable
1177,AGN,think comment mean inversion deal be table not have read rather believe comment be meant tell investor strategic deal be drive less so opportunity lower tax maris say add company seem be rush get deal do dec meeting
1178,AGN,related
1179,AGN,allergan seek salix deal avoid valeant
1180,AGN,follow amy reeve twitter ibd_areeve specialty drug giant valeant pharmaceutical international vrx agree drop litigation hostile takeover target allergan exchange allergan allow originally schedule dec special shareholder meeting speed potential merger meeting go ahead make merger likelier bmo capital market analyst david maris report visit allergan agn executive still sound confident stay independent allergan mentioned not be surprised shareholder be elect participate special meeting actually vote favor allergan maris write research report tuesday base discussion several holder believe have independently confirm be holder participate meeting state intend vote valeant measure allergan be fraction morning trading stock market today valeant stock be fraction allergan shareholder william ackman persh square capital be collaborate valeant bid have be fight make meeting happen hope rally shareholder replace most allergan exist board have steadfastly resist valeant overture allergan part sue valeant ackman august say involvement amount abuse insider information analyst maris say allergan executive also discuss persistent rumor allergan evade buyout make large acquisition own preferably take lower tax locale reportedly try fail british drugmaker shire shpg eventually go abbvie abbv rumor mill have lately focuse jazz pharmaceutical jazz salix pharmaceutical slxp latter be subject fresh round twitter chatter tuesday be mentioned cnbc david faber salix stock be morning trading tuesday jazz stock be fraction maris write allergan executive didn discuss specific name potential buyout do say large tax arbitrage be likely not sustainable think comment mean inversion deal be table not have read rather believe comment be meant tell investor strategic deal be drive less so opportunity lower tax maris say add company seem be rush get deal do dec meeting related allergan seek salix deal avoid valeantfollow amy reeve twitter ibd_areeve
1181,AGN,strong day stock market wednesday result flurry new high particularly medical sector allergan agn clear week consolidation rise botox maker be interested buy salix pharmaceutical slxp fend takeover bid valeant pharmaceutical vrx stay health care space ireland base mallinckrodt mnk extend
1182,AGN,stock finished day moderately nasdaq lower third straight day volume be run lighter previous day accord preliminary figure nasdaq be fall dow jone industrial average drop stock market today ibd stock be higher be lower salix pharmaceutical slxp be top performer more big volume be report allergan agn be talk acquire company allergan be nearly also drugmaker actavis act spiked midday hit new time high chatter pfizer pfe be interested buy worst performer be emerge energy emes plunge day line heavy volume be more stock have nearly triple breaking base march be first trip well support line carmax kmx gap finished nearly lower disappointing quarterly report analyst say subprime lend have be major growth driver company such lend be slow chinese online retailer vipshop vip rise more average volume continue find resistance day move average stock be build new base
1183,AGN,handful lead stock be hold well even market uptrend have once again come pressure ambarella amba designer chip surveillance wearable sport camera lead way jump tuesday time high stock be extend recent buy
1184,AGN,several sector leader be struggle clear buy point reflect sideway action overall market recently salix pharmaceutical slxp soar past flat base buy point aug report drugmaker be takeover target allergan agn be try fend takeover bid valeant pharmaceutical vrx stock have
1185,AGN,several ibd drug tech company release quarterly earning result thursday akorn salix pharmaceutical skywork solution have ibd highest possible composite rating meaning share outperform stock market measure fundamental technical factor factor include price performance past month sale growth
1186,AGN,select stock have superior profit sale growth be not sole key success market neither be simply buy stock outstanding price strength
1187,AGN,invest stock make sure also be favorite biggest investor market mutual fund investment advisor bank critical component be know institutional sponsorship
1188,AGN,proof heavy institutional buy be way confirm sponsorship be time consume find ibd
1189,AGN,paper mutual fund etfs section provide instrument help many feature do double duty reveal top perform fund long term investor help stock strong buyer have target
1190,AGN,mutual fund be design more passive investing tool stock professional fund manager research crew pick time purchase stock so fund client don have sweat detail
1191,AGN,ibd narrow field list lead fund stock holding carry high average ibd composite rating have tend outperform index low
1192,AGN,growth fund lead market feature mutual fund page spotlight fund day be often case ibd feature make worth pull read glass diving fine print box provide basic bio fund volatility rating average ep relative price strength rating stock holding
1193,AGN,perhaps even more importantly box provide fund largest holding well top new buy top sell daily section also provide list other top perform fund screen accord various criterium
1194,AGN,delve even deeper ibd mutual fund monthly quarterly report usually publish first week month feature slice dice top perform fund accord size sector type investment such vital sign point warm cool movement global economy offer clue want tinker fund portfolio
1195,AGN,stock buy perspective monthly quarterly datum stock buy sell be pure gold mine datum table put radio collar smart money prior month stock be top fund buy much
1196,AGN,top fund latest sell table provide number fund buy vs selling net total seller spot stock list closely monitor chart key sell signal
1197,AGN,buy side stock name be familiar ibd big cap weekly review table list industry group name several key ibd rating detail many fund be buy total amount invest
1198,AGN,ibd mutual fund monthly special publish list alaska air alk skywork solution swks zebra techology zbra one top fund pour most dollar most recent month have trace solid gain year nov edition list celgene celg baidu bidu hca holding hca allergan agn select stock have superior profit sale growth be not sole key success market neither be simply buy stock outstanding price strength invest stock make sure also be favorite biggest investor market mutual fund investment advisor bank critical component be know institutional sponsorship proof heavy institutional buy be way confirm sponsorship be time consume find ibd paper mutual fund etfs section provide instrument help many feature do double duty reveal top perform fund long term investor help stock strong buyer have target mutual fund be design more passive investing tool stock professional fund manager research crew pick time purchase stock so fund client don have sweat detail ibd narrow field list lead fund stock holding carry high average ibd composite rating have tend outperform index low growth fund lead market feature mutual fund page spotlight fund day be often case ibd feature make worth pull read glass diving fine print box provide basic bio fund volatility rating average ep relative price strength rating stock holding perhaps even more importantly box provide fund largest holding well top new buy top sell daily section also provide list other top perform fund screen accord various criterium delve even deeper ibd mutual fund monthly quarterly report usually publish first week month feature slice dice top perform fund accord size sector type investment such vital sign point warm cool movement global economy offer clue want tinker fund portfolio stock buy perspective monthly quarterly datum stock buy sell be pure gold mine datum table put radio collar smart money prior month stock be top fund buy much top fund latest sell table provide number fund buy vs selling net total seller spot stock list closely monitor chart key sell signal buy side stock name be familiar ibd big cap weekly review table list industry group name several key ibd rating detail many fund be buy total amount invest ibd mutual fund monthly special publish list alaska air alk skywork solution swks zebra techology zbra one top fund pour most dollar most recent month have trace solid gain year nov edition list celgene celg baidu bidu hca holding hca allergan agn
1199,AGN,share embattled specialty drugmaker allergan agn be midday trading stock market today leerink upgrade stock base valuation
1200,AGN,analyst seamus fernandez lift rating outperform sector perform late thursday follow stock decline previous trading day drop seem have be touch weak earning report valeant pharmaceutical international vrx be attempt hostile takeover allergan valeant stock fall nearly earning report have slip further be midday friday
1201,AGN,allergan contrast earlier issue strong earning report cost cut plan perhaps spark doubt deal get do
1202,AGN,opinion agn weakness be likely drive more technical arbitrage related trading recommend buy share today fernandez write see little weakness agn business vrx bid view plan restructure management overdue believe ep more share be achievable used balance sheet
1203,AGN,recent decline allergan stock retain stellar ibd composite rating
1204,AGN,follow amy reeve twitter ibd_areeve share embattled specialty drugmaker allergan agn be midday trading stock market today leerink upgrade stock base valuation analyst seamus fernandez lift rating outperform sector perform late thursday follow stock decline previous trading day drop seem have be touch weak earning report valeant pharmaceutical international vrx be attempt hostile takeover allergan valeant stock fall nearly earning report have slip further be midday friday allergan contrast earlier issue strong earning report cost cut plan perhaps spark doubt deal get do opinion agn weakness be likely drive more technical arbitrage related trading recommend buy share today fernandez write see little weakness agn business vrx bid view plan restructure management overdue believe ep more share be achievable used balance sheet recent decline allergan stock retain stellar ibd composite rating follow amy reeve twitter ibd_areeve
1205,AGN,jazz pharmaceutical jazz be still buy range clear flaw cup handle base last week huge volume stock be buy point putt buy zone pattern be see flaw handle correct more much deeper decline see
1206,AGN,manager lead mutual fund recent month have continue stock large medical stock such illumina ilmn alexion pharmaceutical alxn celgene celg jazz pharmaceutical jazz allergan agn centene cnc
1207,AGN,biotech biom group be rank industry tuesday big cap biotech medical stock hold better volatile market
1208,AGN,sector theme be play be semiconductor
1209,AGN,fabless chipmaker such technology avgo nxp semiconductor nxpi ambarella amba have be top performer also act well be chipmaker skywork solution swks
1210,AGN,food beverage stock such keurig green mountain coffee gmcr monster beverage mnst cal maine food calm hain celestial group hain be also favore best perform fund
1211,AGN,ibd spot top perform fund have recently buy ulta beauty ulta investing estimate
1212,AGN,mainstay large cap growth fund add ulta holding latest report period
1213,AGN,bolingbrook ill base ulta be beauty retailer provide stop shopping beauty product salon service america
1214,AGN,stock be month second stage base small handle fail attempt break last week put buy point
1215,AGN,ulta increase earning healthy double digit pace past quarters revenue growth also be robust range same period
1216,AGN,more depth coverage drive ulta growth see monday edition manage success page
1217,AGN,first half october spook investor sharp drop major stock index
1218,AGN,most correction earlier year market rebound quickly resume uptrend late october
1219,AGN,sell side
1220,AGN,america top notch fund lighten credit card payment firm visa mastercard latest report period
1221,AGN,have rally past week set get new high
1222,AGN,few retailer have be sell such lowe low petsmart petm william sonoma wsm manager lead mutual fund recent month have continue stock large medical stock such illumina ilmn alexion pharmaceutical alxn celgene celg jazz pharmaceutical jazz allergan agn centene cnc biotech biom group be rank industry tuesday big cap biotech medical stock hold better volatile market sector theme be play be semiconductor fabless chipmaker such technology avgo nxp semiconductor nxpi ambarella amba have be top performer also act well be chipmaker skywork solution swks food beverage stock such keurig green mountain coffee gmcr monster beverage mnst cal maine food calm hain celestial group hain be also favore best perform fund ibd spot top perform fund have recently buy ulta beauty ulta investing estimate mainstay large cap growth fund add ulta holding latest report period bolingbrook ill base ulta be beauty retailer provide stop shopping beauty product salon service america stock be month second stage base small handle fail attempt break last week put buy point ulta increase earning healthy double digit pace past quarters revenue growth also be robust range same period more depth coverage drive ulta growth see monday edition manage success page first half october spook investor sharp drop major stock index most correction earlier year market rebound quickly resume uptrend late october sell sideamerica top notch fund lighten credit card payment firm visa mastercard latest report period have rally past week set get new high few retailer have be sell such lowe low petsmart petm william sonoma wsm
1223,AGN,picking be slim new high list tuesday extend lose streak session salix pharmaceutical slxp jump speculation heated drugmaker be close be buy allergan agn allergan be try thwart hostile takeover valeant pharmaceutical vrx actavis act rise
1224,AGN,major average open lower stay hour tuesday session loss be mild busy day headline flow
1225,AGN,dow jone industrial average lose fall nasdaq ease less nyse nasdaq volume be tracking lower monday
1226,AGN,stock market today salix pharmaceutical slxp jump reuter report company be advanced talk be acquire allergan agn potential union have be rumore allergan be try fend hostile bid valeant pharmaceutical vrx
1227,AGN,elsewhere cf industry cf clear base rise be court norwegian firm yara international
1228,AGN,china base stock ibd bounce back recent weakness include athm vipshop vip bitauto bita reclaim day move average rise still well prior buy point china name strengthen manufacturing datum china come better expect recent chinese ipo giant alibaba baba fall again soar first day trade friday
1229,AGN,mobileye mbly continue impressive rebound daunting slide share jump company go public aug promptly double price stock remain well extend clear buy point ipo base major average open lower stay hour tuesday session loss be mild busy day headline flow dow jone industrial average lose fall nasdaq ease less nyse nasdaq volume be tracking lower monday stock market today salix pharmaceutical slxp jump reuter report company be advanced talk be acquire allergan agn potential union have be rumore allergan be try fend hostile bid valeant pharmaceutical vrx elsewhere cf industry cf clear base rise be court norwegian firm yara international china base stock ibd bounce back recent weakness include athm vipshop vip bitauto bita reclaim day move average rise still well prior buy point china name strengthen manufacturing datum china come better expect recent chinese ipo giant alibaba baba fall again soar first day trade friday mobileye mbly continue impressive rebound daunting slide share jump company go public aug promptly double price stock remain well extend clear buy point ipo base
1230,AGN,earning season continue barrel forward investor be anticipate result several top drugmaker upcoming week week ibd roundup top rate growth stock solid fundamental boast company report earning week include pharma play salix pharmaceutical slxp have make headline recent month allergan agn actavis act have be
1231,AGN,specialty drugmaker salix pharmaceutical announce oct be do something unusual back merger close back july salix slxp have agree acquire cosmo technology irish subsidiary italian drugmaker cosmo pharmaceutical stock swap value deal have allow salix so many
1232,AGN,allergan be look potential acquisition prevent hostile takeover valeant pharmaceutical reportedly have approach salix pharmaceutical least other firm takeover deal salix slxp botox maker allergan agn happen early september source tell wall street journal salix make medicine problem be merge unit italy cosmo pharmaceutical part tax inversion deal not clear allergan buy cosmo unit well allergan use deal inversion process move company headquarters overseas capture cheaper tax rate journal say allergan share rise stock market today salix share jump valeant vrx be nearly allergan acquisition talk be latest move company valeant hostile bid july allergan announce cut work force analyst say job cut make harder valeant show merger proposal add incremental value company allergan have call valeant business model unsustainable say deal valeant hurt research development program valeant activist investor william ackman own large stake valeant have be angle takeover april currently valeant be offer cash stock transaction allergan source tell journal valeant be close have enough support allergan investor call special meeting discuss takeover bid medical ethical drug group be rank industry group ibd track follow gillian rich twitter ibd_grich
1233,AGN,allergan agn blockbuster eye drug restasis outperform expectation year analyst say monday boost price target stock mizuho analyst irina koffler raise price target allergan stock keep neutral rating koffler cite bullish view restasis sale longer term expectation botox vraylar depression drug be still unknown other drug say stock have be edge higher pull model additional year assess be miss something story koffler say report client indeed find additional value especially management remain discipline operational expense koffler expect restasis sale be next quarters top street view respectively restasis increase eye ability produce tear patient chronically dry eye get newsletter deliver inbox more info product service privacy policy term userestasis sale likely be durable july say come fruition allergan increase full year guidance meanwhile botox sale look strong longer term vraylar grab approval treat more form depression koffler model lag consensus be likely run assumption firm grow compound annual rate koffler see only growth time period have conservative view allergan pipeline international segment koffler doesn ascribe value allergan ability treat nonalcoholic steatohepatitis form liver disease also have modest expectation new eye drug treatment digestive disorder further consensus be miss patent cliff drug investor be open management turnover restructure attempt koffler worry allergan engage risky merger acquisition same time see allergan effort sell woman health infection unit neutral valuation however don expect company be acquire be still significant uncertainty capital deployment management pursue risky expensive merger acquisition opt more conservative debt repayment strategy say allergan go more conservative route debt repayment see additional bump stock say stock market today allergan rise close bell get instant access more trading idea exclusive stock list ibd proprietary rating only related chart read basic buy point mark time real tame volatile swing trade half positionnew option strategy limit risk earning
1234,AGN,botox maker allergan agn be look sell woman health infectious disease unit win engage fire sale do so chief executive brent saunder say wednesday allergan be eyee potential sale unit strategic review begin earlier year sale allow allergan focus key segment medical aesthetic central nervous system eye care firm isn feel pressure sell saunder say take party consummate deal say conference host bernstein not sell business get intrinsic value believe deserve be fire sale allergan undue pressure sell bargain basement price get newsletter deliver inbox more info product service privacy policy term uselast year woman health bring sale infective drug account first quarter infective unit outgrow woman health rise woman health decline third biggest drug woman health be birth control pill loestrin tuesday allergan voluntarily recall batch taytulla birth control pill be incorrectly package teflaro drug lead infective unit treat skin infection form pneumonia divest business fall potential outcome strategic review note earlier year saunder also say allergan consider splitting business buy back share make acquisition maintain business be april saunder be seemingly splitting company be long disruptive reiterate viewpoint wednesday bernstein conference analyst ask firm just split medical aesthetic everything else be time future be feasible say today hard see work saunder note medical aesthetic central nervous system eye care share resource be successful botox instance be used medical aesthetic therapeutic call business concentric circle now be point future ll be big enough scale absolutely say be opportunity create meaningful value avail absolutely stock market today allergan share add close year date share be related chart read basic buy point mark time real trade stock most penny stock fail make investor richsell take profit hold here be several guideline follow
1235,AGN,allergan agn topple tuesday voluntarily recall batch birth control pill placebo pill be incorrectly place order stock market today allergan fall close earlier dip much stock be biggest loser pharmaceutical company collectively fall birth control pill package call taytulla place placebo capsule first day therapy most package first pill have be active contraceptive reverse order not be apparent new user previous user product increase likelihood take capsule order allergan say news release capsule take order result unintended pregnancy get newsletter deliver inbox more info product service privacy policy term useallergan notified customer recall letter batch birth control pill related chart read basic buy point mark time real much volume look stock long term retirement investing strategy etfs
1236,AGN,allergan agn fetch close woman health unit analyst say tuesday rumor emerge drugmaker be mull sale rumor come allergan drug esmya struggle europe european official be investigate drug used treat uterine fibroid follow report liver toxicity meanwhile food drug administration be review esmya approval mizuho analyst irina koffler note issue surround esmya generic competition estrace vaginal cream have prompt drugmaker consider sale unit bring be expect generate just allergan be undertaking process have lower expectation esmya approval fibroid especially recent liver toxicity concern europe delay fda review date say note client get newsletter deliver inbox more info product service privacy policy term esmya woman health franchise longer meet allergan criterium market leader koffler say franchise biggest moneymaker be hormonal birth control pill loestrin estrace cream selling unit be solid levering move say chief executive brent saunder say march allergan be consider option address share decline bloomberg report past month share have decline same time broad drug stock have climb regular trading stock market today allergan climb close broader drug market add saunder comment likely have investor hope sale koffler say note be massive undertaking allergan sell entire company number competitive overhang allergan botox business think selling entire company prove be more time consume challenge say however selling division be productive first step koffler keep neutral rating price target allergan related tame volatile swing trade half basic sell stocklooking best stock buy watch start here
1237,AGN,allergan agn crushed botox sale expectation first quarter raise guidance share topple monday report drugmaker be very unlikely make acquisition potential allergan make deal hit fever pitch earlier month firm briefly confirm be consider bid shire shpg hour later follow stock plunge allergan say wouldn rival takeda pharmaceutical shire early monday interview reuter chief executive brent saunder say allergan be consider option part strategic review management deploy capital buy back share divest operation split company make acquisition operate allergan be do deal be very low priority very unlikely outcome reportedly say split take longest be most disruptive note get newsletter deliver inbox more info product service privacy policy term useon stock market today allergan share tumble close news follow earlier pop allergan top first quarter estimate crushed profit view narrowly top full year revenue guidance expectation first quarter allergan report adjust income share grow beat consensus sale grow top view analyst poll zack investment research botox cosmetic sale grow year year top view mizuho analyst irina koffler botox therapeutic bring also beat koffler estimate outside botox sale bring top koffler model total botox revenue advanced juvederm collection facial filler only grow reflect destock fourth quarter koffler say note globally sale juvederm collection grow restasis allergan powerhouse eye disease drug generate sale come year year sale restasis fall allergan cite trade buy pattern lower net selling price decline alone allergan also up guidance year firm see sale midpoint be slightly north view previously allergan have modeled sale adjust income be now expect come share firm earlier estimate midpoint allergan new guidance be share crushed view adjust earning share second quarter allergan expect report adjust profit share sale midpoint metric easily top consensus adjust earning share sale related new option strategy limit risk buy stock ahead earning report look best stock buy watch start here
1238,AGN,minute dow jone industrial average component merck mrk be do battle fellow drugmaker bristol myer squibb bmy drug cancer next biotech giant amgen amgn sanofi sny be tussle court fate cholesterol bust drug meanwhile company gilead science gild be rake coal congress charge day treat hepatitis brave contentious new world pharmaceutical biotechnology company realm science be try develop landmark medicine cure cancer hepatitis other life threaten illness do delicate dance wall street regulator balancing public health issue demand shareholder investor find tricky navigate sector company rise fall drop hat bookmark page stay top latest news biopharma sector get newsletter deliver inbox more info product service privacy policy term useview more biotech pharma stock newsrelated best stock buy watch
1239,AGN,brouhaha surround shire shpg continue friday takeda pharmaceutical make fourth bid buy drugmaker sweetening pot earlier proposal value company earlier friday takeda say pay pound share buy shire bid pound share roughly earlier month shire previously reject proposal takeda say significantly undervalue company new deal value shire accord reuter takeda be willing pay pound share cash remainder paid stock shire investor own takeda deal written statement shire say be consider proposal issue further announcement due course get newsletter deliver inbox more info product service privacy policy term useshire stock climb close stock market today share have be form cup last buy point interest shire come head thursday allergan agn several hour appear interested make offer buy rare disease drugmaker allergan first say be early stage plan proposal allergan stock drop investor digest potential shire merger allergan then backed process say doesn intend make offer share be just midday trade allergan still be dealmake mood thursday firm say still look full range potential strategic action create value shareholder such divestiture combination acquisition other potential acquirer include celgene analyst speculate be eyee agio pharmaceutical jounce therapeutic amgen be face more competition older drug takeda merger shire be takeda have market cap make smaller shire have market cap takeda pipeline be largely focuse cancer treatment neuroscience disease vaccine shire have wide pipeline work hematology immunology oncology neuroscience rare disease other related chart read basic buy point mark time real much money do need start investing long term retirement investing strategy etfs
1240,AGN,aldr stock gap friday rival teva pharmaceutical teva scrap late stage study cgrp migraine prevention drug chronic cluster headach close bell stock market today pop share teva dip fraction rival eli lilly lly rise fraction amgen amgn be first get migraine prevention drug market dip teva study fremanezumab chronic episodic cluster headach well long term safety study researcher find fremanezumab be unlikely work chronic cluster headach week treatment period end study fremanezumab belong class call cgrp drug aim block specific peptide associate migraine possible cgrp drug have other used teva spokesperson tushar shah say statement get newsletter deliver inbox more info product service privacy policy term use be disappoint outcome remain optimistic fremanezumab have clinical benefit additional condition migraine calcitonin gene related peptide play contributory role pathophysiology say amgen partner novartis nvs grab approval cgrp drug aimovig migraine prevention week end june aimovig prescription grow week week rbc analyst kennan mackay say note be testing drug eptinezumab preventive treatment episodic chronic migraine also have migraine prevention drug preclinical study lilly galcanezumab be review migraine prevention be also be study cluster headach meanwhile pharmaceutical bhvn have cgrp drug development acute treatment migraine also testing cgrp drug treat prevent migraine allergan agn too have cgrp development acute treatment migraine related chart read basic buy point mark time real much volume look stock investing basic sell stock
1241,AGN,amgen amgn allergan agn be sideline friday food drug administration delay herceptin biosimilar give roche rhhby blockbuster breast cancer drug herceptin breathe room biotech company didn identify issue herceptin biosimilar work closely fda bring important medicine patient amgen say prepared statement do not expect impact launch plan duo isn first get snag seek approval herceptin biosimilar mylan myl partner biocon grab approval december follow similar delay fda pfizer pfe teva pharmaceutical teva celltrion copy have also be delay get newsletter deliver inbox more info product service privacy policy term useapproval seem be move more smoothly europe european medicine agency committee have recommend approve amgen allergan biosimilar pfizer herceptin biosimilar samsung biogen teva celltrion already have copy market europe herceptin be major cash cow roche bring sale just fellow cancer drug rituxan mabthera generate herceptin sale stem europe roche be work feverishly push back competition herceptin last year roche sue dow jone component pfizer block selling herceptin biosimilar roche genentech unit say pfizer herceptin biosimilar infringe patent patent herceptin begin expire bloomberg report stock market today roche stock rally close hit year close low thursday herceptin biosimilar setback amgen stock advanced share partner allergan climb meanwhile share pharmaceutical company lift biotech stock rise related intuitive surgical break record fda approve new robotibd stock day chinese internet giant power buy zone composite rating stock skyrocket huge earning growth chart basic buy point mark time real invest stock free new apps term retirement investing strategy etfs
1242,AGN,japan takeda pharmaceutical clinch acquisition shire shpg early tuesday week tussle company allergan agn also be briefly interested possible merger approve be largest overseas purchase japanese company accord dealogic dealogic say debt deal be worth takeda add roughly market cap shire be north new takeda be close size bristol myer squibb bmy eli lilly lly rbc analyst dougla miehm say deal alleviate concern notably japanese drugmaker lever sufficiently dividend remain intact firm expect general annual pretax cost synergy end third year do anticipate deal spread remain wider normal give complexity transaction require approval various geography ability realize synergy especially research development long date close date say note client get newsletter deliver inbox more info product service privacy policy term total deal be consistent takeda fifth proposal value dublin base shire pound share together takeda pay pound roughly company expect deal close first half term deal shire shareholder receive cash new takeda share takeda american depositary receipt shire share deal wrapped shire shareholder own new takeda takeda new share also trade tokyo stock exchange new york stock exchange rbc miehm note acquisition be expect be significantly accretive earning first full fiscal year follow close also expect provide return interest takeda cost capital same time period takeda confirm still need approval third exist shareholder be confident get vote miehm say pay acquisition takeda enter bridge credit agreement type loan miehm keep outperform rating shire stock stock market today shire rise close first quarter outperformance valeant pharmaceutical vrx didn help drug stock more broadly dip related do spot major market top easy look heavy tame volatile swing trade half positionlook best stock buy watch start here
1243,AGN,rapid turnaround allergan agn say late thursday doesn intend bid shire shpg leave thrice rebuff takeda pharmaceutical alone race rare disease drugmaker entire saga erupt early thursday report emerge allergan be interested buy shire same time shire confirm have reject bid takeda worth north allergan first say be early stage potential bid shire hour stock plunge later allergan say definitively win make offer take shire meanwhile still evaluate full range potential strategic option allergan say news release share allergan close be flat hour trading stock market today shire sank close bell get newsletter deliver inbox more info product service privacy policy term usespeculation shire takeda merger have be swirl late march then takeda have make bid shire case shire board determine bid significantly undervalue firm growth prospect pipeline takeda confirm put forth buyout bid shire worth share comprise cash stock firm say be willing continue negotiating still takeda be confident remain well position even negotiation fall build takeda exist momentum acquisition shire accelerate transformation result global value base drive leader headquarter japan takeda say prepared statement short live interest allergan come surprise leerink analyst etzer say note firm have say become acquisitive be look strategic option combination shire introduce growth challenge year be reflect negative stock reaction say shire be likely face erosion attention deficit hyperactivity medicine vyvanse begin significant erosion hemophilia business compete rival roche rhhby allergan have have justify bid shareholder say shire interest come flurry biotech acquisition kick earlier year celgene celg announce plan buy juno therapeutic sanofi sny unveil plan acquire bioverativ bivv ablynx ablx novartis nvs sell share glaxosmithkline gsk consumer health unit used part proceed fund plan acquire avexis avxs merck kgaa agree sell counter unit proctor gamble pg day be rumore mylan myl buy earlier week shire say sell cancer unit france servier analyst have speculate celgene also be lookout more acquisition agio pharmaceutical agio jounce therapeutic jnce potential target amgen amgn also have huge war chest be face competition older medicine related chart read basic buy point mark time real opportunitylong term retirement investing strategy etfssell take profit hold here be several guideline follow
1244,AGN,mylan myl share rebound thursday follow worry first quarter sale lag base tough year year comparison allergy drug epipen concern stem commentary mylan investor day mizuho analyst irina koffler say wednesday mylan reiterate guidance call tough comparison first quarter adjust profit sale epipen management indicated first half contain nontrivial amount brand epipen sale result slightly tougher comp first half koffler write note client koffler now expect adjust income first quarter account full year profit year earlier period get newsletter deliver inbox more info product service privacy policy term use therefore push sale earning further second half say mylan cane get least larger approval expect summer think investor get more constructive execution guidance urge investor buy wednesday dip share close investor listen stock market today mylan climb close mylan still expect report sale adjust profit share sale guide be slightly consensus midpoint adjust profit view be just north analyst mylan expect first quarter adjust profit share full year earning be base point lower last year firm also expect higher interest expense follow recent debt financing koffler say koffler have buy rating price target mylan think stock be undervalue say firm recently launch generic copycat teva pharmaceutical teva multiple sclerosis drug copaxone view gradual ramp time koffler say firm also have key approval come year include generic version amgen amgn bone marrow stimulant neulasta glaxosmithkline gsk inhaler advair allergan agn eye disease drug restasis management note fda ask additional clarification advair application even formal information request have be complete lead investor concern approval delay koffler say management note advair be not story mylan be also work theravance biopharma tbph treatment chronic obstructive pulmonary disease condition lung food drug administration be likely make decision drug november related much money do need start investing long term retirement investing strategy etfslook next nvidia start simple routine
1245,AGN,tiny biotech cymabay cbay launch high not see month wednesday unveil strong datum liver disease treatment detriment intercept pharmaceutical icpt have struggle rival drug stock market today share cymabay soar close earlier rocket much meanwhile intercept sank biotech stock collectively advanced cymabay be testing drug call seladelpar second treatment option liver disease know primary biliary cholangitis pbc leerink analyst joseph schwartz note result so far compare favorably intercept drug ocaliva continue view seladelpar attractive agent second treatment option pbc ocaliva advantage earlier market entry schwartz say note client raise expectation seladelpar success prior view get newsletter deliver inbox more info product service privacy policy term useseladelpar be test patient have abnormally high level enzyme alkaline phosphate week patient treat milligram milligram milligram dose seladelpar see alkaline phosphate level cut respectively week patient receive milligram cymabay drug have alkaline phosphate reduction overall patient have normal alkaline phosphate level week drug wasn associate itch sometimes occur pbc cymabay say news release patient milligram dose group see decrease itch week suggest drug have itch activity importantly lack liver toxicity be huge schwartz say be concern patient take intercept ocaliva experience liver injury die intercept argue patient be receive inappropriately high dose ocaliva cymabay note chronic dose milligram seladelpar didn lead liver toxicity mean physician be able adjust patient dose worry liver injury death schwartz say ocaliva recent resolution fda label investor have grow particularly cautious liver toxicity pbc drug say today update quell such concern firm be now track begin phase study second half cymabay expect test milligram milligram dose seladelpar study schwartz also see cymabay grab success seladelpar nonalcoholic steatohepatitis liver disease cymabay be now midstage testing seladelpar nonalcoholic steatohepatitis nash other player nash drug race include intercept gilead science gild shire shpg allergan agn novartis nvs related chart read basic buy point mark time real best stock buy watch start buy stock ahead earning report
1246,AGN,pharmaceutical bhvn crater third early monday unveil result late stage trial migraine drug competitor investigational therapy allergan agn drug call rimegepant be test treatment acute migraine phase trial rimegepant meet key goal pain freedom freedom worst symptom hour mark numerically allergan drug have slight advantage piper jaffray analyst charle duncan warn investor lose forest tree effectiveness datum show rimegepant be approvable clinically meaningful say note client further rimegepant continue improve hour mark be encourage see delta rimegepant placebo widen past hour time point even repeat dose adjunctive therapy rescue med suggest candidate be differentiate prevention recurrence lack rebound effect say get newsletter deliver inbox more info product service privacy policy term usehe see rimegepant drug model peak sale still morning trading stock market today fall much low be stock initial public offer last end regular session monday allergan rise trial patient receive single milligram dose drug rimegepant repeat dose rescue medicine triptan be pain free hour mark vs patient receive placebo receive rimegepant be free worst symptom hour point vs patient receive placebo investor be key compare vs allergan drug ubrogepant drug class medicine call cgrps aim block specific peptide associate migraine allergan drug be be test orally allergan ubrogepant be test milligram milligram dose allow repeat dose rescue medicine hour patient be pain free vs placebo patient worst symptom disappear patient vs placebo group ubrogepant patient have liver issue rimegepant didn allergan trial be patient liver function rise greater time upper limit normal safety board say none case have probable relationship drug leerink analyst geoffrey porge still expect allergan ubrogepant be competitive generic triptan make acute migraine prescription patient carry severe warning patient don respond triptan further note resolution liver worry ubrogepant win be resolve long term safety study allergan drug be available second half rimegepant ubrogepant differ other cgrp drug be investigate aim prevent migraine amgen amgn novartis nvs be lead front teva pharmaceutical teva eli lilly lly aldr be also work drug related much money do need start investing long term retirement investing strategy buy stock ahead earning report
1247,AGN,today screen day feature institutional quality drug medical big cap stock solid fundamental
1248,AGN,jazz pharmaceutical jazz have market cap earn ibd composite rating mean have outperformed stock key metric such earning sale
1249,AGN,best selling narcolepsy medication xyrem make third jazz second quarter sale company acquire italian biotech gentium earlier year
1250,AGN,jazz share rise stock market tuesday best close month
1251,AGN,salix pharmaceutical slxp be spotlight lately potential takeover candidate allergan agn maker botox allergan be aim put stopper valeant pharmaceutical vrx hostile takeover attempt
1252,AGN,salix share soar aug report talk reportedly be dormant salix be largely hold gain move sideway
1253,AGN,salix have market cap also have highest possible composite rating salix most recent result miss view earning share more double revenue shot
1254,AGN,gilead science gild behemoth market cap be mutual fund favorite big stock mover deutsche bank expect company upcoming combo hepatitis treatment have higher expect price point
1255,AGN,gilead make blockbuster hepatitis drug sovaldi also boast composite rating
1256,AGN,gilead share fall tuesday be week
1257,AGN,illumina ilmn have market cap composite rating develop system medical researcher study gene variation function
1258,AGN,company recently say have form strategic partnership number drugmaker include astrazeneca azn sanofi sny create universal next generation sequence base oncology test system
1259,AGN,follow elaine low twitter ibd_elow today screen day feature institutional quality drug medical big cap stock solid fundamental jazz pharmaceutical jazz have market cap earn ibd composite rating mean have outperformed stock key metric such earning sale best selling narcolepsy medication xyrem make third jazz second quarter sale company acquire italian biotech gentium earlier year jazz share rise stock market tuesday best close month salix pharmaceutical slxp be spotlight lately potential takeover candidate allergan agn maker botox allergan be aim put stopper valeant pharmaceutical vrx hostile takeover attempt salix share soar aug report talk reportedly be dormant salix be largely hold gain move sideway salix have market cap also have highest possible composite rating salix most recent result miss view earning share more double revenue shot gilead science gild behemoth market cap be mutual fund favorite big stock mover deutsche bank expect company upcoming combo hepatitis treatment have higher expect price point gilead make blockbuster hepatitis drug sovaldi also boast composite rating gilead share fall tuesday be week illumina ilmn have market cap composite rating develop system medical researcher study gene variation function company recently say have form strategic partnership number drugmaker include astrazeneca azn sanofi sny create universal next generation sequence base oncology test system follow elaine low twitter ibd_elow
1260,AGN,top perform medical stock be panacea depress portfolio today tech leader medical screen feature heavy hitter pharmaceutical field maker disorder drug such pepcid salix pharmaceutical slxp be recent week topic now dormant takeover talk allergan agn fought valeant pharmaceutical vrx allergan maker botox
1261,AGN,allergan report accelerate earning growth bullish guidance monday specialty drugmaker set plan cut workforce face hostile takeover bid share rise earning rise vs year earlier share beating analyst consensus cent be fourth straight quarter
1262,AGN,major average close modestly higher thursday exist home sale weekly jobless claim philly fed factory datum come expectation
1263,AGN,dow industrial lead gain add new high nasdaq eke gain new year high volume be mixed tracking higher nyse lower nasdaq stock market today
1264,AGN,bank fiber optic gear maker be day best performer gold silver miner dairy product maker biotechs be biggest loser gold price fall month low prospect fed raise interest rate sooner expect
1265,AGN,royal gold rgls slump heavy volume close day move average first time june share be still extend past cup handle entry clear february gold miner resume profit revenue growth straight quarters decline
1266,AGN,upside universal display oled leap near month high brisk trade stock have be consolidate choppy fashion march be currently work third series adjacent base pattern potential buy point be be still high
1267,AGN,few leader score big gain salix pharmaceutical slxp reversed higher gain average volume ibd stock be now extend buy point late stage flat base drugmaker surge tuesday record best report rumore takeover allergan agn
1268,AGN,fellow ibd component chipotle grill cmg rise much early trade reversed close session low hold small gain stock have be trading tightly july breakaway gap
1269,AGN,key economic datum be slate tomorrow fed chief janet yellen give keynote speech federal reserve conference jackson hole wyo
1270,AGN,follow nancy gondo twitter ibd_ngondo major average close modestly higher thursday exist home sale weekly jobless claim philly fed factory datum come expectation dow industrial lead gain add new high nasdaq eke gain new year high volume be mixed tracking higher nyse lower nasdaq stock market today bank fiber optic gear maker be day best performer gold silver miner dairy product maker biotechs be biggest loser gold price fall month low prospect fed raise interest rate sooner expect royal gold rgls slump heavy volume close day move average first time june share be still extend past cup handle entry clear february gold miner resume profit revenue growth straight quarters decline upside universal display oled leap near month high brisk trade stock have be consolidate choppy fashion march be currently work third series adjacent base pattern potential buy point be be still high few leader score big gain salix pharmaceutical slxp reversed higher gain average volume ibd stock be now extend buy point late stage flat base drugmaker surge tuesday record best report rumore takeover allergan agn fellow ibd component chipotle grill cmg rise much early trade reversed close session low hold small gain stock have be trading tightly july breakaway gap key economic datum be slate tomorrow fed chief janet yellen give keynote speech federal reserve conference jackson hole wyo follow nancy gondo twitter ibd_ngondo
1271,AGN,major average hit new session high friday afternoon stock have be strong start upbeat job datum
1272,AGN,nasdaq be be close day move average volume be tracking sharply lower stock market today
1273,AGN,alexion pharmaceutical alxn rally best level march stock clear buy point flat base larger pattern even drugmaker have be consolidate february number fund own share grow second quarter quarters lead fund such fidelity contrafund fidelity otc add position
1274,AGN,salix pharmaceutical slxp be session high still fast trade have be much nixing plan buy cosmo technology lower tax bill relocate ireland salix find support day line thursday
1275,AGN,actavis act rally bounce back modest slide have be past session now past buy point flat base clear aug
1276,AGN,energy related stock be only leader volume
1277,AGN,silica slca provide sand used frac fall pace weekly loss diamondback energy fang continental resource clr lose respectively crude oil november delivery have trim intraday loss nearly major average hit new session high friday afternoon stock have be strong start upbeat job datum nasdaq be be close day move average volume be tracking sharply lower stock market today alexion pharmaceutical alxn rally best level march stock clear buy point flat base larger pattern even drugmaker have be consolidate february number fund own share grow second quarter quarters lead fund such fidelity contrafund fidelity otc add position salix pharmaceutical slxp be session high still fast trade have be much nixing plan buy cosmo technology lower tax bill relocate ireland salix find support day line thursday actavis act rally bounce back modest slide have be past session now past buy point flat base clear aug energy related stock be only leader volume silica slca provide sand used frac fall pace weekly loss diamondback energy fang continental resource clr lose respectively crude oil november delivery have trim intraday loss nearly
1278,AGN,valeant pharmaceutical international vrx early thursday report line lower guidance sale guidance next year be consensus valeant be more midday trading stock market today penny nearly month low valeant cash earning rise year earlier quarter
1279,AGN,stock rally close tuesday boost major average moderate gain bullish housing datum strong earning report retailer include home depot hd tjx co tjx dow industrial rise nasdaq advanced extend streak finish highest level march volume be higher board stock market today accord preliminary datum ethical drug maker outperformed ibd industry group salix pharmaceutical slxp lead advance soar record best breaking past buy point late stage base takeover rumor other big mover group include report salix suitor allergan agn jazz pharmaceutical jazz valeant pharmaceutical vrx climb construction product maker also logged big gain mohawk industry mhk add month high heavy trade stock be build right side cup base potential entry group lag enjoy bump homebuilder group builder related group get lift commerce department better expect housing start datum rise build permit home purchase application mortgage banker association energy information administration weekly petroleum inventory datum minute federal open market committee meeting be tap tomorrow follow nancy gondo twitter ibd_ngondo
1280,AGN,stock market clock slight gain last full month summer uptrend be pressure second half september
1281,AGN,manager top perform fund past month continue add share medical issue market pullback
1282,AGN,industry group track ibd medical subgroup hospital ethical drug biotech biom be rank top thursday
1283,AGN,large drug firm allergan agn jazz pharmaceutical jazz actavis act salix pharmaceutical slxp continue grab top fund interest latest report period
1284,AGN,lead fund also biotech firm such gilead science gild biogen idec biib celgene celg
1285,AGN,transportation stock remain spotlight airline luv fedex fdx union pacific unp
1286,AGN,few notable buy top fund worth mention include social medium giant facebook fb burrito chain chipotle grill cmg retailer ulta beauty ulta
1287,AGN,ibd find best perform fund add chipotle investing estimate latest report period rowe price blue chip growth fund own big stake firm
1288,AGN,fast casual chain run restaurant canada also venture southeast asian flavor new concept call southeast asian kitchen december chipotle announce plan expand pizza segment pizzeria locale
1289,AGN,chipotle menu be simple serve burritos taco burrito bowl salad used fresh organic ingredient rival similar menu el pollo make ipo debut july
1290,AGN,stock breakaway gap july share have be trading steadily tight range
1291,AGN,earning have be grow steadily double digit least quarters third quarter earning result be due market close oct analyst currently see earning rise share
1292,AGN,sell side
1293,AGN,nation top perform fund have be take profit handful retailer include cvs health cvs dollartree dltr costco cost william sonoma wsm stock market clock slight gain last full month summer uptrend be pressure second half september manager top perform fund past month continue add share medical issue market pullback industry group track ibd medical subgroup hospital ethical drug biotech biom be rank top thursday large drug firm allergan agn jazz pharmaceutical jazz actavis act salix pharmaceutical slxp continue grab top fund interest latest report period lead fund also biotech firm such gilead science gild biogen idec biib celgene celg transportation stock remain spotlight airline luv fedex fdx union pacific unp few notable buy top fund worth mention include social medium giant facebook fb burrito chain chipotle grill cmg retailer ulta beauty ulta ibd find best perform fund add chipotle investing estimate latest report period rowe price blue chip growth fund own big stake firm fast casual chain run restaurant canada also venture southeast asian flavor new concept call southeast asian kitchen december chipotle announce plan expand pizza segment pizzeria locale chipotle menu be simple serve burritos taco burrito bowl salad used fresh organic ingredient rival similar menu el pollo make ipo debut july stock breakaway gap july share have be trading steadily tight range earning have be grow steadily double digit least quarters third quarter earning result be due market close oct analyst currently see earning rise share sell nation top perform fund have be take profit handful retailer include cvs health cvs dollartree dltr costco cost william sonoma wsm
1294,AGN,large cap stock variety sector continue hold relatively well increase higher volume decline major average overall market uncertainty valeant pharmaceutical vrx be new entrant week list drugmaker have be try acquire botox maker allergan agn april avail allergan think valeant hostile offer be
1295,AGN,corporate tax inversion deal size propose consummate have push global merger acquisition level not see worldwide have be report accord thomson reuter datum most year big jump
1296,AGN,facebook foot locker be ibd stock be hold high other leader come pressure general market
1297,AGN,ibd list company be weathering recent turmoil include face press acquisition
1298,AGN,salix pharmaceutical
1299,AGN,maker brand prescription drug treat disorder such ulcerative colitis acid reflux be play share rise more largest investor urge company put sale
1300,AGN,larger brand drug maker allergan agn have be maneuvering buy salix slxp way fend takeover botox maker valeant vrx
1301,AGN,activist investor bill ackman pentwater capital management be opposed allergan salix merger other be also eyee salix
1302,AGN,salix share fall stock market friday hit record intraday wednesday still well day line
1303,AGN,actavis
1304,AGN,report surface past wednesday ireland base actavis act be talk buy salix potentially undercut allergan defensive strategy valeant
1305,AGN,actavis make brand generic drug treat variety ailment include hypertension sleep disorder pain well contraceptive pill other product
1306,AGN,actavis stock hit time high wednesday be so far year
1307,AGN,facebook
1308,AGN,world largest social network user grow be poise close biggest acquisition ever
1309,AGN,eu antitrust regulator reportedly grant unconditional clearance facebook fb buyout messaging service whatsapp reuter say merger come facebook make rapid gain mobile usage advertising
1310,AGN,report friday also say facebook have reach youtube top content producer invite test video platform variety report say facebook be also add feature similar google googl video site try beef offering
1311,AGN,facebook share have advanced consecutive week
1312,AGN,foot locker
1313,AGN,increase popularity basketball shoe grow trend wear athletic gear outside gym be drive more young person foot locker fl store
1314,AGN,new york base retailer compete finish line finl dsw dsw industry giant nike nke retail outlet
1315,AGN,foot locker share climb friday nike record slam dunk first quarter earning close thursday even finish line report weak earning
1316,AGN,ambarella
1317,AGN,lone semiconductor maker list make chip camera include security system also make chip gopro gpro wearable camera be used action sport law enforcement
1318,AGN,earlier month ambarella amba report result easily top wall street forecast give upbeat guidance
1319,AGN,ambarella share set fresh close high friday
1320,AGN,follow james detar twitter ibd_jdetar facebook foot locker be ibd stock be hold high other leader come pressure general market ibd list company be weathering recent turmoil include face press acquisition salix maker brand prescription drug treat disorder such ulcerative colitis acid reflux be play share rise more largest investor urge company put sale larger brand drug maker allergan agn have be maneuvering buy salix slxp way fend takeover botox maker valeant vrx activist investor bill ackman pentwater capital management be opposed allergan salix merger other be also eyee salix salix share fall stock market friday hit record intraday wednesday still well day line actavisreport surface past wednesday ireland base actavis act be talk buy salix potentially undercut allergan defensive strategy valeant actavis make brand generic drug treat variety ailment include hypertension sleep disorder pain well contraceptive pill other product actavis stock hit time high wednesday be so far year world largest social network user grow be poise close biggest acquisition ever eu antitrust regulator reportedly grant unconditional clearance facebook fb buyout messaging service whatsapp reuter say merger come facebook make rapid gain mobile usage advertising report friday also say facebook have reach youtube top content producer invite test video platform variety report say facebook be also add feature similar google googl video site try beef offering facebook share have advanced consecutive week foot lockerthe increase popularity basketball shoe grow trend wear athletic gear outside gym be drive more young person foot locker fl store new york base retailer compete finish line finl dsw dsw industry giant nike nke retail outlet foot locker share climb friday nike record slam dunk first quarter earning close thursday even finish line report weak earning lone semiconductor maker list make chip camera include security system also make chip gopro gpro wearable camera be used action sport law enforcement earlier month ambarella amba report result easily top wall street forecast give upbeat guidance ambarella share set fresh close high friday follow james detar twitter ibd_jdetar
1321,AGN,selling picked pace major average late afternoon trading tuesday dow jone industrial average fall give nasdaq lose nyse nasdaq volume be tracking lower monday level stock market today base astrazeneca azn lose government release new rule fight tax inversion company avoid taxation move headquarters overseas pfizer pfe be talk acquire astrazeneca ireland base shire shpg meanwhile lose be well session lows agree deal illinois base abbvie abbv earlier year china name bounce back recent weakness cheer better expect manufacturing datum china vipshop vip jump nearly try reclaim day move average day line have be resistance level stock drop heavy volume ibd polaris industry pii outperformed rise nearly surge week end july polaris have show positive technical action trading tightly week move average several week polaris be leaderboard name investor comrailroad operator kansa city southern ksu extend loss fall stock be still buy range hold buy point merger news salix pharmaceutical slxp jump report drugmaker be advanced talk be acquire allergan agn potential union have be rumore time allergan be try fend hostile bid valeant pharmaceutical vrx elsewhere cf industry cf clear base rise news news investor com business cf industry yara talk form fertilizer giant htmthat be be court norwegian firm yara international
1322,AGN,valeant pharmaceutical raise bid fellow specialty drugmaker allergan again friday make offer contingent good faith negotiation contrast previous hostile bid latest proposal raise cash portion retain valeant vrx offer share allergan agn share thursday close new bid value
1323,AGN,specialty drugmaker allergan agn file investor presentation denounce business model be hostile acquirer valeant pharmaceutical international vrx tuesday day valeant host conference call expect raise bid stock slip morning trading stock market today
1324,AGN,allergan say press release employ financial consultant accountant examine valeant financial statement find pro revenue growth valeant sec filing paint picture far different be communicate investor allergan also say product valeant largest acquisition so far medicis bausch lomb have lose market share valeant acquire valeant compensate price increase allergan say be unsustainable
1325,AGN,allergan also question valeant really cut have claim be trim allergan expense harm productivity have be most contentious issue valeant first make bid month figure heavily allergan rejection bid
1326,AGN,research note tuesday sterne agee analyst shibani malhotra speculate valeant make new offer wednesday share raise total price least represent premium more allergan stock price tuesday morning
1327,AGN,malhotra also expressed concern valeant cost cut say be listen call detail work
1328,AGN,surface valeant allergan appear have significant business overlap be focuse ophthalmology dermatology aesthetic however consider value driver allergan such botox therapeutic glaucoma dry eye franchise synergy opportunity seem less obvious write valeant propose reduction eliminate allergan be value destructive longer term
1329,AGN,buckingham research upgrade allergan stock neutral buy tuesday anticipation higher bid lift price target still allergan stock be morning trading tuesday valeant stock be
1330,AGN,follow amy reeve twitter ibd_areeve specialty drugmaker allergan agn file investor presentation denounce business model be hostile acquirer valeant pharmaceutical international vrx tuesday day valeant host conference call expect raise bid stock slip morning trading stock market today allergan say press release employ financial consultant accountant examine valeant financial statement find pro revenue growth valeant sec filing paint picture far different be communicate investor allergan also say product valeant largest acquisition so far medicis bausch lomb have lose market share valeant acquire valeant compensate price increase allergan say be unsustainable allergan also question valeant really cut have claim be trim allergan expense harm productivity have be most contentious issue valeant first make bid month figure heavily allergan rejection bid research note tuesday sterne agee analyst shibani malhotra speculate valeant make new offer wednesday share raise total price least represent premium more allergan stock price tuesday morning malhotra also expressed concern valeant cost cut say be listen call detail work surface valeant allergan appear have significant business overlap be focuse ophthalmology dermatology aesthetic however consider value driver allergan such botox therapeutic glaucoma dry eye franchise synergy opportunity seem less obvious write valeant propose reduction eliminate allergan be value destructive longer term buckingham research upgrade allergan stock neutral buy tuesday anticipation higher bid lift price target still allergan stock be morning trading tuesday valeant stock be follow amy reeve twitter ibd_areeve
1331,AGN,biotech pharmaceutical company be rise life save promise add hope stock also be healthy investment industry be friday general market weakness concern growth stock continue dominate week ibd list company base superior earning strong price performance leadership industry here
1332,AGN,valeant pharmaceutical international vrx officially launch hostile bid allergan wednesday analyst speculate allergan counterattack tax inversion acquisition own
1333,AGN,valeant take directly shareholder sweeten bid allergan unveil amount share cash valeant share allergan share allergan agn director reject offer valeant previous bid friday valeant partner persh square sue allergan attempt hold shareholder meeting trigger poison pill board have adopt response valeant overture
1334,AGN,meanwhile monday irish drugmaker ibd stock wednesday midweek update shire shpg hire citigroup banker evaluate possible takeover offer accord anonymously source reuter report allergan have be rumore be interested acquire shire shortly valeant start bidding wednesday suntrust analyst john boris write research note bid shire now seem likely
1335,AGN,boris write such merger be more appeal valeant allergan lower allergan tax rate offer more sustainable organic growth valeant buyout base model
1336,AGN,make thing more complicate shire be rumore earlier month have make bid nps pharmaceutical npsp nps deny analyst still say shire buy nps similar company be only way stay independent tax inversion crazed environment
1337,AGN,investor seem agree shire stock be nearly morning trading stock market today allergan be more valeant be flat
1338,AGN,follow amy reeve twitter ibd_areeve valeant pharmaceutical international vrx officially launch hostile bid allergan wednesday analyst speculate allergan counterattack tax inversion acquisition own valeant take directly shareholder sweeten bid allergan unveil amount share cash valeant share allergan share allergan agn director reject offer valeant previous bid friday valeant partner persh square sue allergan attempt hold shareholder meeting trigger poison pill board have adopt response valeant overture meanwhile monday irish drugmaker ibd stock wednesday midweek update shire shpg hire citigroup banker evaluate possible takeover offer accord anonymously source reuter report allergan have be rumore be interested acquire shire shortly valeant start bidding wednesday suntrust analyst john boris write research note bid shire now seem likely boris write such merger be more appeal valeant allergan lower allergan tax rate offer more sustainable organic growth valeant buyout base model make thing more complicate shire be rumore earlier month have make bid nps pharmaceutical npsp nps deny analyst still say shire buy nps similar company be only way stay independent tax inversion crazed environment investor seem agree shire stock be nearly morning trading stock market today allergan be more valeant be flat follow amy reeve twitter ibd_areeve
1339,AGN,new buy list top perform fund past month show heavy buy top rate stock nation lead fund have be stocking medical issue fared well market resume uptrend august large heavy hit medical stock be buy top fund latest report period include gilead science gild jazz pharmaceutical ticker
1340,AGN,medical stock be sector leader friday edition most ibd sector show strength sector have be best bottom aug drug developer be new high possible new entry alexion pharmaceutical ticker
1341,AGN,specialty drugmaker ibd stock shire shpg have reject takeover offer big pharma abbvie abbv most recent value company announce friday shire stock vault nearly early trading stock market today time high abbvie stock be fraction company
1342,AGN,stock meander ahead federal reserve announcement monetary policy expect et volume remain lower major exchange
1343,AGN,fed announcement typically roil market hour investor absorb news emerge fed open market committee be expect keep interest rate continue wind bond buy program
1344,AGN,chairwoman janet yellen hold et press conference
1345,AGN,nasdaq dow jone industrial average be be smidgen
1346,AGN,stock market today fedex fdx adobe system adbe report better expect earning gap time high fedex break cup handle base be adobe be be time high
1347,AGN,amazon amzn be set announce smartphone say have capability be less average volume work long consolidation
1348,AGN,valeant pharmaceutical vrx take bid botox maker allergan agn directly shareholder launch tender offer valeant be trading little change just day move average try rise lows base allergan be light trade find support week move average stock meander ahead federal reserve announcement monetary policy expect et volume remain lower major exchange fed announcement typically roil market hour investor absorb news emerge fed open market committee be expect keep interest rate continue wind bond buy program chairwoman janet yellen hold et press conference nasdaq dow jone industrial average be be smidgen stock market today fedex fdx adobe system adbe report better expect earning gap time high fedex break cup handle base be adobe be be time high amazon amzn be set announce smartphone say have capability be less average volume work long consolidation valeant pharmaceutical vrx take bid botox maker allergan agn directly shareholder launch tender offer valeant be trading little change just day move average try rise lows base allergan be light trade find support week move average
1349,AGN,embattled specialty drugmaker allergan agn beat wall street estimate raise guidance wednesday share remain flat stock market today
1350,AGN,allergan report earning share year earlier quarter beating analyst consensus cent sale rise line estimate
1351,AGN,guidance follow similar pattern full year company set sale range bracketing consensus ep range top street last year company make share sale
1352,AGN,second quarter company guide sale year again meeting estimate guide ep consensus vs last year
1353,AGN,announcement come allergan management continue public war word valeant pharmaceutical vrx hostile takeover attempt tuesday time report allergan co founder gavin herbert speak annual shareholder meeting warning valeant decimate allergan research development budget come day activist investor william ackman joined valeant bid say allergan attempt find better buyer likely be fruitless
1354,AGN,nonetheless allergan say be review offer valeant attempt have certainly drive allergan stock price hit time high early trading monday be highest possible composite rating
1355,AGN,follow amy reeve twitter ibd_areeve embattled specialty drugmaker allergan agn beat wall street estimate raise guidance wednesday share remain flat stock market today allergan report earning share year earlier quarter beating analyst consensus cent sale rise line estimate guidance follow similar pattern full year company set sale range bracketing consensus ep range top street last year company make share sale second quarter company guide sale year again meeting estimate guide ep consensus vs last year announcement come allergan management continue public war word valeant pharmaceutical vrx hostile takeover attempt tuesday time report allergan co founder gavin herbert speak annual shareholder meeting warning valeant decimate allergan research development budget come day activist investor william ackman joined valeant bid say allergan attempt find better buyer likely be fruitless nonetheless allergan say be review offer valeant attempt have certainly drive allergan stock price hit time high early trading monday be highest possible composite rating follow amy reeve twitter ibd_areeve
1356,AGN,david pyott admire apple ability innovate longtime ceo like describe global health care firm year old apple pyott become chief executive allergan agn also chairman irvine calif base maker drug medical device counter product specialty market be establish allergan pharmaceutical founder
1357,AGN,alnylam pharmaceutical alny dip early thursday announce collaboration regeneron pharmaceutical regn late wednesday research treatment form nonalcoholic fatty liver disease piper jaffray analyst edward tenthoff be bullish partnership marry regeneron discovery specific genetic variant associate chronic liver disease alnylam work type therapy call rna interference see deal positive alnylam expertise rna interference delivery hepatocyte liver cell complement therapeutic translation regeneron discovery say note client alnylam regeneron be join wide field biotechs drugmaker work treatment nonalcoholic steatohepatitis include gilead science gild allergan agn intercept pharmaceutical icpt novartis nvs get newsletter deliver inbox more info product service privacy policy term useon stock market today alnylam fall breaking consolidation earlier month buy point regeneron fall biotech stock be small fraction deal alnylam regeneron be base regeneron discovery variation hsd gene be tie reduce risk protection various chronic liver disease firm say press release regeneron finding stem large scale human genetic effort undertake regeneron genetic center new potential therapeutic target be used trim risk halt progression chronic liver disease alnylam regeneron plan look potential treatment disease know nonalcoholic steatohepatitis liver suffer damage similar cause alcohol patient be often obese have type diabetes plan use alnylam expertise rna interference target hsd gene rna interference allow researcher specifically target silence gene involved cause pathway human disease piper jaffray tenthoff say collaboration expand co development co deal keep price target overweight rating alnylam related invest stock free new apps aim basic analyze stock cup buy stock ahead earning report
1358,AGN,find best biotech company invest be tricky volatility often pockmark space clinical plan don always come fruition sometimes biotech stock suffer hand regulatory decision food drug administration best biotech company invest tend have commonality strong streak earning growth june investor business daily marketsmith com have biotech stock strong list fastest grow stock top list fastest grow stock supernus pharmaceutical supn be rank eighth past year earning share have grow massive compare top earn stock momo momo chinese social medium firm supernus have make name biotech stock term market cap still trail bigger biotech company amgen amgn gilead science gild biogen biib celgene celg supernus land list consider best biotech company invest strong metric always do research buy stock be sure check company stock chart make sure right time buy have several year double digit quarterly sale growth drug help disorder central nervous system supernus count epilepsy drug oxtellar xr extend release trokendi xr trokendi xr be also approve prevent migraine rival drug botox allergan agn amgen aimovig ligand pharmaceutical lgnd be unique biotech stock ibd rank fastest grow stock put research list possible best biotech company invest doesn market single drug instead ligand acquire early stage technology necessary drug development then license platform pharmaceutical company dow jone stock merck mrk pfizer pfe june ligand have year double digit sale earning growth belt ligand supernus have ibd composite rating meaning perform top stock term key growth metric duo lead other biotech stock term cr get instant access more trading idea exclusive stock list ibd proprietary rating only related chart read basic buy point mark time real build long term profit stock take many gain trade stock most penny stock fail make investor rich
1359,AGN,migraine prevention treatment eli lilly lly face battle amgen amgn late thursday have strong result long term study approve medicine amgen lilly have migraine prevention drug call cgrps drug work block specific peptide associate migraine amgen drug aimovig grab approval lilly be fast approach approval likely september allergan agn botox be well know treatment wrinkle facial line have other used excessive sweat urinary incontinence prevent migraine wednesday lilly show drug call emgality benefit patient botox didn prevent migraine rbc capital market analyst kennen mackay doesn expect study substantially impact position marketplace get newsletter deliver inbox more info product service privacy policy term use do find post botox analysis provide unique perspective marketing point emgality physician have establish familiarity botox estimate patient step botox cgrp therapy say report stock market today lilly advanced close bell amgen sank share pharmaceutical biotech company rise fraction late wednesday lilly say emgality benefit patient botox didn work prevent migraine lilly test cgrp milligram milligram dose patient fail botox migraine prevention treatment average respectively see migraine day month cut half datum be compelling give botox be commonly used agent prophylactic treatment paradigm migraine potentially be require step therapy prior treatment cgrp class rbc mackay say lilly continue face battle amgen mackay say official approve aimovig drug already have establish safety effectiveness profile also beat rival lilly teva pharmaceutical teva aldr market expect aimovig continue benefit first market status say mackay doesn expect aimovig completely fill revenue hole amgen face grow list challenge legacy product notably amgen drug be face potential competition biosimilar nearly identical drug further amgen partner novartis nvs aimovig meaning have share sale amgen be more bullish biotech release result wednesday survey patient experience least migraine month respondent say miss least week work month due migraine effective migraine prevention help ease estimate annually economic cost amgen say half be due lose productivity additional datum show patient be often reluctant admit suffering migraine suggest already extremely large market see potential upside incident prevalent population estimate medical literature well number underpinning assumption model mackay say mackay estimate be chronic episodic migraine patient however potential migraine market be significantly larger vs establish literature see amgen base business erosion create significant challenge revenue hole fill especially give aimovig revenue be share partner novartis say late thursday amgen say aimovig be test year chronic migraine patient biotech also take interim look datum year ongoing year study episodic migraine patient researcher test patient dose milligram milligram average patient see migraine day month decline respective day day monthly migraine day decline half patient respectively day also drop quarters patient respectively just patient milligram dose patient milligram dose have migraine day datum show sustain effectiveness consistent safety tolerability aimovig extend period time be important migraine patient clinician know stewart tepper professor neurology geisel school medicine dartmouth medical school say prepared statement related chart read basic buy point mark time real trade stock most penny stock fail make investor richsell take profit hold here be several guideline follow
1360,AGN,kris bakowski be diagnosed alzheimer disease georgia resident feel relieve finally put name fog be slowly envelop brain even be viable alzheimer treatment month forget own phone number have trouble colleague name mapping route home work become chore day find alone mall recollection be get biopharma company believe be able help soon analyst say biogen biib be first crack code disease modify alzheimer treatment slow disease progression indeed biogen tokyo base eisai announce late thursday phase test alzheimer drug slow progression disease month news send biogen stock soar more point friday novartis nvs roche rhhby amgen amgn other also be develop potential alzheimer drug number development stage biotech company victory be not certain number big pharma company include merck mrk eli lilly lly johnson johnson jnj have be road abandon plan alzheimer treatment least expert see success next decade wouldn come too soon bakowski other alzheimer patient get newsletter deliver inbox more info product service privacy policy term usebakowski now have be blog alzheimer experience year blog post alzheimer association describe month testing lead diagnosis subsequent relief hopeful cure son lifetime family isn so optimistic husband liken titanic ship be sink son be go survive wasn write son reflect be mother be death row innocent crime potential alzheimer market be massive estimate american be live alzheimer other form dementia way intervene alzheimer association expect cost care person disease hit today dollar be estimate bakowski many expert be hopeful privately hold proclara bioscience be cadre biotech company aim develop alzheimer treatment chief medical officer david michelson call field pretty vibrant michelson have hold position merck lilly say steady drumbeat bad news alzheimer treatment reflect not so much failure affect specific target brain issue such side effect specific test recently speak webinar host endpoint news lot really tremendous work ongoing enable new approach be become possible generate promising new target say be actually very hopeful optimistic next year hold research alzheimer several drug have be approve treat dementia alzheimer type include eisai namenda allergan agn treat symptom alzheimer disease neither cure disease elliot goldstein chief executive promis neurosciences count type treatment hand none slow progression disease tell investor business daily promis be also work alzheimer treatment trade toronto stock exchange doesn have sale earning yet goldstein previously work novartis be also develop alzheimer drug biogen strongest hope be drug now dub aducanumab goldstein predict drug come market aducanumab have high potential approval have show small improvement decline patient alzheimer symptom say biogen do not respond request comment article visit ibd stock checkup see biogen rate now key fundamental technical metric total biogen have potential alzheimer treatment pipeline aducanumab be farthest late stage study likely have datum analyst say biogen eisai thursday announcement involved drug know ban test involved patient diagnosed early alzheimer company say drug antibody achieve statistical significance key predefined endpoint evaluate effectiveness month biogen stock jump close have surge intraday high gain point still messy field biogen stock plunge valentine day year add new patient ongoing study aducanumab move catch investor guard also week merck scrap late stage alzheimer treatment study risk look likely outweigh benefit be volatile area canaccord analyst sumant kulkarni tell investor business daily have be very spectacular failure past component investor think next work help stock point view then again say nothing else have work past trouble alzheimer treatment research be scientist aren exactly sure cause disease prevailing theory ty disease buildup toxic plaque brain happen protein call beta amyloid structurally change beta amyloid be sticky clump together become plaque pharmaceutical company be look approach beta amyloid essentially boil remove prevent bace inhibitor work prevent buildup monoclonal antibody biogen aducanumab aim remove promis goldstein note adverse event also be sidestep alzheimer treatment come side effect know amyloid related imaging abnormality aria refer swell brain goldstein say promis alzheimer treatment set begin clinical study doesn cause mizuho analyst salim sy say possible help patient get past aria common idiom industry be don get aria be really treat plaque tell ibd then trouble determine study be design well proclara michelson say first evidence show drug engage intend target beta amyloid second patient be proven actually have alzheimer third study be big appropriate duration turn look back history aren many study many drug have be study way really fulfill element say argue only study have hit design goal be merck now fail bace inhibitor know verubecestat biogen aducanumab february merck scrap study alzheimer treatment patient prodromal very early stage alzheimer disease year earlier say same drug have virtually chance find positive effect patient mild moderate form disease meanwhile field be thin stop midstage test bace inhibitor group patient liver safety concern january pfizer pfe stop research alzheimer parkinson disease lilly alzheimer treatment failure late be acutely painful company monoclonal antibody call solanezumab lose late stage study last study be patient mild form alzheimer promis alzheimer treatment bound several toxic misfold protein cause alzheimer goldstein say function theory be other target alzheimer disease outside beta amyloid drug be also testing theory tangle protein call tau be root cause privately hold unite neurosciences hope come vaccine alzheimer goal be use drug treatment early alzheimer preventive measure physician administer drug too late rescue brain unite neurosciences chief medical officer ajay verma tell investor business daily verma background be biogen direct development drug include aducanumab be merck novartis verma expect aducanumab get approval several sell side analyst model likelihood aducanumab appease food drug administration verma see possibility aducanumab be expensive be first treatment slow progression alzheimer disease think challenge be be solution just rich say verma ultimately expect solution treat alzheimer disease lie combination drug be key treat cancer hiv cardiovascular disease metabolic disease high cholesterol say intervention number alzheimer patient triple james hendrix say endpoint news webinar hendrix be director global science initiative alzheimer association need better therapy need sooner rather later hendrix say alzheimer treatment study be tricky unite neurosciences verma say barrier blood brain make get drug brain difficult animal model aren particularly predictive study run long period time further complicate matter science isn sure stage be best treat reason be center approval rate fda alzheimer treatment accord paper present hendrix industry average be research be improve hendrix say scientist be aware potential impact beta amyloid tau well number approach target different stage end be enough alzheimer treatment just delay begin disease several year say be possible delay onset die something else say also stock market forecast next month build long term profit stock take gain robotic surgery revolution be just get term retirement investing strategy etfsnew option strategy limit risk earning
1361,AGN,allergan agn tank year low thursday mylan myl revance therapeutic rvnc announce plan bring botox copycat market just regulator impose delay allergan drug early trading stock market today allergan topple close fall much share touch lowest point october meanwhile mylan stock weather soft quarter guidance rise botox announcement mizuho analyst irina koffler say note client mylan revance be likely several year market botox copy still downside effect allergan be undeniable say botox account nearly allergan sale allergan sell botox cosmetic drug treat age line forehead eye mouth botox therapeutic also treat number condition include excess sweat chronic migraine create immediate overhang allergan reimburse therapeutic franchise future outlook koffler write be less concern cosmetic pressure aren expect mylan invest dedicate sale force still expect fear weigh stock mylan be pay revance upfront revance be also eligible clinical regulatory milestone sale base milestone piper jaffray analyst david amsellem say note client deal help revance monetize expertise botulinum toxin active ingredient botox amsellem say call deal mylan form downside protection drug know rt injectable neuromodulator botox put way be way revance participate wider chunk botulinum toxin market context decline pricing environment due other brand botulinum toxin product botox biosimilar say revance have say first goal be have rt approve cosmetic treatment frown line eventually expect go therapeutic indication mizuho koffler say allergan also say late wednesday food drug administration push back review application drug call ulipristal acetate august provide full review file ulipristal acetate be be consider treat bleed woman uterine fibroid drug already sell europe canada esmya fibristal related chart read basic buy point mark time real do spot major market top easy look heavy much money do need start investing
1362,AGN,mylan myl jump late wednesday generic drugmaker report mixed fourth quarter revenue lag street continue volatility adjust profit top penny guidance also be mixed mylan sale outlook miss consensus midpoint firm view adjust earning beat expectation midpoint chief executive heather bresch note health care market remain volatile deliver increase total revenue year year strong performance europe rest world segment more offset volatility health care industry marketplace say prepared statement fourth quarter total revenue be year year narrowly miss consensus adjust profit share decline top average view analyst poll zack investment research share north america segment third party net sale decline sale epipen treat emergency allergic reaction decrease launch authorize generic higher governmental rebate follow deal department justice europe segment sale climb revenue rest world grow mylan guide adjust profit share total revenue consensus have expect adjust earning share sale mylan also announce sign license agreement revance therapeutic rvnc bring biosimilar botox market botox be brand allergan agn hour trading stock market today mylan lift close regular session related celgene gamble ozanimod didn pay offcelgene tank fda refuse review multiple sclerosis drugthese biotechs diverge biggest moneymaker lag expectation
1363,AGN,valeant pharmaceutical vrx be take overly optimistic long term view business analyst say firm offer mixed fourth quarter report call be year guidance sale vs analyst view be conservative give reflect potential valeant ulcerative colitis drug apriso uceris lose exclusivity piper jaffray analyst david amsellem say valeant guidance dermatology business double vs be likely overly rosy amsellem say note client doubt valeant call be trough year picture only worsen significant debt mature say be not lose valeant have brisk pace new upcoming launch believe valeant aspirational target double dermatology sale vs be overly optimistic say mizuho analyst irina koffler deem valeant outlook optimistic compound annual growth rate adjust earning interest taxe depreciation appreciation valeant share collapse wednesday follow company fourth quarter report be still free fall thursday stock market today valeant topple close diving much earlier trade valeant be bullish combination drug retinoid tazarotene halobetasol call duobrii plaque psoriasis generic tazarotene allergan agn tazorac be now available higher concentration version halobetasol be not widely available be number other higher concentration topical steroid be generically available say put way duobrii be efficacious well tolerate be economic payer reality consider next year valeant expect significant drug grow north valeant count therapy psoriasis opioid induced constipation glaucoma have square vs allergan psoriasis astrazeneca azn purdue pharmaceutical opioid induced constipation aerie pharmaceutical aeri glaucoma amsellem say cut price target related invest stock free new apps aim beginnerssell take profit hold here be several guideline followstill rule stock investor always cut loss short
1364,AGN,allergan agn say wednesday cut job close open position prepare deal generic competition biggest drug eye medicine call restasis decision follow allergan november conference call chief executive brenton saunder outlined loss exclusivity challenge saunder say company act generic form dry eye drug come market hate say know take cost business do say time know do way protect long term growth driver plan come fruition wednesday allergan say security exchange commission filing eliminate more currently filled job impact employee commercial other function close open slot commercial cut primarily focus product category lose exclusivity allergan say third quarter restasis bring global sale just aesthetic specialty drug botox have sale ibd take allergan have ibd composite rating best possible meaning operate middle stock term key growth metric head ibd stock checkup look better rate pharmaceutical stock allergan expect incur restructure cost primarily due severance majority cost be record fourth quarter end dec allergan say be additional fee build closure contract termination other item overall allergan peg saving vs close bell stock market today allergan slip related spark glaxo gene therapy still bargain smaller biotech rival allergan blockbuster botox biotech dife analyst slash expectation cancer drug
1365,AGN,allergan agn pop tuesday result migraine trial report fourth quarter sale adjust profit top wall street expectation allergan jump stock market today intraday trading climb high fourth quarter allergan report adjust earning share sale rise respectively top consensus adjust income share sale botox cosmetic revenue rise year year beat estimate mizuho analyst irina koffler say note botox therapeutic sale grow lag total botox revenue advanced eye drug restasis bring sale schizophrenia bipolar drug vraylar infection drug avycaz tack strongest growth respective ibd take investing be stock market be not gamble do require finesse head investor corner more time buy sell stock namenda extend release treat dementia alzheimer type fall contraceptive minastrin dip overactive bladder drug enable topple skin drug tazorac decline allergan guide sale adjust earning share top analyst view share respectively march quarter allergan see adjust income share sale midpoint earning sale guidance miss consensus respectively allergan also report strong result trial testing adult acute migraine attack result stem first pivotal phase study evaluate milligram milligram dose drug call ubrogepant ubrogepant be give orally belong class drug know cgrps study patient be treat single migraine attack moderate severe intensity allergan say news release dose show statistically significant result vs placebo hour patient treat milligram milligram dose respectively be pain free vs placebo patient most bothersome symptom disappear patient receive milligram milligram dose ubrogepant vs placebo treat patient key note liver toxicity result be better expect evercore analyst umer raffat say report allergan buy right ubrogepant dow merck mrk prior oral cgrps merck be discontinue toxicity reason patient have elevated liver enzyme be greater time upper limit normal be alternative explanation case allergan say none be note have probable relationship ubrogepant allergan have previously mentioned case elevated liver enzyme greater time upper limit normal blind basis phase raffat say reason appear allergan have clear bar liver safety be key migraine attack be often treat drug know triptan triptan don work migraine patient low response triptan respond milligram milligram dose ubrogepant vs placebo triptan market have more peak sale raffat say allergan be call peak sale oral cgrps ubrogepant atogepant expect launch related biotech stock dive more be sell overdo bristol myer squibb dife strong earning opdivo datacan crispr small biotechs cure disease
1366,AGN,dow jone industrial average index rebound key support level end slightly lower nasdaq composite fuel apple aapl rally tesla tsla skid cash burn elon musk strange conference call mastercard hit buy zone new payment stock struggle alibaba baba pull back strong earning sprint merge mobile tmus headline several big deal job report symmetric fed stance ease rate hike fear crude oil price hit record high shale operator beat earning view dow jone undercut day move average rebound friday finish week nasdaq composite rally retake day line apple aapl fuel earning buyback warren buffett buy more share soar drive major average higher tesla tsla fall alibaba baba rally mastercard enter buy zone treasury yield pull back yield spread narrowing slightly crude oil rise nearly barrel shale earning be strong apparel stock be loser consumer electronic giant apple aapl earn share year year sale fiscal second quarter be best ep gain year latest string accelerate revenue growth report top forecast apple sell iphone just miss consensus service revenue wearable sale be strong apple also announce plan buyback big dividend hike warren buffett disclose berkshire hathaway brkb buy apple share first month bring total stake nearly apple stock surge best weekly gain year hit record high blast buy zone get newsletter deliver inbox more info product service privacy policy term usetesla report smaller expect loss forecast revenue electric car maker model production remain low company burn cash post earning conference call ceo elon musk cut wall street analyst bore question spend next minute take question blogger youtube share fall sharply thursday close week cent alibaba report better expect quarterly earning core commerce revenue swell cloud revenue more double alibaba end quarter monthly active user mobile device alibaba also give bullish outlook share rise friday jobless rate slide april lowest economy add job labor department report friday meanwhile average hourly wage growth rise just year little view fed favore gauge core inflation climb policymaker send message win panic top come month fed stress wednesday inflation target be symmetric qualys qlys fireeye feye fortinet ftnt top earning revenue view share retreat cyberark software cybr rally strong result outlook guide slightly higher meanwhile carbon black cblk jump friday debut ipo price late thursday high end recently raise range zendesk zen pop result guidance show customer support sale automation software company be build momentum rival salesforce com crm larger contract paycom payc report strong earning sale growth forecast line june quarter result send hr payroll process software maker lower fellow payroll hr cloud software firm paylocity pcty break friday result commerce software firm shopify shop top view size sale beat update guidance left investor unimpressed shopify initially fall rebound strong gain ultimate software ulti report adjust ep top estimate revenue grow also beating share rally wednesday close buy point mcdonald mcd surge score double beat ep rise revenue fall shake shack shak sky-rocket friday crushed earning beat revenue wingstop wing also jump friday result taco bell parent yum brand yum earning top share skid weak same store sale yum china yumc tumble weak pizza hut result china offset overall strong earning texas roadhouse txrh slip come par ep cent revenue viper energy partner vnom anadarko petroleum apc concho resource cxo noble energy nbl matador resource mtdr continental resource clr parsley energy pe eog resource eog pioneer natural resource pxd top quarterly estimate integrate energy firm marathon oil mro clear buy point follow earning oil price hit fresh multiyear high inventory production increase odd be rise president trump withdraw iran nuclear pact sprint mobile tmus finally agree merger share fall lack price premium fear antitrust regulator reject deal meanwhile marathon petroleum mpc agree buy andeavor andv create largest base refiner additionally walmart wmt say chain asda merge sainsbury walmart reportedly be deal buy india commerce giant flipkart prologis pld buy dct industrial dct finally marriott vacation vac reveal buy ilg ilg annual developer conference facebook fb say be enter online date business more person facebook identify single match group mtch own match com date app tinder plunge announcement facebook also introduce oculus go stand alone vr headset announce october arista network anet late thursday report ep gain revenue swell beating cisco rival see revenue line view send share tumble friday turnaround project juniper network jnpr late tuesday report ep decline wasn bad expect sale network gear cloud compute customer rebound juniper forecast profit slightly view share pop pare gain allergan agn zoetis zts teva teva exelixis exel top quarterly expectation allergan sank report unlikely make deal zoetis fall adjust profit guidance miss penny dow jone component merck mrk pfizer pfe beat profit lag sale gilead gild miss sale adjust earning hepatitis drug fall vs last year regeneron regn profit beat revenue miss eye drug eylea top view celgene celg topple analyst suggestion key drug be delay year friday celgene say refile application drug ozanimod multiple sclerosis treatment celgene also top first quarter expectation raise full year guidance sarepta srpt sale miss view loss be better expect mastercard share jump credit card giant report earning beat estimate join visa buy range square sq sale also top bitcoin make payment technology firm current quarter profit outlook come short fleetcor flt provide prepay fuel card vehicle fleet other payment product sank low outlook paypal pypl tumble amazon amzn reportedly offer merchant discount use own payment service controversy kanye west comment slavery have tangled adida addyy ceo sportswear company distance not cut ty rapper west yeezy brand be not significant part adida revenue contribute brand style image share tumble buy point adida logging currency neutral revenue growth include solid north america meanwhile armour uaa top estimate give weak outlook susquehanna say inventory be tick time bomb coach kate spade parent tapestry tpr top consensus share plunge upscale purse accessory maker raise guidance be still largely consensus north face van parent vf corp vfc beat view share retreat friday snapchat operator snap snap crash record low miss first quarter view revenue user growth several other key metric grubhub grub top first quarter earning estimate food sale miss target share fall sharply pare loss friday world wrestling entertainment wwe spiked wwe body slam earning estimate continue attract subscriber ep rise cent however revenue be miss disk drive maker seagate technology stx report quarterly earning beat estimate stock fall cautious comment tariff ferrari race zoom buy zone double beat ep rise cent revenue climb tableau datum report sale earning expectation license revenue be ahead consensus company lower full year margin guidance big datum firm stock jump
1367,AGN,astrazeneca azn bristol myer squibb bmy vertex pharmaceutical vrtx be likeliest target biopharma detonation event tax reform spur widespread merger acquisition group analyst say friday leerink analyst seamus fernandez call come consolidation inevitable product make like abbvie abbv roche rhhby amgen amgn dow jone stock merck mrk celgene celg biogen biib shire shpg be soon face new competition generic rival follow unprecedented period innovation new product launch large biopharma say note client several largest company likely experience substantial growth slowdown next year get newsletter deliver inbox more info product service privacy policy term usecelgene biogen astrazeneca be most accretive potential acquirer base short term financial fernandez say average accretion be respectively bristol astrazeneca vertex make most sense long term strategically say appear be best position longer term revenue growth base look consensus expectation last major consolidation period biopharma occur last decade be deal greater value largest be dow jone stock pfizer pfe acquisition warner lambert premium pfizer also paid biggest premium pharmacia fork acquire firm merck paid premium buy schering plough deal combine pfizer astrazeneca allergan agn abbvie shire have fail fernandez see next cycle seller market pfizer be struggle late entry immuno oncology market merck have strong immuno oncology drug keytruda lack robust late stage pipeline roche face biosimilar competition top drug avastin herceptin rituxan novartis nvs be still experience challenge sandoz unit abbvie be strong term key drug humira soon see competition europe strategically astrazeneca be strong fit abbvie pfizer roche merck fernandez say bristol fit abbvie pfizer meanwhile possible abbvie swing vertex financial lens astrazeneca vertex biogen bristol be most compelling target ability enhance long term sale say amgen be acquirer target fund buy something fernandez say assume amgen be look make deal value less vertex rise top list potential target outlasting regeneron pharmaceutical regn shire vertex look more interesting say related chart read basic buy point mark time real opportunitylong term retirement investing strategy buy stock ahead earning report
1368,AGN,valeant pharmaceutical vrx have climb hit low share tumble wednesday analyst suggest rise past month make sense believe movement be confluence factor have little do underlie factor have much more do perception surround liquidity bankruptcy risk piper jaffray analyst christopher raymond say note client short underlie dynamic mean valeant be still trouble say close bell stock market today valeant topple finish share have be run breaking cup handle base buy point late november month alone valeant be tuesday close short interest now stand compare high say be related fact valeant also have long term debt maturity have maturity respectively liquidity risk be likely table now say however do not mean dynamic surround business have change prescription volume valeant dermatology brand eye care legacy segment show decline respectively vs raymond say unit be face payer pressure loss exclusivity key drug further appear antibacterial xifaxan be mature say xifaxan be approve treat traveler diarrhea irritable bowel syndrome diarrhea hepatic encephalopathy condition occur patient liver dysfunction ibd take valeant have ibd composite rating best possible meaning outperform more stock term key growth metric still lag leader abbvie cr head ibd stock checkup look other top rate drug stock xifaxan account sale third quarter be likely earning interest taxe depreciation amortization raymond say mean gross margin be likely range pressure be xifaxan be most important revenue driver valeant raymond say require only small specialty salesforce reach community hospital setting such be topline driver continue demonstrate steady track record order anxiety regard liquidity bankruptcy risk not reemerge say xifaxan be also soon face competition cosmo pharmaceutical aemcolo cosmo be aim file approval aemcolo traveler diarrhea term enter market end year new launch valeant be enter glaucoma space vyzulta rival aerie pharmaceutical aeri rhopressa other player include dow stock pfizer pfe allergan agn novartis nvs competition be likely result wide spread gross net sale vyzulta valeant be also launch siliq treat plaque psoriasis physician feedback suggest go treatment drug class be novartis cosentyx eli lilly lly taltz do not believe be opportunity be significant enough drive sustainable ebitda growth say quite contrary continue believe loss exclusivity payer pressure continue be headwind raymond reiterate underperform rating price target valeant related novartis top high crush fourth quarter earningsabbott spike record top quarterly expectationswhy biotech stock outperform peer
1369,AGN,revance therapeutic rvnc launch nearly year high tuesday phase datum frown line treatment rival allergan agn botox likely win come market approve close bell stock market today revance soar break flat base buy point intraday share touch high last see january allergan sank finish treatment call rt be used treat wrinkle line eyebrow rt rival allergan botox bring be know facial aesthetic product allergan also sell botox therapeutic hyperhidrosis other condition migraine total drug make revance drug have longer duration botox month evercore analyst umer raffat write note client effect botox cosmetic last month not certain rt get label month think case be make not layup raffat say possible revance get language month duration effect pair phase trial percentage patient have none mild wrinkle achieve least point improvement baseline vs placebo be ibd take stock dividend yield have be stingy lately find income have be tough year visit ibd personal finance page more squeeze income investment take big risk also point time patient first trial patient second trial say be satisfied very satisfied treatment experience revance say news release median duration patient treat rt return baseline wrinkle severity be nearly week long term safety trial be fully enrolled expect be complete second half successful revance say plan submit application food drug administration first half launch related amgen regeneron prep battle cholesterol biotechs drugmaker fare senate tax billamazon reportedly talk mylan novartis pharma entry
1370,AGN,sell health stock tuesday joint venture amazon com amzn jpmorgan chase jpm berkshire hathaway brkb wring cost saving health care system appear very unlikely impact industry earning next couple year accord analyst figure rein health cost participation big health care player look impossible task needham analyst kevin caliendo say note cost implement system adjudicate patient datum partner hospital doctor pharmacy national basis be onerous caliendo add scale big new partner wouldn be big enough squeeze discount provider steering patient way compare purchasing power unitedhealth unh cvs health cvs aetna aet anthem antm new company have align other provider way provide best care employee caliendo conclude fact caliendo give cvs big vote confidence earlier tuesday say plan combination aetna position create saving government private employer needham raise rating cvs strong buy target caliendo do think profit industry especially underwriting level be excessive be improvement current care delivery model be make see prime reason cvs aetna deal cvs be look shift more health care service lowest cost location store clinic different take unitedhealth playbook expand urgent care other outpatient locale drive saving customer such path forward be evident announcement amazon jpmorgan berkshire plan establish independent company be early plan stage accord statement trio group do not come problem answer acknowledge berkshire ceo warren buffett success be go require talented expert beginner mind long term orientation say amazon jeff bezos yet unclear point talented expert be wall street weigh long term nature effort dearth substantive detail initial shock wave ripple wall street subside share dow jone industrial average component unitedhealth nation largest insurer sank stock market today diving much earlier cvs health be process buy aetna pare loss drop drug distributor cardinal health cah mckesson mck be respectively prescription benefit management firm express script esrx sank have tumble earlier cvs unitedhealth also operate pbms manage prescription side health insurance contract pharmaceutical biotech stock also lose ground hit didn look much broader market downdraft tuesday merck mrk shed allergan agn gilead science gild pfizer pfe lose top earning view offer bullish guidance ibd take unitedhealth be rank ibd medical manage care industry group base earning sale margin stock performance trend visit ibd stock checkup see leader category insurer have be solid performer rank group long current confirm uptrend equivalent green light stay place lead stock lead group break buy point be more likely not have wind back here good place start look stock be poise move higher knee jerk reaction investor be surely reflection unsustainably high cost health care fact amazon have be itch disrupt retail prescription business be attach effort traditionally fear health care investor have be government not private sector impose cost control get handle runaway budget deficit thin industry profit process medicare negotiating drug cost be such fear industry expert say government be unlikely produce much way saving be willing deny patient access certain drug create political backlash amazon jpmorgan berkshire aren first big employer join force attack health cost leerink analyst ana gupte note tuesday health transformation alliance group large self insure employer launch last year also hope find saving improve employee satisfaction work cvs unitedhealth achieve aim initial report indicated alliance member expect save combine prescription cost year amazon jpmorgan berkshire say initial focus be technology solution provide employee family simplified high quality transparent healthcare reasonable cost new corporate entity say be free profit make incentive constraint just form technology solution take be far clear caliendo suppose berkshire bring underwriting skill ve never underwritten healthcare amzn make pharmacy medical procurement contribution provide expertise leerkink gupte say unclear amazon wading deeper solve health care mess accelerate move supply chain prescription industry also be interested trump state union move market downstock fall market show sign be ready breakgrubhub redhat lead ibd stock buy invest stock free new apps aim invest stock market start simple routine
1371,AGN,share teva pharmaceutical teva drop tuesday generic drug giant rebuff request israeli prime minister benjamin netanyahu spare hundred job tie jerusalem facility close bell stock market today teva fall close fall much share have lose half value begin year competition teva multiple sclerosis drug copaxone new chief executive kare schultz call cut israel jerusalem facility painful step help firm reduce debt end third quarter accord bloomberg report measure include restructure plan be aim achieve share aspiration sustain teva strong global company manage base israel schultz reportedly say prepared statement take step possible teva become takeover candidate firm say teva didn immediately return request investor business daily comment ibd take teva have ibd composite rating best possible meaning underperform more stock term key growth metric head ibd stock checkup look better rate generic drug stock total teva expect eliminate position globally close number manufacturing facility end contend debt debt stem teva spend acquire allergan agn generic unit analyst have applaud teva take step cut cost end israeli official other hand have hope work teva reduce number dismissal offer government help accord bloomberg report other be reportedly call government rescind tax break generic drugmaker have receive large labor group go half day strike sunday again tuesday related teva jump start restructure swipe gilead sale teva restructure plan case be here do amazon reportedly talk mylan novartis pharma entry
1372,AGN,allergan agn re-cover earlier dip wednesday report third quarter earning top expectation sale be soft double digit decline revenue kybella drug design reduce chin fat xby close bell stock market today allergan be finish share rebound dive earlier trade nordisk nvo beat adjust earning view lag sale tick cent quarter allergan post yearly sale gain be just line consensus analyst poll zack investment research adjust earning share grow beat cent revenue restasis eye drug grow allergan be now face slew potential generic version restasis judge tossed patent cover drug drugmaker be appeal decision chief executive brent saunder say release have strong argument appeal file notice appeal court say generic product enter market allergan be ready mitigate impact grow base business reduce cost deploy balance sheet ibd take abbvie lead drugmaker industry group composite rating best possible head ibd stock checkup look other top rate drug stock cfra analyst jeffrey loo say allergan see earning share generic restasis be launch january copy drug be launch july drug account earning write note client still see several attractive fast grow product particularly aesthetic say total medical aesthetic sale grow quarter sale kybella fall allergan note be fewer kybella promotion quarter prior year allergan also narrow full year sale guidance raise lower end adjust earning share view cent now see wrapping year share nordisk report adjust profit cent american depository receipt sale respective vs year earlier period adjust income beat consensus analyst poll zack cent adr sale lag consensus view related mylan topple president name mind blow antitrust allergan public relation backlash deepen weekallergan tank judge invalidate restasis patent
1373,AGN,get tax address ireland headquarters new jersey blockbuster drug native american reservation new trouble washington guess allergan agn re right last month allergan say transfer right restasis blockbuster treatment chronic dry eye have sale last year saint regis mohawk tribe unusual agreement allow drugmaker use tribe status sovereign nation shield restasis patent attack rival drugmaker house committee oversight government reform chairman trey gowdy south carolina republican ranking member elijah cumming democrat write allergan chief executive brent saunder tuesday letter refer unconventional maneuver implication allergan patent transfer raise question congress exchange impair competition pharmaceutical industry ultimately dissuade company pursue less costly generic alternative brand drug gowdy cumming write allergan say prepared statement comply committee request document other information food drug administration approve restasis be allergan second best selling drug last year accord company annual report drug most recent patent expire accord fda patent database relation deal lawmaker ask allergan communication market share projection document present company board director also seek document communication regard consideration future such deal gowdy cumming give allergan oct answer question allergan share end trading tuesday allergan tax domicile be dublin ireland headquarters be parsippany move strike agreement tribe be defense be hold hostage entity such hedge fund seek profit pharmaceutical company demand financial payment exchange not filing challenge patent trademark office saunder write letter tuesday senate judiciary chairman charle grassley republican iowa ranking member dianne feinstein democrat california letter be response letter other senator ask committee investigate restasis agreement deal have impact challenge allergan patent drug await ruling federal district court texas saunder say letter be clear district court ruling be adverse allergan patent position be fda approval generic version restasis product enter market many year advance list patent expiry date saunder write monday senator claire missouri democrat write pharmaceutical research manufacturer america ask lobby group approve allergan deal tribe be most brazen absurd loophole ve ever see be illegal say separate statement give recent comment regard corporate responsibility phrma play role tell member action isn appropriate hope do representative phrma didn immediately return request comment
1374,AGN,apple aapl be initiate broker strong buy early note wednesday allergan agn first solar fslr linkedin lnkd get price target cut mizuho cut price target allergan reduce rating neutral buy pfizer pfe allergan have terminate merger deal cite new tax inversion rule allergan rise stock market today share have plummet nearly tuesday obama administration say be take measure prevent corporate merger result inversion effort avoid higher taxe relocate corporate headquarters overseas pfizer share gain wednesday climb tuesday needham initiate coverage apple strong buy price target apple introduce iphonese last month inch display compact aluminum design apple share rise once again close just day line credit suisse lower price target linkedin linkedin share tick wednesday mizuho cut price target first solar analyst day tuesday first solar decline give estimate note lack clarity next year send share day first solar share be wednesday other action jp morgan chase co upgrade rating cisco system csco neutral underweight cisco share be wednesday
1375,AGN,big biotech gilead science gild beat analyst estimate tuesday guidance be soft send stock more hour trading day several large drugmaker report gilead earning rise year earlier quarter share top analyst ep consensus cent accord thomson reuter revenue increase vs analyst expectation full year ep rise revenue gain gilead guide product sale cover nearly revenue analyst have expect product sale total revenue gilead do not provide total revenue ep guidance do provide guidance expense be slightly expectation sale general administrative line evercore isi analyst mark schoenebaum calculate imply ep guidance be miss consensus hepatitis drug sovaldi harvoni beat estimate entirely due sale outside analyst have less visibility next year expect revenue decline be due anticipate decline hcv market have enormous lift drug be approve have flattened ever larger number patient have be cure disease conference call analyst commercial operation chief paul carter say expect hcv market behave similarly do second half essentially flat grow foreign market be still be launch say see growth payer seem be loosen restriction drug initially strained finance due high price enormous volume patient however acknowledge revenue patient be likely fall less sick patient come require shorter treatment carter also sound confident gilead ability fend competition get new entrant last week merck mrk zepatier be approve last week price well gilead abbvie abbv hcv drug re confident label be very strong re very much support real world datum ve see launch harvoni carter say earlier day big pharma pfizer pfe say revenue rise year earlier quarter beating analyst consensus earning exclude time item slip cent share beating estimate penny year ep decline sale slide however pfizer profit guidance miss wall street expectation share analyst schoenebaum blame foreign exchange headwind exclude roughly negative top line top line fx impact due venezuela currency impact alone bottom line impact due fx top bottom line guidance have bracket street schoenebaum write email speak pfizer believe street underestimated fx impact capital iq analyst jeffrey loo raise rating pfizer buy hold say valuation have become attractive almost other drug stock have sell recent month view growth global innovative product unit positively drive prevnar ibrance loo write research note expect pending acquisition allergan agn be complete second half pfizer stock close mallinckrodt mnk rise close specialty drugmaker report fiscal first quarter earning share year earlier quarter top consensus cent sale climb street average estimate mallinckrodt raise full year ep guidance baxter international bax leader dialysis product also beat expectation most recent quarter pull sharp increase earning decline sale fourth quarter profit continue operation jump cent share cent past wall street consensus revenue drop baxter stock rise tuesday close baxter say expect ep year beating consensus forecast current quarter be street however cent
1376,AGN,allergan agn delta air line dal harris corp hrs have thing common highest percentage buy rating company end fourth quarter re follow mckesson mck avgo facebook fb be most highly rate accord factset research analyst poll factset follow drug company allergan airline company delta defense communication contractor harris have buy rating stock allergan stock rise delta rise harris rise mckesson distributor prescription drug medical supply analyst follow company have buy rating hold chip company ratio be buy hold facebook say buy hold mckesson stock fall rise facebook rise rating company end december be buy rating be hold be sell health care sector have highest percentage buy rating energy sector have highest percentage sell rating follow brian deagon twitter ibd_bdeagon
1377,AGN,special report personal finance action plan patrick kelly have alger spectra fund coveted spot portfolio manager have lead fund ranking large cap growth mutual fund track morningstar last decade spectra have post annual average return period vs
1378,AGN,santa claus rally fizzle later part december oil rout fed long await rate bump rise fourth quarter edge december nasdaq gain last quarter year fall christmas month stock mutual fund follow same track december manager nation top fund past month have be gathering medical stock such icon iclr allergan agn centene cnc akorn akrx intuitive surgical isrg latest report period also top fund buy list be china biologic product cbpo be rank ibd best list ibd personal finance action plan year end edition best perform fund gaming chipmaker nvidia nvda light system provider acuity brand ayi southwest airline luv cosmetic retailer ulta beauty ulta be few standout several financial reit be strong performer include public storage psa extra space storage exr equity lifestyle property el ibd note top rate fund buy constellation brand stz investing estimate latest report period mfs growth fund own big stake firm victor base firm make market alcoholic beverage most popular beer brand include corona pacifico modelo especial constellation wine portfolio include robert mondavi clos du franciscan estate recent global market sell do not rain constellation parade stock shot time high thursday report robust third quarter fiscal result earn share revenue stock fall friday company beer segment specifically corona extra modelo especial boost company third quarter profit keep beer buzz go constellation announce plan build new brewery mexicali mexico cost also expand production exist brewery mexico support growth beer business aerospace defense contractor northrop grumman noc also see heavy buy best perform fund stock have be trading flat base past week seesaw market volatility trading just week high sell sidelead fund have be take profit general electric ge latest report period hit week high
1379,AGN,honeymoon be short investor pump broad market monday tuesday anticipation federal open market committee raise interest rate market climb again wednesday fed finally pull trigger long promise hike turn be percentage point signale plan more small increase
1380,AGN,valeant pharmaceutical raise hostile bid fellow drugmaker allergan wednesday morning campaign increasingly turn debate valeant own business model investor seem unimpressed valeant stock fall allergan slide valeant vrx add share cash last month original offer valeant share allergan agn share come total valeant also provide new contingent value right cvr related sale eye drug development used darpin antibody technology cvr provide share add value darpin drug accumulate sale year market valeant pledge develop drug hour announcement valeant say sell dermatology asset nestle nsrgy divest product include dysport competitor allergan biggest seller botox selling ahead time ve eliminate more roadblock integration allergan valeant ceo michael pearson say investor meeting wednesday pearson say learn talk allergan investor higher price darpin optionality be biggest request also give investor overview valeant history business model describe transform company come board smallish specialty pharma diversify global player series acquisition valeant presentation also address criticism allergan management make tuesday valeant business model hire consultant accounting firm examine valeant financial statement allergan say valeant organic growth rate past quarters be negative be mislead investor cost cut hurt allergan charge valeant last major acquisition target medicis bausch lomb have lose market share be acquire apparent growth have come price increase raise probably be biggest concern allergan management report also say valeant couldn achieve promise cost cut decimate budget wednesday meeting number executive acquire company deliver talk experience join valeant most tout growth division deb jorn executive recently acquire bausch lomb now head dermatology marketing say dermatology suffer last year patent loss integration problem buyout medicis pearson allude situation valeant last earning call say learn experience not muck salesforce large acquisition target pearson also counter allergan allegation valeant financial report say organic growth be negative include impact foreign exchange rate divestiture product discontinuation valeant isn alone pharma industry exclude also point recent growth have be hit valeant top product go patent issue drug business not situation expect occur often valeant raise offer seem leave wall street underwhelm well fargo lawrence biegelsen note valeant last close price offer amount share barely allergan tuesday close price write not be sufficient move allergan shareholder roadbernstein analyst aaron gal agree point long term guidance compound annual earning growth next year allergan issue formally reject valeant first bid think valeant be expect allergan shareholder continue believe stock decline pre offer range offer be not materialize gal write research note wednesday give new guidance stock decline be then likely rebound immediately afterward gal also didn care cvr offer writing darpin drug be better spun someone more commit develop product category valeant bmo alex arfaei biegelsen gal cover valeant rather allergan write offer be expect give report overlap vrx agn shareholder believe most agn shareholder be familiar enough valeant business model invest combine entity say
1381,AGN,expect valeant pharmaceutical international vrx raise hostile bid fellow drugmaker allergan agn wednesday morning offer allergan investor lengthy defense business model market be unimpressed however morning trading stock market today allergan stock be more valeant stock more
1382,AGN,valeant add share cash original offer valeant share allergan share come total valeant also provide new contingent value right cvr related sale eye drug development use darpin antibody technology cvr provide share add value darpin drug accumulate sale year market valeant pledge develop drug
1383,AGN,investor meeting valeant ceo michael pearson say learn talk allergan investor higher price darpin optionality be biggest request also give investor overview valeant history business model describe transform company come board smallish specialty pharma diversify global player series acquisition
1384,AGN,number executive acquire company deliver talk experience join valeant partly counter allergan charge tuesday company acquire valeant get budget slash lose market share most tout growth division deb jorn executive recently acquire bausch lomb now head dermatology marketing say derm suffer last year patent loss integration problem buyout medicis pearson allude situation valeant last earning call say learn experience not muck salesforce large acquisition
1385,AGN,just midnight wednesday valeant say shed chief asset medicis buyout selling nestle nsrgy divest product include dysport competitor allergan biggest seller botox
1386,AGN,selling ahead time ve eliminate more roadblock integration allergan pearson say wednesday
1387,AGN,nonetheless valeant raise offer initially seem leave wall street underwhelm bernstein aaron gal call not impressive well fargo lawrence biegelsen note valeant last close price offer amount share barely allergan tuesday close price write not be sufficient move allergan shareholder
1388,AGN,tuesday sterne agee analyst shibani malhotra have estimate new offer be share buckingham research david buck have raise price target allergan anticipation bid
1389,AGN,follow amy reeve twitter ibd_areeve expect valeant pharmaceutical international vrx raise hostile bid fellow drugmaker allergan agn wednesday morning offer allergan investor lengthy defense business model market be unimpressed however morning trading stock market today allergan stock be more valeant stock more valeant add share cash original offer valeant share allergan share come total valeant also provide new contingent value right cvr related sale eye drug development use darpin antibody technology cvr provide share add value darpin drug accumulate sale year market valeant pledge develop drug investor meeting valeant ceo michael pearson say learn talk allergan investor higher price darpin optionality be biggest request also give investor overview valeant history business model describe transform company come board smallish specialty pharma diversify global player series acquisition number executive acquire company deliver talk experience join valeant partly counter allergan charge tuesday company acquire valeant get budget slash lose market share most tout growth division deb jorn executive recently acquire bausch lomb now head dermatology marketing say derm suffer last year patent loss integration problem buyout medicis pearson allude situation valeant last earning call say learn experience not muck salesforce large acquisition just midnight wednesday valeant say shed chief asset medicis buyout selling nestle nsrgy divest product include dysport competitor allergan biggest seller botox selling ahead time ve eliminate more roadblock integration allergan pearson say wednesday nonetheless valeant raise offer initially seem leave wall street underwhelm bernstein aaron gal call not impressive well fargo lawrence biegelsen note valeant last close price offer amount share barely allergan tuesday close price write not be sufficient move allergan shareholder tuesday sterne agee analyst shibani malhotra have estimate new offer be share buckingham research david buck have raise price target allergan anticipation bid follow amy reeve twitter ibd_areeve
1390,AGN,stock push session lows be still modestly lower midpoint tuesday session overall main index appear be take breather rise past session
1391,AGN,dow jone industrial average nasdaq be volume be tracking higher board stock market today
1392,AGN,lead stock aerospace beav gap slump news split publicly trade company part management strategic review process company focus aircraft cabin interior other deal logistic technical service aircraft energy service market separation likely take place also raise full year profit outlook share still current expectation share
1393,AGN,sandisk sndk fall be downgrade hold buy summit research stock snap session streak monday further pullback stock be still more past buy point flat base clear january
1394,AGN,upside netflix nflx rise best level nearly month stock be cup base buy point pattern be first stage structure netflix reset base count late april
1395,AGN,allergan agn bounce back early weakness rise fraction botox maker board reject buyout offer valeant pharmaceutical vrx persh square capital management allergan say sweeten offer be too low too risky shareholder stock push session lows be still modestly lower midpoint tuesday session overall main index appear be take breather rise past session dow jone industrial average nasdaq be volume be tracking higher board stock market today lead stock aerospace beav gap slump news split publicly trade company part management strategic review process company focus aircraft cabin interior other deal logistic technical service aircraft energy service market separation likely take place also raise full year profit outlook share still current expectation share sandisk sndk fall be downgrade hold buy summit research stock snap session streak monday further pullback stock be still more past buy point flat base clear january upside netflix nflx rise best level nearly month stock be cup base buy point pattern be first stage structure netflix reset base count late april allergan agn bounce back early weakness rise fraction botox maker board reject buyout offer valeant pharmaceutical vrx persh square capital management allergan say sweeten offer be too low too risky shareholder
1396,AGN,stock turn mixed midday monday round similarly mixed earning report well economic report foreign domestic
1397,AGN,nasdaq turn loss gain biotechs software issue outperformed pare deficit dow jone industrial average fall volume be tracking sharply lower board stock market today compare same time friday
1398,AGN,highly rate stock globant glob rally nearly time high clear buy point heavy trading hour session thin stock already match day average volume
1399,AGN,nike nke climb more new high be upgrade buy hold bb now past buy point athletic apparel footwear giant be recently mentioned new high column
1400,AGN,downside microsemi mscc drop news offer buy pmc sierra pmcs bid top buyout offer apple aapl supplier skywork solution swks microsemi fall buy point consolidation clear friday pmc share jump
1401,AGN,valeant vrx slump beating view raise guidance open canadian drugmaker post adjust earning share year sale grow third straight period acceleration almost lift full year sale forecast
1402,AGN,profit be now expect share prior outlook last week valeant say receive subpoena federal prosecutor massachusett new york request information patient assistance program drug pricing decision
1403,AGN,follow vincent mao twitter ibd_vmao stock turn mixed midday monday round similarly mixed earning report well economic report foreign domestic nasdaq turn loss gain biotechs software issue outperformed pare deficit dow jone industrial average fall volume be tracking sharply lower board stock market today compare same time friday highly rate stock globant glob rally nearly time high clear buy point heavy trading hour session thin stock already match day average volume nike nke climb more new high be upgrade buy hold bb now past buy point athletic apparel footwear giant be recently mentioned new high column downside microsemi mscc drop news offer buy pmc sierra pmcs bid top buyout offer apple aapl supplier skywork solution swks microsemi fall buy point consolidation clear friday pmc share jump valeant vrx slump beating view raise guidance open canadian drugmaker post adjust earning share year sale grow third straight period acceleration almost lift full year sale forecast profit be now expect share prior outlook last week valeant say receive subpoena federal prosecutor massachusett new york request information patient assistance program drug pricing decision follow vincent mao twitter ibd_vmao
1404,AGN,already strongest year merger acquisition flurry dealmake have give share large drugmaker shot arm face case botox maker allergan agn
1405,AGN,not offer have be make peacefully valeant pharmaceutical vrx officially announce plan tuesday make bid allergan hostile
1406,AGN,allergan be pharmaceutical company big cap screen day catch wave screen feature large stock strong earning price performance
1407,AGN,allergan have reject valeant previous advance valeant isn back be prepared make third offer
1408,AGN,tuesday valeant ceo mike pearson tell reuter hostile be not prefer approach deal be so strategic financially compelling really make sense
1409,AGN,activist investor bill ackman persh square capital management allergan largest shareholder be push merger be try block allergan effort poison pill
1410,AGN,share have jump nearly early april be stock market tuesday
1411,AGN,allergan have composite rating possible ibd composite rating rate stock area extra weight earning stock price strength
1412,AGN,actavis act be featured screen rating say tuesday receive shareholder approval proposal related takeover forest laboratory frx shareholder also deal
1413,AGN,buyout be announce february be expect close midyear
1414,AGN,actavis have be know maker generic drug especially equivalent cholesterol lower medication lipitor forest deal help branch brand drug
1415,AGN,forest have establish portfolio treatment well brand drug neurological condition hypertension
1416,AGN,actavis share climb
1417,AGN,gilead science gild have top composite rating company share take hit last week fall nearly merck mrk announce pay cash acquire idenix pharmaceutical idix idenix be develop several experimental hepatitis drug gilead be merck biggest rival hep treatment blockbuster drug sovaldi
1418,AGN,hep market be huge drugmaker virus affect american company be look more effective oral therapy vs current injectable drug regime
1419,AGN,gilead share dip
1420,AGN,follow gillian rich twitter already strongest year merger acquisition flurry dealmake have give share large drugmaker shot arm face case botox maker allergan agn not offer have be make peacefully valeant pharmaceutical vrx officially announce plan tuesday make bid allergan hostile allergan be pharmaceutical company big cap screen day catch wave screen feature large stock strong earning price performance allergan have reject valeant previous advance valeant isn back be prepared make third offer tuesday valeant ceo mike pearson tell reuter hostile be not prefer approach deal be so strategic financially compelling really make sense activist investor bill ackman persh square capital management allergan largest shareholder be push merger be try block allergan effort poison pill share have jump nearly early april be stock market tuesday allergan have composite rating possible ibd composite rating rate stock area extra weight earning stock price strength actavis act be featured screen rating say tuesday receive shareholder approval proposal related takeover forest laboratory frx shareholder also deal buyout be announce february be expect close midyear actavis have be know maker generic drug especially equivalent cholesterol lower medication lipitor forest deal help branch brand drug forest have establish portfolio treatment well brand drug neurological condition hypertension actavis share climb gilead science gild have top composite rating company share take hit last week fall nearly merck mrk announce pay cash acquire idenix pharmaceutical idix idenix be develop several experimental hepatitis drug gilead be merck biggest rival hep treatment blockbuster drug sovaldi hep market be huge drugmaker virus affect american company be look more effective oral therapy vs current injectable drug regime gilead share dip follow gillian rich twitter ibd_grich
1421,AGN,valeant pharmaceutical vrx hedge fund persh square early tuesday officially announce unsolicited takeover bid allergan agn value botox maker more news pending deal break late monday tuesday sec filing valeant persh say be offer cash valeant share allergan share valeant stock be more midday trading stock market today value offer stock allergan share accord valeant filing valeant be also offer cash allergan stock be analyst expect offer get poor reception believe allergan likely do resist hostile takeover valeant sterne agee analyst shibani malhotra write research note still offer put allergan play other suitor come forward write malhotra allergan management need take action order keep company independent write allergan shareholder control combine company valeant say sec filing valeant propose deal regulatory filing late monday follow detailed prospectus early tuesday persh square run investor william ackman hold share allergan more stake accord regulatory filing persh square valeant enter partnership feb ackman say regulatory filing firm create fund acquire allergan share valeant initially contribute deal accomplish several important strategic goal valeant write fbr capital market analyst william tanner expand canadian drugmaker product portfolio boost valeant ep write tanner rate valeant stock outperform buy deal include annual operate cost synergy write leerink analyst seamus fernandez likelihood successful vrx bid go assume announce synergy be achievable write fernandez rate allergan stock market perform hold allergan confirm receive bid didn immediately respond request comment say board meet discuss offer
1422,AGN,stock stay rally mode tuesday cheer strong earning bullish outlook dow component home depot hd benign inflation datum better expect housing datum dow jone industrial average rise nasdaq picked nasdaq extend winning streak session close
1423,AGN,nearly sector leader fall tuesday market end day streak few show relative strength valeant pharmaceutical vrx buck market weakness rise third straight gain volume be heavy stock fail close day move average canadian drugmaker say plan hold
1424,AGN,allergan agn reportedly obtain new patent restasis eye drop send share sharply second day row stock market today
1425,AGN,company make announcement word start go thursday patent application company file august have be grant appear next orange book be significant earlier composition patent product be due expire
1426,AGN,cowen analyst ken cacciatore write research note friday legal consultant have confirm acceptance patent say issue early week now write doesn know generic drugmaker have file own application haven confidently model franchise likely be protected least month note subsequent generic filing now be subject month stay
1427,AGN,cacciatore write add least cent ep estimate more consensus be modele estimate year
1428,AGN,allergan stock be afternoon trading friday month high strong ibd composite rating be form possible cup base april
1429,AGN,follow amy reeve twitter ibd_areeve allergan agn reportedly obtain new patent restasis eye drop send share sharply second day row stock market today company make announcement word start go thursday patent application company file august have be grant appear next orange book be significant earlier composition patent product be due expire cowen analyst ken cacciatore write research note friday legal consultant have confirm acceptance patent say issue early week now write doesn know generic drugmaker have file own application haven confidently model franchise likely be protected least month note subsequent generic filing now be subject month stay cacciatore write add least cent ep estimate more consensus be modele estimate year allergan stock be afternoon trading friday month high strong ibd composite rating be form possible cup base april follow amy reeve twitter ibd_areeve
1430,AGN,stock re-cover morning decline be nearly flat midday wednesday volume trail tuesday pace exchange
1431,AGN,nasdaq be mostly unchanged add less dow jone industrial average lose hit record high tuesday nasdaq rise confirm new uptrend
1432,AGN,eye be michael kor kor wednesday company report quarter solid bottom line top line growth earning jump year sale grow
1433,AGN,stock be premarket trading then sell open be midday top end daily range
1434,AGN,homebuilder toll bro tol also deliver better expect number open stock gap open give back most gain underperform stock be build base wednesday action isn constructive
1435,AGN,toll bro specialize luxury home have benefit rise price affluent community west east coast
1436,AGN,drugmaker valeant pharmaceutical vrx raise bid botox maker allergan agn offer detailed defense business model allergan sell more heavy volume valeant be well lows
1437,AGN,ibd stock be be best performer be chinese internet security company qihoo qihu report strong earning profit surge year cent share sale jump
1438,AGN,qihoo gap day move average rise stock re-cover morning decline be nearly flat midday wednesday volume trail tuesday pace exchange nasdaq be mostly unchanged add less dow jone industrial average lose hit record high tuesday nasdaq rise confirm new uptrend eye be michael kor kor wednesday company report quarter solid bottom line top line growth earning jump year sale grow stock be premarket trading then sell open be midday top end daily range homebuilder toll bro tol also deliver better expect number open stock gap open give back most gain underperform stock be build base wednesday action isn constructive toll bro specialize luxury home have benefit rise price affluent community west east coast drugmaker valeant pharmaceutical vrx raise bid botox maker allergan agn offer detailed defense business model allergan sell more heavy volume valeant be well lows ibd stock be be best performer be chinese internet security company qihoo qihu report strong earning profit surge year cent share sale jump qihoo gap day move average rise
1439,AGN,stock fall modestly early tuesday afternoon trade tight range quiet news day
1440,AGN,nasdaq lose dow jone industrial average ease volume nyse nasdaq be tracking very close monday level
1441,AGN,stock market today allergan agn lose company reject valeant pharmaceutical vrx sweeten offer value allergan close share share allergan be recently trading allergan have say valeant growth isn sustainable depend too much acquisition
1442,AGN,day gainer recent new issue navigator holding nvgs be poise extend winning streak session break early buy point gain fade share rise company operate fleet liquefy gas carrier go public november share full year earning be see rise year
1443,AGN,elsewhere top rate small cap matrix service co mtrx strong performer ibd oil gas field service group clear week consolidation rise buy point be sale growth mutual fund ownership have be accelerate recent quarters
1444,AGN,facebook fb be best percentage gainer ibd rise yesterday company hire former paypal president david marcus run messenger unit optimism also abound facebook new slingshot product photo video sharing app be prematurely release monday certain market slingshot be facebook answer snapchat facebook try acquire last year
1445,AGN,loan provider springleaf holding leaf continue work right side first stage ipo base early gain fade share rise accumulation distribution rating be lukewarm meaning not clear institutional investor be buy stock yet institutional buy be good see stock build right side base
1446,AGN,close watch earning ulta beauty ulta share fall ahead result former leader have be downtrend several month buy demand have dry find resistance week move average march recently meet resistance week move average stock fall modestly early tuesday afternoon trade tight range quiet news day nasdaq lose dow jone industrial average ease volume nyse nasdaq be tracking very close monday level stock market today allergan agn lose company reject valeant pharmaceutical vrx sweeten offer value allergan close share share allergan be recently trading allergan have say valeant growth isn sustainable depend too much acquisition day gainer recent new issue navigator holding nvgs be poise extend winning streak session break early buy point gain fade share rise company operate fleet liquefy gas carrier go public november share full year earning be see rise year elsewhere top rate small cap matrix service co mtrx strong performer ibd oil gas field service group clear week consolidation rise buy point be sale growth mutual fund ownership have be accelerate recent quarters facebook fb be best percentage gainer ibd rise yesterday company hire former paypal president david marcus run messenger unit optimism also abound facebook new slingshot product photo video sharing app be prematurely release monday certain market slingshot be facebook answer snapchat facebook try acquire last year loan provider springleaf holding leaf continue work right side first stage ipo base early gain fade share rise accumulation distribution rating be lukewarm meaning not clear institutional investor be buy stock yet institutional buy be good see stock build right side base close watch earning ulta beauty ulta share fall ahead result former leader have be downtrend several month buy demand have dry find resistance week move average march recently meet resistance week move average
1447,AGN,lead stock ibd sector turn strong performance wednesday couple leader get boost strong earning report qihoo technology qihu be biggest gainer rise nearly more double average daily trade chinese search engine report early wednesday first quarter profit soar
1448,AGN,stock fall modestly early tuesday afternoon trade tight range quiet news day
1449,AGN,nasdaq lose dow jone industrial average ease volume nyse nasdaq be tracking very close monday level
1450,AGN,stock market today allergan agn lose company reject valeant pharmaceutical vrx sweeten offer value allergan close share share allergan be recently trading allergan have say valeant growth isn sustainable depend too much acquisition
1451,AGN,day gainer recent new issue navigator holding nvgs be poise extend winning streak session break early buy point gain fade share rise company operate fleet liquefy gas carrier go public november share full year earning be see rise year
1452,AGN,elsewhere top rate small cap matrix service co mtrx strong performer ibd oil gas field service group clear week consolidation rise buy point be sale growth mutual fund ownership have be accelerate recent quarters
1453,AGN,facebook fb be best percentage gainer ibd rise yesterday company hire former paypal president david marcus run messenger unit optimism also abound facebook new slingshot product photo video sharing app be prematurely release monday certain market slingshot be facebook answer snapchat facebook try acquire last year
1454,AGN,loan provider springleaf holding leaf continue work right side first stage ipo base early gain fade share rise accumulation distribution rating be lukewarm meaning not clear institutional investor be buy stock yet institutional buy be good see stock build right side base
1455,AGN,close watch earning ulta beauty ulta share fall ahead result former leader have be downtrend several month buy demand have dry find resistance week move average march recently meet resistance week move average stock fall modestly early tuesday afternoon trade tight range quiet news day nasdaq lose dow jone industrial average ease volume nyse nasdaq be tracking very close monday level stock market today allergan agn lose company reject valeant pharmaceutical vrx sweeten offer value allergan close share share allergan be recently trading allergan have say valeant growth isn sustainable depend too much acquisition day gainer recent new issue navigator holding nvgs be poise extend winning streak session break early buy point gain fade share rise company operate fleet liquefy gas carrier go public november share full year earning be see rise year elsewhere top rate small cap matrix service co mtrx strong performer ibd oil gas field service group clear week consolidation rise buy point be sale growth mutual fund ownership have be accelerate recent quarters facebook fb be best percentage gainer ibd rise yesterday company hire former paypal president david marcus run messenger unit optimism also abound facebook new slingshot product photo video sharing app be prematurely release monday certain market slingshot be facebook answer snapchat facebook try acquire last year loan provider springleaf holding leaf continue work right side first stage ipo base early gain fade share rise accumulation distribution rating be lukewarm meaning not clear institutional investor be buy stock yet institutional buy be good see stock build right side base close watch earning ulta beauty ulta share fall ahead result former leader have be downtrend several month buy demand have dry find resistance week move average march recently meet resistance week move average
1456,AGN,big cap stock valeant pharmaceutical vrx see bid fellow drugmaker allergan agn reject monday stock be modestly explain rejection conference call analyst allergan ceo david pyott say valeant business model cost cut call cut slash only work short term
1457,AGN,action specialty pharma continue monday allergan agn formally reject takeover offer offer bullish guidance shire shpg get fatty liver disease game acquire lumena pharmaceutical allergan board unanimously reject valeant pharmaceutical vrx unsolicited bid not only charge undervalue company question sustainability valeant buyout drive
1458,AGN,embattled specialty drugmaker allergan wednesday beat wall street first quarter earning estimate raise guidance company stock slide close future remain doubt allergan agn report earning share year earlier quarter beating analyst consensus cent sale rise line estimate guidance follow similar pattern full year company set sale range bracketing consensus ep range top street last year company make share sale second quarter firm guide sale year again meeting view allergan guide ep consensus vs last year announcement come allergan shareholder be still weigh valeant pharmaceutical vrx hostile takeover attempt launch april tuesday allergan co founder gavin herbert slam takeover bid annual shareholder meeting warning valeant decimate allergan research development budget allergan ceo david pyott refuse take question valeant drama wednesday conference call discuss result instead focuse company continue growth market share gain chief market ophthalmology dermatology aesthetic sale lead product botox grow company forecast full year botox sale last year botox retain market share valeant dysport take most remainder research note wednesday morningstar analyst michael point company benefit johnson johnson jnj decision last month halt development purtox potential competitor botox sale eye drop restasis climb allergan estimate crack year facial aesthetic category jump help launch skin firm injectable juvederm voluma breast aesthetic product line grow even be stagnant last year call pyott say unit growth be still flat company have succeed shift higher end product seri surgical scaffold tissue reconstruction several time call pyott suggest allergan unveil new strategy future response valeant approach shareholder pressure lower spending sale general administrative expense totale revenue quarter slight decline last year pyott acknowledge investor have be ask ll get mid ve be slow go pyott say board have start talk issue month be hold final decision valeant situation be resolve management simply have run business more aggressively not necessarily forfeit traditional method pharmaceutical value creation internal purchase cowen analyst ken cacciatore write note wednesday however have plausibly convince current shareholder make more sense be buy agn stock rather selling
1459,AGN,stock come session lows midday monday follow weaker expect manufacturing construction datum
1460,AGN,nasdaq slip dow jone industrial average edge small cap russell index drop volume be nasdaq nyse compare same time friday
1461,AGN,stock market today gaslog glog jump volume be run well average citigroup reinstate coverage buy rating raise price target
1462,AGN,gaslog remain week line retreat follow big rally
1463,AGN,valeant pharmaceutical vrx be heavy volume drugmaker recently increase offer buy botox maker allergan agn valeant have retake week line new base take shape
1464,AGN,downside amtrust financial service afsi be heavy trade barron article publish saturday question multimillion dollar incongruity company regulatory filing stock be buy point week tight pattern
1465,AGN,economic news insititute supply management manufacturing index fall point significantly view uptick
1466,AGN,construction spending edge april commerce department report forecast increase march growth be revise initial gain
1467,AGN,meanwhile china factory activity rise month high stock come session lows midday monday follow weaker expect manufacturing construction datum nasdaq slip dow jone industrial average edge small cap russell index drop volume be nasdaq nyse compare same time friday stock market today gaslog glog jump volume be run well average citigroup reinstate coverage buy rating raise price target gaslog remain week line retreat follow big rally valeant pharmaceutical vrx be heavy volume drugmaker recently increase offer buy botox maker allergan agn valeant have retake week line new base take shape downside amtrust financial service afsi be heavy trade barron article publish saturday question multimillion dollar incongruity company regulatory filing stock be buy point week tight pattern economic news insititute supply management manufacturing index fall point significantly view uptick construction spending edge april commerce department report forecast increase march growth be revise initial gain meanwhile china factory activity rise month high
1468,AGN,apple aapl be coolest phone lister earning growth rebound strong china demand tech titan be highly rate large cap stock start letter ibd big cap leader screen day list large stock strong earning price performance large cap company offer better liquidity smaller one apple have be
1469,AGN,nation top perform fund past month have be ramp buy medical internet stock ve have vary degree success resist downward pull stock market july large drug provider such actavis act allergan agn questcor qcor salix pharmaceutical slxp have be steady performer investor hospital stock such
1470,AGN,major average end week gain eke new high friday stock pare earlier loss
1471,AGN,benchmark index climb dow industrial nasdaq finished loss volume be higher nyse lower nasdaq stock market today accord preliminary datum
1472,AGN,retailer meat processor be biggest gainer solar software stock fall weigh nasdaq
1473,AGN,economic datum be mixed midwest factory activity come better expect consumer confidence miss forecast consumer spending dip april
1474,AGN,annie bnny pare loss much intraday turnover be heaviest feb close thursday maker natural organic food report disappointing fiscal result offer current fiscal year guidance be estimate
1475,AGN,twitter twtr lose average volume messaging company share close month decline stock be dec high
1476,AGN,upside valeant pharmaceutical vrx manage hold gain close day move average volume run time higher usual drugmaker persh square sweeten buyout offer allergan agn allergan surge heavy trade
1477,AGN,conn conn krispy kreme doughnut kkd be slate report first quarter result monday economic front exist home sale chicago fed national activity index be due monday
1478,AGN,follow nancy gondo twitter ibd_ngondo major average end week gain eke new high friday stock pare earlier loss benchmark index climb dow industrial nasdaq finished loss volume be higher nyse lower nasdaq stock market today accord preliminary datum retailer meat processor be biggest gainer solar software stock fall weigh nasdaq economic datum be mixed midwest factory activity come better expect consumer confidence miss forecast consumer spending dip april annie bnny pare loss much intraday turnover be heaviest feb close thursday maker natural organic food report disappointing fiscal result offer current fiscal year guidance be estimate twitter twtr lose average volume messaging company share close month decline stock be dec high upside valeant pharmaceutical vrx manage hold gain close day move average volume run time higher usual drugmaker persh square sweeten buyout offer allergan agn allergan surge heavy trade conn conn krispy kreme doughnut kkd be slate report first quarter result monday economic front exist home sale chicago fed national activity index be due monday follow nancy gondo twitter ibd_ngondo
1479,AGN,stock future be pace slightly higher start wednesday market look build recent gain
1480,AGN,nasdaq future climb point vs fair value future gain point dow future rally point
1481,AGN,hit record high monday nasdaq follow put market back uptrend batch upbeat economic report boost sentiment monday economic calender be empty stock market today
1482,AGN,corporate news workday wday jump premarket trading deliver result view late tuesday cloud base software firm also give upbeat sale guidance current quarter qihoo technology qihu be also premarket trading reaction stellar quarterly result late tuesday
1483,AGN,michael kor kor rally premarket trading top view fashion house report fiscal earning cent share year beat cent net sale jump vs view also guide fiscal sale view
1484,AGN,security software maker palo alto network panw report fiscal result close earning be expect dime share year stock clear resistance day line tuesday
1485,AGN,elsewhere valeant pharmaceutical vrx raise bid botox maker allergan agn lift cash portion offer share april valeant offer share share stock share allergan be mildly lower premarket trading
1486,AGN,overseas market be mostly higher shanghai composite hang seng gain respectively european market be more modestly london ftse france cac rise germany dax edge fraction stock future be pace slightly higher start wednesday market look build recent gain nasdaq future climb point vs fair value future gain point dow future rally point hit record high monday nasdaq follow put market back uptrend batch upbeat economic report boost sentiment monday economic calender be empty stock market today corporate news workday wday jump premarket trading deliver result view late tuesday cloud base software firm also give upbeat sale guidance current quarter qihoo technology qihu be also premarket trading reaction stellar quarterly result late tuesday michael kor kor rally premarket trading top view fashion house report fiscal earning cent share year beat cent net sale jump vs view also guide fiscal sale view security software maker palo alto network panw report fiscal result close earning be expect dime share year stock clear resistance day line tuesday elsewhere valeant pharmaceutical vrx raise bid botox maker allergan agn lift cash portion offer share april valeant offer share share stock share allergan be mildly lower premarket trading overseas market be mostly higher shanghai composite hang seng gain respectively european market be more modestly london ftse france cac rise germany dax edge fraction
1487,AGN,stock hold solid gain midday thursday ease session high nasdaq trim gain pare gain dow jone industrial average add turnover be run higher major exchange stock market today
1488,AGN,lead stock wn wn gap bolt nearly best level february blow past buy point cup base open indian outsource firm post fiscal earning view raise guidance
1489,AGN,inphi iphi rally hit time high stock clear buy point consolidation volume be heavy chip designer report earning oct analyst poll thomson reuter see profit double cent share mark eighth straight quarter double digit growth
1490,AGN,downside netflix nflx gap day line dump follow late wednesday disappointing result news soft subscriber growth
1491,AGN,valeant pharmaceutical vrx be session low still news receive federal subpoena drug pricing policy share canadian drugmaker be much intraday
1492,AGN,follow vincent mao twitter ibd_vmao stock hold solid gain midday thursday ease session high nasdaq trim gain pare gain dow jone industrial average add turnover be run higher major exchange stock market today lead stock wn wn gap bolt nearly best level february blow past buy point cup base open indian outsource firm post fiscal earning view raise guidance inphi iphi rally hit time high stock clear buy point consolidation volume be heavy chip designer report earning oct analyst poll thomson reuter see profit double cent share mark eighth straight quarter double digit growth downside netflix nflx gap day line dump follow late wednesday disappointing result news soft subscriber growth valeant pharmaceutical vrx be session low still news receive federal subpoena drug pricing policy share canadian drugmaker be much intraday follow vincent mao twitter ibd_vmao
1493,AGN,most sector leader rise tuesday major average head higher fourth straight session launch new confirm uptrend however heaviest action be downside fleetcor technology flt edge clear buy point cup handle base volume be average however fleetcor issue fuel card commercial vehicle fleet
1494,AGN,much diminish sector leader list contain few stock be set basis now exhibit problem sector leader be ibd toughest screen only most promising stock judge fundamental technical strength make stronger market many stock typically make list correction fewer stock cut
1495,AGN,valeant pharmaceutical vrx report mixed first quarter thursday busy day drugmaker earning report canadian drugmaker report earning share year earlier quarter beating cent consensus analyst poll thomson reuter sale rise short consensus share fall nearly
1496,AGN,canadian drugmaker valeant pharmaceutical international vrx report mixed mostly line thursday management continue press case merger allergan agn valeant stock rise fractionally stock market today
1497,AGN,valeant report earning share year earlier quarter beating analyst consensus cent accord thomson reuter sale rise bit short consensus
1498,AGN,company do not issue new guidance have already raise forecast week earlier announce hostile bid allergan time valeant guide full year sale range last year ep vs
1499,AGN,quarter growth generally come acquisition especially buyout contact lens giant bausch lomb last august organic sale growth be only valeant face generic competition lead product include skin cream retin micro herpes ointment zovirax however management expect growth pick course year launch new product
1500,AGN,bausch lomb outperformed rest business clocking organic growth significant new product launch valeant now expect synergy merger valeant ceo michael pearson say conference call analyst bausch merger provide model valeant integrate allergan
1501,AGN,bausch have centralize model country have general manager run different business vision care pharmaceutical surgery pearson say combine ihealth group different country earlier structure be exact same structure allergan have
1502,AGN,same time pearson say didn touch bausch sale force likely act lesson learn hard way valeant buy medicis attempt overhaul sale staff result high turnover last year pearson say stabilization situation have help boost north american dermatology business year
1503,AGN,thursday be busy day drugmaker earning other high rate stock report early
1504,AGN,mallinckrodt mnk be process buy questcor pharmaceutical qcor report earning cent share number be nickel year earlier quarter mallinckrodt be still part covidien cov beat analyst consensus cent sale shrank short estimate mallinckrodt guide revenue line ep consensus however probably account company stock rise early trading
1505,AGN,regeneron pharmaceutical regn defy pattern season actually beat sale estimate report growth more consensus sale lead drug eylea miss expectation regeneron stock be late morning company restate earlier guidance full year sale eylea
1506,AGN,ibd stock salix pharmaceutical slxp jazz pharmaceutical jazz be report close
1507,AGN,related allergan report strong weigh valeant bid
1508,AGN,follow amy reeve twitter drugmaker valeant pharmaceutical international vrx report mixed mostly line thursday management continue press case merger allergan agn valeant stock rise fractionally stock market today valeant report earning share year earlier quarter beating analyst consensus cent accord thomson reuter sale rise bit short consensus company do not issue new guidance have already raise forecast week earlier announce hostile bid allergan time valeant guide full year sale range last year ep vs quarter growth generally come acquisition especially buyout contact lens giant bausch lomb last august organic sale growth be only valeant face generic competition lead product include skin cream retin micro herpes ointment zovirax however management expect growth pick course year launch new product bausch lomb outperformed rest business clocking organic growth significant new product launch valeant now expect synergy merger valeant ceo michael pearson say conference call analyst bausch merger provide model valeant integrate allergan bausch have centralize model country have general manager run different business vision care pharmaceutical surgery pearson say combine ihealth group different country earlier structure be exact same structure allergan have same time pearson say didn touch bausch sale force likely act lesson learn hard way valeant buy medicis attempt overhaul sale staff result high turnover last year pearson say stabilization situation have help boost north american dermatology business year thursday be busy day drugmaker earning other high rate stock report early mallinckrodt mnk be process buy questcor pharmaceutical qcor report earning cent share number be nickel year earlier quarter mallinckrodt be still part covidien cov beat analyst consensus cent sale shrank short estimate mallinckrodt guide revenue line ep consensus however probably account company stock rise early trading regeneron pharmaceutical regn defy pattern season actually beat sale estimate report growth more consensus sale lead drug eylea miss expectation regeneron stock be late morning company restate earlier guidance full year sale eylea ibd stock salix pharmaceutical slxp jazz pharmaceutical jazz be report close related allergan report strong weigh valeant bidfollow amy reeve twitter ibd_areeve
1509,AGN,tesla motor tsla change way electric car look sleek design scream luxury car instead oddly world shape electric vehicle tesla be car environmentally conscious elite luxury carmaker be other top trendy stock ibd big cap leader screen day screen feature large stock strong earning strong
1510,AGN,specialty drugmaker akorn akrx tuesday report first quarter ep view revenue be light company also raise full year profit outlook lake forest ill base akorn say earn cent share month end march year earlier revenue also rise analyst have estimate profit
1511,AGN,nasdaq medical stock lead market surge tuesday afternoon
1512,AGN,composite be more dow jone industrial average gain volume be sharply higher board
1513,AGN,winning stock lead loser nyse nasdaq stock market today
1514,AGN,medical sector be rally valeant pharmaceutical vrx persh capital make buyout bid allergan agn stock continue trade sharply higher tremendous volume
1515,AGN,news have help revive medical sector have come profit take biotech pharmaceutical stock be session leader
1516,AGN,carlisle csl make decisive past resistance share diversify manufacturer rally heavy trading company beat earn expectation tuesday morning
1517,AGN,synaptic syna edge past buy point cup handle base volume be heavy stock dip back entry synaptic report first quarter result thursday close tuesday announce touchpad be used acer series laptop
1518,AGN,signature bank sbny reach month low sink commercial bank ibd member report result morning nasdaq medical stock lead market surge tuesday afternoon composite be more dow jone industrial average gain volume be sharply higher board winning stock lead loser nyse nasdaq stock market today medical sector be rally valeant pharmaceutical vrx persh capital make buyout bid allergan agn stock continue trade sharply higher tremendous volume news have help revive medical sector have come profit take biotech pharmaceutical stock be session leader carlisle csl make decisive past resistance share diversify manufacturer rally heavy trading company beat earn expectation tuesday morning synaptic syna edge past buy point cup handle base volume be heavy stock dip back entry synaptic report first quarter result thursday close tuesday announce touchpad be used acer series laptop signature bank sbny reach month low sink commercial bank ibd member report result morning
1519,AGN,weaker expect earning report high profile retailer tuesday spark round selling major average
1520,AGN,small cap be hit hardest smallcap lose
1521,AGN,close dow jone industrial average fall weigh weak earning caterpillar cat nasdaq lose preliminary datum show nyse nasdaq volume come higher monday level
1522,AGN,stock market today tjx co tjx crash fall further day move average earning sale miss expectation
1523,AGN,dick sporting good dks also take dive fall weak result be hurt poor performance chain golf hunting category
1524,AGN,home depot hd rally get turn away day move average resistance level now earlier today company report rise quarterly profit slightly ahead view sale come tad expectation investor seem focus more healthy same store sale increase
1525,AGN,salesforce com crm reversed high ahead earning report close share lose provider enterprise cloud compute software be expect report quarter strong sale growth earning growth have be choppy recent quarters software sector whole have be pressure late february
1526,AGN,upside valeant pharmaceutical vrx add news plan increase offer allergan agn valeant recently bid botox maker weaker expect earning report high profile retailer tuesday spark round selling major average small cap be hit hardest smallcap lose close dow jone industrial average fall weigh weak earning caterpillar cat nasdaq lose preliminary datum show nyse nasdaq volume come higher monday level stock market today tjx co tjx crash fall further day move average earning sale miss expectation dick sporting good dks also take dive fall weak result be hurt poor performance chain golf hunting category home depot hd rally get turn away day move average resistance level now earlier today company report rise quarterly profit slightly ahead view sale come tad expectation investor seem focus more healthy same store sale increase salesforce com crm reversed high ahead earning report close share lose provider enterprise cloud compute software be expect report quarter strong sale growth earning growth have be choppy recent quarters software sector whole have be pressure late february upside valeant pharmaceutical vrx add news plan increase offer allergan agn valeant recently bid botox maker
1527,AGN,market wending way correction now be time search stock prime grow market next leg today ibd list highly rate stock be excellent start point computer generate list rank stock base key metric include recent profit growth ibd composite rating also measure return
1528,AGN,big pharmas report light mixed earning tuesday share go different direction stock market today wall street seem focus different detail report
1529,AGN,bristol myer squibb bmy say earning rise year earlier quarter cent share beating analyst consensus cent sale however fall miss consensus bristol add nickel low end previous ep guidance range now midpoint be analyst sale guidance be squarely line consensus represent modest decline last year
1530,AGN,hiv drug sustiva reyataz be largely responsible miss rheumatoid arthritis drug orencia other hand stroke preventer eliquis finally seem be find leg disappointing launch last year sale beating view diabetes also outperformed bristol sell business february astrazeneca azn still collect royalty
1531,AGN,bristol also announce begin roll fda submission process pd inhibitor nivolumab squamous nonsmall cell lung cancer base study expect complete year end nivolumab perform well disease phase trial present significant opportunity prognosis squamous patient today be poor bristol say report phase result meeting october
1532,AGN,company also acquire privately hold biotech ipierian develop treatment class neurogenerative disease call tauopathy
1533,AGN,bristol stock be midday trading
1534,AGN,merck mrk report similarly mixed quarter street be more impressed stock be profit climb year earlier quarter cent share beating estimate cent sale shrank miss consensus merck affirm previous guidance call ep sale
1535,AGN,isi group analyst mark schoenebaum most interesting thing result be beleaguered diabetes drug januvia beat expectation
1536,AGN,quantify price impact point note favorable year year price impact be good news mrk dpp category be plague new aggressive price competition write email client
1537,AGN,merck say leave pipeline update business review meeting next week also didn comment effort sell consumer business have reportedly draw interest reckitt benckiser procter gamble pg bayer bayry past few day
1538,AGN,sanofi sny report number euro sale converted constant exchange rate miss analyst consensus ep miss consensus cent rise constant exchange rate
1539,AGN,rbc capital market note sanofi moved expect filing timeline alirocumab cholesterol drug develop regeneron pharmaceutical regn previously expect file europe early next year somewhat later now expect eu filing late year
1540,AGN,product regeneron partnership dupilumab be be moved phase trial atopic dermatitis perhaps base encourage report regeneron stock be midday trading even sanofi stock be more
1541,AGN,sanofi be also news tuesday be report allergan agn have approach possible buyer allergan bid fend hostile bid valeant pharmaceutical vrx report be base anonymous source company refuse comment
1542,AGN,follow amy reeve twitter ibd_areeve big pharmas report light mixed earning tuesday share go different direction stock market today wall street seem focus different detail report bristol myer squibb bmy say earning rise year earlier quarter cent share beating analyst consensus cent sale however fall miss consensus bristol add nickel low end previous ep guidance range now midpoint be analyst sale guidance be squarely line consensus represent modest decline last year hiv drug sustiva reyataz be largely responsible miss rheumatoid arthritis drug orencia other hand stroke preventer eliquis finally seem be find leg disappointing launch last year sale beating view diabetes also outperformed bristol sell business february astrazeneca azn still collect royalty bristol also announce begin roll fda submission process pd inhibitor nivolumab squamous nonsmall cell lung cancer base study expect complete year end nivolumab perform well disease phase trial present significant opportunity prognosis squamous patient today be poor bristol say report phase result meeting october company also acquire privately hold biotech ipierian develop treatment class neurogenerative disease call tauopathy bristol stock be midday trading merck mrk report similarly mixed quarter street be more impressed stock be profit climb year earlier quarter cent share beating estimate cent sale shrank miss consensus merck affirm previous guidance call ep sale isi group analyst mark schoenebaum most interesting thing result be beleaguered diabetes drug januvia beat expectation quantify price impact point note favorable year year price impact be good news mrk dpp category be plague new aggressive price competition write email client merck say leave pipeline update business review meeting next week also didn comment effort sell consumer business have reportedly draw interest reckitt benckiser procter gamble pg bayer bayry past few day sanofi sny report number euro sale converted constant exchange rate miss analyst consensus ep miss consensus cent rise constant exchange rate rbc capital market note sanofi moved expect filing timeline alirocumab cholesterol drug develop regeneron pharmaceutical regn previously expect file europe early next year somewhat later now expect eu filing late year product regeneron partnership dupilumab be be moved phase trial atopic dermatitis perhaps base encourage report regeneron stock be midday trading even sanofi stock be more sanofi be also news tuesday be report allergan agn have approach possible buyer allergan bid fend hostile bid valeant pharmaceutical vrx report be base anonymous source company refuse comment follow amy reeve twitter ibd_areeve
1543,AGN,stock turn mixed midday monday round similarly mixed earning report well economic report foreign domestic
1544,AGN,nasdaq turn loss gain biotechs software issue outperformed pare deficit dow jone industrial average fall volume be tracking sharply lower board stock market today compare same time friday
1545,AGN,highly rate stock globant glob rally nearly time high clear buy point heavy trading hour session thin stock already match day average volume
1546,AGN,nike nke climb more new high be upgrade buy hold bb now past buy point athletic apparel footwear giant be recently mentioned new high column
1547,AGN,downside microsemi mscc drop news offer buy pmc sierra pmcs bid top buyout offer apple aapl supplier skywork solution swks microsemi fall buy point consolidation clear friday pmc share jump
1548,AGN,valeant vrx slump beating view raise guidance open canadian drugmaker post adjust earning share year sale grow third straight period acceleration almost lift full year sale forecast
1549,AGN,profit be now expect share prior outlook last week valeant say receive subpoena federal prosecutor massachusett new york request information patient assistance program drug pricing decision
1550,AGN,follow vincent mao twitter ibd_vmao stock turn mixed midday monday round similarly mixed earning report well economic report foreign domestic nasdaq turn loss gain biotechs software issue outperformed pare deficit dow jone industrial average fall volume be tracking sharply lower board stock market today compare same time friday highly rate stock globant glob rally nearly time high clear buy point heavy trading hour session thin stock already match day average volume nike nke climb more new high be upgrade buy hold bb now past buy point athletic apparel footwear giant be recently mentioned new high column downside microsemi mscc drop news offer buy pmc sierra pmcs bid top buyout offer apple aapl supplier skywork solution swks microsemi fall buy point consolidation clear friday pmc share jump valeant vrx slump beating view raise guidance open canadian drugmaker post adjust earning share year sale grow third straight period acceleration almost lift full year sale forecast profit be now expect share prior outlook last week valeant say receive subpoena federal prosecutor massachusett new york request information patient assistance program drug pricing decision follow vincent mao twitter ibd_vmao
1551,AGN,sector leader gain monday most advanced lighter usual volume lone decline holdout be valeant pharmaceutical vrx give brisk turnover botox maker allergan agn target recent hostile takeover bid reject valeant offer cite valeant steep cost cut proposal rejection trinity industry trn
1552,AGN,big money flow pharma tuesday novartis glaxosmithkline gsk eli lilly lly unveil giant swap business valeant pharmaceutical vrx bid roughly allergan novartis nvs agree buy glaxo oncology business milestone payment depend product pipeline fare turn
1553,AGN,valeant pharmaceutical vrx slide highlight sector leader list be otherwise unremarkable wednesday valeant fall hit resistance day move average allergan agn adopt poison pill plan defensive mechanism company respond unsolicited buyout bid valeant hedge fund persh square deal be value roughly
1554,AGN,persistence paid big pharma abbvie friday announce takeover shire fifth attempt same time shire report earning ahead schedule earning beat analyst estimate
1555,AGN,abbvie abbv agree pay british pound share combine company shire shpg share more base abbvie thursday close price
1556,AGN,abbvie expect close deal year say be immediately accretive earning accretion rise share
1557,AGN,new firm be domicile
1558,AGN,abbvie say move firm efficient tax structure cut tax rate now
1559,AGN,conference call discuss merger analyst pressed abbvie ceo richard gonzalez detail include tax projection be instead takeover rule restrict say
1560,AGN,gonzalez stress taxe weren only reason abbvie be so determine get shire cite shire strong portfolio neurological rare disease drug
1561,AGN,abbvie fact plan create rare disease division
1562,AGN,transaction have significant strategic financial rationale gonzalez say tax be clearly benefit not primary rationale
1563,AGN,reason brushed concern government recent attack tax inversion deal include call retroactively forbid such move firm have announce such deal do remark see more discussion tax reform try stop company go abroad
1564,AGN,call bmo capital market analyst alex arfaei say be surprised gonzalez assertion deal wasn tax drive not perception
1565,AGN,just last month shire be still spurn abbvie bid shire ceo flem ornskov tell wall street journal think main strategic rationale here be tax inversion
1566,AGN,ornskov wasn friday call gonzalez say shire boss stay deal close help integrate company wasn clear ornskov have permanent role
1567,AGN,shire director join abbvie board
1568,AGN,shire release financial result have be set july earning leap vs year earlier share beating analyst estimate cent sale rise top view
1569,AGN,shire press release didn change recent guidance estimate sale
1570,AGN,leerink analyst jason gerberry cut shire stock market perform say do not expect rival bid pfizer pfe allergan agn pfizer be rumore be interested astrazeneca azn reject tax inversion attempt allergan reportedly mulled shire escape hatch valeant pharmaceutical vrx hostile takeover bid
1571,AGN,shire stock jump june company reveal abbvie takeover bid have rise then include friday rise abbvie rise friday persistence paid big pharma abbvie friday announce takeover shire fifth attempt same time shire report earning ahead schedule earning beat analyst estimate abbvie abbv agree pay british pound share combine company shire shpg share more base abbvie thursday close price abbvie expect close deal year say be immediately accretive earning accretion rise share new firm be domicile abbvie say move firm efficient tax structure cut tax rate now conference call discuss merger analyst pressed abbvie ceo richard gonzalez detail include tax projection be instead takeover rule restrict say gonzalez stress taxe weren only reason abbvie be so determine get shire cite shire strong portfolio neurological rare disease drug abbvie fact plan create rare disease division transaction have significant strategic financial rationale gonzalez say tax be clearly benefit not primary rationale reason brushed concern government recent attack tax inversion deal include call retroactively forbid such move firm have announce such deal do remark see more discussion tax reform try stop company go abroad call bmo capital market analyst alex arfaei say be surprised gonzalez assertion deal wasn tax drive not perception just last month shire be still spurn abbvie bid shire ceo flem ornskov tell wall street journal think main strategic rationale here be tax inversion ornskov wasn friday call gonzalez say shire boss stay deal close help integrate company wasn clear ornskov have permanent role shire director join abbvie board shire release financial result have be set july earning leap vs year earlier share beating analyst estimate cent sale rise top view shire press release didn change recent guidance estimate sale leerink analyst jason gerberry cut shire stock market perform say do not expect rival bid pfizer pfe allergan agn pfizer be rumore be interested astrazeneca azn reject tax inversion attempt allergan reportedly mulled shire escape hatch valeant pharmaceutical vrx hostile takeover bid shire stock jump june company reveal abbvie takeover bid have rise then include friday rise abbvie rise friday
1572,AGN,world look bit flat market standpoint early tuesday global market commodity largely unmoved stock future steering market mixed open dow future be point ibm ibm pull hard downside future be fraction nasdaq future be point focal point stock market today microsoft msft yahoo yhoo chipotle grill cmg also report close do number lead stock include blackhawk network hawk illumina ilmn gopro gpro economic calendar be blank tuesday big name motion early earning report include verizon vz traveler trv lockheed martin lmt unchanged unite technology utx ibm drag lower report earning beat revenue fall slightly more analyst have expect be tech giant straight quarter decline revenue profit margin software division source half company profit narrow quarter ibm share have be gradual uptrend january fight climb month consolidation tesla motor tsla slump nearly ahead open stock have be nick ub downgrade sell note reportedly question company battery storage auto delivery target share rise almost strong trade monday stock be extend rebound week support cup handle buy point india base software engineer infosys infy surge country second largest software developer report better expect earning raise full year revenue guidance consensus expectation management say company sign contract quarter total value infosys have be consolidate february battle retake week line support past week dollar be mixed commodity be generally flat mining stock have drag hard monday be rebound agnico eagle aem barrick gold abx yamana gold auy newmont mining nem post solid premarket gain
1573,AGN,new high list expand tuesday number stock breaking basis drugmaker allergan agn be already extend new high valeant pharmaceutical vrx investor william ackman announce buyout plan monday close see story today stock jump close elsewhere real estate zillow ticker
1574,AGN,drugmaker allergan agn rise sixth straight day monday then soar hour report valeant pharmaceutical vrx investor william ackman be pursue takeover leaderboard stock allergan be maker botox regular session rise close stock have break cup base january then
1575,AGN,oil gas play continue dominate week big cap list half name hail sector not surprisingly most have outperformed market be extend result few other lead nonenergy stock currently work basis provide watch list fodder market come correction
1576,AGN,sector leader muster gain tuesday general market stretched streak straight session valeant pharmaceutical vrx gap rally huge turnover officially announce proposal buy botox maker allergan agn partner persh square capital management news bid first surface late
1577,AGN,stock shake premarket uncertainty grab early gain firm trade tuesday
1578,AGN,nasdaq lead gain dow jone industrial average add volume tick nasdaq jump nyse compare monday open action
1579,AGN,jump foot tuesday monday quiet start week stock diverse harley davidson hog netflix nflx allergan agn lead dow home depot hd traveler trv caterpillar cat be more
1580,AGN,federal housing finance agency housing price index rise month month february be january number gain slight downward revision analyst have project increase
1581,AGN,exist home sale ease notch accord national association realtor move annualize pace march fraction february pace better forecast
1582,AGN,lead stock be healthy start more ibd member climb start bell drugmaker top list
1583,AGN,allergan be uncontested leader joint offer bill ackman persh square capital management valeant pharmaceutical vrx value company irvine calif base maker botox various eye care product be extend tuesday advance rebound back day move average
1584,AGN,valeant also ibd issue gain valeant be second week advance april low correct february first week april
1585,AGN,jazz pharmaceutical jazz riff gain apparently fuel speculation allergan attempt avoid takeover acquisition own jeffery report name jazz shire pharmaceutical shpg possible takeover target allergan jazz be just creep week line attempt climb right side consolidation shire share rise
1586,AGN,tuesday session be likely stay busy well close amgen amgn cree cree yum brand yum many stock schedule report hour stock shake premarket uncertainty grab early gain firm trade tuesday nasdaq lead gain dow jone industrial average add volume tick nasdaq jump nyse compare monday open action jump foot tuesday monday quiet start week stock diverse harley davidson hog netflix nflx allergan agn lead dow home depot hd traveler trv caterpillar cat be more federal housing finance agency housing price index rise month month february be january number gain slight downward revision analyst have project increase exist home sale ease notch accord national association realtor move annualize pace march fraction february pace better forecast lead stock be healthy start more ibd member climb start bell drugmaker top list allergan be uncontested leader joint offer bill ackman persh square capital management valeant pharmaceutical vrx value company irvine calif base maker botox various eye care product be extend tuesday advance rebound back day move average valeant also ibd issue gain valeant be second week advance april low correct february first week april jazz pharmaceutical jazz riff gain apparently fuel speculation allergan attempt avoid takeover acquisition own jeffery report name jazz shire pharmaceutical shpg possible takeover target allergan jazz be just creep week line attempt climb right side consolidation shire share rise tuesday session be likely stay busy well close amgen amgn cree cree yum brand yum many stock schedule report hour
1587,AGN,share valeant pharmaceutical vrx jump extend trading monday news be part buyout group allergan agn william ackman persh square capital be team valeant pursue acquisition allergan accord report wall street journal share valeant surge hour trading regular
1588,AGN,stock continue hold session high wednesday afternoon have little reaction fed beige book
1589,AGN,dow jone industrial average nasdaq rise climb be pace third straight gain volume be again run vastly lower major exchange stock market today
1590,AGN,fed latest beige book note economic activity increase district cleveland st loui be only exception consumer spending manufacturing rise most district housing activity be mixed
1591,AGN,lead stock yahoo yhoo be session peak still heavy trading follow late tuesday quarterly result stock gap climb much yahoo hit resistance day line
1592,AGN,ubiquiti network ubnt rise fast trade stock put big upside reversal regain day line tuesday ubiquiti provider wireless networking product report fiscal earning
1593,AGN,allergan agn rise fast trade putt track fourth straight gain stock regain day line double average trade tuesday allergan have show solid relative strength recent session irvine calif base drugmaker have deliver accelerate earning sale gain recent quarters
1594,AGN,american express axp google googl kansa city southern ksu sandisk sndk unite rental uri be few notable company report earning close stock continue hold session high wednesday afternoon have little reaction fed beige book dow jone industrial average nasdaq rise climb be pace third straight gain volume be again run vastly lower major exchange stock market today fed latest beige book note economic activity increase district cleveland st loui be only exception consumer spending manufacturing rise most district housing activity be mixed lead stock yahoo yhoo be session peak still heavy trading follow late tuesday quarterly result stock gap climb much yahoo hit resistance day line ubiquiti network ubnt rise fast trade stock put big upside reversal regain day line tuesday ubiquiti provider wireless networking product report fiscal earning allergan agn rise fast trade putt track fourth straight gain stock regain day line double average trade tuesday allergan have show solid relative strength recent session irvine calif base drugmaker have deliver accelerate earning sale gain recent quarters american express axp google googl kansa city southern ksu sandisk sndk unite rental uri be few notable company report earning close
1595,AGN,day belong bull monday major average end solid gain be curious lack volume buy
1596,AGN,nasdaq outperformed surge dow jone industrial average close time high rise marked new close high rise preliminary datum show nyse nasdaq volume come lower friday light level
1597,AGN,stock market today software stock be day best performer computer software security group palo alto network panw jump be consolidate gain march hold day move average full year profit be expect surge year earning be due
1598,AGN,enterprise software stock also do well manhattan associate manh surge bounce day move average other big gainer group include workday wday salesforce com crm remain day move average
1599,AGN,other news hillshire brand hsh say pay buy pinnacle food pf hillshire slip nearly pinnacle food jump
1600,AGN,allergan agn fall say valeant pharmaceutical vrx unsolicited takeover bid share valeant also lose
1601,AGN,ibd oil gas field service group emerge energy service emes continue torrid uptrend rise well extend flat base march fast grow group peer matrix service company mtrx be set possible base share fall surge last week strong earning day belong bull monday major average end solid gain be curious lack volume buy nasdaq outperformed surge dow jone industrial average close time high rise marked new close high rise preliminary datum show nyse nasdaq volume come lower friday light level stock market today software stock be day best performer computer software security group palo alto network panw jump be consolidate gain march hold day move average full year profit be expect surge year earning be due enterprise software stock also do well manhattan associate manh surge bounce day move average other big gainer group include workday wday salesforce com crm remain day move average other news hillshire brand hsh say pay buy pinnacle food pf hillshire slip nearly pinnacle food jump allergan agn fall say valeant pharmaceutical vrx unsolicited takeover bid share valeant also lose ibd oil gas field service group emerge energy service emes continue torrid uptrend rise well extend flat base march fast grow group peer matrix service company mtrx be set possible base share fall surge last week strong earning
1602,AGN,most sector leader edge slightly lower weak volume thursday gaslog glog valeant pharmaceutical vrx score gain average trade gaslog surge new high continue find support short term day move average stock be well extend strong rebound day line january
1603,AGN,growth stock be take hit now market be correction biotechs see recent sell concern sector be overheat biotechs medical stock be lead big cap stock ibd big cap screen day list large stock strong earning price performance actavis act alexion pharmaceutical alxn biogen biib allergan ticker
1604,AGN,stock kick heavy week earning positive note monday nasdaq rise fifth straight session morning volatility nasdaq end gain climb close right session high extend recent pattern strong finish be
1605,AGN,wall street rise second day tuesday leave major index just record high higher oil price boost energy stock dow jone industrial average rise nasdaq climb end latter finishing just time peak volume be higher nyse nasdaq compare monday accord preliminary datum
1606,AGN,stock market today oil producer pioneer natural resource pxd driller diamond offshore do rise lead oil price jump more just barrel strike oil worker brazil port shutdown libya
1607,AGN,noah holding noah lead ibd jump heavy volume climb right side deep base provider wealth management service china be due report result nov profit period be see rise cent share be biggest gain quarters
1608,AGN,medical product stock cambrex cbm rise more better expect earning report also climb right side new base
1609,AGN,post session trading luxury electric vehicle maker tesla motor tsla rise sharply narrower expect loss stock fall more regular session end week high
1610,AGN,share real estate zillow be hour follow result
1611,AGN,also close groupon gpn edge higher report provider discount retailer also announce coo rich william replace eric lefkofsky ceo lefkofsky become chairman
1612,AGN,lgi home lgih facebook fb epam system epam cognizant technology solution ctsh be company report quarterly earning wednesday
1613,AGN,economic report due wednesday include institute supply management index service sector activity october adp private sector payroll november crude oil inventory week end oct mortgage banker association index mortgage application week end oct wall street rise second day tuesday leave major index just record high higher oil price boost energy stock dow jone industrial average rise nasdaq climb end latter finishing just time peak volume be higher nyse nasdaq compare monday accord preliminary datum stock market today oil producer pioneer natural resource pxd driller diamond offshore do rise lead oil price jump more just barrel strike oil worker brazil port shutdown libya noah holding noah lead ibd jump heavy volume climb right side deep base provider wealth management service china be due report result nov profit period be see rise cent share be biggest gain quarters medical product stock cambrex cbm rise more better expect earning report also climb right side new base post session trading luxury electric vehicle maker tesla motor tsla rise sharply narrower expect loss stock fall more regular session end week high share real estate zillow be hour follow result also close groupon gpn edge higher report provider discount retailer also announce coo rich william replace eric lefkofsky ceo lefkofsky become chairman lgi home lgih facebook fb epam system epam cognizant technology solution ctsh be company report quarterly earning wednesday economic report due wednesday include institute supply management index service sector activity october adp private sector payroll november crude oil inventory week end oct mortgage banker association index mortgage application week end oct
1614,AGN,major average extend gain midday trade stock rally help upside earning surprise allergan agn buyout news
1615,AGN,nasdaq lead gain dow industrial rise volume be tracking higher board vs monday stock market today
1616,AGN,solar biotech casino stock be top advancer
1617,AGN,report last week potential slowdown macau gaming revenue casino operator exposure chinese gamble enclave advanced la vegas sand lvs rise busy trade rebound close day move average analyst expect casino operator grow profit cent share report thursday close wynn resort wynn also have casino macau gain
1618,AGN,melco crown entertainment mpel hong kong base company operate casino macau be also heavy volume
1619,AGN,harley davidson hog gap vault massive turnover motorcycle maker earning sale be well analyst forecast stock be now past buy point cup handle base
1620,AGN,netflix nflx jump heavy trade late monday video stream service report ep view line revenue also announce plan increase rate new user
1621,AGN,follow nancy gondo twitter major average extend gain midday trade stock rally help upside earning surprise allergan agn buyout news nasdaq lead gain dow industrial rise volume be tracking higher board vs monday stock market today solar biotech casino stock be top advancer report last week potential slowdown macau gaming revenue casino operator exposure chinese gamble enclave advanced la vegas sand lvs rise busy trade rebound close day move average analyst expect casino operator grow profit cent share report thursday close wynn resort wynn also have casino macau gain melco crown entertainment mpel hong kong base company operate casino macau be also heavy volume harley davidson hog gap vault massive turnover motorcycle maker earning sale be well analyst forecast stock be now past buy point cup handle base netflix nflx jump heavy trade late monday video stream service report ep view line revenue also announce plan increase rate new user follow nancy gondo twitter ibd_ngondo
1622,AGN,major average be little change friday weak post holiday trading nasdaq be edge dow jone industrial be flat volume friday half day session be run sharply lower same time wednesday last trading session thanksgiving universal display oled maker light emit flat panel display jump heavy volume new report product be used apple aapl iphone model due stock be approach buy point deep cup base fall oil price hurt energy stock help airline stock market today coal producer consol energy cnx oil stock southwestern energy swn longtime laggard drop weigh other hand american airline aal unite continental ual rise line decline oil price ibd stock hawaiian rise meanwhile walt disney drop heavy volume drag medium stock announce late wednesday espn sport network have lose subscriber past year stock drop cup handle buy point clear nov viacom viab fall time warner twx be
1623,AGN,wag miss third quarter earning forecast share pare loss tuesday drug store giant confirm first time be mull move overseas cut taxe drug retailer earn cent share exclude certain item analyst consensus estimate cent vs year
1624,AGN,air product chemical apd appoint new ceo wednesday mount pressure activist investor bill ackman make leadership change industrial gas producer name seifi ghasemi currently ceo rockwood holding roc helm replace john mcglade retire september ghasemi start july leave rockwood june
1625,AGN,drive health care medium industry have so far be strongest year merger acquisition dawn financial crisis big deal globally totale june last year past few day have be microcosm rise level communication lvlt
1626,AGN,share allergan agn be midday trading stock market monday analyst weigh impact fda decision clear way generic competition company restasis eye drop friday fda publish draft guidance be standard potential generic version allergan restasis explain piper jaffray analyst david amsellem
1627,AGN,share allergan agn bounce back afternoon trading stock market tuesday analyst defend recent rash downgrade stock hit month low monday slew downgrade generic competition allergan restasis eyedrop look be come much sooner expect however analyst disagree
1628,AGN,wall street rise second day tuesday leave major index just record high higher oil price boost energy stock dow jone industrial average rise nasdaq climb end latter finishing just time peak volume be higher nyse nasdaq compare monday accord preliminary datum
1629,AGN,stock market today oil producer pioneer natural resource pxd driller diamond offshore do rise lead oil price jump more just barrel strike oil worker brazil port shutdown libya
1630,AGN,noah holding noah lead ibd jump heavy volume climb right side deep base provider wealth management service china be due report result nov profit period be see rise cent share be biggest gain quarters
1631,AGN,medical product stock cambrex cbm rise more better expect earning report also climb right side new base
1632,AGN,post session trading luxury electric vehicle maker tesla motor tsla rise sharply narrower expect loss stock fall more regular session end week high
1633,AGN,share real estate zillow be hour follow result
1634,AGN,also close groupon gpn edge higher report provider discount retailer also announce coo rich william replace eric lefkofsky ceo lefkofsky become chairman
1635,AGN,lgi home lgih facebook fb epam system epam cognizant technology solution ctsh be company report quarterly earning wednesday
1636,AGN,economic report due wednesday include institute supply management index service sector activity october adp private sector payroll november crude oil inventory week end oct mortgage banker association index mortgage application week end oct wall street rise second day tuesday leave major index just record high higher oil price boost energy stock dow jone industrial average rise nasdaq climb end latter finishing just time peak volume be higher nyse nasdaq compare monday accord preliminary datum stock market today oil producer pioneer natural resource pxd driller diamond offshore do rise lead oil price jump more just barrel strike oil worker brazil port shutdown libya noah holding noah lead ibd jump heavy volume climb right side deep base provider wealth management service china be due report result nov profit period be see rise cent share be biggest gain quarters medical product stock cambrex cbm rise more better expect earning report also climb right side new base post session trading luxury electric vehicle maker tesla motor tsla rise sharply narrower expect loss stock fall more regular session end week high share real estate zillow be hour follow result also close groupon gpn edge higher report provider discount retailer also announce coo rich william replace eric lefkofsky ceo lefkofsky become chairman lgi home lgih facebook fb epam system epam cognizant technology solution ctsh be company report quarterly earning wednesday economic report due wednesday include institute supply management index service sector activity october adp private sector payroll november crude oil inventory week end oct mortgage banker association index mortgage application week end oct
1637,AGN,apple rocked market purchase beat electronic wednesday personal electronic giant share have be uptick report strong quarterly sale april apple be top big cap stock ibd bigger sometimes mean better larger company often have more liquidity usually make business easier ibd
1638,AGN,share allergan agn slip tuesday food drug administration decline approve inhalable version migraine drug
1639,AGN,fda action be base concern manufacturing canister used dispense drug allergan say be something fix
1640,AGN,allergan share be afternoon trading stock market today still stock be year allergan have ibd composite rating putt top stock major metric such sale profit growth
1641,AGN,fda have previously expressed concern canister manufacturer exemplar pharma allergan say complete purchase exemplar pharma last week less help address concern
1642,AGN,drug call levadex be inhalation aerosol acute treatment migraine adult drug be initially approve
1643,AGN,allergan press release tuesday say have already take several step address fda concern continue do so
1644,AGN,company be commit bring levadex market potential new acute treatment address significant unmet need million person live debilitating migraine allergan say
1645,AGN,estimate american suffer migraine
1646,AGN,allergan reiterate earning share guidance present feb say today response not materially impact overall allergan sale guidance
1647,AGN,next fda action drug occur year end company say share allergan agn slip tuesday food drug administration decline approve inhalable version migraine drug fda action be base concern manufacturing canister used dispense drug allergan say be something fix allergan share be afternoon trading stock market today still stock be year allergan have ibd composite rating putt top stock major metric such sale profit growth fda have previously expressed concern canister manufacturer exemplar pharma allergan say complete purchase exemplar pharma last week less help address concern drug call levadex be inhalation aerosol acute treatment migraine adult drug be initially approve allergan press release tuesday say have already take several step address fda concern continue do so company be commit bring levadex market potential new acute treatment address significant unmet need million person live debilitating migraine allergan say estimate american suffer migraine allergan reiterate earning share guidance present feb say today response not materially impact overall allergan sale guidance next fda action drug occur year end company say
1648,AGN,stock break then doesn do too much explanation be possible problem be general market problem be stock problem be investor hasn give stock enough time prove disprove big cap include several stock raise kind question facebook ticker
1649,AGN,stock make sector leader screen wednesday issue tuesday few mid april april market outlook shift correction be stock biggest mover far be gaslog glog pare intraday loss close
1650,AGN,stock capped solid week more gain friday result bumper crop week high philadelphia semiconductor index extend winning streak session lift several stock chip sector new high apply material amat add recent gain report strong earning earlier week share rise cent apply
1651,AGN,megamerger be back major corporation appetite acquisition near pre recession peak especially tax friendly cross border deal global have reach year earlier accord datum compile thomson reuter mark strongest year deal make peak monday biggest announcement be hillshire brand hsh
1652,AGN,allergan agn maker botox breast implant variety eye care product beat analyst earning estimate report result early tuesday recur theme large medical firm quarter miss sale view due foreign currency headwind company report profit share year quarter cent
1653,AGN,weren many medical stock hit new high monday do make move count shire shpg break cup handle base time average volume pharmaceutical company jump clear week pattern allergan agn be target shire buyout way fend
1654,AGN,stock finished mixed volatile session monday see main index erase sharp loss dow jone industrial average lead comeback gain be not index be lead market be make serious advance muster gain defend day
1655,AGN,european exchange be high scorer world map tuesday investor return vigor day holiday
1656,AGN,germany frankfurt exchange lead pack dax index vaulting higher italy milano ftse mib punch cac paris surge london ftse post gain
1657,AGN,european market rally sign thursday agreement russia europe ease rise tension ukraine be falter tuesday ukraine order resumption terror operation
1658,AGN,massive complex deal swiss drug giant novartis nvs glaxosmithkline gsk be centerpiece session company effectively restructure single swap novartis buy glaxosmithkline oncology unit glaxosmithkline grab novartis vaccine business separate deal glaxo say receive indianapoli base eli lilly lly animal health business
1659,AGN,glaxo rise london exchange drugmaker bayer bayry merck mrk be day biggest mover frankfurt
1660,AGN,base astrazeneca azn climb london report new york base pfizer pfe have approach company last year takeover offer talk have reportedly end
1661,AGN,financial time quote mirabaud security steve clayton say crucial point underlie pfizer interest deal be avoid tax penalty company repatriate overseas cash acquisition have allow pfizer avoid hit secure new portion market
1662,AGN,addition ireland base drugmaker shire group shpg jazz pharmaceutical jazz rise heavy trade respectively jeffery report name possible takeover target allergan agn event california base company attempt fend hostile takeover attempt make public monday persh square capital management valeant pharmaceutical vrx
1663,AGN,market also receive assist euro hold week low vs dollar pledge european central bank intercede single currency show sign strength european exchange be high scorer world map tuesday investor return vigor day holiday germany frankfurt exchange lead pack dax index vaulting higher italy milano ftse mib punch cac paris surge london ftse post gain european market rally sign thursday agreement russia europe ease rise tension ukraine be falter tuesday ukraine order resumption terror operation massive complex deal swiss drug giant novartis nvs glaxosmithkline gsk be centerpiece session company effectively restructure single swap novartis buy glaxosmithkline oncology unit glaxosmithkline grab novartis vaccine business separate deal glaxo say receive indianapoli base eli lilly lly animal health business glaxo rise london exchange drugmaker bayer bayry merck mrk be day biggest mover frankfurt base astrazeneca azn climb london report new york base pfizer pfe have approach company last year takeover offer talk have reportedly end financial time quote mirabaud security steve clayton say crucial point underlie pfizer interest deal be avoid tax penalty company repatriate overseas cash acquisition have allow pfizer avoid hit secure new portion market addition ireland base drugmaker shire group shpg jazz pharmaceutical jazz rise heavy trade respectively jeffery report name possible takeover target allergan agn event california base company attempt fend hostile takeover attempt make public monday persh square capital management valeant pharmaceutical vrx market also receive assist euro hold week low vs dollar pledge european central bank intercede single currency show sign strength
1664,AGN,stock rebound narrowly mixed territory slide earlier session
1665,AGN,ease nasdaq fall have fall respectively reverse early gain meanwhile dow jone industrial average rise fraction volume be tracking higher board stock market today
1666,AGN,leader silica slca slump extend recent slide stock be penny away potential support day line now september peak energy related stock tumble crude price slump nearly silica supply sand used frac
1667,AGN,gopro gpro drop be downgrade neutral overweight piper jaffray late tuesday stock be still past buy point ipo base gopro hit new high tuesday fade copperfield research tweet question camera maker accounting practice
1668,AGN,super micro computer smci fall month low fast trade drop undercut low flat base reset base count recent session super micro erased gain past buy point fall trigger thursday
1669,AGN,leader volume be few skecher skx rise bounce back day pullback overall stock appear stabilize selling sale concern
1670,AGN,minute fed september meeting be et stock rebound narrowly mixed territory slide earlier session ease nasdaq fall have fall respectively reverse early gain meanwhile dow jone industrial average rise fraction volume be tracking higher board stock market today leader silica slca slump extend recent slide stock be penny away potential support day line now september peak energy related stock tumble crude price slump nearly silica supply sand used frac gopro gpro drop be downgrade neutral overweight piper jaffray late tuesday stock be still past buy point ipo base gopro hit new high tuesday fade copperfield research tweet question camera maker accounting practice super micro computer smci fall month low fast trade drop undercut low flat base reset base count recent session super micro erased gain past buy point fall trigger thursday leader volume be few skecher skx rise bounce back day pullback overall stock appear stabilize selling sale concern minute fed september meeting be et
1671,AGN,stock market rise broadly tuesday build rebound nasdaq make gain row composite add shave gain final hour half trading small cap russell jump volume increase add positive tone day index
1672,AGN,share allergan agn tumble early trading wednesday drugmaker first quarter result outlook fall short expectation
1673,AGN,allergan make botox breast implant variety eye care product early wednesday report sale year short analyst consensus profit rise cent share penny short estimate
1674,AGN,full year guidance be also low side company forecast sale consensus analyst poll thomson reuter call ep guidance be vs analyst
1675,AGN,stock be early trading reverse month run peaked new high friday share allergan agn tumble early trading wednesday drugmaker first quarter result outlook fall short expectation allergan make botox breast implant variety eye care product early wednesday report sale year short analyst consensus profit rise cent share penny short estimate full year guidance be also low side company forecast sale consensus analyst poll thomson reuter call ep guidance be vs analyst stock be early trading reverse month run peaked new high friday
1676,AGN,health care stock have be strong performer year re largest group big cap entry actavis act be still buy range touch day move average form week tight pattern be most safely used add already successful position buy point week tight pattern be
1677,AGN,tech stock outperformed tuesday nasdaq hit week high market resume uptrend dual upgrade intel intc ahead earning report thursday boost sentiment so do better expect december retail sale release open nasdaq surge add volume fall monday indicate lack conviction
1678,AGN,david pyott take allergan ceo january eye care drug device maker be hardly see growth sale stand flat year stock be year sideway pattern thank innovative product such wrinkle botox skin eye specialist sale last year stand
1679,AGN,high stake game valeant pharmaceutical vrx ceo michael pearson have show skill navigate acquisition trail pearson have make more buyout take helm moved push canadian drugmaker new market build product portfolio pearson aggressive acquisition strategy help valeant nearly quintuple revenue
1680,AGN,stock suffer moderate loss wednesday close session lows end day winning streak have take nasdaq multiyear time high
1681,AGN,nasdaq dow jone industrial average fall first day volume stock market today rise slightly board accord early datum
1682,AGN,economic news adp employment report miss expectation upside fed latest policy statement offer bit hope accord observer central bank say increase decrease bond buy shift prior statement policymaker didn specifically mention increase stock market lift session lows follow fed statement then slump fresh lows session final minute
1683,AGN,ibd stock regeneron pharmaceutical regn be biggest winner developer drug eye disease other condition surge huge volume reach new high get lift news delay experimental eye drug rival allergan agn slide slice day move average stock suffer moderate loss wednesday close session lows end day winning streak have take nasdaq multiyear time high nasdaq dow jone industrial average fall first day volume stock market today rise slightly board accord early datum economic news adp employment report miss expectation upside fed latest policy statement offer bit hope accord observer central bank say increase decrease bond buy shift prior statement policymaker didn specifically mention increase stock market lift session lows follow fed statement then slump fresh lows session final minute ibd stock regeneron pharmaceutical regn be biggest winner developer drug eye disease other condition surge huge volume reach new high get lift news delay experimental eye drug rival allergan agn slide slice day move average
1684,AGN,share regeneron pharmaceutical regn be afternoon trading wednesday time high speculation drugmaker boost sale vision loss drug eylea rival allergan agn continue work longer expect testing rival drug allergan share be stock market today eylea eventually be expect face competition
1685,AGN,merger be usually more popular investor company be acquire acquirer specialty drugmaker akorn akrx agree buy tech pharmacal however stock have go
1686,AGN,akorn payout isn huge drug industry standard price nearly double size company annual revenue be run buyout also address need raise analyst management alike diversification
1687,AGN,akorn principal product be nembutal know generically pentobarbital most famous infamous use execution lethal injection also used anesthetic sedative homicidal use make albatross previous owner lundbeck home country denmark oppose death penalty
1688,AGN,well time acquisition
1689,AGN,akorn acquire nembutal lundbeck late fortuitous moment hospira hsp have stop make sodium thiopental then standard drug lethal injection
1690,AGN,controversial nature drug be akorn advantage sense have generic competitor even long patent however sagent pharmaceutical sgnt have file approval own generic version early august ceo jeff yordon say launch end year
1691,AGN,akorn buyout tech pharmacal hitk get problem build completely different part business company have considerable presence ophthalmology akorn acquire advanced vision research acquire theratear eye drop macutrition supplement expand make private label eye product drugstore
1692,AGN,buyout akorn get tech manufacturing plant further expand capacity make opthalmology product akorn management have say hope be player generic ophthalmic facility also bring capability didn have such cream ointment nasal spray
1693,AGN,anticipate be approximately addressable market opportunity private label counter business category cough cold allergy oral liquid nasal topical akorn ceo raj rai say conference call discuss merger believe give credibility provide cross selling opportunity exist customer further enhance partnership retailer
1694,AGN,counter drug make large chunk tech business single biggest product be fluticasone generic version flonase glaxosmithkline gsk prescription asthma spray drug fuel big growth last year new entrant market put tech train quarterly profit decline never re-cover
1695,AGN,cause concern deutsche bank analyst david steinberg
1696,AGN,specifically be akrx buy company be grow considerably more slowly have product fluticasone be fy revenue have decline year year ask aug research note be more generic entrant
1697,AGN,other analyst mentioned comment merger not be worry
1698,AGN,do not envision pace new generic flonase entrant accelerate go forward bearing mind market be already crowd pricing have already erode considerably write piper jaffray david amsellem
1699,AGN,amsellem raise price target stock do several other analyst actually upgrade probably be already carry good rating street due recent track record
1700,AGN,akorn be come straight quarters double digit profit sale growth combination strategic buyout shortage withdrawal compete product help bring company money lose wilderness spend first decade st century
1701,AGN,stock bottom cent cruised july then spend month consolidate second quarter earning report then tech announcement drive currently trade
1702,AGN,promising pipeline
1703,AGN,more buyout be card analyst also see growth potential akorn pipeline end second quarter have generic drug application process fda represent addressable market accord craig hallum
1704,AGN,company have be work generic version novartis nvs inhaled antibiotic tobi hospira intravenous sedative precedex akorn have also say plan go veterinary product start ophthalmic product possibly expand injectable later
1705,AGN,tech bring pipeline product table addressable market currently wrangling allergan agn right make knock off allergan eye product latisse lumigan zymar
1706,AGN,impatient longer term strategy analyst have raise possibility new akorn tech hybrid get buy
1707,AGN,akorn be likely acquisition target give unique position consolidate industry write guggenheim louise chen initiation report be only few generic ophthalmic company limit number generic injectable company merger be usually more popular investor company be acquire acquirer specialty drugmaker akorn akrx agree buy tech pharmacal however stock have go akorn payout isn huge drug industry standard price nearly double size company annual revenue be run buyout also address need raise analyst management alike diversification akorn principal product be nembutal know generically pentobarbital most famous infamous use execution lethal injection also used anesthetic sedative homicidal use make albatross previous owner lundbeck home country denmark oppose death penalty well time acquire nembutal lundbeck late fortuitous moment hospira hsp have stop make sodium thiopental then standard drug lethal injection controversial nature drug be akorn advantage sense have generic competitor even long patent however sagent pharmaceutical sgnt have file approval own generic version early august ceo jeff yordon say launch end year akorn buyout tech pharmacal hitk get problem build completely different part business company have considerable presence ophthalmology akorn acquire advanced vision research acquire theratear eye drop macutrition supplement expand make private label eye product drugstore buyout akorn get tech manufacturing plant further expand capacity make opthalmology product akorn management have say hope be player generic ophthalmic facility also bring capability didn have such cream ointment nasal spray anticipate be approximately addressable market opportunity private label counter business category cough cold allergy oral liquid nasal topical akorn ceo raj rai say conference call discuss merger believe give credibility provide cross selling opportunity exist customer further enhance partnership retailer counter drug make large chunk tech business single biggest product be fluticasone generic version flonase glaxosmithkline gsk prescription asthma spray drug fuel big growth last year new entrant market put tech train quarterly profit decline never re-cover cause concern deutsche bank analyst david steinberg specifically be akrx buy company be grow considerably more slowly have product fluticasone be fy revenue have decline year year ask aug research note be more generic entrant other analyst mentioned comment merger not be worry do not envision pace new generic flonase entrant accelerate go forward bearing mind market be already crowd pricing have already erode considerably write piper jaffray david amsellem amsellem raise price target stock do several other analyst actually upgrade probably be already carry good rating street due recent track record akorn be come straight quarters double digit profit sale growth combination strategic buyout shortage withdrawal compete product help bring company money lose wilderness spend first decade st century stock bottom cent cruised july then spend month consolidate second quarter earning report then tech announcement drive currently trade promising more buyout be card analyst also see growth potential akorn pipeline end second quarter have generic drug application process fda represent addressable market accord craig hallum company have be work generic version novartis nvs inhaled antibiotic tobi hospira intravenous sedative precedex akorn have also say plan go veterinary product start ophthalmic product possibly expand injectable later tech bring pipeline product table addressable market currently wrangling allergan agn right make knock off allergan eye product latisse lumigan zymar impatient longer term strategy analyst have raise possibility new akorn tech hybrid get buy akorn be likely acquisition target give unique position consolidate industry write guggenheim louise chen initiation report be only few generic ophthalmic company limit number generic injectable company
1708,AGN,seem strange make short side weekly column particularly market be have fine year so far friday ibd market pulse change current outlook confirm uptrend now be awful time sell stock short set kayak tell ocean awesome current
1709,AGN,canadian drugmaker valeant pharmaceutical international vrx beat analyst earning estimate wednesday raise guidance account complete acquisition contact lens giant bausch lomb
1710,AGN,stock already trading record high hit new peak early wednesday close
1711,AGN,valeant report cash ep share year earlier quarter cent analyst consensus sale rise line estimate
1712,AGN,company close buyout bausch lomb tuesday consequently raise full year guidance quite bit management add more sale range now ep range be vs previous guidance post ep sale
1713,AGN,earning conference call analyst cfo howard schiller say valeant expect exceed target cost saving merger plan reduce combine head count most come general administrative expense little impact sale force brand pharmaceutical still make majority combine business schiller point quarters revenue now come cash payment private insurance be significant give pricing pressure drug government payer especially europe
1714,AGN,morningstar analyst david krempa research report caution deal synergy be partly offset higher expect interest rate valeant still be relatively small player ophthalmology vs rival such johnson johnson jnj novartis nvs nonetheless add still believe valeant exemplary stewardship be be undervalue market
1715,AGN,highly acquisitive valeant be already swollen quarter buyout skin cream maker obagi medical product close late april obagi buyout turn complement last year acquisition medicis bring valeant dysport wrinkle injection similar allergan agn botox conference call valeant ceo michael pearson say dysport be gain market share botox other rival merz xeomin
1716,AGN,exclude impact various smaller buyout sale rise more modest develop market emerge market develop market sale take hit unexpected early entry generic competition herpes cream zovirax mylan myl win fda approval knock early april pearson say push promote product sale apart zovirax rest portfolio grow
1717,AGN,outside eastern europe be standout organic growth russia first half year poland mexico also do well organic growth pearson note have be slowdown latin america overall market growth say valeant have manage outperform
1718,AGN,pearson also offer valeant annual review performance recent large acquisition case cover deal october overall compound annual growth rate acquire company be brazilian nutritional company probiotica lead way growth february buyout
1719,AGN,valeant be pull less annual revenue recently pearson have repeatedly say plan turn company large global drugmaker lead ub analyst marc goodman ask call valeant be go have go more mainstream product order get even bigger
1720,AGN,pearson answer valeant strategy remain same think be successful not do large pharma company be do say do put big aspiration approach motivational person certainly be hope achieve canadian drugmaker valeant pharmaceutical international vrx beat analyst earning estimate wednesday raise guidance account complete acquisition contact lens giant bausch lomb stock already trading record high hit new peak early wednesday close valeant report cash ep share year earlier quarter cent analyst consensus sale rise line estimate company close buyout bausch lomb tuesday consequently raise full year guidance quite bit management add more sale range now ep range be vs previous guidance post ep sale earning conference call analyst cfo howard schiller say valeant expect exceed target cost saving merger plan reduce combine head count most come general administrative expense little impact sale force brand pharmaceutical still make majority combine business schiller point quarters revenue now come cash payment private insurance be significant give pricing pressure drug government payer especially europe morningstar analyst david krempa research report caution deal synergy be partly offset higher expect interest rate valeant still be relatively small player ophthalmology vs rival such johnson johnson jnj novartis nvs nonetheless add still believe valeant exemplary stewardship be be undervalue market highly acquisitive valeant be already swollen quarter buyout skin cream maker obagi medical product close late april obagi buyout turn complement last year acquisition medicis bring valeant dysport wrinkle injection similar allergan agn botox conference call valeant ceo michael pearson say dysport be gain market share botox other rival merz xeomin exclude impact various smaller buyout sale rise more modest develop market emerge market develop market sale take hit unexpected early entry generic competition herpes cream zovirax mylan myl win fda approval knock early april pearson say push promote product sale apart zovirax rest portfolio grow outside eastern europe be standout organic growth russia first half year poland mexico also do well organic growth pearson note have be slowdown latin america overall market growth say valeant have manage outperform pearson also offer valeant annual review performance recent large acquisition case cover deal october overall compound annual growth rate acquire company be brazilian nutritional company probiotica lead way growth february buyout valeant be pull less annual revenue recently pearson have repeatedly say plan turn company large global drugmaker lead ub analyst marc goodman ask call valeant be go have go more mainstream product order get even bigger pearson answer valeant strategy remain same think be successful not do large pharma company be do say do put big aspiration approach motivational person certainly be hope achieve
1721,AGN,allergan agn be set report result open tuesday digest couple acquisition aim kick start growth
1722,AGN,analyst poll thomson reuter expect profit share year earlier quarter sale rise company stock have be trading record high last couple week announce buy map pharmaceutical mapp allergan be afternoon trading monday
1723,AGN,map be develop inhaled migraine treatment call levadex complement allergan recent approval use flagship cosmetic drug botox migraine treatment analyst estimate levadex peak sale be still several year
1724,AGN,jan leerink swann analyst seamus fernandez lift price target stock cite long term growth prospect map skinmedica skin care company allergan agree buy december fernandez note allergan business have become quite diverse eye care product breast implant grow number new indication botox most recently bladder control allergan agn be set report result open tuesday digest couple acquisition aim kick start growth analyst poll thomson reuter expect profit share year earlier quarter sale rise company stock have be trading record high last couple week announce buy map pharmaceutical mapp allergan be afternoon trading monday map be develop inhaled migraine treatment call levadex complement allergan recent approval use flagship cosmetic drug botox migraine treatment analyst estimate levadex peak sale be still several year jan leerink swann analyst seamus fernandez lift price target stock cite long term growth prospect map skinmedica skin care company allergan agree buy december fernandez note allergan business have become quite diverse eye care product breast implant grow number new indication botox most recently bladder control
1725,AGN,biotech regeneron pharmaceutical regn trade time high stock market thursday company prepared release result open friday analyst expect report profit cent share ninefold jump year number sale be expect soar most revenue come
1726,AGN,market be ocean spot earth water be calm soothing spot hurricane be build so even major index be rise gentle fashion certain stock be fall hard have day literally year sun look good shorting
1727,AGN,stock open mild loss weak trade wednesday
1728,AGN,nasdaq be fraction lower slip dow jone industrial average slump volume be nasdaq lower nyse compare same time tuesday
1729,AGN,stock market today open mixed economic news surprise jump april producer price index point rekindle inflation
1730,AGN,earning news continue drive much wednesday early stock action cosmetic brand coty coty climb apparel accessory maker kate spade kate bag gain report quarterly result
1731,AGN,deere co slip more farm construction equipment maker beat consensus sale earning forecast fiscal second quarter management lower company full year sale outlook
1732,AGN,stock break long pattern april be slightly buy point
1733,AGN,sear holding shld climb start gun illinois base retail chain say sell part sear canada subsidiary latest series divestment include land end orchard supply hardware sear hometown outlet store sear own sear canada have store report profit
1734,AGN,leader get weak start almost ibd stock open lower
1735,AGN,drugmaker jazz pharmaceutical jazz salix pharmaceutical slxp jump more jazz be climb test support week move average be still week line consolidate salix be fight retake week move average also consolidate stock open mild loss weak trade wednesday nasdaq be fraction lower slip dow jone industrial average slump volume be nasdaq lower nyse compare same time tuesday stock market today open mixed economic news surprise jump april producer price index point rekindle inflation earning news continue drive much wednesday early stock action cosmetic brand coty coty climb apparel accessory maker kate spade kate bag gain report quarterly result deere co slip more farm construction equipment maker beat consensus sale earning forecast fiscal second quarter management lower company full year sale outlook stock break long pattern april be slightly buy point sear holding shld climb start gun illinois base retail chain say sell part sear canada subsidiary latest series divestment include land end orchard supply hardware sear hometown outlet store sear own sear canada have store report profit leader get weak start almost ibd stock open lower drugmaker jazz pharmaceutical jazz salix pharmaceutical slxp jump more jazz be climb test support week move average be still week line consolidate salix be fight retake week move average also consolidate
1736,AGN,future soar point sharply higher open friday labor department paint improve job picture april
1737,AGN,dow future be point rise nasdaq future jump point future pop point
1738,AGN,premarket posture bode well stock market today be focuse overtake resistance nasdaq head friday so far week highest level november be almost just fraction new high territory stifle leader have so far post healthy week ibd index thursday
1739,AGN,nonfarm payroll jump april labor department report march sharply upwardly revise increase analyst have forecast increase private payroll account bulk gain march pace line analyst forecast
1740,AGN,gain whittle unemployment rate vs march analyst have project change
1741,AGN,lead stock be most active ahead friday open
1742,AGN,ibd stock regeneron pharmaceutical regn be ahead premarket action tarrytown base biotech report sale growth triple digit earning gain far analyst forecast sale ocular disease treatment eylea drive large share beat rise quarter management raise full year sale expectation drug
1743,AGN,stock be week end day thursday boost trial delay announce rival allergan agn wednesday
1744,AGN,fleetcor technology flt also ibd stock climb ahead bell provider fuel credit system vehicle fleet report jump earning sale gain first quarter better then analyst consensus view
1745,AGN,stock stick close day line week third test support august just april high
1746,AGN,injured list linkedin lnkd remain ahead open report first quarter result late thursday career networking site report better expect sale earning growth management second quarter revenue net income guidance be expectation company first forecast consensus view
1747,AGN,almost year old stock end thursday more week new high extend rebound week support
1748,AGN,overseas asia market capped mixed session shanghai composite tokyo nikkei hong kong hang seng index inched week shanghai composite climb nikkei dive hang seng end ahead less
1749,AGN,europe market also climb sharply job report major index be tracking mixed gain week lead cac be week mid session friday
1750,AGN,commodity be generally higher head mostly modest gain week oil gold silver copper be trading last friday close corn be natural gas have slip so far week
1751,AGN,later morning factor order datum march be expect census bureau et be institute supply management service sector index april future soar point sharply higher open friday labor department paint improve job picture april dow future be point rise nasdaq future jump point future pop point premarket posture bode well stock market today be focuse overtake resistance nasdaq head friday so far week highest level november be almost just fraction new high territory stifle leader have so far post healthy week ibd index thursday nonfarm payroll jump april labor department report march sharply upwardly revise increase analyst have forecast increase private payroll account bulk gain march pace line analyst forecast gain whittle unemployment rate vs march analyst have project change lead stock be most active ahead friday open ibd stock regeneron pharmaceutical regn be ahead premarket action tarrytown base biotech report sale growth triple digit earning gain far analyst forecast sale ocular disease treatment eylea drive large share beat rise quarter management raise full year sale expectation drug stock be week end day thursday boost trial delay announce rival allergan agn wednesday fleetcor technology flt also ibd stock climb ahead bell provider fuel credit system vehicle fleet report jump earning sale gain first quarter better then analyst consensus view stock stick close day line week third test support august just april high injured list linkedin lnkd remain ahead open report first quarter result late thursday career networking site report better expect sale earning growth management second quarter revenue net income guidance be expectation company first forecast consensus view almost year old stock end thursday more week new high extend rebound week support overseas asia market capped mixed session shanghai composite tokyo nikkei hong kong hang seng index inched week shanghai composite climb nikkei dive hang seng end ahead less europe market also climb sharply job report major index be tracking mixed gain week lead cac be week mid session friday commodity be generally higher head mostly modest gain week oil gold silver copper be trading last friday close corn be natural gas have slip so far week later morning factor order datum march be expect census bureau et be institute supply management service sector index april
1752,AGN,share regeneron pharmaceutical regn vault new high early friday biotech beat analyst estimate expand ophthalmology portfolio acquisition
1753,AGN,quarterly sale rise nearly year earlier quarter handily beating analyst consensus ep gaap basis fall short estimate cent share include stock base compensation expense exclude expense ep nearly quadruple share
1754,AGN,most revenue come eylea treatment age related vision loss beat analyst estimate thoroughly stomp europe company have be guide full year eylea sale thursday lift range
1755,AGN,biggest term opportunity eylea remain uptake use new well experience patient be refractory stop respond roche rhhby lucentis avastin well slow steady shift away compound avastin be grow market write analyst adnan butt rbc capital market client note
1756,AGN,regeneron also announce acquire full right novel antibody big pharma partner sanofi sny say be preclinical development ophthalmology used pay upfront drug further payment road achieve certain milestone
1757,AGN,regeneron stock hit time high wednesday news rival eye drug allergan agn have hit delay be more stock market today trading
1758,AGN,related regeneron succeed putt science first say ceo share regeneron pharmaceutical regn vault new high early friday biotech beat analyst estimate expand ophthalmology portfolio acquisition quarterly sale rise nearly year earlier quarter handily beating analyst consensus ep gaap basis fall short estimate cent share include stock base compensation expense exclude expense ep nearly quadruple share most revenue come eylea treatment age related vision loss beat analyst estimate thoroughly stomp europe company have be guide full year eylea sale thursday lift range biggest term opportunity eylea remain uptake use new well experience patient be refractory stop respond roche rhhby lucentis avastin well slow steady shift away compound avastin be grow market write analyst adnan butt rbc capital market client note regeneron also announce acquire full right novel antibody big pharma partner sanofi sny say be preclinical development ophthalmology used pay upfront drug further payment road achieve certain milestone regeneron stock hit time high wednesday news rival eye drug allergan agn have hit delay be more stock market today trading related regeneron succeed putt science first say ceo
1759,AGN,manager artisan mid cap fund aim broad knowledge global economy help spot trend pounce re do innovation health care housing recovery approach fund be run andrew stephen james hamel jason white matthew kamm have gain
1760,AGN,share obagi medical product ompi pop early trading tuesday get rival bid lure away plan merger valeant pharmaceutical vrx
1761,AGN,germany merz pharma group say offer share obagi top share obagi accept valeant week
1762,AGN,merz valeant be interested obagi skin cream complement wrinkle fight product especially botulinum toxin similar allergan agn botox
1763,AGN,merz sell xeomin earlier year re enter market month ban allegation steal trade secret allergan valeant acquire dysport merged medicis december
1764,AGN,valeant stock be latest ibd ranking top stock hit time high monday be fraction new high early trading stock market today share obagi medical product ompi pop early trading tuesday get rival bid lure away plan merger valeant pharmaceutical vrx germany merz pharma group say offer share obagi top share obagi accept valeant week merz valeant be interested obagi skin cream complement wrinkle fight product especially botulinum toxin similar allergan agn botox merz sell xeomin earlier year re enter market month ban allegation steal trade secret allergan valeant acquire dysport merged medicis december valeant stock be latest ibd ranking top stock hit time high monday be fraction new high early trading stock market today
1765,AGN,stock ease only slightly early lows volume fade midday session punctuate dramatic gain loss
1766,AGN,dow jone industrial average be nasdaq maintain loss trade quiet be nasdaq nyse compare action same time tuesday
1767,AGN,stock market today have fought battle onslaught weak economic news april private sector job march construction spending april manufacturing activity undercut analyst expectation
1768,AGN,gauge purchasing manager manufacturing index slip march analyst have project decline
1769,AGN,medical sector stock propel large piece wednesday action humana hum remain positive first quarter result
1770,AGN,ibd list regeneron pharmaceutical regn erupt huge trade management peer allergan agn announce vision loss drug darpin face possible approval delay year base datum phase trial
1771,AGN,also goldman sachs raise price target regeneron report cite positive result informal survey gauge cardiologist lipidologist awareness cholesterol drug joint venture regenron sanofi sny
1772,AGN,tarrytown base biotech clear cup base buy point early april be now extend buy point sanofi share slip
1773,AGN,allergan tank diving day move average very heavy trade
1774,AGN,base chip designer arm holding armh climb ride surge volume new high move put share almost past buy point flat base april
1775,AGN,software maker also post strong move thinly trade ultimate software group ulti vaulting lead midcap index
1776,AGN,solarwind swi go other direction company report mixed first quarter result late tuesday stock have be back away mid march high be well converge week move average
1777,AGN,federal open market committee wrapped day policy meeting statement set release et comment be carefully dissect hint shift attitude board investor generally expect change current monetary strategy
1778,AGN,commerce department plan release april auto truck sale datum
1779,AGN,busy hour session be set include earning report daniel adm avis budget group car polyone pol facebook fb stock ease only slightly early lows volume fade midday session punctuate dramatic gain loss dow jone industrial average be nasdaq maintain loss trade quiet be nasdaq nyse compare action same time tuesday stock market today have fought battle onslaught weak economic news april private sector job march construction spending april manufacturing activity undercut analyst expectation gauge purchasing manager manufacturing index slip march analyst have project decline medical sector stock propel large piece wednesday action humana hum remain positive first quarter result ibd list regeneron pharmaceutical regn erupt huge trade management peer allergan agn announce vision loss drug darpin face possible approval delay year base datum phase trial also goldman sachs raise price target regeneron report cite positive result informal survey gauge cardiologist lipidologist awareness cholesterol drug joint venture regenron sanofi sny tarrytown base biotech clear cup base buy point early april be now extend buy point sanofi share slip allergan tank diving day move average very heavy trade base chip designer arm holding armh climb ride surge volume new high move put share almost past buy point flat base april software maker also post strong move thinly trade ultimate software group ulti vaulting lead midcap index solarwind swi go other direction company report mixed first quarter result late tuesday stock have be back away mid march high be well converge week move average federal open market committee wrapped day policy meeting statement set release et comment be carefully dissect hint shift attitude board investor generally expect change current monetary strategy commerce department plan release april auto truck sale datum busy hour session be set include earning report daniel adm avis budget group car polyone pol facebook fb
1780,AGN,stock slip first day more give back prior day gain big raft economic corporate news volume cool suggest institutional investor weren desperate sell major index fall close virtually session lows nasdaq fall surrender tuesday gain more
1781,AGN,major average remain moderately lower weak volume late monday afternoon worry government shutdown
1782,AGN,dow jone industrial average lose pare earlier decline pierce day move average early session re-cover bit be trading just key support level benchmark index fall nasdaq give
1783,AGN,preliminary datum show nyse nasdaq volume tracking slightly lower friday level
1784,AGN,stock market today software developer realpage rp slump heavy volume pare earlier loss realpage clear buy point week cup volume be weak stock decline early monday trigger sell rule
1785,AGN,ocwen financial ocn slip modest volume buyer servicer distressed mortgage loan remain add buy range buy point week tight entry
1786,AGN,meanwhile drugmaker actavis act dip strong trade many lead stock continue hold well market recent turmoil actavis be just recent high be past flat base entry
1787,AGN,other drug stock fared better jazz pharmaceutical jazz climb new high strong volume buy point week tight pattern
1788,AGN,wag be ahead earning report tuesday drugstore chain be still nearly buy point major average remain moderately lower weak volume late monday afternoon worry government shutdown dow jone industrial average lose pare earlier decline pierce day move average early session re-cover bit be trading just key support level benchmark index fall nasdaq give preliminary datum show nyse nasdaq volume tracking slightly lower friday level stock market today software developer realpage rp slump heavy volume pare earlier loss realpage clear buy point week cup volume be weak stock decline early monday trigger sell rule ocwen financial ocn slip modest volume buyer servicer distressed mortgage loan remain add buy range buy point week tight entry meanwhile drugmaker actavis act dip strong trade many lead stock continue hold well market recent turmoil actavis be just recent high be past flat base entry other drug stock fared better jazz pharmaceutical jazz climb new high strong volume buy point week tight pattern wag be ahead earning report tuesday drugstore chain be still nearly buy point
1789,AGN,market suffer big setback wednesday round top rate stock manage buck trend put new high biotech regeneron pharmaceutical regn shot record high news late stage trial rival allergan agn vision loss drug darpin be delay year regeneron close past buy
1790,AGN,percent week ibd big cap list lead large cap growth stock be biotech name ve be lead just ve be mainstay list doesn mean re position buy major average continue act well distribution day count remain elevated addition number extend stock
1791,AGN,financial market be set resume normal trading wednesday day hiatus force superstorm sandy nasdaq omx group nyse euronext announce stock option other related market have normal schedule procedure wednesday morning cme group say future market also resume normal trading schedule stock option market have be close
1792,AGN,regeneron pharmaceutical share vault new high friday biotech beat analyst estimate expand ophthalmology portfolio acquisition regeneron regn quarterly sale rise nearly year earlier quarter handily beating analyst consensus ep gaap basis fall short estimate cent share
1793,AGN,botox maker allergan agn report mixed fourth quarter result early tuesday stock rise company guide unexpectedly strong earning year allergan say sale quarter rise year quarter shy analyst consensus accord thomson reuter earning share exclude time item rise
1794,AGN,stock be session lows wednesday ahead today fed statement et nasdaq lose dow jone industrial average fall nyse nasdaq volume be tracking lower tuesday average level not much turnover be tracking lower nasdaq lower
1795,AGN,biogen idec biib questcor pharmaceutical qcor other drugmaker rally friday upbeat news multiple sclerosis conference amsterdam biogen report much ticipate full result phase trial bg new oral ms drug study find mg dose twice time day halved relapse rate biogen share shot
1796,AGN,news multiple sclerosis drug be bust early friday major conference disease wrapped week amsterdam biggest news come biogen idec biib report much anticipate full result phase clinical trial bg new oral ms treatment study test dose mg twice day time day find dosage level cut relapse rate half investor be thrill biogen share be late morning enormous volume miller tabak analyst funtleyder tell ibd bg be lead candidate compete gilenya blockbuster drug launch last year novartis nvs gilenya be first oral treatment disease have previously be treat regime injection big deal haven be lot ms drug market recently say good have new drug come be more safe more effective more convenient other news meeting north american research committee multiple sclerosis release survey ms patient suffer relapse find do not respond traditional treatment corticosteroid bad news patient good news questcor pharmaceutical qcor lone drug acthar be approve exactly purpose datum confirm need additional treatment option ms relapse say questcor chief business officer steve cartt statement many patient do not respond adequately corticosteroid treatment acthar be viable treatment option questcor be late morning trading meanwhile allergan agn be twice average volume late thursday news come small study support use botulinum toxin better know botox treat arm tremor ms patient addition august fda approval botox aid bladder control patient ms other neurological disorder botox be also grant fda approval march treat increase muscle stiffness elbow wrist finger muscle person year older upper limb spasticity ul be also common ms patient
1797,AGN,estee lauder el report profit expectation early tuesday strong sale affluent customer continue spend high end cosmetic prestige make company know mac estee lauder brand say second quarter earning jump share beating analyst estimate cent sale rise estimate
1798,AGN,news be come thick fast medical sector wednesday send stock move direction swiss pharma giant novartis nvs be nearly early trading result beat expectation top bottom line profit share be prior year analyst have expect
1799,AGN,stock show positive muted response monday merger acquisition news market begin holiday shorten week nyse composite add nasdaq dow trade fractionally higher volume be sharply lower exchange significant economic datum tap day gold dollar climb early trade radware rdwr jump early trade put israel base network equipment maker buy point double bottom base stock break powerful gap dec news report be acquisition target riverb rvbd mesabi trust msb climb more strong trade rebound second day week move average stock sell wednesday thursday clear cause share end last week iron ore miner worst week april downside transglobe energy tga drop fat trade canadian oil producer fall hard past week have find support week move average share drop past week remain dec high
1800,AGN,valeant pharmaceutical vrx be lone leader ibd medical sector not only health care stock fund manager strategist see bright prospect mutual fund be big reason run up many stock sector fidelity contrafund boost position valeant celgene celg latest disclosure begin stake illumina ilmn franklin templeton global allocation open stake nordisk nvo alger capital appreciation begin play hca holding hca strategist fundamental other individual stock alec young global equity strategist capital iq say fish be swimming safe pond health care be insulation potential macroeconomic head wind say tim cunningham co manager thornburg core growth international growth like valeant diversify drug lineup valeant build menu acquire drug company get smaller stuff big pharmaceutical firm don care cunningham note don spend huge amount often do not pay have so many drug re not worry lose patent protection wall street consensus estimate put valeant earning earning be higher street estimate cunningham say consensus overlook cost cut valeant do medicis pharmaceutical recently acquire add aggressive guidancecelgene gap jan again jan aggressive long term earning guidance company say expect strong revenue performance drug not yet approve expect launch term say steven silver capital iq analyst launch drug dilute celgene reliance cancer treatment revlimid firm be trading discount biotech peer price earning growth ratio silver say dominant playernovo nordisk have do well be dominant player treatment diabetes be become epidemic say david heupel senior health care analyst follow thrivent fund large cap portfolio many peer drug have few patent expiration issue also like pipeline herman saftla cap iq analyst call allergan agn stronger player niche pharmaceutical be pioneer botox be poise exploit new application treat several eye ailment include macular degeneration medical stock silver say face risk unexpected rival emergence unexpected adverse effect stock run too fast get unattractively pricey saftla say sector face more political hurdle next few month young note
1801,AGN,investing drug stock isn quite investing other stock drugmaker share move earning buyout news anyone else really get investor excited be fda decision allow new drug market here be most important drug await approval next month
1802,AGN,note date be deadline sometimes agency render decision earlier
1803,AGN,march be showtime biogen idec biib agency decide fate multiple sclerosis candidate bg expectation blockbuster have be run high wall street drug study result have show be relatively safe effective treatment go head head new group oral treatment lead novartis nvs gilenya sanofi sny aubagio analyst consensus call truncate year alone expect ramp billion
1804,AGN,trial datum be good just everyone expect bg be approve main question be sort safety warning come label longer expect review time fda have be take revive story study tie bg kidney cancer animal first emerge year lead rumor get dread black box label go riskiest drug stock action however have underline investor confidence lately share hit time high early friday retreat slightly
1805,AGN,march ibd report last month unite therapeutic uthr shock wall street refile approval previously reject oral version bestselling lung drug remodulin fda not only accept filing give unusually short week review new application analyst time offer mixed opinion effort succeed stock market have be optimistic share rise refile be announce
1806,AGN,also march fda be set render verdict johnson johnson jnj invokana diabetes drug clinical trial compare favorably merck mrk popular januvia be interesting fda have be get hardline diabetes drug safety issue lately last month dismayed investor demand more datum nordisk nvo heart risk associate drug candidate insulin degludec thursday word get fda be investigate possible connection several diabetes drug include januvia pancreatic cancer
1807,AGN,april american turn cut income uncle sam investor allergan agn be hope return company recent buyout map pharmaceutical day fda be slate render verdict map lead product candidate levadex inhaled treatment migraine allergan make deal extend migraine franchise begin develop win approval use wrinkle treatment botox purpose analyst hope move allergan cycle resistant medical business make less dependent cosmetic procedure investing drug stock isn quite investing other stock drugmaker share move earning buyout news anyone else really get investor excited be fda decision allow new drug market here be most important drug await approval next month note date be deadline sometimes agency render decision earlier march be showtime biogen idec biib agency decide fate multiple sclerosis candidate bg expectation blockbuster have be run high wall street drug study result have show be relatively safe effective treatment go head head new group oral treatment lead novartis nvs gilenya sanofi sny aubagio analyst consensus call truncate year alone expect ramp billion trial datum be good just everyone expect bg be approve main question be sort safety warning come label longer expect review time fda have be take revive story study tie bg kidney cancer animal first emerge year lead rumor get dread black box label go riskiest drug stock action however have underline investor confidence lately share hit time high early friday retreat slightly march ibd report last month unite therapeutic uthr shock wall street refile approval previously reject oral version bestselling lung drug remodulin fda not only accept filing give unusually short week review new application analyst time offer mixed opinion effort succeed stock market have be optimistic share rise refile be announce also march fda be set render verdict johnson johnson jnj invokana diabetes drug clinical trial compare favorably merck mrk popular januvia be interesting fda have be get hardline diabetes drug safety issue lately last month dismayed investor demand more datum nordisk nvo heart risk associate drug candidate insulin degludec thursday word get fda be investigate possible connection several diabetes drug include januvia pancreatic cancer april american turn cut income uncle sam investor allergan agn be hope return company recent buyout map pharmaceutical day fda be slate render verdict map lead product candidate levadex inhaled treatment migraine allergan make deal extend migraine franchise begin develop win approval use wrinkle treatment botox purpose analyst hope move allergan cycle resistant medical business make less dependent cosmetic procedure
1808,AGN,sale growth be hard come today sluggish economy company big cap end report overall revenue decline first quarter top line growth be key continue bottom line gain not problem regeneron pharmaceutical regn linkedin lnkd google goog blackstone group bx hertz global holding htz
1809,AGN,day major average resume uptrend stock add modest gain tuesday otherwise quiet session nasdaq rise dow jone industrial average preliminary datum show nasdaq volume come higher monday nyse volume rise higher volume day today ve be nice
1810,AGN,update gilead science report fourth quarter profit cent share adjust just vs year earlier estimate revenue rise fractionally higher wall street have expect share edge rise fractionally higher regular session product sale climb royalty contract revenue fall
1811,AGN,delaware select growth fund slip lag midcap growth rival track morningstar rather diving foxhole ratchete back risk shift defensive name fund manager have stick knit fund commentary manager write regardless
1812,AGN,stock future be poise vastly higher open boost optimism deal debt ride greece
1813,AGN,nasdaq future surge point vs fair value future rally point dow future jump point euro gain dollar rebound week low
1814,AGN,corporate news bj wholesale club bj rise preopen trading news receive buyout offer security exchange commission filing reveal equity investor lp leonard green partner lp cvc capital partner offer buy nation warehouse retailer undisclosed sum
1815,AGN,former leader research motion rimm dive premarket trading deliver weaker expect sale late thursday blackberry smartphone maker also give weak outlook rival apple aapl make iphone gain premarket trading
1816,AGN,merit medical system mmsi drop premarket trading announce plan stock offer maker disposable medical device do not disclose size offer say proceed be used possible acquisition repay debt
1817,AGN,reuter university michigan sentiment index june be edt economist see slip
1818,AGN,lead economic indicator also be shortly projection call increase stock future be poise vastly higher open boost optimism deal debt ride greece nasdaq future surge point vs fair value future rally point dow future jump point euro gain dollar rebound week low corporate news bj wholesale club bj rise preopen trading news receive buyout offer security exchange commission filing reveal equity investor lp leonard green partner lp cvc capital partner offer buy nation warehouse retailer undisclosed sum former leader research motion rimm dive premarket trading deliver weaker expect sale late thursday blackberry smartphone maker also give weak outlook rival apple aapl make iphone gain premarket trading merit medical system mmsi drop premarket trading announce plan stock offer maker disposable medical device do not disclose size offer say proceed be used possible acquisition repay debt reuter university michigan sentiment index june be edt economist see slip lead economic indicator also be shortly projection call increase
1819,AGN,stock waver narrowly mixed finish friday mixed economic datum close solid gain week chevron cvx boee ba help dow jone industrial average gain broader nasdaq fall respectively volume drop sharply major exchange stock market today
1820,AGN,rumor mill be show sign let nearly month report first surface generic drug maker watson pharmaceutical wpi be close make biggest buyout ever
1821,AGN,accord latest report watson be track announce acquisition swiss drugmaker actavis end month
1822,AGN,deal go create world largest generic drug maker
1823,AGN,recent report reuter say bank be line back transaction bank america bac say be front runner watson reportedly be also be pursue several other large money center bank official drugmaker have decline comment
1824,AGN,rumor deal be first report march watson stock price shot day next day close share continue trade
1825,AGN,wall street immediately embraced deal fact sizable watson
1826,AGN,previous buyout
1827,AGN,company have make big buyout paid arrow group andrx year earlier nothing scale
1828,AGN,still most analyst say such transaction make sense watson
1829,AGN,need additional financial detail potential transaction believe combination have strong strategic rationale jpmorgan analyst chris schott note march report be meaningfully accretive earning give watson scale need compete globally
1830,AGN,month analyst have wonder watson pursue kind large scale deal kick much higher income bracket
1831,AGN,follow watson fourth quarter earning report february citigroup analyst john boris say watson chief executive paul bisaro have be very vocal acquisition watson note do large transaction watson also indicated be willing issue equity larger deal
1832,AGN,buyout actavis qualify deal privately hold firm top product include oxycodone pain medication kadian brand opioid pain reliever generic version ambien cr neurontin
1833,AGN,presentation actavis say business be come western europe come central eastern europe
1834,AGN,actavis also have operation asia latin america be make latin america priority recent year schott note
1835,AGN,advantage deal be help watson better compete larger generic drug firm such teva pharmaceutical industry teva novartis nov sandoz unit
1836,AGN,israel base teva be world largest generic drug maker sale last year sandoz have sale
1837,AGN,watson report sale last year analyst expect log year detail be available sale actavis
1838,AGN,much wall street keep eye watson possible buy actavis company have keep busy try grow revenue base other way
1839,AGN,april watson say food drug administration approve generic version viropharma vphm vancocin antibiotic viropharma have take step temporarily block generic vancocin watson have start shipping drug logged sale month end feb
1840,AGN,watson also recently announce fda approve company abbreviated new drug application generic version roche hold rhhby boniva drug treatment postmenopausal osteoporosis
1841,AGN,note zack equity research say sale boniva be year end jan
1842,AGN,meanwhile watson recently confirm have file abbreviated new drug application sell generic version allergan agn lumigan latisse drug allergan respond filing lawsuit watson district court eastern district texas
1843,AGN,financially watson have be strong run late earning have grow least last quarters revenue have rise least same period
1844,AGN,earning growth
1845,AGN,last quarter watson earn share prior year be steepest quarterly earning gain year top wall street view cent
1846,AGN,revenue climb line estimate sale generic drug show increase
1847,AGN,quarter also marked watson launch generic lipitor blockbuster cholesterol drug lipitor lose patent protection nov
1848,AGN,watson india ranbaxy be only company selling copycat version lipitor now other drugmaker be expect start selling version june
1849,AGN,watson have guide gross profit lipitor exclusivity translate sale note manoj garg analyst edelweiss research highlight watson have launch lipitor week prior ranbaxy garner significant market share
1850,AGN,watson also have small grow brand drug business post fourth quarter revenue prior year
1851,AGN,company be expect report first quarter result april analyst poll thomson reuter expect earning share prior year rumor mill be show sign let nearly month report first surface generic drug maker watson pharmaceutical wpi be close make biggest buyout ever accord latest report watson be track announce acquisition swiss drugmaker actavis end month deal go create world largest generic drug maker recent report reuter say bank be line back transaction bank america bac say be front runner watson reportedly be also be pursue several other large money center bank official drugmaker have decline comment rumor deal be first report march watson stock price shot day next day close share continue trade wall street immediately embraced deal fact sizable watson previous company have make big buyout paid arrow group andrx year earlier nothing scale still most analyst say such transaction make sense watson need additional financial detail potential transaction believe combination have strong strategic rationale jpmorgan analyst chris schott note march report be meaningfully accretive earning give watson scale need compete globally month analyst have wonder watson pursue kind large scale deal kick much higher income bracket follow watson fourth quarter earning report february citigroup analyst john boris say watson chief executive paul bisaro have be very vocal acquisition watson note do large transaction watson also indicated be willing issue equity larger deal buyout actavis qualify deal privately hold firm top product include oxycodone pain medication kadian brand opioid pain reliever generic version ambien cr neurontin presentation actavis say business be come western europe come central eastern europe actavis also have operation asia latin america be make latin america priority recent year schott note advantage deal be help watson better compete larger generic drug firm such teva pharmaceutical industry teva novartis nov sandoz unit israel base teva be world largest generic drug maker sale last year sandoz have sale watson report sale last year analyst expect log year detail be available sale actavis much wall street keep eye watson possible buy actavis company have keep busy try grow revenue base other way april watson say food drug administration approve generic version viropharma vphm vancocin antibiotic viropharma have take step temporarily block generic vancocin watson have start shipping drug logged sale month end feb watson also recently announce fda approve company abbreviated new drug application generic version roche hold rhhby boniva drug treatment postmenopausal osteoporosis note zack equity research say sale boniva be year end jan meanwhile watson recently confirm have file abbreviated new drug application sell generic version allergan agn lumigan latisse drug allergan respond filing lawsuit watson district court eastern district texas financially watson have be strong run late earning have grow least last quarters revenue have rise least same period earning growthlast quarter watson earn share prior year be steepest quarterly earning gain year top wall street view cent revenue climb line estimate sale generic drug show increase quarter also marked watson launch generic lipitor blockbuster cholesterol drug lipitor lose patent protection nov watson india ranbaxy be only company selling copycat version lipitor now other drugmaker be expect start selling version june watson have guide gross profit lipitor exclusivity translate sale note manoj garg analyst edelweiss research highlight watson have launch lipitor week prior ranbaxy garner significant market share watson also have small grow brand drug business post fourth quarter revenue prior year company be expect report first quarter result april analyst poll thomson reuter expect earning share prior year
1852,AGN,probably come surprise fund pursue capital appreciation have biggest chunk asset technology stock vast category have lot fast grower socially responsible investing have be decade shocker tech socially upright coexist tech be
1853,AGN,molecular diagnostic specialist myriad genetic mygn beat analyst fiscal sale estimate meet profit view late tuesday profit guidance come year come short send share nearly hour quarter end june myriad revenue rise year quarter beating analyst consensus more
1854,AGN,harley davidson hog share drop report second quarter profit early wednesday beat estimate sale come short top motorcycle maker isn alone automaker general motor gm ford motor chrysler group post surprisingly strong sale early year wednesday report lower expect july sale harley davidson earning share climb
1855,AGN,valeant pharmaceutical vrx soar new high friday multiple report cite source say deal buy contact lens maker bausch lomb be sort merger equal ceo michael pearson have say want bausch have sale last year
1856,AGN,frank sand jr be decisive yet patient touchstone sand capital select growth be stack best idea portfolio have just stock july money be work top name give idea plenty room portfolio have just scant annual
1857,AGN,lot drugmaker large small report quarterly result week many strong number keep biotech ethical drug ibd top industry group always company hit unexpected turbulence here day day recap drugmaker earning week news top drug company tuesday swiss pharma giant novartis nvs start thing
1858,AGN,stock stay session high friday buyer continue put money work dow jone industrial average hit new time high
1859,AGN,nasdaq rise add dow jone industrial average picked nasdaq volume be tracking higher thursday nyse volume rise
1860,AGN,economy create job april slightly ahead expectation unemployment rate tick lower big upward revision february march job growth be also welcome market
1861,AGN,stock market today several ibd component make big move many heavy volume proto lab prlb jump nearly double average volume new high stock try break week april didn make much progress share fall follow week heavy volume
1862,AGN,meanwhile green mountain coffee roaster gmcr touch fresh week high ahead earning report close share rise slightly heavier volume
1863,AGN,other big percentage gainer ibd include frac play silica holding slca worthington industry wor fleetcor technology flt system ddd
1864,AGN,earning news fortune brand home security fbhs break heavy volume rise clear flat base buy point late thursday ancillary housing play report profit cent share year well ahead view cent sale growth accelerate third straight quarter company also initiate quarterly dividend cent share give yield
1865,AGN,elsewhere earning regeneron pharmaceutical regn continue recent ascent rise heavy volume late thursday drugmaker report continue strong sale flagship drug eylea used treat age related wet macular degeneration lead cause blindness elderly first quarter profit soar share sale rise analyst be modele cent sale share regeneron soar earlier week allergan agn announce delay eye drug develop ve compete eylea
1866,AGN,new york mercantile exchange june gold trade ounce june oil trade barrel
1867,AGN,energy space oil gas producer bonzana creek energy bcei jump sluggish volume ahead earning report close strong quarter growth be expect profit see rise year cent share sale be forecast rise stock be work right side possible base be now week high stock stay session high friday buyer continue put money work dow jone industrial average hit new time high nasdaq rise add dow jone industrial average picked nasdaq volume be tracking higher thursday nyse volume rise economy create job april slightly ahead expectation unemployment rate tick lower big upward revision february march job growth be also welcome market stock market today several ibd component make big move many heavy volume proto lab prlb jump nearly double average volume new high stock try break week april didn make much progress share fall follow week heavy volume meanwhile green mountain coffee roaster gmcr touch fresh week high ahead earning report close share rise slightly heavier volume other big percentage gainer ibd include frac play silica holding slca worthington industry wor fleetcor technology flt system ddd earning news fortune brand home security fbhs break heavy volume rise clear flat base buy point late thursday ancillary housing play report profit cent share year well ahead view cent sale growth accelerate third straight quarter company also initiate quarterly dividend cent share give yield elsewhere earning regeneron pharmaceutical regn continue recent ascent rise heavy volume late thursday drugmaker report continue strong sale flagship drug eylea used treat age related wet macular degeneration lead cause blindness elderly first quarter profit soar share sale rise analyst be modele cent sale share regeneron soar earlier week allergan agn announce delay eye drug develop ve compete eylea new york mercantile exchange june gold trade ounce june oil trade barrel energy space oil gas producer bonzana creek energy bcei jump sluggish volume ahead earning report close strong quarter growth be expect profit see rise year cent share sale be forecast rise stock be work right side possible base be now week high
1868,AGN,canadian drugmaker valeant pharmaceutical international vrx beat analyst fourth quarter estimate thursday send already elevated stock valeant sale rise year earlier top analyst consensus accord thomson reuter profit exclude various acquisition cost climb share beating estimate cent full year
1869,AGN,stock option market be set remain close second day tuesday hurricane sandy storm surge flooded part new york city pound much east coast heavy rain electronic platform equity index future trading be open overnight close edt
1870,AGN,cme group close nymex trading floor maintain normal electronic trading commodity other future option
1871,AGN,stock bp bp report gain third quarter earning top analyst expectation decline revenue slip better drop expect analyst company also boost dividend more cent share bp agree last week sell half russian joint venture tnk bp russian state own oil operator rosneft cash stake rosneft
1872,AGN,grain trader agribusiness giant daniel adm report adjust ep cent top consensus estimate cent revenue slip less forecast profit company oilseed process unit second largest business revenue double
1873,AGN,allergan agn impax laboratory ipxl ipg photnic ipgp be schedule release earning tuesday polypore international ppo pricesmart psmt triumph group tgi be set report normally be market close
1874,AGN,overseas stock europe muscle solid gain midday cac paris lead china major index be narrowly mixed japan tokyo nikkei slump bank japan increase size asset buy stimulus program dollar slip vs euro italy borrow cost slip lowest level more year
1875,AGN,commodity be little change oil hover just barrel gold ounce economic calendar standard poor report august result case shiller city home price index be release plan edt stock option market be set remain close second day tuesday hurricane sandy storm surge flooded part new york city pound much east coast heavy rain electronic platform equity index future trading be open overnight close edt cme group close nymex trading floor maintain normal electronic trading commodity other future option stock bp bp report gain third quarter earning top analyst expectation decline revenue slip better drop expect analyst company also boost dividend more cent share bp agree last week sell half russian joint venture tnk bp russian state own oil operator rosneft cash stake rosneft grain trader agribusiness giant daniel adm report adjust ep cent top consensus estimate cent revenue slip less forecast profit company oilseed process unit second largest business revenue double allergan agn impax laboratory ipxl ipg photnic ipgp be schedule release earning tuesday polypore international ppo pricesmart psmt triumph group tgi be set report normally be market close overseas stock europe muscle solid gain midday cac paris lead china major index be narrowly mixed japan tokyo nikkei slump bank japan increase size asset buy stimulus program dollar slip vs euro italy borrow cost slip lowest level more year commodity be little change oil hover just barrel gold ounce economic calendar standard poor report august result case shiller city home price index be release plan edt
1876,AGN,week big cap offer quite few name be consolidate be expect top stock do correction general market lineup also feature several big cap have moved new high even tough environment sometimes ll see top rate stock climb fresh peak
1877,AGN,big cap feature several stock buy range few more be just entry mark new market uptrend get way friday follow nasdaq discount retailer ross store rost be entry flat base putt upper limit buy area
1878,AGN,stock erased most gain thursday indicate apprehension ahead key job report friday nasdaq fall nearly be much dow jone industrial average save only advance
1879,AGN,volume be lower nasdaq nyse accord unconfirmed figure
1880,AGN,couple week day move average dow have be day move average so call death cross be sign longer term weakness not always predictor bear market
1881,AGN,netflix nflx fall fifth straight day remain day line report find view stream demand programming have climb sharply
1882,AGN,busy day economic report retail sale be chip telecom solar stock lead market today
1883,AGN,friday august job report come market open consensus estimate be increase new job economist expect jobless rate be nearly unchanged stock erased most gain thursday indicate apprehension ahead key job report friday nasdaq fall nearly be much dow jone industrial average save only advance volume be lower nasdaq nyse accord unconfirmed figure couple week day move average dow have be day move average so call death cross be sign longer term weakness not always predictor bear market netflix nflx fall fifth straight day remain day line report find view stream demand programming have climb sharply busy day economic report retail sale be chip telecom solar stock lead market today friday august job report come market open consensus estimate be increase new job economist expect jobless rate be nearly unchanged
1884,AGN,stock post nice gain wednesday lighter volume dampen want hear ibd analysis today market emerge stock click here watch market wrap video nasdaq tack nyse composite add nasdaq find support day move average nyse composite retook
1885,AGN,update stock step back tuesday post huge gain monday session
1886,AGN,nasdaq fall nyse composite dow index remain day move average
1887,AGN,turnover end lower board sign professional didn unload share
1888,AGN,knight capital nite reversed early gain slump active trading stock be turn tail upside few leader buck retreat
1889,AGN,quality system qsii gain set new record close high nearly twice average trade stock accumulation distribution rating have improve earlier month quality system make record management software health care sector
1890,AGN,green mountain coffee roaster gmcr add heavy trading also new record close high lift put coffee distributor past buy point deep handle
1891,AGN,datum february durable good new home sale be wednesday
1892,AGN,update stock close session lows
1893,AGN,vincent mao
1894,AGN,monday surge stock pull back follow weird session tuesday trading be choppy most session selling step latter half trade stock close session lows
1895,AGN,nasdaq drop nyse composite dow
1896,AGN,volume fall exchange avoid distribution day
1897,AGN,decliner beat advancer more exchange
1898,AGN,update comeback effort fade again
1899,AGN,vincent mao
1900,AGN,stock try rebound effort appear be wane less hour left tuesday session
1901,AGN,nasdaq drop weigh loss millicom international cellular micc amazon com amzn robinson worldwide chrw nyse composite lose respectively dow slip again peek positive territory dow component trade lower mcdonald mcd exxon mobil xom be biggest point loser
1902,AGN,turnover be tracking higher exchange
1903,AGN,pullback equity april gold settle ounce
1904,AGN,update rebound effort fade afternoon trade
1905,AGN,vincent mao
1906,AGN,foray mixed territory fade afternoon trading tuesday leave major index red once again
1907,AGN,nasdaq be still wear nyse composite lose meanwhile dow slip briefly poke positive ground
1908,AGN,volume be tracking roughly even compare same time monday nyse nasdaq turnover be tracking higher
1909,AGN,allergan agn surge speculation be takeover candidate glaxosmithkline gsk be number deal drugmaker recently late january pfizer pfe agree buy wyeth wye earlier month merck mrk say buy rival schering plough sgp
1910,AGN,baidu com bidu jump deutsche bank start coverage buy rating chinese internet search giant be close day move average have be trading line month
1911,AGN,shanda interactive entertainment snda reversed early loss gain month high put stock past buy point cup handle base earlier morning company announce partnership fellow gaming firm linekong
1912,AGN,update stock lower choppy trade
1913,AGN,vincent mao
1914,AGN,major stock index remain choppy action tuesday
1915,AGN,nasdaq be worst wear nyse composite fall dow
1916,AGN,volume be tracking slightly lower nyse tad higher nasdaq
1917,AGN,treasury secretary timothy geithner be news again be ask congress new power regulate nonbank financial firm demise hurt economy such american international group aig geithner tell house financial service committee aig highlight broad failure financial system say ensure country never face situation again
1918,AGN,athenahealth athn fall fifth straight decline stock accumulation distribution rating have crumble worst possible earning grow range past quarters analyst see growth slow current period athenahealth provide business service physician practice
1919,AGN,crucell crxl lose heavy trading breach day move average lose money number year biotech turn profit
1920,AGN,elsewhere gold lose more luster slip nearly just ounce oil fall barrel
1921,AGN,update market trim loss midday rebound
1922,AGN,jonah keri
1923,AGN,stock pare early session loss tuesday lead comeback nyse index
1924,AGN,nyse composite be dow industrial nasdaq hung biggest loss
1925,AGN,volume be tracking higher nasdaq lower nyse compare monday level
1926,AGN,bmc software bmc shed brisk volume enterprise service management software provider be form right side deep month base
1927,AGN,american state water awr drop rapid turnover water utility service company hold day line stock sit week high
1928,AGN,upside thinly trade diamond food dmnd add average trade food service provider nut producer have rebound day move average past day
1929,AGN,update stock retain loss
1930,AGN,update stock step back tuesday post huge gain monday session nasdaq fall nyse composite dow index remain day move average turnover end lower board sign professional didn unload share knight capital nite reversed early gain slump active trading stock be turn tail upside few leader buck retreat quality system qsii gain set new record close high nearly twice average trade stock accumulation distribution rating have improve earlier month quality system make record management software health care sector green mountain coffee roaster gmcr add heavy trading also new record close high lift put coffee distributor past buy point deep handle datum february durable good new home sale be wednesday update stock close session lowsby vincent maoafter monday surge stock pull back follow weird session tuesday trading be choppy most session selling step latter half trade stock close session lows nasdaq drop nyse composite dow volume fall exchange avoid distribution day decliner beat advancer more exchange update comeback effort fade againby vincent maostock try rebound effort appear be wane less hour left tuesday session nasdaq drop weigh loss millicom international cellular micc amazon com amzn robinson worldwide chrw nyse composite lose respectively dow slip again peek positive territory dow component trade lower mcdonald mcd exxon mobil xom be biggest point loser turnover be tracking higher exchange pullback equity april gold settle ounce update rebound effort fade afternoon tradeby vincent maoa foray mixed territory fade afternoon trading tuesday leave major index red once again nasdaq be still wear nyse composite lose meanwhile dow slip briefly poke positive ground volume be tracking roughly even compare same time monday nyse nasdaq turnover be tracking higher allergan agn surge speculation be takeover candidate glaxosmithkline gsk be number deal drugmaker recently late january pfizer pfe agree buy wyeth wye earlier month merck mrk say buy rival schering plough sgp baidu com bidu jump deutsche bank start coverage buy rating chinese internet search giant be close day move average have be trading line month shanda interactive entertainment snda reversed early loss gain month high put stock past buy point cup handle base earlier morning company announce partnership fellow gaming firm linekong update stock lower choppy tradeby vincent maomajor stock index remain choppy action tuesday nasdaq be worst wear nyse composite fall dow volume be tracking slightly lower nyse tad higher nasdaq treasury secretary timothy geithner be news again be ask congress new power regulate nonbank financial firm demise hurt economy such american international group aig geithner tell house financial service committee aig highlight broad failure financial system say ensure country never face situation again athenahealth athn fall fifth straight decline stock accumulation distribution rating have crumble worst possible earning grow range past quarters analyst see growth slow current period athenahealth provide business service physician practice crucell crxl lose heavy trading breach day move average lose money number year biotech turn profit elsewhere gold lose more luster slip nearly just ounce oil fall barrel update market trim loss midday reboundby jonah keristock pare early session loss tuesday lead comeback nyse index nyse composite be dow industrial nasdaq hung biggest loss volume be tracking higher nasdaq lower nyse compare monday level bmc software bmc shed brisk volume enterprise service management software provider be form right side deep month base american state water awr drop rapid turnover water utility service company hold day line stock sit week high upside thinly trade diamond food dmnd add average trade food service provider nut producer have rebound day move average past day update stock retain loss
1931,AGN,update drop continue jobless claim boost stock thursday most index hit best level november late day sell pare gain
1932,AGN,nyse composite climb dow gain respectively be much meanwhile late day retreat be most apparent nasdaq pare gain session index touch best level early october
1933,AGN,volume climb exchange
1934,AGN,green mountain coffee roaster gmcr have wild day gain more time average trade follow disappointing sale announcement late wednesday stock fall much reversed rally
1935,AGN,asiainfo holding asia end session high still rally more triple average trade stock also regain day move average
1936,AGN,reilly automotive orly climb nearly time average trade stock now past buy point cup handle base
1937,AGN,dow chemical dow gap gain month high chemical giant score biggest gain month report surprising profit
1938,AGN,earning friday allergan agn chevron cvx hms holding hmsy unite therapeutic uthr
1939,AGN,advance read second quarter gross domestic product employment cost index chicago pmi also be friday
1940,AGN,update index end session high
1941,AGN,vincent mao
1942,AGN,stock finished higher thursday late session retreat erased good chunk gain
1943,AGN,nyse composite rise intraday high gain dow nasdaq
1944,AGN,accord preliminary datum volume rise sharply board advancer beat decliner more nyse just nasdaq
1945,AGN,metal product distributor insurance chemical maker be thursday top perform group network service office supply firm be couple session worst performer
1946,AGN,update stock hold bulk gain late trade
1947,AGN,vincent mao
1948,AGN,major index hover high late trade thursday be pace close best level year
1949,AGN,nyse composite climb dow nasdaq
1950,AGN,turnover be still tracking vastly higher exchange
1951,AGN,newmarket neu climb fast trade regain chunk wednesday decline
1952,AGN,vistaprint vprt rise ahead earning report close analyst expect online printing service firm profit rise cent share
1953,AGN,walt disney edge brisk trade too report close entertainment medium giant earning be slate fall cent share
1954,AGN,piper jaffray start coverage neutral rating stock be laggard carry relative price strength mean market be do better price performance
1955,AGN,update index strengthen debt auction
1956,AGN,vincent mao
1957,AGN,major index remain session high regain ground stronger expect debt auction
1958,AGN,nyse composite rally dow nasdaq
1959,AGN,volume be again tracking sharply higher exchange
1960,AGN,government sell year note draw less expect yield
1961,AGN,unite therapeutic uthr jump food drug administration approve hypertension treatment
1962,AGN,green mountain coffee roaster gmcr perked nearly go red again share jump nearly surpass monday time high stock have have volatile day so far be more minute open
1963,AGN,reilly automotive orly rev new record high last wednesday auto part retailer report jump earning beating view company raise profit outlook ahead analyst estimate
1964,AGN,downside american medical system ammd gap drop heavy trading suntrust robinson humphrey cut medical device maker neutral buy
1965,AGN,update stock ease early afternoon trading
1966,AGN,vincent mao
1967,AGN,run morning stock pull back early afternoon trading
1968,AGN,nyse composite climb thank part rebound commodity related issue index be session peak
1969,AGN,meanwhile rally dow nasdaq
1970,AGN,turnover continue track sharply higher board
1971,AGN,steven madden shoo gap fly month high open shoemaker deliver jump earning rise sale be view raise full year profit outlook range share vs view steven madden now see revenue rise previously expect sale be flat
1972,AGN,asiainfo holding asia leap regain day move average late wednesday chinese software maker smash view surge profit
1973,AGN,carter cri rally year high put child apparel retailer past buy point cup base
1974,AGN,downside akamai technology akam gap day line plunge monster trade wednesday close internet content delivery firm report result view give weak sale outlook earlier wednesday jeffery co cut share hold buy drop price target
1975,AGN,update major index remain sharply higher midday
1976,AGN,jonah keri
1977,AGN,stock continue rally hold session high midday thursday
1978,AGN,nasdaq vault dow nyse
1979,AGN,volume swell board climb nyse nasdaq compare same period wednesday
1980,AGN,vistaprint vprt rise average volume provider customize marketing product recently find support day move average work tight consolidation
1981,AGN,arcsight arst surge brisk trade maker enterprise security management software be try rebound fall sharply high last week
1982,AGN,priceline com pcln climb nearly twice typical turnover discount online travel service provider marked week high fellow online travel site expedia expe report better expect quarterly result expedia stock rocket
1983,AGN,update stock build gain
1984,AGN,update drop continue jobless claim boost stock thursday most index hit best level november late day sell pare gain nyse composite climb dow gain respectively be much meanwhile late day retreat be most apparent nasdaq pare gain session index touch best level early october volume climb exchange green mountain coffee roaster gmcr have wild day gain more time average trade follow disappointing sale announcement late wednesday stock fall much reversed rally asiainfo holding asia end session high still rally more triple average trade stock also regain day move average reilly automotive orly climb nearly time average trade stock now past buy point cup handle base dow chemical dow gap gain month high chemical giant score biggest gain month report surprising profit earning friday allergan agn chevron cvx hms holding hmsy unite therapeutic uthr advance read second quarter gross domestic product employment cost index chicago pmi also be friday update index end session highsby vincent maostock finished higher thursday late session retreat erased good chunk gain nyse composite rise intraday high gain dow nasdaq accord preliminary datum volume rise sharply board advancer beat decliner more nyse just nasdaq metal product distributor insurance chemical maker be thursday top perform group network service office supply firm be couple session worst performer update stock hold bulk gain late tradeby vincent maothe major index hover high late trade thursday be pace close best level year nyse composite climb dow nasdaq turnover be still tracking vastly higher exchange newmarket neu climb fast trade regain chunk wednesday decline vistaprint vprt rise ahead earning report close analyst expect online printing service firm profit rise cent share walt disney edge brisk trade too report close entertainment medium giant earning be slate fall cent share piper jaffray start coverage neutral rating stock be laggard carry relative price strength mean market be do better price performance update index strengthen debt auctionby vincent maomajor index remain session high regain ground stronger expect debt auction nyse composite rally dow nasdaq volume be again tracking sharply higher exchange government sell year note draw less expect yield unite therapeutic uthr jump food drug administration approve hypertension treatment green mountain coffee roaster gmcr perked nearly go red again share jump nearly surpass monday time high stock have have volatile day so far be more minute open reilly automotive orly rev new record high last wednesday auto part retailer report jump earning beating view company raise profit outlook ahead analyst estimate downside american medical system ammd gap drop heavy trading suntrust robinson humphrey cut medical device maker neutral buy update stock ease early afternoon tradingby vincent maoafter run morning stock pull back early afternoon trading nyse composite climb thank part rebound commodity related issue index be session peak meanwhile rally dow nasdaq turnover continue track sharply higher board steven madden shoo gap fly month high open shoemaker deliver jump earning rise sale be view raise full year profit outlook range share vs view steven madden now see revenue rise previously expect sale be flat asiainfo holding asia leap regain day move average late wednesday chinese software maker smash view surge profit carter cri rally year high put child apparel retailer past buy point cup base downside akamai technology akam gap day line plunge monster trade wednesday close internet content delivery firm report result view give weak sale outlook earlier wednesday jeffery co cut share hold buy drop price target update major index remain sharply higher middayby jonah keristock continue rally hold session high midday thursday nasdaq vault dow nyse volume swell board climb nyse nasdaq compare same period wednesday vistaprint vprt rise average volume provider customize marketing product recently find support day move average work tight consolidation arcsight arst surge brisk trade maker enterprise security management software be try rebound fall sharply high last week priceline com pcln climb nearly twice typical turnover discount online travel service provider marked week high fellow online travel site expedia expe report better expect quarterly result expedia stock rocket update stock build gain
1985,AGN,update stock squander promising start close mixed thursday major index finished higher second straight month
1986,AGN,nasdaq give bulk gain near day move average close
1987,AGN,meanwhile dow fall nyse composite slip
1988,AGN,volume climb exchange
1989,AGN,month nasdaq jump best jump week end oct nyse composite rally dow
1990,AGN,green mountain coffee roaster gcmr gap rocket nearly time average trade stock surge stellar fiscal result news distribution deal wal mart store wmt earning news be announce late wednesday
1991,AGN,fellow coffee related stock starbucks sbux rally nearly more twice average trade peet coffee tea peet add
1992,AGN,neutral tandem tndm gap climb almost heavy trading provider wireless telecom service top view quarter triple digit earning growth
1993,AGN,elsewhere dow chemical dow gap surge deliver surprising profit revenue however miss analyst estimate
1994,AGN,economic calendar friday university michigan sentiment index factory order ism index
1995,AGN,earning allergan agn chevron cvx clorox clx dean food df mastercard
1996,AGN,update stock finish mixed rocky trading
1997,AGN,vincent mao
1998,AGN,rocky trading session end mixed result thursday nasdaq be lone gainer
1999,AGN,nasdaq rise well intraday high pare gain come point day move average
2000,AGN,dow fall nyse composite lose
2001,AGN,volume climb board advancer edge decliner nyse nasdaq advancer decliner be even
2002,AGN,genetic homebuilder be biggest decliner alternative energy heavy machinery score nice gain
2003,AGN,update index rebound late trade
2004,AGN,vincent mao
2005,AGN,major index bounce back late trading thursday be still well session high
2006,AGN,nasdaq be nyse composite dow
2007,AGN,turnover be again tracking higher exchange pace slow
2008,AGN,vistaprint vprt climb nearly fresh month high report earning close analyst see profit rise cent share earlier thursday provider online printing service inked multiyear pact fedex fdx
2009,AGN,athenahealth athn rise regain day move average ahead earning report close provider bill collection service be expect earn cent share sale
2010,AGN,downside pantry ptry reversed early gain fall convenience store operator report earning analyst see loss cent share
2011,AGN,update nasdaq hang tough other falter
2012,AGN,vincent mao
2013,AGN,stock turn mixed leave nasdaq only index black
2014,AGN,dow slip have be much respectively nyse composite be mostly unchanged meanwhile nasdaq be thank strength big cap techs
2015,AGN,volume be run sharply higher board
2016,AGN,akamai technology akam gap rally month high technically stock clear week tight pattern setup usually take place late wednesday provider content delivery service beat view rise earning also announce share buyback earlier thursday goldman sachs raise share neutral sell
2017,AGN,citrix system ctxs gap gain heavy trading wednesday close virtualization software maker deliver smaller expect drop profit broaden share buyback program company also expect flat slightly lower sale current quarter
2018,AGN,downside silgan holding slgn gap day move average drop slice day line open container maker report disappointing sale hurt lower average sale price also guide full year earning view
2019,AGN,fellow container maker crown holding cck lose sympathy
2020,AGN,update rally fade early afternoon trading
2021,AGN,vincent mao
2022,AGN,major stock index pull back sharply early afternoon trade thursday nasdaq nearly hit day move average
2023,AGN,tech laden index be much trimming gain nyse composite rise dow add
2024,AGN,volume be tracking vastly higher board
2025,AGN,first solar fslr gap day move average surge heavy trading late wednesday maker solar module smash view pop earning jump sale stock have be trading day line september
2026,AGN,group mate sunpower spwra rally upgrade suntech power holding stp gain
2027,AGN,peet coffee tea peet add trade month high brisk volume coffee shop operator rally competitor starbucks sbux peet sit buy point cup base watch possible handle
2028,AGN,peet report result tuesday beating estimate earning miss sale starbucks report wednesday edge past view earning miss sale
2029,AGN,downside medasset mda gap lower fall downgrade be more session lows jeffery co cut share hold buy medasset make software health care provider
2030,AGN,update major index trim gain slightly midday
2031,AGN,jonah keri
2032,AGN,stock pare rally back bit midday thursday most morning gain remain intact
2033,AGN,nasdaq gain dow nyse composite small cap fared best motor
2034,AGN,volume surge board rise nyse nasdaq compare same period wednesday
2035,AGN,peet coffee tea peet jump brisk trade chain be rally step starbucks sbux green mountain coffee roaster gmcr bullish earning report
2036,AGN,electronic medical record management software maker quality system qsii vault average volume hit time high financial software maker advent software advs picked
2037,AGN,newmarket neu gain twice typical turnover chemical additive maker be pace eighth straight day gain
2038,AGN,update stock maintain rally chrysler bankruptcy news
2039,AGN,update stock squander promising start close mixed thursday major index finished higher second straight month nasdaq give bulk gain near day move average close meanwhile dow fall nyse composite slip volume climb exchange month nasdaq jump best jump week end oct nyse composite rally dow green mountain coffee roaster gcmr gap rocket nearly time average trade stock surge stellar fiscal result news distribution deal wal mart store wmt earning news be announce late wednesday fellow coffee related stock starbucks sbux rally nearly more twice average trade peet coffee tea peet add neutral tandem tndm gap climb almost heavy trading provider wireless telecom service top view quarter triple digit earning growth elsewhere dow chemical dow gap surge deliver surprising profit revenue however miss analyst estimate economic calendar friday university michigan sentiment index factory order ism index earning allergan agn chevron cvx clorox clx dean food df mastercard update stock finish mixed rocky tradingby vincent maoa rocky trading session end mixed result thursday nasdaq be lone gainer nasdaq rise well intraday high pare gain come point day move average dow fall nyse composite lose volume climb board advancer edge decliner nyse nasdaq advancer decliner be even genetic homebuilder be biggest decliner alternative energy heavy machinery score nice gain update index rebound late tradeby vincent maomajor index bounce back late trading thursday be still well session high nasdaq be nyse composite dow turnover be again tracking higher exchange pace slow vistaprint vprt climb nearly fresh month high report earning close analyst see profit rise cent share earlier thursday provider online printing service inked multiyear pact fedex fdx athenahealth athn rise regain day move average ahead earning report close provider bill collection service be expect earn cent share sale downside pantry ptry reversed early gain fall convenience store operator report earning analyst see loss cent share update nasdaq hang tough other falterby vincent maostock turn mixed leave nasdaq only index black dow slip have be much respectively nyse composite be mostly unchanged meanwhile nasdaq be thank strength big cap techs volume be run sharply higher board akamai technology akam gap rally month high technically stock clear week tight pattern setup usually take place late wednesday provider content delivery service beat view rise earning also announce share buyback earlier thursday goldman sachs raise share neutral sell citrix system ctxs gap gain heavy trading wednesday close virtualization software maker deliver smaller expect drop profit broaden share buyback program company also expect flat slightly lower sale current quarter downside silgan holding slgn gap day move average drop slice day line open container maker report disappointing sale hurt lower average sale price also guide full year earning view fellow container maker crown holding cck lose sympathy update rally fade early afternoon tradingby vincent maomajor stock index pull back sharply early afternoon trade thursday nasdaq nearly hit day move average tech laden index be much trimming gain nyse composite rise dow add volume be tracking vastly higher board first solar fslr gap day move average surge heavy trading late wednesday maker solar module smash view pop earning jump sale stock have be trading day line september group mate sunpower spwra rally upgrade suntech power holding stp gain peet coffee tea peet add trade month high brisk volume coffee shop operator rally competitor starbucks sbux peet sit buy point cup base watch possible handle peet report result tuesday beating estimate earning miss sale starbucks report wednesday edge past view earning miss sale downside medasset mda gap lower fall downgrade be more session lows jeffery co cut share hold buy medasset make software health care provider update major index trim gain slightly middayby jonah keristock pare rally back bit midday thursday most morning gain remain intact nasdaq gain dow nyse composite small cap fared best motor volume surge board rise nyse nasdaq compare same period wednesday peet coffee tea peet jump brisk trade chain be rally step starbucks sbux green mountain coffee roaster gmcr bullish earning report electronic medical record management software maker quality system qsii vault average volume hit time high financial software maker advent software advs picked newmarket neu gain twice typical turnover chemical additive maker be pace eighth straight day gain update stock maintain rally chrysler bankruptcy news
2040,AGN,update stock finished mixed lackluster session friday close week month gain
2041,AGN,mixed round economic datum fail sway major index much way open commerce say economy contract second quarter better view drop be sharp revision gdp consumer spending component fall
2042,AGN,nyse composite climb dow nasdaq settle lower rise much
2043,AGN,volume rise nyse fall nasdaq
2044,AGN,week nyse composite climb dow nasdaq nyse composite also outperformed month surge dow rally nasdaq
2045,AGN,abaxis abax gap vault week high huge trade late thursday maker blood analysis system blow past view jump earning rise sale
2046,AGN,mcafee mfe rally more twice average trade late thursday software maker deliver result view give outlook line analyst estimate company agree buy privately own mx logic
2047,AGN,fuqi international fuqi rise new high chinese jewelry retailer jump pricing share
2048,AGN,downside synaptic syna gap day move average dive more time normal volume late thursday maker touchpad control give weak sale outlook friday morning broker downgrade stock
2049,AGN,earning monday anadarko petroleum apc chesapeake energy chk herbalife hlf humana hum loews mgm mirage mgm molson coor brewing tap micro software smsi stec stec wm industry wm wonder auto technology watg
2050,AGN,datum construction spending ism vehicle sale also be monday
2051,AGN,update index end mixed soft trade
2052,AGN,vincent mao
2053,AGN,stock close narrowly mixed follow quiet choppy session friday
2054,AGN,nyse composite gain dow meanwhile nasdaq slip
2055,AGN,volume drop board
2056,AGN,office supply store tire maker rv manufacturer be few friday top perform issue computer peripheral maker hospital operator solar stock be session worst performer
2057,AGN,update stock track weekly monthly gain
2058,AGN,vincent mao
2059,AGN,stock ease briefly touch new session high late trading friday still major index be pace end week month gain
2060,AGN,nyse composite be dow rise meanwhile nasdaq edge
2061,AGN,turnover be tracking lower exchange
2062,AGN,gold producer shine precious metal jump settle ounce
2063,AGN,anglogold ashanti gold corp gg gain randgold resource gold rise
2064,AGN,american superconductor amsc bounce back loss climb earlier friday raymond james cut electrical equipment maker market perform outperform
2065,AGN,downside vistaprint vprt trim loss stock also regain day move average
2066,AGN,update stock tick higher still range
2067,AGN,vincent mao
2068,AGN,stock improve bit trading continue be mostly sideway last trading session july
2069,AGN,nyse composite climb dow nasdaq rise
2070,AGN,volume continue track vastly lower exchange advancer beat decliner nyse nasdaq
2071,AGN,citi trend ctrn erased morning loss climb brisk trade family apparel retailer report result aug analyst be expect earning nickel share sale citi trend sit past buy point cup base
2072,AGN,oshkosh osk also reversed earlier loss rally new week high earlier morning sterne agee cut truck maker neutral buy
2073,AGN,downside genzyme genz erased earlier gain drop news food drug administration plan reinspect allston mass plant fda have allege manufacturing deficiency
2074,AGN,update stock stick range
2075,AGN,vincent mao
2076,AGN,stock be modestly higher early afternoon friday trading have be mostly sideway
2077,AGN,nyse composite rise dow nasdaq edge be mostly unchanged
2078,AGN,exception nasdaq major index have yet take thursday high low
2079,AGN,nasdaq dip briefly thursday low hasn make run thursday intraday high
2080,AGN,turnover be again tracking lower board
2081,AGN,taleo tleo reversed morning loss rally brisk trade late thursday maker talent management software beat view jump profit
2082,AGN,mcafee mfe rally fast trade late thursday security software maker deliver result view announce acquisition stock recoup previous session decline
2083,AGN,downside synaptic syna gap day move average plunge huge trade late thursday touchpad maker report fiscal result view give weak sale outlook first quarter morning lazard caris collin stewart jeffery downgrade stock
2084,AGN,unite therapeutic uthr reversed earlier gain drop heavy trading open biotech report loss cent share vs expectation profit cent share wedbush morgan cut share neutral outperform
2085,AGN,update major index retain gain midday
2086,AGN,jonah keri
2087,AGN,stock trade modestly higher midday friday volume turn lower
2088,AGN,dow nasdaq rise add nyse composite gain
2089,AGN,volume turn lower board
2090,AGN,lender process service lp rise nearly twice normal trade provider tech service mortgage lend industry stage breakaway gap week base thursday follow bullish earning report
2091,AGN,priceline com pcln gain average volume discount travel service provider marked week high
2092,AGN,downside hms holding hmsy drop huge turnover provider financial service health care industry match profit view send stock slide day move average intraday hms have pare much early loss
2093,AGN,update stock hold modest gain
2094,AGN,update stock finished mixed lackluster session friday close week month gain mixed round economic datum fail sway major index much way open commerce say economy contract second quarter better view drop be sharp revision gdp consumer spending component fall nyse composite climb dow nasdaq settle lower rise much volume rise nyse fall nasdaq week nyse composite climb dow nasdaq nyse composite also outperformed month surge dow rally nasdaq abaxis abax gap vault week high huge trade late thursday maker blood analysis system blow past view jump earning rise sale mcafee mfe rally more twice average trade late thursday software maker deliver result view give outlook line analyst estimate company agree buy privately own mx logic fuqi international fuqi rise new high chinese jewelry retailer jump pricing share downside synaptic syna gap day move average dive more time normal volume late thursday maker touchpad control give weak sale outlook friday morning broker downgrade stock earning monday anadarko petroleum apc chesapeake energy chk herbalife hlf humana hum loews mgm mirage mgm molson coor brewing tap micro software smsi stec stec wm industry wm wonder auto technology watg datum construction spending ism vehicle sale also be monday update index end mixed soft tradeby vincent maostock close narrowly mixed follow quiet choppy session friday nyse composite gain dow meanwhile nasdaq slip volume drop board office supply store tire maker rv manufacturer be few friday top perform issue computer peripheral maker hospital operator solar stock be session worst performer update stock track weekly monthly gainsby vincent maostock ease briefly touch new session high late trading friday still major index be pace end week month gain nyse composite be dow rise meanwhile nasdaq edge turnover be tracking lower exchange gold producer shine precious metal jump settle ounce anglogold ashanti gold corp gg gain randgold resource gold rise american superconductor amsc bounce back loss climb earlier friday raymond james cut electrical equipment maker market perform outperform downside vistaprint vprt trim loss stock also regain day move average update stock tick higher still rangeby vincent maostock improve bit trading continue be mostly sideway last trading session july nyse composite climb dow nasdaq rise volume continue track vastly lower exchange advancer beat decliner nyse nasdaq citi trend ctrn erased morning loss climb brisk trade family apparel retailer report result aug analyst be expect earning nickel share sale citi trend sit past buy point cup base oshkosh osk also reversed earlier loss rally new week high earlier morning sterne agee cut truck maker neutral buy downside genzyme genz erased earlier gain drop news food drug administration plan reinspect allston mass plant fda have allege manufacturing deficiency update stock stick rangeby vincent maostock be modestly higher early afternoon friday trading have be mostly sideway nyse composite rise dow nasdaq edge be mostly unchanged exception nasdaq major index have yet take thursday high low nasdaq dip briefly thursday low hasn make run thursday intraday high turnover be again tracking lower board taleo tleo reversed morning loss rally brisk trade late thursday maker talent management software beat view jump profit mcafee mfe rally fast trade late thursday security software maker deliver result view announce acquisition stock recoup previous session decline downside synaptic syna gap day move average plunge huge trade late thursday touchpad maker report fiscal result view give weak sale outlook first quarter morning lazard caris collin stewart jeffery downgrade stock unite therapeutic uthr reversed earlier gain drop heavy trading open biotech report loss cent share vs expectation profit cent share wedbush morgan cut share neutral outperform update major index retain gain middayby jonah keristock trade modestly higher midday friday volume turn lower dow nasdaq rise add nyse composite gain volume turn lower board lender process service lp rise nearly twice normal trade provider tech service mortgage lend industry stage breakaway gap week base thursday follow bullish earning report priceline com pcln gain average volume discount travel service provider marked week high downside hms holding hmsy drop huge turnover provider financial service health care industry match profit view send stock slide day move average intraday hms have pare much early loss update stock hold modest gain
2095,AGN,update major index squeeze gain backdrop mixed earning economic datum stock seesaw most session buyer come final minute trade
2096,AGN,nyse climb thank commodity related issue financial weigh accord medium report federal reserve unveil stress test result
2097,AGN,meanwhile dow tack nasdaq add
2098,AGN,turnover drop exchange
2099,AGN,stock finished higher week nyse composite rise dow nasdaq extend weekly streak rise
2100,AGN,general cable bgc gap vault time average volume wire cable maker surge follow better expect report outlook stock still sit week high
2101,AGN,hms holding hmsy gap day line rally nearly twice average trade stock shape cup base buy point base have more distribution accumulation
2102,AGN,longtop financial technology lft run double average volume chinese financial software maker clear buy point pullback week move average
2103,AGN,downside cna surety tumble slice day move average heavy trading open provider surety contract surety bond report bigger forecast drop profit
2104,AGN,datum pending home sale construction spending be monday well earning myriad genetic mygn sohu com sohu sprint nextel
2105,AGN,update stock end higher thank late day push
2106,AGN,vincent mao
2107,AGN,stock close higher choppy session friday thank largely late session rally
2108,AGN,nyse composite rise dow rise nasdaq edge
2109,AGN,volume drop sharply exchange
2110,AGN,advancer beat decliner nearly nyse nasdaq
2111,AGN,steel metal energy issue score nice gain insurance firm homebuilder stumble
2112,AGN,update stock pare gain late trade
2113,AGN,vincent mao
2114,AGN,major index trim gain head final hour trade friday be still pace close higher week
2115,AGN,nyse composite be session high rise dow meanwhile nasdaq composite be mostly unchanged
2116,AGN,volume be again tracking vast lower exchange
2117,AGN,research motion rimm rally best level month ub upgrade blackberry smart phone maker buy neutral raise target price broker base upgrade belief company see demand business user once economy pick
2118,AGN,rival apple aapl make iphone rise stock be pace eighth straight weekly gain
2119,AGN,green mountain coffee roaster gmcr reversed gain slip
2120,AGN,update index improve volume still soft
2121,AGN,vincent mao
2122,AGN,major index break away narrow trading range hit new session high
2123,AGN,nyse composite rally boost energy metal steel stock rise dow nasdaq gain
2124,AGN,turnover be tracking sharply lower board
2125,AGN,general cable bgc gap surge month high report much smaller expect drop profit open maker copper fiber optic cable say earning fall cent share cent view also guide full year income estimate cl king raise stock accumulate neutral
2126,AGN,longtop financial technology lft extend gain touch month high chinese financial software maker sit just buy point pullback week move average
2127,AGN,aon aoc gap day move average shed miss view insurance broker earning rise cent share cent view sale slip analyst estimate
2128,AGN,gen probe gpro gap day move average slump slice day line late thursday diagnostic test maker deliver result view give full year guidance be mostly line
2129,AGN,update nyse composite gain other waver
2130,AGN,vincent mao
2131,AGN,major index continue vacillate early afternoon trading friday
2132,AGN,nyse composite climb thank strength energy sector rise meanwhile dow nasdaq edge apiece
2133,AGN,volume be again trading sharply lower board
2134,AGN,hms holding hmsy gap day move average surge top view open provider cost control service health care program report jump earning rise sale stock be featured today base reader
2135,AGN,netlogic microsystem netl rally fresh month high heavy trading late thursday chipmaker report smaller expect drop earning sale also late thursday company agree buy integrate device technology idti search engine business
2136,AGN,downside mastercard gap drop breach day move average downturn come credit card firm deliver better expect first quarter result
2137,AGN,update stock trade tight range midday
2138,AGN,jonah keri
2139,AGN,major index continue show mixed action midday friday market show little change
2140,AGN,nasdaq slip dow industrial slide nyse composite rise
2141,AGN,volume be tracking lower board sank nasdaq nyse compare same period thursday
2142,AGN,peet coffee tea peet continue rally step fellow coffee stock gain average volume stock have surge monday close
2143,AGN,illumina ilmn edge brisk turnover developer system gene analysis other used be build right side deep base start last summer
2144,AGN,downside dolby laboratory dlb slip triple normal trade late thursday sound system licensing company top fiscal second quarter earning view tighten full year outlook jpmorgan chase downgrade stock neutral overweight rating
2145,AGN,buffalo wild wing bwld drop rapid turnover casual restaurant chain be pace third straight day average volume
2146,AGN,update stock turn mostly lower light trade
2147,AGN,update major index squeeze gain backdrop mixed earning economic datum stock seesaw most session buyer come final minute trade nyse climb thank commodity related issue financial weigh accord medium report federal reserve unveil stress test result meanwhile dow tack nasdaq add turnover drop exchange stock finished higher week nyse composite rise dow nasdaq extend weekly streak rise general cable bgc gap vault time average volume wire cable maker surge follow better expect report outlook stock still sit week high hms holding hmsy gap day line rally nearly twice average trade stock shape cup base buy point base have more distribution accumulation longtop financial technology lft run double average volume chinese financial software maker clear buy point pullback week move average downside cna surety tumble slice day move average heavy trading open provider surety contract surety bond report bigger forecast drop profit datum pending home sale construction spending be monday well earning myriad genetic mygn sohu com sohu sprint nextel update stock end higher thank late day pushby vincent maostock close higher choppy session friday thank largely late session rally nyse composite rise dow rise nasdaq edge volume drop sharply exchange advancer beat decliner nearly nyse nasdaq steel metal energy issue score nice gain insurance firm homebuilder stumble update stock pare gain late tradeby vincent maomajor index trim gain head final hour trade friday be still pace close higher week nyse composite be session high rise dow meanwhile nasdaq composite be mostly unchanged volume be again tracking vast lower exchange research motion rimm rally best level month ub upgrade blackberry smart phone maker buy neutral raise target price broker base upgrade belief company see demand business user once economy pick rival apple aapl make iphone rise stock be pace eighth straight weekly gain green mountain coffee roaster gmcr reversed gain slip update index improve volume still softby vincent maomajor index break away narrow trading range hit new session high nyse composite rally boost energy metal steel stock rise dow nasdaq gain turnover be tracking sharply lower board general cable bgc gap surge month high report much smaller expect drop profit open maker copper fiber optic cable say earning fall cent share cent view also guide full year income estimate cl king raise stock accumulate neutral longtop financial technology lft extend gain touch month high chinese financial software maker sit just buy point pullback week move average aon aoc gap day move average shed miss view insurance broker earning rise cent share cent view sale slip analyst estimate gen probe gpro gap day move average slump slice day line late thursday diagnostic test maker deliver result view give full year guidance be mostly line update nyse composite gain other waverby vincent maomajor index continue vacillate early afternoon trading friday nyse composite climb thank strength energy sector rise meanwhile dow nasdaq edge apiece volume be again trading sharply lower board hms holding hmsy gap day move average surge top view open provider cost control service health care program report jump earning rise sale stock be featured today base reader netlogic microsystem netl rally fresh month high heavy trading late thursday chipmaker report smaller expect drop earning sale also late thursday company agree buy integrate device technology idti search engine business downside mastercard gap drop breach day move average downturn come credit card firm deliver better expect first quarter result update stock trade tight range middayby jonah major index continue show mixed action midday friday market show little change nasdaq slip dow industrial slide nyse composite rise volume be tracking lower board sank nasdaq nyse compare same period thursday peet coffee tea peet continue rally step fellow coffee stock gain average volume stock have surge monday close illumina ilmn edge brisk turnover developer system gene analysis other used be build right side deep base start last summer downside dolby laboratory dlb slip triple normal trade late thursday sound system licensing company top fiscal second quarter earning view tighten full year outlook jpmorgan chase downgrade stock neutral overweight rating buffalo wild wing bwld drop rapid turnover casual restaurant chain be pace third straight day average volume update stock turn mostly lower light trade
2148,AGN,breaking news be turkey intelligence tell turkey take russian fighter jet have crossed turkish airspace early report suggest have warn fighter jet yet warning have fall deaf ears shot sky future turn sharply lower news go european mkts be also now sharply lower ftse cac dax eurostoxx spain italy more follow darkness turn light
2149,AGN,asian mkts close mixed overnight note european mkts be lower follow uninspire day yesterday here state well asia concern terrorist threat latest news continue dominate conversation brussel be lockdown straight day polouse hunt prime suspect responsible paris attack ally nation continue punish isis issue global travel warning ahead thanksgiving holiday yesterday stock rise open bell only sell moved close seem neither bull bear be really control mkt waffle major index finished day just south unchanged line dow lower pt nasdaq unchanged slip point small cap russell be only bright spot add pt trading volume be lighter so many stick sideline heel volatility see past few week concern upcoming macro datum due today remember week be usually good week stock think be new concern number front black friday cyber monday live reputation consider weak macro datum late be black friday really thing anyway sale have be go week now so almost comical see retailer be position then medium have say blowout black friday number yawn other hand many be now worry possibility more terrorist attack world week ahead so many celebrate holiday next week
2150,AGN,deal front yesterday bring news pfizer american base allergan agn ireland base have fact reach deal combine company allow pfizer pfe engage reverse merger take full advantage inversion trade speak last week deal value not only create world biggest drug maker also result huge tax saving newly combine company now be domicile dublin corp tax rate be fraction rate here state ink be not even dry yet morning paper scream start fault be happen pfizer be brilliant deal right take full advantage break corp tax system system have be break year dc choose address yes recognize have be talk ad naseum end have do nothing now be scream gop frontrunner donald call deal disgusting take direct aim politician say politician be ashamed tax system encourage such move coincidentally someone have used system advantage bankruptcy number time make wonder be position do inversion deal cut taxe sanction loop hole do be now run president so guess perspective change democrat not be do jump bandwagon well cousin bernie sander former senator call disgusting encourage current administration block hillary former senator secretary state first lady say sudden propose specific business tax proposal urge congress act immediately make sure biggest corporation pay fair share so taxpayer be not left hold bag
2151,AGN,interesting note here be sander clinton be member congress neither choose make corp tax policy individual tax policy top issue tenure now be run president so guess perspective change well funny work so political economic uncertainty hang couple recent volatility be wonder really trading be lackluster directionless usually see activity trend have run course direction mkt appear bit exhaust neither side be control kind action create technical pattern know spin top candlestick pattern spin top be candlestick pattern small real body represent tight trading range represent tug war bull bear have rather long tail end suggest side have control point day end backed technical pattern indicate neither bull bear be control be just spin wheel tight trading range suggest possible reversal trend be work possibility such reversal be enough keep trader investor sideline trend stabilize be shorten week still be slew economic datum next few day see report home sale personal consumption exp today look revise read rd qtr gdp expectation revision show rate vs initial read now know initial inventory build component be low side first go so revise inventory build be reason increase revision
2152,AGN,news latest attack russian jet change course conversation mkt action today macro datum today surprise mkts do not expect break thru resistance thru support yet new international headline be cause renew concern caution force mkts lower day move new uncertainty fact be russian fighter jet only cause more anxiety threaten escalate tension even more look support take good care kp
2153,AGN,kenny polcari be vice president director nyse floor operation behalf neil security inc sister company investor business daily market commentary be opinion author be base decade industry market experience however guarantee be make imply respect opinion commentary be not be intend be rely authoritative take substitution exercise judgment comment note herein not be construe offer sell solicitation offer buy sell financial product official statement endorsement neil security incorporate affiliate breaking news be turkey intelligence tell turkey take russian fighter jet have crossed turkish airspace early report suggest have warn fighter jet yet warning have fall deaf ears shot sky future turn sharply lower news go european mkts be also now sharply lower ftse cac dax eurostoxx spain italy more follow darkness turn light asian mkts close mixed overnight note european mkts be lower follow uninspire day yesterday here state well asia concern terrorist threat latest news continue dominate conversation brussel be lockdown straight day polouse hunt prime suspect responsible paris attack ally nation continue punish isis issue global travel warning ahead thanksgiving holiday yesterday stock rise open bell only sell moved close seem neither bull bear be really control mkt waffle major index finished day just south unchanged line dow lower pt nasdaq unchanged slip point small cap russell be only bright spot add pt trading volume be lighter so many stick sideline heel volatility see past few week concern upcoming macro datum due today remember week be usually good week stock think be new concern number front black friday cyber monday live reputation consider weak macro datum late be black friday really thing anyway sale have be go week now so almost comical see retailer be position then medium have say blowout black friday number yawn other hand many be now worry possibility more terrorist attack world week ahead so many celebrate holiday next week deal front yesterday bring news pfizer american base allergan agn ireland base have fact reach deal combine company allow pfizer pfe engage reverse merger take full advantage inversion trade speak last week deal value not only create world biggest drug maker also result huge tax saving newly combine company now be domicile dublin corp tax rate be fraction rate here state ink be not even dry yet morning paper scream start fault be happen pfizer be brilliant deal right take full advantage break corp tax system system have be break year dc choose address yes recognize have be talk ad naseum end have do nothing now be scream gop frontrunner donald call deal disgusting take direct aim politician say politician be ashamed tax system encourage such move coincidentally someone have used system advantage bankruptcy number time make wonder be position do inversion deal cut taxe sanction loop hole do be now run president so guess perspective change democrat not be do jump bandwagon well cousin bernie sander former senator call disgusting encourage current administration block hillary former senator secretary state first lady say sudden propose specific business tax proposal urge congress act immediately make sure biggest corporation pay fair share so taxpayer be not left hold bag interesting note here be sander clinton be member congress neither choose make corp tax policy individual tax policy top issue tenure now be run president so guess perspective change well funny work so political economic uncertainty hang couple recent volatility be wonder really trading be lackluster directionless usually see activity trend have run course direction mkt appear bit exhaust neither side be control kind action create technical pattern know spin top candlestick pattern spin top be candlestick pattern small real body represent tight trading range represent tug war bull bear have rather long tail end suggest side have control point day end backed technical pattern indicate neither bull bear be control be just spin wheel tight trading range suggest possible reversal trend be work possibility such reversal be enough keep trader investor sideline trend stabilize be shorten week still be slew economic datum next few day see report home sale personal consumption exp today look revise read rd qtr gdp expectation revision show rate vs initial read now know initial inventory build component be low side first go so revise inventory build be reason increase revision news latest attack russian jet change course conversation mkt action today macro datum today surprise mkts do not expect break thru resistance thru support yet new international headline be cause renew concern caution force mkts lower day move new uncertainty fact be russian fighter jet only cause more anxiety threaten escalate tension even more look support take good care kpkenny polcari be vice president director nyse floor operation behalf neil security inc sister company investor business daily market commentary be opinion author be base decade industry market experience however guarantee be make imply respect opinion commentary be not be intend be rely authoritative take substitution exercise judgment comment note herein not be construe offer sell solicitation offer buy sell financial product official statement endorsement neil security incorporate affiliate
2154,AGN,nearly universal experience get older fail eyesight middle age many start need glass focus fine detail problem get much more severe form old age vision loss be age related macular degeneration amd macula be very center retina so
2155,AGN,statement release medium source novartis ag nvs free report be set exit antibacterial antiviral research program swiss pharma giant also plan reduce headcount emeryville campus novartis institutes biomedical research nibr company be reportedly discussion license preclinical program well antibiotic lys candidate be be evaluate treatment complicate intra abdominal infection ciai complicate urinary tract infection cuti phase ii study company be process prioritize resource core area company however plan retain employee san francisco bay area novartis institute tropical disease nitd other function novartis be not only company exit space be once deem promising allergan agn free report too be reportedly look sell infectious disease unit earlier astrazeneca azn free report sell infective business primarily outside unite state pfizer pfe free report novartis be look restructure business late remind investor earlier month novartis announce intend spin ophthalmology division alcon separately trade standalone company order grow medicine company solely alcon business wasn perform management expectation do revive company decide spin same order focus better legacy drug business novartis have strong oncology portfolio drug afinitor exjade jakavi zykadia tasigna jadenu kisqali continue boost sale however be face loss patent protection key drug consequently company have restructure business plan focus build portfolio market promise potential novartis share have decline year so far compare industry gain novartis be look solidify presence gene therapy space earlier acquire base clinical stage gene therapy company avexis inc zack ranknovartis carry zack rank hold see complete list today zack rank strong buy stock here medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
2156,AGN,share adamis pharmaceutical admp free report surge company announce enter exclusive distribution agreement symjepi epinephrine swiss pharma giant novartis nvs free report generic arm sandoz term agreementper agreement sandoz own commercial right symjepi unite state exchange upfront fee potential performance base milestone payment company share profit equally note symjepi injection mg be approve fda use emergency treatment acute allergic reaction include anaphylaxis sandoz also get commercial right symjepi injection mg approval product be fda review now other hand adamis retain right commercialize product territory outside unite state sandoz however get first right negotiation such territory adamis also have option develop symject injection platform additional product candidate include naloxone product candidate be develop treat opioid overdose adamis gain adamis get novartis strong commercial partner give latter dominant position pharmaceutical market moreover financial term agreement be favorable adamis get upfront fee milestone payment remind investor symjepi compete mylan myl free report epipen adamis have be lookout commercial partner long earlier allergan agn free report have terminate license agreement commercialize product be then not approve fda hence agreement novartis bode well adamis news boost investor sentiment well adamis stock gain year so far outperform industry growth other hand addition symjepi further expand sandoz exist portfolio give market potential epinephrine zack rankadamis currently carry zack rank sell see complete list today zack rank strong buy stock here look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
2157,AGN,investor interested stock medical generic drug sector have probably already hear allergan agn free report amphastar pharmaceutical amph free report stock offer value investor better bang buck right now ll need take closer look be plenty strategy discover value stock have find pairing strong zack rank impressive grade value category style score system produce best return zack rank be proven strategy target company positive earning estimate revision trend style score work grade company base specific trait right now allergan be sporting zack rank buy amphastar pharmaceutical have zack rank strong sell system place emphasis company have see positive earning estimate revision so investor feel comfortable know agn be likely see earning outlook improve greater extent be just piece puzzle value investor value investor be also interested number try true valuation metric help show company be undervalue current share price level style score value grade factor variety key fundamental metric include popular ratio ratio earning yield cash flow share number other key stat be commonly used value investor agn currently have forward ratio amph have forward also note agn have peg ratio metric be used similarly famous ratio peg ratio also take account stock expect earning growth rate amph currently have peg ratio notable valuation metric agn be ratio be method compare stock market value book value be defined total asset total liability comparison amph have metric several other help agn earn value grade amph have be give value grade agn have see stronger estimate revision activity sport more attractive valuation metric amph so seem value investor conclude agn be superior option right now
2158,AGN,investor focuse medical space have likely hear allergan plc agn free report be stock perform well comparison rest sector peer let take closer look stock year date performance find allergan plc be individual stock medical sector collectively company sit zack sector rank zack sector rank consider different sector group average zack rank individual stock group be measure sector be list best worst zack rank be proven system emphasize earning estimate estimate revision highlight variety stock be display right characteristic beat market next month agn be currently sporting zack rank buy zack consensus estimate agn full year earning have moved higher past quarter show analyst sentiment have improve company earning outlook be stronger latest available datum show agn have return start calendar year comparison medical company have return average see allergan plc be perform better sector calendar year look more specifically agn belong medical generic drug industry group include individual stock currently sit zack industry rank average group have gain average so far year meaning agn be perform better term year date return investor interest medical stock continue track agn stock be look continue solid performance
2159,AGN,value investing be easily most popular way find great stock market environment wouldn want find stock be fly radar be compelling buy offer tantalize discount compare fair value way find company be look several key metric financial ratio many be crucial value stock selection process let put allergan plc agn free report stock equation find be good choice value oriented investor right now investor subscribe methodology look elsewhere top pick pe ratioa key metric value investor always look be price earning ratio pe short show much investor be willing pay dollar earning give stock be easily most popular financial ratio world best use pe ratio be compare stock current pe ratio ratio have be past compare average industry sector compare market whole front allergan have trail month pe ratio see chart level actually compare pretty favorably market large pe stand focus long term pe trend allergan current pe level put midpoint past year moreover current level be fairly high stock suggest be good entry point further stock pe also compare favorably sector trail month pe ratio stand very least indicate stock be relatively undervalue right now compare peer however point allergan have forward pe ratio price relative year earning so say forward earning estimate indicate company share price likely appreciate future ratioanother key metric note be price sale ratio approach compare give stock price total sale lower read be generally consider better person metric more other value focuse one look sale something be far harder manipulate accounting trick earning right now allergan have ratio be marginally higher average come right now nonetheless see chart current level be well high stock particular past few year anything agn be lower end range time period metric suggest level undervalue trading least compare historical norm broad value outlookin aggregate allergan currently have zack value style score putt top stock cover look make allergan solid choice value investor other key metric make pretty clear too example cf ratio great indicator value come be far better industry average stock overall allergan be good choice value investor be plenty other factor consider investing name particular be worth note company have growth grade momentum score give agn zack vgm score overarch fundamental grade read more zack style score here meanwhile company recent earning estimate have be trend higher current quarter have see estimate go higher past day compare none lower full year estimate have see upward downward revision same time period result current quarter consensus estimate have rise nearly past month full year estimate have inched see consensus estimate trend recent price action stock chart allergan plc price consensus allergan plc price consensus allergan plc somewhat favorable trend be stock have zack rank buy be look outperformance company term bottom lineallergan be inspire choice value investor be hard beat incredible lineup statistic front strong zack rank also indicate robust growth potential future however company prospect be constrain due adverse broader factor have sluggish industry rank bottom more industry fact past year industry have clearly underperform broader market see so value investor want broader factor turn name first once happen stock be compelling pick today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
2160,AGN,paratek pharmaceutical inc prtk free report announce fda advisory committee review new drug application nda lead antibiotic candidate omadacycline aug nda seek approval once daily oral intravenous iv dose omadacycline be file fda april year regulatory body grant priority review nda decision fda be expect early october candidate be also review eu decision be expect second half year omadacycline have be develop treatment community acquire bacterial pneumonia cabp acute bacterial skin skin structure infection absssi candidate enjoy qualify infectious disease product qidp fast track designation treat cabp absssi nda be support datum pivotal study absssi cabp omadacycline meet primary endpoint trial be generally safe well tolerate evaluation process omadacycline be also be develop therapy urinary tract infection apart omadacycline paratek acne candidate seysara be review unite state have be develop partnership allergan plc agn free report share paratek have plunge year date underperform industry decline paratek currently carry zack rank hold better rank stock same sector include crispr therapeutic ag crsp free report genomic health inc ghdx free report sporting zack rank strong buy see complete list today zack rank stock herecrispr therapeutic loss share estimate have be narrow last day stock have sky-rocket year date genomic health earning estimate have be revise upward past day stock have soar so far year make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
2161,AGN,allergan plc agn free report announce positive top line result phase iii study evaluate pipeline candidate bimatoprost sr bimatoprost sr be allergan investigational implant develop first sustain release drop free treatment option lower intraocular pressure iop patient open angle glaucoma ocular hypertension phase iii study compare bimatoprost sr apply patient open angle glaucoma ocular hypertension timolol eye drop trial used dosage bimatoprost sr administer cycle day week week compare timolol eye drop used twice daily month datum study show bimatoprost sr reduce iop approximately week primary efficacy period demonstrate inferiority case timolol well receive patient bimatoprost sr show potential patient stay treatment free more year last implant be insert glaucoma patient uncontrolled elevated iop lead vision loss order reduce elevated iop patient be prescribe eye drop however glaucoma patient fail use eye drop prescribe bimatoprost sr approve provide such patient option drop free therapy free daily eye drop regimen bimatoprost sr be design lower iop least month allergan be expect report additional datum result second phase iii study identical design first half new drug application nda filing fda be also anticipate second half remind investor earlier week allergan announce second cgrp candidate atogepant meet primary endpoint mid stage study cgp md study evaluate dose atogepant prevention episodic migraine week atogepant achieve reduction statistical significance monthly migraine probable migraine mpm headache day baseline dose allergan oral cgrp acute migraine treatment ubrogepant have already show positive result phase iii study however migraine market be grow extremely competitive amgen amgn free report partner novartis nvs free report receive approval commercialize cgrp drug aimovig treat episodic migraine so far year share allergan have increase compare industry rise allergan currently carry zack rank hold better rank stock large cap pharma sector be eli lilly company lly free report zack rank buy see complete list today zack rank strong buy stock hereeli lilly earning share estimate have be revise upward last day stock have inched year date medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
2162,AGN,allergan agn free report calcitonin gene related peptide cgrp candidate atogepant meet primary endpoint phase ii part phase iib iii study cgp md study be evaluate oral dosage candidate acute treatment episodic migraine meanwhile company have cgrp candidate ubrogepant pipeline demonstrated positive result phase iii study evaluate treatment single migraine attack positive datum readout cgp md study boost company cgrp pipeline company be currently discussion regulatory authority follow advance atogepant phase iii stage development allergan share have increase year so far industry rise cgp md study evaluate dose atogepant once daily mg mg mg twice daily mg mg prevention episodic migraine week atogepant achieve reduction statistical significance monthly migraine probable migraine mpm headache day baseline dose allergan present additional detail upcoming scientific meeting moreover potential approval candidate boost company migraine product line include botox treatment chronic migraine oral administration also help ubrogepant atogepant gain advantage other injectable drug approve meanwhile migraine space be attract lot interest due high unmet need several company be develop treatment disease amgen amgn free report partner novartis nvs free report receive approval commercialize cgrp drug aimovig treat episodic migraine other cgrp candidate development include eli lilly lly free report galcanezumab teva pharmaceutical fremanezumab eptinezumab galcanezumab fremanezumab be review unite state migarine be multus dollar market approximately person unite state suffering patient have episodic chronic migraine allergan plc price allergan plc price allergan plc quotezack rankallergan currently carry zack rank hold see complete list today zack rank strong buy stock here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
2163,AGN,amgen amgn free report announce european commission ec have approve label expansion blockbuster drug prolium drug be now approve treatment bone loss associate long term systemic glucocorticoid therapy adult patient increase risk fracture be also call glucocorticoid induced osteoporosis be third approve indication prolium europe approval be backed increase bone mineral density bmd achieve drug phase iii study similar line extension application receive approval unite state last month prolium be presently market europe treatment man postmenopausal woman osteoporosis high risk fracture well increase bone mass man prostate cancer receive hormone ablation amgen share have increase year so far industry decline phase iii study evaluate prolium improvement bmd patient receive glucocorticoid treatment compare allergan agn free report actonel risedronate study comprise patient group patient sustain glucocorticoid treatment glucocorticoid continue arm second patient initiate glucocorticoid therapy glucocorticoid initiate arm arm prolium demonstrated greater improvement lumbar spine bmd patient year year compare actonel study primary endpoint glucocorticoid induced osteoporosis be most common form secondary osteoporosis press release patient receive glucocorticoid treatment long term have show vertebral fracture proportion eligible patient be small line extension be likely boost sale drug further prolium be major revenue source amgen be witness growth market share unite state internationally competition generic other drug approve osteoporosis first quarter drug generate sale almost half dollar year year drug face competition generic other brand drug include eli lilly lly free report evista alendronate merck mrk free report fosamax raloxifene novartis zometa zoledronate amgen inc price amgen inc price amgen inc quotezack rankamgen currently carry zack rank hold see complete list today zack rank strong buy stock here hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
2164,AGN,week be rule cancer datum presentation annual meeting american society clinical oncology asco chicago pharma bigwig bristol myer bmy free report merck mrk free report roche rhhby free report other jak inhibitor be news week lilly lly free report finally gain fda approval rheumatoid arthritis ra candidate olumiant baricitinib unite state abbvie abbv free report present positive top line datum fifth late stage study upadacitinib ra recap week most important storiesupdate asco merck steal show asco present datum several cancer study pd inhibitor keytruda key presentation be pivotal lung cancer trial keynote study evaluate keytruda monotherapy newly diagnosed lung cancer patient keynote study evaluate keytruda combination chemotherapy difficult treat squamous small cell lung cancer nsclc study show treatment keytruda lead improve survival particularly datum keynote study evaluate keytruda combination chemotherapy first line treatment metastatic squamous nsclc be consider practice change investor year follow datum present advanced melanoma study show treatment keytruda lead long term survival benefit interim datum cohort phase ii study keynote evaluate keytruda monotherapy patient previously treat advanced small cell lung cancer sclc demonstrated encourage response rate overall population sclc patient well patient tumor express pd keytruda also demonstrated encourage orr study evaluate lenvima keytruda combination different tumor type keytruda monotherapy first line treatment advanced clear cell rcc bristol myer nektar therapeutic nktr present preliminary datum mid stage study evaluate nktr combination bristol myer pd inhibitor opdivo several tumor type response rate melanoma kidney cancer patient do not impress investor result drop nektar stock monday read more nektar bristol myer present datum cancer study bristol myer also present datum opdivo asco late stage study evaluate opdivo versus yervoy broad range patient resect stage iii iv melanoma opdivo demonstrated sustain superior recurrence free survival versus yervoy study opdivo chemotherapy show improve pfs versus chemotherapy first line lung cancer patient pd expression novartis nvs announce positive datum combination study breast cancer drug kisqali long term leukemia study tasigna read more novartis announce positive datum kisqali tasigna roche present datum late stage study show tecentriq atezolizumab chemotherapy reduce risk disease worsening death pfs advanced squamous nsclc patient versus chemotherapy alone abbvie present early datum phase ii study evaluate combination cancer drug imbruvica venclexta venetoclax first line treatment patient chronic lymphocytic leukemia cll datum demonstrated high rate response such patient also interim datum late stage study evaluate imbruvica roche rituxan waldenström rare form hodgkin lymphoma show combination significantly reduce risk disease progression death compare placebo rituxan pfizer pfe free report astrazeneca also make cancer datum presentation meeting lilly get fda nod lower dose olumiant eli lilly partner incyte gain fda approval lower dose mg company jak inhibitor olumiant fda do not approve higher dose mg drug label be approve box warning state risk serious infection malignancy thrombosis olumiant be already market europe japan generate sale first quarter unite state lilly face significant trouble get fda nod olumiant april last year fda have issue complete response letter new drug application seek approval olumiant request additional information determine most appropriate dose year april fda advisory committee have recommend approval lower dose drug not recommend higher dose mg inadequate safety profile support approval relative benefit read more eli lilly olumiant get fda nod rheumatoid arthritis abbvie late stage upadacitinib study succeed abbvie oral jak selective inhibitor upadacitinib meet primary well secondary endpoint fifth phase iii study select program top line datum study show thata significantly higher proportion patient treat upadacitinib mg dose achieve superior response compare chemotherapy agent methotrexate abbvie plan submit regulatory application upadacitinib rheumatoid arthritis second half year read more abbvie upadacitinib fifth ra study datum positive allergan activist pressure split ceo chairman role allergan agn free report be pressure week hedge fund firm senator investment group appaloosa disclose letter urge company engage management board overhaul firm ask pharmaceutical company split chairman chief executive role presently hold brent saunder other management change appaloosa run david tepper senator investment group run dougla silverman suggest outsider be hire role letter come heel allergan strategic plan announce last week divest woman health infectious disease unit allergan respond say board have be refreshed addition member last month read more allergan request shareholder veto management change glaxo complete buyout novartis stake consumer healthcare jv glaxo announce have complete previously announce deal buy novartis stake consumer healthcare joint venture acquisition novartis stake glaxo now have ownership consumer healthcare unit include product such sensodyne flonase glaxo novartis create jv part part transaction company combine consumer division pfizer invest more venture capital arm pfizer plan invest venture capital arm pfizer venture be invest small biotechs other emerge growth company be earmark company involved promising early stage neuroscience research read more pfizer boost venture capital effort neuroscience focus meanwhile pfizer regulatory application orally available parp inhibitor talazoparib metastatic breast cancer patient inherited brca mutation be accept review fda european medicine agency unite state new drug application nda be grant priority review fda decision accept december year top line result talazoparib registrational study embraca germline brca mutate breast cancer present december demonstrated superiority talazoparib chemotherapy improve progression free survival roche haemophilium candidate get priority review roche sbla look label expansion drug hemlibra person haemophilium factor viii inhibitor be grant priority review fda hemlibra be presently market routine prophylaxis prevent reduce frequency bleed episode haemophilium patient factor viii inhibitor fda grant priority review decision be expect oct separately roche cancer drug rituxan gain fda approval new indication moderate severe pemphigus vulgaris pv potentially life threaten nyse arca pharmaceutical index rise last trading session large cap pharmaceutical industry yr return large cap pharmaceutical industry yr return here be major stock perform last trading session stock be green last week astrazeneca decline merck rise most asco strength past month glaxo gsk have be biggest gainer bristol myer decline most see last pharma stock roundup here pharma stock roundup zoetis buy abaxis nvs get fda nod migraine drug next pharma world watch fda decision many pipeline drug line extension market product month look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
2165,AGN,allergan plc agn free report issue statement response letter public shareholder appaloosa senator investment group company express disappointment recently announce strategic plan divest woman health infectious disease unit activist investor tepper appaloosa dougla silverman senator investment group have request split brent saunder responsibility be currently chairman well chief executive officer ceo suggest recruit new chairman ceo be not company replacement additional board member change management critical operate unit be view company need fresh idea believe change be require drive return else share price continue decline statement company state board management be open input shareholder consider same make decision be focuse build world class company drive return shareholder earning call hold allergan management discuss several strategic plan include divestment share buyback company recently conclude strategic review announce focus lead therapeutic area medical aesthetic cns eye care gi divest unit mentioned january company cut job part restructure process moreover allergan also mentioned board have be refreshed addition member last month meanwhile shareholder have reject proposal splitting role brent appointment independent chairman annual general meeting hold so far year allergan share price have decline compare industry decline note allergan record strong earning first quarter also announce successful result clinical study however share be decline several key product be face loss exclusivity have unfavorable impact top line restasis major revenue contributor be face stiff competition launch shire plc shpg free report dry eye disease drug xiidra last year sale have decline more first quarter generic version drug also be launch mid meanwhile synergy pharmaceutical inc sgyp free report trulance be approve chronic idiopathic constipation last year be expect increase competition linzess several company be look bring generic version drug market moreover january mylan myl free report launch generic version estrace vaginal cream see sale erosion more first quarter company estimate product lose exclusivity be worth expect significant decline revenue product allergan plc price allergan plc price allergan plc quoteallergan currently carry zack rank hold see complete list today zack rank strong buy stock here today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
2166,AGN,month have go last earning report allergan plc agn share have lose time frame recent negative trend continue lead next earning release be agn due dive investor analyst have react late let take quick look most recent earning report order get better handle important driver allergan beat earning salesallergan first quarter earning come share beating zack consensus estimate well guide range earning rise year year drive higher revenue lower operate cost revenue come marginally exceed zack consensus estimate well guide range revenue rise year period organic basis exclude impact foreign exchange sale grow quarter key product botox juvéderm collection filler linzess loestrin continue do well quarter however lower sale namenda xr estrace minastrin asacol due generic competition hurt first quarter sale first quarter revenue also benefit addition alloderm lifecell january coolsculpt body contour system zeltiq april acquisition segment report revenue segment general medicine specialize therapeutic international specialize therapeutic net revenue increase drive continue strong performance facial aesthetic product botox juvéderm collection filler facial aesthetic botox cosmetic rake sale year year juvéderm collection filler rise however sale botox cosmetic juvéderm be hurt unfavorable timing promotional offer year end physician rebate program quarter however allergan be optimistic sale trend normalize remainder year call allergan say sale botox cosmetic juvéderm be expect increase double digit rate eye care ozurdex sale rise restasis sale decrease hurt unfavorable trade buy pattern lower selling price botox therapeutic revenue be drive demand growth plastic surgery breast implant sale increase contribute upside medical dermatology aczone sale plunge report quarter due generic pressure brand acne category higher discount maintain formulary coverage generic launch aczone lifecell alloderm add zeltiq coolsculpt business add sale quarter general medicine net revenue be year year report quarter sale decline diversify brand central nervous system cns woman health franchise infective sale rise inched lower sale namenda xr estrace minastrin asacol due generic competition hurt sale segment be partially offset strong growth vraylar linzess loestrin linzess sale rise drive strong demand loestrin sale rise drive higher average selling price increase demand newer product namzaric once daily fix dose combination namenda xr record sale less previous quarter viberzi record sale also less previous quarter vraylar sale be first quarter lower previous quarter due first quarter seasonality unfavorable payer dynamic however vraylar volume grow sequential basis support demand growth namenda xr sale slump report quarter due generic competition follow loss exclusivity february estrace cream sale decline quarter asacol delzicol sale decline due loss exclusivity woman health segment minastrin revenue plummet quarter due loss exclusivity last march international segment record net revenue exclude foreign exchange year period drive growth medical aesthetic botox therapeutic eye care profit riseadjust gross margin decline basis point bps quarter hurt unfavorable product mix due loss exclusivity higher margin product adjust operate income increase first quarter adjust operate margin rise bps quarter due lower operate cost selling general administrative sg expense decrease first quarter owing substantial reduction selling marketing spending successful execution restructure program research development expense also decline due pipeline re prioritization other detailsin first quarter allergan paid net debt complete share repurchase program announce september outlookallergan raise earning sale guidance range better expect first quarter performance lower share count delay generic restasis entry lead increase guidance generic version restasis be now expect be launch july versus april july expect previously add month top line projection allergan lift sale guidance approximate range compare earlier forecast meanwhile company also raise adjust earning expectation band share guide earlier company maintain guidance range adjust tax rate gross margin sg cost adjust tax rate be still expect be approximately adjust gross margin guidance be expect range be lower level gross margin be expect be hurt loss exclusivity high margin product restasis estrace delzicol unfavorable product mix adjust expense be expect be approximately sg spend be expect be approximately operate margin be expect be line level share count be expect be approximately share versus prior guidance share attributable earlier completion buyback strategic optionson call allergan say be conduct strategic review business due disconnect business performance stock value management discuss several strategic option include incremental aggressive share buyback divest certain asset concentrate more key therapeutic area splitting company make smaller bolt acquisition regard activity allergan say large merger be unlikely make product pipeline acquisition strengthen key area therapeutic focus allergan ceo brent saunder also say splitting company be not quite likely be outcome strategic review prove complicate costlysecond quarter outlookin second quarter revenue be anticipate earning share be likely be call allergan clarify first quarter earning benefit favorable timing operate expense reverse remain quarters year suggest operate cost be higher second quarter have estimate be move then past month investor have witness upward trend fresh estimate have be revision higher current quarter compare lower last month consensus estimate have shift due change allergan plc price consensus allergan plc price consensus allergan plc quotevgm scoresat time agn have great growth score be lag bit momentum front follow exact same course stock be also allocate grade value side putt second quintile investment strategy overall stock have aggregate vgm score aren focuse strategy score be be interested base score stock be more suitable growth investor look value momentum outlookestimate have be broadly trend upward stock magnitude revision look promising notably agn have zack rank hold expect line return stock next few month
2167,AGN,allergan plc agn free report announce nationwide recall sample pack taytulla softgel oral contraceptive capsule mg mcg allergan say hormonal placebo pill be erroneously place contraceptive capsule have be instigate recall follow physician report same allergan warn inactive pill raise risk unintended pregnancy patient have concern consult doctor share allergan be almost tuesday follow recall fact so far year allergan share price have decline compare industry decline strong first quarter performance positive regulatory update share pharma company continue decline year believe be allergan be face loss exclusivity several key product continue be concern analyst first generic version alzheimer treatment namenda xr estrace cream be launch first quarter blockbuster dry eye drug restasis allergan second best selling drug be expect be launch second quarter generic version delzicol be also expect be launch early second quarter allergan estimate product face loss exclusivity wereworth sale product be expect decline significantly introduction generic first quarter conference call management address disconnect business performance stock value allergan ceo brent saunder say company be conduct strategic review business unlock shareholder value allergan currently carry zack rank hold better rank drug biotech stock include eli lilly company lly free report biomarin pharmaceutical inc bmrn free report ligand pharmaceutical lgnd free report zack rank buy see complete list today zack rank strong buy stock here lilly earning estimate increase past day company deliver positive earning surprise trail quarters average beat biomarin earning estimate rise past day share biomarin have rally year so far ligand earning share estimate increase last day company deliver positive earning surprise trail quarters average beat company share have rally year date today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
2168,AGN,share allergan plc agn free report have decline report first quarter result apr fact so far year allergan share price have decline compare industry decline allergan first quarter result be strong beat expectation earning revenue earning rise year year drive higher revenue lower operate cost revenue increase organic basis exclude impact foreign exchange not only allergan raise earning sale guidance range also year allergan announce successful study result late stage study cgrp acute migraine candidate ubrogepant line extension study vraylar bipolar depression meanwhile infective drug avycaz gain fda nod third indication unite state gain eu approval mvasi allergan partner amgen amgn free report biosimilar version roche rhhby free report cancer drug avastin such strong quarterly performance positive regulatory update share pharma company continue decline year believe be allergan be face loss exclusivity several key product continue be concern analyst first generic version alzheimer treatment namenda xr estrace cream be launch first quarter blockbuster dry eye drug restasis allergan second best selling drug be expect be launch second quarter generic version delzicol be also expect be launch early second quarter allergan estimate product face loss exclusivity be worth sale product be expect decline significantly introduction generic first quarter conference call allergan management address disconnect business performance stock value allergan ceo brent saunder say be conduct strategic review business unlock shareholder value management discuss several strategic option include incremental aggressive share buyback divestiture certain asset concentrate more key therapeutic area splitting company make smaller bolt acquisition allergan have hire multiple financial advisor help evaluate different option regard activity allergan say large merger be unlikely make product pipeline acquisition strengthen key area therapeutic focus however saunder also say splitting company be not quite likely be outcome strategic review prove time consume complicate costly need see management optimism surround strategic option get reflect share price go forward allergan currently carry zack rank hold better rank drug biotech stock be ligand pharmaceutical lgnd free report zack rank strong buy see complete list today zack rank stock here ligand earning share estimate increase last day company deliver positive earning surprise trail quarters average beat company share have rally year date hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
2169,AGN,amgen inc amgn free report announce fda have approve supplemental biologic license application sbla seek label expansion prolium treatment glucocorticoid induced osteoporosis giop man woman high risk fracture have fail be intolerant other available osteoporosis therapy be fifth approve indication prolium approval be backed increase bone mineral density bmd achieve drug phase iii study drug be presently market unite state treatment postmenopausal woman osteoporosis high risk fracture well increase bone mass man osteoporosis high risk fracture share amgen be market trading follow news company share have rally year so far industry decline phase iii study evaluate prolium treatment giop patient man woman high risk fracture have fail be intolerant other available osteoporosis therapy compare allergan agn free report actonel risedronate study comprise patient group patient have receive glucocorticoid treatment less month prior study enrollment glucocorticoid initiate arm second patient have receive glucocorticoid treatment least month glucocorticoid continue arm arm glucocorticoid treatment be continue least month datum study show prolium increase lumbar spine bmd compare actonel glucocorticoid initiate arm lumbar spine bmd patient treat prolium glucocorticoid continue arm increase compare actonel glucocorticoid induced osteoporosis be most common form secondary osteoporosis serious condition be presently treat glucocorticoid treatment increase fracture risk first month treatment prolium now cater expand patient population drive sale higher prolium be key revenue generator amgen be witness market share gain unite state internationally competition generic other drug approve osteoporosis drug generate sale year year prolium face competition several drug especially generic version eli lilly lly free report evista alendronate merck mrk free report fosamax raloxifene novartis zometa zoledronate amgen inc price amgen inc price amgen inc quotezack rank amgen currently carry zack rank hold see complete list today zack rank strong buy stock here hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
2170,AGN,biodelivery science international inc bdsi free report report loss cent share first quarter be narrower zack consensus estimate loss cent however year quarter company have record earning cent share biodelivery share have underperform industry year so far stock have decline period compare decrease industry revenue be report quarter year period top line beat zack consensus estimate slight margin year year decline revenue be mainly due recognition defer revenue associate termination license agreement belbuca endo pharmaceutical subsidiary endo international plc endp free report remind investor biodelivery reacquir worldwide right belbuca january endo result reacquisition company start register product revenue belbuca royalty record previously exclude defer revenue total sale rise year year quarter opioid dependence drug bunavail record sale quarter year year however revenue drug rise sequentially biodelivery second market drug belbuca chronic pain generate revenue quarter previous quarter sale rise year year prescription volume belbuca expand sequentially year year support improve manage care coverage expansion sale force quarter biodelivery sign new contract humana procarerx cvs caremark improve coverage month march company record time high prescription volume more prescription marked increase nearly previous high reach january management seem confident belbuca witness continue strong growth belbuca be make commercially available canada biodelivery partner purdue pharma severe pain january drive sale further future quarters research development expense decline year period selling general administrative expense rise year year quarter other update earlier week biodelivery science announce appointment herm cukier new chief operate officer cukier be now serve senior vice president allergan agn free report february biodelivery enter settlement agreement teva pharmaceutical teva free report resolve belbuca patent litigation pursuant exclusive license agreement teva now be permit begin selling generic version belbuca unite state jul earlier certain circumstance biodelivery science international inc price consensus ep surprise biodelivery science international inc price consensus ep surprise biodelivery science international inc quote biodelivery currently carry zack rank hold see complete list today zack rank strong buy stock here look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
2171,AGN,aerie pharmaceutical inc aeri free report report first quarter loss cent share narrower zack consensus estimate loss cent wider year loss cent aerie pharmaceutical inc price consensus aerie pharmaceutical inc price consensus aerie pharmaceutical inc quote quarter detailin december aerie lead drug rhopressa be approve fda reduction elevated intraocular pressure patient open angle glaucoma ocular hypertension approval come month ahead schedule prescription drug user fee act date feb launch be underway report quarter research development expense increase selling general administrative expense surge year quarter also higher operate expense first quarter compare first quarter be primarily due increase activity associate expansion employee base support growth operation preparatory activity associate rhopressa effort aerie be secure formulary contract enable commercial coverage medicare part coverage company expect prefer formulary coverage majority commercial plan end prefer formulary coverage majority medicare part plan commence pipeline updatesaerie be currently evaluate second candidate roclatan once daily quadruple action fix dose combination rhopressa xalatan nda roclatan be expect be file second quarter company initiate phase iii trial mercury third quarter prepare regulatory submission europe trial be inferiority trial compare roclatan prescribe fix dose combination ganfort meanwhile pre ind activity be well underway further development aerie retina program candidate include ar rho kinase protein kinase inhibitor implant ar dexamethasone steroid implant outlookaerie expect rhopress revenue range total cash burn be project range takeaerie report narrower expect loss first quarter aerie receive significant boost approval lead candidate significantly boost prospect glaucoma be largest segment global ophthalmic market aerie share price have outperformed industry last month stock have gain compare industry upside however aerie face stiff competition establish brand generic pharmaceutical company drug such novartis nvs free report simbrinza travtan allergan agn free report lumigan well product other smaller biotechnology pharmaceutical giant valeant pharmaceutical vrx free report vyzulta be also approve open angle glaucoma ocular hypertension rhopressa have tough time gain market share due competition product zack rankaerie carry zack rank hold see complete list today zack rank strong buy stock here hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
2172,AGN,expect biodelivery science international inc bdsi free report beat estimate report first quarter result last report quarter company deliver negative earning surprise biodelivery share have underperform industry year so far stock have decline period compare decrease industry biodelivery earning history have be mixed bag company surpass expectation last quarters miss other deliver average beat biodelivery science international inc price ep surprise biodelivery science international inc price ep surprise biodelivery science international inc quote let see thing be shape announcement factor key product include belbuca chronic pain bunavail opioid dependence bunavail sale performance have be lackluster so far however biodelivery be work improve bunavail performance company have reduce number sale territory be focuse most growth oriented territory improve bunavail profit company be also focuse secure new improve position other manage care contract exclusive prefer status bunavail sale growth remain unchanged sequentially fourth quarter reduce cost structure combine growth opportunity remain be see sale drug improve first quarter belbuca start have also be slower expect due pain market pressure remind investor biodelivery have reacquir worldwide right belbuca january endo pharmaceutical subsidiary endo international result reacquisition company start record product revenue belbuca royalty record previously prescription volume belbuca have show improvement past couple quarters follow re acquisition sale belbuca improve sequentially fourth quarter believe positive trend continue belbuca be make commercially available canada severe pain january support further sale growth drug earlier week biodelivery science announce appointment herm cukier new chief operate officer cukier be now serve senior vice president allergan agn free report be introduce biodelivery first quarter conference call earning whispersour proven model show stock be likely beat earning quarter have right combination key ingredient positive earning esp favorable zack rank strong buy buy hold happen zack esp biodelivery have earning esp represent difference most accurate estimate loss cent zack consensus estimate loss cent be meaningful indicator likely positive earning surprise uncover best stock buy sell re report earning esp filter zack rank biodelivery have zack rank combination biodelivery zack rank positive esp make confident earning beat upcoming release sell rate stock zack rank other hand never be consider go earning announcement especially company be see negative estimate revision other stock warrant lookhere be other health care stock right combination element beat estimate time paratek pharmaceutical inc prtk free report have earning esp currently carry zack rank company be schedule release first quarter result keryx inc kerx free report have earning esp currently carry zack rank company be schedule release first quarter result look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
2173,AGN,first quarter earning season have be relatively strong however stock market recent performance be yet reflect strength positive revision be see ahead start earning season estimate revision trend second quarter have be rather underwhelm member report result accord latest earning preview total earning index member increase year quarter improvement revenue beat ratio be earning revenue report first quarter earning company combine actual result have come estimate still come company be expect grow year year higher revenue please note broader medical sector include drug biotech well medical device company be expect record year year growth revenue earning pharma bigwig report last week include pfizer pfe free report merck mrk free report allergan agn free report merck pfizer beat estimate earning miss same sale pfizer re affirm previously issue guidance merck raise outlook earning sale company witness relatively weaker top line performance quarter allergan beat estimate earning revenue first quarter raise guidance earning sale big biotechs celgene corporation beat estimate earning well sale raise earning expectation full year gilead earning sale miss estimate wider expect decline hcv franchise here have small biotech pharma company be set report first quarter result let see thing be shape announcement jazz pharmaceutical plc jazz free report jazz pharmaceutical be schedule announce result market close late company earning performance have be disappointing company surpass estimate only once last quarters miss same other average beat last quarter company deliver negative surprise however company have earning esp zack rank hold indicate likely positive surprise zack consensus estimate be peg share see complete list today zack rank strong buy stock here previous article show jazz be unlikely beat earning quarter however estimate change thereafter be now more confident likely positive surprise earning season call investor be keen know xyrem jazz lead product cataplexy excessive daytime sleepiness ed have perform also be keen know company pipeline progress business development plan be also expect draw notice read more jazz pharmaceutical earning store arena pharmaceutical inc arna free report arena be also expect report market closearena earning performance have be mixed bag trail quarters company surpass expectation last quarters miss same other occasion deliver average positive beat last report quarter company outpaced zack consensus estimate deliver positive earning surprise sale arena obesity treatment drug belviq only approve product arena portfolio be not expect be better arena have few pipeline candidate update same be expect first quarter conference call read more card arena earning season company have earning esp zack rank zack consensus estimate first quarter be peg loss cent share ligand pharmaceutical incorporate lgnd free report ligand be schedule announce result market close ligand stellar earning history show estimate beat last quarters company miss consensus mark only once also deliver average positive earning surprise last report quarter ligand pull positive surprise company have earning esp zack rank zack consensus estimate soon be report quarter be peg share first quarter conference call expect investor focus remain company update regard partnership well major pipeline asset read more lie ahead ligand earning season valeant pharmaceutical international inc vrx free report valeant be schedule release earning market open deliver negative earning surprise last quarter valeant earning performance have be decent earning miss expectation last quarters beating same remain bring average positive surprise quarter valeant have earning esp zack rank zack consensus estimate be peg cent share uncover best stock buy sell re report earning esp filter here be stock perform year so far more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
2174,AGN,teva pharmaceutical industry limit teva free report report first quarter earning cent share beat zack consensus estimate cent share however earning share decline year year revenue come also beat consensus estimate however sale decline year year exclude impact currency sale be hurt increase pricing erosion generic market rapid erosion sale teva key multiple sclerosis injection copaxone divesture core asset segment discussiona announce november last year teva longer report separate global group business generic specialty medicine instead report new segment base region north america europe growth market north america segment sale be year year due pricing erosion generic market lower sale copaxone divestiture core asset woman health business unite state revenue decline lead brand product copaxone post sale north america year year due generic competition mg well mg formulation glatopa generic version copaxone mg be be market momenta sandoz novartis nvs free report generic arm mylan myl free report launch version mg formulation october same month major blow teva mylan launch risk generic version mg thrice weekly formulation much earlier expect entry generic version mg formulation entry second generic version mg formulation have be rapid erosion sale copaxone moreover second generic version mg formulation glatopa be launch sandoz february year much earlier schedule launch april call teva say mylan introduction mg generic copaxone still command volume mg market however teva have decrease price copaxone increase rebate connection generic competition lower pricing help maintain volume share however teva expect tougher competition year progress exert further pressure pricing sale other brand product bendeka treanda proair qvar increase quarter newest product teva brand portfolio austedo record sale north america austedo sd be approve launch april treatment chorea associate huntington disease second indication dyskinesia unite state august generic product revenue decline quarter due lower volume price erosion significant competitive pricing pressure be hurt generic industry consolidation customer industry have increase ability negotiate lower price generic drug teva launch generic product first revenue be generate anda rise quarter august teva acquire allergan agn free report generic business actavis generic allergan anda inc fourth largest distributor generic pharmaceutical october europe segment record revenue year year however constant currency term sale decline due loss revenue closure distribution business hungary divestiture woman health business generic product include otc product revenue europe rise constant currency basis due new product launch volume growth otc partially offset price decline copaxone sale decline constant currency basis due price reduction follow entry generic growth market sale rise however constant currency term sale be flat segment higher sale israel japan russia be partially offset effect deconsolidation subsidiary venezuela loss revenue sale woman health business country generic product include otc revenue decline constant currency term copaxone sale decline other segment api manufacturing business certain contract manufacturing service record revenue year year due lower api sale third party profit declineadjust gross margin contract basis point bps quarter due lower profitability north america segment adjust research development expense decline year period due pipeline optimization selling marketing expenditure decline year level due cost cut re structuring activity adjust operate margin decline bps quarter lower cost outlook uppedteva raise sale earning guidance follow first quarter beat revenue outlook be raise range range earning guidance be raise band share share generic sale be expect decline roughly level approximately hurt ongoing price erosion cost be expect decline result company cost saving initiative free cash flow guidance be raise delay fda approval migraine candidatealong earning release company say do not expect get fda approval pipeline candidate fremanezumab prevention chronic episodic migraine pdufa date june say expect pre approval inspection take place soon teva expect fremanezumab be approve launch end year remind investor january teva partner celltrion receive fda warning letter facility south korea follow inspection fill finish side facility facility manufacture api fremanezumab eu regulatory application fremanezumab be review please note lilly amgen be also track launch new migraine treatment year taketeva beat expectation earning sale first quarter also raise full year outlook metric however teva stock decline more earning release teva share have decline year so far compare industry decline israel base generic drug maker have tough face significant challenge form accelerate generic competition copaxone new competition brand product pricing erosion generic business lower expect contribution generic launch massive debt load more mylan earlier expect launch first generic version mg strength copaxone be major setback teva teva divest core asset last year mainly woman health business cut significant debt load company also have new organizational structure place be close plant cut generic portfolio eliminate low value project aim cut global workforce more next year part restructure plan reveal december last year teva be progress well re structuring activity still expect save almost end initiative progress restructure activity fact financial position seem more stable believe teva have long way go gain stability teva pharmaceutical industry ltd price consensus ep surprise teva pharmaceutical industry ltd price consensus ep surprise teva pharmaceutical industry ltd quoteteva carry zack rank sell see complete list today zack rank strong buy stock here today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
2175,AGN,first quarter result pharma bigwig pfizer pfe free report merck mrk free report allergan agn free report steal limelight week other novartis nvs free report gain fda approval second indication car therapy kymriah abbvie abbv free report submit regulatory application eu psoriasis candidate risankizumab merck pd inhibitor keytruda gain fda priority review status yet label expansion application recap week most important storiesmixed result merck pfizer pharma giant beat estimate earning miss same sale pfizer re affirm previously issue guidance merck raise outlook earning sale company witness relatively weaker top line performance quarter merck strong sale keytruda gardasil bridion be partially offset lower sale other key therapy rotateq zepatier zostavax meanwhile loss market exclusivity several drug also hurt top line pfizer top line be hurt decline sale key drug lyrica prevnar prevenar enbrel loss exclusivity product viagra pristiq continue supply shortage legacy hospira product allergan beat estimate earning revenue first quarter raise guidance earning sale novartis kymriah get fda approval second indication novartis supplemental biologic license application sbla look get car therapy kymriah approve second indication be grant approval fda latest approval kymriah suspension have be approve intravenous infusion treatment adult patient relapse refractory diffuse large cell lymphoma more line systemic therapy include diffuse large cell lymphoma dlbcl high grade cell lymphoma dlbcl arise follicular lymphoma kymriah be first car therapy obtain fda approval august treatment patient year age cell precursor be refractory second later relapse separately novartis announce fda have give complete response letter bla propose biosimilar version roche cancer drug rituxan merck keytruda news merck supplemental biologic license application sbla look get overall survival datum phase iii keynote study include label pd inhibitor keytruda be grant priority review fda fda give decision sep study evaluate keytruda combination lilly alimta pemetrexed platinum chemotherapy cisplatin carboplatin first line treatment patient metastatic squamous nsclc regardless pd expression combination treatment improve overall survival regardless pd expression include patient tumor test negative pd notably combination therapy be grant accelerate approval fda aforementioned indication approval be base tumor response rate pfs datum keynote study hence positive readout keynote confirmatory study help company gain continue approval combo therapy support uptake sale merck also announce interim datum pivotal lung cancer study keytruda meet pre specify secondary endpoint overall response rate orr early cohort participant phase keynote study evaluate keytruda combination carboplatin paclitaxel nab paclitaxel first line treatment metastatic squamous nsclc abbvie submit application psoriasis candidate eu abbvie submit marketing application european regulatory authority investigational interleukin il inhibitor risankizumab treatment moderate severe plaque psoriasis marketing authorization application maa be support datum pivotal phase iii study datum study have show more half patient receive risankizumab achieve complete skin clearance year meanwhile abbvie also announce commencement self tender offer common stock price not less share not more share unite therapeutic acquire steadyme unite therapeutic corporation uthr free report announce definitive merger agreement steadyme ltd unite therapeutic acquire latter include contingent payment deal unite therapeutic add steadyme drug device pipeline product trevyent pulmonary arterial hypertension pah patient portfolio product have pose competition unite therapeutic remosynch implantable pump be review unite state trevyent be single use pre filled pump have be develop steadyme deliver day supply treprostinil subcutaneously used steadyme patchpump technology treat pah steadyme receive refuse file letter fda want further information steadyme intend resubmit nda end allergan ubrogepant succeed phase iii study allergan announce second pivotal phase iii study evaluate oral cgrp acute migraine treatment ubrogepant meet co primary endpoint phase iii datum show ubrogepant display strong efficacy clean side effect profile achieve ii study evaluate efficacy safety orally administer ubrogepant mg mg treat single migraine attack moderate severe headache intensity study datum demonstrated significant greater percentage patient treat ubrogepant dose be free pain hour initial dose compare treat placebo also statistically significant greater percentage ubrogepant patient take mg dose experience absence most bothersome migraine associate symptom photophobia phonophobia nausea hour initial dose compare treat placebo however mg dose fail demonstrate statistical significance endpoint seek label expansion pah drug jnj free report actelion submit supplemental new drug application snda fda seek approval label expansion pah drug opsumit macitentan include treatment patient chronic thromboembolic pulmonary hypertension cteph also announce definitive agreement acquire private biotech benevir biopharm benevir make oncolytic immunotherapy utilize proprietary stealth oncolytic virus platform have potential treatment solid nyse arca pharmaceutical index decline last trading session large cap pharmaceutical industry yr return large cap pharmaceutical industry yr return here be major stock perform last trading session stock decline last week astrazeneca rise pfizer decline most last month glaxo be biggest gainer bristol myer decline most see last pharma stock roundup here pharma stock roundup nvs jnj sale earning top mrk bmy active aacr next pharma world watch pipeline regulatory update today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
2176,AGN,ironwood pharmaceutical inc irwd free report report first quarter adjust loss cent share wider zack consensus estimate loss cent however company have report adjust loss cent year period total revenue collaborative revenue quarter amount year period miss zack consensus estimate quarter detaila report partner allergan plc agn free report ironwood key market product linzess linaclotide generate net sale year year please note ironwood allergan have equal share brand collaboration profit loss ironwood share net profit sale linzess unite state include collaborative revenue be first quarter year year sale linaclotide active pharmaceutical ingredient company japanese partner astella pharma add revenue accord datum provide im health linzess prescription filled quarter be more year period drug uptake continue grow follow strong performance remain market leader brand prescription drug january ironwood allergan settle patent litigation related abbreviated new drug application sun pharmaceutical industry seek approval generic version linzess settlement agreement sun pharmaceutical be allow market authorize generic version feb zurampic duzallo approve uncontrolled gout generate sale quarter duzallo be launch october oral treatment hyperuricemia associate gout report quarter selling administrative sg expense increase research development expense be year initiativein separate press release ironwood announce intent split company separate entity entity continue current name focus commercial drug gi pipeline development other entity focus development soluble guanylate cyclase pipeline treatment serious orphan disease company expect achieve increase operational performance strategic flexibility follow completion restructure process separation be expect close first half expect incur charge related restructure initiative hence company do not provide financial guidance full year plan provide update second quarter earning release pipeline updateslinzess be approve unite state treatment adult irritable bowel syndrome constipation ib chronic idiopathic constipation cic ironwood allergan be look broaden linzess label additional symptom develop drug opioid pain relieve agent ib patient phase iii study evaluate linzess additional abdominal symptom be expect start mid company be also discussion fda start phase iib study evaluate delay release formulation linaclotide treat subtype ib include ib mixed ib diarrhea label expansion linzess chronic constipation indication be review japan china hong kong macau ironwood have agreement astrazeneca plc azn free report linzess regulatory filing china ib be review company expect review be complete first half company be also develop candidate iw praliciguat iw olinciguat iw reflux disease diabetic nephropathy sickle cell disease respectively ironwood expect advance iw phase iii study third quarter phase ii study evaluate praliciguat diabetic nephropathy heart failure be currently enrolling patient company first quarter loss be wider estimate sale also miss expectation however stock be restructure news prospect new ironwood sole focus market drug gi pipeline be more attractive lower potential cost look company share price movement show stock have outperformed industry year so far ironwood share have gain period industry decline ironwood be focuse expand linzess label geography linzess sale growth be expect continue boost top line potential approval china further boost sale drug meanwhile expect new ironwood be able be turn profitable faster revenue grow operate expense decline restructure ironwood pharmaceutical inc price consensus ep surprise ironwood pharmaceutical inc price consensus ep surprise ironwood pharmaceutical inc quotezack rank key pickironwood currently carry zack rank hold ligand pharmaceutical incorporate lgnd free report be better rank stock health care sector sporting zack rank strong buy see complete list today zack rank stock here ligand earning share estimate moved remain stable last day company deliver positive surprise trail quarters average beat share price company have increase year look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
2177,AGN,stock market end negative territory monday broad base decline push major index red slide healthcare industrial stock more offset gain several merger acquisition telecom mega deal moreover strong first quarter earning result also fail uplift investor sentiment dow jone industrial average dji close decline point index inx decrease close nasdaq composite index ixic close decrease total share be trade first trading day week higher last session average share decliner outnumber advancer nyse ratio nasdaq decliner have edge advancer ratio cboe vix increase close do benchmark perform dow decrease stock stock blue chip index close red trade green decrease lead decline health care select sector spdr xlv decrease industrial select sector spdr xli material select sector spdr xlb sector benchmark index end negative territory index record new week high new week lows nasdaq composite lose index record new week high new week lows healthcare metal industrial stock pull metal industrial sector be worst performer last day trading april sector lead broad base market decline share celgene corp celg free report decline morgan stanley ms free report report state company require year more resubmit application approval company critical drug ozanimod relapse multiple sclerosis share allergen plc agn free report plunge chairman ceo brent saunder expressed view be opposed change company fundamental business structure read more however allergen first quarter earning come share beating zack consensus estimate revenue generate marginally exceed zack consensus estimate arconic inc arnc free report decline massive reduce outlook company adjust earning come share first quarter beat zack consensus estimate revenue surpass zack consensus estimate however arconic now expect adjust earning be range share prior guidance free cash flow be read more share price ak steel hold corp ak free report decline report strong first quarter result net earning come share beating zack consensus estimate revenue generate exceed zack consensus estimate investor be expect more especially president trump impose tariff import steel concern telecom mega deal overshadow slew asa number announcement help market advance initial hour trading share walmart inc wmt free report increase retail giant arm asda group ltd agree merge british supermarket chain sainsbury plc likewise share ilg inc ilg free report rise marriot vacation worldwide corp vac free report agree buy former also share logistic company dct industrial trust inc dct advanced prologis inc pld agree buy former likewise share andeavor andv advanced marathon petroleum corp mro agree buy former however investor concern regard approval merger deal mobile inc tmus sprint corp free report overshadowed investor positive enthusiasm share price mobile sprint decline respectively many industry watcher believe fcc not okay deal even deal be permit be detrimental consumer number national wireless operator come economic datum department commerce report personal consumption expenditure pce grow march first advance end personal income increase personal disposable income increase march pce price index key inflation barometer used fed rise month rate february hit central bank target first time year core pce exclude food energy increase march monthly month april major stock market index witness marginal gain reverse overall negative trend witness last straight month dow increase nasdaq composite gain year date nasdaq composite be trading green dow be red strong earning result most large corporate fail enthuse investor disappointing guidance taiwan semiconductor tsm largest contract chipmaker worldwide lead loss tech major especially apple inc aapl free report moreover caterpillar inc cat free report forecast economic growth decelerate later year also result broad base market decline rise bond yield also dent investor confidence april year treasury yield briefly hit psychological mark first time january additionally stock market fluctuate due fear global trade war geopolitical tension related syrium stock make haedlinesbp post strong earning record upstream businessbp plc bp free report report strong first quarter result oil price have start recover slump witness nearly year back read more wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2178,AGN,allergan plc agn free report first quarter earning come share beating zack consensus estimate bottom line also rise year year drive higher revenue lower operate cost earning also surpass previously expect range revenue generate marginally exceed zack consensus estimate top line also rise year period revenue also surpass past projection key product botox juvéderm collection filler new product vraylar viberzi namzaric do well quarter review however sale erosion namenda xr aczone loss exclusivity mainly asacol hd minastrin hurt top line first quarter revenue also benefit addition alloderm lifecell january coolsculpt body contour system zeltiq april acquisition share allergan increase almost apr pre market trading stock have lose so far year outperform industry decline segment company report revenue segment namely general medicine specialize therapeutic international specialize therapeutic net revenue increase drive consistently strong performance facial aesthetic product botox juvéderm collection filler botox cosmetic rake sale year year botox therapeutic revenue be addition juvéderm collection filler rise eye care ozurdex sale increase blockbuster dry eye drug restasis sale decrease plastic surgery breast implant sale increase contribute upside medical dermatology aczone sale plunge report quarter lifecell alloderm add zeltiq coolsculpt business add sale first quarter general medicine net revenue be year year report quarter sale decline diversify brand central nervous system cns woman health franchise infective sale rise inched establish product linzess loestrin well new product namzaric viberzi vraylar do well first quarter linzess sale rise drive strong demand loestrin sale rise backed strong demand trend newer product namzaric once daily fix dose combination namenda xr record sale compare year figure viberzi record sale year year namenda xr sale slump report quarter due loss patent exclusivity namenda xr february asacol delzicol sale decline due reduction demand ascaol hd follow launch authorize generic august woman health segment minastrin revenue plummet quarter due loss exclusivity last march international segment logged net revenue year period drive growth facial aesthetic botox therapeutic eye care addition coolsculpt selling general administrative sg expense decrease first quarter owing substantial reduction selling marketing spending include impact previous restructuring research development expense also decline due program outlook raisedallergan lift sale guidance approximate range compare former forecast zack consensus estimate metric current year be peg meanwhile company also raise adjust earning expectation band share guide earlier consensus mark metric current year be peg share company however continue estimate adjust tax rate approximately viewin second quarter revenue be anticipate earning share be likely be zack consensus estimate revenue second quarter be peg consensus mark earning be peg share same period migraine candidate succeed second phase iii studyallergan also announce result second pivotal phase iii study evaluate migraine candidate ubrogepant achieve ii trial evaluate efficacy safety tolerability orally administer ubrogepant dose mg mg compare placebo single migraine attack adult datum study demonstrated significant greater percentage patient treat ubrogepant dosage mg mg be free pain hour initial dose compare treat placebo also mg dose show statistically significant greater percentage ubrogepant patient achieve absence most bothersome migraine associate symptom hour initial dose comparison patient treat placebo company expect submit regulatory application ubrogepant fda allergan plc price consensus ep surprise allergan plc price consensus ep surprise allergan plc quote zack rank key picksallergan carry zack rank hold better rank stock health care sector be ligand pharmaceutical incorporate lgnd free report infinity pharmaceutical inc infi free report oncomed pharmaceutical inc omed free report sporting zack rank strong buy see complete list today zack rank stock here ligand earning share estimate have moved north last day company deliver positive surprise trail quarters average beat share price company have surge year infinity loss share estimate have narrow cent cent cent last day company pull positive surprise last quarters average beat oncomed loss share estimate have narrow cent last day company come positive surprise trail quarters average beat hottest tech mega trend last year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
2179,AGN,dublin ireland base allergan plc agn free report be engage development manufacturing marketing sale distribution brand pharmaceutical device biologic surgical regenerative medicine product allergan have be actively pursue deal expand portfolio especially brand product offer have complete acquisition company durata forest allergan acquire botox maker allergan inc mar acquisition allergan be previously know strong presence generic market find company top pharmaceutical company world base sale accretive acquisition lifecell zeltiq allergan have expand medical aesthetic business regenerative medicine body sculpting respectively allergan sell generic anda distribution business teva aug oct respectively allergan earning performance have be strong company beating expectation past quarters average positive earning surprise last quarters be currently allergan have zack rank hold definitely change follow company earning report be just release have highlighted key stat just reveal announcement earning beat allergan first quarter earning share be consensus estimate share revenue beat revenue come marginally beat zack consensus estimate revenue rise year period outlook allergan raise sale guidance range approximately compare previous guide range meanwhile company also raise adjust earning expectation range share share expect previously migraine candidate datum allergan also announce result second pivotal phase iii study evaluate migraine candidate ubrogepant achieve ii study evaluate efficacy safety tolerability orally administer ubrogepant dose mg mg compare placebo single migraine attack adult study datum demonstrated significant greater percentage patient treat ubrogepant dose mg mg be free pain hour initial dose compare treat placebo also mg dose demonstrated statistically significant greater percentage ubrogepant patient achieve absence most bothersome migraine associate symptom hour initial dose compare placebo patient company anticipate submit regulatory application ubrogepant fda share price impact share be more pre market trading check back later full agn earning report later allergan plc price ep surprise allergan plc price ep surprise allergan plc hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
2180,AGN,investor be always look stock be poise beat earning season allergan plc agn free report be such company firm have earning come pretty soon event be shape quite nicely report be allerganis see favorable earning estimate revision activity late be generally precursor earning beat analyst raise estimate right earning most date information possible be pretty good indicator favorable trend surface agn report fact most accurate estimate current quarter be currently share agn compare broader zack consensus estimate share suggest analyst have very recently bump estimate agn give stock zack earning esp head earning season allergan plc price ep surprise allergan plc price ep surprise allergan plc quotewhy be important positive read zack earning esp have proven be very powerful produce positive surprise outperform market recent year backtest show stock have positive earning esp zack rank hold better show positive surprise nearly time have return average annual return see more top earning esp stock here give agn have zack rank esp positive territory investor want consider stock ahead earning see complete list today zack rank strong buy stock here clearly recent earning estimate revision suggest good thing be ahead allergan beat be card upcoming report more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
2181,AGN,expect allergan plc agn free report beat expectation report first quarter result apr market open last quarter company deliver positive earning surprise allergan share price have decline year so far compare industry decline allergan earning performance have be strong company beating expectation past quarters average positive earning surprise last quarters be allergan plc price ep surprise allergan plc price ep surprise allergan plc quotelet see thing be shape announcement factor consideron fourth quarter conference call company guide first quarter revenue earning share be expect be number indicate lowest revenue earning quarter year fourth quarter favorable timing physician rebate program benefit sale allergan facial aesthetic product benefit be absent first quarter hurt revenue such company expect first quarter revenue growth rate be somewhat lower annual growth rate also generic competition estrace namenda xr hurt sale sharply first quarter generic version namenda xr be launch indian company lupin february estrace cream be launch mylan myl free report january allergan expect generic version restasis second best selling drug be launch april july meanwhile generic version delzicol be expect be launch early second quarter investor focus call be management comment potential impact generic competition key growth driver restasis namenda xr zack consensus estimate restasis be nonetheless allergan establish product botox linzess loestrin juvéderm collection filler new product juvéderm collection filler support sale zack consensus estimate botox be fact recent label expansion botox fda approval forehead line treatment vraylar fda approval maintenance treatment schizophrenia avycaz fda approval habp vabp add sale drug meanwhile addition alloderm lifecell january coolsculpt body contour system zeltiq april acquisition continue support top line quarter however believe sale erosion aczone due generic pressure brand acne category loss exclusivity loe mainly asacol hd minastrin continue hurt top line remind investor call company have say do not expect significant activity allergan expect reevaluate strategy second half year once get loe update be expect upcoming conference call earning whispersour proven model show allergan be likely beat earning have right combination key ingredient stock need have positive earning esp zack rank strong buy buy hold happen zack esp earning esp represent difference most accurate estimate share zack consensus estimate share be be meaningful indicator likely positive earning surprise uncover best stock buy sell re report earning esp filter zack rank allergan have zack rank combination allergan zack rank positive esp make confident earning beat upcoming release sell rate stock zack rank other hand never be consider go earning announcement especially company be see negative estimate revision other stock considerhere be large cap health care stock worth consider model also have right combination element beat earning time bristol myer squibb company bmy free report have earning esp zack rank company be schedule report first quarter earning apr see complete list today zack rank stock here pfizer inc pfe free report be also slate announce financial figure company have earning esp be also zack rank stock make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
2182,AGN,expect biotech major amgen inc amgn free report beat expectation report first quarter result apr market close amgen deliver negative earning surprise last quarter amgen share have decline past year still compare favorably decrease register industry period amgen performance have be modest company deliver positive surprise trail quarters average earning beat last quarters be amgen inc price ep surprise amgen inc price ep surprise amgen inc quotelet see thing be shape company quarter factor first quarter usually generate lowest product sale amgen amgen newer product prolium kyproli xgeva blincyto be likely perform well backed higher demand make lower sale mature brand enbrel aranesp epogen neulasta neupogen due competitive pressure early amgen gain fda approval include overall survival datum label kyproli blincyto reflect first quarter sale drug january xgeva gain fda approval prevention skeletal related event patient multiple myeloma label extension boost sale drug neulasta demand be be hurt competition pd other new cancer sale be also be hurt biosimilar competition unite state mainly zarxio sandoz biosimilar version neupogenwe expect neulasta neupogen first quarter sale be hurt competitive dynamic neulasta epogen be expect start face biosimilar competition unite state year also sensipar sale be likely decline sharply soon be report quarter drug lose patent exclusivity march enbrel sale be expect be hurt increase pricing competitive pressure enbrel be main driver amgen revenue fourth quarter conference call amgen say sale enbrel first quarter be expect be lowest represent approximately full year sale also repatha sale first quarter be expect be relatively flat sequentially hurt insurance verification patient pocket cost also investor be keen know sale repatha have improve inclusion fourier outcome datum label amgen partner allergan agn free report biosimilar version roche cancer drug avastin mvasi be approve eu january boost first quarter sale drug investor focus call be management comment preparation potential launch migraine candidate aimovig fda be expect give decision aimovig biologic license application bla mid meanwhile higher investment support product launch be likely result higher sg cost be report quarter earning whispersour proven model show amgen be likely beat earning have right combination key ingredient stock need have positive earning esp zack rank strong buy buy hold happen zack esp earning esp represent difference most accurate estimate share zack consensus estimate share be be meaningful indicator likely positive earning surprise uncover best stock buy sell re report earning esp filter zack rank amgen have zack rank combination amgen zack rank positive esp make confident earning beat upcoming release sell rate stock zack rank other hand never be consider go earning announcement especially company be see negative estimate revision other stock considerbiotech stock have positive esp favorable zack rank include alexion pharmaceutical inc alxn free report schedule release result apr have earning esp zack rank see complete list today zack rank stock here celgene corporation celg free report have earning esp zack rank company be schedule release result wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2183,AGN,allergan agn free report share have fall day shire plc shpg free report be so far fluctuation come light dollar acquisition deal shire be now take competitive turn shire be pharmaceutical company responsible manufacturing adhd medication such adderall thursday takeda pharmaceutical co japanese company see cash stock buyout offer reject shire offer be price share premium shire stock price late march conjunction third reject offer takeda allergan company famous make botox have announce consider produce offer drug maker follow announcement allergen share immediately begin drop most likely due investor concern company overpay overtake shire contrast shire share price begin take today come result increase investor confidence facilitate mega pharmaceutical fight company hope high buyout result takeda order bounce back rejection need find mean acquire much greater capacity wealth wish purchase shire currently hold higher market valuation compete allergan ride wave medium spotlight have help raise share price peak trading day allergan takeda shire earning outlook short term be seemingly positive regardless deal currently shire hold grade growth grade value base style score system shire come discount respective industry average help show stock leave investor strong value option buyout go well only be more discount purchase assume investor get now company growth prospect look strong well debt equity ratio show shire be financially sound cash flow share compare industry average help show investor financial stability company unstable industry be say shire be expect witness ep growth modest annualize basis next year analyst estimate revision point negative trend well current quarter ep estimate past day have be positive current year ep estimate same time range be agreement downside be pharmaceutical company currently hold zack rank sell hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
2184,AGN,abbvie inc abbv free report partner neurocrine bioscience announce fda have extend review period marketing application company pipeline candidate elagolix month result regulatory body now announce decision third quarter instead previously anticipate second quarter timeline abbvie be look get elagolix approve oral medicine pain management associate endometriosis last september fda accept abbvie new drug application nda elagolix subsequently grant priority review status october however regulatory body request extend time frame review additional information provide abbvie nda pertain liver function test result notably management show confidence company datum provide fda continue work regulatory body bring elagolix market remind investor nda filing be support positive result replicate pivotal phase iii trial evaluate elagolix aforementioned indication detailed datum study present last october show treatment elagolix result statistically significant reduction menstrual menstrual pelvic pain associate endometriosis compare placebo datum study also demonstrated superiority compare placebo alleviate pelvic pain menstrual pelvic pain painful intercourse associate endometriosis endometriosis affect estimate woman reproductive age be associate pain symptom present be cure disease pain associate be currently manage oral contraceptive progestin danazol nsaid opioid gnrh agonist many medicine be not specifically indicated treat endometriosis approve elagolix be first option patient need additional treatment apprehend disease abbvie share price have surge year compare favorably industry gain meanwhile elagolix be also be evaluate phase iii program prevent heavy menstrual bleed premenopausal woman uterine fibroid importantly pharma company allergan agn free report also have pipeline candidate ulipristal acetate portfolio be currently evaluation treatment uterine fibroid here too fda february request extend review period company nda candidate august abbvie inc price abbvie inc price abbvie inc quote zack rank key picksabbvie carry zack rank hold better rank stock health care sector be ligand pharmaceutical incorporate lgnd free report infinity pharmaceutical inc infi free report sporting zack rank strong buy see complete list today zack rank stock here ligand earning share estimate have moved last day company deliver positive surprise trail quarters average beat share price company have soar year infinity loss share estimate narrow cent cent cent last day company deliver positive surprise trail quarters average beat medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
2185,AGN,be happen week pharma stock key development week include new car deal pfizer pfe free report successful study result pfizer lilly lly free report allergan agn free report positive regulatory update astrazeneca azn free report recap week most important storiespfizer car deal tafamidis succeed late stage study pfizer announce alliance private biotech allogene therapeutic expedite development allogeneic car therapy pfizer own stake allogene also get representation latter board meanwhile cnbc report say pfizer be talk consumer giant procter gamble regard sale consumer healthcare segment last month glaxo gsk free report reckitt benckiser group pull discussion pfizer buy same unit read more pfizer inks new car deal talk unit sale pfizer pipeline candidate tafamidis develop treatment transthyretin cardiomyopathy ttr cm meet main goal late stage study attr act top line datum attr act study show treatment tafamidis lead statistically significant reduction combination cause mortality frequency cardiovascular related hospitalization primary endpoint compare placebo month read more pfizer rare disease candidate meet endpoint phase iii pfizer regulatory application pipeline candidate dacomitinib be accept priority review unite state response expect september company be look get drug approve first line treatment patient locally advanced metastatic small cell lung cancer nsclc egfr activate mutation read more pfizer lung cancer candidate get fda priority review lilly cyramza meet os endpoint liver cancer study lilly announce already approve cancer drug cyramza show overall survival benefit thereby meeting primary endpoint late stage study evaluate second line treatment liver cancer study also meet secondary endpoint progression free survival read more lilly cyramza show survival benefit liver cancer study astrazeneca provide regulatory update astrazeneca diabetes treatment bydureon gain fda approval add therapy insulin glargine also biologic license application bla seek approval astrazeneca cd recombinant immunotoxin candidate moxetumomab pasudotox second later line treatment hairy cell leukaemia hcl be grant priority review fda fda grant priority review decision be expect third quarter regulatory development astrazeneca partner merck mrk free report regulatory submission look expand label parp inhibitor lynparza include breast cancer indication be accept eu lynparza be already approve treat ovarian cancer eu latest filing astrazeneca look get lynparza approve brca mutate negative metastatic breast cancer eu unite state lynparza be approve same indication january read more astrazeneca bydureon get fda nod expand use allergan vraylar succeed label expansion study allergan partner gedeon richter say vraylar cariprazine meet primary endpoint late stage study adult major depressive episode associate bipolar disorder bipolar depression be third pivotal study conduct indication datum study be include company label expansion application company plan file second half read more allergan vraylar meet endpoint bipolar phase iii bio path mid stage study leukemia candidate show positive early datum bio path holding announce positive interim datum phase ii study bp lead pipeline candidate prexigebersen be be evaluate combination low dose cytarabine ldac treatment patient acute myeloid leukemia aml elect not be treat more intensive chemotherapy combination therapy demonstrated early leukemic activity nearly evaluable aml patient study total patient achieve form response combo treatment share bio path shot response read more bio path leukemia combo study show positive early datum fda approve sonoma skin gel sonoma pharmaceutical small solution maker skin condition advanced tissue care gain fda approval antimicrobial post treatment gel gel aim treat itch pain associate procedure include laser skin resurface post therapy chemical peel share sonoma shot more response nyse arca pharmaceutical index rise last trading session large cap pharmaceutical industry yr return large cap pharmaceutical industry yr return here be major stock perform last trading session stock record gain bristol myer bmy free report glaxo be biggest gainer rise bristol myer decline last month astrazeneca have be biggest gainer merck decline most see last pharma stock roundup here pharma stock roundup abbv rova disappoint unit get buyout offer next pharma world watch regulatory pipeline news pharma stock make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
2186,AGN,fda refusal review plc alk free report depression candidate alk week be major setback company decision send stock tumble more alk once daily oral medication have be develop major depressive disorder mdd patient have not respond standard antidepressant therapy fda refuse review candidate state new drug application nda do not have enough evidence oral medication work fdawa opinion additional study be conduct ascertain drug effectiveness propose indication go say unexpected pipeline setback shift investor focus company market be develop drug treatment depression latest pipeline setback have shift investor focus market depression type depression be medical condition affect brain individual depression feel melancholic have intricacy enjoy routine activity factor such stress brain chemistry be most common cause depression also be genetic be different form depression such persistent depressive disorder perinatal depression disorder psychotic depression seasonal affective disorder bipolar depression psychotic depression persistent depressive disorder bipolar disorder be most severe form depression accord estimate person worldwide be affected depression have be see carry suicidal tendency thus rise press need develop drug condition know antidepressant drug be instrumental identify sign symptom ailment several pharma biotech company be involved develop selling depressantdrug stock focuslet look company be actively pursue development treatment various type depression allergan plc agn free report zack rank hold stock look well position depression market company have quite few product portfolio include vraylar schizophrenia bipolar disorder viibryd major depressive disorder saphris bipolar disorder drug be also several label expansion study earlier week allergan announce pivotal study evaluate vraylar treatment adult major depressive episode associate bipolar disorder bipolar depression meet primary endpoint moreover allergan moved rapastinel nmda receptor modulator phase iii development major depressive disorder rapastinel potentially game change treatment be expect be launch drug be expect generate revenue rapastinel be grant breakthrough therapy status adjunction major depressive disorder fda allergan be also evaluate flagship product botox treatment major depressive disorder allergan have outperformed industry year date company share have moved industry decline johnson johnson jnj free report healthcare giant have strong presence neuroscience segment be core therapeutic area company have product risperdal consta schizophrenia bipolar disorder portfolio most promising candidate pipeline be esketamine investigational antidepressant medication blockbuster potential esketamine nmda receptor antagonist have novel mechanism action get breakthrough therapy designation fda major depressive disorder imminent risk suicide esketamine have be grant breakthrough therapy designation treatment resistant depression regulatory application indication unite state be expect be file year zack rank buy stock have underperform industry year date company stock have lose compare industry decline see complete list today zack strong buy rank stock here eli lilly company lly free report pharmaceutical giant lilly major drug cymbalta be used treatment major depressive disorder generalized anxiety disorder fibromyalgia neuropathic pain neuroscience portfolio lilly include drug prozac treatment major depressive disorder obsessive compulsive disorder bulimia nervosa panic disorder zyprexa treatment schizophrenia acute mixed manic episode associate bipolar disorder bipolar maintenance lilly zack rank stock have underperform industry company share have decline compare industry sdecline sage therapeutic inc sage free report sage be company work development cns treatment company portfolio include novel pipeline candidate target critical cns receptor system gaba nmda company lead program brexanolone sage be late stage development super refractory status epilepticus rare severe seizure disorder well postpartum depression ppd brexanolone have be grant breakthrough therapy designation unite state priority medicine designation eu treatment postpartum depression sage be schedule move phase ii placebo controlled study therapeutic indication mdd ppd essential tremorand parkinson disease sage zack rank stock underperform industry year date company share have lose compare industry decline today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
2187,AGN,paratek pharmaceutical inc prtk free report announce fda have accept new drug application ndas seek approval antibiotic candidate omadacycline ndas be grant priority review thus speeding review process decision be expect october ndas be seek approval once daily oral intravenous iv dose omadacycline treat community acquire bacterial pneumonia cabp acute bacterial skin skin structure infection absssi candidate already enjoy qualify infectious disease product fast track designation indication share company be almost market trading apr however paratek share have decline so far year underperform industry decline say period ndas submit include positive datum phase iii program evaluate omadacycline absssi cabp patient candidate be also well tolerate april paratek have announce inferiority omadacycline bayer bayry free report cabp drug avelox phase iii study chief medical officer paratek state resistance antibiotic be rise increase need new antibiotic paratek be also plan file marketing authorization european union omadacycline similar indication candidate be also be develop treatment urinary tract infection however be approve therapy available treatment cabp absssi include allergan plc agn free report teflaro moreover nabriva therapeutic plc nbrv free report be evaluate antibiotic candidate lefamulin late stage study cabp absssi apart omadacycline paratek acne candidate seysara be review unite state paratek pharmaceutical inc price paratek pharmaceutical inc price paratek pharmaceutical inc quotezack rankparatek have zack rank hold see complete list today zack rank strong buy stock here today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
2188,AGN,allergan plc agn free report hungary base partner gedeon richter plc have announce positive top line result third pivotal study evaluate company schizophrenia drug vraylar cariprazine expand indication entity be look get vraylar approve treatment adult major depressive episode related bipolar disorder notably vraylar be already approve unite state eu acute therapy manic mixed episode associate bipolar disorder well schizophrenia additionally fda approve drug november expand use maintenance therapy treatment schizophrenia share allergan have inched year so far industry decrease phase iii rgh md study be investigate dose vraylar mg mg adult patient major depressive episode associate bipolar disorder bipolar depression compare placebo study meet primary well secondary endpoint vraylar mg dosage show significantly greater improvement placebo montgomery asberg depression rating scale madrs baseline week mg dose fail reach statistical significance however drug be generally well tolerate trial also note total patient vraylar treatment discontinue trial due adverse event comparison treat placebo remind investor last december allergan gedeon produce positive top line result second pivotal phase iii rgh md program examine vraylar treatment bipolar depression study also meet primary endpoint base report datum company be plan submit regulatory application fda second half allergan have licensing agreement gideon richter hungarian multinational pharmaceutical biotechnology company co develop market vraylar unite state well canada schizophrenia drug perform well record sale compare be likely be key driver allergan top line national alliance mental illness bipolar disorder be most common mental disease third most frequent cause hospitalization unite state youth adult age year moreover adult country be affected bipolar disorder hence approval drug expand indication provide company access wider patient population base suffering bipolar issue other player bipolar disorder schizophrenia treatment market include astrazeneca plc azn free report seroquel xr johnson johnson jnj free report risperdal consta plc alk free report aristada allergan plc price allergan plc price allergan plc quote zack rankallergan carry zack rank hold see complete list today zack rank strong buy stock here wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2189,AGN,be week see protagonist stock crash news discontinuation phase iib study amgen reptha get positive chmp opinion verona pharma stock rally positive top line datum copd study fda accept sbla bristol myer opdivo recap past week most important plummet study result share protagonist therapeutic ptgx free report plummet announcement discontinuation phase iib study propel ulcerative colitis uc candidate ptg company decide discontinue study plan interim analysis propel study independent datum monitoring committee determine study not be able achieve primary endpoint clinical remission interim analysis be do datum first patient have complete week treatment ptg total patient population study be company have notified stop further treatment patient currently study protagonist have also postpone decision initiate phase ii iii ptg patient chronic pouchitis await full review interim datum propel study read more protagonist therapeutic stall ulcerative colitis study amgen repatha get positive chmp opinion amgen amgn free report announce committee medicinal product human use chmp european medicine agency ema render positive opinion company regulatory application seek approval include datum cardiovascular outcome study fourier european label pcsk inhibitor repatha application seek new indication repatha label adult establish atherosclerotic cardiovascular disease myocardial infarction stroke peripheral arterial disease reduce cardiovascular risk lower ldl level concurrently chmp give positive opinion marketing authorization amgen allergan agn free report abp biosimilar roche oncology drug herceptin biosimilar have be recommend approval treatment same type cancer positive metastatic breast cancer positive early breast cancer positive metastatic adenocarcinoma stomach junction read more amgen repatha gain chmp nod include outcome datum verona pharma surge study result share verona pharma plc vrna free report surge follow positive top line datum phase iib study evaluate pipeline candidate rpl rpl first class inhaled dual inhibitor be be evaluate maintenance treatment chronic obstructive pulmonary disease copd study meet primary endpoint rpl demonstrated clinically statistically significant improvement lung function dose level additionally secondary endpoint be also meet support potential clinical benefit rpl treatment copd positive result study support progression rpl later stage development inhaled treatment copd patient verona pharma doesn have approve product portfolio successful development drug significantly boost result bristol myer opdivo sbla accept fda fda accept bristol myer squibb company bmy free report supplemental biologic license application sbla blockbuster drug opdivo combination yervoy treatment adult microsatellite instability high msi mismatch repair deficient dmmr metastatic colorectal cancer mcrc have progressed follow treatment oxaliplatin irinotecan agency have also grant application priority review set action date jul combination be already approve variety oncology indication seattle genetic get breakthrough therapy designation enfortumab seattle genetic inc sgen free report partner astella pharma inc announce fda have grant breakthrough therapy designation antibody drug conjugate adc enfortumab vedotin treatment patient suffering locally advanced metastatic urothelial cancer be previously treat checkpoint inhibitor cpi candidate be be study pivotal clinical trial ev nct monotherapy patient set early phase clinical trial combination cpi therapy ev nct company be also evaluate enfortumab vedotin other solid tumor include ovarian small cell lung carcinoma pharma plunge positive trial pharmaceutical hold company ltd bhvn free report share plunge significantly company announce positive top line result phase iii trial bhv bhv migraine candidate rimegepant formerly know bhv rimegepant be oral cgrp receptor antagonist be be evaluate acute treatment migraine cgrp receptor antagonist represent novel class drug candidate treatment migraine result be statistically significant clinically meaningful multiple outcome measure candidate meet co primary efficacy endpoint superiority placebo hour post dose pain freedom freedom most bothersome symptom company be schedule submit nda rimegepant however investor be not much impressed datum compare rival allergan migraine candidate ubrogepant medical biomedical genetic industry yr return medical biomedical genetic industry yr nasdaq biotechnology index lose last trading session major biotech stock biogen lose last month celgene lose vertex gain see last biotech stock roundup here biotech stock roundup alxn arna study datum prta team celgene next biotech world stay tune more regulatory pipeline update make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
2190,AGN,biotech major amgen inc amgn free report announce committee medicinal product human use chmp european medicine agency ema have give positive recommendation regulatory application seek approval include datum cardiovascular outcome study fourier european label pcsk inhibitor repatha label expansion application amgen be look get repatha approve prevent heart attack stroke coronary adult establish atherosclerotic cardiovascular disease europe amgen share have decline so far year be still better decrease register industry fourier outcome datum be already include label repatha follow fda approval december last year datum phase iii fourier study present last year have reveal significant reduction myocardial infarction stroke treatment repatha compare current best therapy alone repatha significantly reduce risk hard mace heart attack stroke cardiovascular death compare standard treatment statin therapy individual component risk heart attack stroke coronary be reduce respectively uptake repatha gain fda approval august have not be encourage so far due pricing re imbursement issue payer restriction sanofi sny free report partner regeneron pharmaceutical inc regn free report also face similar issue pcsk inhibitor praluent priority amgen right now be improve patient access repatha outcome datum fourier be key commercial success repatha broaden use drug cardiovascular indication approve be include repatha label patient access repatha be expect improve however analyst believe datum study look good be not very clear payer be willing improve access repatha base datum separate press release amgen partner allergan agn free report announce chmp have also give positive opinion recommend marketing authorization abp biosimilar version roche cancer drug herceptin amgen allergan be look get abp approve eu same cancer indication reference product include positive metastatic breast cancer positive early breast cancer positive metastatic adenocarcinoma stomach junction company application get biosimilar herceptin approve unite state be review decision fda expect meanwhile amgen allergan mvasi biosimilar version roche cancer drug avastin be approve unite state september last year eu early year amgen carry zack rank hold see complete list today zack rank strong buy stock here medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
2191,AGN,abbvie abbv free report partner neurocrine bioscience announce second pivotal phase iii study evaluate pipeline candidate elagolix uterine fibroid meet primary endpoint abbvie be look get elagolix approve oral medicine reduce heavy menstrual bleed premenopausal woman uterine fibroid elagolix be already review unite state management endometriosis associate pain abbvie share have increase more mar follow news release moreover so far year abbvie share price have increase compare favorably gain record industry come back latest release datum phase iii elaris uf ii study demonstrated elagolix combination low dose add back therapy reduce heavy menstrual bleed woman uterine fibroid compare placebo month safety profile candidate be also find be consistent first phase iii study elaris uf result study meet secondary endpoint well datum elaris uf ii study support regulatory submission elagolix aforementioned indication note positive top line datum first phase iii elaris uf study be announce february study also meet primary endpoint company press release uterine fibroid affect woman age experience symptom such heavy menstrual bleed painful period vaginal bleed time other menstruation anemia present be limit surgical treatment option woman suffering disease uterine fibroid be currently manage oral contraceptive progestin gnrh agonist many medicine be not specifically indicated treatment uterine fibroid hence approval candidate provide company access patient be need additional treatment option apprehend disease meanwhile pharma company allergan agn free report also have pipeline candidate ulipristal acetate portfolio be be evaluate treatment uterine fibroid be first oral treatment hit market be review unite state response expect regulatory agency august abbvie inc price abbvie inc price abbvie inc quotezack rank key picksabbvie carry zack rank buy other top rank stock health care sector be regeneron pharmaceutical inc regn free report ligand pharmaceutical incorporate lgnd free report regeneron sport zack rank strong buy ligand hold zack rank buy see complete list today zack rank stock here regeneron earning share estimate have moved respectively last day company pull positive earning surprise last quarters average beat ligand earning share estimate have moved last day company deliver positive surprise trail quarters average beat share price company have surge year breaking news cryptocurrency now bigger total market cap cryptos recently surpass more increase previous month re now bigger morgan stanley goldman sachs even visa new asset class expand even more rapidly new investor continue pour wall street become increasingly involved zack have just name company enable investor take advantage explosive growth cryptocurrency stock market click here access stock
2192,AGN,month have go last earning report allergan plc agn free report share have lose time frame recent negative trend continue lead next earning release be agn due dive investor analyst have react late let take quick look most recent earning report order get better handle important catalyst allergan beat earning salesallergan fourth quarter earning come share beating zack consensus estimate earning rise year year drive higher revenue lower cost lower share count offset impact lower gross margin higher sg spend revenue come beat zack consensus estimate revenue rise year period key product botox juvéderm collection filler new product vraylar viberzi namzaric do well quarter however sale erosion namenda xr aczone loss exclusivity mainly asacol hd minastrin hurt top line fourth quarter revenue also benefit addition alloderm lifecell january coolsculpt body contour system zeltiq april report revenue segment general medicine specialize therapeutic international specialize therapeutic net revenue increase drive continue strong performance facial aesthetic product botox juvéderm collection filler botox cosmetic rake sale botox therapeutic revenue be addition juvéderm collection filler rise eye care ozurdex sale increase restasis sale rise plastic surgery breast implant sale increase contribute upside medical dermatology aczone sale decline quarter due generic pressure brand acne category higher discount formulary coverage lifecell alloderm add zeltiq coolsculpt business add sale fourth quarter general medicine net revenue be flat report quarter sale decline diversify brand woman health franchise infective sale rise rise central nervous system sale rise establish product linzess loestrin well new product namzaric viberzi vraylar do well quarter linzess sale rise quarter drive strong demand loestrin sale rise backed strong demand trend higher selling price newer product namzaric once daily fix dose combination namenda xr record sale almost flat previous quarter viberzi record sale higher previous quarter vraylar sale be fourth quarter higher previous quarter drive demand growth namenda xr sale decline year year quarter due lower demand generic pressure asacol delzicol sale decline due reduction demand ascaol hd follow launch authorize generic august well lower demand delzicol woman health segment minastrin revenue decline quarter due loss exclusivity march last year international segment record net revenue year period drive growth facial aesthetic botox therapeutic eye care addition coolsculpt profit riseadjust operate income increase fourth quarter adjust operate margin rise basis point quarter quarter due improve operate leverage lower cost selling general administrative sg expense rise quarter primarily due cost related acquisition expense decline due cost control program resultsfull year sale beat zack consensus estimate revenue be guidance sale rise year year adjust earning be share beat zack consensus estimate share be guide range earning rise year year outlookin allergan expect lower revenue earning face generic competition restasis allergan maintain previously issue total sale guidance range approximately assume generic restasis be launch april july meanwhile company say expect adjust earning range share january allergan have say expect earning least share adjust tax rate be expect be approximately adjust gross margin guidance be expect range be lower level gross margin be expect be hurt loss exclusivity high margin product restasis estrace delzicol unfavorable product mix adjust expense be expect be approximately sg spend be expect be approximately operate margin be expect be line slightly level call company say do not expect significant activity allergan expect reevaluate strategy second half year once get loe first quarter outlookin first quarter revenue be expect be earning share be expect be number represent lowest revenue earning quarter year fourth quarter favorable timing physician rebate program benefit sale allergan facial aesthetic product benefit be miss first quarter such company expect first quarter revenue growth rate be somewhat lower annual growth rate also generic competition estrace namenda xr hurt sale sharply first quarter have estimate be move then past month investor have witness downward trend fresh estimate have be revision higher current quarter compare lower allergan plc price consensus allergan plc price consensus allergan plc quotevgm scoresat time agn have nice growth score be lag bit momentum front follow exact same course stock be also allocate grade value side putt middle investment strategy overall stock have aggregate vgm score aren focuse strategy score be be interested base score stock be more suitable growth investor look value momentum outlookestimate have be broadly trend downward stock magnitude revision indicate downward shift interestingly agn have zack rank hold expect line return stock next few month
2193,AGN,aerie pharmaceutical inc aeri free report post fourth quarter loss share wider zack consensus estimate loss year loss cent aerie pharmaceutical inc price consensus aerie pharmaceutical inc price consensus aerie pharmaceutical inc quote quarter detailin december aerie lead drug rhopressa be approve fda reduction elevated intraocular pressure iop patient open angle glaucoma ocular hypertension approval come month ahead schedule prescription drug user fee act date feb report quarter research development expense more double general administrative expense surge also higher operate expense report quarter reflect increase activity associate expansion employee base support operational growth preparatory activity associate rhopressa effort apart research development expense related envisia asset acquisition loss share come wider zack consensus estimate loss pipeline updatesaerie currently evaluate second candidate roclatan once daily quadruple action fix dose combination rhopressa xalatan nda roclatan be expect be file second quarter company have initiate phase iii trial mercury third quarter prepare regulatory submission europe be inferiority trial compare roclatan prescribe fix dose combination ganfort meanwhile aerie plan launch drug rhopressa mid second quarter company have hire regional sale director district manager well more expect territory manager company expect gain prefer formulary coverage majority commercial payer rhopressa late most medicare part coverage expect commence outlookaerie expect rhopress revenue range takea wider expect loss fourth quarter be due higher operate expense aerie receive significant boost approval lead drug rhopressa fda nod come ahead pdufa date february regulatory agency approval significantly boost aerie prospect glaucoma be largest segment global ophthalmic market aerie share price have outperformed industry last month stock have gain versus industry decline however aerie face stiff competition establish brand generic pharmaceutical company drug such novartis nvs free report simbrinza travtan allergan agn free report lumigan well product other smaller biotechnology pharmaceutical giant valeant pharmaceutical vrx free report vyzulta be recently approve open angle glaucoma ocular hypertension rhopressa confront tough time gain market share due competition product zack rankaerie carry zack rank hold see complete list today zack rank strong buy stock here hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
2194,AGN,abbvie inc abbv free report partner neurocrine bioscience announce phase iii study late stage meet primary endpoint woman uterine fibroid top line result first pivotal phase iii study elagolix elaris uf reveal month elagolix combination low dose add back hormone therapy reduce heavy menstrual bleed compare placebo woman uterine fibroid achieve clinical response study also meet rank secondary endpoint month hypoestrogenic effect such hot flush reduction bone mineral density elagolix treatment be observed study however overall safety profile elagolix be consistent be observed phase ii study uterine fibroid datum phase iii study support regulatory submission elagolix be present upcoming medical conference elagolix be review unite state management endometriosis associate pain so far year abbvie share price have return compare favorably gain record industry note be many other company have pipeline candidate be evaluate uterine fibroid bayer bayry free report be evaluate vilaprisan woman suffering uterine fibroid phase iii asteroid studyallergan agn free report pipeline candidate ulipristal acetate be regulatory review unite state company expect fda give decision first half separate press release abbvie also announce have inked anexclusive strategic collaboration option agreement clinical stage gene therapy company voyager therapeutic vygr free report develop commercialize vectorized antibody treatment alzheimer disease other disease deal voyager receive upfront cash payment well potential preclinical phase option payment follow announcement deal share voyager rise almost abbvie inc price abbvie inc price abbvie inc quotezack rankabbvie currently carry zack rank buy see complete list today zack rank strong buy stock here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
2195,AGN,israel base drugmaker teva pharmaceutical industry limit teva free report be major mess right now question now be world largest generic maker recover teva carry zack rank strong sell company have see earning estimate decline respectively past day teva share have slump past year compare industry decline teva be face significant challenge form rapid erosion sale copaxone blockbuster multiple sclerosis injection new competition brand product pricing erosion generic business lower expect contribution generic launch massive debt load generic version copaxone mg be be market momenta pharmaceutical inc mnta free report sandoz novartis nvs free report generic arm mylan myl launch version mg formulation october same month major blow teva mylan launch risk generic version mg thrice weekly formulation much earlier expect entry generic version mg formulation entry second generic version mg formulation have be rapid erosion sale copaxone moreover second generic version mg formulation be launch sandoz february year much earlier expect april copaxone generate sale level teva expect copaxone generate sale globally significantly lower franchise continue erode meanwhile other drug specialty segment be also face generic pressure generic version azilect be launch unite state january sale have start decline sharply proair be also expect see generic competition second half generic industry be face significant competitive pricing pressure thereby hurt sale teva generic segment increase fda generic drug approval ongoing customer consolidation be result additional competitive pressure industry ongoing consolidation customer generic industry lead increase price erosion consolidation industry have increase ability negotiate lower price generic drug accelerate fda approval additional generic version compete patent medicine increase competition largest product concerta authorize generic lower expect contribution generic launch stringent government regulation be also hurt sale generic segment challenge generic market be expect continue management expect lower revenue profit generic unit potentially due generic industry pressure fact generic segment sale be expect decline roughly level due ongoing price erosion generic concerta teva debt be approximately end much higher approximately end due debt finance allergan agn free report actavis generic acquisition increase debt company borrow cost have increase significantly be hurt profit recur issue be not enough fourth quarter conference call teva announce potential delay approval fremanezumab cgrp episodic chronic migraine january teva partner celltrion receive fda warning letter facility south korea facility manufacture api fremanezumab remediation issue celltrion result delay approval fremanezumab teva new ceo kare schultz announce restructure plan december turn company fortune teva have new organizational structure place be close plant cut generic portfolio divest core asset eliminate low value project aim cut global workforce more next year revive growth however resumption organic growth seem unlikely prior especially teva face erosion largest product copaxone revelation warren buffett berkshire hathaway own big stake company recently give boost stock however believe be only temporary impact downtrend share price continue year well nothing go right stock see complete list today zack rank strong buy stock here today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
2196,AGN,ironwood pharmaceutical inc irwd free report report fourth quarter adjust loss cent share narrower zack consensus estimate loss cent however company have report adjust loss cent year period total revenue collaborative revenue quarter amount year period beat zack consensus estimate quarter detaila report partner allergan plc agn free report ironwood key market product linzess linaclotide generate net sale year year please note ironwood allergan have equal share brand collaboration profit loss ironwood share net profit sale linzess unite state include collaborative revenue be fourth quarter year year milestone payment related approval linzess japan be include revenue accord datum provide im health linzess prescription filled quarter be more year period drug uptake continue grow remain market leader brand prescription drug report quarter selling administrative sg expense increase research development expense be year periodzurampic duzallo approve uncontrolled gout generate sale quarter august fda approve duzallo oral treatment hyperuricemia associate gout patient drug be launch october combine prescription drug filled quarter be higher prescription filled only zurampic previous quarter full year be year period revenue include receive milestone payment astella pharma related approval linzess japan loss share widen year year cent expense increase year sg expense rise company end cash cash equivalent available sale security guidance company expect use less operation company provide sg expense guidance range respectively pipeline updateslinzess be approve unite state treatment adult irritable bowel syndrome constipation ib chronic idiopathic constipation cic ironwood allergan be look broaden linzess label additional symptom develop drug opioid pain relieve agent ib patient phase iii study evaluate linzess additional abdominal symptom be expect start company be also discussion fda start phase iib study evaluate delay release formulation linaclotide treat subtype ib include ib mixed ib diarrhea ironwood partner japan astella pharma submit supplemental new drug application japan september label expansion linzess chronic constipation china hong kong macau ironwood have agreement astrazeneca plc azn free report linzess regulatory filing china ib be review company expect review be complete first half company be also develop candidate iw iw iw reflux disease diabetic nephropathy sickle cell disease respectively ironwood expect advance iw phase iii study second half december ironwood announce encourage top line datum phase iia study evaluate iw patient type ii diabetes hypertension candidate reduce blood pressure improve metabolic parameter fasting plasma glucose cholesterol diabetic hypertension patient compare baseline company fourth quarter loss be narrower estimate sale also beat expectation ironwood share gain almost thursday better expect result however look company share price movement show stock have underperform industry year so far ironwood share have lose period industry register increase ironwood be focuse expand linzess label geography company be also progress well other pipeline candidate moreover sale growth linzess be expect continue boost top line potential approval china be further boost sale drug ironwood pharmaceutical inc price consensus ep surprise ironwood pharmaceutical inc price consensus ep surprise ironwood pharmaceutical inc quotezack rank stock carry zack rank hold better rank stock pharma sector be xoma corp xoma free report carry zack rank buy see complete list today zack rank strong buy stock here xoma loss share estimate have narrow cent cent last day company pull positive earning surprise last quarters average beat share price company have sky-rocket past year wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2197,AGN,teva pharmaceutical industry limit teva free report report fourth quarter earning cent share beat zack consensus estimate cent share come ahead guide range cent cent however earning share decline year year revenue be marginally beat consensus estimate however sale decline year year exclude impact currency sale be hurt increase pricing erosion volume decline generic unit rapid erosion sale copaxone teva blockbuster multiple sclerosis injection specialty segment segment discussionteva revise segment structure follow actavis acquisition generic segment now include revenue otc business well api business generic medicine segment revenue be year year revenue generic business decline due significant competitive pricing pressure generic industry ongoing consolidation customer generic industry lead increase price erosion decrease volume consolidation industry have increase ability negotiate lower price generic drug accelerate fda approval additional generic version compete patent medicine increase competition concerta authorize generic stringent government regulation also hurt sale european generic revenue be flat year year however sale decline local currency term year period mainly due absence revenue generic business actavis unite kingdom be divest january rest world row generic revenue decline quarter local currency basis sale rise mainly due higher sale russia israel api revenue be flat otc revenue be local currency term specialty medicine revenue be year period due lower sale central nervous system cns product divesture core asset woman health business teva various therapeutic area cns sale decline due lower sale copaxone sale respiratory product decline oncology product sale rise woman health business record decrease revenue other specialty revenue decline worldwide revenue copaxone decline mainly due lower sale unite state sale decline unite state mainly due generic competition result higher rebate lower volume glatopa generic version copaxone mg be be market momenta mnta free report sandoz novartis generic arm mylan myl free report launch version mg formulation october same month major blow teva mylan launch risk generic version mg thrice weekly formulation much earlier expect entry generic version mg formulation entry second generic version mg formulation have be rapid erosion sale copaxone moreover second generic version mg formulation be expect be launch april year ex sale copaxone be flat local currency basis other product azilect sale decline generic version drug be launch unite state proair decline qvar decline hurt negative net pricing effect combine treanda bendeka revenue rise millionthe other segment distribution other activity record revenue year year company sell distribution business profit declineadjust gross margin contract basis point bps quarter research development expense decline almost year period selling marketing expenditure decline year level adjust operate income decline quarter lower cost resultsfull year sale beat zack consensus estimate also come ahead guide range sale rise year year gain inclusion actavis generic revenue teva acquire allergan agn free report generic segment actavis generic also generic distribution business anda adjust earning be share beat zack consensus estimate share exceed guide range share earning decline year year outlook expect revenue range fall short current zack consensus estimate company expect earning band share also short current zack consensus estimate share teva expect copaxone generate sale globally significantly lower franchise continue erode generic sale be expect decline roughly level approximately hurt ongoing price erosion generic concerta also proair franchise be expect see generic competition second half cost be expect decline teva beat expectation earning sale fourth quarter stock crash more thursday company issue weak outlook expect sale profit decline further year teva share have slump past year compare industry decline israel base generic drug maker have tough face significant challenge form accelerate generic competition copaxone new competition brand product pricing erosion generic business lower expect contribution generic launch massive debt load more mylan earlier expect launch first generic version mg strength copaxone be major setback teva teva divest core asset mainly woman health business cut significant debt load company also have new organizational structure place be close plant cut generic portfolio eliminate low value project aim cut global workforce more next year part restructure plan reveal december company expect save almost end restructure initiative clear path growth be not visible effort not be enough revive company fortune challenge period especially face erosion largest product copaxone other divesture pricing pressure generic business continue hurt top line teva carry zack rank sell teva pharmaceutical industry limit price consensus ep surprise teva pharmaceutical industry limit price consensus ep surprise teva pharmaceutical industry limit see complete list today zack rank strong buy stock here hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
2198,AGN,allergan plc agn free report fourth quarter earning come share beating zack consensus estimate earning rise year year drive higher revenue lower cost revenue come beat zack consensus estimate revenue rise year period key product botox juvéderm collection filler new product vraylar viberzi namzaric do well quarter however sale erosion namenda xr aczone loss exclusivity mainly asacol hd minastrin hurt top line fourth quarter revenue also benefit addition alloderm lifecell january coolsculpt body contour system zeltiq april company report revenue segment general medicine specialize therapeutic international specialize therapeutic net revenue increase drive continue strong performance facial aesthetic product botox juvéderm collection filler botox cosmetic rake sale botox therapeutic revenue be addition juvéderm collection filler rise eye care ozurdex sale increase blockbuster dry eye drug restasis sale rise plastic surgery breast implant sale increase contribute upside medical dermatology aczone sale decline quarter lifecell alloderm add zeltiq coolsculpt business add sale fourth quarter general medicine net revenue be flat report quarter sale decline diversify brand woman health franchise infective sale rise rise central nervous system sale rise establish product linzess loestrin well new product namzaric viberzi vraylar do well quarter linzess sale rise quarter drive strong demand loestrin sale rise backed strong demand trend higher selling price newer product namzaric once daily fix dose combination namenda xr record sale almost flat previous quarter viberzi record sale drive higher selling price namenda xr sale decline quarter due lower demand generic pressure asacol delzicol sale decline due reduction demand ascaol hd follow launch authorize generic august well lower demand delzicol woman health segment minastrin revenue decline quarter due loss exclusivity march last year international segment record net revenue year period drive growth facial aesthetic botox therapeutic eye care addition coolsculpt sg cost rise declinessel general administrative sg expense rise quarter primarily due cost related acquisition expense decline due cost control program resultsfull year sale beat zack consensus estimate revenue be guidance sale rise year year adjust earning be share beat zack consensus estimate share be guide range earning rise year year outlookallergan maintain previously issue total sale guidance range approximately meanwhile company say expect adjust earning range share last month allergan have say expect earning least share adjust tax rate be expect be approximately migraine candidate succeed phase iii studyallergan announce phase iii study evaluate migraine candidate ubrogepant meet co primary endpoint achieve study evaluate efficacy safety orally administer ubrogepant treat single migraine attack moderate severe headache intensity study datum demonstrated significant greater percentage patient treat ubrogepant dose mg mg be free pain hour initial dose compare treat placebo also statistically significant greater percentage ubrogepant patient experience absence most bothersome migraine associate symptom hour initial dose compare treat placebo takeallergan fourth quarter result be strong beat expectation earning revenue strong demand key drug botox addition positive top line datum ubrogepant study push share price pre market trading however past year allergan share price have decline compare industry decline allergan be face potential loss exclusivity several key product include namenda xr restasis generic version namenda xr be expect be launch early first quarter generic version restasis allergan second best selling drug be expect be launch second quarter also december mylan myl free report launch first generic version estrace cream generic version ulcerative colitis drug delzicol be expect be launch early second quarter meanwhile new competition key growth driver botox restasis linzess be investor concern december revance therapeutic next generation neuromodulator rt demonstrated substantial reduction severity glabellar line phase iii study longer duration efficacy compare currently market neuromodulator include botox product be be consider potential threat botox be market same indication shire shpg free report dry eye disease drug xiidra launch last year be pose strong competition restasis meanwhile synergy pharmaceutical inc sgyp free report trulance plecanatide be launch chronic idiopathic constipation competition linzess nonetheless allergan product botox linzess new product such viberzi vraylar support sale growth also boast strong brand pipeline biosimilar also represent significant opportunity also last month allergan announce cost save restructure program allergan be layer employee protect potential revenue decline allergan carry zack rank sell allergan plc price consensus ep surprise allergan plc price consensus ep surprise allergan plc see complete list today zack rank strong buy stock here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
2199,AGN,dublin ireland base allergan plc agn free report be engage development manufacturing marketing sale distribution brand pharmaceutical device biologic surgical regenerative medicine product allergan have be actively pursue deal expand portfolio especially brand product offer have complete acquisition company durata forest allergan acquire botox maker allergan inc mar acquisition allergan be previously know strong presence generic market find company top pharmaceutical company world base sale accretive acquisition lifecell zeltiq allergan have expand medical aesthetic business regenerative medicine body sculpting respectively allergan sell generic anda distribution business teva aug oct respectively allergan earning performance have be strong company beating expectation past quarters average positive earning surprise last quarters be allergan plc price ep surprise allergan plc price ep surprise allergan plc quotecurrently allergan have zack rank sell definitely change follow company earning report be just release have highlighted key stat just reveal announcement earning beat allergan fourth quarter earning share be consensus estimate share revenue beat revenue come beat zack consensus estimate revenue rise year period outlook allergan maintain previously issue total sale guidance range approximately meanwhile company say expect adjust earning range share last month allergan have say expect earning least share migraine candidate datum allergan also announce phase iii study evaluate migraine candidate ubrogepant meet co primary endpoint achieve study evaluate ubrogepant treat single migraine attack moderate severe headache intensity study datum demonstrated significant greater percentage patient treat ubrogepant dose mg mg be free pain hour initial dose compare treat placebo also statistically significant greater percentage ubrogepant patient experience absence most bothersome migraine associate symptom hour initial dose compare treat placebo share price impact share be pre market trading check back later full agn earning report later more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
2200,AGN,teva pharmaceutical industry ltd teva free report announce have complete divestment global woman health business privately hold private equity firm cvc capital partner deal be close cash divest portfolio include product contraception fertility menopause osteoporosis category drug portfolio include ovaleap zoely seasonique colpotrophine actonel be sell outside unite state product now be sell theramex woman health unit previously hold teva sale be part teva plan divestment specialty product woman health remind investor teva have sign definitive agreement sale cvc capital partner september moreover company also sign definitive agreement foundation consumer healthcare sale plan step brand emergency contraception cvc capital partner have appoint anish mehta former head international business development allergan agn free report theramex chief executive officer separate sec filing teva report have enter settlement agreement allergan jointly dismiss work capital dispute arbitration allergan pay teva part settlement teva share rise feb follow news however share company have decline past year underperform industry decline teva decline be attribute industry pressure generic competition blockbuster drug copaxone massive debt load teva also suffer setback october mylan myl free report launch generic version mg formulation copaxone much earlier expect order combat challenge teva have divest core asset cut significant debt load aim cut global workforce more next year teva pharmaceutical industry limit price teva pharmaceutical industry limit price teva pharmaceutical industry limit quotezack rank stock considerteva carry zack rank sell zoetis inc zts free report be better rank health care stock carry zack rank buy see complete list today zack rank strong buy stock here zoetis earning share estimate have increase last day company deliver positive earning surprise trail quarters average beat breaking news cryptocurrency now bigger total market cap cryptos recently surpass more increase previous month re now bigger morgan stanley goldman sachs even visa new asset class expand even more rapidly new investor continue pour wall street become increasingly involved zack have just name company enable investor take advantage explosive growth cryptocurrency stock market click here access stock
2201,AGN,allergan plc agn free report announce fda have approve label expansion infective drug avycaz ceftazidime avibactam nod drug be now approve treatment patient hospital acquire bacterial pneumonia ventilator associate bacterial pneumonia habp vabp due gram negative bacterium approval mark third therapeutic indication drug unite state notably avycaz be market treatment complicate urinary tract infection cuti include pyelonephritis cause designate susceptible pathogen consist certain pseudomona aeruginosa avycaz be also indicated cure adult patient complicate intra abdominal infection ciai combination metronidazole remind investor company supplemental new drug application snda avycaz be accept fda priority review october base precede qualify infectious disease product designation aforementioned indication importantly avycaz be first gram negative antibiotic approve unite state treat habp vabp year allergan share have lose year time outperform industry decline approval be base inferiority datum pivotal phase iii reprove study evaluate safety efficacy avycaz adult patient habp vabp trial meet primary endpoint show drug be inferior meropenem broad spectrum antibiotic reduce death risk irrespective cause drug also show study controlled environment outside human body activity certain gram negative bacterium cause habp vabp significantly avycaz be jointly market allergan pfizer pfe free report allergan have right avycaz north america right rest world be own pfizer avycaz rake sale month end sep year figure fda approval expand patient population improve commercial potential company press release habp vabp be second most common type nosocomial hospital originated infection unite state mainly intensive care unit hence potential market opportunity avycaz be huge country apart avycaz allergan infective portfolio comprise antibiotic namely teflaro allergan plc price allergan plc price allergan plc quote zack rank key picksallergan carry zack rank sell better rank stock health care sector be xoma corporation xoma free report exelixis inc exel free report carry zack rank buy see complete list today zack rank strong buy stock here xoma loss share estimate have narrow cent cent last day company come average beat stock have sky-rocket last month exelixis earning share estimate have be revise upward cent cent last day company deliver positive surprise trail quarters average beat share price company have soar year time breaking news cryptocurrency now bigger total market cap cryptos recently surpass more increase previous month re now bigger morgan stanley goldman sachs even visa new asset class expand even more rapidly new investor continue pour wall street become increasingly involved zack have just name company enable investor take advantage explosive growth cryptocurrency stock market click here access stock
2202,AGN,allergan plc agn free report report fourth quarter full year earning feb market open last quarter company deliver positive earning surprise allergan share price have decline past year industry witness decline allergan earning performance have be strong company beating expectation past quarters average positive earning surprise last quarters be allergan plc price ep surprise allergan plc price ep surprise allergan plc quotelet see thing be shape announcement factor establish product botox linzess loestrin restasis new product vraylar namzaric support sale fourth quarter fact label expansion botox fda approval forehead line treatment vraylar fda approval maintenance treatment schizophrenia be likely boost sale drug fourth quarter however believe sale erosion namenda xr due lower demand loss exclusivity mainly asacol hd minastrin again hurt top line zack consensus estimate botox linzess namenda xr be peg respectively third quarter new product viberzi kybella perform expectation remain be see sale product rise time addition alloderm lifecell january coolsculpt body contour system zeltiq april be expect support top line quarter higher promotional expense key product increase cost support advance pipeline acquisition lower margin lifecell zeltiq put pressure allergan margin investor focus be management comment impact new competition key growth driver restasis linzess remind investor third quarter call allergan say refrain activity next few month get better handle restasis situation allergan be face potential loss exclusivity restasis second best selling product october texas federal district court invalidate patent cover restasis potentially open door early generic competition restasis patent be schedule expire august generic version be launch second quarter also company say split company be not card moment update strategy be expect fourth quarter call expect management also comment cost save restructure program announce earlier year regulatory filing allergan say be layer employee protect potential revenue decline allergan also say plan eliminate additional open position company estimate incur cost approximately job cut other cost saving measure be expect save operate cost year also majority cost primarily due severance be reflect fourth quarter result also investor expect management comment weaker expect sale outlook allergan announce early january earning whispersour proven model do not conclusively show allergan be likely beat earning quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp most accurate estimate stand zack consensus estimate be peg lower result earning esp uncover best stock buy sell re report earning esp filter zack rank allergan have zack rank sell caution stock zack rank strong sell go earning announcement especially company be see negative estimate revision stock considersome stock biotech pharma sector have positive earning esp favorable zack rank be alexion pharmaceutical inc alxn free report earning esp zack rank company be schedule release result feb see complete list today zack rank stock here nordisk nvo free report have earning esp zack rank company be schedule release result feb astrazeneca plc azn free report be slate announce financial figure feb company have earning esp be zack rank stock wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2203,AGN,amgen amgn free report announce fully human monoclonal antibody aimovig erenumab meet primary secondary endpoint unique phase iiib study prevention patient episodic migraine have fail multiple prior preventive treatment notably aimovig be only investigational therapy design selectively block calcitonin gene related peptide cgrp receptor play significant role migraine activation aimovig be review unite state eu prevention episodic chronic migraine decision fda be expect moreover share company be year compare favorably industry increase phase iiib liberty study be design evaluate efficacy safety aimovig broad spectrum migraine patient range preventive treatment well have try fail such therapy result study demonstrated least patient achieve reduction monthly migraine day baseline last week compare placebo primary endpoint study datum trial also show consistent efficacy safety tolerability aimovig wider spectrum migraine patient include complicate case remind investor amgen develop aimovig collaboration novartis nvs free report company have now agree combine capability co commercialize candidate unite state incidentally amgen retain exclusive right japan novartis retain exist right rest world have exclusive right commercialize aimovig canada expand deal world health organization migraine be most debilitating illness approximately american daily activity be affected frequency severity migraine subject be undergo preventive therapy discontinue treatment year hence approval aimovig provide company much need access huge patient population unite state be need additional curative option apprehend disease however several company include teva pharmaceutical industry limit teva free report allergan agn free report other be also develop migraine treatment target cgrp amgen inc price amgen inc price amgen inc quote zack rankamgen carry zack rank hold see complete list today zack rank strong buy stock here wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2204,AGN,teva pharmaceutical industry limit teva free report announce phase iii study evaluate subcutaneous formulation asthma injection cinqair reslizumab do not meet primary endpoint cinqair be already available market intravenous formulation treat patient severe asthma elevated blood eosinophil phase iii registration study evaluate subcutaneously administer reslizumab fix dose mg pre filled syringe patient uncontrolled asthma elevated blood eosinophil top line result study show reslizumab be unsuccessful significantly reduce frequency clinical asthma exacerbation caes thereby fail meet primary endpoint other phase iii claim support study evaluate subcutaneous dose option patient oral corticosteroid ocs dependent asthma here too reslizumab fail meet primary endpoint reduction daily ocs dose teva state determine subsequent course action full review datum teva share have slump past year compare industry decline teva be face significant challenge form generic competition largest brand drug copaxone new competition brand product pricing erosion generic business lower expect contribution generic launch massive debt load generic industry be face significant competitive pricing pressure be hurt company top line teva blockbuster multiple sclerosis drug copaxone sale have be decline quite time now october major blow teva mylan myl free report launch risk generic version mg formulation much earlier expect meanwhile glatopa generic version copaxone mg be market momenta sandoz novartis nvs free report generic arm mylan also launch version mg formulation october entry generic version mg formulation second generic version mg formulation copaxone sale be expect erode rapidly additionally company debt burden increase result acquisition allergan agn free report generic unit allergan generic nearly debt company borrow cost have increase significantly be hurt profit order combat challenge teva have divest core asset cut significant debt load aim cut global workforce more next year however clear path growth be not visible effort not prove enough revive company fortune challenge period especially face erosion largest product copaxone teva carry zack rank sell see complete list today zack rank strong buy stock here wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2205,AGN,amgen inc amgn free report partner allergan agn free report announce european commission have grant marketing approval biosimilar version roche rhhby free report blockbuster cancer drug avastin bevacizumab mvasi drug be approve unite state september mvasi be approve eu treatment multiple type cancer note mvasi be first bevacizumab biosimilar be approve european union approval be line expectation consider committee medicinal product human use chmp european medicine agency ema have render positive opinion approval mvasi november approval be support comprehensive datum package demonstrated similarity mvasi bevacizumab amgen have collaborate allergan worldwide development oncology antibody biosimilar medicine other mvasi amgen allergan portfolio also include biosimilar version herceptin review unite state eu rituxan late stage study overall amgen have biosimilar pipeline include biosimilar version johnson johnson merck remicade alexion soliris amgen biosimilar version abbvie abbv free report blockbuster rheumatoid arthritis drug humira amjevita be approve fda september eu trade name amgevita march same indication humira amjevita be first biosimilar version humira be approve fda well amgen first biosimilar medicine be approve settlement agreement abbvie amgen begin selling amjevita most country eu year unite state january amgen biosimilar opportunity be likely translate annual revenue more amgen have also partner daiichi sankyo biosimilar japan past year amgen share have return compare increase register industry amgen carry zack rank hold see complete list today zack rank stock here make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
2206,AGN,biosimilar space be focus key fda approval biosimilar contain version active substance already approve original biological drug development biosimilar be technically more challenge development generic drug former require clinical study patient be engineer match reference drug quality safety efficacy due complex nature product development regulatory pathway biosimilar differ significantly generic biosimilar be usually less expensive brand drug thus market same be highly lucrative acceleration approval biosimilar market have thus attract lot many player be witness rapid growth here go progress report merck co inc mrk free report launch reneflexis biosimilar version remicade infliximab unite state july approval april fda also grant tentative approval lusduna nexvue biosimilar version lantus basal insulin pre filled dose device merck currently carry zack rank hold see complete list today zack rank strong buy stock here remicade have be see intense competition biosimilar space late note pfizer inc pfe free report supply inflectra biosimilar version remicade pfizer be strong player biosimilar market december pfizer get fda approval remicade biosimilar ixifi treatment rheumatoid arthritis crohn disease pediatric crohn disease ulcerative colitis ankylose spondylitis psoriatic arthritis plaque psoriasis company have portfolio market biosimilar medicine outside unite state include inflectra retacrit epoetin zeta nivestim filgrastim strong pipeline distinct biosimilar molecule various stage development pfizer currently carry zack rank generic leader mylan nv myl free report be also explore biosimilar market have potential grow early last december mylan partner biocon ltd announce fda approval ogivri trastuzumab dkst biosimilar version herceptin trastuzumab ogivri have be approve indication include label reference product herceptin include treatment overexpressing breast cancer metastatic stomach cancer ogivri be first fda approve biosimilar herceptin first biosimilar mylan biocon joint portfolio mylan currently carry zack rank meanwhile amgen inc amgn free report allergan plc agn free report win fda approval biosimilar version avastin september treatment multiple type cancer note mvasi be first biosimilar approve unite state treatment cancer amgen biosimilar version humir amjevita be already approve fda be launch unite state jan company resolve litigation abbvie inc abbv free report company have also submit bla fda abp biosimilar candidate herceptin july note company be collaborate oncology biosimilar include abp be second be submit fda approval company also submit marketing authorization application european medicine agency candidate note amgen have total biosimilar pipeline have be approve fda amgen currently carry zack rank boehringer ingelheim cyltezo adalimumab adbm biosimilar humira be also approve fda august medical generic drug industry yr return medical generic drug industry yr slew fda approval expect investor remain focuse space future zack editor chief go stockfull disclosure kevin matra now have more own money particular stock other believe short term profit potential also prospect more double today reveal explain surprising move new special report download free
2207,AGN,week have be pretty slow key announcement include allergan agn free report job cut announcement pfizer pfe free report collaboration agreement company sangamo arvina recap week most important storiesallergan announce job cut time announce third quarter result november allergan have say have look cost reduction order deal impact loss exclusivity loe key product include restasis week company announce cost cut restructure program lead elimination more currently filled position primarily commercial other function open position also be eliminate restructure cost primarily due severance be record mostly fourth quarter overall operate expense saving expect range compare company expect achieve additional cost reduction headcount spending rationalization read more allergan cut job loss exclusivity key drug pfizer protein degradation deal arvina pfizer have agree shell private biotech company arvina be focuse create new class drug base protein degradation company announce research collaboration license agreement discovery development drug candidate used arvina proprietary protac proteolysis target chimera platform novel technology be used creation small molecule therapeutic aim degrading disease cause cellular protein multus year agreement cover different therapeutic area see arvina drive discovery effort pfizer be responsible clinical development product result collaboration cover upfront milestone payment depend achievement specify preclinical clinical commercial milestone deal term include tiered royalty well protein degradation be area have be attract interest large cap company arvina have agreement roche rhhby free report well pfizer sangamo sign collaboration agreement pfizer have sign collaboration agreement sangamo development potential gene therapy used zinc finger protein transcription factor zfp tfs treatment amyotrophic lateral sclerosis al frontotemporal lobar degeneration ftld link mutation orf gene agreement see pfizer shell upfront payment well milestone payment worth tiered royalty net sale sangamo be responsible development zfp tf candidate pfizer be operationally financially responsible subsequent research development manufacturing orf zfp tf program other result product sangamo pfizer already have collaboration agreement be announce last year development gene therapy product hemophilia include sb read more pfizer collaborate sangamo gene therapy pfizer be zack rank hold stock see complete list today zack rank strong buy stock here company stock be last year compare rally industry belong roche macrogenic ink deal roche clinical stage biopharma company macrogenic be collaborate discovery development innovative monoclonal antibody base therapeutic treatment cancer well several autoimmune disorder infectious disease company respective platform include macrogenic dart platform roche crossmab dutafab technology be used selection bispecific format lead pipeline candidate roche be responsible further development such pipeline candidate deal see roche make upfront payment achievement milestone royalty future sale mylan partner start eylea biosimilar study mylan myl free report partner momenta announce intend start pivotal study propose biosimilar regeneron blockbuster eye drug eylea vascular endothelial growth factor vegf inhibitor eylea be indicated treatment neovascular wet age related macular degeneration macular edema follow retinal vein occlusion diabetic macular edema diabetic retinopathy patient diabetic macular edema study be schedule commence first half patient diabetic macular edema eylea be flagship product regeneron global sale come first month read more momenta mylan initiate trial biosimilar eylea cap pharmaceutical industry yr return large cap pharmaceutical industry yr nyse arca pharmaceutical index be last trading session major stock astrazeneca azn free report be last month pfizer be glaxosmithkline gsk free report decline see last pharma stock roundup here roche mnk announce acquisition agreement regulatory update novartis next pharma world watch update outlook be provide several company next week annual morgan healthcare conference zack editor chief go stockfull disclosure kevin matra now have more own money particular stock other believe short term profit potential also prospect more double today reveal explain surprising move new special report download free
2208,AGN,valeant pharmaceutical international inc vrx free report announce party case basile valeant pharmaceutical international inc et al case cv doc timber hill llc persh square capital management et al case cv doc have agree resolve claim litigation allergan plc agn free report subject court approval term recently revise litigation management agreement other defendant company pay settlement perish pay remain valeant be earlier require pay claim litigation remind investor december anthony basile allege shareholder allergan file lawsuit behalf putative class allergan shareholder valeant persh square ps management gp llc ps fund william ackman district court central district california valeant stock have rally last month industry decline company have be mired various controversy due price hike specialty drug erroneous financial report termination contract philidor rx service valeant start rebuild process new ceo joseph papa even be still too early comment reformation company effort sell core asset clear huge level debt be commendable bode well upcoming quarters valeant sell equity interest dendreon pharmaceutical inc china base sanpower group co ltd have also announce plan divest obagi additionally company sell inova pharmaceutical company be also divest pharmaceutical addyi business nov company lower debt approximately end first quarter divestiture core asset help company streamline product portfolio focus better core area dermatology clear debt well zack rank key picksvaleant carry zack rank hold better rank stock pharma sector be sucampo pharmaceutical inc exelixis inc exel free report sporting zack rank strong buy see complete list today zack rank stock here sucampo earning share estimate moved last day company deliver positive earning surprise trail quarters average beat exelixis earning share estimate increase cent cent last day company come positive earning surprise trail quarters average beat company share have climb last month investor alert breakthrough pendinga medical advance be now flashpoint theory realization billion dollar research have pour company be already generate substantial revenue even more wondrous product be pipeline cure variety deadly disease be sight so be big potential profit early investor zack name stock buy now click here see
2209,AGN,teva pharmaceutical industry limit teva free report announce fda have accept biologic license application bla seek approval monoclonal antibody candidate fremanezumab preventive treatment migraine fda grant priority review designation bla decision fda be expect mid teva look launch fremanezumab next year bla submission be support positive datum phase iii study halo program evaluate candidate patient episodic migraine chronic migraine cm fremanezumab be also be evaluate late stage study enforce prevention chronic episodic cluster headache latest press release company also say fda have grant fast track designation fremanezumab prevention cluster headache addition recently phase ii clinical program post traumatic headache have also be initiate meanwhile teva restructure plan announce last week aim lay more global workforce shut plant have result massive protest strike israel employee well country main public sector labor union strike briefly shut ben gurion airport bank stock exchange government office sunday teva be israel biggest employer last month teva new chief executive officer kare schultz announce new organizational leadership structure save cost increase productivity organizational change include departure head division teva share have slump so far year compare industry decline teva be face significant challenge form generic competition largest brand drug copaxone new competition brand product pricing erosion generic business lower expect contribution new generic launch massive debt load generic industry be face significant competitive pricing pressure be hurt company topline meanwhile teva blockbuster multiple sclerosis drug copaxone sale have be decline quite time now october major blow teva mylan myl free report launch risk generic version mg formulation much earlier expect meanwhile glatopa generic version copaxone mg be market momenta sandoz novartis nvs free report generic arm mylan also launch version mg formulation october entry generic version mg formulation entry second generic version mg formulation copaxone sale be expect erode rapidly additionally company debt burden increase result acquisition allergan agn free report generic unit allergan generic nearly debt company borrow cost have increase significantly be hurt profit order combat challenge teva have divest core asset cut significant debt load remain see latest corporate shake plan layoff divesture be enough revive company fortune challenge period especially face erosion largest product copaxone teva carry zack rank sell see complete list today zack rank strong buy stock here zack editor chief go stock full disclosure kevin matra now have more own money particular stock other believe short term profit potential also prospect more double today reveal explain surprising move new special report download free
2210,AGN,aerie pharmaceutical inc aeri free report announce fda have approve lead candidate rhopressa netarsudil ophthalmic solution lower elevated intraocular pressure iop patient open angle glaucoma ocular hypertension news come significant boost aerie give company have approve product portfolio fda approval come month ahead schedule prescription drug user fee act goal date feb aerie plan hire sale force representative first quarter plan launch drug mid approval be card dermatologic ophthalmic drug advisory committee fda vote favor rhopressa approval october member committee unanimously agree trial support efficacy netarsudil ophthalmic solution reduce elevated intraocular pressure patient open angle glaucoma ocular hypertension addition majority member agree rhopressa efficacy outweigh safety risk news surely relieve investor october aerie withdraw nda rhopressa unite state be submit third quarter third party manufacturing facility tampa fl not be ready pre approval inspection lead withdrawal contract drug product manufacturer have previously inform aerie fda be prepared inspection january then delay further manufacturer clarify delay be not result new find additional time need complete validation new equipment glaucoma be largest segment global ophthalmic market accord national eye institute have be estimate more individual unite state suffer glaucoma number be expect reach aerie share price have increase last month industry rally however aerie face stiff competition establish brand generic pharmaceutical company such novartis nvs free report simbrinza travtan allergan agn free report lumigan well other smaller biotechnology pharmaceutical company valeant pharmaceutical vrx free report vyzulta be recently approve open angle glaucoma ocular hypertension rhopressa face tough time gain market share due competition product meanwhile aerie second product candidate roclatan netarsudil latanoprost ophthalmic solution be fix dose combination rhopressa latanoprost achieve primary efficacy endpoint phase iii registration trial name mercury mercury also achieve successful month safety efficacy result mercury company expect submit nda roclatan second quarter zack rank aerie currently carry zack rank sell see complete list today zack rank strong buy stock here zack editor chief go stockfull disclosure kevin matra now have more own money particular stock other believe short term profit potential also prospect more double today reveal explain surprising move new special report download free
2211,AGN,irish pharma giant allergan plc agn free report have recently inked definitive agreement acquire texas base development stage company repro therapeutic repro be focuse develop new drug treat hormonal reproductive system disorder share allergan have decline year so far compare favorably industry decrease repro share plunge so far year same jump more follow news dec pursuant agreement allergan execute acquisition subsidiary cash tender offer share repro common stock close transaction be subject customary close condition repro anticipate completion buyout first quarter notably agreement add late stage candidate proellex enclomiphene allergan pipeline repro plan initiate phase iii study proellex treatment uterine fibroid hand company currently evaluate proellex selective progesterone modulator sprm phase iib study uterine fibroid vaginal delivery other enclomiphene be evaluation treat low testosterone level overweight man notably company have submit regulatory application european medicine agency ema september subsequently accept regulatory body positive note addition candidate boost allergan pipeline bode well company long term growth remind investor acquisition form integral part allergan expansion strategy company complete major takeover arrow specifar actavis group warner chilcott apart forest allergan inc deal past few year year so far allergan have burgeon medical aesthetic business regenerative medicine body sculpting accretive acquisition lifecell zeltiq respectively buyout not only provide allergan operational expertise also aid company enhance commercial presence fortify foothold key market allergan plc price allergan plc price allergan plc quotezack rank key picksallergan carry zack rank hold better rank stock health care sector be therapeutic inc cort free report achillion pharmaceutical inc achn free report carry zack rank buy see complete list today zack rank strong buy stock here earning share estimate have moved cent cent last day company deliver positive earning surprise trail quarters average beat share price company have sky-rocket year date estimate achillion loss share have narrow cent cent cent cent last day company surpass expectation last quarters average positive surprise make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
2212,AGN,market react negatively speculation surround likely retention alternate minimum tax amt amend tax reform bill pass senate last saturday latest draft await finalization conference committee house senate member inclusion amt final bill weigh corporate earning company have pay tax reinvest defer cash earning be believe tax reform aim lower corporate tax rate stimulate economic well employment growth not prove beneficial large cap entity however propose tax reform approve leave more cash hand drug biotech company cash be invest merger acquisition have be relatively fewer year compare last go say significant uncertainty regard timely pass tax reform have cast pall future biotech sector fact drug biotech space picked year debacle have be witness correction october sector have lose so far fourth quarter oct date major factor result correction be uncertainty surround pass tax reform drug biotech market have witness decline so far week due broader market pressure be same time frame market drug biotech sector be week be still quite few hide biotech treasure have witness significant upside stock risehere be stock have gain week have excellent prospect prove be good bet go forward revance therapeutic inc rvnc free report revance be california base biotechnology company have soar so far week increase be support positive top line result pivotal phase iii study evaluate revance next generation neuromodulator rt reduce wrinkle brow glabellar line datum study show rt achieve substantial reduction severity glabellar line long act duration month notably time take rt treat glabellar line be better currently market neuromodulator include allergan agn free report botox sucampo pharmaceutical inc share rockville md base sucampo have rise so far week rumor takeover probably push share price week sucampo share have be rise last couple month backed several positive development late september sucampo announce supplemental new drug application snda company market drug amitiza have be accept grant priority review fda be currently approve chronic idiopathic constipation cic adult irritable bowel syndrome constipation ib adult woman opioid induced constipation oic patient chronic cancer pain company be look get drug label expand include child age year pediatric functional constipation decision be expect jan moreover strong earning third quarter couple increase earning revenue guidance lead consistent rise stock vistagen therapeutic inc vtgn free report vistagen be california base company share company have surge so far week increase share price be drive patent grant patent trademark office uspto mid stage candidate av regard method production candidate be currently be evaluate treatment major depressive disorder mdd notably early november vistagen announce av have be grant european patent patent grant unite state eu strengthen company strategy intellectual property wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2213,AGN,roche hold ag rhhby free report announce positive result phase iii study immotion immuno oncology drug tecentriq study evaluate efficacy safety tecentriq avastin versus sutent renal cell carcinoma patient study meet co primary endpoint investigator assessed progression free survival pfs demonstrated combination tecentriq avastin provide statistically significant clinically meaningful reduction disease worsening death pfs patient pd protein compare sutent first line treatment patient suffering advanced metastatic renal cell carcinoma top line result co primary endpoint overall survival be not mature immotion be second successive positive phase iii study tecentriq include avastin combination component initial treatment study follow positive phase iii squamous small cell lung cancer nsclc impower study reveal tecentriq avastin chemotherapy have pfs advantage avastin chemotherapy note tecentriq be already approve european union unite state previously treat metastatic nsclc metastatic urothelial cancer so far year share company have moved compare industry gain addition roche announce positive result randomise phase ii go study compare polatuzumab vedotin combination bendamustine mabthera rituxan br br alone patient suffering relapse refractory diffuse large cell lymphoma be not candidate haematopoietic stem cell transplant study meet primary endpoint demonstrate addition polatuzumab vedotin br increase complete response rate end treatment measure positron emission tomography assessed independent review committee approval new drug potential label expansion exist drug bode well roche legacy drug herceptin mabthera be already face competition biosimilar novartis ag nvs have already launch biosimilar version rituxan mabthera europe amgen amgn free report partner allergan agn free report have also obtain fda approval biosimilar version avastin treatment type cancer include lung cancer colorectal cancer glioblastoma renal cell carcinoma cervix cancer biosimilar be market trade name mvasi be first cancer biosimilar approve unite state zack rank roche currently carry zack rank sell see complete list today zack rank strong buy stock here today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
2214,AGN,market react negatively speculation surround likely retention alternate minimum tax amt amend tax reform bill pass senate last saturday latest draft await finalization conference committee house senate member inclusion amt final bill weigh corporate earning company have pay tax reinvest defer cash earning be believe tax reform aim lower corporate tax rate stimulate economic well employment growth not prove beneficial large cap entity however propose tax reform approve leave more cash hand drug biotech company cash be invest merger acquisition have be relatively fewer year compare last go say significant uncertainty regard timely pass tax reform have cast pall future biotech sector fact drug biotech space picked year debacle have be witness correction october sector have lose so far fourth quarter oct date major factor result correction be uncertainty surround pass tax reform drug biotech market have witness decline so far week due broader market pressure be same time frame market drug biotech sector be week be still quite few hide biotech treasure have witness significant upside stock risehere be stock have gain week have excellent prospect prove be good bet go forward revance therapeutic inc rvnc free report revance be california base biotechnology company have soar so far week increase be support positive top line result pivotal phase iii study evaluate revance next generation neuromodulator rt reduce wrinkle brow glabellar line datum study show rt achieve substantial reduction severity glabellar line long act duration month notably time take rt treat glabellar line be better currently market neuromodulator include allergan agn free report botox sucampo pharmaceutical inc share rockville md base sucampo have rise so far week rumor takeover probably push share price week sucampo share have be rise last couple month backed several positive development late september sucampo announce supplemental new drug application snda company market drug amitiza have be accept grant priority review fda be currently approve chronic idiopathic constipation cic adult irritable bowel syndrome constipation ib adult woman opioid induced constipation oic patient chronic cancer pain company be look get drug label expand include child age year pediatric functional constipation decision be expect jan moreover strong earning third quarter couple increase earning revenue guidance lead consistent rise stock vistagen therapeutic inc vtgn free report vistagen be california base company share company have surge so far week increase share price be drive patent grant patent trademark office uspto mid stage candidate av regard method production candidate be currently be evaluate treatment major depressive disorder mdd notably early november vistagen announce av have be grant european patent patent grant unite state eu strengthen company strategy intellectual property wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2215,AGN,roche hold ag rhhby free report member genentech announce fda have converted accelerate approval avastin receive previously treat glioblastoma most aggressive form brain cancer full approval full approval be base datum phase iii eortc study avastin base treatment increase time disease progression death compare chemotherapy alone study however do not meet primary endpoint be significant increase overall survival avastin base treatment however show patient be able completely stop intake corticosteroid treatment avastin arm compare control arm evidence study show avastin treatment delay disease progression reduce need corticosteroid lead conversion provisional approval full apart recent approval drug be already approve unite state various indication include first second line treatment metastatic colorectal cancer advanced nonsquamous small cell lung cancer nsclc metastatic kidney cancer advanced cervical cancer recurrent ovarian cancer so far year share company have increase compare industry gain however drug have be face competition have be witness decline sale september amgen amgn free report partner allergan agn free report announce fda approve biosimilar version avastin treatment type cancer include lung cancer colorectal cancer glioblastoma renal cell carcinoma cervix cancer biosimilar be market trade name mvasi be first cancer biosimilar approve unite state be also first biosimilar avastin same country zack rank stock considerroche carry zack rank sell top rank health care stock same space be johnson johnson jnj free report sporting zack rank buy see complete list today zack rank strong buy stock here johnson johnson earning share estimate have moved last day company deliver positive earning surprise trail quarters average beat share price company have increase year date wall street next amazon zack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2216,AGN,revance therapeutic inc rvnc free report share surge more dec company announce positive top line result pivotal phase iii study evaluate next generation neuromodulator rt reduce wrinkle lie brow glabellar line phase iii study sakura sakura meet primary secondary endpoint demonstrate highly statistically significant improvement severity glabellar line rt placebo datum study show rt deliver substantial reduction severity glabellar line long act duration month candidate be generally well tolerate trial notably duration achieve rt treat glabellar line be better other market neuromodulator demonstrate duration month be important note allergan agn free report share drop almost follow news release rt be consider potential threat company lead drug botox be market same indication rt have longer duration compare allergan botox month revance share have significantly outperformed industry year date stock have soar compare industry gain same time frame notably company be conduct long term safety trial sakura rt already enrolled more patient site unite state canada study be expect complete second half study be successful plan be afoot submit regulatory application fda first half potential launch company rt be first neuromodulator long act duration month approve datum global industry analyst global aesthetic market represent revenue treatment neuromodulator moreover patient physician consider effect treatment duration most significant component injectable neuromodulator hence approval candidate be expect cater hugely unmet need patient prefer longer duration treatment glabellar line remind investor rt be also be evaluate other clinical program different indication revance plan initiate phase iii study rt treat cervical dystonia neurological muscle movement disorder rt be recently grant orphan drug designation cervical dystonia indication unite state moreover also plan release result phase ii study evaluate rt management plantar fasciitis year end revance therapeutic inc price revance therapeutic inc price revance therapeutic inc quotezack rank key picksrevance carry zack rank hold better rank stock health care sector be therapeutic incorporate cort free report achillion pharmaceutical inc achn free report carry zack rank buy see complete list today zack rank strong buy stock here earning share estimate have moved cent cent last day company deliver positive earning surprise trail quarters average beat share price company have sky-rocket year date achillion loss share estimate have narrow cent cent cent cent last day company come positive earning surprise trail quarters average beat wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2217,AGN,share sarepta therapeutic inc srpt free report have be rise past month biotech company stock have rally significantly outperform rise industry period company have only market product portfolio exondys receive accelerate approval last year september drug be approve treat patient duchenne muscular dystrophy dmd rare genetic disorder affect child have confirm mutation dmd gene susceptible exon skip company have progressed well exondys development pipeline candidate past monthsexondys pick wellcombine sale drug quarters be sale increase sequentially third quarter sarepta have increase revenue guidance fiscal second third quarter result due impressive adoption exondys patient company expect end year total sale range indicate sequential growth fourth quarter july sarepta have launch manage access program europe americas increase reach drug july sarepta settle ongoing global patent litigation biomarin pharmaceutical inc bmrn free report regard exclusive license patent pertain exon skip technology used dmd therapy settlement remove major overhang sarepta biomarin have grant global exclusive right dmd patent estate exondys future exon skip product sarepta pipeline progresssarepta be look build dmd pipeline exondys develop other exon skip treatment sarepta lead candidate golodirsen have demonstrated response rate time increase mean protein baseline dmd patient phase ii study datum be report september remind investor exondys have achieve nearly time increase mean protein baseline better efficacy show golodirsen production have increase investor skepticism potential become new better treatment option dmd patient sarepta have also enter gene therapy research collaboration french muscular dystrophy association genethon gain access latter micro gene therapy be capable target majority dmd patient meanwhile june company appoint dougla ingram new president ceo ingram have extensive experience lead biotech company have work various capacity allergan plc agn free report remain be see ingram used expertise help sarepta achieve potential sarepta therapeutic inc price sarepta therapeutic inc price sarepta therapeutic inc quotezack rank key picksarepta carry zack rank buy therapeutic incorporate cort free report be health care stock carry same rank sarepta see complete list today zack rank strong buy stock here earning share estimate have increase cent cent cent cent last day company deliver positive earning surprise trail quarters average beat company stock be so far year look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
2218,AGN,couple quiet week cancer space witness activity fda action label expansion positive datum readout major drug several company meanwhile biosimilar blockbuster cancer drug receive approval europe new drug be also grant approval treatment leukemia amgen inc amgn free report multiple myeloma drug kyproli receive fda nod include overall survival os datum head head endeavor study label first car therapy receive approval novartis ag nvs free report kymriah get boost fda accept supplemental biologic license application sbla seek label expansion diffuse large cell lymphoma dlbcl moreover astrazeneca azn free report lynparza get fda nod label expansion metastatic breast cancer teva pharmaceutical also announce approval label expansion acute promyelocytic leukemia drug trisenox injection first line set combination tretinoin moreover amgen partner allergan agn free report announce approval mvasi biosimilar version roche rhhby free report blockbuster cancer drug avastin europe datum readout include encourage datum merck mrk free report keytruda confirmatory phase iii lung cancer study exelixis inc exel free report cabometyx phase iii hepatocellular carcinoma study apart biolinerx ltd blrx free report also announce encourage partial result phase iia combat study pancreatic cancer lead pipeline candidate bl partial datum study show bl monotherapy be safe well tolerate patient give indication let see news detail amgen kyproli get label update avastin biosimilar approve fda approve regulatory application include os datum endeavor study label kyproli fda decision come much earlier expect be initially expect april similar application be review europe read more amgen get fda nod add endeavor datum kyproli label amgen inc price amgen inc price amgen inc quotenovartis car therapy sbla accept fda novartis announce fda have accept grant priority review sbla seek label expansion car therapy kymriah potential approval expand drug access patient relapse refractory dlbcl be ineligible relapse autologous stem cell transplant read more novartis sbla car therapy kymriah accept fda novartis ag price novartis ag price novartis ag announce label expansion lynparza breast cancer astrazeneca parp inhibit ovarian cancer treatment lynparza be grant label expansion unite state include metastatic breast cancer indication lynparza become first parp inhibitor approve treat metastatic breast cancer expand label certainly boost drug prospect give advantage other parp inhibitor be only approve ovarian cancer read more astrazeneca lynparza label now include breast cancer astrazeneca plc price astrazeneca plc price astrazeneca plc quotemerck keytruda impressive phase iii lung cancer study merck share get boost jan follow announcement keytruda combination lilly alimta carboplatin achieve dual primary endpoint confirmatory phase iii keynote study study be evaluate combination treatment metastatic squamous small cell lung cancer nsclc first line set datum be report much earlier anticipate february combination be grant accelerate approval aforementioned indication read more merck strong confirmatory phase iii lung cancer study merck company inc price merck company inc price merck company inc quoteexelixis cabometyx positive phase iii carcinoma study exelixis partner ipsen announce datum pivotal phase iii celestial study cabometyx datum study evaluate drug advanced hepatocellular carcinoma show achieve significant os benefit patient have receive prior treatment median os achieve drug be month versus month placebo read more exelixis ipsen report positive result lead cancer drug exelixis inc price exelixis inc price exelixis inc quoteapart gilead announce week have enter collaboration agreement pfizer develop car therapy yesacrta combination latter utomilumab patient refractory large cell lymphoma make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
2219,AGN,teva pharmaceutical industry ltd teva free report announce fda have approve label expansion trisenox injection include first line treatment acute promyelocytic leukemia apl patient combination tretinoin eligible apl patient have translocation pml rar alpha gene expression trisenox be currently approve similar indication patient be refractory relapse retinoid anthracycline chemotherapy drug be already approve eu first line second line treatment indication teva share have decline past year underperform industry decline period accord company trisenox combination retinoic acid increase survival rate dramatically reduce risk relapse help avoid chemotherapy related side effect low intermediate risk apl patient have be see clinical study trisenox combination retinoic acid lead overall survival rate almost relapse more year month median follow teva oncology portfolio include drug perform well third quarter register year year growth reach label expansion trisenox be expect further boost portfolio performance come quarters however teva be face headwind due pricing pressure generic industry also approval mylan myl free report generic version key drug copaxone october last year have negative impact fourth quarter revenue guidance moreover israeli firm be also face huge debt load swell acquisition allergan agn free report generic division bid get rid problem company bring new chief executive officer ceo kare schultz have play instrumental role turnaround denmark lundbeck be struggle string loss also work chief operate officer denmark base drug giant nordisk nvo free report new ceo announce restructure plan december order reduce cost improve business performance profitability cash flow generation productivity teva have announce cut job cut more company global workforce next year majority expect company also shut many office facility globe divest asset move be expect reduce cost base estimate end teva pharmaceutical industry limit price teva pharmaceutical industry limit price teva pharmaceutical industry limit quotezack rankteva carry zack rank sell see complete list today zack rank strong buy stock here today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
2220,AGN,amgen inc amgn free report stock be compare favorably gain record industry last year share price surge be support series positive news include promising datum several pivotal study rapid progress pipeline line extension positive trend be likely continue year well backed stock rally few new product be approve last year fda approve mvasi amgen allergan agn free report biosimilar version roche rhhby free report cancer drug avastin parsabiv secondary shpt eu approve amgevita amgen biosimilar version humira amgen also gain approval several line extension fda approval include new indication risk reduction major cardiovascular event datum repatha overall survival tower study leukemia drug blincyto label approval arefined indication metastatic colorectal cancerdrug vectibix eu approval pediatric formulation secondary shpt line extension expand eligible patient population drug drive sale higher future quarters amgen make several datum presentation study evaluate line extension key market product repatha kyproli blockbuster potential other study pipeline candidate tezepelumab asthma evenity osteoporosis factor likely support stock several pivotal datum readout regulatory milestone expect bullish run stock be likely continue year amgen expect regulatory approval pipeline candidate aimovig erenumab prevention episodic chronic migraine evenity label expansion prolium kyproli month amgen already receive fda approval expand patient population xgeva multiple myeloma patient biosimilar portfolio amgen expect eu approval mvasi fda eu approval biosimilar version roche other cancer drug herceptin also amgen newer drug prolium xgeva vectibix nplate sensipar be perform well trend expect continue next year drive sale sale other newer product kyproli repatha blincyto be expect pick be approve forlabel expansion last year amgen restructure plan be make leaner more cost efficient lend support bottom line amgen face challenge give presenceof biosimilar competition slowdown sale mature drug mainly blockbuster drug enbrel positive be expect outweigh headwind amgen market enbrel partnership pfizer inc pfe free report amgen carry zack rank hold see complete list today zack rank strong buy stock here today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
2221,AGN,quite few pharmaceutical industry merger include large deal be card now tax reform be place tax bill be sign law president donald trump december last tax rate corporate now go boost profit large drug biotech company meanwhile change tax code also allow company bring back huge cash hold overseas time tax rate also tax cut be expect prevent inversion be rampant drug industry change definitely leave more cash hand drug biotech company cash be invest merger acquisition have be few compare gilead gild free report nearly acquisition kite pharma johnson johnson jnj free report acquisition swiss biotech actelion be only noteworthy deal week senior executive largest pharmaceutical biotech company discuss impact tax reform merger acquisition plan use excess cash jp morgan healthcare conference ceo say brent saunder chief executive officer ceo allergan agn free report say first half year be likely see smaller deal such celgene celg free report bigger high profile merger large pharmaceutical biotech company probably happen latter half year next year last week celgene announce have offer buy small cancer drug developer impact biomedicine read more celgene acquire impact biomedicine boost pipeline lilly lly free report ceo dave rick chief financial officer dominic caruso say tax cut american company compete better foreign counterpart operate better tax environment caruso say new tax law provide more flexibility ease analysis term get transaction do same line merck mrk free report ceo meg tirrell say have access overseas cash give more financial flexibility think different way go transaction tirrell however confidently say even new tax law be implement company have enough power balance sheet make bolt acquisition want do michel vounatsos biogen biib free report ceo smartly argue tax overhaul spur activity rationale activity not be cash available go say be look set potential target gilead ceo john milligan say tax reform be good company allow plan long term fda approval process be quite lengthy meanwhile maintain goal investing replenish pipeline also say excess cash allow clean balance sheet repay debt conclusion overall be quite clear drug industry be optimistic tax reform fuel greater activity be major drug biotech player struggle organic growth need infusion new growth driver pipeline product portfolio internal development buyout strategic licensing deal be therefore inevitable innovation starve drug biotech company look growth highly competitive global marketplace give take several year million dollar develop new therapeutic scratch large pharmaceutical company sit huge pile cash prefer buy innovative small mid cap biotech company build pipeline matter company look buy drug biotech stock be current sale performance latter drug product prospect sale growth quality pipeline wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2222,AGN,allergan plc agn free report regulatory filing announce be layer employee part cost save restructure program protect potential revenue decline allergan say job cut impact employee commercial function revolve product category already face face loss exclusivity allergan also say plan eliminate additional open position company estimate incur cost approximately job cut other cost saving measure be expect save operate cost year also majority cost primarily due severance be record fourth quarter allergan currently employ more person job cut come time allergan be face potential loss exclusivity several key product include alzheimer treatment namenda xr blockbuster dry eye drug restasis be expect hurt sale allergan be adopt different way protect restasis second best selling drug generic competition restasis record sale first month allergan come fire enter agreement saint regis mohawk tribe latter obtain right patent cover restasis allergan be grant exclusive license restasis product lawmaker question unconventional move adopt company protect restasis generic competition deal tribe have raise concern curb generic competition pharmaceutical industry discourage generic drug maker make cheaper version expensive drug however october texas federal district court invalidate patent cover restasis potentially open door early generic competition restasis patent be schedule expire august generic version be launch early mid also year allergan face loss patent exclusivity estrace vaginal cream ulcerative colitis drug delzicol last week mylan myl free report launch first generic version estrace cream also new competition key growth driver restasis linzess be investor concern shire shpg free report dry eye disease drug xiidra launch last year be pose strong competition restasis meanwhile synergy pharmaceutical inc sgyp free report trulance plecanatide be launch last chronic idiopathic constipation competition allergan linzess past year allergan share have decline compare industry decline job cut be aim save dollar time allergan be face competitive generic pressure related highest revenue generate product allergan carry zack rank sell seethe complete list today zack rank strong buy stock here wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2223,AGN,key announcement week include couple acquisition announcement regulatory update novartis nvs free report recap week most important storiesroche buy cancer focuse ignyta roche rhhby free report have strong presence cancer market announce intention acquire ignyta deal value share ignyta be focuse development precisely target therapeutic guide diagnostic test cancer patient acquisition add entrectinib selective cns active tyrosine kinase inhibitor tki roche pipeline entrectinib be be develop tumor harbor ro ntrk fusion be currently pivotal phase ii study support dual nda submission successful entrectinib have breakthrough therapy designation unite state prime designation eu deal be expect close first half read more roche clinch deal acquire ignyta roche be zack rank hold stock see complete list today zack rank strong buy stock here mallinckrodt boost rare disease portfolio sucampo acquisition acquisition deal be announce week specialty pharma company mallinckrodt plc mnk free report say acquire sucampo approximately share deal close first quarter be expect boost mallinckrodt earning least cent share earning least cent share deal add market product amitiza rescula mallinckrodt portfolio couple phase iii asset vts niemann pick type npc cpp sulindac familial adenomatous polyposis fap pipeline peak net sale potential vts be estimate be more cpp sulindac be estimate be more target be file vts potential approval cpp sulindac early follow potential approval later year acquisition addition boost mallinckrodt rare disease portfolio show company effort diversify market product portfolio read more mallinckrodt buy sucampo diversify portfolio regulatory update novartis fda have expand label novartis tasigna so treatment free remission tfr datum be now part label inclusion datum provide additional novel option management philadelphia chromosome positive chronic myeloid leukemia chronic phase ph cml cp novartis also announce tafinlar mekinist combination therapy have be grant priority review fda adjuvant treatment stage iii braf mutation positive melanoma approval make tafinlar mekinist first adjuvant target therapy combination demonstrate significant clinical benefit patient braf mutation fda grant priority review agency be expect respond month date submission application instead usual month novartis have gain year date compare rally industry belong allergan announce combigan ruling allergan agn free report suffer setback unite state court appeal federal circuit ruling certain combigan patent be valid not infringe court say sandoz propose generic version combigan do not infringe patent cover combigan reversed earlier district court decision generic product infringe patent allergan intend file petition day combigan be part allergan eye care portfolio cap pharmaceutical industry yr return large cap pharmaceutical industry yr nyse arca pharmaceutical index be slightly last trading session major stock astrazeneca azn free report be lilly decline last month bristol myer squibb bmy free report be glaxosmithkline gsk free report decline see last pharma stock roundup here aerie rhopressa approve label expansion bmy pfizer drug next pharma world watch regulatory pipeline news pharma stock more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
2224,AGN,share intercept pharmaceutical inc icpt free report have decline industry rally intercept lead drug ocaliva be approve unite state combination ursodeoxycholic udca treatment primary biliary cholangitis pbc adult inadequate response udca monotherapy adult be unable endure udca drug be also grant conditional approval european commission initial uptake drug be encourage third quarter ocaliva record sale record second quarter however prescription demand softened follow dear health care provider letter fda safety communication ocaliva fda report death due ocaliva state drug also affect liver however intercept conduct analysis conclude patient be prescribe once daily dose ocaliva be time higher recommend weekly dose analysis be conduct consultation fda consequently intercept issue dear healthcare provider letter thereafter fda issue own safety communication reinforce recommend label dose intercept be also work fda further update ocaliva label safety purpose thus such news be likely dent sale potential meanwhile ocaliva be be evaluate other indication include alcoholic steatohepatitis nash primary sclerosing cholangitis psc company have earlier state plan initiate phase iii trial ocaliva nash patient cirrhosis second half expect trial start fda have approve redesign phase iii trial regenerate ocaliva safety efficacy treat nash patient liver fibrosis company now need achieve only co primary endpoint fibrosis improvement nash resolution compare earlier target achieve sample size trial have also be reduce approximately patient patient arm company complete enrolment interim analysis cohort regenerate trial datum readout first half nash market have huge potential tentative approval boost ocaliva prospect however bigwig novartis ag nvs free report gilead science inc gild free report have fxr agonist phase ii earlier stage clinical development be used treat pbc nash other liver disease gilead be conduct multiple phase iii trial nash patient various disease severity selonsertib inhibitor apoptosis signal regulate kinase company be also explore additional study nash gs small molecule allosteric inhibitor act protein protein homodimer interface acetyl coa carboxylase acquire nimbus therapeutic llc fxr agonist know gs gilead be also study number compound other liver disease include pbc psc allergan plc agn free report also have ongoing phase iii trial cenicriviroc immunomodulator block chemokine receptor type type treatment nash thus stiff competition intercept be unlikely stock turnaround tentative approval nash boost investore sentiment zack rankintercept currently carry zack rank hold see complete list today zack rank stock strong buy here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
2225,AGN,key announcement week include fda approval eye disease drug well diabetes treatment label expansion exist product regulatory pipeline update be also provide company astrazeneca azn free report johnson johnson jnj free report recap week most important storiesaerie rhopressa gain fda approval aerie pharmaceutical aeri free report get boost earlier expect fda approval rhopressa lower elevated intraocular pressure iop patient open angle glaucoma ocular hypertension approval be expect consider favorable advisory panel vote october approval come couple month ahead feb pdufa prescription drug user fee act goal date rhopressa be first product aerie portfolio company expect launch product mid second quarter read more aerie get early fda approval lead drug rhopressa merck pfizer diabetes drug get fda nod sglt inhibitor steglatro ertugliflozin have be develop merck mrk free report pfizer pfe free report gain fda approval treatment type ii diabetes steglatro be enter highly crowd diabetes market already have other sglt inhibitor form invokana farxiga jardiance steglatro have also be approve use combination metformin brand name segluromet januvia brand name steglujan priority review astrazeneca tagrisso label expansion astrazeneca supplemental new drug application snda use tagrisso osimertinib first line treatment patient metastatic small cell lung cancer nsclc tumor have egfr mutation have be grant priority review fda approval indication expand patient population significantly read more astrazeneca tagrisso label expansion filing accept fda janssen car deal priority review apalutamide janssen biotech have inked worldwide collaboration license agreement legend biotech usa inc legend biotech ireland limit subsidiary genscript biotech corporation development manufacture chimeric antigen receptor car cell drug candidate lcar lcar specifically target cell maturation antigen bcma be currently regulatory review china multiple myeloma mm meanwhile clinical study be be plan unite state term deal global net trade sale exclude greater china area be record janssen company split cost profit equally greater china janssen legend have cost sharing profit split arrangement deal term also include upfront payment janssen additional payment achievement development regulatory sale milestone be latest agreement field car have be attract lot interest recent quarters janssen also announce get priority review status fda new drug application nda apalutamide company investigational next generation oral androgen receptor ar inhibitor treatment man metastatic castration resistant prostate cancer crpc fda grant priority review response be april give be fda approve treatment currently available patient population timely approval be boost company cancer portfolio have gain year date compare rally industry belong allergan provide update vraylar seysara allergan agn free report provide couple update pipeline front company partner gedeon richter say vraylar cariprazine meet primary endpoint late stage adult major depressive episode associate bipolar disorder bipolar depression company plan seek label expansion indication second half read more allergan vraylar positive bipolar disease phase iii allergan also announce nda seysara have be accept review allergan partner paratek pharmaceutical be look get antibiotic approve treatment moderate severe acne vulgaris patient year age older approval come second half fda expand label pfizer bosulif grant btd bavencio fda have give nod label expansion pfizer bosulif use newly diagnosed chronic phase ph chronic myelogenous leukemia ph cml patient bosulif initial approval be use patient chronic accelerate blast phase ph cml resistance intolerance prior therapy expand indication increase addressable patient population significantly accord american cancer society new cml case be diagnosed unite state pfizer also announce fda have grant breakthrough therapy designation btd bavencio avelumab use combination inlyta treatment naïve patient advanced renal cell carcinoma rcc avelumab be partner merck kgaa breakthrough therapy designation help fasten development review drug be be evaluate treatment serious condition preliminary clinical evidence indicate drug be substantially better exist treatment clinically significant endpoint be second time bavencio have receive btd hard treat cancer first time be treatment patient metastatic merkel cell carcinoma mmcc disease have progressed least previous chemotherapy regimen label expansion clinical trial collaboration bmy opdivo bristol myer squibb bmy free report pd immune checkpoint inhibitor opdivo gain fda approval yet indication regulatory agency grant approval opdivo intravenous use adjuvant treatment patient completely resect melanoma lymph node involvement metastatic disease opdivo be already approve wide range indication alone well combination other agent be currently several study well fact company also announce clinical trial collaboration taris biomedical evaluation safety tolerability preliminary efficacy taris tar gemris combination opdivo phase ib study evaluate combination patient muscle invasive bladder cancer mibc be schedule radical cystectomy opdivo be prioritize brand bristol myer portfolio product bring sale first month bristol myer be zack rank hold stock see complete list today zack rank strong buy stock here cap pharmaceutical industry yr return large cap pharmaceutical industry yr nyse arca pharmaceutical index be slightly last trading session major stock merck be lilly bristol myer decline last month bristol myer be glaxo decline see last pharma stock roundup here teva announce major job cut lilly provide outlook next pharma world watch regulatory pipeline news pharma stock look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
2226,AGN,allergan plc agn free report partner paratek pharmaceutical prtk free report announce new drug application nda investigational once daily seysara sarecycline have be accept review fda treatment patient age year moderate severe acne vulgaris company expect response fda second half look allergan share price movement so far year show stock have outperformed industry stock have lose industry have decrease also share paratek be period allergan complete nda submission seysara october base positive datum phase iii study sc sc respectively trial meet primary endpoint reveal patient treat seysara mg kg demonstrated statistically significant improvement acne severity compare placebo week notably allergan own right development seysara unite state paratek retain right ex market other player conduct trial candidate same space foamix pharmaceutical ltd fomx free report be develop fmx late stage study treat moderate severe acne remind investor allergan have more project mid late stage development company have extend pipeline adjacent category nash parkinson disease gene therapy many promising phase ii iii program development track allergan also boast strong brand pipeline meaningful datum read out expect next year allergan plc price allergan plc price allergan plc quotezack rank key pickallergan carry zack rank hold better rank stock health care sector be therapeutic incorporate cort free report carry zack rank buy see complete list today zack rank strong buy stock here earning share estimate have moved cent cent last day company deliver positive earning surprise trail quarters average beat share price company have sky-rocket year date zack best private investment ideaswhile be happy share many article best recommendation most depth research be not available public start today next month follow zack private buy sell real time expert cover kind trade value momentum stock etf option move stock corporate insider be buy company be report positive earning surprise even look exclusive portfolio be normally close new investor click here zack private trade
2227,AGN,allergan plc agn free report partner gedeon richter announce positive top line result second pivotal phase iii study schizophrenia drug vraylar study evaluate vraylar cariprazine treatment adult patient major depressive episode associate bipolar disorder bipolar depression notably vraylar be already approve unite state eu acute treatment manic mixed episode associate bipolar disorder well schizophrenia additionally fda approve drug last month expand use maintenance therapy treatment schizophrenia share allergan have decline year so far compare favorably industry decrease phase iii rgh md study be investigate dose vraylar mg mg total patient bipolar depression study meet primary endpoint show significant improvement patient compare placebo drug be generally well tolerate study however also note total number patient be treat vraylar discontinue trial due adverse event comparison treat placebo base report datum company be plan submit regulatory application fda second half significantly allergan have licensing agreement gideon richter hungarian multinational pharmaceutical biotechnology company co develop market vraylar unite state well canada vraylar have perform well first month record sale compare register same period year drug be likely be key driver allergan top line national alliance mental illness bipolar disorder be most common mental disease third most common cause hospitalization unite state youth adult age year moreover adult country live bipolar disorder hence approval drug expand indication provide company access wider patient population base bipolar issue other player bipolar disorder schizophrenia treatment market include astrazeneca plc azn free report seroquel xr johnson johnson jnj free report risperdal consta plc alk free report aristada allergan plc price allergan plc price allergan plc quotezack rankallergan carry zack rank hold see complete list today zack rank strong buy stock here zack editor chief go stock full disclosure kevin matra now have more own money particular stock other believe short term profit potential also prospect more double today reveal explain surprising move new special report download free
2228,AGN,astrazeneca azn free report announce positive top line datum phase iv study evaluate market drug tudorza pressair aclidinium bromide mg twice daily expand indication phase iv ascent be conduct expand label tudorza include patient chronic obstructive pulmonary disease copd cardiovascular risk factor post marketing requirement pmr study be request fda be conduct total patient study meet primary efficacy safety endpoint datum study demonstrated treatment tudorza lead statistically significant reduction annual rate moderate severe copd exacerbation compare placebo notably tudorza be long act muscarinic antagonist lama be also market brand name eklira bretaris treatment copd more country globally include unite state astrazeneca share have outperformed industry year date stock have rally compare industry gain same time frame full evaluation ascent datum be underway further result be present forthcoming medical meeting base positive ascent datum astrazeneca expect submit supplemental new drug application nda fda expand label tudorza potential label expansion tudorza provide company access wider patient population base suffering copd remind investor march astrazeneca acquire right allergan agn free report brand respiratory business add tudorza portfolio april company enter strategic collaboration circassia pharmaceutical plc development tudorza copd drug duaklir unite state astrazeneca copd product market include symbicort pulmicort et al sale respiratory portfolio have decline first month year due pricing pressure competition unite state eu importantly company promising respiratory treatment pipeline include tralokinumab phase iii study severe asthma pt also phase iii study treat copd astrazeneca expect launch new respiratory medicine remain be see candidate improve company respiratory sale approval company press release copd be progressive serious lung disease commonly find affect approximately person worldwide moreover cardiovascular risk be see have biggest effect patient copd represent significant need such therapy astrazeneca plc price astrazeneca plc price astrazeneca plc quotezack rank key carry zack rank hold better rank stock health care sector be therapeutic incorporate cort free report achillion pharmaceutical inc achn free report carry zack rank buy see complete list today zack rank strong buy stock here earning share estimate have moved cent cent last day company deliver positive earning surprise trail quarters average beat share price company have sky-rocket year date achillion loss share estimate have narrow cent cent cent cent last day company come positive earning surprise trail quarters average beat look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
2229,AGN,ironwood pharmaceutical inc irwd free report announce encourage top line datum phase iia study evaluate lead soluble guanylate cyclase sgc stimulator candidate iw patient type ii diabetes hypertension candidate reduce blood pressure improve metabolic parameter fasting plasma glucose cholesterol diabetic compare baseline share company be pre market trading follow news however be close trade monday follow broader market pressure fact ironwood share have fall past month underperform industry gain period sgc candidate be evaluate separate phase iia study diabetic patient hypertension study evaluate dose regimen once daily mg day mg daily time first day follow once daily mg next day other be dose escalate study datum study show iw reduce blood pressure mmhg baseline mmhg placebo moreover candidate reduce fasting glucose cholesterol level mg dl mg dl respectively baseline patient population treat iw keep exist treatment regimen intact treatment regimen include separate medication hypertension diabetes encourage result achieve candidate pave way potential single medication treat disease candidate also be able treat other metabolic abnormality high cholesterol serum lipid level apart study ironwood be also develop candidate phase ii study treat diabetic nephropathy heart failure preserve ejection fraction pipeline progress ironwood key market product linzess be also grow back broad payer access continue demand however ironwood share brand collaboration profit loss equally allergan plc agn free report meanwhile potential approval synergy pharmaceutical inc sgyp free report supplemental new drug application january next year seek approval label expansion trulance irritable bowel syndrome constipation increase competition ironwood pharmaceutical inc price ironwood pharmaceutical inc price ironwood pharmaceutical inc quotezack rank stock carry zack rank hold therapeutic incorporate cort free report be better rank health care stock carry zack rank buy see complete list today zack rank strong buy stock here earning share estimate have increase cent cent cent cent last day company deliver positive earning surprise trail quarters average beat company stock be so far year look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
2230,AGN,teva pharmaceutical industry limit teva free report new chief executive officer kare schultz announce new organizational leadership structure save cost increase productivity organizational change include departure head division be effective immediately share teva rise monday however share have slump so far year compare industry decline israeli drugmaker longer have separate global group business generic specialty medicine instead teva now operate region north america europe growth market include generic specialty counter otc medicine generic specialty organization be combine consolidated global unit be head dr hafrun fridriksdottir be now serve president global generic marketing portfolio function have be form take care interface region operation however schultz joined teva nov make mention workforce reduction rumor have be do round lately last week israeli newspaper publish report state teva cut workforce ten percent israeli workforce however company do say be work detailed restructure plan detail be share next month israeli newspaper report also say current head chief scientific officer michael hayden be remove latest press release teva confirm rumor state hayden retire end year dr rob koreman dipankar bhattacharjee head specialty medicine generic medicine group respectively teva also announce top leadership change include michael mcclellan executive vice president chief financial officer effective immediately teva be face significant challenge form generic competition largest brand drug copaxone new competition brand product pricing erosion generic business lower expect contribution new generic launch massive debt load generic industry be face significant competitive pricing pressure affect company top line performance increase fda generic drug approval ongoing customer consolidation be result additional competitive pressure industry challenge generic market be expect continue rest year probably next teva blockbuster multiple sclerosis drug copaxone sale have be decline quite time now last month major blow teva mylan myl free report launch risk generic version mg formulation much earlier expect meanwhile glatopa generic version copaxone mg be market momenta sandoz novartis nvs free report generic arm mylan launch version mg formulation last month entry generic version mg formulation entry second generic version mg formulation copaxone sale be expect erode rapidly additionally company debt burden accrue result acquisition allergan agn free report generic unit allergan generic nearly debt company borrow cost have increase significantly be hurt profit order combat challenge teva have divest core asset cut significant debt load remain see latest corporate shake rumore layoff divesture be enough revive company fortune challenge period especially face erosion largest product copaxone teva carry zack rank strong sell see complete list today zack rank strong buy stock here today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
2231,AGN,accord israeli newspaper teva pharmaceutical industry ltd teva free report be expect reduce workforce consequently share company be more pre market trading nov however so far year stock have be compare industry decline daily teva be also plan lay current president global research development chief scientific officer michael hayden meanwhile company be face significant challenge form generic competition copaxone new competition brand product pricing erosion generic business lower expect contribution new generic launch massive debt load generic industry be also confront significant competitive pricing pressure thereby affect company top line performance also increase fda generic drug approval ongoing customer consolidation be result additional competitive pressure industry challenge generic market be expect continue year probably next well company lead brand drug copaxone be witness decline sale quite time now october mylan myl free report launch risk generic version mg formulation much earlier expect be major blow teva glatopa generic version copaxone mg be already be market momenta novartis nvs free report generic arm sandoz mylan myl free report launch version mg formulation october additionally company profitability be hurt huge debt burden accrue result teva acquisition allergan agn free report generic unit allergan generic order combat challenge teva have divest core asset cut significant debt load rumor workforce reduction plan probably cheer investor save cost company remain see effort be enough revive company fortune challenge scenario especially face erosion largest product copaxone zack rank teva have zack rank strong sell see complete list today zack rank strong buy stock here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
2232,AGN,allergan plc agn free report announce fda have approve supplemental new drug application snda label expansion schizophrenia capsule vraylar cariprazine maintenance treatment notably vraylar be already approve unite state acute treatment schizophrenia bipolar disorder be also approve europe give indication share allergan have decline year so far compare favorably industry decrease fda approval be base new datum week study prevention relapse adult patient schizophrenia datum study demonstrated long term treatment vraylar delay time relapse compare placebo course week significantly vraylar have perform expectation record sale year drug be likely be key driver allergan top line growth company press release approximately person be affected schizophrenia unite state also disease relapse patient year maintenance treatment be take hence vraylar label expansion maintenance therapy cater hugely unmet need patient require long term treatment option disease other player bipolar disorder schizophrenia treatment market be astrazeneca plc azn free report seroquel xr johnson johnson jnj free report risperdal consta plc alk free report aristada allergan plc price allergan plc price allergan plc quotezack rankallergan carry zack rank hold see complete list today zack rank strong buy stock here today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
2233,AGN,amgen inc amgn free report announce committee medicinal product human use chmp european medicine agency ema have give positive opinion expand label nplate include pediatric population nplate be presently market treatment chronic immune purpura itp autoimmune disease characterize low platelet count adult amgen be look get nplate approve use pediatric patient year age older be refractory other treatment corticosteroid immunoglobulin positive opinion be base study demonstrate nplate reduce rate bleed child rare blood disorder amgen share have rally year so far better industry growth separate press release amgen partner allergan agn free report announce chmp have render positive opinion marketing application biosimilar version roche rhhby free report cancer drug avastin abp accord company be first bevacizumab biosimilar have be recommend approval avastin biosimlar be approve unite state september be market trade name mvasi remind investor amgen allergan have collaborate worldwide development oncology antibody biosimilar medicine include roche avastin herceptin ritixan fact amgen have biosimilar pipeline biosimilar version abbvie abbv free report rheumatoid arthritis drug humira amjevita be approve fda last year eu march year same indication however settlement abbvie amgen begin selling amjevita most country eu next year unite state january currently amgen have zack rank hold see complete list today zack rank strong buy stock here make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
2234,AGN,aerie pharmaceutical inc aeri free report post third quarter loss cent share include stock base compensation wider zack consensus estimate loss cent year loss cent be development stage company aerie have not generate revenue product sale yet aerie share price have increase last month industry decline last month aerie stock price have surge positive news lead drug rhopressa quarter detailin report quarter research development expense decline general administrative expense surge higher operate expense quarter be attribute expansion employee base support operation preparatory activity include commercial manufacturing cost rhopressa aerie pharmaceutical inc price consensus aerie pharmaceutical inc price consensus aerie pharmaceutical inc quote pipeline updatesaerie resubmit new drug application nda lead candidate rhopressa feb expect review period month withdraw nda file september third party manufacturing facility tampa fl be not ready pre approval inspection fda company initiate preparation bring second contract manufacturer online oct dermatologic ophthalmic drug advisory committee fda vote favor rhopressa approval member committee unanimously agree trial support efficacy netarsudil ophthalmic solution reduce elevated intraocular pressure patient open angle glaucoma ocular hypertension addition majority member agree rhopressa efficacy outweigh safety risk fda have set prescription drug user fee act date feb note fda be not bound advisory committee guidance take advice consideration review drug apart rhopressa aerie be evaluate roclatan once daily quadruple action fix dose combination rhopressa pfizer inc pfe free report xalatan nda roclatan be expect be file second quarter company also initiate mercury support filing europe trial be inferiority trial compare roclatan prescribe fix dose combination ganfort combination bimatoprost timolol market allergan plc agn free report europe narrower expect loss third quarter be encourage be encourage company effort develop pipeline candidate potential approval rhopressa early significantly boost growth prospect zack rank key pick aerie currently carry zack rank hold better rank stock health care sector worth consider be exelixis inc exel free report carry zack rank buy see complete list today zack rank strong buy stock here exelixis earning share estimate increase cent cent increase cent cent last day company deliver positive earning surprise trail quarters average beat company share have moved so far year today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
2235,AGN,third quarter report cycle be draw close quarterly result have be strong overall beat percentage be line recent quarters growth rate have be particularly impressive also estimate revision trend have be mostly favorable nov member accounting index total market capitalization have report result accord earning preview total earning index member be year quarter improvement revenue beat ratio be earning revenue report total earning company be expect grow year year higher revenue please note broader medical sector include drug biotech well medical device company be expect record year year growth revenue earning big biotech pharma company report week generic maker mylan myl free report miss estimate earning sale due lower epipen sale one report last week pfizer pfe free report allergan agn free report beat earning expectation revenue come line zoetis zts free report beat expectation earning sale pfizer zoetis raise earning guidance allergan increase only upper end earning outlook here have small biotech pharma company be set report third quarter result nov let see thing be shape quarter puma biotechnology inc pbyi free report puma biotech be schedule release earning market close deliver positive surprise last quarter company earning track record have be good so far have deliver average positive surprise last quarters quarter puma have earning esp zack rank hold indicate likely positive surprise zack consensus estimate be peg loss share uncover best stock buy sell re report earning esp filter puma biotechnology only market product nerlynx neratinib be launch treatment positive breast cancer august so be first quarter puma record sale nerlynx read more puma earning surpass estimate again intrexon corporation xon free report intrexon be also schedule announce result market close last quarter company deliver positive earning surprise trail quarters miss expectation twice surpass estimate once meeting same other result average negative surprise company have earning esp zack rank sell zack consensus estimate be peg loss cent share investor focus be expect be intrexon pipeline conference call company be develop several candidate partnership other company read more store intrexon earning season ligand pharmaceutical inc lgnd free report ligand be expect report market close ligand earning history have be mixed bag company surpass estimate last quarters miss same other also deliver trail quarter average positive surprise last quarter company come positive earning surprise company have earning esp zack rank strong buy see complete list today zack rank stock here zack consensus estimate earning be peg cent share expect investor focus remain company update regard partnership major pipeline asset third quarter conference call read more store ligand earning season wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2236,AGN,ironwood pharmaceutical inc irwd free report report third quarter adjust loss cent share narrower zack consensus estimate loss cent flat year year total revenue collaborative revenue quarter amount year period beat zack consensus estimate ironwood share gain nov fact look company share price movement show stock have underperform industry year so far ironwood share have lose period industry register decrease quarter detaila report partner allergan plc agn free report ironwood key market product linzess generate net sale year year please note ironwood allergan have equal share brand collaboration profit loss ironwood share net profit sale linzess unite state include collaborative revenue be third quarter year year accord datum provide im health linzess prescription filled quarter be more year period report quarter selling administrative sg expense increase research development expense be year period zurampic approve uncontrolled gout generate sale quarter zurampic prescription filled quarter be higher prescription filled previous quarter august fda approve duzallo oral treatment hyperuricemia associate gout patient drug be launch october approval duzallo become first dual mechanism treatment patient uncontrolled gout pipeline updateslinzess be currently approve unite state treatment adult irritable bowel syndrome constipation ib mcg chronic idiopathic constipation cic mcg mcg ironwood allergan be look broaden linzess label additional symptom develop drug opioid pain relieve agent ib patient phase iii study evaluate linzess additional symptom be expect start company be plan advance delay release formulation linzess stop development delay release ironwood partner japan astella pharma submit supplemental new drug application japan september label expansion linzess chronic constipation china hong kong macau ironwood have agreement astrazeneca plc azn free report linzess regulatory filing be review china ib company expect review be complete first quarter july ironwood report positive datum iw phase iib study conduct patient uncontrolled gerd study meet primary endpoint result demonstrated oral dose iw mg administer twice daily combination proton pump inhibitor ppi significantly reduce heartburn severity patient compare ppi alone company be also develop candidate iw iw diabetic nephropathy sickle cell disease respectively guidance company expect use less operation previously company however maintain expense sg expense guidance range respectively ironwood pharmaceutical inc price consensus ep surprise ironwood pharmaceutical inc price consensus ep surprise ironwood pharmaceutical inc quotezack rank stock currently carry zack rank hold better rank stock pharma sector be inc agen free report carry zack rank buy see complete list today zack rank strong buy stock here loss estimate remain stable narrow last day company deliver positive earning surprise trail quarters average beat look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
2237,AGN,teva pharmaceutical industry limit teva free report report third quarter earning share miss zack consensus estimate share decline year year revenue be line zack consensus estimate sale increase year year exclude impact currency mainly due inclusion extra month revenue actavis acquisition compare third quarter last year teva acquire allergan agn free report generic segment actavis generic also generic distribution business anda inc last year exclude benefit actavis generic acquisition core sale performance be expectation sale quarter be hurt increase pricing erosion volume decline generic unit ongoing political turmoil venezuela loss exclusivity specialty segment quarter segment fourth quarter teva revise segment structure follow actavis acquisition generic segment now include revenue otc business well api business generic medicine segment revenue be year year revenue generic business decline due significant competitive pricing pressure generic industry ongoing consolidation customer generic industry have lead increase price erosion decrease volume consolidation industry have increase ability negotiate lower price generic drug moreover accelerate fda approval additional generic version compete patent medicine increase competition concerta authorize generic also hurt sale european generic revenue be local currency year period be due inclusion month revenue generic business actavis versus month year quarter rest world row generic revenue decline quarter local currency basis sale rise mainly due inclusion revenue actavis api revenue decline otc revenue be local currency term specialty medicine revenue be year period due lower sale central nervous system cns product teva various therapeutic area cns sale decline due lower sale multiple sclerosis drug copaxone teva lead brand product sale respiratory product rise oncology product sale rise woman health business record increase revenue other specialty revenue rise worldwide revenue copaxone decline mainly due lower sale unite state sale decline unite state due lower volume mg formulation negative net pricing effect price increase take january glatopa generic version copaxone mg be be market momenta sandoz novartis nvs free report generic arm mylan myl free report launch version mg formulation last month major blow teva last month mylan also launch generic version mg thrice weekly tw time week formulation much earlier expect mg formulation copaxone account more total copaxone scrip unite state end report quarter ex sale copaxone decline other product azilect sale decline generic version drug be launch unite state year proair rise combine treanda bendeka revenue decline qvar decline other segment distribution other activity record revenue year year segment mainly gain inclusion distribution revenue anda profit declineadjust gross margin contract basis point bps quarter due addition low margin anda distribution business low margin generic medicine specialty medicine segment research development expense decline year period selling marketing expenditure decline year level adjust operate margin decline bps quarter lower cost outlook slashedteva lower sale earning outlook second time year teva now expect revenue range compare expect previously company expect earning band share significantly lower share expect price erosion volume decline generic market lower expect contribution new generic launch unite state accelerate erosion copaxone sale follow earlier expect launch mg generic result guidance cut entry generic version mg formulation second generic version mg formulation teva estimate negative impact least cent share fourth quarter earning higher teva previous assumption cent meanwhile many other filer include momenta be also look get approval generic version mg formulation approve erode sale further teva now expect new product launch contribute revenue compare expect previously takeamid already lower expectation teva disappointing third quarter result slash outlook lead sharp decline share price share decline almost thursday hit week low fact share have slump so far year compare industry decline teva brand drug pipeline be progress decently have also divest core asset mainly woman health business include paragard plan step contraceptive cut significant debt load however not be enough revive company fortune challenge period particularly face erosion largest product copaxone be interesting see new chief executive officer kåre schultz guide israel base generic drug maker post turnaround teva carry zack rank strong sell teva pharmaceutical industry limit price consensus ep surprise teva pharmaceutical industry limit price consensus ep surprise teva pharmaceutical industry limit see complete list today zack rank strong buy stock here look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
2238,AGN,be approach tail end third quarter report cycle result have be strong overall accelerate revenue growth have be particularly impressive number company come positive surprise have be significantly higher revenue surprise trend historical average also estimate revision trend have be mostly favorable nov member accounting index total market capitalization have report result accord earning outlook total earning index member be year quarter improvement revenue beat ratio be earning revenue report total earning company be expect grow year year higher revenue meanwhile earning growth be currently expect be please note broader medical sector include drug biotech well medical device company be expect record year year growth revenue earning big biotech pharma company report week pfizer pfe free report allergan agn free report beat earning expectation revenue come line zoetis zts free report beat expectation earning sale pfizer zoetis raise earning guidance allergan increase only upper end earning outlook here have biotech pharma company be set report third quarter result nov let see thing be shape quarter mylan myl free report mylan be schedule release earning market open deliver negative earning surprise last quarter mylan earning have be mixed so far company top earning estimate trail quarters miss same other company deliver average negative earning surprise trail quarters quarter mylan have earning esp zack rank buy indicate likely positive surprise zack consensus estimate be peg share uncover best stock buy sell re report earning esp filter newly launch product acquisition meda renaissance topical business be likely aid top line however sale epipen auto injector be anticipate decline current quarter result increase competition impact authorize generic launch read more be beat card mylan earning season horizon pharma public limit company hznp free report horizon pharma be also schedule announce result open bell earning performance have be pretty impressive so far have deliver positive surprise last quarters average earning beat last quarters be last quarter company deliver positive earning surprise company have earning esp zack rank sell zack consensus estimate be peg cent share company expect continue double digit net sale growth ravicti meanwhile horizon pharma primary care business be pressure due implementation new commercial model read more horizon pharma earning disappointment store keryx inc kerx free report keryx be expect report market close last quarter company deliver negative earning surprise keryx performance last quarters have be disappointing company report wider expect loss trail quarters average negative surprise company have earning esp zack rank see complete list today zack rank strong buy stock here zack consensus estimate be peg loss cent share apart license fee keryx top line comprise revenue generate only market product auryxia be approve treat patient suffering chronic kidney disease ckd dialysis company believe recent formulary addition major part provider boost aurexia sale read more expect keryx earning season look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
2239,AGN,astrazeneca plc azn free report announce have enter agreement dispose theremaining right anaesthetic medicine aspen global incorporate agi mauritian subsidiary aspen group upfront consideration remind investor astrazeneca have divest right anaesthetic medicine outside market agi collaboration agreement sign june new deal agi acquire remain right intellectual property manufacturing know related astrazeneca anaesthetic medicine comprise diprivan emla xylocaine xylocard xyloproct marcaine naropin carbocaine citanest meanwhile astrazeneca continue manufacture supply medicine agi next year also company be entitle sale base milestone payment sep nov however new agreement agi not pay royalty astrazeneca be condition older agreement notably new deal be expect close fourth quarter so far year astrazeneca share have gain compare favorably industry growth astrazeneca have be regularly divest core asset marketing right treatment so focus resource main therapy area include oncology respiratory june company sell global right migraine treatment drug zomig outside japan grünenthal german pharmaceutical company march sell right inhaled respiratory medicine tudorza duaklir copd circassia pharmaceutical also enter deal sanofi sny vaccine unit sanofi pasteur development medi prevention respiratory syncytial virus rsv associate illness newborn infant same month again february enter agreement tersera therapeutic selling commercial right zoladex unite state canada last year astrazeneca divest outside right rhinocort aqua nasal spray indicated allergic allergic rhinitis affiliate johnson johnson jnj free report global right develop commercialize experimental crohn disease drug medi allergan plc agn free report right brand well authorize generic verison beta blocker heart medicine toprol xl aralez pharmaceutical inc astrazeneca currently carry zack rank hold see complete list today zack rank strong buy stock here trade profit big league trump policy stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
2240,AGN,share teva pharmaceutical teva free report open more higher monday struggle drugmaker picked lundbeck hluyy free report chief kare schultz fill long vacant ceo role schultz have be helm lundbeck be set take teva generic giant have be permanent ceo more month new job promise present several interesting challenge schultz change industry trend increasingly competitive market environment have lead significant headwind teva fact teva debt load have swell whopping follow acquisition allergan agn free report generic division company be now pressure shed asset effort pay debt accord bloomberg schultz likely be encourage consider splitting company business focuse specifically specialty medicine maintain generic operation last month report emerge teva be consider sale medis iceland base generic drug manufacturer other rumor suggest company be consider sale respiratory treatment asset regardless clear more deal need come wake teva lackluster earning management slash full year outlook cut dividend say asset sale likely generate least well level be previously forecast however teva scramble pay debt have not satisfied everyone recently moody say teva debt reduction have be slower expect lower credit rating course investor have also punish company prior today teva share be more year date stock be currently sporting zack rank strong sell nevertheless schultz seem task speaking bloomberg television earlier today new ceo say be kind person like challenge be inspire challenge schultz continue say important work very fast create clear strategy bring company strategic course want more stock market analysis author make sure follow ryan_mcqueeney twitter more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
2241,AGN,aerie pharmaceutical inc aeri free report announce initiation phase iii study mercury europe pipeline candidate roclatan roclatan be once daily quadruple action fix dose combination rhopressa pfizer pfe free report xalatan iis be evaluate lower intraocular pressure iop patient glaucoma ocular hypertension aerie stock have surge year date compare industry gain company be conduct mercury facilitate regulatory filing europe be not necessary approval unite state company expect patient enroll study study be arm month safety trial provide day interim efficacy readout study compare roclatan inferiority prescribe fix dose combination be ganfort combination bimatoprost timolol market allergan agn free report europe study be conduct mainly unite kingdom france germany italy spain belgium topline day efficacy datum be expect early remind investor company report positive month safety result july mercury phase iii study positive top line day efficacy safety datum second phase iii study mercury aerie expect submit new drug appication nda roclatan fda first half apart roclatan aerie be also evaluate rhopressa be design lower iop patient novel mechanism action moas treat patient glaucoma ocular hypertension feb company resubmit nda rhopressa expect standard review period month company also expect start clinical study rhopressa later address japanese market aerie pharmaceutical inc price aerie pharmaceutical inc price aerie pharmaceutical inc quotezack rank stock consideraerie currently carry zack rank hold better rank stock health care sector include alexion pharmaceutical inc alxn free report sporting zack rank strong buy see complete list today zack rank stock here alexion pharmaceutical earning share estimate have moved last day company deliver positive earning surprise trail quarters average beat share price company have increase year date simple trading idea zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar proven stock pick system be ground single big idea be fortune shape life change apply portfolio start today learn more
2242,AGN,month have go last earning report allergan plc agn free report share have lose time frame underperform market recent negative trend continue lead stock next earning release be due dive investor analyst have react late let take quick look most recent earning report order get better handle important driver allergan beat earning sale topallergan second quarter earning come share beating zack consensus estimate earning rise year year drive higher revenue lower share count interest expense offset lower gross margin higher tax rate revenue come year period beat zack consensus estimate key product botox new product vraylar namzaric viberzi do well quarter sale be once again hurt sale erosion namenda xr loss exclusivity mainly asacol hd minastrin also lower sale restasis aczone hurt top line second quarter revenue however gain addition alloderm lifecell jan coolsculpt body contour system zeltiq apr acquisition segment report revenue segment general medicine specialize therapeutic international specialize therapeutic net revenue increase drive strong growth botox addition lifecell alloderm zeltiq coolsculpt business botox cosmetic rake sale botox therapeutic revenue be addition juvéderm collection filler rise ozurdex sale increase contribute upside alloderm add coolsculpt add sale second quarter importantly restasis sale decline quarter due unfavorable trade buy pattern company expect stable restasis revenue year general medicine net revenue decline report quarter sale decline diversify brand woman health franchise infective sale rise central nervous system sale rise establish product linzess loestrin well new product viberzi namzaric vraylar do well quarter linzess sale rise quarter drive strong demand continue otc conversion loestrin sale rise backed strong prescription growth however lower namenda xr sale hurt performance cns franchise namenda xr sale decline quarter due lower demand lower pricing shift promotional effort namzaric company do not expect generic version namenda xr be launch first quarter delay prior expectation fourth quarter also allergan do not expect generic version estrace cream be launch year namzaric once daily fix dose combination namenda xr record sale compare previous quarter continue conversion namenda xr higher demand follow expand label new dosage pull sale namzaric asacol delzicol sale decline due generic competition ascaol hd follow launch authorize generic aug well lower demand delzicol woman health segment minastrin revenue decline quarter due loss exclusivity mar international segment record net revenue exclude currency impact year period drive growth facial aesthetic botox therapeutic addition lifecell coolsculpt profit declineadjust operate income increase second quarter adjust operate margin however decline basis point quarter quarter due higher operate expense addition lower margin lifecell zeltiq acquisition selling general administrative sg expense rise quarter primarily due higher foreign exchange transactional loss cost related acquisition promotional expense key product expense increase support advance pipeline company raise previously issue earning sale guidance follow strong first half performance solid outlook rest year allergan expect total revenue range compare previously currency headwind be now not expect hurt revenue versus negative impact approximately expect previously company say revenue be expect be highest fourth quarter mainly drive seasonality formulary coverage dynamic third quarter revenue be expect be similar level second quarter adjust earning share be expect range compare previously adjust earning guidance continue reflect strong double digit growth range adjust gross margin be expect slightly more expect previously due higher expect gross margin first half second half gross margin be expect be lower first half expense be expect be approximately maintain sg spend be expect compare previously meanwhile sg expense be expect be higher third quarter versus fourth quarter higher promotional activity give timing new launch continue strong promotion key brand be expect lead higher sale marketing cost third quarter have estimate be move then follow release investor have witness downward trend fresh estimate have be revision higher current quarter compare lower allergan plc price consensus allergan plc price consensus allergan plc quotevgm scoresat time stock have subpar growth score grade same score momentum front charting somewhat similar path stock be allocate grade value side putt top investment strategy overall stock have aggregate vgm score aren focuse strategy score be be interested style score indicate stock be more suitable value investor growth momentum investor outlookestimate have be broadly trend downward stock magnitude revision also indicate downward shift notably stock have zack rank hold be look inline return stock next few month
2243,AGN,be historic week not just novartis nvs free report also medical community patient fda give nod first gene therapy unite state novartis kymriah mark begin new era treatment cancer other serious life threaten disease recap week most important storiesnovartis get head start car market kymriah approval novartis get huge boost fda approve company car cell therapy kymriah child young adult cell acute lymphoblastic leukemia be refractory have relapse least twice make kymriah first car cell treatment be approve unite state path breaking immunocellular therapy be time treatment used patient own cell fight cancer cancer bone marrow blood progress quickly be most common childhood cancer unite state accord national cancer institute patient year younger be diagnosed year kymriah not only provide patient new treatment option have also show promising remission survival rate study novartis intend seek label expansion kymriah later year additional indication include treatment adult patient diffuse large cell lymphoma also read novartis car therapy kymriah receive fda approval share novartis have gain year date outperform industry rally novartis be zack rank hold stock see complete list today zack rank strong buy stock here allergan settlement agreement famy care restasis allergan agn free report enter settlement agreement famy care be look bring generic version allergan eye drug restasis market patent infringement lawsuit be settle famy care get license market generic version unite state feb earlier certain circumstance patent be schedule expire aug teva austedo nabs fda approval second indication teva pharmaceutical industry teva free report get good news finally company gain fda approval second indication austedo austedo have gain fda approval apr treatment chorea associate huntington disease be now approve treatment dyskinesia adult well dyskinesia debilitating often irreversible movement disorder be estimate affect person unite state also read teva austedo get fda nod label expansion dyskinesia teva be currently go tough time company performance be impact generic pricing erosion teva have many challenge ahead pay debt divest core business increase focus core area generate cash hire permanent ceo deliver pipeline get generic business back track lilly provide baricitinib regulatory update eli lilly company lly free report partner incyte provide update regard resubmission regulatory application unite state experimental rheumatoid arthritis ra treatment baricitinib company have previously say expect delay least month resubmission regulatory application baricitinib announce be resubmit regulatory application jan new safety efficacy datum be include resubmission also read lilly incyte re file baricitinib nda faster expect bayer hemophilia drug submit fda approval bayer ag bayry free report have submit biologic license application bla unite state long act site specifically pegylate recombinant human factor viii bay treatment hemophilia bayer portfolio already include hemophilia product form kogenate approve bay provide patient less frequent dose option astrazeneca inks deal takeda astrazeneca azn free report have sign takeda pharmaceutical joint development medi alpha synuclein antibody be develop parkinson disease pd investigational treatment be schedule enter early stage development later year phase development be conduct astrazeneca future clinical development activity be handled takeda future development cost well future revenue be share company deal term include astrazeneca include initial revenue development sale milestone thereafter parkinson disease second most common disease be estimate affect person world also read astrazeneca takeda ink deal develop parkinson drug cap pharmaceutical industry yr returnlarge cap pharmaceutical industry yr nyse arca pharmaceutical index be last trading session major stock record gain bristol myer squibb rise lilly be baricitinib update last month be merck mrk free report decline see last pharma stock roundup here roche drug get priority review eu nod novartis drug next pharma world watch usual pipeline regulatory update company astrazeneca be present european society medical oncology esmo congress datum presentation approve pipeline candidate more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
2244,AGN,allergan plc agn free report third quarter earning come share beating zack consensus estimate earning rise year year higher revenue offset higher cost quarter company record impairment charge primarily related restasis aczone impairment charge related loss investment teva pharma teva free report security include charge company report loss share compare loss share year quarter last month texas federal district court invalidate patent cover dry eye drug restasis allergan second best selling drug potentially open door early generic competition restasis patent be schedule expire august however generic be launch much earlier earning release company say have file notice appeal court impairment charge restasis be relation adverse ruling aczone be response generic pressure brand acne category revenue come year period line zack consensus estimate key product botox restasis new product vraylar namzaric viberzi do well quarter however sale erosion namenda xr loss exclusivity mainly asacol hd minastrin hurt top line third quarter revenue also benefit addition alloderm lifecell january coolsculpt body contour system zeltiq april company report revenue segment general medicine specialize therapeutic international specialize therapeutic net revenue increase drive continue strong performance botox higher sale juvéderm collection filler restasis botox cosmetic rake sale botox therapeutic revenue be addition juvéderm collection filler rise ozurdex sale increase contribute upside restasis sale rise quarter aczone sale decline quarter lifecell alloderm add zeltiq coolsculpt business add sale third quarter general medicine net revenue be flat report quarter sale decline diversify brand woman health franchise infective sale rise rise central nervous system sale rise establish product linzess loestrin well new product namzaric vraylar do well quarter linzess sale rise quarter drive strong demand favorable trade buy pattern loestrin sale rise backed strong prescription growth higher selling price however lower namenda xr sale hurt performance cns franchise namenda xr sale decline quarter due lower demand lower pricing shift promotional effort namzaric namzaric once daily fix dose combination namenda xr record sale compare previous quarter continue conversion namenda xr higher demand follow expand label new dosage pull sale namzaric asacol delzicol sale decline due reduction demand ascaol hd follow launch authorize generic august well lower demand delzicol woman health segment minastrin revenue decline quarter due loss exclusivity march international segment record net revenue year period drive growth facial aesthetic eye care addition coolsculpt cost risesel general administrative sg expense rise quarter primarily due higher foreign exchange transactional loss cost related acquisition expense increase support advance pipeline outlook company narrow previously issue earning sale guidance allergan expect total revenue range compare previously adjust earning share be expect range compare previously adjust gross margin guidance be maintain range approximately company maintain sg expense guidance expense be expect be approximately sg spend be expect takeallergan third quarter result be mixed company beat expectation earning deliver line revenue company slightly lower sale guidance raise lower end earning guidance probably boost investor confidence time allergan be face multiple challenge share be pre market trading so far year allergan share price be compare industry decline allergan be face patent challenge quite few product include generess fe namenda xr asacol hd other adverse ruling related restasis allergan also recently come fire enter agreement saint regis mohawk tribe protect restasis generic competition lawmaker question unconventional move adopt company deal tribe have basically raise concern curb generic competition pharmaceutical industry discourage generic drug maker make cheaper version expensive drug meanwhile new competition key growth driver restasis linzess be investor concern shire shpg free report dry eye disease drug xiidra launch last year be pose strong competition restasis meanwhile synergy pharmaceutical inc sgyp free report trulance plecanatide have be launch year chronic idiopathic constipation competition linzess nonetheless allergan product botox linzess new product such viberzi vraylar support sale growth also boast strong brand pipeline biosimilar also represent significant opportunity allergan carry zack rank sell allergan plc price consensus ep surprise allergan plc price consensus ep surprise allergan plc seethe complete list today zack rank strong buy stock here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
2245,AGN,dublin ireland base allergan plc agn free report be engage development manufacturing marketing sale distribution brand pharmaceutical device biologic surgical regenerative medicine product allergan have be actively pursue deal expand portfolio especially brand product offer have complete acquisition company durata forest allergan acquire botox maker allergan inc mar acquisition allergan be previously know strong presence generic market find company top pharmaceutical company world base sale so far accretive acquisition lifecell zeltiq allergan have expand medical aesthetic business regenerative medicine body sculpting respectively allergan sell generic anda distribution business teva aug oct respectively allergan earning performance have be mixed so far company beating expectation past quarters miss occasion average negative earning surprise last quarters be currently allergan have zack rank sell definitely change follow company earning report be just release have highlighted key stat just reveal announcement earning beat allergan third quarter earning share be consensus estimate share revenue line revenue come year period line zack consensus estimate outlook company narrow previously issue earning sale guidance allergan expect total revenue range compare previously adjust earning share be expect range compare previously share price impact share be more pre market trading check back later full agn earning report later more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
2246,AGN,aerie pharmaceutical inc aeri free report be expect report third quarter result nov last quarter company report narrow expect loss fact aerie performance last quarters have be decent company report narrower expect loss trail quarters post wider expect loss remain average positive surprise aerie share price have increase year date industry decline earlier month aerie stock price surge positive news lead drug rhopressa likely positive surprise proven model indicate aerie beat earning estimate quarter be stock need have positive earning esp zack rank strong buy buy hold happen be case here zack esp earning esp represent difference most accurate estimate zack consensus estimate be be most accurate estimate stand loss cent zack consensus estimate be peg loss cent uncover best stock buy sell re report earning esp filter zack rank aerie have zack rank be favorable combination zack rank positive esp indicate likely positive surprise note caution stock zack rank sell rate go earning announcement especially company be see negative estimate revision factor approve product portfolio aerie depend heavily late stage candidate rhopressa roclatan hence expect investor focus pipeline update aerie lead candidate rhopressa once daily formulation lower intraocular pressure iop be be evaluate patient suffering open angle glaucoma ocular hypertension oct dermatologic ophthalmic drug advisory committee fda vote favor rhopressa approval member committee unanimously agree trial support efficacy netarsudil ophthalmic solution reduce elevated intraocular pressure patient open angle glaucoma ocular hypertension addition majority member agree rhopressa efficacy outweigh safety risk fda have set prescription drug user fee act date feb note fda be not bound advisory committee guidance take advice consideration review drug apart rhopressa aerie be also evaluate roclatan aerie initiate phase iii study mercury europe other pipeline candidate roclatan roclatan be once daily quadruple action fix dose combination rhopressa pfizer pfe free report xalatan be be evaluate lower iop patient glaucoma ocular hypertension company plan submit nda same first half trial be inferiority trial compare roclatan prescribe fix dose combination ganfort combination bimatoprost timolol market allergan plc agn free report europe expect investor focus further pipeline update call cash burn year be project due further pipeline development aerie pharmaceutical inc price ep surprise aerie pharmaceutical inc price ep surprise aerie pharmaceutical inc quotestock considerhere be health care stock want consider model show too have right combination element post earning beat quarter clovis oncology inc clvs free report have earning esp zack rank company be schedule release result nov see complete list today zack rank stock here zack best private investment ideaswhile be happy share many article best recommendation most depth research be not available public start today next month follow zack private buy sell real time expert cover kind trade value momentum stock etf option move stock corporate insider be buy company be report positive earning surprise even look exclusive portfolio be normally close new investor click here zack private trade
2247,AGN,be big week earning company expect report include most watch name street tracey go chart so don have find best bunch be report early week company have excellent earning track record beating nearly quarter year not easy beat quarter year be only couple dozen company be able beat quarter consistently course earning beat doesn necessarily mean stock rise other factor also play stock performance include guidance investor sentiment company be just favor industry be name be watch lead week earning star start week mastercard free report have miss just once year chart look lot competitor visa share new high visa beat mastercard do same electronic art ea free report have miss only time come just quarters last quarter turn massive beat share bust new high again week allergan agn free report have only miss twice last year biopharmas be really favor so stock be multus year lows be buy opportunity zimmer biomet zbh free report be come rare miss last quarter share have be choppy investor haven completely throw towel share yet groupon grpn free report hasn miss share have be relegate club several year last quarter be solid good quarter put even more fire share want learn trade option have always want trade stock option be unsure begin look week zack dave bartosiak bring detailed explanation trade live youtube watch go trade answer question real time become dave minion join zack live trader community today free click here join dave more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
2248,AGN,allergan plc agn free report report third quarter earning nov market open last quarter company deliver positive earning surprise allergan share price have decline year so far outperform decline witness industry allergan earning performance have be mixed so far company beating expectation past quarters miss occasion average negative earning surprise last quarters be let see thing be shape announcement factor considerat call allergan have say third quarter revenue be expect be similar level second quarter second quarter revenue rise year year third quarter revenue be likely be drive new product vraylar namzaric viberzi international growth growth key establish product botox linzess however namenda ir be face generic competition continue hurt sale drug meanwhile namenda xr sale also decline previous quarters due lower demand shift promotional effort namzaric once daily fix dose combination namenda xr company do not expect generic version namenda xr be launch first quarter investor be interested find namzaric perform quarter last quarter allergan see improve sale namzaric due continue conversion namenda xr higher demand follow expand label new dosage positive trend be expect continue meanwhile addition alloderm lifecell jan coolsculpt body contour system zeltiq apr acquisition be likely support top line quarter however loss exclusivity asacol hd minastrin remain overhang top line higher promotional expense key product increase cost support advance pipeline addition lower margin lifecell zeltiq acquisition put pressure allergan margin fact call allergan mentioned sg expense be higher third quarter compare fourth quarter higher promotional activity give timing new launch continue strong promotion key brand be expect lead higher sale marketing cost third quarter investor also be keen know management plan protect restasis second best selling drug generic competition earlier month texas federal district court invalidate patent cover restasis potentially open door early generic competition restasis patent be schedule expire aug allergan also come fire recently agreement saint regis mohawk tribe lawmaker question unconventional move adopt company protect restasis generic competition deal tribe have basically raise concern curb generic competition pharmaceutical industry discourage generic drugmaker make cheaper version expensive drug investor also be interested know impact new competition allergan key product restasis linzess shire shpg free report dry eye disease drug xiidra launch last year be pose strong competition restasis meanwhile synergy trulance plecanatide be launch second quarter cic competition linzess earning whispersour proven model do not conclusively show allergan be likely beat earning quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp most accurate estimate stand zack consensus estimate be peg higher result earning esp uncover best stock buy sell re report earning esp filter zack rank allergan have zack rank caution sell rate stock zack rank go earning announcement especially company be see negative estimate revision stock considersome stock biotech pharma sector have positive earning esp favorable zack rank be acorda therapeutic inc acor free report schedule release result oct have earning esp zack rank see complete list today zack rank stock here clovis oncology inc clvs free report schedule release result nov have earning esp zack rank buy look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
2249,AGN,johnson johnson jnj free report kick third quarter earning season pharmaceutical sector strong note company beating earning revenue focus remain strong earning result company allergan agn free report be also news regard patent litigation recap week most important storiesj result impress raise outlook earning result be strong company beating earning revenue segment consumer medical device pharmaceutical do well oncology record robust growth result include contribution pulmonary hypertension product become part company portfolio follow acquisition actelion base solid third quarter result raise outlook year well read more beat earning actelion buyout drife sale company have gain year date compare rally industry belong sanofi dupixent top allergic inflammatory disease study sanofi partner regeneron pharmaceutical announce positive phase ii result dupixent dupilumab adult active moderate severe eosinophilic esophagitis chronic allergic inflammatory disease patient receive dupixent weekly report significant improvement ability swallow versus placebo read more sanofi regeneron dupixent succeed phase ii study market be huge dupixent gain timely approval give lack fda approve treatment dupixent have orphan drug status unite state indication dupixent have blockbuster potential be currently approve eczema be be evaluate additional indication apart eosinophilic esophagitis fact last month company have announce positive top line datum late stage study dupixent uncontrolled persistent asthma regeneron sanofi be also collaborate aimmune therapeutic clinical stage company focuse development treatment potentially life threaten food allergy clinical collaboration aimmune ar be evaluate adjunctive dupixent peanut allergic patient mid stage study be schedule commence next year study be sponsored regeneron aimmune provide clinical supply ar food challenge material datum merck keytruda priority review lynparza snda merck mrk free report present update overall survival os datum pd therapy keytruda first line treatment patient suffering metastatic small cell lung cancer high level pd company say additional month available datum continue show reduction risk death keytruda compare chemotherapy keytruda more double median os compare chemotherapy year follow keytruda be key product merck portfolio drug bring sale first half merck partner astrazeneca also announce have be grant priority review fda supplemental new drug application snda use parp inhibitor lynparza tablet patient gbrca negative metastatic breast cancer mbc have be previously treat chemotherapy neoadjuvant adjuvant metastatic setting response agency be expect first quarter nordisk diabetes drug get fda panel support nordisk nvo free report get boost fda advisory panel endocrinologic metabolic drug advisory committee voting unanimously favor approve once weekly semaglutide use type ii diabetes patient give favorable vote chance gain fda approval look pretty high second quarter call nordisk have say expect decision fda year end semaglutide approval be major positive company drug expect be key growth driver nordisk be zack rank buy stock see complete list today zack rank strong buy stock here priority review bmy drug label expansion bristol myer squibb company bmy free report immuno oncology therapy opdivo have be grant priority review fda label expansion treatment melanoma patient be high risk disease recurrence follow complete surgical resection opdivo prioritize brand bristol myer portfolio bring sale first half read more bristol myer get priority review opdivo label expansion adverse ruling allergan restasis patent litigation allergan continue make headline related blockbuster eye drug restasis time round company announce have receive adverse ruling district court eastern district texas regard patent cover drug court find patent be invalid allergan intend appeal ruling say fda be yet approve generic version drug however ophthalmology focuse company imprimis pharmaceutical announce be work make lower cost alternative restasis available company say initial prescription be cent month supply refill start month include shipping accord allergan restasis patent be schedule expire aug allergan enter settlement agreement generic challenger recently innopharma have be adopt different way protect restasis generic competition company come fire enter agreement saint regis mohawk tribe lawmaker question unconventional move adopt company protect drug generic competition restasis be allergan second best selling drug bring sale almost lawmaker point sovereign status native american tribe make patent challenge lengthy complex tribe be immune legal claim make generic drug maker challenge patent deal have basically raise concern curb generic competition pharmaceutical industry discourage generic drugmaker make cheaper copy cat version expensive drug impax combine amneal specialty pharma company impax laboratory be merge privately hold generic company amneal pharmaceutical stock transaction merger combine company have high value generic product pipeline grow specialty business deal be expect boost impax stand alone earning share first month generate double digit revenue earning share growth year follow close transaction annual cost synergy be expect be achieve year merger be expect go first half read more impax laboratory amneal pharmaceutical agree merge cap pharmaceutical industry yr return large cap pharmaceutical industry yr nyse arca pharmaceutical index be week sector react positively result major stock be bristol myer decline last month bristol myer be see last pharma stock roundup here pfizer mull option consumer healthcare lly pipeline setback next pharma world watch earning result company novartis eli lilly lly free report bristol myer other come week wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2250,AGN,share fogo chao inc tank company expect adjust earning cent cent share year lower analyst expectation cent share abbott laboratory free report gain company report third quarter earning share cent ahead zack consensus estimate penny allergan plc agn free report share slump texas district court judge rule company patent lawsuit share electronic art inc ea free report decline news company be close unit be work come star war videogame
2251,AGN,conatus pharmaceutical inc cnat free report announce appointment marshall executive vice president chief operate officer chief financial officer notably marshall have year experience finance operation business advisory role also be agent private placement private biotechnology company advisor buyer seller biotechnology well pharmaceutical company transaction therefore company be banking marshall contribution aim complete ongoing phase iib study lead candidate emricasan expand pipeline meanwhile conatus be focuse effort develop emricasan january company start encore nf study encore program potential improvement fibrosis steatohepatitis patient fibrosis cause nonalcoholic steatohepatitis nash top line datum be expect first half conatus also initiate study encore lf be phase iib trial study emri monotherapy patient decompensate nash cirrhosis top line datum study be expect go forward company plan initiate new study encore xt plan extension study patient complete encore ph encore lf study continue monitoring efficacy safety clinical outcome health related quality life fact encore study be be conduct provide clinically relevant efficacy dose safety datum support initial registration emricasan chronic administration patient nash cirrhosis potentially support future label expansion december conatus sign exclusive option collaboration license agreement novartis nvs free report worldwide development emricasan be positive strategic agreement novartis not only lend expertise conatus also provide company much need fund development emricasan yet conatus have have share pipeline setback fda have place clinical hold emricasan be be develop pfizer pfe free report due preclinical observation however clinical hold be lift currently several study emricasan be ongoing datum readout schedule next couple year also stiff competition remain threat fact several company allergan agn free report intercept pharmaceutical galectin therapeutic enanta pharmaceutical be work develop treatment nash today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
2252,AGN,share aerie pharmaceutical inc aeri free report have moved last week positive news lead drug rhopressa fact aerie stock have surge year date compare industry gain oct dermatologic ophthalmic drug advisory committee fda vote favor rhopressa approval member committee unanimously agree trial support efficacy netarsudil ophthalmic solution reduce elevated intraocular pressure patient open angle glaucoma ocular hypertension addition majority member agree rhopressa efficacy outweigh safety risk fda have set prescription drug user fee act date feb note fda be not bound advisory committee guidance take advice consideration review drug rhopressa be design lower intraocular pressure iop patient novel mechanism action moas company believe rhopressa represent first new moas lower iop patient glaucoma year potential approval drug significantly boost aerie growth prospect however rhopressa be expect face tough competion establish brand generic drug such novartis ag nvs free report simbrinza travtan allergan plc agn free report lumigan well other smaller biotechnology pharmaceutical company meanwhile aerie initiate phase iii study mercury europe other pipeline candidate roclatan roclatan be once daily quadruple action fix dose combination rhopressa pfizer pfe free report xalatan be be evaluate lower iop patient glaucoma ocular hypertension company plan submit nda same first half zack rank aerie currently carry zack rank sell see complete list today zack rank strong buy stock here look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
2253,AGN,ironwood pharmaceutical inc irwd free report report second quarter adjust loss cent share wider zack consensus estimate loss cent year loss cent total revenue collaborative revenue quarter amount year period zack consensus estimate ironwood share gain afterhour trading aug positive pipeline update fact look company share price movement show stock have outperformed industry year so far ironwood share have gain period industry register increase quarter detaila report partner allergan plc agn free report ironwood key market product linzess generate net sale year year please note ironwood allergan have equal share brand collaboration profit loss ironwood share net profit sale linzess include collaborative revenue be second quarter year year accord datum provide im health linzess prescription filled quarter crossed year period report quarter selling administrative sg expense increase research development expense be year periodzurampic ironwood second commercial product treatment uncontrolled gout be launch oct zurampic rake sale quarter zurampic prescription filled quarter be higher prescription filled previous quarter pipeline updateslinzess be currently approve treatment adult irritable bowel syndrome constipation ib mcg chronic idiopathic constipation cic mcg mcg ironwood allergan be look broaden linzess label expand target patient population gain approval additional indication partner be also develop delay release version linzess ib constipate subtype ib ironwood have partnership astella pharma market linzess japan astella be look submit regulatory application label expansion chronic constipation japanese regulatory authorityin china hong kong macau ironwood have agreement astrazeneca plc azn free report linzess regulatory filing be review china ib company expect review be complete first quarter year ironwood expect launch duzallo fix dose combination zurampic allopurinol new drug application duzallo be review fda decision be expect second half drug be expect be launch late approve duzallo become first dual mechanism treatment patient uncontrolled gout guidance maintainedthe company continue expect use less operation be however much higher level be due full year commercial expense related launch zurampic support potential launch duzallo pipeline advancement company also maintain expense sg expense guidance range respectively ironwood pharmaceutical inc price consensus ep surprise ironwood pharmaceutical inc price consensus ep surprise ironwood pharmaceutical inc quotezack rank stock currently carry zack rank hold better rank stock pharma sector be summit therapeutic plc smmt free report carry zack rank buy see complete list today zack rank strong buy stock here summit loss estimate narrow cent last day company deliver positive earning surprise trail quarters average beat share price be so far year today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
2254,AGN,teva pharmaceutical industry limit teva free report report second quarter earning cent share include equity compensation expense miss zack consensus estimate share year adjust earning be share revenue miss zack consensus estimate sale however increase year year exclude impact currency mainly due inclusion revenue allergan plc agn free report generic segment actavis generic include andateva acquire actavis generic aug also allegan generic distribution business anda inc oct exclude benefit actavis generic acquisition core sale performance be expectation sale quarter be hurt increase pricing erosion generic unit ongoing political turmoil venezuela loss exclusivity specialty segment quarter segment discussionbegin fourth quarter teva revise segment structure follow actavis acquisition generic segment now include revenue otc business well api business generic medicine segment revenue rise mainly attributable inclusion revenue actavis generic business revenue generic business rise due inclusion revenue generic business actavis european generic revenue be local currency year period be due inclusion revenue generic business actavis rest world row generic revenue decline quarter local currency basis sale rise mainly due inclusion revenue actavis api revenue decline otc revenue rise local currency term exclude benefit actavis generic acquisition core sale performance segment be poor due accelerate generic drug price erosion decrease volume meanwhile delay launch new generic drug increase competition other also hurt sale segment generic industry be face significant competitive pricing pressure increase fda generic drug approval ongoing customer consolidation be result additional competitive pressure generic industry drug price erosion be expect accelerate second half year teva say price erosion generic business be expect be high single digit range specialty medicine revenue decline year period due lower sale central nervous system cns oncology product teva various therapeutic area cns sale decline due lower sale multiple sclerosis drug copaxone teva lead brand product sale respiratory product rise oncology product sale decline woman health business record decline revenue other specialty revenue rise worldwide revenue copaxone decline sale decline due lower volume mg formulation be face generic competition negative net pricing effect price increase take january jun novartis ag nvs free report generic arm sandoz launch glatopa once daily generic version mg formulation copaxone ex sale copaxone decline mg thrice weekly tw time week formulation copaxone account more total copaxone scrip end report quarter note teva be face patent challenge mg formulation company mylan myl free report momenta pharmaceutical be look get approval generic version mg thrice weekly formulation copaxone late january teva suffer major setback district court district delaware invalidate orange book patent protect copaxone mg teva intend appeal decision however generic version mg formulation have not be launch yet fda approval momenta generic version copaxone have be delay owing manufacturing issue teva do not expect generic competition copaxone mg year however company say case generic version be launch full quarter year hurt earning cent other product azilect sale decline generic version drug be launch proair decline combine treanda bendeka revenue decline qvar decline other segment distribution other activity record revenue segment mainly gain inclusion distribution revenue anda profit declineadjust gross margin contract basis point bps quarter due addition low margin anda distribution business low margin generic medicine segment gross margin rise specialty segment research development expense increase year period selling marketing expenditure be year level adjust operate margin exclude equity compensation expense decline bps quarter outlook slashedteva slash previously issue sale earning guidance increase price erosion generic market delay generic launch greater instability venezuela market lead cut guidance revenue guidance be cut range earning be expect band much lower share expect previously teva expect continue sale erosion copaxone due increase competition management say venezuelan business be not expect contribute anything earning last quarters dividend cutteva announce cut dividend second quarter cent share cent share paid first quarter taketeva second quarter earning sale be dismal generic industry continue face significant competitive pricing pressure israel base generic drug maker also slash earning sale outlook reflect challenge environment generic business venezuela devaluation generic industry pressure be expect persist management expect lower revenue profit generic potentially major cut dividend help pay debt invest business be big disappointment also company do not provide update new chief executive officer ceo say be process be not go rush teva ceo erez vigodman have step february year teva chief financial officer eyal desheh also retire june share decline thursday hit week low share fact share have slump so far year compare industry sdecline teva carry zack rank hold see complete list today zack rank strong buy stock here teva pharmaceutical industry limit price consensus ep surprise teva pharmaceutical industry limit price consensus ep surprise teva pharmaceutical industry limit quotetoday stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
2255,AGN,week company pfizer pfe free report allergan agn free report teva teva free report report second quarter result pfizer report mixed quarter allergan top expectation teva however have tough quarter meanwhile bristol myer bmy free report announce immune oncology io focuse deal include acquisition recap week most important storiesa look earning result big company pfizer allergan teva report second quarter result week pfizer surpass earning estimate miss revenue raise concern company top line growth prospect prevnar enbrel sale decline quarter pfizer be face key loss exclusivity loe viagra later year lyrica end read more pfizer surpass earning estimate miss sale meanwhile allergan top earning sale estimate raise outlook well read more allergan earning sale top restasis sale teva share fall dismal quarter company miss earning sale reflect performance generic business continue deterioration venezuela generic business be hit accelerate price erosion lower volume mainly due customer consolidation higher competition delay new product launch teva lower outlook year slash dividend well company also expect exit market globe year end be cut headcount close actavis generic business deal teva have lose value year date versus decline industry abbvie drug get fda nod cgvhd johnson johnson jnj free report abbvie btk inhibitor imbruvica gain fda approval first cancer indication chronic graft versus host disease cgvhd adult failure more systemic line therapy make imbruvica first only approve treatment patient population mark sixth indication imbruvica stock have gain year date outperform rally industry belong bristol myer acquisition deal worth bristol myer announce be acquire ifm therapeutic venture backed biotech company work treatment modulate novel target innate immune system treat cancer autoimmunity inflammatory disorder acquisition bristol myer gain full right ifm preclinical sting stimulator interferon gene nlrp agonist program be focuse cancer sting agonist program include lead asset nlrp agonist program include potential first class pipeline candidate acquisition schedule close third quarter strengthen bristol myer immune oncology io pipeline deal see bristol myer shell upfront additional payment be make first product program achievement certain milestone additional milestone payment be make further product result program bristol myer sign io focuse deal week company sign clinical collaboration agreement clovis oncology immunotherapy opdivo be evaluate combination clovis parp inhibitor rubraca mid late stage study different type tumor meanwhile opdivo label be expand week treatment adult pediatric year older patient microsatellite instability high msi mismatch repair deficient dmmr metastatic colorectal cancer mcrc have progressed follow treatment oxaliplatin irinotecan accelerate approval be grant basis overall response rate orr duration response however note merck keytruda gain approval earlier year patient msi dmmr wider patient population merck label include patient solid tumor have progressed follow prior treatment have satisfactory alternative treatment option well colorectal cancer patient disease have progressed follow treatment certain chemotherapy drug ra drug fail get fda advisory panel support investigational rheumatoid arthritis ra treatment plivensia sirukumab il inhibitor fail get support fda arthritis advisory committee safety concern company be look get plivensia approve treatment adult patient moderately severely active ra have have inadequate response be intolerant more disease modify rheumatic drug dmard ra be common chronic life long autoimmune disease affect person fda be not require do so usually follow advice advisory panel consider safety concern raise panel agency well ask additional information grant approval pfizer drug get advisory panel support pfizer supplemental new drug application snda jak inhibitor xeljanz mg twice daily xeljanz xr mg once daily treatment adult patient active psoriatic arthritis psa get support fda arthritis advisory committee advisory panel vote favor approve propose dose xeljanz psa indication decision fda be dec xeljanz currently approve ra bring sale first half priority review astrazeneca btk inhibitor astrazeneca azn free report investigational btk inhibitor acalabrutinib be grant priority review fda company be look get drug approve use patient relapse refractory mantle cell lymphoma mcl have receive least prior therapy response agency be expect first quarter acalabrutinib be also give breakthrough therapy designation btd indication astrazeneca imfinzi also get btd week treatment patient locally advanced unresectable small cell lung cancer nsclc disease have not progressed follow platinum base chemoradiation therapy positive datum lilly migraine drug lilly lly free report present late stage datum investigational migraine drug lasmiditan say meet primary endpoint well key secondary endpoint result be consistent result present earlier late stage study lilly expect file fda approval second half lilly be zack rank buy stock see complete list today zack rank strong buy stock here cap pharmaceutical industry yr return large cap pharmaceutical industry yr nyse arca pharmaceutical index decline last trading session major stock pfizer be lilly lose last month be astrazeneca gain see last pharma stock roundup here nvs earning merck drug get tentative fda nod next pharma world watch usual pipeline regulatory update today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
2256,AGN,allergan plc agn free report announce texas federal district court invalidate patent cover restasis allergan second bestselling drug potentially open door early generic competition share company fall almost response monday company be disappoint court ruling be plan appeal however ruling be upheld even appeal negatively impact restasis sale invalidate patent be list orange book be set expire aug restasis be approve treatment chronic dry eye allegan share have outperformed industry so far year company stock fall industry be period allergan have file patent infringement lawsuit group generic drug manufacturer include teva pharma teva free report mylan myl free report other company be seek approval generic version restasis unite state meanwhile last week allergan settle innopharma grant latter right market generic restasis begin feb moreover bid dismiss parte review restasis allergan sign agreement last month saint regis mohawk tribe gain sovereign immunity however court litigation be purview sovereign immunity unconventional move company have be question many lawmaker be criticize generic manufacturer such deal gain sovereign immunity make launch generic lengthy complex legal process curb competition restasis generate sale worldwide first month fda approval shire plc shpg free report xiidra last year have already increase competition drug earlier expect generic entry follow invalidation patent further increase competition allergan plc price consensus allergan plc price consensus allergan plc quoteallergan carry zack rank sell see complete list today zack rank strong buy stock here look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
2257,AGN,company pfizer pfe free report merck mrk free report eli lilly lly free report be news week pfizer be mull strategic option consumer healthcare business merck say not file cetp inhibitor recap week most important storiespfizer divest consumer healthcare segment pfizer be currently review different strategic option consumer healthcare business include full partial separation spin sale company also ultimately decide retain business be not first time pfizer have decide spin sell core business segment strategic step take pfizer include sale hospira infusion system business icu medical february spin animal health business lead creation zoetis well divestment nutrition business nestle pfizer have sell capsugel business affiliate kohlberg kravis robert co divestment consumer healthcare business help pfizer focus innovative health segment also bring fund company use return value shareholder form share buyback dividend read more pfizer consider sale spin consumer healthcare unit pfizer be zack rank hold stock see complete list today zack rank strong buy stock here company have gain year date compare rally industry belong merck collaborate kalvista clinical stage pharma company kalvista pharmaceutical see share shoot collaboration agreement merck kvd future oral diabetic macular edema dme compound base plasma kallikrein inhibition kvd investigational intravitreal ivt injection be schedule move phase ii proof concept study later year merck have option acquire right candidate follow completion study merck have similar option certain other dme candidate kalvista receive refundable upfront payment well payment associate exercise option merck achievement milestone program add company also stand receive tiered royalty net sale candidate commercialize deal merck also acquire ownership stake kalvista worth pipeline setback lilly lilly suffer setback recently approve breast cancer drug verzenio fail meet primary endpoint late stage study kra mutate advanced small cell lung cancer cdk inhibitor fail meet primary endpoint overall survival os analysis secondary endpoint progression free survival pfs overall response rate orr show evidence monotherapy activity read more lilly verzenio fail phase iii lung cancer study meanwhile verzenio have be grant priority review fda use initial treatment advanced breast cancer mean response agency be month receive regulatory application instead usual timeframe month seek fda nod new prostate cancer treatment johnson johnson janssen biotech be seek fda approval apalutamide investigational next generation oral androgen receptor ar inhibitor man metastatic castration resistant prostate cancer crpc be significant unmet need patient population give absence fda approve treatment patient prostate cancer most common cancer american man be expect be diagnosed more man american cancer society apalutamide become part pipeline follow acquisition privately hold aragon pharmaceutical apalutamide approval strengthen expand presence prostate cancer market company currently sell zytiga be approve use combination prednisone treatment patient metastatic castration resistant prostate cancer mcrpc be look expand zytiga label earlier stage metastatic prostate cancer allergan settle restasis litigation innopharma allergan agn free report enter settlement agreement innopharma related litigation regard restasis patent challenged patent be list orange book be schedule expire aug settlement agreement innopharma start selling generic version eye drug unite state feb earlier certain circumstance moreover certain circumstance innopharma be allow launch authorize generic version restasis aug allergan be adopt different way protect restasis generic competition company recently come fire enter agreement saint regis mohawk tribe lawmaker question unconventional move adopt company protect blockbuster eye drug generic competition restasis be allergan second best selling drug bring sale almost lawmaker point sovereign status native american tribe make patent challenge lengthy complex tribe be immune legal claim make generic drug maker challenge patent fact tribe be filing dismiss ongoing parte review ipr restasis patent base sovereign immunity ipr challenge deal tribe have basically raise concern curb generic competition pharmaceutical industry discourage generic drugmaker make cheaper copy cat version expensive drug allergan have be ask committee oversight government reform provide certain document information deal oct merck not file anacetrapib merck have decide not seek regulatory approval investigational cetp inhibitor anacetrapib company decision be base thorough review clinical profile drug note merck be not first company drop cetp inhibitor plan company lilly roche pfizer have have high profile setback cetp inhibitor class be more less written read more merck not seek approval cetp inhibitor anacetrapib crl acelrx acelrx pharmaceutical acrx free report share plunge company get complete response letter crl fda sufentanil sublingual tablet fda say approve regulatory application current form have ask additional safety datum agency have also ask company make certain change direction use ensure proper administration tablet acelrx have be ask validate same human factor study acelrx be look get approve reduction moderate severe acute pain dose error associate iv administration invasive single dose applicator sda medically supervised setting cap pharmaceutical industry yr return large cap pharmaceutical industry yr nyse arca pharmaceutical index gain week major stock be lilly decline last month bristol myer squibb bmy free report be see last pharma stock roundup here mylan teva copaxone news lawmaker question allergan deal next pharma world aerie pharmaceutical aeri free report rhopressa be evaluate fda advisory panel treatment patient open angle glaucoma ocular hypertension october company share be favorable briefing document be report earning october read more kickstart pharma earning store stock watch massive equifax stock spiked recent news datum breach affect american stock be best buy candidate right now do future hold cybersecurity industry equifax be just most recent victim computer hacking identity theft be more common ever zack have just release cybersecurity investor guide inform zack com reader year space more importantly highlight cybersecurity pick strong profit potential get new investing guide now
2258,AGN,big time investor late have be investing substantial portion source treatment alcoholic steatohepatitis nash market nash be poise witness rapid growth other lucrative saturate market cancer chronic liver disease nash be cause excessive fat accumulation liver turn be know steatosis nash be know affect person unite state lead inflammation hepatocellular injury progressive fibrosis cirrhosis be expect be lead cause liver transplantation notably be currently lead cause liver transplant person unite state nash patient be also know be affected obesity type ii diabetes disease be prevalent european country develop country market disease be project treatment currently approve disease market opportunity be significant let take look company candidate be be evaluate present treatment nash intercept pharmaceuticial inc icpt free report be presently evaluate lead drug ocaliva drug be already approve unite state treatment primary biliary cholangitis pbc inadequate response intolerant standard care udca company currently have ongoing phase iii trial regenerate cirrhotic nash patient liver fibrosis top line datum interim analysis be expect first half company also complete phase ii trial control evaluate lipid metabolic effect ocaliva cholesterol management effect concomitant statin administration nash patient company also plan initiate phase iii trial nash patient cirrhosis second half give success phase ii trial expect intercept be first company obtain approval nash biotech bigwig gilead science inc gild free report also have quite few program patient diagnosed nash advanced fibrosis include selonsertib ask inhibitor phase iii gs fxr agonist phase ii gs acc inhibitor phase ii company plan initiate combination study agent give increase competition once lucrative hepatitis market gilead be look diversify portfolio foray emerge field car therapy nash company earlier acquire phenex farnesoid receptor program comprise small molecule fxr agonist treatment liver disease include nash major player biotech space bristol myer squibb company bmy free report have mid stage candidate nash space bms investigational pegylate analogue human fibroblast growth factor fgf key regulator metabolism patient biopsy confirm nash achieve primary endpoint significant reduction liver fat versus placebo april company be entitle right research develop commercialize bms ambrx inc swiss major novartis inc nvs free report enter clinical trial agreement allergan plc agn free report conduct phase iib study april involve combination novartis fxr agonist allergan cenicriviroc treatment nash company have collaboration license agreement conatus pharmaceutical inc cnat free report global development emricasan patient decompensate liver cirrhosis cause nash medical biomedical genetic industry yr return medical biomedical genetic industry yr returnbottom line give potential market be many other big pharma biotech company have pipeline candidate treatment nash expect lot activity space go forward potential approval drug nash attract more player wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2259,AGN,ardelyx inc ardx free report announce meeting primary endpoint second phase iii study mpo evaluate tenapanor patient irritable bowel syndrome constipation ib base positive top line datum study well previously complete mpo study company be plan file new drug application nda second half ardelyx stock surge more market trading wednesday follow announcement however share company be so far year significantly underperform industry gain period datum mpo study show candidate achieve primary endpoint secondary endpoint statistical significance candidate reduce abdominal pain greater number patient compare placebo vs increase more complete spontaneous bowel movement csbm same week least week week treatment period improvement be consistent week study company have announce positive datum first phase iii study mpo tenapanor same indication meanwhile phase iii study mpo be evaluate candidate indication patient be treat year study be expect be complete datum study also be include nda ardelyx be currently focuse find collaboration partner expand reach successful candidate be also be evaluate phase iii study patient be suffering end stage renal disease be dialysis ib be disorder patient suffer significant abdominal pain constipation ardelyx estimate patient ib unite state however be other company marketing develop drug treatment ib unite state ironwood pharmaceutical inc irwd free report partner allergan plc agn free report market linzess ib synergy pharmaceutical inc sgyp free report be develop chronic idiopathic constipation drug trulance treatment ib application label expansion review decision trulance be expect january next year ardelyx inc price consensus ardelyx inc price consensus ardelyx inc quoteardelyx carry zack rank hold see complete list today zack rank strong buy stock here wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2260,AGN,allergan plc agn free report announce fda have accept new drug application nda pipeline candidate ulipristal acetate allergan be look get ulipristal acetate approve treatment abnormal uterine bleed fibroid organ company expect fda give decision first half once approve ulipristal acetate be first once daily surgical oral treatment option approve condition allergan share have decline compare industry decline be other company have pipeline candidate be evaluate uterine fibroid july bayer bayry free report be evaluate vilaprisan woman suffering uterine fibroid july initiate phase iii study asteroid same abbvie inc abbv free report neurocrine bioscience inc be evaluate pipeline candidate elagolix reduce heavy menstrual bleed premenopausal woman uterine fibroid april year company announce positive result phase iib study show elagolix meet primary endpoint significantly reduce number heavy bleed day rapidly assessment period month baseline comparison placebo utilize alkaline hematin method allergan plc price allergan plc price allergan plc quote zack rank stock allergan carry zack rank hold better rank stock health care sector be acadium pharmaceutical inc acad free report carry zack rank buy see complete list today zack rank strong buy stock here last day acadium loss share estimate narrow company deliver positive earning surprise trail quarters average beat year date share price company have climb wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2261,AGN,unite natural food inc unfi free report have recently approve authorization new share buyback plan bid boost shareholder value however number value share time repurchase be decide company depend various factor sep unite natural have roughly outstanding share be be buy back accord applicable security law notably company repurchase share cash operation borrowing credit facility addition available cash fund apart unite natural allergan plc agn free report autobytel inc have recently sanction stock repurchase program reward shareholder allergan authorize fresh share repurchase program autobytel approve repurchase additional common stock unite natural performancewe note unite natural have be gain increase consumer preference natural organic brand spite ongoing industry challenge such headwind include stiff competition aggressive promotional spending tight margin recently unite natural report fourth quarter fiscal result earning surpass zack consensus estimate revenue lag fact company top line have miss estimate consecutive quarters now nevertheless management expect net sale fiscal range signify increase net sale fiscal also earning be envision band share zack consensus estimate have moved cent last day be currently peg fiscal moreover acquisition have be primary growth driver unite natural past few year such acquisition have aid company expand distribution network footprint customer base key market launch new brand also management remain focuse reduce operate expense enhance operate efficiency consequently zack rank hold company share have rally past month zack food miscellaneous industry decline currently industry be place bottom zack classify industry believe latest share buyback program significantly boost stock shareholder return reflect company healthy balance sheet free cash flow better rank stock same industry include mccormick company inc mkc free report have long term earning growth rate sport zack rank strong buy see complete list today zack rank stock here look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
2262,AGN,week company allergan agn free report teva teva free report mylan myl free report be limelight mylan teva be news related fda approval mylan generic version teva top selling brand drug copaxone allergan be fire agreement saint regis mohawk tribe restasis recap week most important storiesallergan restasis deal fire allergan deal saint regis mohawk tribe announce early september have come fire lawmaker question unconventional move adopt company protect blockbuster eye drug restasis generic competition term deal allergan transfer patent related restasis tribe be grant exclusive license patent return allergan pay execution agreement well annual royalty restasis be allergan second best selling drug bring sale almost original patent drug active ingredient be set expire allergan file additional patent extend protection lawmaker point sovereign status native american tribe make patent challenge lengthy complex tribe be immune legal claim make generic drug maker challenge patent fact tribe be filing dismiss ongoing parte review ipr restasis patent base sovereign immunity ipr challenge deal have basically raise concern curb generic competition pharmaceutical industry discourage generic drugmaker make cheaper copy cat version expensive drug allergan have be ask committee oversight government reform provide certain document information deal oct mylan gain teva loss major development mylan gain fda approval generic version teva top selling brand drug copaxone multiple sclerosis mylan gain approval mg thrice weekly dosage well once daily mg formulation mylan be first applicant challenge mg patent company therefore enjoy day exclusivity formal communication fda regard same be yet come mylan have launch product accord quintilesim brand sale mg mg dose be approximately respectively month end jul mylan also gain approval mg dose eu fda approval generic copaxone be big boost mylan be major blow teva be currently face whole lot challenge teva issue statement say launch mg formulation final resolution pending patent infringement lawsuit mylan be treat risk launch mean mylan have pay significant damage court uphold patent protect drug entry mg formulation entry second generic version mg formulation sandoz momenta have be market quite glatopa generic version mg dose be expect cut teva earning least cent share additional detail be company announce third quarter result november entry generic copaxone just add exist list problem be face teva read more teva share plummet mylan copaxone generic get fda approval nordisk get fda approval fiasp nordisk nvo free report have strong presence diabetes market provide regulatory update diabetes franchise company gain fda approval fiasp fast act mealtime insulin treatment adult diabetes approval process be not exactly company receive complete response letter last year agency have ask additional information related assay immunogenicity clinical pharmacology datum read more nordisk fiasp get fda nod diabetes adult meanwhile european medicine agency ema committee medicinal product human use chmp endorse company plan update eu label tresiba include result devote study show significant reduction risk severe hypoglycemia nordisk be zack rank buy stock see complete list today zack rank strong buy stock here sanofi regeneron score pcsk inhibitor litigation sanofi sny free report partner regeneron get major boost court appeal federal circuit order new trial related amgen claim regard patent pcsk inhibitor court also vacated permanent injunction lawsuit mean sanofi regeneron continue selling pcsk inhibitor praluent unite state favorable court ruling lilly company get positive ruling patent front be eli lilly company lly free report company say patent trial appeal board patent trademark office pto rule favor regard vitamin regimen patent cancer therapy alimta pemetrexed injection patent be upheld alimta be safe generic competition decision have remove overhang share alimta bring sale more dollar first half week lilly also gain fda approval new cancer treatment verzenio use woman hr advanced breast cancer lilly have gain year date compare rally industry belong cap pharmaceutical industry yr return large cap pharmaceutical industry yr nyse arca pharmaceutical index gain so far week major stock lilly be last month bristol myer be glaxo gsk free report decline see last pharma stock roundup here drug get crl label expansion merck bmy drug next pharma world watch usual pipeline regulatory update stock watch massive equifax stock spiked recent news datum breach affect american stock be best buy candidate right now do future hold cybersecurity industry equifax be just most recent victim computer hacking identity theft be more common ever zack have just release cybersecurity investor guide inform zack com reader year space more importantly highlight cybersecurity pick strong profit potential get new investing guide now
2263,AGN,share teva pharmaceutical teva free report open more lower wednesday plunge close week low process struggle israeli pharma firm have face significant pressure reduce debt load be slide once again time brand new competitor indeed big news rocking pharmaceutical world today be mylan myl free report major drugmaker wrapped own chaos past year so have receive fda approval sell generic version teva multiple sclerosis drug copaxone mylan say want quickly introduce slew new generic market effort curb rise drug cost today approval certainly help company top line also be first step new plan contribute mylan ongoing effort regain public trust be embroil epipen price hike scandal share mylan open higher touch nearly month high teva other hand plummet share be now more year mylan have miss approval copaxone generic twice year company management be recently force lower earning forecast due delay launch key drug note morning well fargo analyst say new generic add cent share mylan quarterly earning so long fda grant company day exclusivity period teva new competition have serious consequence copaxone generate more sale second quarter alone ongoing challenge generic business fda approval mylan generic copaxone earning cash flow be likely affected jeffery analyst david steinberg write note copaxone have be strong contributor cash flow last decade grow generic competition franchise have be overhang teva share recent year fresh generic competition mylan only add teva grow list problem past few month israeli firm have be desperately scramble ramp asset effort preserve credit rating cut mount debt complete deal buy allergan agn free report generic division last year teva debt pile swell whopping august same day company report lackluster earning slash full year outlook cut dividend teva ceo yitzhak peterburg say asset sale likely generate least well level be previously forecast now teva remain zack rank hold however company need improve performance own generic unit pare debt quickly want lift share price anytime soon want more stock market analysis author make sure follow ryan_mcqueeney twitter hacker put money portfolio just last month credit bureau equifax announce massive datum breach affect american cybersecurity industry be expand quickly response similar event stock be better investment other zack have just release cybersecurity investor guide help zack com reader make most year investment opportunity create hacker other threat reveal stock worth look right away download new report now
2264,AGN,allergan plc agn free report announce fda have approve botox cosmetic product third indication temporary improvement moderate severe forehead line appearance associate frontali muscle activity adult so far year allergan share price have slip compare industry decline approve therapeutic aesthetic use botox be key top line driver allergan cosmetic indication include improvement appearance glabellar line frown line brow severe crow foot latest fda approval make botox cosmetic only neurotoxin treatment approve facial aesthetic treatment forehead line crow foot wrinkle outer corner eye glabellar line botox therapeutic disease include overactive bladder cervical dystonia chronic migraine strabismus other drug generate sale first half increase year year drive strong demand trend latest label expansion approval forehead line treatment enjoy pent demand drive sale further remind investor botox become part allergan portfolio follow march acquisition allergan inc have previously command strong presence generic market allergan merger have find place top list world wide pharma company base sale later allergan sell generic business well anda distribution arm teva pharmaceutical industry ltd teva free report however april pfizer inc pfe free report have terminate agreement combine allergan allergan carry zack rank hold seethe complete list today zack rank strong buy stock here stock considera better rank biotech drug stock be biogen inc biib free report zack rank buy biogen have see zack consensus estimate current year earning be revise upward past day share company have rally year hacker put money portfolio earlier month credit bureau equifax announce massive datum breach affect american cybersecurity industry be expand quickly response similar event stock be better investment other zack have just release cybersecurity investor guide help zack com reader make most year investment opportunity create hacker other threat reveal stock worth look right away download new report now
2265,AGN,allergan plc agn free report announce supplemental new drug application snda infective drug avycaz have be accept grant priority review fda remind investor avycaz be currently approve treatment complicate urinary tract infection cuti include pyelonephritis drug combination metronidazole be approve treat complicate intra abdominal infection ciai company be look get label drug expand include hospital acquire bacterial pneumonia ventilator associate bacterial pneumonia habp vabp decision fda be expect first quarter allergan share be so far year outperform industry decline same period snda submission be base inferiority datum pivotal reprove study evaluate safety efficacy avycaz adult patient habp vabp study show avycaz be inferior meropenem reduce death irrespective cause drug also show study controlled environment outside human body activity certain gram negative bacterium cause habp vabp remind investor fda issue refusal file letter last month snda vraylar expand label include negative symptom associate schizophrenia however boost generic portfolio company receive approval september biosimilar version roche hold ag rhhby free report cancer drug avastin treatment type cancer allergan plc price consensus allergan plc price consensus allergan plc quotezack rank stock carry zack rank hold better rank stock health care sector include regeneron pharmaceutical inc regn free report biogen inc biib free report regeneron sport zack rank strong buy biogen carry zack rank buy see complete list today zack rank stock here regeneron earning share estimate have increase last day company pull positive earning surprise trail quarters average beat share price company have increase year date biogen earning share estimate have moved last day company deliver positive earning surprise trail quarters average beat share price company have increase year date make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
2266,AGN,issue update research report allergan plc agn free report sep allergan boast dominant growth franchise several area be strengthen product portfolio strategic acquisition so far accretive acquisition lifecell zeltiq allergan have expand medical aesthetic business regenerative medicine body sculpting respectively allergan sell generic business aug anda distribution business teva pharmaceutical teva free report oct follow closure teva deal allergan now focus brand segment be used proceed buy back share pay debt pursue additional deal key product botox linzess new product such viberzi vraylar be support sale growth allergan fact second quarter conference call allergan raise previously issue earning sale guidance follow strong first half performance solid outlook rest year allergan also boast strong brand pipeline meaningful datum read out next few month company have more project mid late stage development include key phase iii program year allergan be extend pipeline adjacent category nash parkinson disease gene therapy many promising phase ii iii program development allergan have product launch plan biosimilar also represent significant opportunity allergan amgen inc amgn free report have collaboration agreement worldwide development biosimilar version roche rhhby free report cancer drug avastin herceptin rituxan biosimilar version avastin be market trade name mvasi receive fda approval month make first cancer biosimilar get fda nod however remain optimistic company growth prospect be face generic competition legacy brand namenda asacol hd well patent challenge other product brand portfolio meanwhile new competition key growth driver restasis linzess be investor concern shire dry eye disease drug xiidra launch last year pose strong competition restasis meanwhile synergy trulance plecanatide be launch second quarter cic competition linzess make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
2267,AGN,sep issue update report conatus pharmaceutical inc cnat free report approve product conatus portfolio moment company be yet generate revenue however be focuse develop lead candidate emricasan orally active pan caspase protease inhibitor emricasan be be develop treat patient chronic liver disease be now ongoing emricasan phase iib clinical study comprise encore study patient fibrosis cirrhosis cause nonalcoholic steatohepatitis nash various patient population fourth encore program polt hcv svr patient datum study be expect be release result combine encore study be expect support undertrial candidate efficacy safety phase iii further strength outcome determine discussion regulatory agency secure potential accelerate approval candidate treatment currently sanction nash fibrosis market opportunity emricasan seem significant nash be predict be lead cause liver transplantation however emricasan be still quite few year away enter market setback develop emricasan pull stock substantially notably several company be work develop treatment nash namely allergan plc agn free report intercept pharmaceutical icpt free report galectin therapeutic enanta pharmaceutical enta free report other hence emricasan be expect face intense competition once approve candidate company portfolio other emricasan be idn currently undergo phase ii assessment treatment primary sclerosing cholangitis psc june fda have grant orphan drug designation odd idn indication more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
2268,AGN,key highlight pharma sector include complete response letter crl fda johnson johnson jnj free report investigational rheumatoid arthritis ra treatment fda approval merck mrk free report bristol myer squibb bmy free report cancer drug recap week most important storiescrl ra drug janssen biotech get crl fda sirukumab treatment moderately severely active ra agency have ask additional datum safety sirukumab do not come surprise consider investigational treatment fail get support fda advisory panel last month give safety concern raise panel request additional datum be more less expect intend meet agency determine requirement gain approval il inhibitor meanwhile company have submit new drug application nda first darunavir base single tablet regimen treatment hiv approval make combination only complete regimen potential deliver advantage single table regimen high genetic barrier resistance darunavir demonstrated safety profile taf fda nod merck keytruda merck pd therapy keytruda have gain fda approval yet indication cancer therapy be already available wide range indication now be used previously treat patient recurrent locally advanced metastatic gastric junction gej adenocarcinoma tumor express pd mark tenth new indication keytruda year period keytruda be key product merck portfolio drug bring sale first half company be work expand label drug be currently more study cover wide range cancer treatment setting read more merck keytruda get fda nod advanced gastric cancer merck be zack rank hold stock see complete list today zack rank strong buy stock here allergan announce share buy back cfo departure allergan agn free report continue work return capital shareholder company announce intention buy back share worth come shortly company complete share buyback program allergan also reaffirm commitment increase cash dividend year reiterate commitment maintain investment grade credit rating pay debt company also announce departure tessa hilado executive vice president chief financial officer cfo be retire company once successor be appoint bristol myer opdivo get approval bristol myer also gain approval indication immune oncology therapy opdivo latest approval opdivo now be used treatment hepatocellular carcinoma patient previously treat nexavar sorafenib make opdivo first only immuno oncology agent be approve patient population read more bristol myer opdivo get approval liver cancer company also gain approval japan use opdivo treatment unresectable advanced recurrent gastric cancer have progressed chemotherapy gastric cancer be highly prevalent asian country be second most commonly diagnosed cancer japan bristol myer also enter clinical trial collaboration abbvie combination opdivo abbvie investigational antibody drug conjugate abbv be evaluate meet overexpressing small cell lung cancer nsclc bristol myer stock have gain year date compare rally industry belong priority review aradigm drug aradigm get priority review linhaliq treatment cystic fibrosis bronchiectasis ncfbe patient chronic infection pseudomona aeruginosa aeruginosa response agency regard approval status drug be jan ncfbe severe chronic rare disease affect more person unite state person europe drug currently approve treatment condition be significant unmet need aradigm share be news cap pharmaceutical industry yr returnlarge cap pharmaceutical industry yr nyse arca pharmaceutical index be so far week major stock lilly lly free report be pfizer pfe free report be last month bristol myer be glaxo gsk free report decline see last pharma stock roundup here pfizer file suit supernus hit study update next pharma world watch usual pipeline regulatory update hacker put money portfolio earlier month credit bureau equifax announce massive datum breach affect american cybersecurity industry be expand quickly response similar event stock be better investment other zack have just release cybersecurity investor guide help zack com reader make most year investment opportunity create hacker other threat reveal stock worth look right away download new report now
2269,AGN,allergan plc agn free report announce fda have issue refusal file rtf letter supplemental new drug application snda vraylar cariprazine company be look get vraylar label expand include new datum support drug use maintenance treatment vraylar be presently approve europe treatment schizophrenia allergan share price be year so far compare favorably industry decrease fda say snda be not sufficiently complete allow substantive review company plan meet fda official understand additional information be require remind investor earlier march fda have accept company snda vraylar snda be base datum phase iii study evaluate vraylar maintenance efficacy adult schizophrenia datum study show vraylar have significantly delay time relapse compare placebo also relapse occur nearly twice many placebo patient comparison treat vraylar vraylar have perform expectation record sale year drug be likely be key driver allergan top line growth other player bipolar disorder schizophrenia treatment market include astrazeneca plc azn free report seroquel xr johnson johnson jnj free report risperdal consta plc alk free report aristada separate press release allergan announce new datum centaur phase iib study evaluate pipeline candidate cenicriviroc cvc treat liver fibrosis adult patient nash phase iib datum support continue development cenicriviroc cvc ongoing phase iii aurora study evaluate safety efficacy candidate liver fibrosis adult patient nash centaur study demonstrated significant difference fibrosis improvement be observed cvc placebo second year patient administer cvc couple year patient switch cvc year remain placebo year such patient receive cvc achieve combine endpoint reduction fibrosis least stage worsening nash find lie straight comparison remain placebo allergan plc price allergan plc price allergan plc quotezack rankallergan currently carry zack rank hold see complete list today zack rank strong buy stock here look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
2270,AGN,age related macular degeneration amd space have be spotlight late due number development earlier month swiss pharma company roche holding ag rhhby free report suffer setback ophthalmology candidate lampalizumab fail achieve primary endpoint late stage study candidate be be evaluate treatment geographic atrophy ga advanced form amd lampalizumab do not reduce mean change ga lesion area compare sham treatment year week last month ophthotech corporation opht free report also announce disappointing result phase iii study oph study evaluate pipeline candidate fovista pdgf therapy combination regeneron pharmaceutical inc regn free report eylea roche avastin bevacizumab treatment wet amd amd typesamd be disorder central portion retina know macula lead blindness be form amd dry amd wet amd dry amd lead wet amd ga be progressive irreversible form amd american academy ophthalmology dry amd occur part macula get thinner age tiny clump protein grow dry amd be most common form amd be approve therapy unite state europe treat condition other hand wet amd occur new abnormal blood vessel grow retina turn leak blood other fluid scarring macula vegf drug help treat wet amd reduce number abnormal blood vessel retina apart laser therapy drug availablea number drug have be make available treat disorder lead be regeneron eylea drug be approve treatment wet amd diabetic macular edema dme macular edema follow retinal vein occlusion other sale drug unite state come highlight huge market potential indication regeneron currently carry zack rank strong buy see complete list today zack rank stock here novartis ag nvs free report roche lucentis be also vegf therapy approve various ocular indication include neovascular age related macular degeneration visual impairment due dme other novartis currently carry zack rank hold roche avastin be also used wet amd roche currently carry zack rank pipeline candidatesgiven huge potential market several company have host candidate line pipeline novartis be develop rth brolucizumab wet amd candidate be expect competition eylea earlier novartis release positive datum rth candidate meet primary key secondary endpoint phase iii study hawk harrier however novartis expect complete pharmacokinetic study final manufacturing process enable filing hence candidate be not likely hit market give eylea breather allergan plc agn free report be also develop pegol vegf darpin wet amd related condition company also have other candidate bimatoprost sr brimonidine sr dry amd allergan currently carry zack rank meanwhile ophthotech be also develop zimura combination vegf drug treatment wet amd treatment naïve patient ophthotech currently carry zack rank medical sector yr return medical sector yr returnbottom linegiven potential amd market number company develop treatment same expect investor keep eye new approval make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
2271,AGN,value investing be easily most popular way find great stock market environment wouldn want find stock be fly radar be compelling buy offer tantalize discount compare fair value way find company be look several key metric financial ratio many be crucial value stock selection process let put allergan plc agn free report stock equation find be good choice value oriented investor right now investor subscribe methodology look elsewhere top pick pe ratioa key metric value investor always look be price earning ratio pe short show much investor be willing pay dollar earning give stock be easily most popular financial ratio world best use pe ratio be compare stock current pe ratio ratio have be past compare average industry sector compare market whole front allergan have trail month pe ratio see chart level actually compare pretty favorably market large pe compare focus stock long term pe trend current level put allergan current pe ratio somewhat midpoint be past year further stock pe also compare favorably sector trail month pe ratio stand very least indicate stock be relatively undervalue right now compare peer also point allergan have forward pe ratio price relative year earning just so be fair say slightly more value oriented path be ahead allergan stock term too cf ratioan often overlooked ratio still be great indicator value be price cash flow metric ratio doesn take amortization depreciation account so give more accurate picture financial health business be prefer metric valuation investor cash flow be generally less prone manipulation company management be less affected variation accounting policy different company ratio be generally apply find company stock be overpriced underpriced reference cash flow generation potential compare competitor however be not commonly used cross industry comparison average price cash flow ratio vary industry industry case allergan cf ratio be significantly lower industry average indicate stock be somewhat undervalue respect broad value outlookin aggregate allergan currently have value style score putt top stock cover look make agn solid choice value investor other key metric make pretty clear too example peg ratio allergan be just level be considerably lower industry average peg ratio be modify pe ratio take account stock earning growth rate clearly agn be solid choice value front multiple angle stock overall allergan be good choice value investor be plenty other factor consider investing name particular be worth note company have growth grade momentum score give jwn vgm score overarch fundamental grade read more zack style score here meanwhile company recent earning estimate have be mixed best current quarter have see estimate go higher past day lower full year estimate have see upward downward revision same time period have have noticeable impact consensus estimate current quarter consensus estimate have dip past month full year estimate have inched see consensus estimate trend recent price action stock chart allergan plc price consensus allergan plc price consensus allergan plc somewhat mixed trend be stock have just zack rank hold be look line performance company term bottom lineallergan be inspire choice value investor be hard beat incredible lineup statistic front however sluggish industry rank bottom more industry zack rank be hard get too excited company overall fact past year sector have clearly underperform broader market see so value investor want estimate analyst sentiment broader factor turn favorable name first once happen stock be compelling pick promising stock pick keep eye news story computer hacking identity theft become increasingly commonplace cybersecurity industry look promising investment opportunity stock buy zack just release cybersecurity investor guide locking profit help answer question new special report give information need make well inform investment choice space more importantly also highlight cybersecurity pick strong profit potential get new investing guide now
2272,AGN,amgen amgn free report partner allergan agn free report announce fda approve biosimilar version roche rhhby free report cancer drug avastin bevacizumab treatment type cancer include lung cancer colorectal cancer glioblastoma renal cell carcinoma cervix cancer biosimilar be market trade name mvasi mvasi be first cancer biosimilar approve unite state be also first bevacizumab biosimilar country notably amgen have also submit regulatory application same eu remind investor july fda oncologic drug advisory committee have unanimously vote recommend approval mvasi amgen share have outperformed industry so far year stock have plunge versus broader industry rally approval be support comprehensive datum package demonstrated similarity mvasi bevacizumab datum also include result phase iii comparative efficacy safety immunogenicity study confirm clinically meaningful difference mvasi reference product amgen allergan be also develop biosimilar version roche herceptin abp review unite state eu rituxan abp phase iii amgen biosimilar version abbvie humira amjevita be approve fda september last year however amjevita have not be launch yet due ongoing litigation other development include amgen biosimilar version alexion soliris lilly erbitux johnson johnson jnj free report merck remicade interestingly biosimilar endeavor offer lucrative opportunity annual revenue worth amgen company have also collaborate japan daiichi sankyo biosimilar japan accelerate approval biosimilar number pharmaceutical biotech company be work bring biosimilar market many biosimilar be market eu very few be available unite state last november pfizer have launch inflectra biosimilar version remicade sandoz also market zarxio first biosimilar be approve unite state product be turn biosimilar amgen neupogen july merck have launch reneflexis biosimilar version remicade unite state august last year sandoz have gain fda approval erelzi biosimilar version amgen enbrel however product be hold due ongoing litigation be yet be unveil unite state amgen inc priceamgen inc price amgen inc quotezack rankamgen currently carry zack rank hold see complete list today zack rank strong buy stock here look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
2273,AGN,several important development be report week key highlight include termination hepatitis virus deal approval first cancer biosimilar unite state presentation datum company pfizer pfe free report bristol myer squibb bmy free report other recap week most important hcv deal termination achillion pharmaceutical achn free report share fall termination company partnership agreement johnson johnson janssen pharmaceutical hepatitis virus hcv janssen say not continue development jnj combination direct act antiviral al odalasvir simeprevir decision discontinue development do not come big surprise give intense competition pricing dynamic hcv market achillion intend focus development advanced multiple small molecule factor inhibitor complement alternative pathway read more achillion hcv partnership terminate stock fall first cancer biosimilar get fda nod fda approve allergan agn free report amgen mvasi biosimilar version roche blockbuster cancer drug avastin bevacizumab mvasi be used eligible indication reference product approval be line expectation consider favorable vote biosimilar get fda advisory panel recently approval be quite boost company well effort lower drug price so far biosimilar be yet make significant dent reference product sale unite state mvasi be review eu pfizer xtandi prosper late stage study pfizer partner astella pharma well be path boost sale prostate cancer drug xtandi company announce positive top line datum late stage study prosper patient metastatic castration resistant prostate cancer crpc company plan discuss datum regulatory authority expansion drug label xtandi sale have be pressure receive boost approval patient population bristol myer sign deal present cancer datum bristol myer squibb present datum european society medical oncology esmo congress show treatment opdivo lead superior recurrence free survival compare yervoy patient resect high risk melanoma read more bristol myer report positive result melanoma study meanwhile company have sign deal halozyme latter enhanze technology global collaboration license agreement be focuse use halozyme technology subcutaneous administration bristol myer immuno oncology drug thereby provide patient more flexible convenient treatment delivery option bristol myer shell upfront make future milestone royalty payment dilutive transaction be expect hit bristol myer earning penny earning cent lilly baricitinib fare well mid stage eczema study eli lilly company lly free report incyte present new safety efficacy datum mid stage study baricitinib eczema annual meeting european academy dermatology venereology eadv baricitinib combine mid potency topical corticosteroid tcs significantly improve sign symptom eczema compare tcs alone company intend commence phase iii program eczema indication later year baricitinib be currently approve eu trade name olumiant moderate severe active rheumatoid arthritis however approval be yet come unite state regulatory filing be resubmit jan lilly stock have gain year date compare rally industry belong teva appoint new ceo teva teva free report have finally end search chief executive officer ceo company announce appointment kare schultz company president ceo seasoned veteran healthcare industry schulz bring almost year experience segment schulz be recently serve president ceo lundbeck be responsible implement significant restructure initiative launch robust turnaround strategy schulz have daunting task ahead consider challenge be face teva include generic pricing erosion company need work pay debt divest core business increase focus core area generate cash deliver pipeline get generic business back track read more teva hire kare schultz ceo be recovery card positive fda panel vote glaxo shingle vaccine glaxosmithkline gsk free report get positive vote fda vaccine related biological product advisory committee vrbpac shingrix prevention herpes zoster shingle adult age give positive vote chance gain approval look pretty high note merck zostavax live attenuate virus vaccine be currently available prevention shingle same patient population read more glaxo shingle candidate get positive fda committee vote glaxo be zack rank hold stock see complete list today zack rank strong buy stock here cap pharmaceutical industry yr return large cap pharmaceutical industry yr nyse arca pharmaceutical index be last trading session almost major stock record gain pfizer gain bristol myer slip last month bristol myer be glaxo decline see last pharma stock roundup here lilly cut job streamline operation nvs ceo step next pharma world watch usual pipeline regulatory update fda advisory panel be meeting sep discuss supplemental new drug application snda submit pfizer cancer drug sutent adjuvant treatment adult patient high risk recurrent renal cell carcinoma rcc follow nephrectomy surgical removal cancer contain kidney moreover fda decision regard label expansion merck pd therapy keytruda use treatment recurrent advanced gastric junction adenocarcinoma be sep look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
2274,AGN,biosimilar space remain spotlight number regulatory decision be pending generic drug be follow version chemically synthesize molecule biosimilar contain version active substance already approve original biological drug development biosimilar be technically challenge development generic drug former require clinical study patient be engineer match reference drug quality safety efficacy due complex nature product development regulatory pathway biosimilar differ significantly generic biosimilar be usually less expensive brand drug thus market same remain highly lucrative acceleration approval biosimilar market have thus attract lot player be witness rapid growth here be few latest development space lead biosimilar space be novartis ag nvs free report generic arm sandoz be strong player biosimilar market market biosimilar omnitrope human growth hormone binocrit erythropoiesis stimulating agent used treat anemia filgrastim neutropenia brand name zarzio outside unite state zarxio unite state company plan launch major oncology immunology biosimilar include biosimilar version rituxan rituximab be approve european commission june market rixathon recently fda accept biologic license application bla propose biosimilar version rituxan august sandoz erelzi biosimilar version amgen inc amgn free report blockbuster drug enbrel gain approval unite state indication erelzi be also approve european commission european medicine agency also accept company marketing authorization application biosimilar version humira adalimumab remicade infliximab review novartis currently carry zack rank hold see complete list today zack rank strong buy stock here generic leader mylan nv myl free report be also explore world biosimilar market have potential grow fda recently notified mylan partner biocon target action date biosimilar version herceptin trastuzumab have be extend dec decision fda be expect sep fda extend review period due review clarificatory information submit agency part application review process note biocon partnership include biosimilar program such biosimilar version herceptin neulasta humira avastin enbrel neupogen insulin analog lantus humalog novolog mylan have collaboration agreement momenta pharmaceutical inc mnta free report develop manufacture commercialize momenta current biosimilar candidate include momenta biosimilar candidate orencia mylan currently carry zack rank strong sell meanwhile amgen allergan plc agn free report have also submit bla fda abp biosimilar candidate herceptin jul note company be collaborate oncology biosimilar include abp be second be submit fda approval company have also submit marketing authorization application european medicine agency candidate earlier note amgen have total biosimilar pipeline have be approve fda march european commission grant marketing authorization amgevita biosimilar version humira available indication company have important event line fda be expect give decision approval abp biosimilar version avastin shortly amgen currently carry zack rank hold last month biotech major biogen inc biib free report announce european commission grant marketing authorization imraldi biosimilar version humira be third tnf biosimilar biogen receive marketing authorization european union follow approval benepali biosimilar enbrel flixabi infliximab biosimilar version remicade biogen currently carry zack rank hold july merck co inc mrk free report launch reneflexis biosimilar version remicade unite state be approve fda april fda also grant tentative approval lusduna nexvue biosimilar version lantus basal insulin pre filled dose device merck currently carry zack rank hold medical sector yr return medical sector yr give fact so much be happen space expect investor focus upcoming approval date trade profit big league trump policiesif stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
2275,AGN,aug issue update report conatus pharmaceutical inc cnat free report conatus share have significantly underperform industry so far year have lose industry increase approve product conatus portfolio moment company have yet generate revenue however be focuse develop lead candidate emricasan orally active pan caspase protease inhibitor emricasan be be evaluate various phase iib study treatment chronic liver disease include nash fibrosis ongoing study include encore ph encore nf evaluate emricasan patient compensate early decompensate nash cirrhosis potential improvement fibrosis steatohepatitis respectively datum encore ph trial be expect encore nf conatus initiate study encore lf phase iib trial examine emricasan monotherapy patient decompensate nash cirrhosis company also plan soon initiate additional study call encore xt emricasan encore program conatus be also conduct phase iib study polt hcv svr evaluate emricasan patient liver fibrosis cirrhosis post liver transplant top line datum study be anticipate next year result combine encore study be expect support undertrial candidate efficacy safety phase iii further strength outcome determine discussion regulatory agency secure potential accelerate approval candidate treatment currently sanction nash fibrosis market opportunity emricasan seem significant nash be predict be lead cause liver transplantation however emricasan be still quite few year away enter market setback develop emricasan pull stock substantially notably several company be work develop treatment nash namely allergan plc agn free report intercept pharmaceutical icpt free report galectin therapeutic enanta pharmaceutical enta free report other hence emricasan be expect face intense competition once approve conatus pharmaceutical inc price consensus conatus pharmaceutical inc price consensus conatus pharmaceutical inc quotezack rankconatus currently carry zack rank sell see complete list today zack rank strong buy stock here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
2276,AGN,shire plc shpg free report announce have submit marketing authorization application maa lifitegrast treatment dry eye disease europe fact application have be validate uk reference member state involved decentralize procedure dcp approve lifitegrast be first only treatment new class drug consequently give significant boost shire effort build ophthalmology unit notably maa drug be support datum clinical trial include patient share company have decline compare zack classify industry fall year date basis be be note lifitegra be launch august brand name xiidra fact shire receive major boost fda approve xiidra twice daily eye drop solution indicated treatment sign symptom dry eye disease ded adult company xiidra be only prescription eye drop indicated treatment sign symptom condition approximately adult be diagnosed dry eye disease underscore significant need treatment field xiidra also strongly compete allergan plc agn free report eye care drug restasis meanwhile company have deep pipeline ophthalmology comprise early mid late stage candidate gain organic growth strategic acquisition also remain commit continue innovation ophthalmic be opportunity address unmet need improve life patient shire plc price shire plc price shire plc quotezack rank stock considershire currently carry zack rank hold better rank stock health care sector include alexion pharmaceutical inc alxn free report sanofi sny free report alexion sport zack rank strong buy sanofi hold zack rank buy see complete list today zack rank stock here alexion pharmaceutical earning share estimate have moved last day company deliver positive earning surprise trail quarters average beat share price company have increase year date sanofi earning share estimate have increase last day company pull positive earning surprise trail quarters average beat share price company have increase year date hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
2277,AGN,issue update research report amgen inc amgn free report aug lead biotech beat estimate earning sale second quarter result be announce jul amgen slightly tighten sale guidance raise earning outlook backed strong performance first half amgen newer drug prolium xgeva kyproli vectibix nplate sensipar be perform well backed strong demand amgen be also progress pipeline include biosimilar drug important pipeline candidate include aimovig erenumab prevention migraine review cnp bace inhibitor alzheimer disease phase iii omecamtiv mecarbil heart failure phase iii amgen have biosimilar pipeline company have collaborate allergan plc agn free report worldwide development oncology antibody biosimilar medicine roche herceptin avastin rituxan however company have challenge store give presence biosimilar competition slowdown sale mature product volume growth new product not be enough offset lose sale due decline mature brand enbrel epogen neulasta neupogen due competitive pressure neulasta sale be be hurt competition pd other new cancer therapy neupogen sale be go due biosimilar competition zarxio zarxio be sandoz novartis ag nvs free report generic arm biosimilar version neupogen be launch sep company expect neulasta neupogen sale continue be hurt competitive dynamic rest meanwhile neulasta epogen start face biosimilar competition next year also softness enbrel sale due stiff competitive pressure be key cause concern pricing pressure stiff competition be hurt sale enbrel main driver amgen revenue year meanwhile uptake amgen pcsk inhibitor repatha gain fda approval aug have not be very encourage so far due pricing re imbursement issue payer restriction sanofi sny free report partner regeneron pharmaceutical also face similar issue pcsk inhibitor praluent second quarter however company do notice improve share trend drug follow presentation outcome study fourier datum march year datum show significant reduction myocardial infarction stroke company file regulatory application eu include fourier datum repatha label jun fda decision expect dec lastly amgen have have share pipeline setback latest be complete response letter crl receive fda evenity romosozumab osteoporosis postmenopausal woman increase risk fracture july follow heart related safety issue emerge otherwise successful arch result fda ask safety efficacy datum pivotal phase iii study arch bridge be include original application be file only basis pivotal frame study lead delay drug approval amgen inc price consensus amgen inc price consensus amgen inc quotezack minute stock pick secretsince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar here something even more remarkable master proven system go single class seminar then apply portfolio little minute month learn secret
2278,AGN,share teva pharmaceutical teva free report favorite investor chasing large dividend yield fall more hit year intraday low wednesday just say company report sluggish earning investor be continue ditch stock report teva be desperately try sell asset accord source cite bloomberg teva be look ramp asset sale effort preserve credit rating cut mount debt report claim medis iceland base generic drug manufacturer be teva unit table bloomberg also claim teva be consider sale respiratory treatment asset publication anonymous source say decision sell have not be finalize consideration be still early stage teva be look opportunity focus business streamline operation process structure company say statement update teva be not position comment market speculation teva be increase pressure reduce debt load have swell whopping follow acquisition allergan agn free report generic division new asset sale come addition pending offloading teva woman health european cancer pain treatment unit just last week same day company report lackluster earning slash full year outlook cut dividend teva ceo yitzhak peterburg say asset sale likely generate least well level be previously forecast also last week moody say teva debt reduction have be slower expect lower credit rating moody hasn be only analyst firm question teva recently morgan stanley david risinger also chime week believe teva disappointing generic business performance take more time improve give combination generic industry intensify secular challenge teva own difficulty execute pipeline risinger say note risinger downgrade teva underweight cut price target represent further slide wednesday close want more stock market analysis author make sure follow ryan_mcqueeney twitter more stock news tech opportunity worth driverless car artificial intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
2279,AGN,allergan plc agn free report second quarter earning come share beating zack consensus estimate earning rise year year drive higher revenue operate profitsrevenue come year period beat zack consensus estimate key product botox new product vraylar namzaric viberzi do well quarter sale be once again hurt sale erosion namenda xr loss exclusivity mainly asacol hd minastrin also lower sale key dry eye disease drug restasis hurt top line second quarter revenue however gain addition alloderm lifecell jan coolsculpt body contour system zeltiq apr acquisition adjust operate income increase quarter selling general administrative sg expense rise quarter primarily due higher promotional spend support new product launch expense increase support advance pipeline segment company report revenue segment general medicine specialize therapeutic international specialize therapeutic net revenue increase drive strong growth botox addition lifecell alloderm zeltiq coolsculpt business botox cosmetic rake sale botox therapeutic revenue be addition juvéderm collection filler rise ozurdex sale increase contribute upside alloderm add coolsculpt add sale second quarter importantly restasis sale decline quarter due unfavorable trade buy pattern remind investor shire plc shpg free report launch dry eye disease drug xiidra last year have be investor concern xiidra pose strong competition restasis company expect stable restasis revenue year general medicine net revenue decline report quarter sale decline diversify brand woman health franchise infective sale rise central nervous system sale rise establish product linzess loestrin well new product viberzi namzaric vraylar do well quarter linzess sale rise quarter drive strong demand continue otc conversion however lower namenda xr sale hurt performance cns franchise namenda xr sale decline quarter due lower demand lower pricing shift promotional effort namzaric company do not expect generic version namenda xr be launch first quarter delay prior expectation fourth quarter also allergan do not expect generic version estrace cream be launch year namzaric once daily fix dose combination namenda xr record sale compare previous quarter asacol delzicol sale decline due reduction demand ascaol hd follow launch authorize generic aug well lower demand delzicol woman health segment minastrin revenue decline quarter due loss exclusivity mar international segment record net revenue year period drive growth facial aesthetic botox therapeutic addition lifecell coolsculpt outlook company raise previously issue earning sale guidance allergan expect total revenue range compare previously currency headwind be now not expect hurt revenue versus negative impact approximately expect previously adjust earning share be expect range compare previously adjust gross margin be expect expense be expect be approximately maintain sg spend be expect compare previously takeallergan do fairly well beating estimate earning sale second quarter company also raise outlook share be slightly pre market trading however so far year allergan share price be industry decline allergan be reshape portfolio strategic acquisition drugmaker sell generic anda distribution business teva pharmaceutical industry limit teva free report aug oct respectively order focus brand segment allergan also boast strong brand pipeline product launch plan allergan be extend pipeline adjacent category nash parkinson disease gene therapy many promising phase ii iii program development be also encourage allergan focus build biosimilar pipeline allergan have collaboration agreement amgen inc amgn free report worldwide development oncology antibody biosimilar include biosimilar roche cancer drug herceptin avastin however generic competition legacy brand namenda ir xr asacol hd well new competition key growth driver restasis linzess be investor concern allergan carry zack rank hold see complete list today zack rank strong buy stock here more stock news tech opportunity worth driverless car artificial intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
2280,AGN,dublin ireland base allergan plc agn free report be engage development manufacturing marketing sale distribution brand pharmaceutical select counter product allergan have be actively pursue deal expand portfolio especially brand product offer have complete acquisition company durata forest allergan acquire botox maker allergan inc mar acquisition allergan be previously know strong presence generic market find company top pharmaceutical company world base sale so far accretive acquisition lifecell zeltiq allergan have expand medical aesthetic business regenerative medicine body sculpting respectively allergan sell generic anda distribution business teva aug oct respectively allergan earning performance have be mixed so far company beating expectation past quarters miss occasion average negative earning surprise last quarters be currently allergan have zack rank hold definitely change follow company earning report be just release have highlighted key stat just reveal announcement earning beat allergan second quarter earning share be consensus estimate share revenue beat revenue also beat expectation revenue come year period also beat zack consensus estimate outlook company raise previously issue earning sale guidance allergan expect total revenue range compare previously currency headwind be now not expect hurt revenue versus negative impact approximately expect previously adjust earning be expect range compare share previously share price impact share decline more pre market trading allergan plc price consensus allergan plc price consensus allergan plc quotecheck back later full agn earning report later more stock news tech opportunity worth driverless car artificial intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
2281,AGN,week be busiest entire earning season company be expect report week not company be create equal have history beating consensus nearly quarter spite person think not easy beat nearly quarter year think slowdown bad weather management change company have have endure time period lot go wrong company be able manage earning expectation better other company be best week be truly earning star keep quarter best earning chart finish week allergan agn free report have miss only twice last year share maker botox haven go anywhere last year earning report boost trading range wingstop wing free report hasn miss ipo stock isn exactly pretty price chicken wing be head wingstop adjust choppy trade be shake shack shak free report be darling wall street ipo back share have go nowhere few year hasn miss yet mastec mtz free report have only miss twice last year be trump trade stock build infrastructure especially pipeline even infrastructure plan white house share be still new year high newell nwl free report hasn miss year now have best chart week maker crockpot yankee candle have be expand brand universe beat again full disclosure author article own share nwl personal portfolio want learn trade option have always want trade stock option be unsure begin look week zack dave bartosiak bring detailed explanation trade live youtube watch go trade answer question real time become dave minion join zack live trader community today click here free day trial more stock news tech opportunity worth driverless car artificial intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
2282,AGN,aerie pharmaceutical inc aeri free report post second quarter loss cent share include stock base compensation narrower zack consensus estimate loss cent year loss cent be development stage company aerie have not generate revenue product sale yet note share aerie have rally year so far outperform industry rally quarter detailin report quarter research development expense decline company complete trial general administrative expense increase higher operate expense quarter be attribute expansion employee base support operation preparatory activity include commercial manufacturing cost rhopressa aerie pharmaceutical inc price consensus ep surprise aerie pharmaceutical inc price consensus ep surprise aerie pharmaceutical inc quotepipeline updateson feb company resubmit new drug application nda lead candidate rhopressa expect review period month note aerie withdraw rhopressa nda file september third party manufacturing facility tampa fl be not ready pre approval inspection fda company initiate preparation bring second contract manufacturer online apart rhopressa aerie be evaluate roclatan once daily quadruple action fix dose combination rhopressa pfizer inc pfe free report xalatan company report positive top line day efficacy safety datum second phase iii clinical trial mercury datum mercury be expect third quarter mercury mercury be successful nda roclatan be expect be file early company also expect commence trial mercury third quarter europe support filing trial be inferiority trial compare roclatan prescribe fix dose combination ganfort combination bimatoprost timolol market allergan plc agn free report europe meanwhile company recently inked acollaboration agreement dsm primary focus potential aerie compound treat retinal disease narrower expect loss second quarter be encourage be encourage company effort develop pipeline candidate potential approval rhopressa early significantly boost growth prospect zack rank other key pickaerie currently carry zack rank buy top rank stock healthcare sector be gilead science inc gild free report currently carry zack rank see complete list today zack rank strong buy stock here gilead earning share estimate increase last sevenday follow strong result second quarter company deliver positive earning surprise trail quarters average beat share price company have increase year date more stock news tech opportunity worth driverless car artificial intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
2283,AGN,allergan plc agn free report be report second quarter earning aug market open last quarter company deliver positive earning surprise allergan share price be year so far outperform increase witness industry allergan earning performance have be mixed so far company beating expectation past quarters miss occasion average negative earning surprise last quarters be let see thing be shape announcement factor considerwhile revenue be likely be drive new product launch international growth growth key establish product botox linzess restasis earning growth likely be drive revenue operate expense management performance new product avycaz treatment adult patient complicate intra abdominal urinary tract infection vraylar bipolar disorder schizophrenia kybella double chin reduction viberzi adult suffering irritable bowel syndrome diarrhea also be focus viberzi vraylar do well past quarters expect trend continue soon be report quarter well viberzi be approve canada year be likely contribute sale however namenda ir be face generic competition continue hurt sale drug namenda xr sale also decline previous quarters due lower demand shift promotional effort namzaric be once daily fix dose combination namenda xr investor be interested hear namzaric performance quarter first quarter conference call management have mentioned namzaric sale be benefitting increase use combination therapy patient be transition monotherapy namzaric asacol delzicol sale also continue be hurt reduction demand ascaol hd follow launch authorize generic aug minastrin revenue be also likely be hurt loss exclusivity mar meanwhile recent acquisition lifecell close feb zeltiq aesthetic close apr support top line quarter first quarter call company have hint operate margin improve remain quarters year revenue grow second quarter company expect revenue approximately sg expense be expect be highest second quarter due continue strong promotion key brand addition zeltiq launch rhofade cream rosacea earning whispersour proven model do not conclusively show allergan be likely beat earning quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp most accurate estimate stand zack consensus estimate be peg higher result earning esp uncover best stock buy sell re report earning esp filter zack rank allergan zack rank increase predictive power esp however need have positive esp be confident earning beat caution sell rate stock zack rank go earning announcement especially company be see negative estimate revision allergan plc price ep surprise allergan plc price ep surprise allergan plc quotestock considersome stock pharmaceutical sector have positive earning esp favorable zack rank be nordisk nvo free report schedule release result aug have earning esp zack rank see complete list today zack rank stock here pfizer inc pfe free report have earning esp zack rank company be schedule release result aug mallinckrodt public limit company mnk free report be schedule release result aug company have earning esp zack rank more stock news company verge apple rundid miss apple stock explosion launch iphone now look be pivotal year get emerge technology expect rock market demand soar almost nothing report suggest save life decade turn save healthcare cost bonus zack special report name breakthrough best stock exploit apple company be already strong coil potential mega gain click see right now
2284,AGN,last week several pharma major report second quarter result meanwhile important study datum be release merck mrk free report astrazeneca azn free report recap week most important storiesa look earning result big pharma company merck lilly lly free report glaxo roche bristol myer bmy free report astrazeneca report second quarter result last week bristol myer lilly merck beat expectation merck maintain outlook year read more merck beat earning sale keep view bristol myer update same read more bristol myer beat earning tweak view lilly be hit baricitinib update report beat raise quarter read more key takeaway lilly call baricitinib cancer pipeline meanwhile astrazeneca result be shadow disappointing mystic datum imfinzi treatment naïve small cell lung cancer nsclc patient company share fall read more astrazeneca beat earning fall fail study british drugmaker glaxo set new priority company company decide allocate capital priority asset current respiratory hiv infectious disease potential oncology immuno inflammation therapy area glaxo also say more pre clinical clinical program be stop read more glaxosmithkline beat earning lower guidance lilly merck be zack rank buy stock see complete list today zack rank strong buy stock here merck keytruda miss endpoint hnscc study be lot update merck last week addition earning result company be hit disappointing result late stage study evaluate pd therapy keytruda monotherapy patient previously treat recurrent metastatic head neck squamous cell carcinoma hnscc study fail meet pre specify primary endpoint overall survival os be latest keytruda related setback merck earlier month company have announce fda have place clinical hold combination study keynote keynote keynote be conduct keytruda multiple myeloma mm meanwhile look merck second quarter result show keytruda remain strong lung cancer set keytruda be currently more study include more combination study merck astrazeneca sign oncology collaboration merck astrazeneca be collaborate global development merck keytruda astrazeneca parp inhibitor lynparza different type cancer lynparza currently approve brca mutate ovarian cancer multiple line treatment be different study range tumor type include breast prostate pancreatic cancer deal cover evaluation parp mek inhibitor pd pd inhibitor astrazeneca stand receive include upfront payment certain license option additional achievement regulatory sale milestone merck stock have gain year date ytd lag rally industry belong astrazeneca have gain ytd janssen inks deal bavarian nordic johnson johnson janssen pharmaceutical company denmark base biotech company bavarian nordic enter additional worldwide exclusive license collaboration agreement janssen get exclusive right bavarian nordic mva bn technology additional program target vaccine hepatitis virus hbv hiv make upfront payment equity investment worth bavarian nordic also be eligible receive milestone payment worth tiered royalty future sale deal company be now collaborate program combine bavarian nordic mva bn technology janssen advac technology platform pfizer astella xtandi breast cancer program drop astella report result last week provide update pipeline show company partner pfizer pfe free report have decide drop development xtandi breast cancer development program include phase iii study triple negative breast cancer phase ii study pr positive positive breast cancer astella say decision be base discussion pfizer change competitive landscape need further diagnostic development new phase ii datum ongoing program xtandi include metastatic castration resistant prostate cancer phase iii prostate cancer patient metastatic biochemical recurrence phase iii metastatic hormone sensitive prostate cancer phase iii hepatocellular cancer phase ii cap pharmaceutical industry yr return large cap pharmaceutical industry yr nyse arca pharmaceutical index decline last trading session major stock merck be astrazeneca lose last month be bristol myer gain see last pharma stock roundup here nvs earning merck drug get tentative fda nod next pharma world watch second quarter earning result company pfizer shire shpg free report allergan agn free report other moreover fda arthritis advisory committee be meeting aug discuss regulatory application investigational rheumatoid arthritis treatment plivensia sirukumab more stock news company verge apple rundid miss apple stock explosion launch iphone now look be pivotal year get emerge technology expect rock market demand soar almost nothing report suggest save life decade turn save healthcare cost bonus zack special report name breakthrough best stock exploit apple company be already strong coil potential mega gain click see right now
2285,AGN,paratek pharmaceutical inc prtk free report announce positive result phase iii study oasis compare antibiotic candidate omadacycline pfizer inc pfe free report zyvox treatment acute bacterial skin skin structure infection absssi study meet key primary secondary endpoint paratek pharma look set file new drug application nda fda first half share be more hour trading oasis study evaluate efficacy safety oral once daily dose omadacycline twice daily dose zyvox study meet fda specify primary efficacy endpoint statistical inferiority ni early clinical response ecr hour first dose drug study ecr omadacycline be find be compare zyvox additionally study meet statistical ni european medicine agency specify co primary endpoint post treatment evaluation pte clinical success rate modify intent treat population omadacycline zyvox arm be respectively rate be omadacycline versus zyvox arm clinically evaluable population remind investor omadacycline have now show positive result phase iii study namely oasis oasis optic study oasis study datum show omadacycline be prescribe oral only dose regimen outpatient set be expect reduce need hospital admission treatment absssi datum oasis announce last year show candidate meet fda specify primary efficacy endpoint ecr ecr omadacycline be find be compare zyvox arm datum optic study announce apr demonstrated statistical inferiority omadacycline bayer ag bayry free report avelox treatment adult community acquire bacterial pneumonia cabp ecr hour initiation therapy be also find be statistically inferior avelox post treatment evaluation paratek intend present result study datum secondary endpoint upcoming scientific congress nda omadacycline be treatment absssi cabp include datum study note omadacycline enjoy fast track status company also intend file fda approval pipeline candidate sarecycline treatment acne second half year paratek be develop candidate allergan plc agn free report announce positive result first quarter study meet primary endpoint positive development have push paratek share price so far year outperformed zack classify medical generic drug industry increase same period zack rankparatek currently carry zack rank hold see complete list today zack rank strong buy stock here trade profit big league trump policiesif stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
2286,AGN,mylan myl free report partner biocon ltd announce fda oncologic drug advisory committee odac unanimously recommend approval roche rhhby free report breast cancer drug herceptin trastuzumab fact fda odac vote favor biosimilar candidate have be develop treat positive breast cancer be more aggressive form disease notably share mylan inched follow news release however company have outperformed zack categorize medical generic drug industry year so far stock gain industry decline meanwhile datum present odac include result show propose biosimilar trastuzumab be highly similar herceptin line fda assessment provide pre meeting briefing document odac be clinically meaningful difference mylan biosimilar candidate herceptin term safety purity potency biosimilar trastuzumab be also review regulatory authority australia canada europe several emerge market be good news mylan be blow roche herceptin be key drug last week biosimilar roche be put review odac amgen amgn free report partner allergan plc agn free report announce supplemental biologic license application sbla candidate abp biosimilar roche cancer drug avastin also be review odac herceptin avastin be key drug roche biosimiar version drug once approve hurt sale drug mylan price consensus mylan price consensus mylan quotezack rankmylan currently sport zack rank strong buy see complete list today zack rank stock here today stock zack hottest strategy hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
2287,AGN,allergan plc agn free report announce weaker expect sale outlook face potential loss exclusivity key product allergan expect total sale range approximately fall short zack consensus estimate meanwhile company say expect adjust earning least share not directly comparable earning projection also appear short zack consensus estimate share allergan be face potential loss exclusivity several key product include alzheimer treatment namenda xr blockbuster dry eye drug restasis latest press release company say expect generic version namenda xr be launch early first quarter restasis allergan second best selling drug be not expect be launch prior second quarter remind investor october texas federal district court invalidate patent cover restasis patent loss open door early generic competition restasis patent be schedule expire august please note generic version restasis have be approve yet also remind investor third quarter earning call allergan have say generic version restasis be launch mid adjust earning share be less also company say generic enter market jan adjust earning share be more share also year allergan face loss patent exclusivity estrace vaginal cream ulcerative colitis drug delzicol december last year mylan myl free report launch first generic version estrace cream generic version delzicol be expect be launch early second quarter last week allergan regulatory filing announce be layer employee part cost save restructure program latest press release allergan say cost reduction effort reduce operate expense also new competition key growth driver restasis linzess be investor concern shire shpg free report dry eye disease drug xiidra launch last year be pose strong competition restasis meanwhile synergy pharmaceutical inc sgyp free report trulance plecanatide be launch last year chronic idiopathic constipation competition allergan linzess past year allergan share have decline compare industry sdecline allergan also provide other update issue outlook company say impact tax reform be broadly neutral adjust effective tax rate time moderate increase rate level allergan guide adjust tax rate approximately new share buyback plan announce september last year allergan say have already buy back approximately authorize amount month end december also company say plan sell remain stake teva security year allergan carry zack rank sell seethe complete list today zack rank strong buy stock here zack best private investment ideaswhile be happy share many article best recommendation most depth research be not available public start today next month follow zack private buy sell real time expert cover kind trade value momentum stock etf option move stock corporate insider be buy company be report positive earning surprise even look exclusive portfolio be normally close new investor click here zack private trade
